ID   A8K6P0_HUMAN            Unreviewed;       773 AA.
AC   A8K6P0;
DT   04-DEC-2007, integrated into UniProtKB/TrEMBL.
DT   04-DEC-2007, sequence version 1.
DT   22-APR-2020, entry version 90.
DE   SubName: Full=cDNA FLJ75039, highly similar to Homo sapiens aryl hydrocarbon receptor nuclear translocator (ARNT), transcript variant 3, mRNA {ECO:0000313|EMBL:BAF84394.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAF84394.1};
RN   [1] {ECO:0000313|EMBL:BAF84394.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Placenta {ECO:0000313|EMBL:BAF84394.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A.,
RA   Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y.,
RA   Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T.,
RA   Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|SAAS:SAAS00895706}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK291705; BAF84394.1; -; mRNA.
DR   RefSeq; NP_001184254.1; NM_001197325.1.
DR   PeptideAtlas; A8K6P0; -.
DR   PRIDE; A8K6P0; -.
DR   DNASU; 405; -.
DR   GeneID; 405; -.
DR   CTD; 405; -.
DR   eggNOG; ENOG410IQ5T; Eukaryota.
DR   eggNOG; ENOG410XVHF; LUCA.
DR   GenomeRNAi; 405; -.
DR   Genevisible; A8K6P0; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005667; C:transcription factor complex; IEA:InterPro.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 2.
DR   TIGRFAMs; TIGR00229; sensory_box; 1.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
PE   2: Evidence at transcript level;
KW   DNA-binding {ECO:0000256|SAAS:SAAS00929448};
KW   Nucleus {ECO:0000256|SAAS:SAAS00896251};
KW   Receptor {ECO:0000313|EMBL:BAF84394.1};
KW   Repeat {ECO:0000256|SAAS:SAAS01052434};
KW   Transcription {ECO:0000256|SAAS:SAAS00896243};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS00896243}.
FT   DOMAIN          74..127
FT                   /note="BHLH"
FT                   /evidence="ECO:0000259|PROSITE:PS50888"
FT   DOMAIN          146..220
FT                   /note="PAS"
FT                   /evidence="ECO:0000259|PROSITE:PS50112"
FT   DOMAIN          353..404
FT                   /note="PAS"
FT                   /evidence="ECO:0000259|PROSITE:PS50112"
FT   REGION          1..35
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          450..491
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          656..773
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        450..470
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        676..707
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        715..762
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   773 AA;  84721 MW;  37743C0A0AD918FA CRC64;
     MAATTANPEM TSDVPSLGPA IASGNSGPGI QGGGAIVQRA IKRRPGLDFD DDGEGNSKFL
     RCDDDQMSND KERFARENHS EIERRRRNKM TAYITELSDM VPTCSALARK PDKLTILRMA
     VSHMKSLRGT GNTSTDGSYK PSFLTDQELK HLILEAADGF LFIVSCETGR VVYVSDSVTP
     VLNQPQSEWF GSTLYDQVHP DDVDKLREQL STSENALTGR ILDLKTGTVK KEGQQSSMRM
     CMGSRRSFIC RMRCGSSSVD PVSVNRLSFV RNRCRNGLGS VKDGEPHFVV VHCTGYIKAW
     PPAGVSLPDD DPEAGQGSKF CLVAIGRLQV TSSPNCTDMS NVCQPTEFIS RHNIEGIFTF
     VDHRCVATVG YQPQELLGKN IVEFCHPEDQ QLLRDSFQQV VKLKGQVLSV MFRFRSKNQE
     WLWMRTSSFT FQNPYSDEIE YIICTNTNVK NSSQEPRPTL SNTIQRPQLG PTANLPLEMG
     SGQLAPGQQQ QQTELDMVPG RDGLASYNHS QVVQPVTTTG PEHSKPLEKS DGLFAQDRDP
     RFSEIYHNIN ADQSKGISSS TVPATQQLFS QGNTFPPTPR PAENFRNSGL APPVTIVQPS
     ASAGQMLAQI SRHSNPTQGA TPTWTPTTRS GFSAQVATQA TAKTRTSQFG VGSFQTPSSF
     SSMSLPGAPT ASPGAAAYPS LTNRGSNFAP ETGQTAGQFQ TRTAEGVGVW PQWQGQQPHH
     RSSSSEQHVQ QPPAQQPGQP EVFQEMLSML GDQSNSYNNE EFPDLTMFPP FSE
//
ID   B0AZM1_HUMAN            Unreviewed;       774 AA.
AC   B0AZM1;
DT   26-FEB-2008, integrated into UniProtKB/TrEMBL.
DT   26-FEB-2008, sequence version 1.
DT   22-APR-2020, entry version 91.
DE   SubName: Full=cDNA, FLJ79461, highly similar to Aryl hydrocarbon receptor nuclear translocator {ECO:0000313|EMBL:BAF98703.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAF98703.1};
RN   [1] {ECO:0000313|EMBL:BAF98703.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Brain {ECO:0000313|EMBL:BAF98703.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A.,
RA   Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y.,
RA   Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T.,
RA   Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project.";
RL   Submitted (JAN-2008) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|SAAS:SAAS00895706}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK315812; BAF98703.1; -; mRNA.
DR   RefSeq; NP_848514.1; NM_178427.2.
DR   IntAct; B0AZM1; 1.
DR   MINT; B0AZM1; -.
DR   PeptideAtlas; B0AZM1; -.
DR   PRIDE; B0AZM1; -.
DR   DNASU; 405; -.
DR   GeneID; 405; -.
DR   CTD; 405; -.
DR   eggNOG; ENOG410IQ5T; Eukaryota.
DR   eggNOG; ENOG410XVHF; LUCA.
DR   GenomeRNAi; 405; -.
DR   Genevisible; B0AZM1; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005667; C:transcription factor complex; IEA:InterPro.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 2.
DR   TIGRFAMs; TIGR00229; sensory_box; 1.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
PE   2: Evidence at transcript level;
KW   DNA-binding {ECO:0000256|SAAS:SAAS00929448};
KW   Nucleus {ECO:0000256|SAAS:SAAS00896251};
KW   Receptor {ECO:0000313|EMBL:BAF98703.1};
KW   Repeat {ECO:0000256|SAAS:SAAS01052434};
KW   Transcription {ECO:0000256|SAAS:SAAS00896243};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS00896243}.
FT   DOMAIN          74..127
FT                   /note="BHLH"
FT                   /evidence="ECO:0000259|PROSITE:PS50888"
FT   DOMAIN          146..220
FT                   /note="PAS"
FT                   /evidence="ECO:0000259|PROSITE:PS50112"
FT   DOMAIN          353..404
FT                   /note="PAS"
FT                   /evidence="ECO:0000259|PROSITE:PS50112"
FT   REGION          1..41
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          46..65
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          450..477
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          657..774
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        450..470
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        677..708
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        716..763
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   774 AA;  84994 MW;  7DB22949B18F149C CRC64;
     MAATTANPEM TSDVPSLGPA IASGNSGPGI QGGGAIVQRA IKRRPGLDFD DDGEGNSKFL
     RCDDDQMSND KERYARENHS EIERRRRNKM TAYITELSDM VPTCSALARK PDKLTILRMA
     VSHMKSLRGT GNTSTDGSYK PSFLTDQELK HLILEATDGF LFIVSCETGR VVYVSDSVTP
     VLNQPQSEWF GSTLYDQVHP DDVDKLREQL STSENALTGR ILDLKTGTVK KEGQQSSMRM
     CMGSRRSFIC RMRCGSSSVD PVSVNRLSFV RNRCRNGLGS VKDGEPHFVV VHCTGYIKAW
     PPAGVSLPDD DPEAGQGSKF CLVAIGRLQV TSSPNCTDMS NVCQPTEFIS RHNIEGIFTF
     VDHRCVATVG YQPQELLGKN IVEFCHPEDQ QLLRDSFQQV VKLKGQVLSV MFRFRSKNQE
     WLWMRTSSFT FQNPYSDEIE YIICTNTNVK NSSQEPRPTL SNTIQRPQLG PTANLPLEMG
     SGQLAPRQQQ QQTELDMVPG RDGLASYNHS QVVQPVTTTG PEHSKPLEKS DGLFAQDRDP
     RFSEIYHNIN ADQSKGISSS TVPATQQLFS QGNTFPPTPR PAENFRNSGL APPVTIVQPS
     ASAGQMLAQI SRHSNPTQGA TPTWTPTTRS GFSAQQVATQ ATAKTRTSQF GVGSFQTPSS
     FSSMSLPGAP TASPGAAAYP SLTNRGSNFA PETGQTAGQF QTRTAEGVGV WPQWQGQQPH
     HRSSSSEQHV QQPPAQQPGQ PEVFQEMLSM LGDQSNSYNN EEFPDLTMFP PFSE
//
ID   ARNT_HUMAN              Reviewed;         789 AA.
AC   P27540; B2R9H1; C4AMA1; F8WAP6; Q59ED4; Q5QP39; Q8NDC7;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1992, sequence version 1.
DT   22-APR-2020, entry version 216.
DE   RecName: Full=Aryl hydrocarbon receptor nuclear translocator;
DE            Short=ARNT protein;
DE   AltName: Full=Class E basic helix-loop-helix protein 2;
DE            Short=bHLHe2;
DE   AltName: Full=Dioxin receptor, nuclear translocator;
DE   AltName: Full=Hypoxia-inducible factor 1-beta;
DE            Short=HIF-1-beta;
DE            Short=HIF1-beta;
GN   Name=ARNT; Synonyms=BHLHE2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=1852076; DOI=10.1126/science.1852076;
RA   Hoffman E.C., Reyes H., Chu F.-F., Sander F., Conley L.H., Brooks B.A.,
RA   Hankinson O.;
RT   "Cloning of a factor required for activity of the Ah (dioxin) receptor.";
RL   Science 252:954-958(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Scheel J.;
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis, Thalamus, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Aortic endothelium;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLU-517.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   PROTEIN SEQUENCE OF 186-203 AND 662-694.
RX   PubMed=7539918; DOI=10.1073/pnas.92.12.5510;
RA   Wang G.L., Jiang B.-H., Rue E.A., Semenza G.L.;
RT   "Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer
RT   regulated by cellular O2 tension.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:5510-5514(1995).
RN   [10]
RP   CHARACTERIZATION.
RX   PubMed=1317062; DOI=10.1126/science.256.5060.1193;
RA   Reyes H., Reisz-Porszasz S., Hankinson O.;
RT   "Identification of the Ah receptor nuclear translocator protein (Arnt) as a
RT   component of the DNA binding form of the Ah receptor.";
RL   Science 256:1193-1195(1992).
RN   [11]
RP   DNA-BINDING, AND MUTAGENESIS OF ARG-91; ASN-93; HIS-94; GLU-98; ARG-99;
RP   ARG-101 AND ARG-102.
RX   PubMed=8621524; DOI=10.1074/jbc.271.15.8843;
RA   Bacsi S.G., Hankinson O.;
RT   "Functional characterization of DNA-binding domains of the subunits of the
RT   heterodimeric aryl hydrocarbon receptor complex imputing novel and
RT   canonical basic helix-loop-helix protein-DNA interactions.";
RL   J. Biol. Chem. 271:8843-8850(1996).
RN   [12]
RP   INTERACTION WITH NOCA7.
RX   PubMed=10395741; DOI=10.1006/abbi.1999.1282;
RA   Nguyen T.A., Hoivik D., Lee J.-E., Safe S.;
RT   "Interactions of nuclear receptor coactivator/corepressor proteins with the
RT   aryl hydrocarbon receptor complex.";
RL   Arch. Biochem. Biophys. 367:250-257(1999).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   INTERACTION WITH HIF1A.
RX   PubMed=20699359; DOI=10.1242/jcs.068122;
RA   Kalousi A., Mylonis I., Politou A.S., Chachami G., Paraskeva E., Simos G.;
RT   "Casein kinase 1 regulates human hypoxia-inducible factor HIF-1.";
RL   J. Cell Sci. 123:2976-2986(2010).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   INTERACTION WITH AHRR.
RX   PubMed=28904176; DOI=10.1074/jbc.m117.812974;
RA   Sakurai S., Shimizu T., Ohto U.;
RT   "The crystal structure of the AhRR-ARNT heterodimer reveals the structural
RT   basis of the repression of AhR-mediated transcription.";
RL   J. Biol. Chem. 292:17609-17616(2017).
RN   [19]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-58, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [20] {ECO:0000244|PDB:1X0O, ECO:0000244|PDB:2A24}
RP   STRUCTURE BY NMR OF 356-470 IN COMPLEX WITH EPAS1, SUBUNIT, AND INTERACTION
RP   WITH EPAS1.
RX   PubMed=16181639; DOI=10.1016/j.jmb.2005.08.043;
RA   Card P.B., Erbel P.J., Gardner K.H.;
RT   "Structural basis of ARNT PAS-B dimerization: use of a common beta-sheet
RT   interface for hetero- and homodimerization.";
RL   J. Mol. Biol. 353:664-677(2005).
RN   [21] {ECO:0000244|PDB:2K7S}
RP   STRUCTURE BY NMR OF 356-470.
RX   PubMed=19196990; DOI=10.1073/pnas.0808270106;
RA   Evans M.R., Card P.B., Gardner K.H.;
RT   "ARNT PAS-B has a fragile native state structure with an alternative beta-
RT   sheet register nearby in sequence space.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:2617-2622(2009).
RN   [22] {ECO:0000244|PDB:5V0L}
RP   X-RAY CRYSTALLOGRAPHY (4.00 ANGSTROMS) OF 70-346 IN COMPLEXES WITH AHR AND
RP   DNA, FUNCTION, INTERACTION WITH AHR, AND REGION.
RX   PubMed=28396409; DOI=10.1073/pnas.1617035114;
RA   Seok S.H., Lee W., Jiang L., Molugu K., Zheng A., Li Y., Park S.,
RA   Bradfield C.A., Xing Y.;
RT   "Structural hierarchy controlling dimerization and target DNA recognition
RT   in the AHR transcriptional complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:5431-5436(2017).
CC   -!- FUNCTION: Required for activity of the Ah (dioxin) receptor. This
CC       protein is required for the ligand-binding subunit to translocate from
CC       the cytosol to the nucleus after ligand binding. The complex then
CC       initiates transcription of genes involved in the activation of PAH
CC       procarcinogens. The heterodimer binds to core DNA sequence 5'-TACGTG-3'
CC       within the hypoxia response element (HRE) of target gene promoters and
CC       functions as a transcriptional regulator of the adaptive response to
CC       hypoxia (By similarity). The heterodimer ARNT:AHR binds to core DNA
CC       sequence 5'-TGCGTG-3' within the dioxin response element (DRE) of
CC       target gene promoters and activates their transcription
CC       (PubMed:28396409). {ECO:0000250|UniProtKB:P53762,
CC       ECO:0000269|PubMed:28396409}.
CC   -!- SUBUNIT: Monomer. Homodimer only upon binding to a DNA (By similarity).
CC       Efficient DNA binding requires dimerization with another bHLH protein.
CC       Interacts with TACC3 (By similarity). Interacts with HIF1A, EPAS1,
CC       NPAS1 and NPAS3; forms a heterodimer that binds core DNA sequence 5'-
CC       TACGTG-3' within the hypoxia response element (HRE) of target gene
CC       promoters (PubMed:20699359, PubMed:16181639) (By similarity). Forms a
CC       heterodimer with AHRR, as well as with other bHLH proteins (Probable).
CC       Interacts with NOCA7 (PubMed:10395741). Interacts with TACC3 (By
CC       similarity). Interacts with AHR; the heterodimer ARNT:AHR binds to core
CC       DNA sequence 5'-TGCGTG-3' within the dioxin response element (DRE) of
CC       target gene promoters and activates their transcription
CC       (PubMed:28396409). Interacts with SIM1 and NPAS4 (By similarity).
CC       {ECO:0000250, ECO:0000250|UniProtKB:P53762,
CC       ECO:0000269|PubMed:10395741, ECO:0000269|PubMed:16181639,
CC       ECO:0000269|PubMed:20699359, ECO:0000269|PubMed:28396409,
CC       ECO:0000305|PubMed:28904176}.
CC   -!- INTERACTION:
CC       P27540; P35869: AHR; NbExp=6; IntAct=EBI-80809, EBI-80780;
CC       P27540; Q99814: EPAS1; NbExp=7; IntAct=EBI-80809, EBI-447470;
CC       P27540; Q16665: HIF1A; NbExp=12; IntAct=EBI-80809, EBI-447269;
CC       P27540; Q8NI08: NCOA7; NbExp=2; IntAct=EBI-80809, EBI-80799;
CC       P27540; Q9Y618: NCOR2; NbExp=2; IntAct=EBI-80809, EBI-80830;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long;
CC         IsoId=P27540-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P27540-2; Sequence=VSP_002092;
CC       Name=3;
CC         IsoId=P27540-3; Sequence=VSP_036532, VSP_036533;
CC       Name=4;
CC         IsoId=P27540-4; Sequence=VSP_055030;
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD93114.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAD38953.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ARNTID223ch1q21.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/arnt/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M69238; AAA51777.1; -; mRNA.
DR   EMBL; Y18859; CAC21446.1; -; Genomic_DNA.
DR   EMBL; AJ251863; CAC21446.1; JOINED; Genomic_DNA.
DR   EMBL; AJ404851; CAC21446.1; JOINED; Genomic_DNA.
DR   EMBL; AJ404852; CAC21446.1; JOINED; Genomic_DNA.
DR   EMBL; AJ404853; CAC21446.1; JOINED; Genomic_DNA.
DR   EMBL; AJ404854; CAC21446.1; JOINED; Genomic_DNA.
DR   EMBL; AK290177; BAF82866.1; -; mRNA.
DR   EMBL; AK293027; BAF85716.1; -; mRNA.
DR   EMBL; AK313780; BAG36518.1; -; mRNA.
DR   EMBL; AB209877; BAD93114.1; ALT_INIT; mRNA.
DR   EMBL; AL834279; CAD38953.1; ALT_INIT; mRNA.
DR   EMBL; AY430083; AAQ96598.1; -; Genomic_DNA.
DR   EMBL; AL355860; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471121; EAW53510.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53513.1; -; Genomic_DNA.
DR   CCDS; CCDS65641.1; -. [P27540-3]
DR   CCDS; CCDS65642.1; -. [P27540-4]
DR   CCDS; CCDS970.1; -. [P27540-1]
DR   CCDS; CCDS971.1; -. [P27540-2]
DR   PIR; I59550; I59550.
DR   RefSeq; NP_001184254.1; NM_001197325.1.
DR   RefSeq; NP_001272964.1; NM_001286035.1. [P27540-3]
DR   RefSeq; NP_001272965.1; NM_001286036.1. [P27540-4]
DR   RefSeq; NP_001659.1; NM_001668.3. [P27540-1]
DR   RefSeq; NP_848514.1; NM_178427.2. [P27540-2]
DR   RefSeq; XP_016856778.1; XM_017001289.1. [P27540-3]
DR   PDB; 1D7G; Model; -; C=87-145.
DR   PDB; 1X0O; NMR; -; A=356-470.
DR   PDB; 2A24; NMR; -; B=358-465.
DR   PDB; 2ARN; Model; -; A=335-462.
DR   PDB; 2B02; X-ray; 1.50 A; A=354-470.
DR   PDB; 2HV1; NMR; -; A/B=356-470.
DR   PDB; 2K7S; NMR; -; A=356-470.
DR   PDB; 3F1N; X-ray; 1.48 A; B=356-470.
DR   PDB; 3F1O; X-ray; 1.60 A; B=356-470.
DR   PDB; 3F1P; X-ray; 1.17 A; B=356-470.
DR   PDB; 3H7W; X-ray; 1.65 A; B=356-470.
DR   PDB; 3H82; X-ray; 1.50 A; B=356-470.
DR   PDB; 4EQ1; X-ray; 1.60 A; A/B=357-464.
DR   PDB; 4GHI; X-ray; 1.50 A; B=356-470.
DR   PDB; 4GS9; X-ray; 1.72 A; B=356-470.
DR   PDB; 4H6J; X-ray; 1.52 A; B=357-470.
DR   PDB; 4LPZ; X-ray; 3.15 A; A/B=356-470.
DR   PDB; 4PKY; X-ray; 3.20 A; A/D=356-470.
DR   PDB; 4XT2; X-ray; 1.70 A; B/D=356-470.
DR   PDB; 5TBM; X-ray; 1.85 A; B=356-467.
DR   PDB; 5UFP; X-ray; 1.90 A; B=356-467.
DR   PDB; 5V0L; X-ray; 4.00 A; A=70-346.
DR   PDB; 6CZW; X-ray; 1.60 A; B=356-470.
DR   PDB; 6D09; X-ray; 1.85 A; B=356-470.
DR   PDB; 6D0B; X-ray; 1.60 A; B=356-470.
DR   PDB; 6D0C; X-ray; 1.50 A; B=356-470.
DR   PDBsum; 1D7G; -.
DR   PDBsum; 1X0O; -.
DR   PDBsum; 2A24; -.
DR   PDBsum; 2ARN; -.
DR   PDBsum; 2B02; -.
DR   PDBsum; 2HV1; -.
DR   PDBsum; 2K7S; -.
DR   PDBsum; 3F1N; -.
DR   PDBsum; 3F1O; -.
DR   PDBsum; 3F1P; -.
DR   PDBsum; 3H7W; -.
DR   PDBsum; 3H82; -.
DR   PDBsum; 4EQ1; -.
DR   PDBsum; 4GHI; -.
DR   PDBsum; 4GS9; -.
DR   PDBsum; 4H6J; -.
DR   PDBsum; 4LPZ; -.
DR   PDBsum; 4PKY; -.
DR   PDBsum; 4XT2; -.
DR   PDBsum; 5TBM; -.
DR   PDBsum; 5UFP; -.
DR   PDBsum; 5V0L; -.
DR   PDBsum; 6CZW; -.
DR   PDBsum; 6D09; -.
DR   PDBsum; 6D0B; -.
DR   PDBsum; 6D0C; -.
DR   SMR; P27540; -.
DR   BioGrid; 106898; 194.
DR   CORUM; P27540; -.
DR   DIP; DIP-30886N; -.
DR   ELM; P27540; -.
DR   IntAct; P27540; 36.
DR   MINT; P27540; -.
DR   STRING; 9606.ENSP00000351407; -.
DR   ChEMBL; CHEMBL5618; -.
DR   MoonDB; P27540; Predicted.
DR   iPTMnet; P27540; -.
DR   PhosphoSitePlus; P27540; -.
DR   BioMuta; ARNT; -.
DR   DMDM; 114163; -.
DR   EPD; P27540; -.
DR   jPOST; P27540; -.
DR   MassIVE; P27540; -.
DR   MaxQB; P27540; -.
DR   PaxDb; P27540; -.
DR   PeptideAtlas; P27540; -.
DR   PRIDE; P27540; -.
DR   ProteomicsDB; 30540; -.
DR   ProteomicsDB; 54398; -. [P27540-1]
DR   ProteomicsDB; 54399; -. [P27540-2]
DR   ProteomicsDB; 54400; -. [P27540-3]
DR   Antibodypedia; 916; 635 antibodies.
DR   DNASU; 405; -.
DR   Ensembl; ENST00000354396; ENSP00000346372; ENSG00000143437. [P27540-4]
DR   Ensembl; ENST00000358595; ENSP00000351407; ENSG00000143437. [P27540-1]
DR   Ensembl; ENST00000505755; ENSP00000427571; ENSG00000143437. [P27540-2]
DR   Ensembl; ENST00000515192; ENSP00000423851; ENSG00000143437. [P27540-3]
DR   GeneID; 405; -.
DR   KEGG; hsa:405; -.
DR   UCSC; uc001evr.2; human. [P27540-1]
DR   CTD; 405; -.
DR   DisGeNET; 405; -.
DR   GeneCards; ARNT; -.
DR   HGNC; HGNC:700; ARNT.
DR   HPA; ENSG00000143437; Low tissue specificity.
DR   MIM; 126110; gene.
DR   neXtProt; NX_P27540; -.
DR   OpenTargets; ENSG00000143437; -.
DR   PharmGKB; PA24994; -.
DR   eggNOG; ENOG410IQ5T; Eukaryota.
DR   eggNOG; ENOG410XVHF; LUCA.
DR   GeneTree; ENSGT00940000157585; -.
DR   HOGENOM; CLU_011864_1_1_1; -.
DR   InParanoid; P27540; -.
DR   KO; K09097; -.
DR   OMA; VSVWPQW; -.
DR   OrthoDB; 331262at2759; -.
DR   PhylomeDB; P27540; -.
DR   TreeFam; TF319983; -.
DR   Reactome; R-HSA-1234158; Regulation of gene expression by Hypoxia-inducible Factor.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-211945; Phase I - Functionalization of compounds.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   Reactome; R-HSA-211981; Xenobiotics.
DR   Reactome; R-HSA-8937144; Aryl hydrocarbon receptor signalling.
DR   SignaLink; P27540; -.
DR   SIGNOR; P27540; -.
DR   ChiTaRS; ARNT; human.
DR   EvolutionaryTrace; P27540; -.
DR   GeneWiki; Aryl_hydrocarbon_receptor_nuclear_translocator; -.
DR   GenomeRNAi; 405; -.
DR   Pharos; P27540; Tbio.
DR   PRO; PR:P27540; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P27540; protein.
DR   Bgee; ENSG00000143437; Expressed in endocervix and 220 other tissues.
DR   ExpressionAtlas; P27540; baseline and differential.
DR   Genevisible; P27540; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0090575; C:RNA polymerase II transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0017162; F:aryl hydrocarbon receptor binding; IPI:BHF-UCL.
DR   GO; GO:0035326; F:cis-regulatory region binding; IDA:MGI.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0004879; F:nuclear receptor activity; IEA:Ensembl.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; TAS:ProtInc.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; IEA:Ensembl.
DR   GO; GO:0001892; P:embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0042789; P:mRNA transcription by RNA polymerase II; IC:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IC:BHF-UCL.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IC:BHF-UCL.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; IC:BHF-UCL.
DR   GO; GO:0046886; P:positive regulation of hormone biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0033235; P:positive regulation of protein sumoylation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IDA:BHF-UCL.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; IC:BHF-UCL.
DR   GO; GO:0061418; P:regulation of transcription from RNA polymerase II promoter in response to hypoxia; TAS:Reactome.
DR   GO; GO:0043619; P:regulation of transcription from RNA polymerase II promoter in response to oxidative stress; IDA:BHF-UCL.
DR   GO; GO:0001666; P:response to hypoxia; IDA:BHF-UCL.
DR   GO; GO:0006351; P:transcription, DNA-templated; TAS:ProtInc.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 2.
DR   TIGRFAMs; TIGR00229; sensory_box; 1.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Direct protein sequencing; DNA-binding; Isopeptide bond; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:22814378"
FT   CHAIN           2..789
FT                   /note="Aryl hydrocarbon receptor nuclear translocator"
FT                   /id="PRO_0000127118"
FT   DOMAIN          89..142
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   DOMAIN          161..235
FT                   /note="PAS 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          349..419
FT                   /note="PAS 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          424..467
FT                   /note="PAC"
FT   REGION          88..128
FT                   /note="DNA-binding"
FT                   /evidence="ECO:0000269|PubMed:28396409"
FT   REGION          112..264
FT                   /note="Required for heterodimer formation with EPAS1"
FT                   /evidence="ECO:0000250|UniProtKB:P53762"
FT   REGION          112..168
FT                   /note="Required for heterodimer formation with HIF1A"
FT                   /evidence="ECO:0000250|UniProtKB:P53762"
FT   REGION          167..171
FT                   /note="Mediates the transcription activity and dimerization
FT                   of the AHR:ARNT complex"
FT                   /evidence="ECO:0000250|UniProtKB:P53762"
FT   COMPBIAS        99..102
FT                   /note="Poly-Arg"
FT   COMPBIAS        503..507
FT                   /note="Poly-Gln"
FT   COMPBIAS        710..769
FT                   /note="Gln-rich"
FT   COMPBIAS        738..741
FT                   /note="Poly-Ser"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000244|PubMed:22814378"
FT   MOD_RES         77
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   CROSSLNK        58
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         1..9
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11230166"
FT                   /id="VSP_036532"
FT   VAR_SEQ         77..91
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1852076"
FT                   /id="VSP_002092"
FT   VAR_SEQ         319..323
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11230166"
FT                   /id="VSP_036533"
FT   VAR_SEQ         601..602
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_055030"
FT   VARIANT         430
FT                   /note="R -> Q (in dbSNP:rs2229175)"
FT                   /id="VAR_024280"
FT   VARIANT         511
FT                   /note="D -> N (in dbSNP:rs1805133)"
FT                   /id="VAR_014819"
FT   VARIANT         517
FT                   /note="D -> E (in dbSNP:rs10305741)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_018906"
FT   VARIANT         706
FT                   /note="P -> L (in dbSNP:rs2275237)"
FT                   /id="VAR_020189"
FT   MUTAGEN         91
FT                   /note="R->A: Diminishes DNA interaction."
FT                   /evidence="ECO:0000269|PubMed:8621524"
FT   MUTAGEN         93
FT                   /note="N->A: Diminishes DNA interaction."
FT                   /evidence="ECO:0000269|PubMed:8621524"
FT   MUTAGEN         94
FT                   /note="H->A: Severely diminishes DNA interaction."
FT                   /evidence="ECO:0000269|PubMed:8621524"
FT   MUTAGEN         98
FT                   /note="E->A: Severely diminishes DNA interaction."
FT                   /evidence="ECO:0000269|PubMed:8621524"
FT   MUTAGEN         99
FT                   /note="R->A: Diminishes DNA interaction."
FT                   /evidence="ECO:0000269|PubMed:8621524"
FT   MUTAGEN         101
FT                   /note="R->A: Severely diminishes DNA interaction."
FT                   /evidence="ECO:0000269|PubMed:8621524"
FT   MUTAGEN         102
FT                   /note="R->A: Severely diminishes DNA interaction."
FT                   /evidence="ECO:0000269|PubMed:8621524"
FT   CONFLICT        627
FT                   /note="R -> H (in Ref. 3; BAG36518)"
FT                   /evidence="ECO:0000305"
FT   STRAND          356..358
FT                   /evidence="ECO:0000244|PDB:2K7S"
FT   STRAND          362..367
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   STRAND          371..376
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   HELIX           380..384
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   HELIX           388..390
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   TURN            391..393
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   HELIX           396..399
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   TURN            402..404
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   HELIX           405..415
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   TURN            416..420
FT                   /evidence="ECO:0000244|PDB:3F1N"
FT   STRAND          423..430
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   STRAND          436..446
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   TURN            449..451
FT                   /evidence="ECO:0000244|PDB:2B02"
FT   STRAND          456..463
FT                   /evidence="ECO:0000244|PDB:3F1P"
SQ   SEQUENCE   789 AA;  86636 MW;  2E278F8E62BFBF6D CRC64;
     MAATTANPEM TSDVPSLGPA IASGNSGPGI QGGGAIVQRA IKRRPGLDFD DDGEGNSKFL
     RCDDDQMSND KERFARSDDE QSSADKERLA RENHSEIERR RRNKMTAYIT ELSDMVPTCS
     ALARKPDKLT ILRMAVSHMK SLRGTGNTST DGSYKPSFLT DQELKHLILE AADGFLFIVS
     CETGRVVYVS DSVTPVLNQP QSEWFGSTLY DQVHPDDVDK LREQLSTSEN ALTGRILDLK
     TGTVKKEGQQ SSMRMCMGSR RSFICRMRCG SSSVDPVSVN RLSFVRNRCR NGLGSVKDGE
     PHFVVVHCTG YIKAWPPAGV SLPDDDPEAG QGSKFCLVAI GRLQVTSSPN CTDMSNVCQP
     TEFISRHNIE GIFTFVDHRC VATVGYQPQE LLGKNIVEFC HPEDQQLLRD SFQQVVKLKG
     QVLSVMFRFR SKNQEWLWMR TSSFTFQNPY SDEIEYIICT NTNVKNSSQE PRPTLSNTIQ
     RPQLGPTANL PLEMGSGQLA PRQQQQQTEL DMVPGRDGLA SYNHSQVVQP VTTTGPEHSK
     PLEKSDGLFA QDRDPRFSEI YHNINADQSK GISSSTVPAT QQLFSQGNTF PPTPRPAENF
     RNSGLAPPVT IVQPSASAGQ MLAQISRHSN PTQGATPTWT PTTRSGFSAQ QVATQATAKT
     RTSQFGVGSF QTPSSFSSMS LPGAPTASPG AAAYPSLTNR GSNFAPETGQ TAGQFQTRTA
     EGVGVWPQWQ GQQPHHRSSS SEQHVQQPPA QQPGQPEVFQ EMLSMLGDQS NSYNNEEFPD
     LTMFPPFSE
//
ID   Q53F30_HUMAN            Unreviewed;       315 AA.
AC   Q53F30;
DT   24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT   24-MAY-2005, sequence version 1.
DT   22-APR-2020, entry version 97.
DE   SubName: Full=Aryl hydrocarbon receptor nuclear translocator isoform 2 variant {ECO:0000313|EMBL:BAD97179.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD97179.1};
RN   [1] {ECO:0000313|EMBL:BAD97179.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Kidney {ECO:0000313|EMBL:BAD97179.1};
RX   PubMed=8125298; DOI=10.1016/0378-1119(94)90802-8;
RA   Maruyama K., Sugano S.;
RT   "Oligo-capping: a simple method to replace the cap structure of eukaryotic
RT   mRNAs with oligoribonucleotides.";
RL   Gene 138:171-174(1994).
RN   [2] {ECO:0000313|EMBL:BAD97179.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Kidney {ECO:0000313|EMBL:BAD97179.1};
RX   PubMed=9373149; DOI=10.1016/S0378-1119(97)00411-3;
RA   Suzuki Y., Yoshitomo K., Maruyama K., Suyama A., Sugano S.;
RT   "Construction and characterization of a full length-enriched and a 5'-end-
RT   enriched cDNA library.";
RL   Gene 200:149-156(1997).
RN   [3] {ECO:0000313|EMBL:BAD97179.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Kidney {ECO:0000313|EMBL:BAD97179.1};
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|SAAS:SAAS00895706}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK223459; BAD97179.1; -; mRNA.
DR   RefSeq; NP_001272964.1; NM_001286035.1.
DR   RefSeq; NP_001272965.1; NM_001286036.1.
DR   SMR; Q53F30; -.
DR   PeptideAtlas; Q53F30; -.
DR   GeneID; 405; -.
DR   CTD; 405; -.
DR   eggNOG; ENOG410IQ5T; Eukaryota.
DR   eggNOG; ENOG410XVHF; LUCA.
DR   GenomeRNAi; 405; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005667; C:transcription factor complex; IEA:InterPro.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 1.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00091; PAS; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 1.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 1.
PE   2: Evidence at transcript level;
KW   Nucleus {ECO:0000256|SAAS:SAAS00896251};
KW   Receptor {ECO:0000313|EMBL:BAD97179.1};
KW   Transcription {ECO:0000256|SAAS:SAAS00896243};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS00896243}.
FT   DOMAIN          89..142
FT                   /note="BHLH"
FT                   /evidence="ECO:0000259|PROSITE:PS50888"
FT   DOMAIN          161..235
FT                   /note="PAS"
FT                   /evidence="ECO:0000259|PROSITE:PS50112"
FT   REGION          1..97
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        43..97
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:BAD97179.1"
FT   NON_TER         315
FT                   /evidence="ECO:0000313|EMBL:BAD97179.1"
SQ   SEQUENCE   315 AA;  34822 MW;  40F79278697E6EB8 CRC64;
     MAATTANPEM TSDVPSLVPA IASGNSGPGI QGGGAIVQRA IKRRPGLDFD DDGEGNSKFL
     RCDDDQMSND KERFARSDDE QSSADKERLA RENHSEIERR RRNKMTAYIT ELSDMVPTCS
     ALARKPDKLT ILRMAVSHMK SLRGTGNTST DGSYKPSFLT DQELKHLILE AADGFLFIVS
     CETGRVVYVS DSVTPVLNQP QSEWFGSTLY DQVHPDDVDK LREQLSTSEN ALTGRILDLK
     TGTVKKEGQQ SSMRMCMGSR RSFICRMRCG SSSVDPVSVN RLSFVRNRCR NGLGSVKDGE
     PHFVVVHCTG YIKAW
//
ID   L8B567_HUMAN            Unreviewed;       823 AA.
AC   L8B567;
DT   03-APR-2013, integrated into UniProtKB/TrEMBL.
DT   03-APR-2013, sequence version 1.
DT   22-APR-2020, entry version 53.
DE   SubName: Full=ATL1-gamma zinc finger protein {ECO:0000313|EMBL:BAM78284.1};
DE   SubName: Full=B-cell CLL/lymphoma 11B (Zinc finger protein), isoform CRA_a {ECO:0000313|EMBL:EAW81662.1};
GN   Name=ATL1-gamma {ECO:0000313|EMBL:BAM78284.1};
GN   Synonyms=BCL11B {ECO:0000313|EMBL:EAW81662.1};
GN   ORFNames=hCG_1657560 {ECO:0000313|EMBL:EAW81662.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAM78284.1};
RN   [1] {ECO:0000313|EMBL:EAW81662.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:BAM78284.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thymus {ECO:0000313|EMBL:BAM78284.1};
RA   Isobe M., Ozawa T.;
RT   "Identification of the human candidate tumor suppressor gene (ATL1)
RT   encoding novel Zinc finger protein.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:EAW81662.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB057669; BAM78284.1; -; mRNA.
DR   EMBL; CH471061; EAW81662.1; -; Genomic_DNA.
DR   RefSeq; NP_075049.1; NM_022898.2.
DR   Antibodypedia; 27407; 253 antibodies.
DR   GeneID; 64919; -.
DR   CTD; 64919; -.
DR   EuPathDB; HostDB:ENSG00000127152.17; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   ChiTaRS; BCL11B; human.
DR   GenomeRNAi; 64919; -.
DR   Bgee; ENSG00000127152; Expressed in forebrain and 166 other tissues.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF00096; zf-C2H2; 5.
DR   SMART; SM00355; ZnF_C2H2; 6.
DR   SUPFAM; SSF57667; SSF57667; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 6.
PE   2: Evidence at transcript level;
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00042}.
FT   DOMAIN          150..173
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          356..383
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          384..411
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          725..752
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          753..775
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          783..806
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   REGION          299..357
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          400..512
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          582..609
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          666..723
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        329..354
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        440..456
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        457..476
FT                   /note="Acidic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        479..493
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        666..681
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   823 AA;  88476 MW;  589266E55A4C367E CRC64;
     MSRRKQGNPQ HLSQRELITP EADHVEAAIL EEDEGLEIEE PSGLGLMVGG PDPDLLTCGQ
     CQMNFPLGDI LVFIEHKRKQ CGGSLGACYD KALDKDSPPP SSRSELRKVS EPVEIGIQVT
     PDEDDHLLSP TKGICPKQEN IAGKDEPSSY ICTTCKQPFN SAWFLLQHAQ NTHGFRIYLE
     PGPASSSLTP RLTIPPPLGP EAVAQSPLMN FLGDSNPFNL LRMTGPILRD HPGFGEGRLP
     GTPPLFSPPP RHHLDPHRLS AEEMGLVAQH PSAFDRVMRL NPMAIDSPAM DFSRRLRELA
     GNSSTPPPVS PGRGNPMHRL LNPFQPSPKS PFLSTPPLPP MPPGGTPPPQ PPAKSKSCEF
     CGKTFKFQSN LIVHRRSHTG EKPYKCQLCD HACSQASKLK RHMKTHMHKA GSLAGRSDDG
     LSAASSPEPG TSELAGEGLK AADGDFRHHE SDPSLGHEPE EEDEEEEEEE EELLLENESR
     PESSFSMDSE LSRNRENGGG GVPGVPGAGG GAAKALADEK ALVLGKVMEN VGLGALPQYG
     ELLADKQKRG AFLKRAAGGG DAGDDDDAGG CGDAGAGGAV NGRGGGFAPG TEPFPGLFPR
     KPAPLPSPGL NSAAKRIKVE KDLELPPAAL IPSENVYSQW LVGYAASRHF MKDPFLGFTD
     ARQSPFATSS EHSSENGSLR FSTPPGDLLD GGLSGRSGTA SGGSTPHLGG PGPGRPSSKE
     GRRSDTCEYC GKVFKNCSNL TVHRRSHTGE RPYKCELCNY ACAQSSKLTR HMKTHGQIGK
     EVYRCDICQM PFSVYSTLEK HMKKWHGEHL LTNDVKIEQA ERS
//
ID   L8B7P7_HUMAN            Unreviewed;       894 AA.
AC   L8B7P7;
DT   03-APR-2013, integrated into UniProtKB/TrEMBL.
DT   03-APR-2013, sequence version 1.
DT   22-APR-2020, entry version 66.
DE   SubName: Full=ATL1-alpha zinc finger protein {ECO:0000313|EMBL:BAM78282.1};
DE   SubName: Full=B-cell CLL/lymphoma 11B (Zinc finger protein), isoform CRA_b {ECO:0000313|EMBL:EAW81663.1};
GN   Name=ATL1-alpha {ECO:0000313|EMBL:BAM78282.1};
GN   Synonyms=BCL11B {ECO:0000313|EMBL:EAW81663.1};
GN   ORFNames=hCG_1657560 {ECO:0000313|EMBL:EAW81663.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAM78282.1};
RN   [1] {ECO:0000313|EMBL:BAM78282.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thymus {ECO:0000313|EMBL:BAM78282.1};
RA   Isobe M., Ozawa T.;
RT   "Identification of the human candidate tumor suppressor gene (ATL1-alpha)
RT   encoding novel Zinc finger protein.";
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2] {ECO:0000313|EMBL:EAW81663.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [3] {ECO:0000313|EMBL:EAW81663.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB041218; BAM78282.1; -; mRNA.
DR   EMBL; CH471061; EAW81663.1; -; Genomic_DNA.
DR   RefSeq; NP_612808.1; NM_138576.3.
DR   Antibodypedia; 27407; 253 antibodies.
DR   GeneID; 64919; -.
DR   KEGG; hsa:64919; -.
DR   CTD; 64919; -.
DR   EuPathDB; HostDB:ENSG00000127152.17; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   KO; K22046; -.
DR   OMA; CPKQENM; -.
DR   OrthoDB; 224109at2759; -.
DR   ChiTaRS; BCL11B; human.
DR   GenomeRNAi; 64919; -.
DR   Bgee; ENSG00000127152; Expressed in forebrain and 166 other tissues.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0046632; P:alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0021902; P:commitment of neuronal cell to specific neuron type in forebrain; IEA:Ensembl.
DR   GO; GO:0003382; P:epithelial cell morphogenesis; IEA:Ensembl.
DR   GO; GO:0003334; P:keratinocyte development; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0071678; P:olfactory bulb axon guidance; IEA:Ensembl.
DR   GO; GO:0043368; P:positive T cell selection; IEA:Ensembl.
DR   GO; GO:0031077; P:post-embryonic camera-type eye development; IEA:Ensembl.
DR   GO; GO:0010837; P:regulation of keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; IEA:Ensembl.
DR   GO; GO:0045664; P:regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0021773; P:striatal medium spiny neuron differentiation; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0033153; P:T cell receptor V(D)J recombination; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF00096; zf-C2H2; 5.
DR   SMART; SM00355; ZnF_C2H2; 6.
DR   SUPFAM; SSF57667; SSF57667; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 6.
PE   2: Evidence at transcript level;
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00042}.
FT   DOMAIN          221..244
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          427..454
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          455..482
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          796..823
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          824..846
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          854..877
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   REGION          370..428
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          471..583
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          653..680
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          737..794
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        400..425
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        511..527
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        528..547
FT                   /note="Acidic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        550..564
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        737..752
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   894 AA;  95519 MW;  DF6C467AE2EEC122 CRC64;
     MSRRKQGNPQ HLSQRELITP EADHVEAAIL EEDEGLEIEE PSGLGLMVGG PDPDLLTCGQ
     CQMNFPLGDI LVFIEHKRKQ CGGSLGACYD KALDKDSPPP SSRSELRKVS EPVEIGIQVT
     PDEDDHLLSP TKGICPKQEN IAGPCRPAQL PAVAPIAASS HPHSSVITSP LRALGALPPC
     LPLPCCSARP VSGDGTQGEG QTEAPFGCQC QLSGKDEPSS YICTTCKQPF NSAWFLLQHA
     QNTHGFRIYL EPGPASSSLT PRLTIPPPLG PEAVAQSPLM NFLGDSNPFN LLRMTGPILR
     DHPGFGEGRL PGTPPLFSPP PRHHLDPHRL SAEEMGLVAQ HPSAFDRVMR LNPMAIDSPA
     MDFSRRLREL AGNSSTPPPV SPGRGNPMHR LLNPFQPSPK SPFLSTPPLP PMPPGGTPPP
     QPPAKSKSCE FCGKTFKFQS NLIVHRRSHT GEKPYKCQLC DHACSQASKL KRHMKTHMHK
     AGSLAGRSDD GLSAASSPEP GTSELAGEGL KAADGDFRHH ESDPSLGHEP EEEDEEEEEE
     EEELLLENES RPESSFSMDS ELSRNRENGG GGVPGVPGAG GGAAKALADE KALVLGKVME
     NVGLGALPQY GELLADKQKR GAFLKRAAGG GDAGDDDDAG GCGDAGAGGA VNGRGGGFAP
     GTEPFPGLFP RKPAPLPSPG LNSAAKRIKV EKDLELPPAA LIPSENVYSQ WLVGYAASRH
     FMKDPFLGFT DARQSPFATS SEHSSENGSL RFSTPPGDLL DGGLSGRSGT ASGGSTPHLG
     GPGPGRPSSK EGRRSDTCEY CGKVFKNCSN LTVHRRSHTG ERPYKCELCN YACAQSSKLT
     RHMKTHGQIG KEVYRCDICQ MPFSVYSTLE KHMKKWHGEH LLTNDVKIEQ AERS
//
ID   L8B862_HUMAN            Unreviewed;       822 AA.
AC   L8B862;
DT   03-APR-2013, integrated into UniProtKB/TrEMBL.
DT   03-APR-2013, sequence version 1.
DT   22-APR-2020, entry version 30.
DE   SubName: Full=ATL1-delta zinc finger protein {ECO:0000313|EMBL:BAM78285.1};
GN   Name=ATL1-delta {ECO:0000313|EMBL:BAM78285.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAM78285.1};
RN   [1] {ECO:0000313|EMBL:BAM78285.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thymus {ECO:0000313|EMBL:BAM78285.1};
RA   Isobe M., Ozawa T.;
RT   "Identification of the human candidate tumor suppressor gene (ATL1)
RT   encoding novel Zinc finger protein.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB057670; BAM78285.1; -; mRNA.
DR   RefSeq; NP_001269167.1; NM_001282238.1.
DR   PeptideAtlas; L8B862; -.
DR   PRIDE; L8B862; -.
DR   GeneID; 64919; -.
DR   CTD; 64919; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   ChiTaRS; BCL11B; human.
DR   GenomeRNAi; 64919; -.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF00096; zf-C2H2; 5.
DR   SMART; SM00355; ZnF_C2H2; 6.
DR   SUPFAM; SSF57667; SSF57667; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 6.
PE   2: Evidence at transcript level;
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00042}.
FT   DOMAIN          149..172
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          355..382
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          383..410
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          724..751
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          752..774
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          782..805
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   REGION          298..356
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          399..511
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          581..608
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          665..722
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        328..353
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        439..455
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        456..475
FT                   /note="Acidic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        478..492
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        665..680
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   822 AA;  88378 MW;  7E91064476C479E3 CRC64;
     MSRRKQGNPQ HLSQRELITQ ADHVEAAILE EDEGLEIEEP SGLGLMVGGP DPDLLTCGQC
     QMNFPLGDIL VFIEHKRKQC GGSLGACYDK ALDKDSPPPS SRSELRKVSE PVEIGIQVTP
     DEDDHLLSPT KGICPKQENI AGKDEPSSYI CTTCKQPFNS AWFLLQHAQN THGFRIYLEP
     GPASSSLTPR LTIPPPLGPE AVAQSPLMNF LGDSNPFNLL RMTGPILRDH PGFGEGRLPG
     TPPLFSPPPR HHLDPHRLSA EEMGLVAQHP SAFDRVMRLN PMAIDSPAMD FSRRLRELAG
     NSSTPPPVSP GRGNPMHRLL NPFQPSPKSP FLSTPPLPPM PPGGTPPPQP PAKSKSCEFC
     GKTFKFQSNL IVHRRSHTGE KPYKCQLCDH ACSQASKLKR HMKTHMHKAG SLAGRSDDGL
     SAASSPEPGT SELAGEGLKA ADGDFRHHES DPSLGHEPEE EDEEEEEEEE ELLLENESRP
     ESSFSMDSEL SRNRENGGGG VPGVPGAGGG AAKALADEKA LVLGKVMENV GLGALPQYGE
     LLADKQKRGA FLKRAAGGGD AGDDDDAGGC GDAGAGGAVN GRGGGFAPGT EPFPGLFPRK
     PAPLPSPGLN SAAKRIKVEK DLELPPAALI PSENVYSQWL VGYAASRHFM KDPFLGFTDA
     RQSPFATSSE HSSENGSLRF STPPGDLLDG GLSGRSGTAS GGSTPHLGGP GPGRPSSKEG
     RRSDTCEYCG KVFKNCSNLT VHRRSHTGER PYKCELCNYA CAQSSKLTRH MKTHGQIGKE
     VYRCDICQMP FSVYSTLEKH MKKWHGEHLL TNDVKIEQAE RS
//
ID   L8B8F6_HUMAN            Unreviewed;       893 AA.
AC   L8B8F6;
DT   03-APR-2013, integrated into UniProtKB/TrEMBL.
DT   03-APR-2013, sequence version 1.
DT   22-APR-2020, entry version 35.
DE   SubName: Full=ATL1 zinc finger protein {ECO:0000313|EMBL:BAM78533.1};
DE   SubName: Full=ATL1-beta zinc finger protein {ECO:0000313|EMBL:BAM78283.1};
GN   Name=ATL1 {ECO:0000313|EMBL:BAM78533.1};
GN   Synonyms=ATL1-beta {ECO:0000313|EMBL:BAM78283.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAM78533.1};
RN   [1] {ECO:0000313|EMBL:BAM78533.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thymus {ECO:0000313|EMBL:BAM78283.1};
RA   Isobe M., Ozawa T.;
RT   "Identification of the human candidate tumor suppressor gene (ATL1)
RT   encoding novel Zinc finger protein.";
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB057668; BAM78283.1; -; mRNA.
DR   EMBL; AB041222; BAM78533.1; -; Genomic_DNA.
DR   RefSeq; NP_001269166.1; NM_001282237.1.
DR   SMR; L8B8F6; -.
DR   PeptideAtlas; L8B8F6; -.
DR   PRIDE; L8B8F6; -.
DR   GeneID; 64919; -.
DR   CTD; 64919; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   ChiTaRS; ATL1; human.
DR   GenomeRNAi; 64919; -.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF00096; zf-C2H2; 5.
DR   SMART; SM00355; ZnF_C2H2; 6.
DR   SUPFAM; SSF57667; SSF57667; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 6.
PE   2: Evidence at transcript level;
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00042}.
FT   DOMAIN          220..243
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          426..453
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          454..481
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          795..822
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          823..845
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   DOMAIN          853..876
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50157"
FT   REGION          369..427
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          470..582
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          652..679
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          736..793
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        399..424
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        510..526
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        527..546
FT                   /note="Acidic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        549..563
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        736..751
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   893 AA;  95421 MW;  36BAB220D2FB1FB5 CRC64;
     MSRRKQGNPQ HLSQRELITQ ADHVEAAILE EDEGLEIEEP SGLGLMVGGP DPDLLTCGQC
     QMNFPLGDIL VFIEHKRKQC GGSLGACYDK ALDKDSPPPS SRSELRKVSE PVEIGIQVTP
     DEDDHLLSPT KGICPKQENI AGPCRPAQLP AVAPIAASSH PHSSVITSPL RALGALPPCL
     PLPCCSARPV SGDGTQGEGQ TEAPFGCQCQ LSGKDEPSSY ICTTCKQPFN SAWFLLQHAQ
     NTHGFRIYLE PGPASSSLTP RLTIPPPLGP EAVAQSPLMN FLGDSNPFNL LRMTGPILRD
     HPGFGEGRLP GTPPLFSPPP RHHLDPHRLS AEEMGLVAQH PSAFDRVMRL NPMAIDSPAM
     DFSRRLRELA GNSSTPPPVS PGRGNPMHRL LNPFQPSPKS PFLSTPPLPP MPPGGTPPPQ
     PPAKSKSCEF CGKTFKFQSN LIVHRRSHTG EKPYKCQLCD HACSQASKLK RHMKTHMHKA
     GSLAGRSDDG LSAASSPEPG TSELAGEGLK AADGDFRHHE SDPSLGHEPE EEDEEEEEEE
     EELLLENESR PESSFSMDSE LSRNRENGGG GVPGVPGAGG GAAKALADEK ALVLGKVMEN
     VGLGALPQYG ELLADKQKRG AFLKRAAGGG DAGDDDDAGG CGDAGAGGAV NGRGGGFAPG
     TEPFPGLFPR KPAPLPSPGL NSAAKRIKVE KDLELPPAAL IPSENVYSQW LVGYAASRHF
     MKDPFLGFTD ARQSPFATSS EHSSENGSLR FSTPPGDLLD GGLSGRSGTA SGGSTPHLGG
     PGPGRPSSKE GRRSDTCEYC GKVFKNCSNL TVHRRSHTGE RPYKCELCNY ACAQSSKLTR
     HMKTHGQIGK EVYRCDICQM PFSVYSTLEK HMKKWHGEHL LTNDVKIEQA ERS
//
ID   BC11B_HUMAN             Reviewed;         894 AA.
AC   Q9C0K0; Q9H162;
DT   01-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   22-APR-2020, entry version 159.
DE   RecName: Full=B-cell lymphoma/leukemia 11B;
DE            Short=BCL-11B;
DE   AltName: Full=B-cell CLL/lymphoma 11B;
DE   AltName: Full=COUP-TF-interacting protein 2;
DE   AltName: Full=Radiation-induced tumor suppressor gene 1 protein;
DE            Short=hRit1;
GN   Name=BCL11B; Synonyms=CTIP2, RIT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=11719382; DOI=10.1182/blood.v98.12.3413;
RA   Satterwhite E., Sonoki T., Willis T.G., Harder L., Nowak R., Arriola E.L.,
RA   Liu H., Price H.P., Gesk S., Steinemann D., Schlegelberger B., Oscier D.G.,
RA   Siebert R., Tucker P.W., Dyer M.J.;
RT   "The BCL11 gene family: involvement of BCL11A in lymphoid malignancies.";
RL   Blood 98:3413-3420(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Thymus;
RX   PubMed=12565905; DOI=10.1016/s0006-291x(02)03069-3;
RA   Wakabayashi Y., Inoue J., Takahashi Y., Matsuki A., Kosugi-Okano H.,
RA   Shinbo T., Mishima Y., Niwa O., Kominami R.;
RT   "Homozygous deletions and point mutations of the Rit1/Bcl11b gene in gamma-
RT   ray induced mouse thymic lymphomas.";
RL   Biochem. Biophys. Res. Commun. 301:598-603(2003).
RN   [3]
RP   FUNCTION, AND INTERACTION WITH EP300.
RX   PubMed=16809611; DOI=10.1182/blood-2006-05-021790;
RA   Cismasiu V.B., Ghanta S., Duque J., Albu D.I., Chen H.M., Kasturi R.,
RA   Avram D.;
RT   "BCL11B participates in the activation of IL2 gene expression in CD4+ T
RT   lymphocytes.";
RL   Blood 108:2695-2702(2006).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97; THR-120; SER-256;
RP   THR-260; SER-277; SER-358; THR-376; SER-381; SER-398; THR-417; SER-483;
RP   SER-488; SER-496; SER-497; SER-678 AND SER-765, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [5]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-851, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-381, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [7]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-591 AND LYS-887, SUMOYLATION
RP   [LARGE SCALE ANALYSIS] AT LYS-137 (ISOFORM 2), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [8]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-137; LYS-591; LYS-617; LYS-686;
RP   LYS-723 AND LYS-887, SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-137 (ISOFORM
RP   2), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [9]
RP   VARIANT [LARGE SCALE ANALYSIS] PRO-331.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [10]
RP   VARIANTS VAL-32 AND SER-229.
RX   PubMed=21220648; DOI=10.1001/archneurol.2010.351;
RA   Daoud H., Valdmanis P.N., Gros-Louis F., Belzil V., Spiegelman D.,
RA   Henrion E., Diallo O., Desjarlais A., Gauthier J., Camu W., Dion P.A.,
RA   Rouleau G.A.;
RT   "Resequencing of 29 candidate genes in patients with familial and sporadic
RT   amyotrophic lateral sclerosis.";
RL   Arch. Neurol. 68:587-593(2011).
RN   [11]
RP   FUNCTION, INTERACTION WITH EP300, INVOLVEMENT IN IMD49, VARIANT IMD49
RP   LYS-441, AND CHARACTERIZATION OF VARIANT IMD49 LYS-441.
RX   PubMed=27959755; DOI=10.1056/nejmoa1509164;
RA   Punwani D., Zhang Y., Yu J., Cowan M.J., Rana S., Kwan A., Adhikari A.N.,
RA   Lizama C.O., Mendelsohn B.A., Fahl S.P., Chellappan A., Srinivasan R.,
RA   Brenner S.E., Wiest D.L., Puck J.M.;
RT   "Multisystem anomalies in severe combined immunodeficiency with mutant
RT   BCL11B.";
RL   N. Engl. J. Med. 375:2165-2176(2016).
RN   [12]
RP   INVOLVEMENT IN IDDSFTA, VARIANT IMD49 LYS-807, AND VARIANT IDDSFTA
RP   499-GLU--SER-894 DEL.
RX   PubMed=29985992; DOI=10.1093/brain/awy173;
RA   Lessel D., Gehbauer C., Bramswig N.C., Schluth-Bolard C.,
RA   Venkataramanappa S., van Gassen K.L.I., Hempel M., Haack T.B., Baresic A.,
RA   Genetti C.A., Funari M.F.A., Lessel I., Kuhlmann L., Simon R., Liu P.,
RA   Denecke J., Kuechler A., de Kruijff I., Shoukier M., Lek M., Mullen T.,
RA   Luedecke H.J., Lerario A.M., Kobbe R., Krieger T., Demeer B., Lebrun M.,
RA   Keren B., Nava C., Buratti J., Afenjar A., Shinawi M., Guillen Sacoto M.J.,
RA   Gauthier J., Hamdan F.F., Laberge A.M., Campeau P.M., Louie R.J.,
RA   Cathey S.S., Prinz I., Jorge A.A.L., Terhal P.A., Lenhard B., Wieczorek D.,
RA   Strom T.M., Agrawal P.B., Britsch S., Tolosa E., Kubisch C.;
RT   "BCL11B mutations in patients affected by a neurodevelopmental disorder
RT   with reduced type 2 innate lymphoid cells.";
RL   Brain 141:2299-2311(2018).
CC   -!- FUNCTION: Key regulator of both differentiation and survival of T-
CC       lymphocytes during thymocyte development in mammals. Essential in
CC       controlling the responsiveness of hematopoietic stem cells to
CC       chemotactic signals by modulating the expression of the receptors CCR7
CC       and CCR9, which direct the movement of progenitor cells from the bone
CC       marrow to the thymus (PubMed:27959755). Is a regulator of IL2 promoter
CC       and enhances IL2 expression in activated CD4(+) T-lymphocytes
CC       (PubMed:16809611). Tumor-suppressor that represses transcription
CC       through direct, TFCOUP2-independent binding to a GC-rich response
CC       element (By similarity). May also function in the P53-signaling pathway
CC       (By similarity). {ECO:0000250|UniProtKB:Q99PV8,
CC       ECO:0000269|PubMed:16809611, ECO:0000269|PubMed:27959755}.
CC   -!- SUBUNIT: Interacts with TFCOUP1, SIRT1, ARP1 and EAR2 (By similarity).
CC       Interacts with EP300; the interaction is detected in activated T-
CC       lymphocytes, but not under resting conditions (PubMed:27959755).
CC       {ECO:0000250|UniProtKB:Q99PV8, ECO:0000269|PubMed:27959755}.
CC   -!- INTERACTION:
CC       Q9C0K0; Q13547: HDAC1; NbExp=3; IntAct=EBI-6597578, EBI-301834;
CC       Q9C0K0; Q92769: HDAC2; NbExp=3; IntAct=EBI-6597578, EBI-301821;
CC       Q9C0K0; O43463: SUV39H1; NbExp=3; IntAct=EBI-6597578, EBI-349968;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Alpha;
CC         IsoId=Q9C0K0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9C0K0-2; Sequence=VSP_009565;
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain and in malignant T-cell
CC       lines derived from patients with adult T-cell leukemia/lymphoma.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000250}.
CC   -!- DISEASE: Immunodeficiency 49 (IMD49) [MIM:617237]: A form of severe
CC       combined immunodeficiency characterized by severe T-cell lymphopenia,
CC       no detectable T-cell receptor excision circles, no naive helper CD4+ T-
CC       cells, and impaired T-cell proliferative response. In addition to
CC       primary immunodeficiency, affected individuals manifest multiple
CC       abnormal systemic features, including severe delayed psychomotor
CC       development, intellectual disability, spastic quadriplegia, and
CC       craniofacial abnormalities. {ECO:0000269|PubMed:27959755,
CC       ECO:0000269|PubMed:29985992}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Intellectual developmental disorder with speech delay,
CC       dysmorphic facies, and T-cell abnormalities (IDDSFTA) [MIM:618092]: An
CC       autosomal dominant developmental disorder with onset in first months of
CC       life, and characterized by delayed psychomotor development with
CC       intellectual disability and speech delay. Additional features include
CC       autistic features, attention deficit-hyperactivity disorder, anxiety,
CC       and other behavioral abnormalities. Some patients suffer from recurrent
CC       infections, asthma and allergies. {ECO:0000269|PubMed:29985992}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be due to exon skipping. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BCL11BID392.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ404614; CAC17726.1; -; mRNA.
DR   EMBL; AB043584; BAB32731.1; -; mRNA.
DR   CCDS; CCDS9949.1; -. [Q9C0K0-2]
DR   CCDS; CCDS9950.1; -. [Q9C0K0-1]
DR   RefSeq; NP_001269166.1; NM_001282237.1.
DR   RefSeq; NP_001269167.1; NM_001282238.1.
DR   RefSeq; NP_075049.1; NM_022898.2. [Q9C0K0-2]
DR   RefSeq; NP_612808.1; NM_138576.3. [Q9C0K0-1]
DR   SMR; Q9C0K0; -.
DR   BioGrid; 122343; 21.
DR   DIP; DIP-44025N; -.
DR   IntAct; Q9C0K0; 9.
DR   MINT; Q9C0K0; -.
DR   STRING; 9606.ENSP00000349723; -.
DR   iPTMnet; Q9C0K0; -.
DR   MetOSite; Q9C0K0; -.
DR   PhosphoSitePlus; Q9C0K0; -.
DR   BioMuta; BCL11B; -.
DR   DMDM; 44887723; -.
DR   jPOST; Q9C0K0; -.
DR   MassIVE; Q9C0K0; -.
DR   MaxQB; Q9C0K0; -.
DR   PaxDb; Q9C0K0; -.
DR   PeptideAtlas; Q9C0K0; -.
DR   PRIDE; Q9C0K0; -.
DR   ProteomicsDB; 80066; -. [Q9C0K0-1]
DR   ProteomicsDB; 80067; -. [Q9C0K0-2]
DR   Antibodypedia; 27407; 253 antibodies.
DR   Ensembl; ENST00000345514; ENSP00000280435; ENSG00000127152. [Q9C0K0-2]
DR   Ensembl; ENST00000357195; ENSP00000349723; ENSG00000127152. [Q9C0K0-1]
DR   GeneID; 64919; -.
DR   KEGG; hsa:64919; -.
DR   UCSC; uc001yga.5; human. [Q9C0K0-1]
DR   CTD; 64919; -.
DR   DisGeNET; 64919; -.
DR   GeneCards; BCL11B; -.
DR   HGNC; HGNC:13222; BCL11B.
DR   HPA; ENSG00000127152; Tissue enhanced (brain, lymphoid tissue, skin).
DR   MalaCards; BCL11B; -.
DR   MIM; 606558; gene.
DR   MIM; 617237; phenotype.
DR   MIM; 618092; phenotype.
DR   neXtProt; NX_Q9C0K0; -.
DR   OpenTargets; ENSG00000127152; -.
DR   PharmGKB; PA25301; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   GeneTree; ENSGT00940000161060; -.
DR   InParanoid; Q9C0K0; -.
DR   KO; K22046; -.
DR   OMA; CPKQENM; -.
DR   PhylomeDB; Q9C0K0; -.
DR   TreeFam; TF318131; -.
DR   SIGNOR; Q9C0K0; -.
DR   ChiTaRS; BCL11B; human.
DR   GeneWiki; BCL11B; -.
DR   GenomeRNAi; 64919; -.
DR   Pharos; Q9C0K0; Tbio.
DR   PRO; PR:Q9C0K0; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q9C0K0; protein.
DR   Bgee; ENSG00000127152; Expressed in forebrain and 166 other tissues.
DR   ExpressionAtlas; Q9C0K0; baseline and differential.
DR   Genevisible; Q9C0K0; HS.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0046632; P:alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0021902; P:commitment of neuronal cell to specific neuron type in forebrain; IEA:Ensembl.
DR   GO; GO:0003382; P:epithelial cell morphogenesis; IEA:Ensembl.
DR   GO; GO:0035701; P:hematopoietic stem cell migration; IMP:UniProtKB.
DR   GO; GO:0003334; P:keratinocyte development; IEA:Ensembl.
DR   GO; GO:0097535; P:lymphoid lineage cell migration into thymus; IMP:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0071678; P:olfactory bulb axon guidance; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:MGI.
DR   GO; GO:0043368; P:positive T cell selection; IEA:Ensembl.
DR   GO; GO:0031077; P:post-embryonic camera-type eye development; IEA:Ensembl.
DR   GO; GO:0010837; P:regulation of keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; IEA:Ensembl.
DR   GO; GO:0045664; P:regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IBA:GO_Central.
DR   GO; GO:0021773; P:striatal medium spiny neuron differentiation; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0033153; P:T cell receptor V(D)J recombination; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF00096; zf-C2H2; 5.
DR   SMART; SM00355; ZnF_C2H2; 6.
DR   SUPFAM; SSF57667; SSF57667; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 6.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Disease mutation; Isopeptide bond;
KW   Mental retardation; Metal-binding; Methylation; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Repressor; SCID; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..894
FT                   /note="B-cell lymphoma/leukemia 11B"
FT                   /id="PRO_0000047104"
FT   ZN_FING         221..251
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         427..454
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         455..482
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         796..823
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         824..853
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         854..884
FT                   /note="C2H2-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   COMPBIAS        529..553
FT                   /note="Glu-rich"
FT   COMPBIAS        569..661
FT                   /note="Gly-rich"
FT   MOD_RES         97
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         110
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PV8"
FT   MOD_RES         120
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         129
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PV8"
FT   MOD_RES         256
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         260
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         277
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         293
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PV8"
FT   MOD_RES         322
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PV8"
FT   MOD_RES         358
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         376
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         381
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:24275569"
FT   MOD_RES         398
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         401
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PV8"
FT   MOD_RES         406
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PV8"
FT   MOD_RES         417
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         483
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         488
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         496
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         497
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         678
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         754
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PV8"
FT   MOD_RES         765
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         772
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PV8"
FT   MOD_RES         851
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   CROSSLNK        137
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        591
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25755297,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        617
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        686
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        723
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        887
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25755297,
FT                   ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         143..213
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11719382"
FT                   /id="VSP_009565"
FT   VARIANT         32
FT                   /note="E -> V (in a patient with amyotrophic lateral
FT                   sclerosis)"
FT                   /evidence="ECO:0000269|PubMed:21220648"
FT                   /id="VAR_065741"
FT   VARIANT         229
FT                   /note="P -> S (in a patient with amyotrophic lateral
FT                   sclerosis; dbSNP:rs749837100)"
FT                   /evidence="ECO:0000269|PubMed:21220648"
FT                   /id="VAR_065742"
FT   VARIANT         331
FT                   /note="S -> P (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035554"
FT   VARIANT         441
FT                   /note="N -> K (in IMD49; loss of stimulation of T-
FT                   lymphocyte development; dominant negative loss of
FT                   activation of IL2 expression; results in reduced binding to
FT                   known canonical promoters and abnormal binding to novel DNA
FT                   sites not recognized by the wild-type protein; no effect on
FT                   interaction with EP300; dbSNP:rs750610248)"
FT                   /evidence="ECO:0000269|PubMed:27959755"
FT                   /id="VAR_078423"
FT   VARIANT         499..894
FT                   /note="Missing (in IDDSFTA)"
FT                   /evidence="ECO:0000269|PubMed:29985992"
FT                   /id="VAR_081174"
FT   VARIANT         807
FT                   /note="N -> K (in IMD49)"
FT                   /evidence="ECO:0000269|PubMed:29985992"
FT                   /id="VAR_081175"
FT   CROSSLNK        Q9C0K0-2:137
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25755297,
FT                   ECO:0000244|PubMed:28112733"
SQ   SEQUENCE   894 AA;  95519 MW;  DF6C467AE2EEC122 CRC64;
     MSRRKQGNPQ HLSQRELITP EADHVEAAIL EEDEGLEIEE PSGLGLMVGG PDPDLLTCGQ
     CQMNFPLGDI LVFIEHKRKQ CGGSLGACYD KALDKDSPPP SSRSELRKVS EPVEIGIQVT
     PDEDDHLLSP TKGICPKQEN IAGPCRPAQL PAVAPIAASS HPHSSVITSP LRALGALPPC
     LPLPCCSARP VSGDGTQGEG QTEAPFGCQC QLSGKDEPSS YICTTCKQPF NSAWFLLQHA
     QNTHGFRIYL EPGPASSSLT PRLTIPPPLG PEAVAQSPLM NFLGDSNPFN LLRMTGPILR
     DHPGFGEGRL PGTPPLFSPP PRHHLDPHRL SAEEMGLVAQ HPSAFDRVMR LNPMAIDSPA
     MDFSRRLREL AGNSSTPPPV SPGRGNPMHR LLNPFQPSPK SPFLSTPPLP PMPPGGTPPP
     QPPAKSKSCE FCGKTFKFQS NLIVHRRSHT GEKPYKCQLC DHACSQASKL KRHMKTHMHK
     AGSLAGRSDD GLSAASSPEP GTSELAGEGL KAADGDFRHH ESDPSLGHEP EEEDEEEEEE
     EEELLLENES RPESSFSMDS ELSRNRENGG GGVPGVPGAG GGAAKALADE KALVLGKVME
     NVGLGALPQY GELLADKQKR GAFLKRAAGG GDAGDDDDAG GCGDAGAGGA VNGRGGGFAP
     GTEPFPGLFP RKPAPLPSPG LNSAAKRIKV EKDLELPPAA LIPSENVYSQ WLVGYAASRH
     FMKDPFLGFT DARQSPFATS SEHSSENGSL RFSTPPGDLL DGGLSGRSGT ASGGSTPHLG
     GPGPGRPSSK EGRRSDTCEY CGKVFKNCSN LTVHRRSHTG ERPYKCELCN YACAQSSKLT
     RHMKTHGQIG KEVYRCDICQ MPFSVYSTLE KHMKKWHGEH LLTNDVKIEQ AERS
//
ID   BIRC3_HUMAN             Reviewed;         604 AA.
AC   Q13489; Q16628; Q9HC27; Q9UP46;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   22-APR-2020, entry version 205.
DE   RecName: Full=Baculoviral IAP repeat-containing protein 3;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:21931591, ECO:0000269|PubMed:23453969};
DE   AltName: Full=Apoptosis inhibitor 2;
DE            Short=API2;
DE   AltName: Full=Cellular inhibitor of apoptosis 2;
DE            Short=C-IAP2 {ECO:0000303|PubMed:8548810};
DE   AltName: Full=IAP homolog C;
DE   AltName: Full=Inhibitor of apoptosis protein 1;
DE            Short=hIAP-1;
DE            Short=hIAP1;
DE   AltName: Full=RING finger protein 49;
DE   AltName: Full=RING-type E3 ubiquitin transferase BIRC3 {ECO:0000305};
DE   AltName: Full=TNFR2-TRAF-signaling complex protein 1;
GN   Name=BIRC3; Synonyms=API2, MIHC, RNF49;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8548810; DOI=10.1016/0092-8674(95)90149-3;
RA   Rothe M., Pan M.-G., Henzel W.J., Ayres T.M., Goeddel D.V.;
RT   "The TNFR2-TRAF signaling complex contains two novel proteins related to
RT   baculoviral inhibitor of apoptosis proteins.";
RL   Cell 83:1243-1252(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=8552191; DOI=10.1038/379349a0;
RA   Liston P., Roy N., Tamai K., Lefebvre C., Baird S., Cherton-Horvat G.,
RA   Farahani R., McLean M., Ikeda J., Mackenzie A., Korneluk R.G.;
RT   "Suppression of apoptosis in mammalian cells by NAIP and a related family
RT   of IAP genes.";
RL   Nature 379:349-353(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal liver;
RX   PubMed=8643514; DOI=10.1073/pnas.93.10.4974;
RA   Uren A.G., Pakusch M., Hawkins C.J., Puls K.L., Vaux D.L.;
RT   "Cloning and expression of apoptosis inhibitory protein homologs that
RT   function to inhibit apoptosis and/or bind tumor necrosis factor receptor-
RT   associated factors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:4974-4978(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10233894;
RA   Horrevoets A.J.G., Fontijn R.D., van Zonneveld A.J., de Vries C.J.M.,
RA   ten Cate J.W., Pannekoek H.;
RT   "Vascular endothelial genes that are responsive to tumor necrosis factor-
RT   alpha in vitro are expressed in atherosclerotic lesions, including
RT   inhibitor of apoptosis protein-1, stannin, and two novel genes.";
RL   Blood 93:3418-3431(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-260 AND LYS-401.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 362-441.
RX   PubMed=11066071;
RX   DOI=10.1002/1098-2264(2000)9999:9999<::aid-gcc1036>3.0.co;2-i;
RA   Baens M., Steyls A., Dierlamm J., De Wolf-Peeters C., Marynen P.;
RT   "Structure of the MLT gene and molecular characterization of the genomic
RT   breakpoint junctions in the t(11;18)(q21;q21) of marginal zone B-cell
RT   lymphomas of MALT type.";
RL   Genes Chromosomes Cancer 29:281-291(2000).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15665297;
RA   Samuel T., Okada K., Hyer M., Welsh K., Zapata J.M., Reed J.C.;
RT   "cIAP1 Localizes to the nuclear compartment and modulates the cell cycle.";
RL   Cancer Res. 65:210-218(2005).
RN   [9]
RP   REVIEW ON FUNCTION.
RX   PubMed=18414036; DOI=10.4161/cc.7.8.5783;
RA   Dubrez-Daloz L., Dupoux A., Cartier J.;
RT   "IAPs: more than just inhibitors of apoptosis proteins.";
RL   Cell Cycle 7:1036-1046(2008).
RN   [10]
RP   REVIEW ON FUNCTION.
RX   PubMed=20888210; DOI=10.1016/j.ceb.2010.08.025;
RA   Lopez J., Meier P.;
RT   "To fight or die - inhibitor of apoptosis proteins at the crossroad of
RT   innate immunity and death.";
RL   Curr. Opin. Cell Biol. 22:872-881(2010).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=20651737; DOI=10.1038/nrc2889;
RA   Gyrd-Hansen M., Meier P.;
RT   "IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and
RT   cancer.";
RL   Nat. Rev. Cancer 10:561-574(2010).
RN   [12]
RP   REVIEW ON FUNCTION.
RX   PubMed=21447281;
RA   Damgaard R.B., Gyrd-Hansen M.;
RT   "Inhibitor of apoptosis (IAP) proteins in regulation of inflammation and
RT   innate immunity.";
RL   Discov. Med. 11:221-231(2011).
RN   [13]
RP   ACTIVITY REGULATION, AND INTERACTION WITH USP19.
RX   PubMed=21849505; DOI=10.1074/jbc.m111.282020;
RA   Mei Y., Hahn A.A., Hu S., Yang X.;
RT   "The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2.";
RL   J. Biol. Chem. 286:35380-35387(2011).
RN   [14]
RP   FUNCTION IN THE UBIQUITINATION OF RIPK1; RIPK2; RIPK3 AND RIPK4,
RP   INTERACTION WITH RIPK1; RIPK2; RIPK3 AND RIPK4, AND CATALYTIC ACTIVITY.
RX   PubMed=21931591; DOI=10.1371/journal.pone.0022356;
RA   Bertrand M.J., Lippens S., Staes A., Gilbert B., Roelandt R., De Medts J.,
RA   Gevaert K., Declercq W., Vandenabeele P.;
RT   "cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin
RT   chains to receptor interacting proteins kinases 1 to 4 (RIP1-4).";
RL   PLoS ONE 6:E22356-E22356(2011).
RN   [15]
RP   REVIEW ON FUNCTION.
RX   PubMed=22095281; DOI=10.1038/cdd.2011.163;
RA   Darding M., Meier P.;
RT   "IAPs: guardians of RIPK1.";
RL   Cell Death Differ. 19:58-66(2012).
RN   [16]
RP   FUNCTION IN IKBKE UBIQUITINATION, AND CATALYTIC ACTIVITY.
RX   PubMed=23453969; DOI=10.1016/j.celrep.2013.01.031;
RA   Zhou A.Y., Shen R.R., Kim E., Lock Y.J., Xu M., Chen Z.J., Hahn W.C.;
RT   "IKKepsilon-mediated tumorigenesis requires K63-linked polyubiquitination
RT   by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex.";
RL   Cell Rep. 3:724-733(2013).
CC   -!- FUNCTION: Multi-functional protein which regulates not only caspases
CC       and apoptosis, but also modulates inflammatory signaling and immunity,
CC       mitogenic kinase signaling and cell proliferation, as well as cell
CC       invasion and metastasis. Acts as an E3 ubiquitin-protein ligase
CC       regulating NF-kappa-B signaling and regulates both canonical and non-
CC       canonical NF-kappa-B signaling by acting in opposite directions: acts
CC       as a positive regulator of the canonical pathway and suppresses
CC       constitutive activation of non-canonical NF-kappa-B signaling. The
CC       target proteins for its E3 ubiquitin-protein ligase activity include:
CC       RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and
CC       BCL10. Acts as an important regulator of innate immune signaling via
CC       regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and
CC       RIG-I like receptors (RLRs), collectively referred to as pattern
CC       recognition receptors (PRRs). Protects cells from spontaneous formation
CC       of the ripoptosome, a large multi-protein complex that has the
CC       capability to kill cancer cells in a caspase-dependent and caspase-
CC       independent manner. Suppresses ripoptosome formation by ubiquitinating
CC       RIPK1 and CASP8. {ECO:0000269|PubMed:21931591,
CC       ECO:0000269|PubMed:23453969}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000269|PubMed:21931591,
CC         ECO:0000269|PubMed:23453969};
CC   -!- ACTIVITY REGULATION: USP19 regulates the stability of BIRC3/c-IAP2 by
CC       preventing its ubiquitination. {ECO:0000269|PubMed:21849505}.
CC   -!- SUBUNIT: Interacts with DIABLO/SMAC and with PRSS25; these interactions
CC       inhibit apoptotic suppressor activity. The BIR motifs region interacts
CC       with TNF receptor associated factors 1 and 2 (TRAF1 and TRAF2) to form
CC       a heteromeric complex, which is then recruited to the tumor necrosis
CC       factor receptor 2 (TNFR2). Interaction with TRAF2 is required for
CC       ubiquitination of IKBKE, degradation of NFKBIA and activation of NF-
CC       kappa-B. Interacts with RIP1, RIP2, RIP3, RIP4 and USP19.
CC       {ECO:0000269|PubMed:21849505, ECO:0000269|PubMed:21931591}.
CC   -!- INTERACTION:
CC       Q13489; P55211: CASP9; NbExp=2; IntAct=EBI-517709, EBI-516799;
CC       Q13489; Q13546: RIPK1; NbExp=3; IntAct=EBI-517709, EBI-358507;
CC       Q13489; O43353: RIPK2; NbExp=3; IntAct=EBI-517709, EBI-358522;
CC       Q13489; Q9Y572: RIPK3; NbExp=3; IntAct=EBI-517709, EBI-298250;
CC       Q13489; P57078: RIPK4; NbExp=3; IntAct=EBI-517709, EBI-4422308;
CC       Q13489; Q13077: TRAF1; NbExp=2; IntAct=EBI-517709, EBI-359224;
CC       Q13489; Q12933: TRAF2; NbExp=7; IntAct=EBI-517709, EBI-355744;
CC       Q13489; P62837: UBE2D2; NbExp=2; IntAct=EBI-517709, EBI-347677;
CC       Q13489; P61088: UBE2N; NbExp=2; IntAct=EBI-517709, EBI-1052908;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15665297}. Nucleus
CC       {ECO:0000269|PubMed:15665297}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in fetal lung, and kidney. In the
CC       adult, expression is mainly seen in lymphoid tissues, including spleen,
CC       thymus and peripheral blood lymphocytes.
CC   -!- PTM: Auto-ubiquitinated and degraded by the proteasome in apoptotic
CC       cells.
CC   -!- DISEASE: Note=A chromosomal aberration involving BIRC3 is recurrent in
CC       low-grade mucosa-associated lymphoid tissue (MALT lymphoma).
CC       Translocation t(11;18)(q21;q21) with MALT1. This translocation is found
CC       in approximately 50% of cytogenetically abnormal low-grade MALT
CC       lymphoma.
CC   -!- SIMILARITY: Belongs to the IAP family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BIRC3ID239.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/birc3/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L49432; AAC41943.1; -; mRNA.
DR   EMBL; U45878; AAC50371.1; -; mRNA.
DR   EMBL; U37546; AAC50507.1; -; mRNA.
DR   EMBL; AF070674; AAC83232.1; -; mRNA.
DR   EMBL; AY764389; AAU88144.1; -; Genomic_DNA.
DR   EMBL; BC037420; AAH37420.1; -; mRNA.
DR   EMBL; AF178945; AAG09369.1; -; Genomic_DNA.
DR   CCDS; CCDS8315.1; -.
DR   PIR; S68449; S68449.
DR   RefSeq; NP_001156.1; NM_001165.4.
DR   RefSeq; NP_892007.1; NM_182962.2.
DR   RefSeq; XP_016873132.1; XM_017017643.1.
DR   PDB; 2UVL; X-ray; 1.91 A; A/B=244-337.
DR   PDB; 3EB5; X-ray; 2.00 A; A=536-604.
DR   PDB; 3EB6; X-ray; 3.40 A; A=536-604.
DR   PDB; 3M0A; X-ray; 2.61 A; D=26-99.
DR   PDB; 3M0D; X-ray; 2.80 A; D=26-99.
DR   PDBsum; 2UVL; -.
DR   PDBsum; 3EB5; -.
DR   PDBsum; 3EB6; -.
DR   PDBsum; 3M0A; -.
DR   PDBsum; 3M0D; -.
DR   SMR; Q13489; -.
DR   BioGrid; 106827; 82.
DR   CORUM; Q13489; -.
DR   DIP; DIP-33720N; -.
DR   IntAct; Q13489; 40.
DR   MINT; Q13489; -.
DR   STRING; 9606.ENSP00000263464; -.
DR   BindingDB; Q13489; -.
DR   ChEMBL; CHEMBL5335; -.
DR   GuidetoPHARMACOLOGY; 2792; -.
DR   MEROPS; I32.007; -.
DR   iPTMnet; Q13489; -.
DR   PhosphoSitePlus; Q13489; -.
DR   BioMuta; BIRC3; -.
DR   DMDM; 2497236; -.
DR   EPD; Q13489; -.
DR   jPOST; Q13489; -.
DR   MassIVE; Q13489; -.
DR   MaxQB; Q13489; -.
DR   PaxDb; Q13489; -.
DR   PeptideAtlas; Q13489; -.
DR   PRIDE; Q13489; -.
DR   ProteomicsDB; 59483; -.
DR   Antibodypedia; 1035; 682 antibodies.
DR   Ensembl; ENST00000263464; ENSP00000263464; ENSG00000023445.
DR   Ensembl; ENST00000532808; ENSP00000432907; ENSG00000023445.
DR   Ensembl; ENST00000615299; ENSP00000481903; ENSG00000023445.
DR   GeneID; 330; -.
DR   KEGG; hsa:330; -.
DR   UCSC; uc001pgx.5; human.
DR   CTD; 330; -.
DR   DisGeNET; 330; -.
DR   GeneCards; BIRC3; -.
DR   HGNC; HGNC:591; BIRC3.
DR   HPA; ENSG00000023445; Tissue enhanced (intestine, lymphoid tissue).
DR   MalaCards; BIRC3; -.
DR   MIM; 601721; gene.
DR   neXtProt; NX_Q13489; -.
DR   OpenTargets; ENSG00000023445; -.
DR   Orphanet; 52417; MALT lymphoma.
DR   PharmGKB; PA25360; -.
DR   eggNOG; KOG1101; Eukaryota.
DR   eggNOG; ENOG410YPNM; LUCA.
DR   GeneTree; ENSGT00940000154175; -.
DR   HOGENOM; CLU_016347_1_1_1; -.
DR   InParanoid; Q13489; -.
DR   KO; K16060; -.
DR   OMA; WLEAECN; -.
DR   OrthoDB; 1340284at2759; -.
DR   PhylomeDB; Q13489; -.
DR   TreeFam; TF105356; -.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168927; TICAM1, RIP1-mediated IKK complex recruitment.
DR   Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   Reactome; R-HSA-5668541; TNFR2 non-canonical NF-kB pathway.
DR   Reactome; R-HSA-5675482; Regulation of necroptotic cell death.
DR   Reactome; R-HSA-5676594; TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1.
DR   SignaLink; Q13489; -.
DR   SIGNOR; Q13489; -.
DR   ChiTaRS; BIRC3; human.
DR   EvolutionaryTrace; Q13489; -.
DR   GeneWiki; Baculoviral_IAP_repeat-containing_protein_3; -.
DR   GenomeRNAi; 330; -.
DR   Pharos; Q13489; Tchem.
DR   PRO; PR:Q13489; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q13489; protein.
DR   Bgee; ENSG00000023445; Expressed in epithelium of nasopharynx and 171 other tissues.
DR   ExpressionAtlas; Q13489; baseline and differential.
DR   Genevisible; Q13489; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0016740; F:transferase activity; EXP:Reactome.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; TAS:Reactome.
DR   GO; GO:1990001; P:inhibition of cysteine-type endopeptidase activity involved in apoptotic process; IBA:GO_Central.
DR   GO; GO:0002756; P:MyD88-independent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IBA:GO_Central.
DR   GO; GO:0060546; P:negative regulation of necroptotic process; IBA:GO_Central.
DR   GO; GO:0038061; P:NIK/NF-kappaB signaling; TAS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; TAS:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:2000116; P:regulation of cysteine-type endopeptidase activity; TAS:UniProtKB.
DR   GO; GO:0050727; P:regulation of inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045088; P:regulation of innate immune response; TAS:UniProtKB.
DR   GO; GO:0060544; P:regulation of necroptotic process; IMP:UniProtKB.
DR   GO; GO:0070424; P:regulation of nucleotide-binding oligomerization domain containing signaling pathway; TAS:UniProtKB.
DR   GO; GO:0039535; P:regulation of RIG-I signaling pathway; TAS:UniProtKB.
DR   GO; GO:0034121; P:regulation of toll-like receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; TAS:Reactome.
DR   CDD; cd00022; BIR; 3.
DR   InterPro; IPR001370; BIR_rpt.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR001841; Znf_RING.
DR   Pfam; PF00653; BIR; 3.
DR   Pfam; PF00619; CARD; 1.
DR   SMART; SM00238; BIR; 3.
DR   SMART; SM00114; CARD; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   PROSITE; PS01282; BIR_REPEAT_1; 3.
DR   PROSITE; PS50143; BIR_REPEAT_2; 3.
DR   PROSITE; PS50209; CARD; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Chromosomal rearrangement; Cytoplasm;
KW   Metal-binding; Nucleus; Polymorphism; Reference proteome; Repeat;
KW   Transferase; Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..604
FT                   /note="Baculoviral IAP repeat-containing protein 3"
FT                   /id="PRO_0000122349"
FT   REPEAT          29..96
FT                   /note="BIR 1"
FT   REPEAT          169..235
FT                   /note="BIR 2"
FT   REPEAT          255..322
FT                   /note="BIR 3"
FT   DOMAIN          439..529
FT                   /note="CARD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00046"
FT   ZN_FING         557..592
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   METAL           292
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00029"
FT   METAL           295
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00029"
FT   METAL           312
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00029"
FT   METAL           319
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00029"
FT   SITE            442..443
FT                   /note="Breakpoint for translocation to form BIRC3-MALT1"
FT   VARIANT         260
FT                   /note="K -> R (in dbSNP:rs2276113)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_021069"
FT   VARIANT         386
FT                   /note="V -> M (in dbSNP:rs12222256)"
FT                   /id="VAR_049536"
FT   VARIANT         401
FT                   /note="R -> K (in dbSNP:rs17881197)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_021070"
FT   CONFLICT        18
FT                   /note="N -> Y (in Ref. 4; AAC83232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        119
FT                   /note="N -> H (in Ref. 2; AAC50371)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        153
FT                   /note="D -> E (in Ref. 2; AAC50371)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        163
FT                   /note="H -> P (in Ref. 2; AAC50371)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        165
FT                   /note="A -> P (in Ref. 2; AAC50371)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        191
FT                   /note="K -> R (in Ref. 2; AAC50371)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        364
FT                   /note="F -> L (in Ref. 2; AAC50371)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        552
FT                   /note="Q -> P (in Ref. 2; AAC50371)"
FT                   /evidence="ECO:0000305"
FT   HELIX           28..34
FT                   /evidence="ECO:0000244|PDB:3M0A"
FT   HELIX           35..38
FT                   /evidence="ECO:0000244|PDB:3M0A"
FT   HELIX           47..52
FT                   /evidence="ECO:0000244|PDB:3M0A"
FT   STRAND          55..57
FT                   /evidence="ECO:0000244|PDB:3M0A"
FT   STRAND          64..66
FT                   /evidence="ECO:0000244|PDB:3M0A"
FT   TURN            67..69
FT                   /evidence="ECO:0000244|PDB:3M0A"
FT   HELIX           82..89
FT                   /evidence="ECO:0000244|PDB:3M0A"
FT   TURN            94..97
FT                   /evidence="ECO:0000244|PDB:3M0A"
FT   HELIX           250..252
FT                   /evidence="ECO:0000244|PDB:2UVL"
FT   HELIX           255..260
FT                   /evidence="ECO:0000244|PDB:2UVL"
FT   HELIX           261..264
FT                   /evidence="ECO:0000244|PDB:2UVL"
FT   HELIX           273..278
FT                   /evidence="ECO:0000244|PDB:2UVL"
FT   STRAND          281..285
FT                   /evidence="ECO:0000244|PDB:2UVL"
FT   TURN            286..288
FT                   /evidence="ECO:0000244|PDB:2UVL"
FT   STRAND          289..292
FT                   /evidence="ECO:0000244|PDB:2UVL"
FT   TURN            293..295
FT                   /evidence="ECO:0000244|PDB:2UVL"
FT   STRAND          298..301
FT                   /evidence="ECO:0000244|PDB:2UVL"
FT   HELIX           308..315
FT                   /evidence="ECO:0000244|PDB:2UVL"
FT   HELIX           320..334
FT                   /evidence="ECO:0000244|PDB:2UVL"
FT   HELIX           544..555
FT                   /evidence="ECO:0000244|PDB:3EB5"
FT   TURN            558..560
FT                   /evidence="ECO:0000244|PDB:3EB5"
FT   STRAND          561..564
FT                   /evidence="ECO:0000244|PDB:3EB5"
FT   STRAND          567..570
FT                   /evidence="ECO:0000244|PDB:3EB5"
FT   STRAND          575..577
FT                   /evidence="ECO:0000244|PDB:3EB5"
FT   TURN            579..581
FT                   /evidence="ECO:0000244|PDB:3EB5"
FT   HELIX           582..584
FT                   /evidence="ECO:0000244|PDB:3EB5"
FT   STRAND          589..591
FT                   /evidence="ECO:0000244|PDB:3EB5"
FT   STRAND          597..600
FT                   /evidence="ECO:0000244|PDB:3EB5"
SQ   SEQUENCE   604 AA;  68372 MW;  8581A00BA9AAB4A7 CRC64;
     MNIVENSIFL SNLMKSANTF ELKYDLSCEL YRMSTYSTFP AGVPVSERSL ARAGFYYTGV
     NDKVKCFCCG LMLDNWKRGD SPTEKHKKLY PSCRFVQSLN SVNNLEATSQ PTFPSSVTNS
     THSLLPGTEN SGYFRGSYSN SPSNPVNSRA NQDFSALMRS SYHCAMNNEN ARLLTFQTWP
     LTFLSPTDLA KAGFYYIGPG DRVACFACGG KLSNWEPKDN AMSEHLRHFP KCPFIENQLQ
     DTSRYTVSNL SMQTHAARFK TFFNWPSSVL VNPEQLASAG FYYVGNSDDV KCFCCDGGLR
     CWESGDDPWV QHAKWFPRCE YLIRIKGQEF IRQVQASYPH LLEQLLSTSD SPGDENAESS
     IIHFEPGEDH SEDAIMMNTP VINAAVEMGF SRSLVKQTVQ RKILATGENY RLVNDLVLDL
     LNAEDEIREE ERERATEEKE SNDLLLIRKN RMALFQHLTC VIPILDSLLT AGIINEQEHD
     VIKQKTQTSL QARELIDTIL VKGNIAATVF RNSLQEAEAV LYEHLFVQQD IKYIPTEDVS
     DLPVEEQLRR LQEERTCKVC MDKEVSIVFI PCGHLVVCKD CAPSLRKCPI CRSTIKGTVR
     TFLS
//
ID   CBL_HUMAN               Reviewed;         906 AA.
AC   P22681; A3KMP8;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   07-JUL-2009, sequence version 2.
DT   22-APR-2020, entry version 234.
DE   RecName: Full=E3 ubiquitin-protein ligase CBL;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:10514377, ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:17509076};
DE   AltName: Full=Casitas B-lineage lymphoma proto-oncogene;
DE   AltName: Full=Proto-oncogene c-Cbl;
DE   AltName: Full=RING finger protein 55;
DE   AltName: Full=RING-type E3 ubiquitin transferase CBL {ECO:0000305};
DE   AltName: Full=Signal transduction protein CBL;
GN   Name=CBL; Synonyms=CBL2, RNF55;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2030914;
RA   Blake T.J., Shapiro M., Morse H.C. III, Langdon W.Y.;
RT   "The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was
RT   generated by a large truncation encompassing a proline-rich domain and a
RT   leucine zipper-like motif.";
RL   Oncogene 6:653-657(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION BY HCK, AND INTERACTION WITH HCK.
RX   PubMed=10092522; DOI=10.1006/bbrc.1999.0427;
RA   Howlett C.J., Bisson S.A., Resek M.E., Tigley A.W., Robbins S.M.;
RT   "The proto-oncogene p120(Cbl) is a downstream substrate of the Hck protein-
RT   tyrosine kinase.";
RL   Biochem. Biophys. Res. Commun. 257:129-138(1999).
RN   [5]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=10514377; DOI=10.1126/science.286.5438.309;
RA   Joazeiro C.A., Wing S.S., Huang H.-K., Leverson J.D., Hunter T., Liu Y.-C.;
RT   "The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent
RT   ubiquitin-protein ligase.";
RL   Science 286:309-312(1999).
RN   [6]
RP   INTERACTION WITH BLK.
RX   PubMed=8083187;
RA   Donovan J.A., Wange R.L., Langdon W.Y., Samelson L.E.;
RT   "The protein product of the c-cbl protooncogene is the 120-kDa tyrosine-
RT   phosphorylated protein in Jurkat cells activated via the T cell antigen
RT   receptor.";
RL   J. Biol. Chem. 269:22921-22924(1994).
RN   [7]
RP   PHOSPHORYLATION BY EGFR, AND INTERACTION WITH EGFR.
RX   PubMed=7657591; DOI=10.1074/jbc.270.35.20242;
RA   Galisteo M.L., Dikic I., Batzer A.G., Langdon W.Y., Schlessinger J.;
RT   "Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and
RT   association with epidermal growth factor (EGF) receptor upon EGF
RT   stimulation.";
RL   J. Biol. Chem. 270:20242-20245(1995).
RN   [8]
RP   INTERACTION WITH ZAP70.
RX   PubMed=9407100; DOI=10.1074/jbc.272.52.33140;
RA   Lupher M.L. Jr., Songyang Z., Shoelson S.E., Cantley L.C., Band H.;
RT   "The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and binds
RT   to the Tyr292 negative regulatory phosphorylation site of ZAP-70.";
RL   J. Biol. Chem. 272:33140-33144(1997).
RN   [9]
RP   PHOSPHORYLATION BY SYK AND FYN.
RX   PubMed=9535867; DOI=10.1074/jbc.273.15.8867;
RA   Deckert M., Elly C., Altman A., Liu Y.C.;
RT   "Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn and
RT   Syk tyrosine kinases.";
RL   J. Biol. Chem. 273:8867-8874(1998).
RN   [10]
RP   INTERACTION WITH LAT2.
RX   PubMed=12486104; DOI=10.1084/jem.20021405;
RA   Brdicka T., Imrich M., Angelisova P., Brdickova N., Horvath O., Spicka J.,
RA   Hilgert I., Luskova P., Draber P., Novak P., Engels N., Wienands J.,
RA   Simeoni L., Oesterreicher J., Aguado E., Malissen M., Schraven B.,
RA   Horejsi V.;
RT   "Non-T cell activation linker (NTAL): a transmembrane adaptor protein
RT   involved in immunoreceptor signaling.";
RL   J. Exp. Med. 196:1617-1626(2002).
RN   [11]
RP   INTERACTION WITH CSF1R, AND PHOSPHORYLATION.
RX   PubMed=11850825; DOI=10.1038/sj.onc.1205166;
RA   Wilhelmsen K., Burkhalter S., van der Geer P.;
RT   "C-Cbl binds the CSF-1 receptor at tyrosine 973, a novel phosphorylation
RT   site in the receptor's carboxy-terminus.";
RL   Oncogene 21:1079-1089(2002).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION, MUTAGENESIS OF CYS-381, AND
RP   INTERACTION WITH HCK.
RX   PubMed=11896602; DOI=10.1038/sj.onc.1205228;
RA   Howlett C.J., Robbins S.M.;
RT   "Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated
RT   cellular transformation.";
RL   Oncogene 21:1707-1716(2002).
RN   [13]
RP   INTERACTION WITH FGR, AND PHOSPHORYLATION BY FGR.
RX   PubMed=12435267; DOI=10.1042/bj20021201;
RA   Melander F., Andersson T., Dib K.;
RT   "Fgr but not Syk tyrosine kinase is a target for beta 2 integrin-induced c-
RT   Cbl-mediated ubiquitination in adherent human neutrophils.";
RL   Biochem. J. 370:687-694(2003).
RN   [14]
RP   INTERACTION WITH SH2B2.
RX   PubMed=10374881; DOI=10.1038/sj.leu.2401397;
RA   Wakioka T., Sasaki A., Mitsui K., Yokouchi M., Inoue A., Komiya S.,
RA   Yoshimura A.;
RT   "APS, an adaptor protein containing pleckstrin homology (PH) and Src
RT   homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration
RT   with c-Cbl.";
RL   Leukemia 13:760-767(1999).
RN   [15]
RP   INTERACTION WITH SH2B2.
RX   PubMed=9989826; DOI=10.1038/sj.onc.1202326;
RA   Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S., Sasaki A.,
RA   Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A.;
RT   "APS, an adaptor protein containing PH and SH2 domains, is associated with
RT   the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis.";
RL   Oncogene 18:759-767(1999).
RN   [16]
RP   INTERACTION WITH SLA AND ZAP70, AND MUTAGENESIS OF GLY-306.
RX   PubMed=10449770; DOI=10.1073/pnas.96.17.9775;
RA   Tang J., Sawasdikosol S., Chang J.-H., Burakoff S.J.;
RT   "SLAP, a dimeric adapter protein, plays a functional role in T cell
RT   receptor signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:9775-9780(1999).
RN   [17]
RP   INTERACTION WITH SLA2.
RX   PubMed=11696592; DOI=10.1084/jem.194.9.1263;
RA   Holland S.J., Liao X.C., Mendenhall M.K., Zhou X., Pardo J., Chu P.,
RA   Spencer C., Fu A.C., Sheng N., Yu P., Pali E., Nagin A., Shen M., Yu S.,
RA   Chan E., Wu X., Li C., Woisetschlager M., Aversa G., Kolbinger F.,
RA   Bennett M.K., Molineaux S., Luo Y., Payan D.G., Mancebo H.S.Y., Wu J.;
RT   "Functional cloning of Src-like adapter protein-2 (SLAP-2), a novel
RT   inhibitor of antigen receptor signaling.";
RL   J. Exp. Med. 194:1263-1276(2001).
RN   [18]
RP   INTERACTION WITH CD2AP.
RX   PubMed=11067845; DOI=10.1074/jbc.m005784200;
RA   Kirsch K.H., Georgescu M.M., Shishido T., Langdon W.Y., Birge R.B.,
RA   Hanafusa H.;
RT   "The adapter type protein CMS/CD2AP binds to the proto-oncogenic protein c-
RT   Cbl through a tyrosine phosphorylation-regulated Src homology 3 domain
RT   interaction.";
RL   J. Biol. Chem. 276:4957-4963(2001).
RN   [19]
RP   INTERACTION WITH SH2B2, MUTAGENESIS OF TYR-371; TYR-700; TYR-731 AND
RP   TYR-774, AND PHOSPHORYLATION AT TYR-371; TYR-700 AND TYR-774.
RX   PubMed=11997497; DOI=10.1128/mcb.22.11.3599-3609.2002;
RA   Liu J., Kimura A., Baumann C.A., Saltiel A.R.;
RT   "APS facilitates c-Cbl tyrosine phosphorylation and GLUT4 translocation in
RT   response to insulin in 3T3-L1 adipocytes.";
RL   Mol. Cell. Biol. 22:3599-3609(2002).
RN   [20]
RP   INTERACTION WITH INPPL1.
RX   PubMed=12504111; DOI=10.1016/s0006-291x(02)02894-2;
RA   Vandenbroere I., Paternotte N., Dumont J.E., Erneux C., Pirson I.;
RT   "The c-Cbl-associated protein and c-Cbl are two new partners of the SH2-
RT   containing inositol polyphosphate 5-phosphatase SHIP2.";
RL   Biochem. Biophys. Res. Commun. 300:494-500(2003).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=12522270; DOI=10.1073/pnas.2436191100;
RA   Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T., Ericson C.,
RA   Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
RT   "Profiling of tyrosine phosphorylation pathways in human cells using mass
RT   spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [23]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=14661060; DOI=10.1038/sj.onc.1207298;
RA   Kim M., Tezuka T., Tanaka K., Yamamoto T.;
RT   "Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent
RT   protein degradation.";
RL   Oncogene 23:1645-1655(2004).
RN   [24]
RP   REVIEW ON ROLE IN KIT SIGNALING AND KIT DEGRADATION.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [25]
RP   PHOSPHORYLATION AT TYR-700.
RX   PubMed=15556646; DOI=10.1016/j.febslet.2004.10.054;
RA   Grossmann A.H., Kolibaba K.S., Willis S.G., Corbin A.S., Langdon W.S.,
RA   Deininger M.W., Druker B.J.;
RT   "Catalytic domains of tyrosine kinases determine the phosphorylation sites
RT   within c-Cbl.";
RL   FEBS Lett. 577:555-562(2004).
RN   [26]
RP   FUNCTION, PHOSPHORYLATION AT TYR-731, AND MUTAGENESIS OF TYR-731.
RX   PubMed=14739300; DOI=10.1074/jbc.m311032200;
RA   Miyazaki T., Sanjay A., Neff L., Tanaka S., Horne W.C., Baron R.;
RT   "Src kinase activity is essential for osteoclast function.";
RL   J. Biol. Chem. 279:17660-17666(2004).
RN   [27]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH FGFR2; LYN AND FYN.
RX   PubMed=15190072; DOI=10.1074/jbc.m402469200;
RA   Kaabeche K., Lemonnier J., Le Mee S., Caverzasio J., Marie P.J.;
RT   "Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast
RT   growth factor receptor-2 activation supports osteoblast differentiation.";
RL   J. Biol. Chem. 279:36259-36267(2004).
RN   [28]
RP   INTERACTION WITH ALK, AND PHOSPHORYLATION BY ALK.
RX   PubMed=15226403; DOI=10.1242/jcs.01183;
RA   Motegi A., Fujimoto J., Kotani M., Sakuraba H., Yamamoto T.;
RT   "ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth.";
RL   J. Cell Sci. 117:3319-3329(2004).
RN   [29]
RP   INTERACTION WITH AXL.
RX   PubMed=15958209; DOI=10.1016/j.bbrc.2005.05.086;
RA   Valverde P.;
RT   "Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and
RT   downregulation.";
RL   Biochem. Biophys. Res. Commun. 333:180-185(2005).
RN   [30]
RP   REVIEW ON ROLE IN KIT SIGNALING AND KIT DEGRADATION.
RX   PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055;
RA   Roskoski R. Jr.;
RT   "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.";
RL   Biochem. Biophys. Res. Commun. 337:1-13(2005).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-900, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [33]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION.
RX   PubMed=17509076; DOI=10.1111/j.1742-4658.2007.05835.x;
RA   Bonaventure J., Horne W.C., Baron R.;
RT   "The localization of FGFR3 mutations causing thanatophoric dysplasia type I
RT   differentially affects phosphorylation, processing and ubiquitylation of
RT   the receptor.";
RL   FEBS J. 274:3078-3093(2007).
RN   [34]
RP   INTERACTION WITH PDGFRB.
RX   PubMed=17620338; DOI=10.1074/jbc.m701797200;
RA   Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P., Druker B.J.,
RA   Naramura M., Band V., Band H.;
RT   "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived
RT   growth factor receptor beta provides a dual mechanism of negative
RT   regulation.";
RL   J. Biol. Chem. 282:29336-29347(2007).
RN   [35]
RP   INTERACTION WITH LYN.
RX   PubMed=18235045; DOI=10.1182/blood-2007-08-109330;
RA   Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., Talpaz M.,
RA   Donato N.J.;
RT   "Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein
RT   stability in imatinib-resistant chronic myelogenous leukemia cells.";
RL   Blood 111:3821-3829(2008).
RN   [36]
RP   FUNCTION, INTERACTION WITH FGFR2, AND SUBCELLULAR LOCATION.
RX   PubMed=18374639; DOI=10.1016/j.bone.2008.02.009;
RA   Dufour C., Guenou H., Kaabeche K., Bouvard D., Sanjay A., Marie P.J.;
RT   "FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt
RT   signaling and osteoblast survival.";
RL   Bone 42:1032-1039(2008).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [38]
RP   INTERACTION WITH EPHB1, AND PHOSPHORYLATION.
RX   PubMed=18034775; DOI=10.1111/j.1600-0854.2007.00679.x;
RA   Fasen K., Cerretti D.P., Huynh-Do U.;
RT   "Ligand binding induces Cbl-dependent EphB1 receptor degradation through
RT   the lysosomal pathway.";
RL   Traffic 9:251-266(2008).
RN   [39]
RP   INTERACTION WITH TEK/TIE2, AND FUNCTION.
RX   PubMed=19689429; DOI=10.1042/bj20091010;
RA   Wehrle C., Van Slyke P., Dumont D.J.;
RT   "Angiopoietin-1-induced ubiquitylation of Tie2 by c-Cbl is required for
RT   internalization and degradation.";
RL   Biochem. J. 423:375-380(2009).
RN   [40]
RP   INTERACTION WITH EGFR.
RX   PubMed=19836242; DOI=10.1016/j.cub.2009.09.048;
RA   Tarcic G., Boguslavsky S.K., Wakim J., Kiuchi T., Liu A., Reinitz F.,
RA   Nathanson D., Takahashi T., Mischel P.S., Ng T., Yarden Y.;
RT   "An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase
RT   controlling EGFR endocytosis.";
RL   Curr. Biol. 19:1788-1798(2009).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-452, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [42]
RP   INTERACTION WITH PDGFRB, AND PHOSPHORYLATION.
RX   PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004;
RA   Wardega P., Heldin C.H., Lennartsson J.;
RT   "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell
RT   proliferation but not migration.";
RL   Cell. Signal. 22:1363-1368(2010).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [44]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [45]
RP   FUNCTION, AND INTERACTION WITH FGFR2.
RX   PubMed=21596750; DOI=10.1074/jbc.m110.197525;
RA   Severe N., Miraoui H., Marie P.J.;
RT   "The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic
RT   differentiation in human mesenchymal stromal cells in part by decreased
RT   Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast
RT   growth factor receptor 2 ubiquitination.";
RL   J. Biol. Chem. 286:24443-24450(2011).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-439; SER-483 AND SER-669, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [47]
RP   CHARACTERIZATION OF VARIANTS NSLL GLU-382; TYR-390 AND GLN-420.
RX   PubMed=25178484; DOI=10.1002/humu.22682;
RA   Brand K., Kentsch H., Glashoff C., Rosenberger G.;
RT   "RASopathy-associated CBL germline mutations cause aberrant ubiquitylation
RT   and trafficking of EGFR.";
RL   Hum. Mutat. 35:1372-1381(2014).
RN   [48]
RP   REVIEW ON FUNCTION IN FGF SIGNALING, AND UBIQUITINATION OF FGFR1.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [49]
RP   SUBUNIT, INTERACTION WITH IFT20 AND CBLB, UBIQUITINATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=29237719; DOI=10.1083/jcb.201611050;
RA   Schmid F.M., Schou K.B., Vilhelm M.J., Holm M.S., Breslin L., Farinelli P.,
RA   Larsen L.A., Andersen J.S., Pedersen L.B., Christensen S.T.;
RT   "IFT20 modulates ciliary PDGFRalpha signaling by regulating the stability
RT   of Cbl E3 ubiquitin ligases.";
RL   J. Cell Biol. 217:151-161(2018).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 47-350 IN COMPLEX WITH ZAP70
RP   PEPTIDE AND CALCIUM IONS, CALCIUM-BINDING SITE, AND MUTAGENESIS OF SER-80;
RP   PRO-82; ASP-229; GLU-240; ARG-294 AND GLY-306.
RX   PubMed=10078535; DOI=10.1038/18050;
RA   Meng W., Sawasdikosol S., Burakoff S.J., Eck M.J.;
RT   "Structure of the amino-terminal domain of Cbl complexed to its binding
RT   site on ZAP-70 kinase.";
RL   Nature 398:84-90(1999).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 47-434 IN COMPLEX WITH ZAP70 AND
RP   UBE2L3.
RX   PubMed=10966114; DOI=10.1016/s0092-8674(00)00057-x;
RA   Zheng N., Wang P., Jeffrey P.D., Pavletich N.P.;
RT   "Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-
RT   protein ligases.";
RL   Cell 102:533-539(2000).
RN   [52]
RP   VARIANTS NSLL PRO-367; GLU-382; TYR-390 AND GLN-420, AND CHARACTERIZATION
RP   OF VARIANTS NSLL TYR-390 AND GLN-420.
RX   PubMed=20619386; DOI=10.1016/j.ajhg.2010.06.015;
RA   Martinelli S., De Luca A., Stellacci E., Rossi C., Checquolo S., Lepri F.,
RA   Caputo V., Silvano M., Buscherini F., Consoli F., Ferrara G., Digilio M.C.,
RA   Cavaliere M.L., van Hagen J.M., Zampino G., van der Burgt I., Ferrero G.B.,
RA   Mazzanti L., Screpanti I., Yntema H.G., Nillesen W.M., Savarirayan R.,
RA   Zenker M., Dallapiccola B., Gelb B.D., Tartaglia M.;
RT   "Heterozygous germline mutations in the CBL tumor-suppressor gene cause a
RT   Noonan syndrome-like phenotype.";
RL   Am. J. Hum. Genet. 87:250-257(2010).
RN   [53]
RP   VARIANTS ARG-287; SER-LYS-365 INS; HIS-371 AND LEU-499, CHARACTERIZATION OF
RP   VARIANTS SER-LYS-365 INS AND HIS-371, AND PHOSPHORYLATION AT TYR-674;
RP   TYR-700 AND TYR-774.
RX   PubMed=20622007; DOI=10.1074/jbc.m110.106161;
RA   Fernandes M.S., Reddy M.M., Croteau N.J., Walz C., Weisbach H., Podar K.,
RA   Band H., Carroll M., Reiter A., Larson R.A., Salgia R., Griffin J.D.,
RA   Sattler M.;
RT   "Novel oncogenic mutations of CBL in human acute myeloid leukemia that
RT   activate growth and survival pathways depend on increased metabolism.";
RL   J. Biol. Chem. 285:32596-32605(2010).
CC   -!- FUNCTION: Adapter protein that functions as a negative regulator of
CC       many signaling pathways that are triggered by activation of cell
CC       surface receptors. Acts as an E3 ubiquitin-protein ligase, which
CC       accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and
CC       then transfers it to substrates promoting their degradation by the
CC       proteasome. Recognizes activated receptor tyrosine kinases, including
CC       KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and
CC       terminates signaling. Recognizes membrane-bound HCK, SRC and other
CC       kinases of the SRC family and mediates their ubiquitination and
CC       degradation. Participates in signal transduction in hematopoietic
CC       cells. Plays an important role in the regulation of osteoblast
CC       differentiation and apoptosis. Essential for osteoclastic bone
CC       resorption. The 'Tyr-731' phosphorylated form induces the activation
CC       and recruitment of phosphatidylinositol 3-kinase to the cell membrane
CC       in a signaling pathway that is critical for osteoclast function. May be
CC       functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In
CC       association with CBLB, required for proper feedback inhibition of
CC       ciliary platelet-derived growth factor receptor-alpha (PDGFRA)
CC       signaling pathway via ubiquitination and internalization of PDGFRA (By
CC       similarity). {ECO:0000250|UniProtKB:P22682,
CC       ECO:0000269|PubMed:10514377, ECO:0000269|PubMed:11896602,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:14739300,
CC       ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:17509076,
CC       ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19689429,
CC       ECO:0000269|PubMed:21596750}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000269|PubMed:10514377,
CC         ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:17509076};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Forms homodimers; IFT20 promotes the formation of stable
CC       homodimers (PubMed:29237719). Interacts (phosphorylated at Tyr-731)
CC       with PIK3R1. Associates with NCK via its SH3 domain. The phosphorylated
CC       C-terminus interacts with CD2AP via its second SH3 domain. Binds to
CC       UBE2L3. Interacts with adapters SLA, SLA2 and with the phosphorylated
CC       C-terminus of SH2B2. Interacts with EGFR, SYK and ZAP70 via the highly
CC       conserved Cbl-N region. Also interacts with SORBS1 and INPPL1/SHIP2.
CC       Interacts with phosphorylated LAT2 (By similarity). Interacts with CBLB
CC       (PubMed:29237719). Interacts with ALK, AXL, BLK, FGR and FGFR2.
CC       Interacts with CSF1R, EPHB1, FLT1, KDR, PDGFRA and PDGFRB; regulates
CC       receptor degradation through ubiquitination. Interacts with HCK and
CC       LYN. Interacts with TEK/TIE2 (tyrosine phosphorylated). Interacts with
CC       SH3KBP1 and this interaction is inhibited in the presence of SHKBP1 (By
CC       similarity). Interacts with SIGLEC10 (By similarity). Interacts with
CC       IFT20 (PubMed:29237719). {ECO:0000250|UniProtKB:P22682,
CC       ECO:0000269|PubMed:10078535, ECO:0000269|PubMed:10092522,
CC       ECO:0000269|PubMed:10374881, ECO:0000269|PubMed:10449770,
CC       ECO:0000269|PubMed:10966114, ECO:0000269|PubMed:11067845,
CC       ECO:0000269|PubMed:11696592, ECO:0000269|PubMed:11850825,
CC       ECO:0000269|PubMed:11896602, ECO:0000269|PubMed:11997497,
CC       ECO:0000269|PubMed:12435267, ECO:0000269|PubMed:12486104,
CC       ECO:0000269|PubMed:12504111, ECO:0000269|PubMed:15190072,
CC       ECO:0000269|PubMed:15226403, ECO:0000269|PubMed:15958209,
CC       ECO:0000269|PubMed:17620338, ECO:0000269|PubMed:18034775,
CC       ECO:0000269|PubMed:18235045, ECO:0000269|PubMed:18374639,
CC       ECO:0000269|PubMed:19689429, ECO:0000269|PubMed:19836242,
CC       ECO:0000269|PubMed:20494825, ECO:0000269|PubMed:21596750,
CC       ECO:0000269|PubMed:29237719, ECO:0000269|PubMed:7657591,
CC       ECO:0000269|PubMed:8083187, ECO:0000269|PubMed:9407100,
CC       ECO:0000269|PubMed:9989826}.
CC   -!- INTERACTION:
CC       P22681; Q8IZP0-2: ABI1; NbExp=3; IntAct=EBI-518228, EBI-7358775;
CC       P22681; Q14155: ARHGEF7; NbExp=9; IntAct=EBI-518228, EBI-717515;
CC       P22681; Q9Y5K6: CD2AP; NbExp=4; IntAct=EBI-518228, EBI-298152;
CC       P22681; P46108: CRK; NbExp=10; IntAct=EBI-518228, EBI-886;
CC       P22681; P46109: CRKL; NbExp=3; IntAct=EBI-518228, EBI-910;
CC       P22681; P00533: EGFR; NbExp=22; IntAct=EBI-518228, EBI-297353;
CC       P22681; P55085: F2RL1; NbExp=3; IntAct=EBI-518228, EBI-4303189;
CC       P22681; P17948: FLT1; NbExp=2; IntAct=EBI-518228, EBI-1026718;
CC       P22681; P39688: Fyn; Xeno; NbExp=3; IntAct=EBI-518228, EBI-524514;
CC       P22681; P62993: GRB2; NbExp=13; IntAct=EBI-518228, EBI-401755;
CC       P22681; P08631-2: HCK; NbExp=2; IntAct=EBI-518228, EBI-9834454;
CC       P22681; Q15811: ITSN1; NbExp=12; IntAct=EBI-518228, EBI-602041;
CC       P22681; P45983: MAPK8; NbExp=2; IntAct=EBI-518228, EBI-286483;
CC       P22681; P08581: MET; NbExp=15; IntAct=EBI-518228, EBI-1039152;
CC       P22681; P04629: NTRK1; NbExp=2; IntAct=EBI-518228, EBI-1028226;
CC       P22681; P27986: PIK3R1; NbExp=5; IntAct=EBI-518228, EBI-79464;
CC       P22681; O00459: PIK3R2; NbExp=4; IntAct=EBI-518228, EBI-346930;
CC       P22681; Q92569: PIK3R3; NbExp=4; IntAct=EBI-518228, EBI-79893;
CC       P22681; F1SDV6: PLCG1; Xeno; NbExp=2; IntAct=EBI-518228, EBI-15628084;
CC       P22681; P08487: PLCG1; Xeno; NbExp=3; IntAct=EBI-518228, EBI-8013886;
CC       P22681; O14492: SH2B2; NbExp=7; IntAct=EBI-518228, EBI-7507432;
CC       P22681; Q96B97: SH3KBP1; NbExp=20; IntAct=EBI-518228, EBI-346595;
CC       P22681; O43597: SPRY2; NbExp=17; IntAct=EBI-518228, EBI-742487;
CC       P22681; Q9C004: SPRY4; NbExp=9; IntAct=EBI-518228, EBI-354861;
CC       P22681; P12931: SRC; NbExp=8; IntAct=EBI-518228, EBI-621482;
CC       P22681; P43405: SYK; NbExp=2; IntAct=EBI-518228, EBI-78302;
CC       P22681; P62837: UBE2D2; NbExp=4; IntAct=EBI-518228, EBI-347677;
CC       P22681; P31946: YWHAB; NbExp=3; IntAct=EBI-518228, EBI-359815;
CC       P22681; Q04917: YWHAH; NbExp=3; IntAct=EBI-518228, EBI-306940;
CC       P22681; P27348: YWHAQ; NbExp=6; IntAct=EBI-518228, EBI-359854;
CC       P22681; P43403: ZAP70; NbExp=3; IntAct=EBI-518228, EBI-1211276;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Cell projection, cilium
CC       {ECO:0000269|PubMed:29237719}. Golgi apparatus
CC       {ECO:0000269|PubMed:29237719}. Note=Colocalizes with FGFR2 in lipid
CC       rafts at the cell membrane.
CC   -!- DOMAIN: The RING-type zinc finger domain mediates binding to an E2
CC       ubiquitin-conjugating enzyme.
CC   -!- DOMAIN: The N-terminus is composed of the phosphotyrosine binding (PTB)
CC       domain, a short linker region and the RING-type zinc finger. The PTB
CC       domain, which is also called TKB (tyrosine kinase binding) domain, is
CC       composed of three different subdomains: a four-helix bundle (4H), a
CC       calcium-binding EF hand and a divergent SH2 domain.
CC   -!- PTM: Phosphorylated on tyrosine residues by ALK, EGFR, SYK, FYN and
CC       ZAP70 (By similarity). Phosphorylated on tyrosine residues in response
CC       to FLT1 and KIT signaling. Phosphorylated on tyrosine residues by INSR
CC       and FGR. Phosphorylated on several tyrosine residues by constitutively
CC       activated FGFR3. Not phosphorylated at Tyr-731 by FGFR3. Phosphorylated
CC       on tyrosine residues by activated CSF1R, PDGFRA and PDGFRB.
CC       Phosphorylated on tyrosine residues by HCK. {ECO:0000250,
CC       ECO:0000269|PubMed:10092522, ECO:0000269|PubMed:11850825,
CC       ECO:0000269|PubMed:11997497, ECO:0000269|PubMed:12435267,
CC       ECO:0000269|PubMed:14739300, ECO:0000269|PubMed:15190072,
CC       ECO:0000269|PubMed:15226403, ECO:0000269|PubMed:15556646,
CC       ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:18034775,
CC       ECO:0000269|PubMed:20494825, ECO:0000269|PubMed:20622007,
CC       ECO:0000269|PubMed:7657591, ECO:0000269|PubMed:9535867}.
CC   -!- PTM: Ubiquitinated, leading to its degradation via the proteasome
CC       (PubMed:11896602, PubMed:20094046). Ubiquitination is negatively
CC       regulated by IFT20 (PubMed:29237719). {ECO:0000269|PubMed:11896602,
CC       ECO:0000269|PubMed:20094046, ECO:0000269|PubMed:29237719}.
CC   -!- DISEASE: Noonan syndrome-like disorder with or without juvenile
CC       myelomonocytic leukemia (NSLL) [MIM:613563]: A syndrome characterized
CC       by a phenotype reminiscent of Noonan syndrome. Clinical features are
CC       highly variable, including facial dysmorphism, short neck,
CC       developmental delay, hyperextensible joints and thorax abnormalities
CC       with widely spaced nipples. The facial features consist of triangular
CC       face with hypertelorism, large low-set ears, ptosis, and flat nasal
CC       bridge. Some patients manifest cardiac defects. Some have an increased
CC       risk for certain malignancies, particularly juvenile myelomonocytic
CC       leukemia. {ECO:0000269|PubMed:20619386, ECO:0000269|PubMed:25178484}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: This protein has one functional calcium-binding site.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CBLID171.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X57110; CAA40393.1; -; mRNA.
DR   EMBL; AP002956; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC132733; AAI32734.1; -; mRNA.
DR   EMBL; BC136463; AAI36464.1; -; mRNA.
DR   CCDS; CCDS8418.1; -.
DR   PIR; A43817; A43817.
DR   RefSeq; NP_005179.2; NM_005188.3.
DR   PDB; 1B47; X-ray; 2.20 A; A/B/C=47-350.
DR   PDB; 1FBV; X-ray; 2.90 A; A=47-434.
DR   PDB; 1YVH; X-ray; 2.05 A; A=25-351.
DR   PDB; 2CBL; X-ray; 2.10 A; A=47-351.
DR   PDB; 2JUJ; NMR; -; A=851-906.
DR   PDB; 2K4D; NMR; -; A=358-437.
DR   PDB; 2OO9; X-ray; 2.10 A; A/B/C=856-895.
DR   PDB; 2Y1M; X-ray; 2.67 A; A/B/C/D/E/F=47-435.
DR   PDB; 2Y1N; X-ray; 2.00 A; A/C=47-435.
DR   PDB; 3BUM; X-ray; 2.00 A; B=25-351.
DR   PDB; 3BUN; X-ray; 2.00 A; B=25-351.
DR   PDB; 3BUO; X-ray; 2.60 A; B/D=25-351.
DR   PDB; 3BUW; X-ray; 1.45 A; B/D=25-351.
DR   PDB; 3BUX; X-ray; 1.35 A; B/D=25-351.
DR   PDB; 3OB1; X-ray; 2.20 A; B=25-351.
DR   PDB; 3OB2; X-ray; 2.10 A; B=25-351.
DR   PDB; 3PLF; X-ray; 1.92 A; B/D=25-351.
DR   PDB; 4A49; X-ray; 2.21 A; A=354-435.
DR   PDB; 4A4B; X-ray; 2.79 A; A=47-435.
DR   PDB; 4A4C; X-ray; 2.70 A; A=47-435.
DR   PDB; 4GPL; X-ray; 3.00 A; B=47-351.
DR   PDB; 5HKW; X-ray; 2.25 A; A/B/C=47-351.
DR   PDB; 5HKX; X-ray; 1.85 A; A=47-435.
DR   PDB; 5HKY; X-ray; 1.80 A; A=47-351.
DR   PDB; 5HKZ; X-ray; 1.80 A; A=47-351.
DR   PDB; 5HL0; X-ray; 2.20 A; A=47-351.
DR   PDB; 5J3X; X-ray; 2.82 A; A/B/C/D/E/F=47-435.
DR   PDB; 5O76; X-ray; 2.47 A; A/C=47-435.
DR   PDBsum; 1B47; -.
DR   PDBsum; 1FBV; -.
DR   PDBsum; 1YVH; -.
DR   PDBsum; 2CBL; -.
DR   PDBsum; 2JUJ; -.
DR   PDBsum; 2K4D; -.
DR   PDBsum; 2OO9; -.
DR   PDBsum; 2Y1M; -.
DR   PDBsum; 2Y1N; -.
DR   PDBsum; 3BUM; -.
DR   PDBsum; 3BUN; -.
DR   PDBsum; 3BUO; -.
DR   PDBsum; 3BUW; -.
DR   PDBsum; 3BUX; -.
DR   PDBsum; 3OB1; -.
DR   PDBsum; 3OB2; -.
DR   PDBsum; 3PLF; -.
DR   PDBsum; 4A49; -.
DR   PDBsum; 4A4B; -.
DR   PDBsum; 4A4C; -.
DR   PDBsum; 4GPL; -.
DR   PDBsum; 5HKW; -.
DR   PDBsum; 5HKX; -.
DR   PDBsum; 5HKY; -.
DR   PDBsum; 5HKZ; -.
DR   PDBsum; 5HL0; -.
DR   PDBsum; 5J3X; -.
DR   PDBsum; 5O76; -.
DR   SMR; P22681; -.
DR   BioGrid; 107315; 291.
DR   CORUM; P22681; -.
DR   DIP; DIP-189N; -.
DR   IntAct; P22681; 102.
DR   MINT; P22681; -.
DR   STRING; 9606.ENSP00000264033; -.
DR   iPTMnet; P22681; -.
DR   MetOSite; P22681; -.
DR   PhosphoSitePlus; P22681; -.
DR   BioMuta; CBL; -.
DR   DMDM; 251757253; -.
DR   EPD; P22681; -.
DR   jPOST; P22681; -.
DR   MassIVE; P22681; -.
DR   MaxQB; P22681; -.
DR   PaxDb; P22681; -.
DR   PeptideAtlas; P22681; -.
DR   PRIDE; P22681; -.
DR   ProteomicsDB; 54017; -.
DR   Antibodypedia; 3815; 1096 antibodies.
DR   Ensembl; ENST00000264033; ENSP00000264033; ENSG00000110395.
DR   GeneID; 867; -.
DR   KEGG; hsa:867; -.
DR   UCSC; uc001pwe.5; human.
DR   CTD; 867; -.
DR   DisGeNET; 867; -.
DR   GeneCards; CBL; -.
DR   HGNC; HGNC:1541; CBL.
DR   HPA; ENSG00000110395; Tissue enhanced (lymphoid).
DR   MalaCards; CBL; -.
DR   MIM; 165360; gene.
DR   MIM; 613563; phenotype.
DR   neXtProt; NX_P22681; -.
DR   OpenTargets; ENSG00000110395; -.
DR   Orphanet; 86834; Juvenile myelomonocytic leukemia.
DR   Orphanet; 363972; Noonan syndrome-like disorder with juvenile myelomonocytic leukemia.
DR   PharmGKB; PA26115; -.
DR   eggNOG; KOG1785; Eukaryota.
DR   eggNOG; ENOG410YDNH; LUCA.
DR   GeneTree; ENSGT00940000155772; -.
DR   HOGENOM; CLU_013535_3_0_1; -.
DR   InParanoid; P22681; -.
DR   KO; K04707; -.
DR   OMA; PGEQCES; -.
DR   OrthoDB; 540689at2759; -.
DR   PhylomeDB; P22681; -.
DR   TreeFam; TF314210; -.
DR   BRENDA; 2.3.2.B10; 2681.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; R-HSA-1295596; Spry regulation of FGF signaling.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-182971; EGFR downregulation.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII.
DR   Reactome; R-HSA-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-HSA-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-HSA-6807004; Negative regulation of MET activity.
DR   Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8875360; InlB-mediated entry of Listeria monocytogenes into host cell.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   SignaLink; P22681; -.
DR   SIGNOR; P22681; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; CBL; human.
DR   EvolutionaryTrace; P22681; -.
DR   GeneWiki; CBL_(gene); -.
DR   GenomeRNAi; 867; -.
DR   Pharos; P22681; Tbio.
DR   PRO; PR:P22681; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P22681; protein.
DR   Bgee; ENSG00000110395; Expressed in blood and 209 other tissues.
DR   ExpressionAtlas; P22681; baseline and differential.
DR   Genevisible; P22681; HS.
DR   GO; GO:0005929; C:cilium; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016600; C:flotillin complex; IEA:Ensembl.
DR   GO; GO:0005925; C:focal adhesion; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0042629; C:mast cell granule; IEA:GOC.
DR   GO; GO:0045121; C:membrane raft; IBA:GO_Central.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:HGNC-UCL.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0046875; F:ephrin receptor binding; IPI:UniProtKB.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IEA:Ensembl.
DR   GO; GO:0036312; F:phosphatidylinositol 3-kinase regulatory subunit binding; IEA:Ensembl.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IEA:InterPro.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IBA:GO_Central.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:BHF-UCL.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; TAS:HGNC-UCL.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:HGNC-UCL.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IEA:Ensembl.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0090650; P:cellular response to oxygen-glucose deprivation; IEA:Ensembl.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0035635; P:entry of bacterium into host cell; TAS:Reactome.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:HGNC-UCL.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0043303; P:mast cell degranulation; IEA:Ensembl.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007175; P:negative regulation of epidermal growth factor-activated receptor activity; IBA:GO_Central.
DR   GO; GO:1901215; P:negative regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0070997; P:neuron death; IEA:Ensembl.
DR   GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:BHF-UCL.
DR   GO; GO:0048260; P:positive regulation of receptor-mediated endocytosis; IMP:UniProtKB.
DR   GO; GO:0006513; P:protein monoubiquitination; IEA:Ensembl.
DR   GO; GO:0000209; P:protein polyubiquitination; IEA:Ensembl.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:HGNC-UCL.
DR   GO; GO:2000583; P:regulation of platelet-derived growth factor receptor-alpha signaling pathway; ISS:UniProtKB.
DR   GO; GO:0032487; P:regulation of Rap protein signal transduction; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0042594; P:response to starvation; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   CDD; cd16709; RING-HC_Cbl-b; 1.
DR   CDD; cd09920; SH2_Cbl-b_TKB; 1.
DR   Gene3D; 1.20.930.20; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR024162; Adaptor_Cbl.
DR   InterPro; IPR014741; Adaptor_Cbl_EF_hand-like.
DR   InterPro; IPR036537; Adaptor_Cbl_N_dom_sf.
DR   InterPro; IPR003153; Adaptor_Cbl_N_hlx.
DR   InterPro; IPR014742; Adaptor_Cbl_SH2-like.
DR   InterPro; IPR039520; CBL-B_RING-HC.
DR   InterPro; IPR024159; Cbl_PTB.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR015940; UBA.
DR   InterPro; IPR009060; UBA-like_sf.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR23007; PTHR23007; 1.
DR   Pfam; PF02262; Cbl_N; 1.
DR   Pfam; PF02761; Cbl_N2; 1.
DR   Pfam; PF02762; Cbl_N3; 1.
DR   Pfam; PF00627; UBA; 1.
DR   SMART; SM00184; RING; 1.
DR   SMART; SM00165; UBA; 1.
DR   SUPFAM; SSF46934; SSF46934; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   SUPFAM; SSF47668; SSF47668; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS51506; CBL_PTB; 1.
DR   PROSITE; PS50030; UBA; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cell membrane; Cell projection; Cytoplasm;
KW   Disease mutation; Golgi apparatus; Membrane; Metal-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome; Repeat; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..906
FT                   /note="E3 ubiquitin-protein ligase CBL"
FT                   /id="PRO_0000055858"
FT   DOMAIN          47..351
FT                   /note="Cbl-PTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00839"
FT   DOMAIN          856..895
FT                   /note="UBA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00212"
FT   CA_BIND         227..240
FT   ZN_FING         381..420
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          1..357
FT                   /note="Sufficient for interaction with EPHB1"
FT                   /evidence="ECO:0000269|PubMed:18034775"
FT   REGION          47..175
FT                   /note="4H"
FT   REGION          176..248
FT                   /note="EF-hand-like"
FT   REGION          249..351
FT                   /note="SH2-like"
FT   REGION          352..380
FT                   /note="Linker"
FT   REGION          648..906
FT                   /note="Interaction with CD2AP"
FT                   /evidence="ECO:0000269|PubMed:11067845"
FT   COMPBIAS        357..476
FT                   /note="Asp/Glu-rich (acidic)"
FT   COMPBIAS        477..688
FT                   /note="Pro-rich"
FT   COMPBIAS        689..834
FT                   /note="Asp/Glu-rich (acidic)"
FT   BINDING         294
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         371
FT                   /note="Phosphotyrosine; by INSR"
FT                   /evidence="ECO:0000269|PubMed:11997497"
FT   MOD_RES         439
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         483
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         619
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P22682"
FT   MOD_RES         642
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P22682"
FT   MOD_RES         668
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P22682"
FT   MOD_RES         669
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         674
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:20622007"
FT   MOD_RES         700
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000269|PubMed:11997497,
FT                   ECO:0000269|PubMed:15556646, ECO:0000269|PubMed:20622007"
FT   MOD_RES         731
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000269|PubMed:14739300"
FT   MOD_RES         774
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:11997497,
FT                   ECO:0000269|PubMed:20622007"
FT   MOD_RES         900
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:16964243"
FT   VARIANT         287
FT                   /note="K -> R (found in patients with acute myeloid
FT                   leukemia; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:20622007"
FT                   /id="VAR_071040"
FT   VARIANT         365
FT                   /note="Q -> QSK (found in patients with acute myeloid
FT                   leukemia; unknown pathological significance; loss of the
FT                   ability to negatively regulate signaling pathways; promotes
FT                   cell cycle progression; decreases apoptosis)"
FT                   /id="VAR_071041"
FT   VARIANT         367
FT                   /note="Q -> P (in NSLL; dbSNP:rs267606704)"
FT                   /evidence="ECO:0000269|PubMed:20619386"
FT                   /id="VAR_064332"
FT   VARIANT         371
FT                   /note="Y -> H (found in patients with acute myeloid
FT                   leukemia; unknown pathological significance; loss of the
FT                   ability to negatively regulate signaling pathways; promotes
FT                   cell cycle progression; decreases apoptosis;
FT                   dbSNP:rs267606706)"
FT                   /evidence="ECO:0000269|PubMed:20622007"
FT                   /id="VAR_071042"
FT   VARIANT         382
FT                   /note="K -> E (in NSLL; dominant-negative; impairs CBL-
FT                   mediated ubiquitination, internalization and degradation of
FT                   the EGF receptor/EGFR; decreases the ability to negatively
FT                   regulate EGFR signaling; dbSNP:rs267606705)"
FT                   /evidence="ECO:0000269|PubMed:25178484"
FT                   /id="VAR_064333"
FT   VARIANT         390
FT                   /note="D -> Y (in NSLL; dominant-negative; impairs CBL-
FT                   mediated ubiquitination, internalization and degradation of
FT                   the EGF receptor/EGFR; decreases the ability to negatively
FT                   regulate EGFR signaling; dbSNP:rs267606707)"
FT                   /evidence="ECO:0000269|PubMed:20619386,
FT                   ECO:0000269|PubMed:25178484"
FT                   /id="VAR_064334"
FT   VARIANT         420
FT                   /note="R -> Q (in NSLL; dominant-negative; impairs CBL-
FT                   mediated ubiquitination, internalization and degradation of
FT                   the EGF receptor/EGFR; decreases the ability to negatively
FT                   regulate EGFR signaling; dbSNP:rs267606708)"
FT                   /evidence="ECO:0000269|PubMed:20619386,
FT                   ECO:0000269|PubMed:25178484"
FT                   /id="VAR_064335"
FT   VARIANT         499
FT                   /note="R -> L (found in patients with acute myeloid
FT                   leukemia; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:20622007"
FT                   /id="VAR_071043"
FT   VARIANT         620
FT                   /note="L -> F (in dbSNP:rs2227988)"
FT                   /id="VAR_057211"
FT   VARIANT         782
FT                   /note="P -> L (in dbSNP:rs2229073)"
FT                   /id="VAR_057212"
FT   VARIANT         904
FT                   /note="V -> I (in dbSNP:rs17122769)"
FT                   /id="VAR_057213"
FT   MUTAGEN         80
FT                   /note="S->D: Abolishes interaction with ZAP70."
FT                   /evidence="ECO:0000269|PubMed:10078535"
FT   MUTAGEN         82
FT                   /note="P->A: Abolishes interaction with ZAP70."
FT                   /evidence="ECO:0000269|PubMed:10078535"
FT   MUTAGEN         229
FT                   /note="D->Q: Abolishes interaction with ZAP70."
FT                   /evidence="ECO:0000269|PubMed:10078535"
FT   MUTAGEN         240
FT                   /note="E->S: Abolishes interaction with ZAP70."
FT                   /evidence="ECO:0000269|PubMed:10078535"
FT   MUTAGEN         294
FT                   /note="R->K: Abolishes interaction with ZAP70."
FT                   /evidence="ECO:0000269|PubMed:10078535"
FT   MUTAGEN         306
FT                   /note="G->E: Abolishes interaction with ZAP70 and EPHB1,
FT                   but does not affect interaction with SLA."
FT                   /evidence="ECO:0000269|PubMed:10078535,
FT                   ECO:0000269|PubMed:10449770"
FT   MUTAGEN         371
FT                   /note="Y->F: Strongly reduces tyrosine phosphorylation by
FT                   INSR; when associated with F-700 and F-774."
FT                   /evidence="ECO:0000269|PubMed:11997497"
FT   MUTAGEN         381
FT                   /note="C->A: Loss of ubiquitin ligase activity."
FT                   /evidence="ECO:0000269|PubMed:11896602"
FT   MUTAGEN         700
FT                   /note="Y->F: Strongly reduces tyrosine phosphorylation by
FT                   INSR; when associated with F-371 and F-774."
FT                   /evidence="ECO:0000269|PubMed:11997497"
FT   MUTAGEN         731
FT                   /note="Y->F: No effect on tyrosine phosphorylation by INSR.
FT                   Loss of phosphorylation by SRC. Inhibition of bone
FT                   resorption. Abolishes interaction with PIK3R1."
FT                   /evidence="ECO:0000269|PubMed:11997497,
FT                   ECO:0000269|PubMed:14739300"
FT   MUTAGEN         774
FT                   /note="Y->F: Strongly reduces tyrosine phosphorylation by
FT                   INSR; when associated with F-371 and F-700."
FT                   /evidence="ECO:0000269|PubMed:11997497"
FT   CONFLICT        15
FT                   /note="S -> T (in Ref. 1; CAA40393)"
FT                   /evidence="ECO:0000305"
FT   HELIX           53..70
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           73..75
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   STRAND          80..82
FT                   /evidence="ECO:0000244|PDB:5HKY"
FT   HELIX           84..101
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   TURN            102..104
FT                   /evidence="ECO:0000244|PDB:5HKY"
FT   HELIX           106..111
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           113..136
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           137..141
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           146..168
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           170..172
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           176..178
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           184..194
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   STRAND          198..201
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           202..212
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           218..228
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   STRAND          233..237
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           238..247
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           251..253
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           254..261
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   TURN            262..264
FT                   /evidence="ECO:0000244|PDB:2Y1M"
FT   STRAND          268..271
FT                   /evidence="ECO:0000244|PDB:5HKX"
FT   HELIX           274..281
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           282..284
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   STRAND          290..295
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   STRAND          297..299
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   STRAND          302..308
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   TURN            310..312
FT                   /evidence="ECO:0000244|PDB:3BUO"
FT   STRAND          314..317
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   STRAND          320..322
FT                   /evidence="ECO:0000244|PDB:3BUW"
FT   HELIX           324..333
FT                   /evidence="ECO:0000244|PDB:3BUX"
FT   HELIX           350..352
FT                   /evidence="ECO:0000244|PDB:5HKX"
FT   STRAND          354..356
FT                   /evidence="ECO:0000244|PDB:1FBV"
FT   STRAND          360..362
FT                   /evidence="ECO:0000244|PDB:4A49"
FT   HELIX           365..378
FT                   /evidence="ECO:0000244|PDB:5HKX"
FT   TURN            382..384
FT                   /evidence="ECO:0000244|PDB:5HKX"
FT   STRAND          385..388
FT                   /evidence="ECO:0000244|PDB:5HKX"
FT   STRAND          391..394
FT                   /evidence="ECO:0000244|PDB:5HKX"
FT   STRAND          398..400
FT                   /evidence="ECO:0000244|PDB:2K4D"
FT   HELIX           402..410
FT                   /evidence="ECO:0000244|PDB:5HKX"
FT   TURN            417..419
FT                   /evidence="ECO:0000244|PDB:5HKX"
FT   STRAND          425..428
FT                   /evidence="ECO:0000244|PDB:5HKX"
FT   STRAND          430..432
FT                   /evidence="ECO:0000244|PDB:4A49"
FT   HELIX           856..866
FT                   /evidence="ECO:0000244|PDB:2OO9"
FT   HELIX           871..880
FT                   /evidence="ECO:0000244|PDB:2OO9"
FT   TURN            881..883
FT                   /evidence="ECO:0000244|PDB:2OO9"
FT   HELIX           885..895
FT                   /evidence="ECO:0000244|PDB:2OO9"
SQ   SEQUENCE   906 AA;  99633 MW;  1AA6BF67377322CA CRC64;
     MAGNVKKSSG AGGGSGSGGS GSGGLIGLMK DAFQPHHHHH HHLSPHPPGT VDKKMVEKCW
     KLMDKVVRLC QNPKLALKNS PPYILDLLPD TYQHLRTILS RYEGKMETLG ENEYFRVFME
     NLMKKTKQTI SLFKEGKERM YEENSQPRRN LTKLSLIFSH MLAELKGIFP SGLFQGDTFR
     ITKADAAEFW RKAFGEKTIV PWKSFRQALH EVHPISSGLE AMALKSTIDL TCNDYISVFE
     FDIFTRLFQP WSSLLRNWNS LAVTHPGYMA FLTYDEVKAR LQKFIHKPGS YIFRLSCTRL
     GQWAIGYVTA DGNILQTIPH NKPLFQALID GFREGFYLFP DGRNQNPDLT GLCEPTPQDH
     IKVTQEQYEL YCEMGSTFQL CKICAENDKD VKIEPCGHLM CTSCLTSWQE SEGQGCPFCR
     CEIKGTEPIV VDPFDPRGSG SLLRQGAEGA PSPNYDDDDD ERADDTLFMM KELAGAKVER
     PPSPFSMAPQ ASLPPVPPRL DLLPQRVCVP SSASALGTAS KAASGSLHKD KPLPVPPTLR
     DLPPPPPPDR PYSVGAESRP QRRPLPCTPG DCPSRDKLPP VPSSRLGDSW LPRPIPKVPV
     SAPSSSDPWT GRELTNRHSL PFSLPSQMEP RPDVPRLGST FSLDTSMSMN SSPLVGPECD
     HPKIKPSSSA NAIYSLAARP LPVPKLPPGE QCEGEEDTEY MTPSSRPLRP LDTSQSSRAC
     DCDQQIDSCT YEAMYNIQSQ APSITESSTF GEGNLAAAHA NTGPEESENE DDGYDVPKPP
     VPAVLARRTL SDISNASSSF GWLSLDGDPT TNVTEGSQVP ERPPKPFPRR INSERKAGSC
     QQGSGPAASA ATASPQLSSE IENLMSQGYS YQDIQKALVI AQNNIEMAKN ILREFVSISS
     PAHVAT
//
ID   A0A0A0MQR4_HUMAN        Unreviewed;      1606 AA.
AC   A0A0A0MQR4;
DT   07-JAN-2015, integrated into UniProtKB/TrEMBL.
DT   07-JAN-2015, sequence version 1.
DT   22-APR-2020, entry version 44.
DE   SubName: Full=Protein capicua homolog {ECO:0000313|Ensembl:ENSP00000160740};
GN   Name=CIC {ECO:0000313|Ensembl:ENSP00000160740};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000160740, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000160740, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [2] {ECO:0000213|PubMed:17081983}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [3] {ECO:0000213|PubMed:18220336}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.D., Yates J.R.;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [4] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [5] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [6] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [7] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [8] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9] {ECO:0000213|PubMed:24275569}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10] {ECO:0000213|PubMed:24129315}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24129315;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [11] {ECO:0000313|Ensembl:ENSP00000160740}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (NOV-2014) to UniProtKB.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC006486; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; XP_005258730.1; XM_005258673.2.
DR   jPOST; A0A0A0MQR4; -.
DR   PeptideAtlas; A0A0A0MQR4; -.
DR   PRIDE; A0A0A0MQR4; -.
DR   Antibodypedia; 17427; 251 antibodies.
DR   Ensembl; ENST00000160740; ENSP00000160740; ENSG00000079432.
DR   GeneID; 23152; -.
DR   UCSC; uc060zgk.1; human.
DR   CTD; 23152; -.
DR   EuPathDB; HostDB:ENSG00000079432.7; -.
DR   HGNC; HGNC:14214; CIC.
DR   OpenTargets; ENSG00000079432; -.
DR   eggNOG; ENOG410ITBG; Eukaryota.
DR   eggNOG; ENOG4111S7E; LUCA.
DR   GeneTree; ENSGT00940000159960; -.
DR   HOGENOM; CLU_003486_0_0_1; -.
DR   ChiTaRS; CIC; human.
DR   GenomeRNAi; 23152; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000079432; Expressed in right testis and 218 other tissues.
DR   ExpressionAtlas; A0A0A0MQR4; baseline and differential.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-UniRule.
DR   Gene3D; 1.10.30.10; -; 1.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   Pfam; PF00505; HMG_box; 1.
DR   SMART; SM00398; HMG; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 1.
PE   1: Evidence at protein level;
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00267,
KW   ECO:0000256|SAAS:SAAS00879239};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00267};
KW   Proteomics identification {ECO:0000213|EPD:A0A0A0MQR4,
KW   ECO:0000213|MaxQB:A0A0A0MQR4, ECO:0000213|PeptideAtlas:A0A0A0MQR4,
KW   ECO:0000213|ProteomicsDB:A0A0A0MQR4};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   DOMAIN          200..268
FT                   /note="HMG box"
FT                   /evidence="ECO:0000259|PROSITE:PS50118"
FT   DNA_BIND        200..268
FT                   /note="HMG box"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00267"
FT   REGION          48..201
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          270..311
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          326..365
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          381..438
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          470..630
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          686..719
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          785..804
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          890..909
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1129..1153
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1189..1431
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1519..1606
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        50..75
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        99..113
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        134..152
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        174..201
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        470..489
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        508..522
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        530..567
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        890..905
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1131..1147
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1221..1253
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1262..1277
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1284..1298
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1313..1327
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1334..1363
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1390..1417
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1527..1556
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1569..1606
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   1606 AA;  163678 MW;  05017395BCD6FE5F CRC64;
     MYSAHRPLMP ASSAASRGLG MFVWTNVEPR SVAVFPWHSL VPFLAPSQPD PSVQPSEAQQ
     PASHPVASNQ SKEPAESAAV AHERPPGGTG SADPERPPGA TCPESPGPGP PHPLGVVESG
     KGPPPTTEEE ASGPPGEPRL DSETESDHDD AFLSIMSPEI QLPLPPGKRR TQSLSALPKE
     RDSSSEKDGR SPNKREKDHI RRPMNAFMIF SKRHRALVHQ RHPNQDNRTV SKILGEWWYA
     LGPKEKQKYH DLAFQVKEAH FKAHPDWKWC NKDRKKSSSE AKPTSLGLAG GHKETRERSM
     SETGTAAAPG VSSELLSVAA QTLLSSDTKA PGSSSCGAER LHTVGGPGSA RPRAFSHSGV
     HSLDGGEVDS QALQELTQMV SGPASYSGPK PSTQYGAPGP FAAPGEGGAL AATGRPPLLP
     TRASRSQRAA SEDMTSDEER MVICEEEGDD DVIADDGFGT TDIDLKCKER VTDSESGDSS
     GEDPEGNKGF GRKVFSPVIR SSFTHCRPPL DPEPPGPPDP PVAFGKGYGS APSSSASSPA
     SSSASAATSF SLGSGTFKAQ ESGQGSTAGP LRPPPPGAGG PATPSKATRF LPMDPATFRR
     KRPESVGGLE PPGPSVIAAP PSGGGNILQT LVLPPNKEEQ EGGGARVPSA PAPSLAYGAP
     AAPLSRPAAT MVTNVVRPVS STPVPIASKP FPTSGRAEAS PNDTAGARTE MGTGSRVPGG
     SPLGVSLVYS DKKSAAATSP APHLVAGPLL GTVGKAPATV TNLLVGTPGY GAPAPPAVQF
     IAQGAPGGGT TAGSGAGAGS GPNGPVPLGI LQPGALGKAG GITQVQYILP TLPQQLQVAP
     APAPAPGTKA AAPSGPAPTT SIRFTLPPGT STNGKVLAAT APTPGIPILQ SVPSAPPPKA
     QSVSPVQAPP PGGSAQLLPG KVLVPLAAPS MSVRGGGAGQ PLPLVSPPFS VPVQNGAQPP
     SKIIQLTPVP VSTPSGLVPP LSPATLPGPT SQPQKVLLPS STRITYVQSA GGHALPLGTS
     PASSQAGTVT SYGPTSSVAL GFTSLGPSGP AFVQPLLSGQ APLLAPGQVG VSPVPSPQLP
     PACAAPGGPV ITAFYSGSPA PTSSAPLAQP SQAPPSLVYT VATSTTPPAA TILPKGPPAP
     ATATPAPTSP FPSATGSMTY SLVAPKAQRP SPKAPQKVKA AIASIPVGSF EAGASGRPGP
     APRQPLEPGP VREPTAPESE LEGQPTPPAP PPLPETWTPT ARSSPPLPPP AEERTSAKGP
     ETMASKFPSS SSDWRVPGQG LENRGEPPTP PSPAPAPAVA PGGSSESSSG RAAGDTPERK
     EAAGTGKKVK VRPPPLKKTF DSVDNRVLSE VDFEERFAEL PEFRPEEVLP SPTLQSLATS
     PRAILGSYRK KRKNSTDLDS APEDPTSPKR KMRRRSSCSS EPNTPKSAKC EGDIFTFDRT
     GTEAEDVLGE LEYDKVPYSS LRRTLDQRRA LVMQLFQDHG FFPSAQATAA FQARYADIFP
     SKVCLQLKIR EVRQKIMQAA TPTEQPPGAE APLPVPPPTG TAAAPAPTPS PAGGPDPTSP
     SSDSGTAQAA PPLPPPPESG PGQPGWEGAP QPSPPPPGPS TAATGR
//
ID   CIC_HUMAN               Reviewed;        1608 AA.
AC   Q96RK0; Q7LGI1; Q9UEG5; Q9Y6T1;
DT   27-SEP-2005, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   22-APR-2020, entry version 166.
DE   RecName: Full=Protein capicua homolog;
GN   Name=CIC; Synonyms=KIAA0306;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], POSSIBLE FUNCTION, AND VARIANT GLY-982.
RX   PubMed=12393275; DOI=10.1016/s0169-328x(02)00439-4;
RA   Lee C.-J., Chan W.-I., Cheung M., Cheng Y.-C., Appleby V.J., Orme A.T.,
RA   Scotting P.J.;
RT   "CIC, a member of a novel subfamily of the HMG-box superfamily, is
RT   transiently expressed in developing granule neurons.";
RL   Brain Res. Mol. Brain Res. 106:151-156(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 158-1608, AND VARIANT GLY-982.
RC   TISSUE=Brain;
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [4]
RP   TISSUE SPECIFICITY, AND EXPRESSION IN MEDULLOBLASTOMA.
RX   PubMed=15981098; DOI=10.1007/s11060-004-4598-2;
RA   Lee C.-J., Chan W.-I., Scotting P.J.;
RT   "CIC, a gene involved in cerebellar development and ErbB signaling, is
RT   significantly expressed in medulloblastomas.";
RL   J. Neurooncol. 73:101-108(2005).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1378, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-173; SER-721; SER-1373 AND
RP   SER-1382, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-721; SER-1373; SER-1382;
RP   SER-1397; SER-1402 AND SER-1409, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-721 AND SER-1373, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1402, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-173; SER-277; SER-721;
RP   SER-739; SER-1294; SER-1351; SER-1373; SER-1389; SER-1397 AND SER-1409, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-173; SER-362; SER-700;
RP   SER-1397; THR-1398; SER-1409 AND SER-1595, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-863, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-104 AND THR-652.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [15]
RP   VARIANT MRD45 TRP-492.
RX   PubMed=21076407; DOI=10.1038/ng.712;
RA   Vissers L.E., de Ligt J., Gilissen C., Janssen I., Steehouwer M.,
RA   de Vries P., van Lier B., Arts P., Wieskamp N., del Rosario M.,
RA   van Bon B.W., Hoischen A., de Vries B.B., Brunner H.G., Veltman J.A.;
RT   "A de novo paradigm for mental retardation.";
RL   Nat. Genet. 42:1109-1112(2010).
RN   [16]
RP   VARIANTS MRD45 353-ARG--ARG-1608 DEL AND 992-GLN--ARG-1608 DEL, AND
RP   CHARACTERIZATION OF VARIANT MRD45 353-ARG--ARG-1608 DEL.
RX   PubMed=28288114; DOI=10.1038/ng.3808;
RA   Lu H.C., Tan Q., Rousseaux M.W., Wang W., Kim J.Y., Richman R., Wan Y.W.,
RA   Yeh S.Y., Patel J.M., Liu X., Lin T., Lee Y., Fryer J.D., Han J.,
RA   Chahrour M., Finnell R.H., Lei Y., Zurita-Jimenez M.E., Ahimaz P.,
RA   Anyane-Yeboa K., Van Maldergem L., Lehalle D., Jean-Marcais N.,
RA   Mosca-Boidron A.L., Thevenon J., Cousin M.A., Bro D.E., Lanpher B.C.,
RA   Klee E.W., Alexander N., Bainbridge M.N., Orr H.T., Sillitoe R.V.,
RA   Ljungberg M.C., Liu Z., Schaaf C.P., Zoghbi H.Y.;
RT   "Disruption of the ATXN1-CIC complex causes a spectrum of neurobehavioral
RT   phenotypes in mice and humans.";
RL   Nat. Genet. 49:527-536(2017).
RN   [17]
RP   VARIANT 492-ARG--ARG-1608 DEL.
RX   PubMed=30397230; DOI=10.1038/s41467-018-06014-6;
RA   Snijders Blok L., Rousseau J., Twist J., Ehresmann S., Takaku M.,
RA   Venselaar H., Rodan L.H., Nowak C.B., Douglas J., Swoboda K.J.,
RA   Steeves M.A., Sahai I., Stumpel C.T.R.M., Stegmann A.P.A., Wheeler P.,
RA   Willing M., Fiala E., Kochhar A., Gibson W.T., Cohen A.S.A., Agbahovbe R.,
RA   Innes A.M., Au P.Y.B., Rankin J., Anderson I.J., Skinner S.A., Louie R.J.,
RA   Warren H.E., Afenjar A., Keren B., Nava C., Buratti J., Isapof A.,
RA   Rodriguez D., Lewandowski R., Propst J., van Essen T., Choi M., Lee S.,
RA   Chae J.H., Price S., Schnur R.E., Douglas G., Wentzensen I.M., Zweier C.,
RA   Reis A., Bialer M.G., Moore C., Koopmans M., Brilstra E.H., Monroe G.R.,
RA   van Gassen K.L.I., van Binsbergen E., Newbury-Ecob R., Bownass L.,
RA   Bader I., Mayr J.A., Wortmann S.B., Jakielski K.J., Strand E.A., Kloth K.,
RA   Bierhals T., Roberts J.D., Petrovich R.M., Machida S., Kurumizaka H.,
RA   Lelieveld S., Pfundt R., Jansen S., Deriziotis P., Faive L., Thevenon J.,
RA   Assoum M., Shriberg L., Kleefstra T., Brunner H.G., Wade P.A., Fisher S.E.,
RA   Campeau P.M.;
RT   "CHD3 helicase domain mutations cause a neurodevelopmental syndrome with
RT   macrocephaly and impaired speech and language.";
RL   Nat. Commun. 9:4619-4619(2018).
CC   -!- FUNCTION: Transcriptional repressor which plays a role in development
CC       of the central nervous system (CNS). In concert with ATXN1 and ATXN1L,
CC       involved in brain development. {ECO:0000250|UniProtKB:Q924A2}.
CC   -!- SUBUNIT: Interacts with ATXN1 and ATXN1L. Found in a complex with ATXN1
CC       and ATXN1L. {ECO:0000250|UniProtKB:Q924A2}.
CC   -!- INTERACTION:
CC       Q96RK0; P54253: ATXN1; NbExp=8; IntAct=EBI-945857, EBI-930964;
CC       Q96RK0; Q9HC77: CENPJ; NbExp=2; IntAct=EBI-945857, EBI-946194;
CC       Q96RK0; Q08379: GOLGA2; NbExp=4; IntAct=EBI-945857, EBI-618309;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00267}.
CC   -!- TISSUE SPECIFICITY: Expressed in fetal brain.
CC       {ECO:0000269|PubMed:15981098}.
CC   -!- DISEASE: Mental retardation, autosomal dominant 45 (MRD45)
CC       [MIM:617600]: A form of mental retardation, a disorder characterized by
CC       significantly below average general intellectual functioning associated
CC       with impairments in adaptive behavior and manifested during the
CC       developmental period. MRD45 patients manifest developmental delay,
CC       variable intellectual disability, and behavioral disorders, including
CC       autistic features, attention deficit, and hyperactivity.
CC       {ECO:0000269|PubMed:21076407, ECO:0000269|PubMed:28288114}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Expressed in medulloblastoma, a pediatric brain tumor
CC       which may arise from the granule cell lineage.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD11988.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF363689; AAK73515.1; -; mRNA.
DR   EMBL; AC006486; AAD11988.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AB002304; BAA20765.1; -; mRNA.
DR   CCDS; CCDS12601.1; -.
DR   RefSeq; NP_001291744.1; NM_001304815.1.
DR   RefSeq; NP_055940.3; NM_015125.4.
DR   PDB; 2M41; NMR; -; A=34-48.
DR   PDB; 4J2J; X-ray; 2.50 A; D/E/F=28-48.
DR   PDB; 4J2L; X-ray; 3.15 A; C/D=21-48.
DR   PDB; 6JRP; X-ray; 3.00 A; A/D/G/J=199-276.
DR   PDBsum; 2M41; -.
DR   PDBsum; 4J2J; -.
DR   PDBsum; 4J2L; -.
DR   PDBsum; 6JRP; -.
DR   SMR; Q96RK0; -.
DR   BioGrid; 116767; 26.
DR   CORUM; Q96RK0; -.
DR   DIP; DIP-49964N; -.
DR   IntAct; Q96RK0; 24.
DR   MINT; Q96RK0; -.
DR   STRING; 9606.ENSP00000458663; -.
DR   iPTMnet; Q96RK0; -.
DR   PhosphoSitePlus; Q96RK0; -.
DR   BioMuta; CIC; -.
DR   DMDM; 116241300; -.
DR   CPTAC; CPTAC-1346; -.
DR   EPD; Q96RK0; -.
DR   jPOST; Q96RK0; -.
DR   MassIVE; Q96RK0; -.
DR   MaxQB; Q96RK0; -.
DR   PaxDb; Q96RK0; -.
DR   PeptideAtlas; Q96RK0; -.
DR   PRIDE; Q96RK0; -.
DR   ProteomicsDB; 77973; -.
DR   Antibodypedia; 17427; 251 antibodies.
DR   DNASU; 23152; -.
DR   Ensembl; ENST00000575354; ENSP00000458663; ENSG00000079432.
DR   GeneID; 23152; -.
DR   KEGG; hsa:23152; -.
DR   UCSC; uc002otf.1; human.
DR   CTD; 23152; -.
DR   DisGeNET; 23152; -.
DR   GeneCards; CIC; -.
DR   HGNC; HGNC:14214; CIC.
DR   HPA; ENSG00000079432; Low tissue specificity.
DR   MalaCards; CIC; -.
DR   MIM; 612082; gene.
DR   MIM; 617600; phenotype.
DR   neXtProt; NX_Q96RK0; -.
DR   OpenTargets; ENSG00000079432; -.
DR   Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability.
DR   PharmGKB; PA26513; -.
DR   eggNOG; ENOG410ITBG; Eukaryota.
DR   eggNOG; ENOG4111S7E; LUCA.
DR   GeneTree; ENSGT00940000159960; -.
DR   InParanoid; Q96RK0; -.
DR   KO; K20225; -.
DR   OrthoDB; 14207at2759; -.
DR   PhylomeDB; Q96RK0; -.
DR   TreeFam; TF323412; -.
DR   SignaLink; Q96RK0; -.
DR   SIGNOR; Q96RK0; -.
DR   ChiTaRS; CIC; human.
DR   GeneWiki; CIC_(gene); -.
DR   GenomeRNAi; 23152; -.
DR   Pharos; Q96RK0; Tbio.
DR   PRO; PR:Q96RK0; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q96RK0; protein.
DR   Bgee; ENSG00000079432; Expressed in right testis and 218 other tissues.
DR   ExpressionAtlas; Q96RK0; baseline and differential.
DR   Genevisible; Q96RK0; HS.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0007420; P:brain development; ISS:UniProtKB.
DR   GO; GO:0007612; P:learning; ISS:UniProtKB.
DR   GO; GO:0048286; P:lung alveolus development; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0035176; P:social behavior; ISS:UniProtKB.
DR   Gene3D; 1.10.30.10; -; 1.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   Pfam; PF00505; HMG_box; 1.
DR   SMART; SM00398; HMG; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Disease mutation; DNA-binding;
KW   Mental retardation; Methylation; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repressor; Transcription; Transcription regulation.
FT   CHAIN           1..1608
FT                   /note="Protein capicua homolog"
FT                   /id="PRO_0000048598"
FT   DNA_BIND        200..268
FT                   /note="HMG box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00267"
FT   REGION          28..46
FT                   /note="Interaction with ATXN1"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        42..138
FT                   /note="Pro-rich"
FT   COMPBIAS        508..1303
FT                   /note="Pro-rich"
FT   COMPBIAS        1524..1601
FT                   /note="Pro-rich"
FT   MOD_RES         146
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q924A2"
FT   MOD_RES         173
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163, ECO:0000244|PubMed:24275569"
FT   MOD_RES         190
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q924A2"
FT   MOD_RES         277
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         362
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         431
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q924A2"
FT   MOD_RES         436
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q924A2"
FT   MOD_RES         496
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q924A2"
FT   MOD_RES         700
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         721
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         739
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         863
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         934
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q924A2"
FT   MOD_RES         1268
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q924A2"
FT   MOD_RES         1291
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q924A2"
FT   MOD_RES         1294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1351
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1373
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         1378
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18220336"
FT   MOD_RES         1382
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332"
FT   MOD_RES         1389
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1397
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:23186163, ECO:0000244|PubMed:24275569"
FT   MOD_RES         1398
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         1402
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:21406692"
FT   MOD_RES         1409
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:23186163, ECO:0000244|PubMed:24275569"
FT   MOD_RES         1595
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   VARIANT         104
FT                   /note="E -> K (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035936"
FT   VARIANT         353..1608
FT                   /note="Missing (in MRD45; decreased protein expression)"
FT                   /evidence="ECO:0000269|PubMed:28288114"
FT                   /id="VAR_079294"
FT   VARIANT         492..1608
FT                   /note="Missing (probable-disease associated mutation found
FT                   in a patient with Snijders Blok-Campeau syndrome; the
FT                   patient also carries a likely pathogenic variant in CHD3;
FT                   both variants may contribute to disease phenotype)"
FT                   /evidence="ECO:0000269|PubMed:30397230"
FT                   /id="VAR_081527"
FT   VARIANT         492
FT                   /note="R -> W (in MRD45; unknown pathological significance;
FT                   dbSNP:rs373584239)"
FT                   /evidence="ECO:0000269|PubMed:21076407"
FT                   /id="VAR_065090"
FT   VARIANT         652
FT                   /note="A -> T (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs770323488)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035937"
FT   VARIANT         982
FT                   /note="S -> G (in dbSNP:rs17339472)"
FT                   /evidence="ECO:0000269|PubMed:12393275,
FT                   ECO:0000269|PubMed:9205841"
FT                   /id="VAR_028302"
FT   VARIANT         992..1608
FT                   /note="Missing (in MRD45)"
FT                   /evidence="ECO:0000269|PubMed:28288114"
FT                   /id="VAR_079295"
FT   STRAND          31..33
FT                   /evidence="ECO:0000244|PDB:4J2J"
FT   HELIX           37..39
FT                   /evidence="ECO:0000244|PDB:4J2J"
FT   STRAND          44..46
FT                   /evidence="ECO:0000244|PDB:2M41"
FT   HELIX           206..221
FT                   /evidence="ECO:0000244|PDB:6JRP"
FT   HELIX           227..239
FT                   /evidence="ECO:0000244|PDB:6JRP"
FT   HELIX           243..263
FT                   /evidence="ECO:0000244|PDB:6JRP"
FT   STRAND          264..266
FT                   /evidence="ECO:0000244|PDB:6JRP"
SQ   SEQUENCE   1608 AA;  163820 MW;  355603C8BD67244E CRC64;
     MYSAHRPLMP ASSAASRGLG MFVWTNVEPR SVAVFPWHSL VPFLAPSQPD PSVQPSEAQQ
     PASHPVASNQ SKEPAESAAV AHERPPGGTG SADPERPPGA TCPESPGPGP PHPLGVVESG
     KGPPPTTEEE ASGPPGEPRL DSETESDHDD AFLSIMSPEI QLPLPPGKRR TQSLSALPKE
     RDSSSEKDGR SPNKREKDHI RRPMNAFMIF SKRHRALVHQ RHPNQDNRTV SKILGEWWYA
     LGPKEKQKYH DLAFQVKEAH FKAHPDWKWC NKDRKKSSSE AKPTSLGLAG GHKETRERSM
     SETGTAAAPG VSSELLSVAA QTLLSSDTKA PGSSSCGAER LHTVGGPGSA RPRAFSHSGV
     HSLDGGEVDS QALQELTQMV SGPASYSGPK PSTQYGAPGP FAAPGEGGAL AATGRPPLLP
     TRASRSQRAA SEDMTSDEER MVICEEEGDD DVIADDGFGT TDIDLKCKER VTDSESGDSS
     GEDPEGNKGF GRKVFSPVIR SSFTHCRPPL DPEPPGPPDP PVAFGKGYGS APSSSASSPA
     SSSASAATSF SLGSGTFKAQ ESGQGSTAGP LRPPPPGAGG PATPSKATRF LPMDPATFRR
     KRPESVGGLE PPGPSVIAAP PSGGGNILQT LVLPPNKEEQ EGGGARVPSA PAPSLAYGAP
     AAPLSRPAAT MVTNVVRPVS STPVPIASKP FPTSGRAEAS PNDTAGARTE MGTGSRVPGG
     SPLGVSLVYS DKKSAAATSP APHLVAGPLL GTVGKAPATV TNLLVGTPGY GAPAPPAVQF
     IAQGAPGGGT TAGSGAGAGS GPNGPVPLGI LQPGALGKAG GITQVQYILP TLPQQLQVAP
     APAPAPGTKA AAPSGPAPTT SIRFTLPPGT STNGKVLAAT APTPGIPILQ SVPSAPPPKA
     QSVSPVQAPP PGGSAQLLPG KVLVPLAAPS MSVRGGGAGQ PLPLVSPPFS VPVQNGAQPP
     SKIIQLTPVP VSTPSGLVPP LSPATLPGPT SQPQKVLLPS STRITYVQSA GGHALPLGTS
     PASSQAGTVT SYGPTSSVAL GFTSLGPSGP AFVQPLLSAG QAPLLAPGQV GVSPVPSPQL
     PPACAAPGGP VITAFYSGSP APTSSAPLAQ PSQAPPSLVY TVATSTTPPA ATILPKGPPA
     PATATPAPTS PFPSATAGSM TYSLVAPKAQ RPSPKAPQKV KAAIASIPVG SFEAGASGRP
     GPAPRQPLEP GPVREPTAPE SELEGQPTPP APPPLPETWT PTARSSPPLP PPAEERTSAK
     GPETMASKFP SSSSDWRVPG QGLENRGEPP TPPSPAPAPA VAPGGSSESS SGRAAGDTPE
     RKEAAGTGKK VKVRPPPLKK TFDSVDNRVL SEVDFEERFA ELPEFRPEEV LPSPTLQSLA
     TSPRAILGSY RKKRKNSTDL DSAPEDPTSP KRKMRRRSSC SSEPNTPKSA KCEGDIFTFD
     RTGTEAEDVL GELEYDKVPY SSLRRTLDQR RALVMQLFQD HGFFPSAQAT AAFQARYADI
     FPSKVCLQLK IREVRQKIMQ AATPTEQPPG AEAPLPVPPP TGTAAAPAPT PSPAGGPDPT
     SPSSDSGTAQ AAPPLPPPPE SGPGQPGWEG APQPSPPPPG PSTAATGR
//
ID   CBP_HUMAN               Reviewed;        2442 AA.
AC   Q92793; D3DUC9; O00147; Q16376; Q4LE28;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   22-APR-2020, entry version 241.
DE   RecName: Full=CREB-binding protein;
DE   AltName: Full=Histone lysine acetyltransferase CREBBP;
DE            EC=2.3.1.48 {ECO:0000269|PubMed:24616510};
DE   AltName: Full=Protein-lysine acetyltransferase CREBBP;
DE            EC=2.3.1.- {ECO:0000269|PubMed:11154691, ECO:0000269|PubMed:12738767, ECO:0000269|PubMed:24207024, ECO:0000269|PubMed:24939902, ECO:0000269|PubMed:28790157, ECO:0000269|PubMed:30540930};
GN   Name=CREBBP; Synonyms=CBP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9238046; DOI=10.1073/pnas.94.16.8732;
RA   Sobulo O.M., Borrow J., Tomek R., Reshimi S., Harden A., Schlegelberger B.,
RA   Housman D., Doggett N.A., Rowley J.D., Zeleznik-Le N.J.;
RT   "MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute
RT   myeloid leukemia with a t(11;16)(q23;p13.3).";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:8732-8737(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9177780; DOI=10.1006/geno.1997.4699;
RA   Giles R.H., Petrij F., Dauwerse H.G., den Hollander A.I., Lushnikova T.,
RA   van Ommen G.J.B., Goodman R.H., Deaven L.L., Doggett N.A., Peters D.J.M.,
RA   Breuning M.H.;
RT   "Construction of a 1.2-Mb contig surrounding, and molecular analysis of,
RT   the human CREB-binding protein (CBP/CREBBP) gene on chromosome 16p13.3.";
RL   Genomics 42:96-114(1997).
RN   [3]
RP   SEQUENCE REVISION TO 1724-1725; 1789 AND 1812.
RA   Petrij F., den Hollander A.I., Chrivia J.C.;
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M., Ohara R.,
RA   Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long cDNAs
RT   encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-405, AND CHROMOSOMAL TRANSLOCATION WITH
RP   KAT6A.
RX   PubMed=8782817; DOI=10.1038/ng0996-33;
RA   Borrow J., Stanton V.P. Jr., Andresen J.M., Becher R., Behm F.G.,
RA   Chaganti R.S.K., Civin C.I., Disteche C., Dube I., Frischauf A.M.,
RA   Horsman D., Mitelman F., Volinia S., Watmore A.E., Housman D.E.;
RT   "The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a
RT   putative acetyltransferase to the CREB-binding protein.";
RL   Nat. Genet. 14:33-41(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-83, AND CHROMOSOMAL TRANSLOCATION WITH
RP   KAT6B.
RX   PubMed=11157802; DOI=10.1093/hmg/10.4.395;
RA   Panagopoulos I., Fioretos T., Isaksson M., Samuelsson U., Billstroem R.,
RA   Stroembeck B., Mitelman F., Johansson B.;
RT   "Fusion of the MORF and CBP genes in acute myeloid leukemia with the
RT   t(10;16)(q22;p13).";
RL   Hum. Mol. Genet. 10:395-404(2001).
RN   [8]
RP   INTERACTION WITH PCAF.
RX   PubMed=8684459; DOI=10.1038/382319a0;
RA   Yang X.-J., Ogryzko V.V., Nishikawa J., Howard B.H., Nakatani Y.;
RT   "A p300/CBP-associated factor that competes with the adenoviral oncoprotein
RT   E1A.";
RL   Nature 382:319-324(1996).
RN   [9]
RP   INTERACTION WITH HIF1A AND EP300.
RX   PubMed=8917528; DOI=10.1073/pnas.93.23.12969;
RA   Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C., Goldberg M.A.,
RA   Bunn H.F., Livingston D.M.;
RT   "An essential role for p300/CBP in the cellular response to hypoxia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:12969-12973(1996).
RN   [10]
RP   INTERACTION WITH DHX9.
RX   PubMed=9323138; DOI=10.1016/s0092-8674(00)80376-1;
RA   Nakajima T., Uchida C., Anderson S.F., Lee C.-G., Hurwitz J., Parvin J.D.,
RA   Montminy M.;
RT   "RNA helicase A mediates association of CBP with RNA polymerase II.";
RL   Cell 90:1107-1112(1997).
RN   [11]
RP   INTERACTION WITH HTLV-1 TAX (MICROBIAL INFECTION).
RX   PubMed=9528808; DOI=10.1128/mcb.18.4.2392;
RA   Bex F., Yin M.-J., Burny A., Gaynor R.B.;
RT   "Differential transcriptional activation by human T-cell leukemia virus
RT   type 1 Tax mutants is mediated by distinct interactions with CREB binding
RT   protein and p300.";
RL   Mol. Cell. Biol. 18:2392-2405(1998).
RN   [12]
RP   INTERACTION WITH KLF1, AND FUNCTION.
RX   PubMed=9707565; DOI=10.1073/pnas.95.17.9855;
RA   Zhang W., Bieker J.J.;
RT   "Acetylation and modulation of erythroid Krueppel-like factor (EKLF)
RT   activity by interaction with histone acetyltransferases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9855-9860(1998).
RN   [13]
RP   INTERACTION WITH SRCAP.
RX   PubMed=10347196; DOI=10.1074/jbc.274.23.16370;
RA   Johnston H., Kneer J., Chackalaparampil I., Yaciuk P., Chrivia J.;
RT   "Identification of a novel SNF2/SWI2 protein family member, SRCAP, which
RT   interacts with CREB-binding protein.";
RL   J. Biol. Chem. 274:16370-16376(1999).
RN   [14]
RP   INTERACTION WITH PML.
RX   PubMed=10077561; DOI=10.1073/pnas.96.6.2627;
RA   Doucas V., Tini M., Egan D.A., Evans R.M.;
RT   "Modulation of CREB binding protein function by the promyelocytic (PML)
RT   oncoprotein suggests a role for nuclear bodies in hormone signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2627-2632(1999).
RN   [15]
RP   ACETYLATION OF NCOA3.
RX   PubMed=10490106; DOI=10.1016/s0092-8674(00)80054-9;
RA   Chen H., Lin R.J., Xie W., Wilpitz D., Evans R.M.;
RT   "Regulation of hormone-induced histone hyperacetylation and gene activation
RT   via acetylation of an acetylase.";
RL   Cell 98:675-686(1999).
RN   [16]
RP   INTERACTION WITH CITED1.
RX   PubMed=10722728; DOI=10.1074/jbc.275.12.8825;
RA   Yahata T., de Caestecker M.P., Lechleider R.J., Andriole S., Roberts A.B.,
RA   Isselbacher K.J., Shioda T.;
RT   "The MSG1 non-DNA-binding transactivator binds to the p300/CBP
RT   coactivators, enhancing their functional link to the Smad transcription
RT   factors.";
RL   J. Biol. Chem. 275:8825-8834(2000).
RN   [17]
RP   INTERACTION WITH NCOA6.
RX   PubMed=10866662; DOI=10.1128/mcb.20.14.5048-5063.2000;
RA   Mahajan M.A., Samuels H.H.;
RT   "A new family of nuclear receptor coregulators that integrates nuclear
RT   receptor signaling through CBP.";
RL   Mol. Cell. Biol. 20:5048-5063(2000).
RN   [18]
RP   INTERACTION WITH MAFG, AND FUNCTION IN ACETYLATION OF MAFG.
RX   PubMed=11154691; DOI=10.1074/jbc.m007846200;
RA   Hung H.-L., Kim A.Y., Hong W., Rakowski C., Blobel G.A.;
RT   "Stimulation of NF-E2 DNA binding by CREB-binding protein (CBP)-mediated
RT   acetylation.";
RL   J. Biol. Chem. 276:10715-10721(2001).
RN   [19]
RP   INTERACTION WITH NFATC4.
RX   PubMed=11514544; DOI=10.1074/jbc.m102961200;
RA   Yang T.T.C., Davis R.J., Chow C.-W.;
RT   "Requirement of two NFATc4 transactivation domains for CBP potentiation.";
RL   J. Biol. Chem. 276:39569-39576(2001).
RN   [20]
RP   INTERACTION WITH MECOM.
RX   PubMed=11568182; DOI=10.1074/jbc.m106733200;
RA   Chakraborty S., Senyuk V., Sitailo S., Chi Y., Nucifora G.;
RT   "Interaction of EVI1 with cAMP-responsive element-binding protein-binding
RT   protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible
RT   acetylation of EVI1 and in co-localization in nuclear speckles.";
RL   J. Biol. Chem. 276:44936-44943(2001).
RN   [21]
RP   INTERACTION WITH HTLV-1 TAX (MICROBIAL INFECTION).
RX   PubMed=11463834; DOI=10.1128/mcb.21.16.5520-5530.2001;
RA   Scoggin K.E.S., Ulloa A., Nyborg J.K.;
RT   "The oncoprotein Tax binds the SRC-1-interacting domain of CBP/p300 to
RT   mediate transcriptional activation.";
RL   Mol. Cell. Biol. 21:5520-5530(2001).
RN   [22]
RP   INTERACTION WITH HTLV-1 ACCESSORY PROTEIN P30II (MICROBIAL INFECTION).
RX   PubMed=11559821; DOI=10.1128/jvi.75.20.9885-9895.2001;
RA   Zhang W., Nisbet J.W., Albrecht B., Ding W., Kashanchi F., Bartoe J.T.,
RA   Lairmore M.D.;
RT   "Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by
RT   binding CREB binding protein/p300.";
RL   J. Virol. 75:9885-9895(2001).
RN   [23]
RP   INTERACTION WITH TRERF1.
RX   PubMed=11349124; DOI=10.1074/jbc.m100113200;
RA   Gizard F., Lavallee B., DeWitte F., Hum D.W.;
RT   "A novel zinc finger protein TReP-132 interacts with CBP/p300 to regulate
RT   human CYP11A1 gene expression.";
RL   J. Biol. Chem. 276:33881-33892(2001).
RN   [24]
RP   INTERACTION WITH PELP1.
RX   PubMed=11481323; DOI=10.1074/jbc.m103783200;
RA   Vadlamudi R.K., Wang R.-A., Mazumdar A., Kim Y.-S., Shin J., Sahin A.,
RA   Kumar R.;
RT   "Molecular cloning and characterization of PELP1, a novel human coregulator
RT   of estrogen receptor alpha.";
RL   J. Biol. Chem. 276:38272-38279(2001).
RN   [25]
RP   INTERACTION WITH HHV-8 PROTEIN VIRF1 (MICROBIAL INFECTION).
RX   PubMed=11314014; DOI=10.1038/sj.onc.1204163;
RA   Lin R., Genin P., Mamane Y., Sgarbanti M., Battistini A.,
RA   Harrington W.J. Jr., Barber G.N., Hiscott J.;
RT   "HHV-8 encoded vIRF-1 represses the interferon antiviral response by
RT   blocking IRF-3 recruitment of the CBP/p300 coactivators.";
RL   Oncogene 20:800-811(2001).
RN   [26]
RP   INTERACTION WITH SPIB.
RX   PubMed=11864910;
RA   Yamamoto H., Kihara-Negishi F., Yamada T., Suzuki M., Nakano T., Oikawa T.;
RT   "Interaction between the hematopoietic Ets transcription factor Spi-B and
RT   the coactivator CREB-binding protein associated with negative cross-talk
RT   with c-Myb.";
RL   Cell Growth Differ. 13:69-75(2002).
RN   [27]
RP   INTERACTION WITH CITED4.
RX   PubMed=11744733; DOI=10.1074/jbc.m110850200;
RA   Braganca J., Swingler T., Marques F.I.R., Jones T., Eloranta J.J.,
RA   Hurst H.C., Shioda T., Bhattacharya S.;
RT   "Human CREB-binding protein/p300-interacting transactivator with ED-rich
RT   tail (CITED) 4, a new member of the CITED family, functions as a co-
RT   activator for transcription factor AP-2.";
RL   J. Biol. Chem. 277:8559-8565(2002).
RN   [28]
RP   IDENTIFICATION IN A COMPLEX WITH NCOA2; NCOA3; IKKA; IKKB AND IKBKG.
RX   PubMed=11971985; DOI=10.1128/mcb.22.10.3549-3561.2002;
RA   Wu R.-C., Qin J., Hashimoto Y., Wong J., Xu J., Tsai S.Y., Tsai M.-J.,
RA   O'Malley B.W.;
RT   "Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by
RT   I kappa B kinase.";
RL   Mol. Cell. Biol. 22:3549-3561(2002).
RN   [29]
RP   INTERACTION WITH IRF2, AND FUNCTION IN ACETYLATION OF IRF2.
RX   PubMed=12738767; DOI=10.1074/jbc.m213037200;
RA   Masumi A., Yamakawa Y., Fukazawa H., Ozato K., Komuro K.;
RT   "Interferon regulatory factor-2 regulates cell growth through its
RT   acetylation.";
RL   J. Biol. Chem. 278:25401-25407(2003).
RN   [30]
RP   INTERACTION WITH N4BP2.
RX   PubMed=12730195; DOI=10.1074/jbc.m303518200;
RA   Watanabe N., Wachi S., Fujita T.;
RT   "Identification and characterization of BCL-3-binding protein: implications
RT   for transcription and DNA repair or recombination.";
RL   J. Biol. Chem. 278:26102-26110(2003).
RN   [31]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12929931; DOI=10.1359/jbmr.2003.18.8.1419;
RA   Iioka T., Furukawa K., Yamaguchi A., Shindo H., Yamashita S., Tsukazaki T.;
RT   "P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1),
RT   paired-like homeoprotein, through acetylation of the conserved lysine
RT   residue adjacent to the homeodomain.";
RL   J. Bone Miner. Res. 18:1419-1429(2003).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH NPAS2 AND CLOCK.
RX   PubMed=14645221; DOI=10.1074/jbc.m311973200;
RA   Curtis A.M., Seo S.B., Westgate E.J., Rudic R.D., Smyth E.M.,
RA   Chakravarti D., FitzGerald G.A., McNamara P.;
RT   "Histone acetyltransferase-dependent chromatin remodeling and the vascular
RT   clock.";
RL   J. Biol. Chem. 279:7091-7097(2004).
RN   [33]
RP   INTERACTION WITH ELF3.
RX   PubMed=15075319; DOI=10.1074/jbc.m401356200;
RA   Wang H., Fang R., Cho J.-Y., Libermann T.A., Oettgen P.;
RT   "Positive and negative modulation of the transcriptional activity of the
RT   ETS factor ESE-1 through interaction with p300, CREB-binding protein, and
RT   Ku 70/86.";
RL   J. Biol. Chem. 279:25241-25250(2004).
RN   [34]
RP   INTERACTION WITH MLLT7.
RX   PubMed=15126506; DOI=10.1074/jbc.m401138200;
RA   van der Horst A., Tertoolen L.G.J., de Vries-Smits L.M.M., Frye R.A.,
RA   Medema R.H., Burgering B.M.T.;
RT   "FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity
RT   protein hSir2(SIRT1).";
RL   J. Biol. Chem. 279:28873-28879(2004).
RN   [35]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15488321; DOI=10.1016/j.neulet.2004.08.062;
RA   Pradhan A., Liu Y.;
RT   "The calcium-responsive transactivator recruits CREB binding protein to
RT   nuclear bodies.";
RL   Neurosci. Lett. 370:191-195(2004).
RN   [36]
RP   INTERACTION WITH FOXO1.
RX   PubMed=15220471; DOI=10.1073/pnas.0400593101;
RA   Daitoku H., Hatta M., Matsuzaki H., Aratani S., Ohshima T., Miyagishi M.,
RA   Nakajima T., Fukamizu A.;
RT   "Silent information regulator 2 potentiates Foxo1-mediated transcription
RT   through its deacetylase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:10042-10047(2004).
RN   [37]
RP   INTERACTION WITH SS18L1/CREST.
RX   PubMed=14716005; DOI=10.1126/science.1089845;
RA   Aizawa H., Hu S.-C., Bobb K., Balakrishnan K., Ince G., Gurevich I.,
RA   Cowan M., Ghosh A.;
RT   "Dendrite development regulated by CREST, a calcium-regulated
RT   transcriptional activator.";
RL   Science 303:197-202(2004).
RN   [38]
RP   PHOSPHORYLATION AT SER-1382 AND SER-1386 BY CHUK/IKKA.
RX   PubMed=17434128; DOI=10.1016/j.molcel.2007.02.019;
RA   Huang W.C., Ju T.K., Hung M.C., Chen C.C.;
RT   "Phosphorylation of CBP by IKKalpha promotes cell growth by switching the
RT   binding preference of CBP from p53 to NF-kappaB.";
RL   Mol. Cell 26:75-87(2007).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1030, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [40]
RP   INTERACTION WITH MTDH.
RX   PubMed=18316612; DOI=10.1158/0008-5472.can-07-6164;
RA   Sarkar D., Park E.S., Emdad L., Lee S.-G., Su Z.-Z., Fisher P.B.;
RT   "Molecular basis of nuclear factor-kappaB activation by astrocyte elevated
RT   gene-1.";
RL   Cancer Res. 68:1478-1484(2008).
RN   [41]
RP   INTERACTION WITH HUMAN T-CELL LEUKEMIA VIRUS 1/HTLV-1 PROTEIN HBZ.
RX   PubMed=18599479; DOI=10.1074/jbc.m803116200;
RA   Clerc I., Polakowski N., Andre-Arpin C., Cook P., Barbeau B., Mesnard J.M.,
RA   Lemasson I.;
RT   "An interaction between the human T cell leukemia virus type 1 basic
RT   leucine zipper factor (HBZ) and the KIX domain of p300/CBP contributes to
RT   the down-regulation of tax-dependent viral transcription by HBZ.";
RL   J. Biol. Chem. 283:23903-23913(2008).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-121; SER-2063; SER-2076 AND
RP   SER-2079, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [43]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2063, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [45]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1014; LYS-1216; LYS-1583;
RP   LYS-1591; LYS-1592; LYS-1595; LYS-1597; LYS-1741 AND LYS-1744, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-121, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [47]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [48]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1076; SER-1763 AND SER-2063,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [50]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=24207024; DOI=10.1016/j.molcel.2013.10.010;
RA   Chen S., Seiler J., Santiago-Reichelt M., Felbel K., Grummt I., Voit R.;
RT   "Repression of RNA polymerase I upon stress is caused by inhibition of RNA-
RT   dependent deacetylation of PAF53 by SIRT7.";
RL   Mol. Cell 52:303-313(2013).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [52]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-220, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [53]
RP   FUNCTION AS ACETYLTRANSFERASE OF PCNA, AND INTERACTION WITH PCNA.
RX   PubMed=24939902; DOI=10.1093/nar/gku533;
RA   Cazzalini O., Sommatis S., Tillhon M., Dutto I., Bachi A., Rapp A.,
RA   Nardo T., Scovassi A.I., Necchi D., Cardoso M.C., Stivala L.A.,
RA   Prosperi E.;
RT   "CBP and p300 acetylate PCNA to link its degradation with nucleotide
RT   excision repair synthesis.";
RL   Nucleic Acids Res. 42:8433-8448(2014).
RN   [54]
RP   FUNCTION, AND INTERACTION WITH SMAD4.
RX   PubMed=25514493; DOI=10.1016/j.bbagrm.2014.12.008;
RA   Yang Y., Cui J., Xue F., Zhang C., Mei Z., Wang Y., Bi M., Shan D.,
RA   Meredith A., Li H., Xu Z.Q.;
RT   "Pokemon (FBI-1) interacts with Smad4 to repress TGF-beta-induced
RT   transcriptional responses.";
RL   Biochim. Biophys. Acta 1849:270-281(2015).
RN   [55]
RP   INTERACTION WITH DUX4.
RX   PubMed=26951377; DOI=10.1093/nar/gkw141;
RA   Choi S.H., Gearhart M.D., Cui Z., Bosnakovski D., Kim M., Schennum N.,
RA   Kyba M.;
RT   "DUX4 recruits p300/CBP through its C-terminus and induces global H3K27
RT   acetylation changes.";
RL   Nucleic Acids Res. 44:5161-5173(2016).
RN   [56]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=28790157; DOI=10.1101/gad.300624.117;
RA   Song C., Hotz-Wagenblatt A., Voit R., Grummt I.;
RT   "SIRT7 and the DEAD-box helicase DDX21 cooperate to resolve genomic R loops
RT   and safeguard genome stability.";
RL   Genes Dev. 31:1370-1381(2017).
RN   [57]
RP   INTERACTION WITH DDX3X.
RX   PubMed=28128295; DOI=10.1038/srep41452;
RA   Tsai T.Y., Wang W.T., Li H.K., Chen W.J., Tsai Y.H., Chao C.H.,
RA   Wu Lee Y.H.;
RT   "RNA helicase DDX3 maintains lipid homeostasis through upregulation of the
RT   microsomal triglyceride transfer protein by interacting with HNF4 and
RT   SHP.";
RL   Sci. Rep. 7:41452-41452(2017).
RN   [58]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=30540930; DOI=10.1016/j.celrep.2018.11.051;
RA   Iyer-Bierhoff A., Krogh N., Tessarz P., Ruppert T., Nielsen H., Grummt I.;
RT   "SIRT7-dependent deacetylation of fibrillarin controls histone H2A
RT   methylation and rRNA synthesis during the cell cycle.";
RL   Cell Rep. 25:2946-2954(2018).
RN   [59]
RP   STRUCTURE BY NMR OF 345-439 IN COMPLEX WITH 776-826 OF HIF1A.
RX   PubMed=11959977; DOI=10.1073/pnas.082121399;
RA   Dames S.A., Martinez-Yamout M., De Guzman R.N., Dyson H.J., Wright P.E.;
RT   "Structural basis for Hif-1 alpha /CBP recognition in the cellular hypoxic
RT   response.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:5271-5276(2002).
RN   [60]
RP   CHROMOSOMAL TRANSLOCATION WITH KAT6A.
RX   PubMed=11742995; DOI=10.1093/emboj/20.24.7184;
RA   Kitabayashi I., Aikawa Y., Nguyen L.A., Yokoyama A., Ohki M.;
RT   "Activation of AML1-mediated transcription by MOZ and inhibition by the
RT   MOZ-CBP fusion protein.";
RL   EMBO J. 20:7184-7196(2001).
RN   [61]
RP   STRUCTURE BY NMR OF 589-679 IN COMPLEX WITH HIV-1 TAT (MICROBIAL
RP   INFECTION).
RX   PubMed=14744133; DOI=10.1021/bi035612l;
RA   Vendel A.C., Lumb K.J.;
RT   "NMR mapping of the HIV-1 Tat interaction surface of the KIX domain of the
RT   human coactivator CBP.";
RL   Biochemistry 43:904-908(2004).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1081-1197.
RX   PubMed=22464331; DOI=10.1016/j.cell.2012.02.013;
RA   Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P.,
RA   Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T.,
RA   Gingras A.C., Arrowsmith C.H., Knapp S.;
RT   "Histone recognition and large-scale structural analysis of the human
RT   bromodomain family.";
RL   Cell 149:214-231(2012).
RN   [63] {ECO:0000244|PDB:2LXS, ECO:0000244|PDB:2LXT}
RP   STRUCTURE BY NMR OF 587-673 IN COMPLEX WITH KMT2A AND CREB1.
RX   PubMed=23651431; DOI=10.1021/cb4002188;
RA   Bruschweiler S., Konrat R., Tollinger M.;
RT   "Allosteric communication in the KIX domain proceeds through dynamic
RT   repacking of the hydrophobic core.";
RL   ACS Chem. Biol. 8:1600-1610(2013).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 1082-1197, FUNCTION, INTERACTION
RP   WITH ASF1A; ASF1B; ACETYLATED HISTONES AND TP53, MUTAGENESIS OF ASP-1116;
RP   PHE-1126; ASN-1162; TRP-1165; SER-1179; LYS-1180 AND GLU-1183,
RP   CHARACTERIZATION OF VARIANT RSTS1 CYS-1175, CATALYTIC ACTIVITY, AND
RP   AUTOACETYLATION.
RX   PubMed=24616510; DOI=10.1073/pnas.1319122111;
RA   Das C., Roy S., Namjoshi S., Malarkey C.S., Jones D.N., Kutateladze T.G.,
RA   Churchill M.E., Tyler J.K.;
RT   "Binding of the histone chaperone ASF1 to the CBP bromodomain promotes
RT   histone acetylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:E1072-E1081(2014).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (1.83 ANGSTROMS) OF 1080-1316 IN COMPLEX WITH ZINC.
RX   PubMed=24361270; DOI=10.1016/j.str.2013.10.021;
RA   Plotnikov A.N., Yang S., Zhou T.J., Rusinova E., Frasca A., Zhou M.M.;
RT   "Structural insights into acetylated-histone H4 recognition by the
RT   bromodomain-PHD finger module of human transcriptional coactivator CBP.";
RL   Structure 22:353-360(2014).
RN   [66] {ECO:0000244|PDB:5JEM}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 2065-2111 IN COMPLEX WITH IRF3.
RX   PubMed=27302953; DOI=10.1073/pnas.1603269113;
RA   Zhao B., Shu C., Gao X., Sankaran B., Du F., Shelton C.L., Herr A.B.,
RA   Ji J.Y., Li P.;
RT   "Structural basis for concerted recruitment and activation of IRF-3 by
RT   innate immune adaptor proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:E3403-E3412(2016).
RN   [67]
RP   VARIANT RSTS1 PRO-1378.
RX   PubMed=11331617; DOI=10.1093/hmg/10.10.1071;
RA   Murata T., Kurokawa R., Krones A., Tatsumi K., Ishii M., Taki T.,
RA   Masuno M., Ohashi H., Yanagisawa M., Rosenfeld M.G., Glass C.K.,
RA   Hayashi Y.;
RT   "Defect of histone acetyltransferase activity of the nuclear
RT   transcriptional coactivator CBP in Rubinstein-Taybi syndrome.";
RL   Hum. Mol. Genet. 10:1071-1076(2001).
RN   [68]
RP   VARIANT RSTS1 CYS-1175.
RX   PubMed=12114483; DOI=10.1136/jmg.39.7.496;
RA   Bartsch O., Locher K., Meinecke P., Kress W., Seemanova E., Wagner A.,
RA   Ostermann K., Roedel G.;
RT   "Molecular studies in 10 cases of Rubinstein-Taybi syndrome, including a
RT   mild variant showing a missense mutation in codon 1175 of CREBBP.";
RL   J. Med. Genet. 39:496-501(2002).
RN   [69]
RP   VARIANTS RSTS1 LYS-1278 AND HIS-1664, AND CHARACTERIZATION OF VARIANTS
RP   RSTS1 LYS-1278 AND HIS-1664.
RX   PubMed=12566391; DOI=10.1093/hmg/ddg039;
RA   Kalkhoven E., Roelfsema J.H., Teunissen H., den Boer A., Ariyuerek Y.,
RA   Zantema A., Breuning M.H., Hennekam R.C.M., Peters D.J.M.;
RT   "Loss of CBP acetyltransferase activity by PHD finger mutations in
RT   Rubinstein-Taybi syndrome.";
RL   Hum. Mol. Genet. 12:441-450(2003).
RN   [70]
RP   VARIANTS RSTS1 LYS-1278; ILE-1447; HIS-1450; ARG-1470 AND HIS-1664.
RX   PubMed=15706485; DOI=10.1086/429130;
RA   Roelfsema J.H., White S.J., Ariyuerek Y., Bartholdi D., Niedrist D.,
RA   Papadia F., Bacino C.A., den Dunnen J.T., van Ommen G.-J.B., Breuning M.H.,
RA   Hennekam R.C., Peters D.J.M.;
RT   "Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the
RT   CBP and EP300 genes cause disease.";
RL   Am. J. Hum. Genet. 76:572-580(2005).
RN   [71]
RP   VARIANT RSTS1 ALA-910.
RX   PubMed=20684013; DOI=10.1002/ajmg.a.33598;
RA   Bartsch O., Kress W., Kempf O., Lechno S., Haaf T., Zechner U.;
RT   "Inheritance and variable expression in Rubinstein-Taybi syndrome.";
RL   Am. J. Med. Genet. A 152A:2254-2261(2010).
RN   [72]
RP   VARIANTS HIS-503; THR-532 AND ASN-546, AND VARIANTS RSTS1 PHE-650; THR-789;
RP   CYS-1175; ALA-1278; PRO-1378; TYR-1406; PRO-1415; THR-1475; PHE-1503;
RP   PRO-1507 AND ASN-1543.
RX   PubMed=25388907; DOI=10.1111/cge.12537;
RA   Spena S., Milani D., Rusconi D., Negri G., Colapietro P., Elcioglu N.,
RA   Bedeschi F., Pilotta A., Spaccini L., Ficcadenti A., Magnani C.,
RA   Scarano G., Selicorni A., Larizza L., Gervasini C.;
RT   "Insights into genotype-phenotype correlations from CREBBP point mutation
RT   screening in a cohort of 46 Rubinstein-Taybi syndrome patients.";
RL   Clin. Genet. 88:431-440(2015).
RN   [73]
RP   VARIANTS MKHK1 ARG-1710; ARG-1747; PRO-1786; PHE-1819; TRP-1826; TYR-1838;
RP   GLN-1867; TRP-1867; TRP-1868 AND VAL-1872, AND INVOLVEMENT IN MKHK1.
RX   PubMed=27311832; DOI=10.1002/ajmg.a.37800;
RG   DDD Study;
RA   Menke L.A., van Belzen M.J., Alders M., Cristofoli F., Ehmke N.,
RA   Fergelot P., Foster A., Gerkes E.H., Hoffer M.J., Horn D., Kant S.G.,
RA   Lacombe D., Leon E., Maas S.M., Melis D., Muto V., Park S.M., Peeters H.,
RA   Peters D.J., Pfundt R., van Ravenswaaij-Arts C.M., Tartaglia M.,
RA   Hennekam R.C.;
RT   "CREBBP mutations in individuals without Rubinstein-Taybi syndrome
RT   phenotype.";
RL   Am. J. Med. Genet. A 170:2681-2693(2016).
RN   [74]
RP   VARIANTS MKHK1 ASP-1719; VAL-1782; ASP-1829; 1865-MET-ARG-1866 DELINS ILE;
RP   GLN-1867; GLN-1868; TRP-1868; PRO-1870 AND VAL-1872, AND INVOLVEMENT IN
RP   MKHK1.
RX   PubMed=29460469; DOI=10.1002/ajmg.a.38626;
RG   DDD study;
RA   Menke L.A., Gardeitchik T., Hammond P., Heimdal K.R., Houge G.,
RA   Hufnagel S.B., Ji J., Johansson S., Kant S.G., Kinning E., Leon E.L.,
RA   Newbury-Ecob R., Paolacci S., Pfundt R., Ragge N.K., Rinne T.,
RA   Ruivenkamp C., Saitta S.C., Sun Y., Tartaglia M., Terhal P.A.,
RA   van Essen A.J., Vigeland M.D., Xiao B., Hennekam R.C.;
RT   "Further delineation of an entity caused by CREBBP and EP300 mutations but
RT   not resembling Rubinstein-Taybi syndrome.";
RL   Am. J. Med. Genet. A 176:862-876(2018).
RN   [75]
RP   VARIANT MKHK1 LYS-1724.
RX   PubMed=30737887; DOI=10.1002/ajmg.a.61052;
RA   Angius A., Uva P., Oppo M., Persico I., Onano S., Olla S., Pes V.,
RA   Perria C., Cuccuru G., Atzeni R., Serra G., Cucca F., Sotgiu S.,
RA   Hennekam R.C., Crisponi L.;
RT   "Confirmation of a new phenotype in an individual with a variant in the
RT   last part of exon 30 of CREBBP.";
RL   Am. J. Med. Genet. A 179:634-638(2019).
CC   -!- FUNCTION: Acetylates histones, giving a specific tag for
CC       transcriptional activation (PubMed:24616510). Also acetylates non-
CC       histone proteins, like DDX21, FBL, IRF2, MAFG, NCOA3, POLR1E/PAF53 and
CC       FOXO1 (PubMed:10490106, PubMed:11154691, PubMed:12738767,
CC       PubMed:12929931, PubMed:9707565, PubMed:24207024, PubMed:28790157,
CC       PubMed:30540930). Binds specifically to phosphorylated CREB and
CC       enhances its transcriptional activity toward cAMP-responsive genes.
CC       Acts as a coactivator of ALX1. Acts as a circadian transcriptional
CC       coactivator which enhances the activity of the circadian
CC       transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1
CC       heterodimers (PubMed:14645221). Acetylates PCNA; acetylation promotes
CC       removal of chromatin-bound PCNA and its degradation during nucleotide
CC       excision repair (NER) (PubMed:24939902). Acetylates POLR1E/PAF53,
CC       leading to decreased association of RNA polymerase I with the rDNA
CC       promoter region and coding region (PubMed:24207024). Acetylates DDX21,
CC       thereby inhibiting DDX21 helicase activity (PubMed:28790157).
CC       Acetylates FBL, preventing methylation of 'Gln-105' of histone H2A
CC       (H2AQ104me) (PubMed:30540930). Functions as a transcriptional
CC       coactivator for SMAD4 in the TGF-beta signaling pathway
CC       (PubMed:25514493). {ECO:0000269|PubMed:10490106,
CC       ECO:0000269|PubMed:11154691, ECO:0000269|PubMed:12738767,
CC       ECO:0000269|PubMed:12929931, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:24207024, ECO:0000269|PubMed:24616510,
CC       ECO:0000269|PubMed:24939902, ECO:0000269|PubMed:25514493,
CC       ECO:0000269|PubMed:28790157, ECO:0000269|PubMed:30540930,
CC       ECO:0000269|PubMed:9707565}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=acetyl-CoA + L-lysyl-[histone] = CoA + H(+) + N(6)-acetyl-L-
CC         lysyl-[histone]; Xref=Rhea:RHEA:21992, Rhea:RHEA-COMP:9845,
CC         Rhea:RHEA-COMP:11338, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57288, ChEBI:CHEBI:61930; EC=2.3.1.48;
CC         Evidence={ECO:0000269|PubMed:24616510};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21993;
CC         Evidence={ECO:0000269|PubMed:24616510};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=acetyl-CoA + L-lysyl-[protein] = CoA + H(+) + N(6)-acetyl-L-
CC         lysyl-[protein]; Xref=Rhea:RHEA:45948, Rhea:RHEA-COMP:9752,
CC         Rhea:RHEA-COMP:10731, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57288, ChEBI:CHEBI:61930;
CC         Evidence={ECO:0000269|PubMed:11154691, ECO:0000269|PubMed:12738767,
CC         ECO:0000269|PubMed:24207024, ECO:0000269|PubMed:24939902,
CC         ECO:0000269|PubMed:30540930};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45949;
CC         Evidence={ECO:0000269|PubMed:11154691, ECO:0000269|PubMed:12738767,
CC         ECO:0000269|PubMed:24207024, ECO:0000269|PubMed:24939902,
CC         ECO:0000269|PubMed:28790157, ECO:0000269|PubMed:30540930};
CC   -!- SUBUNIT: Found in a complex containing NCOA2; NCOA3; IKKA; IKKB and
CC       IKBKG. Probably part of a complex with HIF1A and EP300. Interacts with
CC       GATA1; the interaction results in acetylation and enhancement of
CC       transcriptional activity of GATA1. Interacts with MAF AND ZCCHC12.
CC       Interacts with DAXX; the interaction is dependent on CBP sumoylation
CC       and results in suppression of the transcriptional activity via
CC       recruitment of HDAC2 to DAXX (By similarity). Interacts with
CC       phosphorylated CREB1. Interacts with CITED4 (C-terminal region).
CC       Interacts (via the TAZ-type 1 domain) with HIF1A. Interacts with SRCAP,
CC       CARM1, ELF3, MLLT7/FOXO4, N4BP2, NCOA1, NCOA3, NCOA6, PCAF, DDX5,
CC       DDX17, PELP1, PML, SMAD1, SMAD2, SMAD3, SPIB and TRERF1. Interacts with
CC       KLF1; the interaction results in acetylation of KLF1 and enhancement of
CC       its transcriptional activity. Interacts with MTDH. Interacts with
CC       NFATC4. Interacts with MAFG; the interaction acetylates MAFG in the
CC       basic region and stimulates NFE2 transcriptional activity through
CC       increasing its DNA-binding activity. Interacts with IRF2; the
CC       interaction acetylates IRF2 and regulates its activity on the H4
CC       promoter. Interacts with IRF3 (when phosphorylated); forming the dsRNA-
CC       activated factor 1 (DRAF1), a complex which activates the transcription
CC       of the type I interferon genes (PubMed:27302953). Interacts (via N-
CC       terminus) with SS18L1/CREST (via C-terminus). Interacts with MECOM.
CC       Interacts with CITED1 (via C-terminus). Interacts with FOXO1; the
CC       interaction acetylates FOXO1 and inhibits its transcriptional activity.
CC       Interacts with NPAS2, CLOCK and ARNTL/BMAL1. Interacts with ASF1A and
CC       ASF1B; this promotes histone acetylation. Interacts with acetylated
CC       TP53/p53 and with the acetylated histones H3 and H4. Interacts (via
CC       transactivation domain and C-terminus) with PCNA; the interaction
CC       occurs on chromatin in UV-irradiated damaged cells (PubMed:24939902).
CC       Interacts with DHX9 (via N-terminus); this interaction mediates
CC       association with RNA polymerase II holoenzyme and stimulates CREB-
CC       dependent transcriptional activation (PubMed:9323138). Interacts with
CC       SMAD4; negatively regulated by ZBTB7A (PubMed:25514493). Interacts with
CC       DUX4 (via C-terminus) (PubMed:26951377). Forms a complex with KMT2A and
CC       CREB1 (PubMed:23651431). Interacts with DDX3X; this interaction may
CC       facilitate HNF4A acetylation (PubMed:28128295). {ECO:0000250,
CC       ECO:0000269|PubMed:10077561, ECO:0000269|PubMed:10347196,
CC       ECO:0000269|PubMed:10722728, ECO:0000269|PubMed:10866662,
CC       ECO:0000269|PubMed:11154691, ECO:0000269|PubMed:11349124,
CC       ECO:0000269|PubMed:11481323, ECO:0000269|PubMed:11514544,
CC       ECO:0000269|PubMed:11568182, ECO:0000269|PubMed:11744733,
CC       ECO:0000269|PubMed:11864910, ECO:0000269|PubMed:11959977,
CC       ECO:0000269|PubMed:11971985, ECO:0000269|PubMed:12730195,
CC       ECO:0000269|PubMed:12738767, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:14716005, ECO:0000269|PubMed:15075319,
CC       ECO:0000269|PubMed:15126506, ECO:0000269|PubMed:15220471,
CC       ECO:0000269|PubMed:18316612, ECO:0000269|PubMed:23651431,
CC       ECO:0000269|PubMed:24616510, ECO:0000269|PubMed:24939902,
CC       ECO:0000269|PubMed:25514493, ECO:0000269|PubMed:26951377,
CC       ECO:0000269|PubMed:27302953, ECO:0000269|PubMed:28128295,
CC       ECO:0000269|PubMed:8684459, ECO:0000269|PubMed:8917528,
CC       ECO:0000269|PubMed:9323138, ECO:0000269|PubMed:9707565}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HTLV-1 Tax, p30II and
CC       HBZ. {ECO:0000269|PubMed:11463834, ECO:0000269|PubMed:11559821,
CC       ECO:0000269|PubMed:9528808}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human herpes virus 8/HHV-
CC       8 protein vIRF-1; this interaction inhibits CREBBP binding to IRF3.
CC       {ECO:0000269|PubMed:11314014}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Tat.
CC       {ECO:0000269|PubMed:14744133}.
CC   -!- INTERACTION:
CC       Q92793; P03070; Xeno; NbExp=2; IntAct=EBI-81215, EBI-617698;
CC       Q92793; P03255; Xeno; NbExp=3; IntAct=EBI-81215, EBI-2603114;
CC       Q92793; P03259; Xeno; NbExp=5; IntAct=EBI-81215, EBI-6947456;
CC       Q92793; P03259-2; Xeno; NbExp=3; IntAct=EBI-81215, EBI-7225021;
CC       Q92793; P31749: AKT1; NbExp=3; IntAct=EBI-81215, EBI-296087;
CC       Q92793; P10275: AR; NbExp=2; IntAct=EBI-81215, EBI-608057;
CC       Q92793; P61201: COPS2; NbExp=3; IntAct=EBI-81215, EBI-1050386;
CC       Q92793; P16220: CREB1; NbExp=3; IntAct=EBI-81215, EBI-711855;
CC       Q92793; P35222: CTNNB1; NbExp=2; IntAct=EBI-81215, EBI-491549;
CC       Q92793; Q9UER7: DAXX; NbExp=2; IntAct=EBI-81215, EBI-77321;
CC       Q92793; Q12778: FOXO1; NbExp=3; IntAct=EBI-81215, EBI-1108782;
CC       Q92793; O43524: FOXO3; NbExp=3; IntAct=EBI-81215, EBI-1644164;
CC       Q92793; P62805: H4C9; NbExp=6; IntAct=EBI-81215, EBI-302023;
CC       Q92793; Q16665: HIF1A; NbExp=2; IntAct=EBI-81215, EBI-447269;
CC       Q92793; P42858: HTT; NbExp=2; IntAct=EBI-81215, EBI-466029;
CC       Q92793; P48551: IFNAR2; NbExp=4; IntAct=EBI-81215, EBI-958408;
CC       Q92793; O14920: IKBKB; NbExp=2; IntAct=EBI-81215, EBI-81266;
CC       Q92793; Q14653: IRF3; NbExp=10; IntAct=EBI-81215, EBI-2650369;
CC       Q92793; Q13568: IRF5; NbExp=3; IntAct=EBI-81215, EBI-3931258;
CC       Q92793; Q92831: KAT2B; NbExp=4; IntAct=EBI-81215, EBI-477430;
CC       Q92793; Q13351: KLF1; NbExp=2; IntAct=EBI-81215, EBI-8284732;
CC       Q92793; Q86UE4: MTDH; NbExp=2; IntAct=EBI-81215, EBI-1046588;
CC       Q92793; P55209: NAP1L1; NbExp=3; IntAct=EBI-81215, EBI-356392;
CC       Q92793; Q14686: NCOA6; NbExp=2; IntAct=EBI-81215, EBI-78670;
CC       Q92793; Q04206: RELA; NbExp=6; IntAct=EBI-81215, EBI-73886;
CC       Q92793; O95863: SNAI1; NbExp=9; IntAct=EBI-81215, EBI-1045459;
CC       Q92793; P36956-1: SREBF1; NbExp=3; IntAct=EBI-81215, EBI-948328;
CC       Q92793; P36956-3: SREBF1; NbExp=2; IntAct=EBI-81215, EBI-948338;
CC       Q92793; Q12772: SREBF2; NbExp=2; IntAct=EBI-81215, EBI-465059;
CC       Q92793; P04608: tat; Xeno; NbExp=2; IntAct=EBI-81215, EBI-6164389;
CC       Q92793; Q9UL17: TBX21; NbExp=4; IntAct=EBI-81215, EBI-3922312;
CC       Q92793; P04637: TP53; NbExp=11; IntAct=EBI-81215, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Recruited to nuclear
CC       bodies by SS18L1/CREST. In the presence of ALX1 relocalizes from the
CC       cytoplasm to the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q92793-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q92793-2; Sequence=VSP_045700;
CC   -!- DOMAIN: The KIX domain mediates binding to HIV-1 Tat.
CC   -!- PTM: Methylation of the KIX domain by CARM1 blocks association with
CC       CREB. This results in the blockade of CREB signaling, and in activation
CC       of apoptotic response (By similarity). {ECO:0000250|UniProtKB:P45481}.
CC   -!- PTM: Phosphorylated by CHUK/IKKA at Ser-1382 and Ser-1386; these
CC       phosphorylations promote cell growth by switching the binding
CC       preference of CREBBP from TP53 to NF-kappa-B.
CC       {ECO:0000269|PubMed:17434128}.
CC   -!- PTM: Sumoylation negatively regulates transcriptional activity via the
CC       recruitment of DAAX. {ECO:0000250|UniProtKB:P45481}.
CC   -!- PTM: Autoacetylation is required for binding to protein substrates,
CC       such as acetylated histones and acetylated TP53/p53.
CC       {ECO:0000269|PubMed:24616510}.
CC   -!- DISEASE: Note=Chromosomal aberrations involving CREBBP may be a cause
CC       of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with KAT6A;
CC       translocation t(11;16)(q23;p13.3) with KMT2A/MLL1; translocation
CC       t(10;16)(q22;p13) with KAT6B. KAT6A-CREBBP may induce leukemia by
CC       inhibiting RUNX1-mediated transcription.
CC   -!- DISEASE: Rubinstein-Taybi syndrome 1 (RSTS1) [MIM:180849]: A disorder
CC       characterized by craniofacial abnormalities, postnatal growth
CC       deficiency, broad thumbs, broad big toes, mental retardation and a
CC       propensity for development of malignancies.
CC       {ECO:0000269|PubMed:11331617, ECO:0000269|PubMed:12114483,
CC       ECO:0000269|PubMed:12566391, ECO:0000269|PubMed:15706485,
CC       ECO:0000269|PubMed:20684013, ECO:0000269|PubMed:24616510,
CC       ECO:0000269|PubMed:25388907}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Menke-Hennekam syndrome 1 (MKHK1) [MIM:618332]: A form of
CC       Menke-Hennekam syndrome, a congenital autosomal dominant disease
CC       characterized by developmental delay, growth retardation, and
CC       craniofacial dysmorphism. Patients have intellectual disability of
CC       variable severity, speech delay, autistic behavior, short stature and
CC       microcephaly. Main facial characteristics include short palpebral
CC       fissures, telecanthi, depressed nasal ridge, short nose, anteverted
CC       nares, short columella and long philtrum. {ECO:0000269|PubMed:27311832,
CC       ECO:0000269|PubMed:29460469, ECO:0000269|PubMed:30737887}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAE06125.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CBPID42.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=P300/CBP entry;
CC       URL="https://en.wikipedia.org/wiki/P300/CBP";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U85962; AAC51331.2; -; mRNA.
DR   EMBL; U89354; AAC51339.1; -; mRNA.
DR   EMBL; U89355; AAC51340.1; -; mRNA.
DR   EMBL; U47741; AAC51770.1; -; mRNA.
DR   EMBL; AB210043; BAE06125.1; ALT_INIT; mRNA.
DR   EMBL; CH471112; EAW85335.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85336.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85337.1; -; Genomic_DNA.
DR   CCDS; CCDS10509.1; -. [Q92793-1]
DR   CCDS; CCDS45399.1; -. [Q92793-2]
DR   PIR; S39162; S39162.
DR   RefSeq; NP_001073315.1; NM_001079846.1. [Q92793-2]
DR   RefSeq; NP_004371.2; NM_004380.2. [Q92793-1]
DR   PDB; 1JSP; NMR; -; B=1081-1197.
DR   PDB; 1LIQ; NMR; -; A=376-402.
DR   PDB; 1RDT; X-ray; 2.40 A; E=58-80.
DR   PDB; 1WO3; NMR; -; A=387-398.
DR   PDB; 1WO4; NMR; -; A=387-398.
DR   PDB; 1WO5; NMR; -; A=387-398.
DR   PDB; 1WO6; NMR; -; A=376-400.
DR   PDB; 1WO7; NMR; -; A=376-400.
DR   PDB; 1ZOQ; X-ray; 2.37 A; C/D=2065-2111.
DR   PDB; 2D82; NMR; -; A=1081-1197.
DR   PDB; 2KJE; NMR; -; A=1763-1854.
DR   PDB; 2KWF; NMR; -; A=587-673.
DR   PDB; 2L84; NMR; -; A=1081-1197.
DR   PDB; 2L85; NMR; -; A=1081-1197.
DR   PDB; 2LXS; NMR; -; A=587-673.
DR   PDB; 2LXT; NMR; -; A=587-673.
DR   PDB; 2N1A; NMR; -; B=1699-1751.
DR   PDB; 2RNY; NMR; -; A=1081-1197.
DR   PDB; 3DWY; X-ray; 1.98 A; A/B=1081-1197.
DR   PDB; 3P1C; X-ray; 1.82 A; A/B=1081-1197.
DR   PDB; 3P1D; X-ray; 1.86 A; A/B=1081-1197.
DR   PDB; 3P1E; X-ray; 1.80 A; A/B=1081-1197.
DR   PDB; 3P1F; X-ray; 1.63 A; A/B=1081-1197.
DR   PDB; 3SVH; X-ray; 1.80 A; A/B=1081-1197.
DR   PDB; 4A9K; X-ray; 1.81 A; A/B=1081-1197.
DR   PDB; 4N3W; X-ray; 1.90 A; A=1080-1316.
DR   PDB; 4N4F; X-ray; 1.83 A; A=1080-1316.
DR   PDB; 4NR4; X-ray; 1.69 A; A/B=1081-1197.
DR   PDB; 4NR5; X-ray; 1.66 A; A=1081-1197.
DR   PDB; 4NR6; X-ray; 1.66 A; A=1081-1197.
DR   PDB; 4NR7; X-ray; 1.20 A; A=1081-1197.
DR   PDB; 4NYV; X-ray; 1.83 A; A/B/C/D=1081-1197.
DR   PDB; 4NYW; X-ray; 1.43 A; A=1081-1197.
DR   PDB; 4NYX; X-ray; 1.10 A; A=1081-1197.
DR   PDB; 4OUF; X-ray; 1.40 A; A/B=1082-1197.
DR   PDB; 4TQN; X-ray; 1.70 A; A=1081-1197.
DR   PDB; 4TS8; X-ray; 2.00 A; A=1081-1197.
DR   PDB; 4WHU; X-ray; 2.11 A; A=1081-1197.
DR   PDB; 4YK0; X-ray; 1.65 A; A/B/C/D=1083-1196.
DR   PDB; 5CGP; X-ray; 1.96 A; A=1081-1197.
DR   PDB; 5DBM; X-ray; 1.86 A; A/B/C=1082-1197.
DR   PDB; 5EIC; X-ray; 1.50 A; A/B=1081-1197.
DR   PDB; 5ENG; X-ray; 1.30 A; A=1081-1197.
DR   PDB; 5EP7; X-ray; 1.20 A; A=1081-1197.
DR   PDB; 5GH9; X-ray; 1.45 A; A=1081-1196.
DR   PDB; 5H85; X-ray; 1.70 A; A=1081-1197.
DR   PDB; 5I83; X-ray; 1.35 A; A=1082-1197.
DR   PDB; 5I86; X-ray; 1.05 A; A/B=1082-1197.
DR   PDB; 5I89; X-ray; 1.07 A; A=1082-1197.
DR   PDB; 5I8B; X-ray; 1.52 A; A=1081-1312.
DR   PDB; 5I8G; X-ray; 1.41 A; A=1081-1312.
DR   PDB; 5J0D; X-ray; 1.05 A; A=1081-1197.
DR   PDB; 5JEM; X-ray; 2.50 A; C/D/F/H=2065-2111.
DR   PDB; 5KTU; X-ray; 1.38 A; A/B=1082-1197.
DR   PDB; 5KTW; X-ray; 1.09 A; A/B/C=1085-1194.
DR   PDB; 5KTX; X-ray; 1.27 A; A=1085-1194.
DR   PDB; 5LPJ; X-ray; 1.65 A; A=1081-1197.
DR   PDB; 5LPL; X-ray; 1.65 A; A=1081-1197.
DR   PDB; 5MME; X-ray; 1.35 A; A/B=1081-1197.
DR   PDB; 5MMG; X-ray; 1.23 A; A=1081-1197.
DR   PDB; 5MPK; X-ray; 1.90 A; A/B=1081-1197.
DR   PDB; 5MPN; X-ray; 1.23 A; A=1081-1197.
DR   PDB; 5MPZ; X-ray; 1.40 A; A=1081-1197.
DR   PDB; 5MQE; X-ray; 1.65 A; A/B=1081-1197.
DR   PDB; 5MQG; X-ray; 1.35 A; A/B=1081-1197.
DR   PDB; 5MQK; X-ray; 1.53 A; A/B=1081-1197.
DR   PDB; 5NLK; X-ray; 1.80 A; A=1081-1197.
DR   PDB; 5NRW; X-ray; 1.70 A; A=1081-1197.
DR   PDB; 5NU3; X-ray; 1.75 A; A=1081-1197.
DR   PDB; 5OWK; X-ray; 1.25 A; A=1081-1197.
DR   PDB; 5SVH; X-ray; 2.05 A; A=587-673.
DR   PDB; 5TB6; X-ray; 1.79 A; A=1081-1197.
DR   PDB; 5W0E; X-ray; 1.41 A; A=1082-1197.
DR   PDB; 5W0F; X-ray; 1.60 A; A=1082-1197.
DR   PDB; 5W0L; X-ray; 1.55 A; A/B=1082-1197.
DR   PDB; 5W0Q; X-ray; 1.70 A; A=1082-1197.
DR   PDB; 5XXH; X-ray; 1.62 A; A=1081-1197.
DR   PDB; 6ALB; X-ray; 2.05 A; A=1081-1312.
DR   PDB; 6ALC; X-ray; 1.39 A; A/B=1085-1196.
DR   PDB; 6AXQ; X-ray; 1.30 A; A/B/C/D=1085-1196.
DR   PDB; 6AY3; X-ray; 1.39 A; A/B=1083-1197.
DR   PDB; 6AY5; X-ray; 1.44 A; A=1083-1197.
DR   PDB; 6DMK; X-ray; 1.66 A; A=1083-1195.
DR   PDB; 6ES5; NMR; -; B=2061-2105.
DR   PDB; 6ES6; NMR; -; B=2061-2108.
DR   PDB; 6ES7; NMR; -; B=2061-2109.
DR   PDB; 6FQO; X-ray; 1.35 A; A/B=1081-1197.
DR   PDB; 6FQT; X-ray; 1.80 A; A=1081-1197.
DR   PDB; 6FQU; X-ray; 1.43 A; A=1081-1197.
DR   PDB; 6FR0; X-ray; 1.50 A; A/B=1081-1197.
DR   PDB; 6FRF; X-ray; 2.10 A; A/B/C/D=1081-1197.
DR   PDBsum; 1JSP; -.
DR   PDBsum; 1LIQ; -.
DR   PDBsum; 1RDT; -.
DR   PDBsum; 1WO3; -.
DR   PDBsum; 1WO4; -.
DR   PDBsum; 1WO5; -.
DR   PDBsum; 1WO6; -.
DR   PDBsum; 1WO7; -.
DR   PDBsum; 1ZOQ; -.
DR   PDBsum; 2D82; -.
DR   PDBsum; 2KJE; -.
DR   PDBsum; 2KWF; -.
DR   PDBsum; 2L84; -.
DR   PDBsum; 2L85; -.
DR   PDBsum; 2LXS; -.
DR   PDBsum; 2LXT; -.
DR   PDBsum; 2N1A; -.
DR   PDBsum; 2RNY; -.
DR   PDBsum; 3DWY; -.
DR   PDBsum; 3P1C; -.
DR   PDBsum; 3P1D; -.
DR   PDBsum; 3P1E; -.
DR   PDBsum; 3P1F; -.
DR   PDBsum; 3SVH; -.
DR   PDBsum; 4A9K; -.
DR   PDBsum; 4N3W; -.
DR   PDBsum; 4N4F; -.
DR   PDBsum; 4NR4; -.
DR   PDBsum; 4NR5; -.
DR   PDBsum; 4NR6; -.
DR   PDBsum; 4NR7; -.
DR   PDBsum; 4NYV; -.
DR   PDBsum; 4NYW; -.
DR   PDBsum; 4NYX; -.
DR   PDBsum; 4OUF; -.
DR   PDBsum; 4TQN; -.
DR   PDBsum; 4TS8; -.
DR   PDBsum; 4WHU; -.
DR   PDBsum; 4YK0; -.
DR   PDBsum; 5CGP; -.
DR   PDBsum; 5DBM; -.
DR   PDBsum; 5EIC; -.
DR   PDBsum; 5ENG; -.
DR   PDBsum; 5EP7; -.
DR   PDBsum; 5GH9; -.
DR   PDBsum; 5H85; -.
DR   PDBsum; 5I83; -.
DR   PDBsum; 5I86; -.
DR   PDBsum; 5I89; -.
DR   PDBsum; 5I8B; -.
DR   PDBsum; 5I8G; -.
DR   PDBsum; 5J0D; -.
DR   PDBsum; 5JEM; -.
DR   PDBsum; 5KTU; -.
DR   PDBsum; 5KTW; -.
DR   PDBsum; 5KTX; -.
DR   PDBsum; 5LPJ; -.
DR   PDBsum; 5LPL; -.
DR   PDBsum; 5MME; -.
DR   PDBsum; 5MMG; -.
DR   PDBsum; 5MPK; -.
DR   PDBsum; 5MPN; -.
DR   PDBsum; 5MPZ; -.
DR   PDBsum; 5MQE; -.
DR   PDBsum; 5MQG; -.
DR   PDBsum; 5MQK; -.
DR   PDBsum; 5NLK; -.
DR   PDBsum; 5NRW; -.
DR   PDBsum; 5NU3; -.
DR   PDBsum; 5OWK; -.
DR   PDBsum; 5SVH; -.
DR   PDBsum; 5TB6; -.
DR   PDBsum; 5W0E; -.
DR   PDBsum; 5W0F; -.
DR   PDBsum; 5W0L; -.
DR   PDBsum; 5W0Q; -.
DR   PDBsum; 5XXH; -.
DR   PDBsum; 6ALB; -.
DR   PDBsum; 6ALC; -.
DR   PDBsum; 6AXQ; -.
DR   PDBsum; 6AY3; -.
DR   PDBsum; 6AY5; -.
DR   PDBsum; 6DMK; -.
DR   PDBsum; 6ES5; -.
DR   PDBsum; 6ES6; -.
DR   PDBsum; 6ES7; -.
DR   PDBsum; 6FQO; -.
DR   PDBsum; 6FQT; -.
DR   PDBsum; 6FQU; -.
DR   PDBsum; 6FR0; -.
DR   PDBsum; 6FRF; -.
DR   SMR; Q92793; -.
DR   BioGrid; 107777; 378.
DR   CORUM; Q92793; -.
DR   DIP; DIP-952N; -.
DR   ELM; Q92793; -.
DR   IntAct; Q92793; 91.
DR   MINT; Q92793; -.
DR   STRING; 9606.ENSP00000262367; -.
DR   BindingDB; Q92793; -.
DR   ChEMBL; CHEMBL5747; -.
DR   DrugBank; DB08655; 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE.
DR   GuidetoPHARMACOLOGY; 2734; -.
DR   iPTMnet; Q92793; -.
DR   PhosphoSitePlus; Q92793; -.
DR   BioMuta; CREBBP; -.
DR   DMDM; 116241283; -.
DR   EPD; Q92793; -.
DR   jPOST; Q92793; -.
DR   MassIVE; Q92793; -.
DR   MaxQB; Q92793; -.
DR   PaxDb; Q92793; -.
DR   PeptideAtlas; Q92793; -.
DR   PRIDE; Q92793; -.
DR   ProteomicsDB; 62237; -.
DR   ProteomicsDB; 75472; -. [Q92793-1]
DR   Antibodypedia; 3781; 679 antibodies.
DR   Ensembl; ENST00000262367; ENSP00000262367; ENSG00000005339. [Q92793-1]
DR   Ensembl; ENST00000382070; ENSP00000371502; ENSG00000005339. [Q92793-2]
DR   GeneID; 1387; -.
DR   KEGG; hsa:1387; -.
DR   UCSC; uc002cvv.4; human. [Q92793-1]
DR   CTD; 1387; -.
DR   DisGeNET; 1387; -.
DR   GeneCards; CREBBP; -.
DR   GeneReviews; CREBBP; -.
DR   HGNC; HGNC:2348; CREBBP.
DR   HPA; ENSG00000005339; Low tissue specificity.
DR   MalaCards; CREBBP; -.
DR   MIM; 180849; phenotype.
DR   MIM; 600140; gene.
DR   MIM; 618332; phenotype.
DR   neXtProt; NX_Q92793; -.
DR   OpenTargets; ENSG00000005339; -.
DR   Orphanet; 370026; Acute myeloid leukemia with t(8;16)(p11;p13) translocation.
DR   Orphanet; 353281; Rubinstein-Taybi syndrome due to 16p13.3 microdeletion.
DR   Orphanet; 353277; Rubinstein-Taybi syndrome due to CREBBP mutations.
DR   PharmGKB; PA26866; -.
DR   eggNOG; KOG1778; Eukaryota.
DR   eggNOG; COG5076; LUCA.
DR   GeneTree; ENSGT00940000155364; -.
DR   HOGENOM; CLU_000162_2_0_1; -.
DR   InParanoid; Q92793; -.
DR   KO; K04498; -.
DR   OMA; HSNNMMG; -.
DR   OrthoDB; 236283at2759; -.
DR   PhylomeDB; Q92793; -.
DR   TreeFam; TF101097; -.
DR   Reactome; R-HSA-1234158; Regulation of gene expression by Hypoxia-inducible Factor.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-210744; Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-3134973; LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-3371568; Attenuation phase.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-3899300; SUMOylation of transcription cofactors.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by PPARalpha.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-8866907; Activation of the TFAP2 (AP-2) family of transcription factors.
DR   Reactome; R-HSA-8939246; RUNX1 regulates transcription of genes involved in differentiation of myeloid cells.
DR   Reactome; R-HSA-8941856; RUNX3 regulates NOTCH signaling.
DR   Reactome; R-HSA-9013508; NOTCH3 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-9013695; NOTCH4 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-9018519; Estrogen-dependent gene expression.
DR   Reactome; R-HSA-918233; TRAF3-dependent IRF activation pathway.
DR   Reactome; R-HSA-933541; TRAF6 mediated IRF7 activation.
DR   Reactome; R-HSA-9614657; FOXO-mediated transcription of cell death genes.
DR   Reactome; R-HSA-9617629; Regulation of FOXO transcriptional activity by acetylation.
DR   SignaLink; Q92793; -.
DR   SIGNOR; Q92793; -.
DR   ChiTaRS; CREBBP; human.
DR   EvolutionaryTrace; Q92793; -.
DR   GeneWiki; CREB-binding_protein; -.
DR   GenomeRNAi; 1387; -.
DR   Pharos; Q92793; Tchem.
DR   PRO; PR:Q92793; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q92793; protein.
DR   Bgee; ENSG00000005339; Expressed in testis and 240 other tissues.
DR   ExpressionAtlas; Q92793; baseline and differential.
DR   Genevisible; Q92793; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0000123; C:histone acetyltransferase complex; IEA:InterPro.
DR   GO; GO:0016604; C:nuclear body; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016407; F:acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0043426; F:MRF binding; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0061733; F:peptide-lysine-N-acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; TAS:BHF-UCL.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:BHF-UCL.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; TAS:BHF-UCL.
DR   GO; GO:0016573; P:histone acetylation; IDA:UniProtKB.
DR   GO; GO:1990258; P:histone glutamine methylation; IDA:UniProtKB.
DR   GO; GO:0042592; P:homeostatic process; NAS:UniProtKB.
DR   GO; GO:0018076; P:N-terminal peptidyl-lysine acetylation; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; TAS:Reactome.
DR   GO; GO:0007221; P:positive regulation of transcription of Notch receptor target; TAS:Reactome.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0006473; P:protein acetylation; IDA:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IMP:UniProtKB.
DR   GO; GO:0065003; P:protein-containing complex assembly; TAS:ProtInc.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; TAS:Reactome.
DR   GO; GO:0045637; P:regulation of myeloid cell differentiation; TAS:Reactome.
DR   GO; GO:0008589; P:regulation of smoothened signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0061418; P:regulation of transcription from RNA polymerase II promoter in response to hypoxia; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:HGNC-UCL.
DR   GO; GO:0001666; P:response to hypoxia; TAS:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd15802; RING_CBP-p300; 1.
DR   DisProt; DP02004; -.
DR   Gene3D; 1.10.1630.10; -; 1.
DR   Gene3D; 1.10.246.20; -; 1.
DR   Gene3D; 1.20.1020.10; -; 2.
DR   Gene3D; 1.20.920.10; -; 1.
DR   Gene3D; 2.10.110.40; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR031162; CBP_P300_HAT.
DR   InterPro; IPR013178; Histone_AcTrfase_Rtt109/CBP.
DR   InterPro; IPR003101; KIX_dom.
DR   InterPro; IPR036529; KIX_dom_sf.
DR   InterPro; IPR009110; Nuc_rcpt_coact.
DR   InterPro; IPR014744; Nuc_rcpt_coact_CREBbp.
DR   InterPro; IPR037073; Nuc_rcpt_coact_CREBbp_sf.
DR   InterPro; IPR010303; RING_CBP-p300.
DR   InterPro; IPR038547; RING_CBP-p300_sf.
DR   InterPro; IPR035898; TAZ_dom_sf.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR000197; Znf_TAZ.
DR   InterPro; IPR000433; Znf_ZZ.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF09030; Creb_binding; 1.
DR   Pfam; PF06001; DUF902; 1.
DR   Pfam; PF08214; HAT_KAT11; 1.
DR   Pfam; PF02172; KIX; 1.
DR   Pfam; PF02135; zf-TAZ; 2.
DR   Pfam; PF00569; ZZ; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM01250; KAT11; 1.
DR   SMART; SM00551; ZnF_TAZ; 2.
DR   SMART; SM00291; ZnF_ZZ; 1.
DR   SUPFAM; SSF47040; SSF47040; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57933; SSF57933; 2.
DR   SUPFAM; SSF69125; SSF69125; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS51727; CBP_P300_HAT; 1.
DR   PROSITE; PS50952; KIX; 1.
DR   PROSITE; PS50134; ZF_TAZ; 2.
DR   PROSITE; PS01357; ZF_ZZ_1; 1.
DR   PROSITE; PS50135; ZF_ZZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Acyltransferase;
KW   Alternative splicing; Biological rhythms; Bromodomain;
KW   Chromosomal rearrangement; Cytoplasm; Disease mutation;
KW   Host-virus interaction; Isopeptide bond; Mental retardation; Metal-binding;
KW   Methylation; Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Transcription; Transcription regulation; Transferase;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:19413330,
FT                   ECO:0000244|PubMed:22814378"
FT   CHAIN           2..2442
FT                   /note="CREB-binding protein"
FT                   /id="PRO_0000211190"
FT   DOMAIN          587..666
FT                   /note="KIX"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00311"
FT   DOMAIN          1103..1175
FT                   /note="Bromo"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   DOMAIN          1323..1700
FT                   /note="CBP/p300-type HAT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01065"
FT   ZN_FING         347..433
FT                   /note="TAZ-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00203"
FT   ZN_FING         1701..1744
FT                   /note="ZZ-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00228"
FT   ZN_FING         1765..1846
FT                   /note="TAZ-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00203"
FT   REGION          227..410
FT                   /note="Interaction with SRCAP"
FT                   /evidence="ECO:0000269|PubMed:10347196"
FT   REGION          1124..1170
FT                   /note="Interaction with histone"
FT                   /evidence="ECO:0000269|PubMed:24361270"
FT   REGION          1162..1180
FT                   /note="Interaction with ASF1A"
FT                   /evidence="ECO:0000269|PubMed:24616510"
FT   REGION          1433..1435
FT                   /note="Interaction with histone"
FT                   /evidence="ECO:0000250|UniProtKB:Q09472"
FT   REGION          1434..1436
FT                   /note="Acetyl-CoA binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q09472"
FT   REGION          1446..1447
FT                   /note="Acetyl-CoA binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q09472"
FT   REGION          1460..1891
FT                   /note="Interaction with TRERF1"
FT                   /evidence="ECO:0000269|PubMed:11349124"
FT   COMPBIAS        1061..1064
FT                   /note="Poly-Glu"
FT   COMPBIAS        1199..1487
FT                   /note="Cys/His-rich"
FT   COMPBIAS        1555..1562
FT                   /note="Poly-Glu"
FT   COMPBIAS        1943..1948
FT                   /note="Poly-Pro"
FT   COMPBIAS        1967..1970
FT                   /note="Poly-Gln"
FT   COMPBIAS        2081..2085
FT                   /note="Poly-Gln"
FT   COMPBIAS        2199..2216
FT                   /note="Poly-Gln"
FT   COMPBIAS        2245..2248
FT                   /note="Poly-Gln"
FT   COMPBIAS        2297..2300
FT                   /note="Poly-Gln"
FT   METAL           363
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250"
FT   METAL           367
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250"
FT   METAL           380
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250"
FT   METAL           385
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250"
FT   METAL           394
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250"
FT   METAL           398
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250"
FT   METAL           404
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250"
FT   METAL           409
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250"
FT   METAL           418
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000250"
FT   METAL           422
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000250"
FT   METAL           427
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000250"
FT   METAL           430
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000250"
FT   BINDING         1493
FT                   /note="Acetyl-CoA; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:Q09472"
FT   BINDING         1498
FT                   /note="Acetyl-CoA"
FT                   /evidence="ECO:0000250|UniProtKB:Q09472"
FT   BINDING         1502
FT                   /note="Acetyl-CoA"
FT                   /evidence="ECO:0000250|UniProtKB:Q09472"
FT   SITE            29..30
FT                   /note="Breakpoint for translocation to form KAT6B-CREBBP"
FT   SITE            266..267
FT                   /note="Breakpoint for translocation to form KAT6A-CREBBP"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000244|PubMed:19413330,
FT                   ECO:0000244|PubMed:22814378"
FT   MOD_RES         121
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231"
FT   MOD_RES         220
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         601
FT                   /note="Omega-N-methylated arginine"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         625
FT                   /note="Omega-N-methylated arginine"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         657
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P45481"
FT   MOD_RES         1014
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         1030
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17525332"
FT   MOD_RES         1076
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1216
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         1382
FT                   /note="Phosphoserine; by IKKA"
FT                   /evidence="ECO:0000269|PubMed:17434128"
FT   MOD_RES         1386
FT                   /note="Phosphoserine; by IKKA"
FT                   /evidence="ECO:0000269|PubMed:17434128"
FT   MOD_RES         1583
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         1591
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         1592
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         1595
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         1597
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         1741
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         1744
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         1763
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         2063
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:23186163"
FT   MOD_RES         2076
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         2079
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         2351
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P45481"
FT   CROSSLNK        998
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1)"
FT                   /evidence="ECO:0000250|UniProtKB:P45481"
FT   CROSSLNK        1033
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1)"
FT                   /evidence="ECO:0000250|UniProtKB:P45481"
FT   CROSSLNK        1056
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1)"
FT                   /evidence="ECO:0000250|UniProtKB:P45481"
FT   VAR_SEQ         406..444
FT                   /note="VAHCASSRQIISHWKNCTRHDCPVCLPLKNASDKRNQQT -> A (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_045700"
FT   VARIANT         503
FT                   /note="Q -> H (in dbSNP:rs748447855)"
FT                   /evidence="ECO:0000269|PubMed:25388907"
FT                   /id="VAR_072912"
FT   VARIANT         532
FT                   /note="P -> T (in dbSNP:rs902901184)"
FT                   /evidence="ECO:0000269|PubMed:25388907"
FT                   /id="VAR_072913"
FT   VARIANT         546
FT                   /note="I -> N"
FT                   /evidence="ECO:0000269|PubMed:25388907"
FT                   /id="VAR_072914"
FT   VARIANT         650
FT                   /note="Y -> F (in RSTS1)"
FT                   /evidence="ECO:0000269|PubMed:25388907"
FT                   /id="VAR_072915"
FT   VARIANT         789
FT                   /note="A -> T (in RSTS1; dbSNP:rs746728741)"
FT                   /evidence="ECO:0000269|PubMed:25388907"
FT                   /id="VAR_072916"
FT   VARIANT         910
FT                   /note="T -> A (in RSTS1; incomplete; dbSNP:rs143247685)"
FT                   /evidence="ECO:0000269|PubMed:20684013"
FT                   /id="VAR_072917"
FT   VARIANT         1175
FT                   /note="Y -> C (in RSTS1; mild form; impairs binding to
FT                   ASF1A and acetylated histone H3; dbSNP:rs28937315)"
FT                   /evidence="ECO:0000269|PubMed:12114483,
FT                   ECO:0000269|PubMed:24616510, ECO:0000269|PubMed:25388907"
FT                   /id="VAR_037305"
FT   VARIANT         1278
FT                   /note="E -> A (in RSTS1)"
FT                   /evidence="ECO:0000269|PubMed:25388907"
FT                   /id="VAR_072918"
FT   VARIANT         1278
FT                   /note="E -> K (in RSTS1; abolishes acetyltransferase
FT                   activity; dbSNP:rs267606752)"
FT                   /evidence="ECO:0000269|PubMed:12566391,
FT                   ECO:0000269|PubMed:15706485"
FT                   /id="VAR_035080"
FT   VARIANT         1378
FT                   /note="R -> P (in RSTS1; abolishes acetyltransferase
FT                   activity and the ability of transactivate CREB;
FT                   dbSNP:rs121434626)"
FT                   /evidence="ECO:0000269|PubMed:11331617,
FT                   ECO:0000269|PubMed:25388907"
FT                   /id="VAR_015578"
FT   VARIANT         1406
FT                   /note="D -> Y (in RSTS1)"
FT                   /evidence="ECO:0000269|PubMed:25388907"
FT                   /id="VAR_072919"
FT   VARIANT         1414
FT                   /note="V -> I (in dbSNP:rs130015)"
FT                   /id="VAR_027953"
FT   VARIANT         1415
FT                   /note="Q -> P (in RSTS1)"
FT                   /evidence="ECO:0000269|PubMed:25388907"
FT                   /id="VAR_072920"
FT   VARIANT         1447
FT                   /note="T -> I (in RSTS1)"
FT                   /evidence="ECO:0000269|PubMed:15706485"
FT                   /id="VAR_035081"
FT   VARIANT         1450
FT                   /note="Y -> H (in RSTS1; dbSNP:rs1555473499)"
FT                   /evidence="ECO:0000269|PubMed:15706485"
FT                   /id="VAR_035082"
FT   VARIANT         1470
FT                   /note="H -> R (in RSTS1; dbSNP:rs797044860)"
FT                   /evidence="ECO:0000269|PubMed:15706485"
FT                   /id="VAR_035083"
FT   VARIANT         1475
FT                   /note="P -> T (in RSTS1)"
FT                   /evidence="ECO:0000269|PubMed:25388907"
FT                   /id="VAR_072921"
FT   VARIANT         1503
FT                   /note="Y -> F (in RSTS1)"
FT                   /evidence="ECO:0000269|PubMed:25388907"
FT                   /id="VAR_072922"
FT   VARIANT         1507
FT                   /note="L -> P (in RSTS1; dbSNP:rs1057520191)"
FT                   /evidence="ECO:0000269|PubMed:25388907"
FT                   /id="VAR_072923"
FT   VARIANT         1543
FT                   /note="D -> N (in RSTS1)"
FT                   /evidence="ECO:0000269|PubMed:25388907"
FT                   /id="VAR_072924"
FT   VARIANT         1664
FT                   /note="R -> H (in RSTS1; abolishes acetyltransferase
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:12566391,
FT                   ECO:0000269|PubMed:15706485"
FT                   /id="VAR_035084"
FT   VARIANT         1710
FT                   /note="C -> R (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:27311832"
FT                   /id="VAR_078557"
FT   VARIANT         1719
FT                   /note="H -> D (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:29460469"
FT                   /id="VAR_081979"
FT   VARIANT         1724
FT                   /note="E -> K (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:30737887"
FT                   /id="VAR_081980"
FT   VARIANT         1747
FT                   /note="L -> R (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:27311832"
FT                   /id="VAR_078558"
FT   VARIANT         1782
FT                   /note="A -> V (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:29460469"
FT                   /id="VAR_081981"
FT   VARIANT         1786
FT                   /note="R -> P (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:27311832"
FT                   /id="VAR_078559"
FT   VARIANT         1819
FT                   /note="C -> F (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:27311832"
FT                   /id="VAR_078560"
FT   VARIANT         1826
FT                   /note="C -> W (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:27311832"
FT                   /id="VAR_078561"
FT   VARIANT         1829
FT                   /note="H -> D (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:29460469"
FT                   /id="VAR_081982"
FT   VARIANT         1838
FT                   /note="C -> Y (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:27311832"
FT                   /id="VAR_078562"
FT   VARIANT         1865..1866
FT                   /note="MR -> I (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:29460469"
FT                   /id="VAR_081983"
FT   VARIANT         1867
FT                   /note="R -> Q (in MKHK1; dbSNP:rs1131691326)"
FT                   /evidence="ECO:0000269|PubMed:27311832,
FT                   ECO:0000269|PubMed:29460469"
FT                   /id="VAR_078563"
FT   VARIANT         1867
FT                   /note="R -> W (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:27311832"
FT                   /id="VAR_078564"
FT   VARIANT         1868
FT                   /note="R -> Q (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:29460469"
FT                   /id="VAR_081984"
FT   VARIANT         1868
FT                   /note="R -> W (in MKHK1; dbSNP:rs886039491)"
FT                   /evidence="ECO:0000269|PubMed:27311832,
FT                   ECO:0000269|PubMed:29460469"
FT                   /id="VAR_078565"
FT   VARIANT         1870
FT                   /note="A -> P (in MKHK1)"
FT                   /evidence="ECO:0000269|PubMed:29460469"
FT                   /id="VAR_081985"
FT   VARIANT         1872
FT                   /note="M -> V (in MKHK1; dbSNP:rs797045037)"
FT                   /evidence="ECO:0000269|PubMed:27311832,
FT                   ECO:0000269|PubMed:29460469"
FT                   /id="VAR_078566"
FT   MUTAGEN         1116
FT                   /note="D->R: Impairs binding to acetylated histones."
FT                   /evidence="ECO:0000269|PubMed:24616510"
FT   MUTAGEN         1126
FT                   /note="F->A: Impairs binding to acetylated histones."
FT                   /evidence="ECO:0000269|PubMed:24616510"
FT   MUTAGEN         1162
FT                   /note="N->E,R: Abolishes interaction with ASF1A."
FT                   /evidence="ECO:0000269|PubMed:24616510"
FT   MUTAGEN         1165
FT                   /note="W->A: Abolishes interaction with ASF1A."
FT                   /evidence="ECO:0000269|PubMed:24616510"
FT   MUTAGEN         1170
FT                   /note="K->E: Impairs binding to acetylated histones."
FT                   /evidence="ECO:0000269|PubMed:24616510"
FT   MUTAGEN         1179
FT                   /note="S->I: Impairs interaction with ASF1A."
FT                   /evidence="ECO:0000269|PubMed:24616510"
FT   MUTAGEN         1180
FT                   /note="K->E: Abolishes interaction with ASF1A."
FT                   /evidence="ECO:0000269|PubMed:24616510"
FT   MUTAGEN         1183
FT                   /note="E->R: Abolishes interaction with ASF1A."
FT                   /evidence="ECO:0000269|PubMed:24616510"
FT   CONFLICT        1511..1513
FT                   /note="FAE -> NSG (in Ref. 2; AAC51340)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1724..1725
FT                   /note="ED -> VV (in Ref. 2; AAC51340)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1770
FT                   /note="L -> V (in Ref. 1; AAC51770)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1789
FT                   /note="N -> F (in Ref. 2; AAC51340)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1812
FT                   /note="T -> P (in Ref. 2; AAC51340)"
FT                   /evidence="ECO:0000305"
FT   HELIX           69..73
FT                   /evidence="ECO:0000244|PDB:1RDT"
FT   HELIX           377..379
FT                   /evidence="ECO:0000244|PDB:1LIQ"
FT   TURN            383..388
FT                   /evidence="ECO:0000244|PDB:1LIQ"
FT   HELIX           391..395
FT                   /evidence="ECO:0000244|PDB:1LIQ"
FT   HELIX           592..595
FT                   /evidence="ECO:0000244|PDB:5SVH"
FT   HELIX           598..612
FT                   /evidence="ECO:0000244|PDB:5SVH"
FT   HELIX           618..622
FT                   /evidence="ECO:0000244|PDB:5SVH"
FT   HELIX           624..641
FT                   /evidence="ECO:0000244|PDB:5SVH"
FT   HELIX           647..670
FT                   /evidence="ECO:0000244|PDB:5SVH"
FT   HELIX           1087..1102
FT                   /evidence="ECO:0000244|PDB:5I86"
FT   TURN            1105..1108
FT                   /evidence="ECO:0000244|PDB:5I86"
FT   HELIX           1109..1111
FT                   /evidence="ECO:0000244|PDB:5I86"
FT   HELIX           1117..1120
FT                   /evidence="ECO:0000244|PDB:5I86"
FT   HELIX           1125..1128
FT                   /evidence="ECO:0000244|PDB:5I86"
FT   HELIX           1135..1143
FT                   /evidence="ECO:0000244|PDB:5I86"
FT   STRAND          1146..1149
FT                   /evidence="ECO:0000244|PDB:2L85"
FT   HELIX           1150..1167
FT                   /evidence="ECO:0000244|PDB:5I86"
FT   TURN            1169..1171
FT                   /evidence="ECO:0000244|PDB:1JSP"
FT   HELIX           1173..1195
FT                   /evidence="ECO:0000244|PDB:5I86"
FT   STRAND          1214..1218
FT                   /evidence="ECO:0000244|PDB:5I8G"
FT   STRAND          1226..1230
FT                   /evidence="ECO:0000244|PDB:5I8G"
FT   TURN            1231..1233
FT                   /evidence="ECO:0000244|PDB:5I8G"
FT   STRAND          1234..1237
FT                   /evidence="ECO:0000244|PDB:5I8G"
FT   TURN            1238..1240
FT                   /evidence="ECO:0000244|PDB:5I8G"
FT   STRAND          1266..1272
FT                   /evidence="ECO:0000244|PDB:5I8G"
FT   STRAND          1280..1282
FT                   /evidence="ECO:0000244|PDB:5I8G"
FT   TURN            1284..1286
FT                   /evidence="ECO:0000244|PDB:5I8G"
FT   STRAND          1289..1291
FT                   /evidence="ECO:0000244|PDB:5I8G"
FT   HELIX           1292..1295
FT                   /evidence="ECO:0000244|PDB:5I8G"
FT   TURN            1309..1311
FT                   /evidence="ECO:0000244|PDB:5I8G"
FT   TURN            1708..1710
FT                   /evidence="ECO:0000244|PDB:2N1A"
FT   STRAND          1718..1721
FT                   /evidence="ECO:0000244|PDB:2N1A"
FT   STRAND          1725..1728
FT                   /evidence="ECO:0000244|PDB:2N1A"
FT   HELIX           1730..1736
FT                   /evidence="ECO:0000244|PDB:2N1A"
FT   STRAND          1742..1744
FT                   /evidence="ECO:0000244|PDB:2N1A"
FT   HELIX           1765..1784
FT                   /evidence="ECO:0000244|PDB:2KJE"
FT   HELIX           1793..1805
FT                   /evidence="ECO:0000244|PDB:2KJE"
FT   TURN            1811..1815
FT                   /evidence="ECO:0000244|PDB:2KJE"
FT   HELIX           1817..1832
FT                   /evidence="ECO:0000244|PDB:2KJE"
FT   HELIX           1841..1853
FT                   /evidence="ECO:0000244|PDB:2KJE"
FT   TURN            2063..2065
FT                   /evidence="ECO:0000244|PDB:6ES5"
FT   HELIX           2066..2072
FT                   /evidence="ECO:0000244|PDB:1ZOQ"
FT   HELIX           2080..2091
FT                   /evidence="ECO:0000244|PDB:1ZOQ"
FT   HELIX           2094..2103
FT                   /evidence="ECO:0000244|PDB:1ZOQ"
FT   TURN            2104..2106
FT                   /evidence="ECO:0000244|PDB:1ZOQ"
SQ   SEQUENCE   2442 AA;  265351 MW;  3BEA9B8558BA1A5E CRC64;
     MAENLLDGPP NPKRAKLSSP GFSANDSTDF GSLFDLENDL PDELIPNGGE LGLLNSGNLV
     PDAASKHKQL SELLRGGSGS SINPGIGNVS ASSPVQQGLG GQAQGQPNSA NMASLSAMGK
     SPLSQGDSSA PSLPKQAAST SGPTPAASQA LNPQAQKQVG LATSSPATSQ TGPGICMNAN
     FNQTHPGLLN SNSGHSLINQ ASQGQAQVMN GSLGAAGRGR GAGMPYPTPA MQGASSSVLA
     ETLTQVSPQM TGHAGLNTAQ AGGMAKMGIT GNTSPFGQPF SQAGGQPMGA TGVNPQLASK
     QSMVNSLPTF PTDIKNTSVT NVPNMSQMQT SVGIVPTQAI ATGPTADPEK RKLIQQQLVL
     LLHAHKCQRR EQANGEVRAC SLPHCRTMKN VLNHMTHCQA GKACQVAHCA SSRQIISHWK
     NCTRHDCPVC LPLKNASDKR NQQTILGSPA SGIQNTIGSV GTGQQNATSL SNPNPIDPSS
     MQRAYAALGL PYMNQPQTQL QPQVPGQQPA QPQTHQQMRT LNPLGNNPMN IPAGGITTDQ
     QPPNLISESA LPTSLGATNP LMNDGSNSGN IGTLSTIPTA APPSSTGVRK GWHEHVTQDL
     RSHLVHKLVQ AIFPTPDPAA LKDRRMENLV AYAKKVEGDM YESANSRDEY YHLLAEKIYK
     IQKELEEKRR SRLHKQGILG NQPALPAPGA QPPVIPQAQP VRPPNGPLSL PVNRMQVSQG
     MNSFNPMSLG NVQLPQAPMG PRAASPMNHS VQMNSMGSVP GMAISPSRMP QPPNMMGAHT
     NNMMAQAPAQ SQFLPQNQFP SSSGAMSVGM GQPPAQTGVS QGQVPGAALP NPLNMLGPQA
     SQLPCPPVTQ SPLHPTPPPA STAAGMPSLQ HTTPPGMTPP QPAAPTQPST PVSSSGQTPT
     PTPGSVPSAT QTQSTPTVQA AAQAQVTPQP QTPVQPPSVA TPQSSQQQPT PVHAQPPGTP
     LSQAAASIDN RVPTPSSVAS AETNSQQPGP DVPVLEMKTE TQAEDTEPDP GESKGEPRSE
     MMEEDLQGAS QVKEETDIAE QKSEPMEVDE KKPEVKVEVK EEEESSSNGT ASQSTSPSQP
     RKKIFKPEEL RQALMPTLEA LYRQDPESLP FRQPVDPQLL GIPDYFDIVK NPMDLSTIKR
     KLDTGQYQEP WQYVDDVWLM FNNAWLYNRK TSRVYKFCSK LAEVFEQEID PVMQSLGYCC
     GRKYEFSPQT LCCYGKQLCT IPRDAAYYSY QNRYHFCEKC FTEIQGENVT LGDDPSQPQT
     TISKDQFEKK KNDTLDPEPF VDCKECGRKM HQICVLHYDI IWPSGFVCDN CLKKTGRPRK
     ENKFSAKRLQ TTRLGNHLED RVNKFLRRQN HPEAGEVFVR VVASSDKTVE VKPGMKSRFV
     DSGEMSESFP YRTKALFAFE EIDGVDVCFF GMHVQEYGSD CPPPNTRRVY ISYLDSIHFF
     RPRCLRTAVY HEILIGYLEY VKKLGYVTGH IWACPPSEGD DYIFHCHPPD QKIPKPKRLQ
     EWYKKMLDKA FAERIIHDYK DIFKQATEDR LTSAKELPYF EGDFWPNVLE ESIKELEQEE
     EERKKEESTA ASETTEGSQG DSKNAKKKNN KKTNKNKSSI SRANKKKPSM PNVSNDLSQK
     LYATMEKHKE VFFVIHLHAG PVINTLPPIV DPDPLLSCDL MDGRDAFLTL ARDKHWEFSS
     LRRSKWSTLC MLVELHTQGQ DRFVYTCNEC KHHVETRWHC TVCEDYDLCI NCYNTKSHAH
     KMVKWGLGLD DEGSSQGEPQ SKSPQESRRL SIQRCIQSLV HACQCRNANC SLPSCQKMKR
     VVQHTKGCKR KTNGGCPVCK QLIALCCYHA KHCQENKCPV PFCLNIKHKL RQQQIQHRLQ
     QAQLMRRRMA TMNTRNVPQQ SLPSPTSAPP GTPTQQPSTP QTPQPPAQPQ PSPVSMSPAG
     FPSVARTQPP TTVSTGKPTS QVPAPPPPAQ PPPAAVEAAR QIEREAQQQQ HLYRVNINNS
     MPPGRTGMGT PGSQMAPVSL NVPRPNQVSG PVMPSMPPGQ WQQAPLPQQQ PMPGLPRPVI
     SMQAQAAVAG PRMPSVQPPR SISPSALQDL LRTLKSPSSP QQQQQVLNIL KSNPQLMAAF
     IKQRTAKYVA NQPGMQPQPG LQSQPGMQPQ PGMHQQPSLQ NLNAMQAGVP RPGVPPQQQA
     MGGLNPQGQA LNIMNPGHNP NMASMNPQYR EMLRRQLLQQ QQQQQQQQQQ QQQQQQGSAG
     MAGGMAGHGQ FQQPQGPGGY PPAMQQQQRM QQHLPLQGSS MGQMAAQMGQ LGQMGQPGLG
     ADSTPNIQQA LQQRILQQQQ MKQQIGSPGQ PNPMSPQQHM LSGQPQASHL PGQQIATSLS
     NQVRSPAPVQ SPRPQSQPPH SSPSPRIQPQ PSPHHVSPQT GSPHPGLAVT MASSIDQGHL
     GNPEQSAMLP QLNTPSRSAL SSELSLVGDT TGDTLEKFVE GL
//
ID   ELF4_HUMAN              Reviewed;         663 AA.
AC   Q99607; D3DTG1; O60435;
DT   21-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   22-APR-2020, entry version 168.
DE   RecName: Full=ETS-related transcription factor Elf-4;
DE   AltName: Full=E74-like factor 4;
DE   AltName: Full=Myeloid Elf-1-like factor;
GN   Name=ELF4 {ECO:0000312|EMBL:CAI42882.1};
GN   Synonyms=ELFR {ECO:0000312|EMBL:AAC17452.1},
GN   MEF {ECO:0000312|EMBL:AAB53693.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAB53693.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Promyelocytic leukemia {ECO:0000269|PubMed:8895518};
RX   PubMed=8895518;
RA   Miyazaki Y., Sun X., Uchida H., Zhang J., Nimer S.;
RT   "MEF, a novel transcription factor with an Elf-1 like DNA binding domain
RT   but distinct transcriptional activating properties.";
RL   Oncogene 13:1721-1729(1996).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAC17452.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Ewing sarcoma {ECO:0000269|PubMed:9524226};
RX   PubMed=9524226; DOI=10.1016/s0378-1119(98)00022-5;
RA   Aryee D.N.T., Petermann R., Kos K., Henn T., Haas O.A., Kovar H.;
RT   "Cloning of a novel human ELF-1-related ETS transcription factor, ELFR, its
RT   characterization and chromosomal assignment relative to ELF-1.";
RL   Gene 210:71-78(1998).
RN   [3] {ECO:0000305, ECO:0000312|EMBL:CAI42882.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5] {ECO:0000312|EMBL:AAH17194.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta {ECO:0000312|EMBL:AAH17194.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6] {ECO:0000305}
RP   FUNCTION, AND INTERACTION WITH RUNX1.
RX   PubMed=10207087; DOI=10.1128/mcb.19.5.3635;
RA   Mao S., Frank R.C., Zhang J., Miyazaki Y., Nimer S.D.;
RT   "Functional and physical interactions between AML1 proteins and an ETS
RT   protein, MEF: implications for the pathogenesis of t(8;21)-positive
RT   leukemias.";
RL   Mol. Cell. Biol. 19:3635-3644(1999).
RN   [7] {ECO:0000305}
RP   FUNCTION, AND INDUCTION.
RX   PubMed=14625302; DOI=10.1074/jbc.m307524200;
RA   Hedvat C.V., Yao J., Sokolic R.A., Nimer S.D.;
RT   "Myeloid ELF1-like factor is a potent activator of interleukin-8 expression
RT   in hematopoietic cells.";
RL   J. Biol. Chem. 279:6395-6400(2004).
RN   [8] {ECO:0000305}
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PML.
RX   PubMed=14976184; DOI=10.1074/jbc.m312439200;
RA   Suico M.A., Yoshida H., Seki Y., Uchikawa T., Lu Z., Shuto T.,
RA   Matsuzaki K., Nakao M., Li J.-D., Kai H.;
RT   "Myeloid Elf-1-like factor, an ETS transcription factor, up-regulates
RT   lysozyme transcription in epithelial cells through interaction with
RT   promyelocytic leukemia protein.";
RL   J. Biol. Chem. 279:19091-19098(2004).
RN   [9]
RP   CHROMOSOMAL TRANSLOCATION WITH ERG.
RX   PubMed=16303180; DOI=10.1016/j.leukres.2005.10.014;
RA   Moore S.D., Offor O., Ferry J.A., Amrein P.C., Morton C.C., Dal Cin P.;
RT   "ELF4 is fused to ERG in a case of acute myeloid leukemia with a
RT   t(X;21)(q25-26;q22).";
RL   Leuk. Res. 30:1037-1042(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151 AND SER-648, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   FUNCTION.
RX   PubMed=19380490; DOI=10.1128/mcb.01551-08;
RA   Sashida G., Liu Y., Elf S., Miyata Y., Ohyashiki K., Izumi M., Menendez S.,
RA   Nimer S.D.;
RT   "ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16
RT   activation to promote transformation.";
RL   Mol. Cell. Biol. 29:3687-3699(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-648, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-648, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; SER-188 AND SER-641, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: Transcriptional activator that binds to DNA sequences
CC       containing the consensus 5'-WGGA-3'. Transactivates promoters of the
CC       hematopoietic growth factor genes CSF2, IL3, IL8, and of the bovine
CC       lysozyme gene. Acts synergistically with RUNX1 to transactivate the IL3
CC       promoter (By similarity). Also transactivates the PRF1 promoter in
CC       natural killer (NK) cells. Plays a role in the development and function
CC       of NK and NK T-cells and in innate immunity. Controls the proliferation
CC       and homing of CD8+ T-cells via the Kruppel-like factors KLF4 and KLF2
CC       (By similarity). Controls cell senescence in a p53-dependent manner.
CC       Can also promote cellular transformation through inhibition of the p16
CC       pathway. {ECO:0000250, ECO:0000269|PubMed:10207087,
CC       ECO:0000269|PubMed:14625302, ECO:0000269|PubMed:14976184,
CC       ECO:0000269|PubMed:19380490, ECO:0000269|PubMed:8895518,
CC       ECO:0000269|PubMed:9524226}.
CC   -!- SUBUNIT: Interacts with RUNX1 (via the Runt domain); the interaction
CC       transactivates the IL3 promoter. Interacts (via its C-terminus) with
CC       PML; the interaction translocates ELF4 to PML nuclear bodies and
CC       enhances transactivation of LYZ. {ECO:0000269|PubMed:10207087,
CC       ECO:0000269|PubMed:14976184}.
CC   -!- SUBCELLULAR LOCATION: Nucleus, PML body {ECO:0000269|PubMed:14976184}.
CC       Note=Accumulation into PML nuclear bodies is mediated by PML.
CC   -!- TISSUE SPECIFICITY: Abundantly expressed in the placenta and in a
CC       variety of myeloid leukemia cell lines. Moderate levels of expression
CC       in heart, lung, spleen, thymus, peripheral blood lymphocytes, ovary and
CC       colon. Lower levels of expression in Jurkat T-cells and other T-cell
CC       lines and no expression in brain. {ECO:0000269|PubMed:8895518,
CC       ECO:0000269|PubMed:9524226}.
CC   -!- INDUCTION: By ponisterone A in erythroleukemia cells.
CC       {ECO:0000269|PubMed:14625302}.
CC   -!- DISEASE: Note=A chromosomal aberration involving ELF4 has been found in
CC       a case of acute myeloid leukemia (AML). Translocation t(X;21)(q25-
CC       26;q22) with ERG. {ECO:0000269|PubMed:16303180}.
CC   -!- SIMILARITY: Belongs to the ETS family. {ECO:0000255}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC17452.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U32645; AAB53693.1; -; mRNA.
DR   EMBL; AF000670; AAC17452.1; ALT_FRAME; mRNA.
DR   EMBL; AL136450; CAI42882.1; -; Genomic_DNA.
DR   EMBL; Z81363; CAI42882.1; JOINED; Genomic_DNA.
DR   EMBL; Z81363; CAI42371.1; -; Genomic_DNA.
DR   EMBL; AL136450; CAI42371.1; JOINED; Genomic_DNA.
DR   EMBL; CH471107; EAX11813.1; -; Genomic_DNA.
DR   EMBL; CH471107; EAX11814.1; -; Genomic_DNA.
DR   EMBL; BC017194; AAH17194.1; -; mRNA.
DR   CCDS; CCDS14617.1; -.
DR   RefSeq; NP_001120669.1; NM_001127197.1.
DR   RefSeq; NP_001412.1; NM_001421.3.
DR   RefSeq; XP_005262446.1; XM_005262389.3.
DR   SMR; Q99607; -.
DR   BioGrid; 108315; 8.
DR   IntAct; Q99607; 4.
DR   STRING; 9606.ENSP00000311280; -.
DR   iPTMnet; Q99607; -.
DR   PhosphoSitePlus; Q99607; -.
DR   BioMuta; ELF4; -.
DR   DMDM; 68052244; -.
DR   EPD; Q99607; -.
DR   jPOST; Q99607; -.
DR   MassIVE; Q99607; -.
DR   MaxQB; Q99607; -.
DR   PaxDb; Q99607; -.
DR   PeptideAtlas; Q99607; -.
DR   PRIDE; Q99607; -.
DR   ProteomicsDB; 78352; -.
DR   Antibodypedia; 16200; 353 antibodies.
DR   DNASU; 2000; -.
DR   Ensembl; ENST00000308167; ENSP00000311280; ENSG00000102034.
DR   Ensembl; ENST00000335997; ENSP00000338608; ENSG00000102034.
DR   GeneID; 2000; -.
DR   KEGG; hsa:2000; -.
DR   UCSC; uc004evd.5; human.
DR   CTD; 2000; -.
DR   DisGeNET; 2000; -.
DR   GeneCards; ELF4; -.
DR   HGNC; HGNC:3319; ELF4.
DR   HPA; ENSG00000102034; Low tissue specificity.
DR   MalaCards; ELF4; -.
DR   MIM; 300775; gene.
DR   neXtProt; NX_Q99607; -.
DR   OpenTargets; ENSG00000102034; -.
DR   Orphanet; 632; Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia.
DR   PharmGKB; PA27747; -.
DR   eggNOG; KOG3804; Eukaryota.
DR   eggNOG; ENOG4111K4J; LUCA.
DR   GeneTree; ENSGT00940000161870; -.
DR   HOGENOM; CLU_027279_1_0_1; -.
DR   InParanoid; Q99607; -.
DR   KO; K09428; -.
DR   OMA; DGTLCMA; -.
DR   OrthoDB; 837296at2759; -.
DR   PhylomeDB; Q99607; -.
DR   TreeFam; TF318679; -.
DR   SIGNOR; Q99607; -.
DR   ChiTaRS; ELF4; human.
DR   GeneWiki; ELF4; -.
DR   GenomeRNAi; 2000; -.
DR   Pharos; Q99607; Tbio.
DR   PRO; PR:Q99607; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q99607; protein.
DR   Bgee; ENSG00000102034; Expressed in blood and 191 other tissues.
DR   ExpressionAtlas; Q99607; baseline and differential.
DR   Genevisible; Q99607; HS.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IEA:InterPro.
DR   GO; GO:0001787; P:natural killer cell proliferation; ISS:UniProtKB.
DR   GO; GO:0001866; P:NK T cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR033070; Elf4.
DR   InterPro; IPR000418; Ets_dom.
DR   InterPro; IPR022084; TF_Elf_N.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR11849:SF170; PTHR11849:SF170; 1.
DR   Pfam; PF12310; Elf-1_N; 1.
DR   Pfam; PF00178; Ets; 1.
DR   PRINTS; PR00454; ETSDOMAIN.
DR   SMART; SM00413; ETS; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00345; ETS_DOMAIN_1; 1.
DR   PROSITE; PS00346; ETS_DOMAIN_2; 1.
DR   PROSITE; PS50061; ETS_DOMAIN_3; 1.
PE   1: Evidence at protein level;
KW   Activator; Chromosomal rearrangement; DNA-binding; Nucleus; Phosphoprotein;
KW   Proto-oncogene; Reference proteome; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..663
FT                   /note="ETS-related transcription factor Elf-4"
FT                   /id="PRO_0000204089"
FT   DNA_BIND        209..291
FT                   /note="ETS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00237"
FT   REGION          87..206
FT                   /note="RUNX1-binding"
FT                   /evidence="ECO:0000269|PubMed:10207087"
FT   SITE            25..26
FT                   /note="Breakpoint for translocation to form ELF4-ERG
FT                   oncogene"
FT   MOD_RES         151
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         188
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         641
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         648
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231"
FT   CONFLICT        293..294
FT                   /note="MP -> IA (in Ref. 2; AAC17452)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        499
FT                   /note="P -> L (in Ref. 2; AAC17452)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   663 AA;  70730 MW;  1696085D31B09BC5 CRC64;
     MAITLQPSDL IFEFASNGMD DDIHQLEDPS VFPAVIVEQV PYPDLLHLYS GLELDDVHNG
     IITDGTLCMT QDQILEGSFL LTDDNEATSH TMSTAEVLLN MESPSDILDE KQIFSTSEML
     PDSDPAPAVT LPNYLFPASE PDALNRAGDT SDQEGHSLEE KASREESAKK TGKSKKRIRK
     TKGNRSTSPV TDPSIPIRKK SKDGKGSTIY LWEFLLALLQ DRNTCPKYIK WTQREKGIFK
     LVDSKAVSKL WGKQKNKPDM NYETMGRALR YYYQRGILAK VEGQRLVYQF KEMPKDLVVI
     EDEDESSEAT AAPPQASTAS VASASTTRRT SSRVSSRSAP QGKGSSSWEK PKIQHVGLQP
     SASLELGPSL DEEIPTTSTM LVSPAEGQVK LTKAVSASSV PSNIHLGVAP VGSGSALTLQ
     TIPLTTVLTN GPPASTTAPT QLVLQSVPAA STFKDTFTLQ ASFPLNASFQ DSQVAAPGAP
     LILSGLPQLL AGANRPTNPA PPTVTGAGPA GPSSQPPGTV IAAFIRTSGT TAAPRVKEGP
     LRSSSYVQGM VTGAPMEGLL VPEETLRELL RDQAHLQPLP TQVVSRGSHN PSLLGNQTLS
     PPSRPTVGLT PVAELELSSG SGSLLMAEPS VTTSGSLLTR SPTPAPFSPF NPTSLIKMEP
     HDI
//
ID   A0A125SXW3_HUMAN        Unreviewed;       483 AA.
AC   A0A125SXW3;
DT   13-APR-2016, integrated into UniProtKB/TrEMBL.
DT   13-APR-2016, sequence version 1.
DT   11-DEC-2019, entry version 26.
DE   SubName: Full=Estrogen receptor alpha splice variant, ERalphai67 {ECO:0000313|EMBL:BAU46553.1};
GN   Name=ESR1 {ECO:0000313|EMBL:BAU46553.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAU46553.1};
RN   [1] {ECO:0000313|EMBL:BAU46553.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Uterus {ECO:0000313|EMBL:BAU46553.1};
RX   PubMed=26835991; DOI=10.1016/j.mce.2016.01.026;
RA   Hattori Y., Ishii H., Munetomo A., Watanabe H., Morita A., Sakuma Y.,
RA   Ozawa H.;
RT   "Human C-terminally truncated ER? variants resulting from the use of
RT   alternative exons in the ligand-binding domain.";
RL   Mol. Cell. Endocrinol. 425:111-122(2016).
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PIRNR:PIRNR002527,
CC       ECO:0000256|SAAS:SAAS01037405}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3
CC       subfamily. {ECO:0000256|PIRNR:PIRNR002527}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; LC120330; BAU46553.1; -; mRNA.
DR   RefSeq; XP_011533849.1; XM_011535547.2.
DR   PeptideAtlas; A0A125SXW3; -.
DR   GeneID; 2099; -.
DR   CTD; 2099; -.
DR   ChiTaRS; ESR1; human.
DR   GenomeRNAi; 2099; -.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0030284; F:estrogen receptor activity; IEA:InterPro.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0005496; F:steroid binding; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   Gene3D; 1.10.565.10; -; 1.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR024178; Oest_rcpt/oest-rel_rcp.
DR   InterPro; IPR001292; Oestr_rcpt.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF02159; Oest_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PIRSF; PIRSF002527; ER-like_NR; 1.
DR   PRINTS; PR00543; OESTROGENR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   2: Evidence at transcript level;
KW   DNA-binding {ECO:0000256|SAAS:SAAS00476383};
KW   Metal-binding {ECO:0000256|SAAS:SAAS00476458};
KW   Nucleus {ECO:0000256|PIRNR:PIRNR002527, ECO:0000256|SAAS:SAAS01037386};
KW   Receptor {ECO:0000256|PIRNR:PIRNR002527, ECO:0000256|SAAS:SAAS01037471,
KW   ECO:0000313|EMBL:BAU46553.1};
KW   Transcription {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS01037387};
KW   Transcription regulation {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS01037387}; Zinc {ECO:0000256|SAAS:SAAS00476458};
KW   Zinc-finger {ECO:0000256|SAAS:SAAS00476458}.
FT   DOMAIN          182..257
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000259|PROSITE:PS51030"
FT   DOMAIN          311..483
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000259|PROSITE:PS51843"
FT   REGION          147..174
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          259..282
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   483 AA;  53748 MW;  2BD7CE2C94A8D1B9 CRC64;
     MTMTLHTKAS GMALLHQIQG NELEPLNRPQ LKIPLERPLG EVYLDSSKPA VYNYPEGAAY
     EFNAAAAANA QVYGQTGLPY GPGSEAAAFG SNGLGGFPPL NSVSPSPLML LHPPPQLSPF
     LQPHGQQVPY YLENEPSGYT VREAGPPAFY RPNSDNRRQG GRERLASTND KGSMAMESAK
     ETRYCAVCND YASGYHYGVW SCEGCKAFFK RSIQGHNDYM CPATNQCTID KNRRKSCQAC
     RLRKCYEVGM MKGGIRKDRR GGRMLKHKRQ RDDGEGRGEV GSAGDMRAAN LWPSPLMIKR
     SKKNSLALSL TADQMVSALL DAEPPILYSE YDPTRPFSEA SMMGLLTNLA DRELVHMINW
     AKRVPGFVDL TLHDQVHLLE CAWLEILMIG LVWRSMEHPG KLLFAPNLLL DRNQGKCVEG
     MVEIFDMLLA TSSRFRMMNL QGEEFVCLKS IILLNSVLTT GRPGDTLPCL AQWVTRPWRL
     AHC
//
ID   A8KAF4_HUMAN            Unreviewed;       594 AA.
AC   A8KAF4;
DT   04-DEC-2007, integrated into UniProtKB/TrEMBL.
DT   04-DEC-2007, sequence version 1.
DT   11-DEC-2019, entry version 86.
DE   RecName: Full=Estrogen receptor {ECO:0000256|PIRNR:PIRNR002527};
DE            Short=ER {ECO:0000256|PIRNR:PIRNR002527};
DE   AltName: Full=ER-alpha {ECO:0000256|PIRNR:PIRNR002527};
DE   AltName: Full=Estradiol receptor {ECO:0000256|PIRNR:PIRNR002527};
DE   AltName: Full=Nuclear receptor subfamily 3 group A member 1 {ECO:0000256|PIRNR:PIRNR002527};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAF85708.1};
RN   [1] {ECO:0000313|EMBL:BAF85708.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Uterus {ECO:0000313|EMBL:BAF85708.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A.,
RA   Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y.,
RA   Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T.,
RA   Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: The steroid hormones and their receptors are involved in the
CC       regulation of eukaryotic gene expression and affect cellular
CC       proliferation and differentiation in target tissues.
CC       {ECO:0000256|PIRNR:PIRNR002527}.
CC   -!- SUBUNIT: Binds DNA as a homodimer. {ECO:0000256|PIRNR:PIRNR002527}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PIRNR:PIRNR002527,
CC       ECO:0000256|SAAS:SAAS01037405}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3
CC       subfamily. {ECO:0000256|PIRNR:PIRNR002527}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK293019; BAF85708.1; -; mRNA.
DR   RefSeq; NP_001278170.1; NM_001291241.1.
DR   PeptideAtlas; A8KAF4; -.
DR   PRIDE; A8KAF4; -.
DR   GeneID; 2099; -.
DR   CTD; 2099; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   eggNOG; ENOG410XRZC; LUCA.
DR   GenomeRNAi; 2099; -.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0030284; F:estrogen receptor activity; IEA:InterPro.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0005496; F:steroid binding; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   Gene3D; 1.10.565.10; -; 1.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR024178; Oest_rcpt/oest-rel_rcp.
DR   InterPro; IPR001292; Oestr_rcpt.
DR   InterPro; IPR024736; Oestrogen-typ_rcpt_final_C_dom.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF12743; ESR1_C; 1.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF02159; Oest_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PIRSF; PIRSF500101; ER-a; 1.
DR   PIRSF; PIRSF002527; ER-like_NR; 1.
DR   PRINTS; PR00543; OESTROGENR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   2: Evidence at transcript level;
KW   DNA-binding {ECO:0000256|PIRNR:PIRNR002527, ECO:0000256|SAAS:SAAS00476383};
KW   Lipid-binding {ECO:0000256|PIRNR:PIRNR002527};
KW   Metal-binding {ECO:0000256|SAAS:SAAS00476458};
KW   Nucleus {ECO:0000256|PIRNR:PIRNR002527, ECO:0000256|SAAS:SAAS01037386};
KW   Receptor {ECO:0000256|PIRNR:PIRNR002527, ECO:0000256|SAAS:SAAS01037471,
KW   ECO:0000313|EMBL:BAF85708.1};
KW   Steroid-binding {ECO:0000256|PIRNR:PIRNR002527};
KW   Transcription {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS01037387};
KW   Transcription regulation {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS01037387}; Zinc {ECO:0000256|SAAS:SAAS00476458};
KW   Zinc-finger {ECO:0000256|SAAS:SAAS00476458}.
FT   DOMAIN          182..257
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000259|PROSITE:PS51030"
FT   DOMAIN          310..546
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000259|PROSITE:PS51843"
FT   REGION          147..174
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          258..281
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          552..572
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        557..572
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   594 AA;  66169 MW;  48F6B6D48709786B CRC64;
     MTMTLHTKAS GMALLHQIQG NELEPLNRPQ LKIPLERPLG EVYLDSSKPA VYNYPEGAAY
     EFNAAAAANA QVYGQTGLPY GPGSEAAAFG SNGLGGFPPL NSVSPSPLML LHPPPQLSPF
     LQPHGQQVPY YLENEPSGYT VREAGPPAFY RPNSDNRRQG GRERLASTND KGSMAMESAK
     ETRYCAVCND YASGYHYGVW SCEGCKAFFK RSIQGHNDYM CPATNQCTID KNRRKSCQAC
     RLRKCYEVGM MKGIRKDRRG GRMLKHKRQR DDGEGRGEVG SAGDMRAANL WPSPLMIKRS
     KKNSLALSLT ADQMVSALLD AEPPILYPEY DPTRPFSEAS MMGLLTNLAD RELVHMINWA
     KRVPGFVDLT LHDQVHLLEC AWLEILMIGL VWRSMEHPGK LLFAPNLLLD RNQGKCVEGM
     VEIFDMLLAT SSRFRMMNLQ GEEFVCLKSI ILLNSGVYTF LSSTLKSLEE KDHIHRVLDK
     ITDTLIHLMA KAGLTLQQQH QRLAQLLLIL SHIRHMSNKG MEHLYSMKCK NVVPLYDLLL
     EMLDAHRLHA PTSRGGASVE ETDQSHLATA GSTSSHSLQK YYITGEAEGF PATV
//
ID   G4XH65_HUMAN            Unreviewed;       595 AA.
AC   G4XH65;
DT   14-DEC-2011, integrated into UniProtKB/TrEMBL.
DT   14-DEC-2011, sequence version 1.
DT   22-APR-2020, entry version 73.
DE   RecName: Full=Estrogen receptor {ECO:0000256|PIRNR:PIRNR002527};
DE            Short=ER {ECO:0000256|PIRNR:PIRNR002527};
DE   AltName: Full=ER-alpha {ECO:0000256|PIRNR:PIRNR002527};
DE   AltName: Full=Estradiol receptor {ECO:0000256|PIRNR:PIRNR002527};
DE   AltName: Full=Nuclear receptor subfamily 3 group A member 1 {ECO:0000256|PIRNR:PIRNR002527};
GN   Name=ESR1 {ECO:0000313|EMBL:AEP43755.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AEP43755.1};
RN   [1] {ECO:0000313|EMBL:AEP43755.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Kidney {ECO:0000313|EMBL:AEP43755.1};
RA   Kaighin V.A., Martin A.L., Aronstam R.S.;
RL   Submitted (APR-2011) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: The steroid hormones and their receptors are involved in the
CC       regulation of eukaryotic gene expression and affect cellular
CC       proliferation and differentiation in target tissues.
CC       {ECO:0000256|PIRNR:PIRNR002527}.
CC   -!- SUBUNIT: Binds DNA as a homodimer. {ECO:0000256|PIRNR:PIRNR002527}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PIRNR:PIRNR002527,
CC       ECO:0000256|SAAS:SAAS01037405}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3
CC       subfamily. {ECO:0000256|PIRNR:PIRNR002527}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; JF810888; AEP43755.1; -; mRNA.
DR   RefSeq; NP_000116.2; NM_000125.3.
DR   RefSeq; NP_001116212.1; NM_001122740.1.
DR   RefSeq; NP_001116213.1; NM_001122741.1.
DR   RefSeq; NP_001116214.1; NM_001122742.1.
DR   RefSeq; XP_011533845.1; XM_011535543.2.
DR   RefSeq; XP_011533846.1; XM_011535544.2.
DR   RefSeq; XP_011533847.1; XM_011535545.2.
DR   RefSeq; XP_016865865.1; XM_017010376.1.
DR   RefSeq; XP_016865866.1; XM_017010377.1.
DR   RefSeq; XP_016865867.1; XM_017010378.1.
DR   RefSeq; XP_016865868.1; XM_017010379.1.
DR   RefSeq; XP_016865869.1; XM_017010380.1.
DR   RefSeq; XP_016865870.1; XM_017010381.1.
DR   SMR; G4XH65; -.
DR   PRIDE; G4XH65; -.
DR   Antibodypedia; 739; 3921 antibodies.
DR   GeneID; 2099; -.
DR   KEGG; hsa:2099; -.
DR   CTD; 2099; -.
DR   EuPathDB; HostDB:ENSG00000091831.21; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   eggNOG; ENOG410XRZC; LUCA.
DR   KO; K08550; -.
DR   OMA; TMEPLHD; -.
DR   PhylomeDB; G4XH65; -.
DR   ChiTaRS; ESR1; human.
DR   GenomeRNAi; 2099; -.
DR   Bgee; ENSG00000091831; Expressed in endometrium and 151 other tissues.
DR   ExpressionAtlas; G4XH65; baseline and differential.
DR   Genevisible; G4XH65; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0030284; F:estrogen receptor activity; IEA:InterPro.
DR   GO; GO:0004879; F:nuclear receptor activity; IEA:Ensembl.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0005496; F:steroid binding; IEA:UniProtKB-KW.
DR   GO; GO:0008134; F:transcription factor binding; IEA:Ensembl.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0008209; P:androgen metabolic process; IEA:Ensembl.
DR   GO; GO:0001547; P:antral ovarian follicle growth; IEA:Ensembl.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IEA:Ensembl.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IEA:Ensembl.
DR   GO; GO:0002064; P:epithelial cell development; IEA:Ensembl.
DR   GO; GO:0060750; P:epithelial cell proliferation involved in mammary gland duct elongation; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0060749; P:mammary gland alveolus development; IEA:Ensembl.
DR   GO; GO:0060745; P:mammary gland branching involved in pregnancy; IEA:Ensembl.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; IEA:Ensembl.
DR   GO; GO:0060523; P:prostate epithelial cord elongation; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0060687; P:regulation of branching involved in prostate gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0050727; P:regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0034121; P:regulation of toll-like receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048863; P:stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   GO; GO:0060068; P:vagina development; IEA:Ensembl.
DR   Gene3D; 1.10.565.10; -; 1.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR024178; Oest_rcpt/oest-rel_rcp.
DR   InterPro; IPR001292; Oestr_rcpt.
DR   InterPro; IPR024736; Oestrogen-typ_rcpt_final_C_dom.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF12743; ESR1_C; 1.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF02159; Oest_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PIRSF; PIRSF500101; ER-a; 1.
DR   PIRSF; PIRSF002527; ER-like_NR; 1.
DR   PRINTS; PR00543; OESTROGENR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   2: Evidence at transcript level;
KW   DNA-binding {ECO:0000256|PIRNR:PIRNR002527, ECO:0000256|SAAS:SAAS00476383};
KW   Lipid-binding {ECO:0000256|PIRNR:PIRNR002527};
KW   Metal-binding {ECO:0000256|SAAS:SAAS00476458};
KW   Nucleus {ECO:0000256|PIRNR:PIRNR002527, ECO:0000256|SAAS:SAAS01037386};
KW   Receptor {ECO:0000256|PIRNR:PIRNR002527, ECO:0000256|SAAS:SAAS01037471,
KW   ECO:0000313|EMBL:AEP43755.1};
KW   Steroid-binding {ECO:0000256|PIRNR:PIRNR002527};
KW   Transcription {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS01037387};
KW   Transcription regulation {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS01037387}; Zinc {ECO:0000256|SAAS:SAAS00476458};
KW   Zinc-finger {ECO:0000256|SAAS:SAAS00476458}.
FT   DOMAIN          182..257
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000259|PROSITE:PS51030"
FT   DOMAIN          311..547
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000259|PROSITE:PS51843"
FT   REGION          147..174
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          259..282
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          553..573
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        558..573
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   595 AA;  66216 MW;  5455C57AB0CCCAA7 CRC64;
     MTMTLHTKAS GMALLHQIQG NELEPLNRPQ LKIPLERPLG EVYLDSSKPA VYNYPEGAAY
     EFNAAAAANA QVYGQTGLPY GPGSEAAAFG SNGLGGFPPL NSVSPSPLML LHPPPQLSPF
     LQPHGQQVPY YLENEPSGYT VREAGPPAFY RPNSDNRRQG GRERLASTND KGSMAMESAK
     ETRYCAVCND YASGYHYGVW SCEGCKAFFK RSIQGHNDYM CPATNQCTID KNRRKSCQAC
     RLRKCYEVGM MKGGIRKDRR GGRMLKHKRQ RDDGEGRGEV GSAGDMRAAN LWPSPLMIKR
     SKKNSLALSL TADQMVSALL DAEPPILYSE YDPTRPFSEA SMMGLLTNLA DRELVHMINW
     AKRVPGFVDL TLHDQVHLLE CAWLEILMIG LVWRSMEHPG KLLFAPNLLL DRNQGKCVEG
     MVEIFDMLLA TSSRFRMMNL QGEEFVCLKS IILLNSGVYT FLSSTLKSLE EKDHIHRVLD
     KITDTLIHLM AKAGLTLQQQ HQRLAQLLLI LSHIRHMSNK GMEHLYSMKC KNVVPLYDLL
     LEMLDAHRLH APTSRGGASV EETDQSHLAT AGSTSSHSLQ KYYITGEAEG FPATV
//
ID   H0Y4W6_HUMAN            Unreviewed;       310 AA.
AC   H0Y4W6;
DT   22-FEB-2012, integrated into UniProtKB/TrEMBL.
DT   19-FEB-2014, sequence version 2.
DT   22-APR-2020, entry version 65.
DE   SubName: Full=Estrogen receptor {ECO:0000313|Ensembl:ENSP00000394721};
GN   Name=ESR1 {ECO:0000313|Ensembl:ENSP00000394721};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000394721, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000394721, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [2] {ECO:0000313|Ensembl:ENSP00000394721}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JAN-2012) to UniProtKB.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|SAAS:SAAS01037405}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family.
CC       {ECO:0000256|SAAS:SAAS01037406}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL035695; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL049821; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356311; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590993; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF454881; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458326; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458327; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001315029.1; NM_001328100.1.
DR   SMR; H0Y4W6; -.
DR   jPOST; H0Y4W6; -.
DR   PeptideAtlas; H0Y4W6; -.
DR   PRIDE; H0Y4W6; -.
DR   ProteomicsDB; 34846; -.
DR   Antibodypedia; 739; 3921 antibodies.
DR   Ensembl; ENST00000427531; ENSP00000394721; ENSG00000091831.
DR   GeneID; 2099; -.
DR   UCSC; uc063shm.1; human.
DR   CTD; 2099; -.
DR   EuPathDB; HostDB:ENSG00000091831.21; -.
DR   HGNC; HGNC:3467; ESR1.
DR   OpenTargets; ENSG00000091831; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   eggNOG; ENOG410XRZC; LUCA.
DR   GeneTree; ENSGT00940000158133; -.
DR   HOGENOM; CLU_007368_11_1_1; -.
DR   ChiTaRS; ESR1; human.
DR   GenomeRNAi; 2099; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000091831; Expressed in endometrium and 151 other tissues.
DR   ExpressionAtlas; H0Y4W6; baseline and differential.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0005496; F:steroid binding; IEA:InterPro.
DR   GO; GO:0003707; F:steroid hormone receptor activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   Gene3D; 1.10.565.10; -; 1.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR024178; Oest_rcpt/oest-rel_rcp.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PIRSF; PIRSF002527; ER-like_NR; 1.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   DNA-binding {ECO:0000256|SAAS:SAAS00476383};
KW   Metal-binding {ECO:0000256|SAAS:SAAS00476458};
KW   Nucleus {ECO:0000256|SAAS:SAAS01037386};
KW   Proteomics identification {ECO:0000213|EPD:H0Y4W6,
KW   ECO:0000213|MaxQB:H0Y4W6, ECO:0000213|PeptideAtlas:H0Y4W6,
KW   ECO:0000213|ProteomicsDB:H0Y4W6}; Receptor {ECO:0000256|SAAS:SAAS01037471};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|SAAS:SAAS01037387};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS01037387};
KW   Zinc {ECO:0000256|SAAS:SAAS00476458};
KW   Zinc-finger {ECO:0000256|SAAS:SAAS00476458}.
FT   DOMAIN          9..84
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000259|PROSITE:PS51030"
FT   DOMAIN          138..310
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000259|PROSITE:PS51843"
FT   REGION          84..109
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   310 AA;  35298 MW;  051CA0996E56C356 CRC64;
     MAMESAKETR YCAVCNDYAS GYHYGVWSCE GCKAFFKRSI QGHNDYMCPA TNQCTIDKNR
     RKSCQACRLR KCYEVGMMKG GIRKDRRGGR MLKHKRQRDD GEGRGEVGSA GDMRAANLWP
     SPLMIKRSKK NSLALSLTAD QMVSALLDAE PPILYSEYDP TRPFSEASMM GLLTNLADRE
     LVHMINWAKR VPGFVDLTLH DQVHLLECAW LEILMIGLVW RSMEHPGKLL FAPNLLLDRN
     QGKCVEGMVE IFDMLLATSS RFRMMNLQGE EFVCLKSIIL LNSGISHVEA KKRILNLHPK
     IFGNKWFPRV
//
ID   ESR1_HUMAN              Reviewed;         595 AA.
AC   P03372; Q13511; Q14276; Q5T5H7; Q6MZQ9; Q9NU51; Q9UDZ7; Q9UIS7;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   22-APR-2020, entry version 271.
DE   RecName: Full=Estrogen receptor;
DE            Short=ER;
DE   AltName: Full=ER-alpha;
DE   AltName: Full=Estradiol receptor;
DE   AltName: Full=Nuclear receptor subfamily 3 group A member 1;
GN   Name=ESR1; Synonyms=ESR, NR3A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-400.
RX   PubMed=3754034; DOI=10.1038/320134a0;
RA   Green S., Walter P., Kumar V., Krust A., Bornert J.-M., Argos P.,
RA   Chambon P.;
RT   "Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-
RT   A.";
RL   Nature 320:134-139(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-400.
RX   PubMed=3753802; DOI=10.1126/science.3753802;
RA   Greene G.L., Gilna P., Waterfield M., Baker A., Hort Y., Shine J.;
RT   "Sequence and expression of human estrogen receptor complementary DNA.";
RL   Science 231:1150-1154(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Mammary gland;
RX   PubMed=8600466; DOI=10.1093/nar/24.5.962;
RA   Pink J.J., Wu S.Q., Wolf D.M., Bilimoria M.M., Jordan V.C.;
RT   "A novel 80 kDa human estrogen receptor containing a duplication of exons 6
RT   and 7.";
RL   Nucleic Acids Res. 24:962-969(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), ALTERNATIVE PROMOTER USAGE, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=16165085; DOI=10.1016/j.bbrc.2005.08.226;
RA   Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F.;
RT   "Identification, cloning, and expression of human estrogen receptor-
RT   alpha36, a novel variant of human estrogen receptor-alpha66.";
RL   Biochem. Biophys. Res. Commun. 336:1023-1027(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 110-117, PHOSPHORYLATION, AND MUTAGENESIS.
RX   PubMed=7476978; DOI=10.1210/mend.9.8.7476978;
RA   Joel P.B., Traish A.M., Lannigan D.A.;
RT   "Estradiol and phorbol ester cause phosphorylation of serine 118 in the
RT   human estrogen receptor.";
RL   Mol. Endocrinol. 9:1041-1052(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 152-595 (ISOFORM 1).
RX   PubMed=10619354; DOI=10.1016/s0960-0760(99)00126-0;
RA   Schubert E.L., Lee M.K., Newman B., King M.C.;
RT   "Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and
RT   breast cancer susceptibility.";
RL   J. Steroid Biochem. Mol. Biol. 71:21-27(1999).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 216-434 (ISOFORM 2).
RC   TISSUE=Mammary carcinoma;
RX   PubMed=7916651;
RA   Pfeffer U., Fecarotta E., Castagnetta L., Vidali G.;
RT   "Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-
RT   responsive human breast cancer cell lines.";
RL   Cancer Res. 53:741-743(1993).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 354-548.
RC   TISSUE=Mammary carcinoma;
RA   Naundorf H., Becker M., Fiebig C., Buettner B., Fichtner I.;
RT   "Mechanisms of acquired tamoxifen resistance in a xenotransplanted human
RT   breast carcinoma.";
RL   Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   PROTEIN SEQUENCE OF 532-542, AND PHOSPHORYLATION AT TYR-537.
RX   PubMed=7539106; DOI=10.1210/mend.9.1.7539106;
RA   Arnold S.F., Obourn J.D., Jaffe H., Notides A.C.;
RT   "Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and
RT   by src family tyrosine kinases in vitro.";
RL   Mol. Endocrinol. 9:24-33(1995).
RN   [15]
RP   MUTAGENESIS OF CYS-447.
RX   PubMed=1577818;
RA   Reese J.C., Katzenellenbogen B.S.;
RT   "Characterization of a temperature-sensitive mutation in the hormone
RT   binding domain of the human estrogen receptor. Studies in cell extracts and
RT   intact cells and their implications for hormone-dependent transcriptional
RT   activation.";
RL   J. Biol. Chem. 267:9868-9873(1992).
RN   [16]
RP   INTERACTION WITH GTF2B.
RX   PubMed=1517211;
RA   Ing N.H., Beekman J.M., Tsai S.Y., Tsai M.J., O'Malley B.W.;
RT   "Members of the steroid hormone receptor superfamily interact with TFIIB
RT   (S300-II).";
RL   J. Biol. Chem. 267:17617-17623(1992).
RN   [17]
RP   PHOSPHORYLATION AT SER-167 BY CK2.
RX   PubMed=7838153; DOI=10.1210/mend.8.9.7838153;
RA   Arnold S.F., Obourn J.D., Jaffe H., Notides A.C.;
RT   "Serine 167 is the major estradiol-induced phosphorylation site on the
RT   human estrogen receptor.";
RL   Mol. Endocrinol. 8:1208-1214(1994).
RN   [18]
RP   FUNCTION IN TRANSREPRESSION OF NF-KAPPA-B.
RX   PubMed=7651415; DOI=10.1128/mcb.15.9.4971;
RA   Stein B., Yang M.X.;
RT   "Repression of the interleukin-6 promoter by estrogen receptor is mediated
RT   by NF-kappa B and C/EBP beta.";
RL   Mol. Cell. Biol. 15:4971-4979(1995).
RN   [19]
RP   MUTAGENESIS OF VAL-364.
RX   PubMed=8961262; DOI=10.1210/mend.10.12.8961262;
RA   McInerney E.M., Ince B.A., Shapiro D.J., Katzenellenbogen B.S.;
RT   "A transcriptionally active estrogen receptor mutant is a novel type of
RT   dominant negative inhibitor of estrogen action.";
RL   Mol. Endocrinol. 10:1519-1526(1996).
RN   [20]
RP   INTERACTION WITH DDX5, AND MUTAGENESIS OF SER-118.
RX   PubMed=10409727; DOI=10.1128/mcb.19.8.5363;
RA   Endoh H., Maruyama K., Masuhiro Y., Kobayashi Y., Goto M., Tai H.,
RA   Yanagisawa J., Metzger D., Hashimoto S., Kato S.;
RT   "Purification and identification of p68 RNA helicase acting as a
RT   transcriptional coactivator specific for the activation function 1 of human
RT   estrogen receptor alpha.";
RL   Mol. Cell. Biol. 19:5363-5372(1999).
RN   [21]
RP   FUNCTION (ISOFORM 3), TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE
RP   (ISOFORM 3), AND SUBUNIT.
RX   PubMed=10970861; DOI=10.1093/emboj/19.17.4688;
RA   Flouriot G., Brand H., Denger S., Metivier R., Kos M., Reid G.,
RA   Sonntag-Buck V., Gannon F.;
RT   "Identification of a new isoform of the human estrogen receptor-alpha (hER-
RT   alpha) that is encoded by distinct transcripts and that is able to repress
RT   hER-alpha activation function 1.";
RL   EMBO J. 19:4688-4700(2000).
RN   [22]
RP   MUTAGENESIS OF LEU-39 AND TYR-43.
RX   PubMed=11075817; DOI=10.1210/mend.14.11.0546;
RA   Metivier R., Petit F.G., Valotaire Y., Pakdel F.;
RT   "Function of N-terminal transactivation domain of the estrogen receptor
RT   requires a potential alpha-helical structure and is negatively regulated by
RT   the A domain.";
RL   Mol. Endocrinol. 14:1849-1871(2000).
RN   [23]
RP   INTERACTION WITH NCOA1; NCOA2 AND NCOA3, SUBUNIT, AND MUTAGENESIS OF
RP   LEU-539.
RX   PubMed=12554772; DOI=10.1210/me.2002-0351;
RA   Bai Y., Giguere V.;
RT   "Isoform-selective interactions between estrogen receptors and steroid
RT   receptor coactivators promoted by estradiol and ErbB-2 signaling in living
RT   cells.";
RL   Mol. Endocrinol. 17:589-599(2003).
RN   [24]
RP   SUBCELLULAR LOCATION (ISOFORMS 1 AND 3), AND PALMITOYLATION (ISOFORM 3).
RX   PubMed=12682286; DOI=10.1073/pnas.0831079100;
RA   Li L., Haynes M.P., Bender J.R.;
RT   "Plasma membrane localization and function of the estrogen receptor alpha
RT   variant (ER46) in human endothelial cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:4807-4812(2003).
RN   [25]
RP   GLYCOSYLATION.
RX   PubMed=8999954; DOI=10.1074/jbc.272.4.2421;
RA   Jiang M.S., Hart G.W.;
RT   "A subpopulation of estrogen receptors are modified by O-linked N-
RT   acetylglucosamine.";
RL   J. Biol. Chem. 272:2421-2428(1997).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH SP1.
RX   PubMed=9328340; DOI=10.1210/mend.11.11.9916;
RA   Porter W., Saville B., Hoivik D., Safe S.;
RT   "Functional synergy between the transcription factor Sp1 and the estrogen
RT   receptor.";
RL   Mol. Endocrinol. 11:1569-1580(1997).
RN   [27]
RP   INTERACTION WITH AKAP13.
RX   PubMed=9627117; DOI=10.1038/sj.onc.1201783;
RA   Rubino D., Driggers P., Arbit D., Kemp L., Miller B., Coso O., Pagliai K.,
RA   Gray K., Gutkind S., Segars J.;
RT   "Characterization of Brx, a novel Dbl family member that modulates estrogen
RT   receptor action.";
RL   Oncogene 16:2513-2526(1998).
RN   [28]
RP   PHOSPHORYLATION AT SER-104 AND SER-106, AND MUTAGENESIS.
RX   PubMed=10428798; DOI=10.1074/jbc.274.32.22296;
RA   Rogatsky I., Trowbridge J.M., Garabedian M.J.;
RT   "Potentiation of human estrogen receptor alpha transcriptional activation
RT   through phosphorylation of serines 104 and 106 by the cyclin A-CDK2
RT   complex.";
RL   J. Biol. Chem. 274:22296-22302(1999).
RN   [29]
RP   INTERACTION WITH NCOA6.
RX   PubMed=10567404; DOI=10.1074/jbc.274.48.34283;
RA   Lee S.-K., Anzick S.L., Choi J.-E., Bubendorf L., Guan X.-Y., Jung Y.-K.,
RA   Kallioniemi O.-P., Kononen J., Trent J.M., Azorsa D., Jhun B.-H.,
RA   Cheong J.H., Lee Y.C., Meltzer P.S., Lee J.W.;
RT   "A nuclear factor ASC-2, as a cancer-amplified transcriptional coactivator
RT   essential for ligand-dependent transactivation by nuclear receptors in
RT   vivo.";
RL   J. Biol. Chem. 274:34283-34293(1999).
RN   [30]
RP   INTERACTION WITH PHB2.
RX   PubMed=10359819; DOI=10.1073/pnas.96.12.6947;
RA   Montano M.M., Ekena K., Delage-Mourroux R., Chang W., Martini P.,
RA   Katzenellenbogen B.S.;
RT   "An estrogen receptor-selective coregulator that potentiates the
RT   effectiveness of antiestrogens and represses the activity of estrogens.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:6947-6952(1999).
RN   [31]
RP   INTERACTION WITH NCOA2.
RX   PubMed=11265755; DOI=10.1093/embo-reports/kvd028;
RA   Benecke A., Chambon P., Gronemeyer H.;
RT   "Synergy between estrogen receptor alpha activation functions AF1 and AF2
RT   mediated by transcription intermediary factor TIF2.";
RL   EMBO Rep. 1:151-157(2000).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH SP1.
RX   PubMed=10681512; DOI=10.1074/jbc.275.8.5379;
RA   Saville B., Wormke M., Wang F., Nguyen T., Enmark E., Kuiper G.,
RA   Gustafsson J.A., Safe S.;
RT   "Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent
RT   activation at GC-rich (Sp1) promoter elements.";
RL   J. Biol. Chem. 275:5379-5387(2000).
RN   [33]
RP   FUNCTION, AND INTERACTION WITH SP3.
RX   PubMed=10816575; DOI=10.1074/jbc.m002188200;
RA   Stoner M., Wang F., Wormke M., Nguyen T., Samudio I., Vyhlidal C.,
RA   Marme D., Finkenzeller G., Safe S.;
RT   "Inhibition of vascular endothelial growth factor expression in HEC1A
RT   endometrial cancer cells through interactions of estrogen receptor alpha
RT   and Sp3 proteins.";
RL   J. Biol. Chem. 275:22769-22779(2000).
RN   [34]
RP   INTERACTION WITH CITED1 AND EP300.
RX   PubMed=11581164; DOI=10.1101/gad.906301;
RA   Yahata T., Shao W., Endoh H., Hur J., Coser K.R., Sun H., Ueda Y., Kato S.,
RA   Isselbacher K.J., Brown M., Shioda T.;
RT   "Selective coactivation of estrogen-dependent transcription by CITED1
RT   CBP/p300-binding protein.";
RL   Genes Dev. 15:2598-2612(2001).
RN   [35]
RP   FUNCTION, AND INTERACTION WITH JUN; JUNB AND JUND.
RX   PubMed=11477071; DOI=10.1074/jbc.m101806200;
RA   Teyssier C., Belguise K., Galtier F., Chalbos D.;
RT   "Characterization of the physical interaction between estrogen receptor
RT   alpha and JUN proteins.";
RL   J. Biol. Chem. 276:36361-36369(2001).
RN   [36]
RP   INTERACTION WITH KDM5A.
RX   PubMed=11358960; DOI=10.1074/jbc.m100313200;
RA   Chan S.W., Hong W.;
RT   "Retinoblastoma-binding protein 2 (Rbp2) potentiates nuclear hormone
RT   receptor-mediated transcription.";
RL   J. Biol. Chem. 276:28402-28412(2001).
RN   [37]
RP   INTERACTION WITH NCOA5.
RX   PubMed=11113208; DOI=10.1128/mcb.21.1.343-353.2001;
RA   Sauve F., McBroom L.D.B., Gallant J., Moraitis A.N., Labrie F., Giguere V.;
RT   "CIA, a novel estrogen receptor coactivator with a bifunctional nuclear
RT   receptor interacting determinant.";
RL   Mol. Cell. Biol. 21:343-353(2001).
RN   [38]
RP   FUNCTION, AND INTERACTION WITH NCOA1 AND DDX5.
RX   PubMed=11682626; DOI=10.1210/mend.15.11.0727;
RA   Metivier R., Penot G., Flouriot G., Pakdel F.;
RT   "Synergism between ERalpha transactivation function 1 (AF-1) and AF-2
RT   mediated by steroid receptor coactivator protein-1: requirement for the AF-
RT   1 alpha-helical core and for a direct interaction between the N- and C-
RT   terminal domains.";
RL   Mol. Endocrinol. 15:1953-1970(2001).
RN   [39]
RP   INTERACTION WITH PRMT2.
RX   PubMed=12039952; DOI=10.1074/jbc.m201053200;
RA   Qi C., Chang J., Zhu Y., Yeldandi A.V., Rao S.M., Zhu Y.-J.;
RT   "Identification of protein arginine methyltransferase 2 as a coactivator
RT   for estrogen receptor alpha.";
RL   J. Biol. Chem. 277:28624-28630(2002).
RN   [40]
RP   INTERACTION WITH NR2C1.
RX   PubMed=12093804; DOI=10.1074/jbc.m203531200;
RA   Hu Y.C., Shyr C.R., Che W., Mu X.M., Kim E., Chang C.;
RT   "Suppression of estrogen receptor-mediated transcription and cell growth by
RT   interaction with TR2 orphan receptor.";
RL   J. Biol. Chem. 277:33571-33579(2002).
RN   [41]
RP   INTERACTION WITH NCOA7.
RX   PubMed=11971969; DOI=10.1128/mcb.22.10.3358-3372.2002;
RA   Shao W., Halachmi S., Brown M.;
RT   "ERAP140, a conserved tissue-specific nuclear receptor coactivator.";
RL   Mol. Cell. Biol. 22:3358-3372(2002).
RN   [42]
RP   INTERACTION WITH RBFOX2.
RX   PubMed=11875103; DOI=10.1210/mend.16.3.0787;
RA   Norris J.D., Fan D., Sherk A., McDonnell D.P.;
RT   "A negative coregulator for the human ER.";
RL   Mol. Endocrinol. 16:459-468(2002).
RN   [43]
RP   INTERACTION WITH PELP1.
RX   PubMed=12415108; DOI=10.1073/pnas.192569699;
RA   Wong C.-W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.;
RT   "Estrogen receptor-interacting protein that modulates its nongenomic
RT   activity-crosstalk with Src/Erk phosphorylation cascade.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14783-14788(2002).
RN   [44]
RP   INTERACTION WITH SMARD1.
RX   PubMed=12917342; DOI=10.1128/mcb.23.17.6210-6220.2003;
RA   Hsiao P.W., Fryer C.J., Trotter K.W., Wang W., Archer T.K.;
RT   "BAF60a mediates critical interactions between nuclear receptors and the
RT   BRG1 chromatin-remodeling complex for transactivation.";
RL   Mol. Cell. Biol. 23:6210-6220(2003).
RN   [45]
RP   INTERACTION WITH DNTTIP2.
RX   PubMed=15047147; DOI=10.1016/j.bbrc.2004.02.179;
RA   Bu H., Kashireddy P., Chang J., Zhu Y.T., Zhang Z., Zheng W., Rao S.M.,
RA   Zhu Y.-J.;
RT   "ERBP, a novel estrogen receptor binding protein enhancing the activity of
RT   estrogen receptor.";
RL   Biochem. Biophys. Res. Commun. 317:54-59(2004).
RN   [46]
RP   FUNCTION.
RX   PubMed=15078875; DOI=10.1074/jbc.m402148200;
RA   Merot Y., Metivier R., Penot G., Manu D., Saligaut C., Gannon F.,
RA   Pakdel F., Kah O., Flouriot G.;
RT   "The relative contribution exerted by AF-1 and AF-2 transactivation
RT   functions in estrogen receptor alpha transcriptional activity depends upon
RT   the differentiation stage of the cell.";
RL   J. Biol. Chem. 279:26184-26191(2004).
RN   [47]
RP   INTERACTION WITH TXNRD1.
RX   PubMed=15199063; DOI=10.1074/jbc.m402753200;
RA   Damdimopoulos A.E., Miranda-Vizuete A., Treuter E., Gustafsson J.-A.,
RA   Spyrou G.;
RT   "An alternative splicing variant of the selenoprotein thioredoxin reductase
RT   is a modulator of estrogen signaling.";
RL   J. Biol. Chem. 279:38721-38729(2004).
RN   [48]
RP   FUNCTION, PHOSPHORYLATION AT SER-118, DEPHOSPHORYLATION AT SER-118 BY
RP   PPP5C, AND MUTAGENESIS OF SER-118.
RX   PubMed=14764652; DOI=10.1210/me.2003-0308;
RA   Ikeda K., Ogawa S., Tsukui T., Horie-Inoue K., Ouchi Y., Kato S.,
RA   Muramatsu M., Inoue S.;
RT   "Protein phosphatase 5 is a negative regulator of estrogen receptor-
RT   mediated transcription.";
RL   Mol. Endocrinol. 18:1131-1143(2004).
RN   [49]
RP   FUNCTION IN NF-KAPPA-B TRANSREPRESSION.
RX   PubMed=16043358; DOI=10.1016/j.cyto.2004.12.008;
RA   Liu H., Liu K., Bodenner D.L.;
RT   "Estrogen receptor inhibits interleukin-6 gene expression by disruption of
RT   nuclear factor kappaB transactivation.";
RL   Cytokine 31:251-257(2005).
RN   [50]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH DYNLL1.
RX   PubMed=15891768; DOI=10.1038/sj.embor.7400417;
RA   Rayala S.K., den Hollander P., Balasenthil S., Yang Z., Broaddus R.R.,
RA   Kumar R.;
RT   "Functional regulation of oestrogen receptor pathway by the dynein light
RT   chain 1.";
RL   EMBO Rep. 6:538-544(2005).
RN   [51]
RP   ERRATUM OF PUBMED:15891768.
RA   Rayala S.K., den Hollander P., Balasenthil S., Yang Z., Broaddus R.R.,
RA   Kumar R.;
RL   EMBO Rep. 6:1101-1101(2005).
RN   [52]
RP   INTERACTION WITH HEXIM1.
RX   PubMed=15940264; DOI=10.1038/sj.onc.1208728;
RA   Wittmann B.M., Fujinaga K., Deng H., Ogba N., Montano M.M.;
RT   "The breast cell growth inhibitor, estrogen down regulated gene 1,
RT   modulates a novel functional interaction between estrogen receptor alpha
RT   and transcriptional elongation factor cyclin T1.";
RL   Oncogene 24:5576-5588(2005).
RN   [53]
RP   INTERACTION WITH KMT2D.
RX   PubMed=16603732; DOI=10.1074/jbc.m513245200;
RA   Mo R., Rao S.M., Zhu Y.-J.;
RT   "Identification of the MLL2 complex as a coactivator for estrogen receptor
RT   alpha.";
RL   J. Biol. Chem. 281:15714-15720(2006).
RN   [54]
RP   FUNCTION.
RX   PubMed=16684779; DOI=10.1074/jbc.m600021200;
RA   Rayala S.K., den Hollander P., Manavathi B., Talukder A.H., Song C.,
RA   Peng S., Barnekow A., Kremerskothen J., Kumar R.;
RT   "Essential role of KIBRA in co-activator function of dynein light chain 1
RT   in mammalian cells.";
RL   J. Biol. Chem. 281:19092-19099(2006).
RN   [55]
RP   INTERACTION WITH MUC1.
RX   PubMed=16427018; DOI=10.1016/j.molcel.2005.11.030;
RA   Wei X., Xu H., Kufe D.;
RT   "MUC1 oncoprotein stabilizes and activates estrogen receptor alpha.";
RL   Mol. Cell 21:295-305(2006).
RN   [56]
RP   INTERACTION WITH UBE3A AND WBP2.
RX   PubMed=16772533; DOI=10.1210/me.2005-0533;
RA   Dhananjayan S.C., Ramamoorthy S., Khan O.Y., Ismail A., Sun J.,
RA   Slingerland J., O'Malley B.W., Nawaz Z.;
RT   "WW domain binding protein-2, an E6-associated protein interacting protein,
RT   acts as a coactivator of estrogen and progesterone receptors.";
RL   Mol. Endocrinol. 20:2343-2354(2006).
RN   [57]
RP   INTERACTION WITH ZNF366.
RX   PubMed=17085477; DOI=10.1093/nar/gkl875;
RA   Lopez-Garcia J., Periyasamy M., Thomas R.S., Christian M., Leao M., Jat P.,
RA   Kindle K.B., Heery D.M., Parker M.G., Buluwela L., Kamalati T., Ali S.;
RT   "ZNF366 is an estrogen receptor corepressor that acts through CtBP and
RT   histone deacetylases.";
RL   Nucleic Acids Res. 34:6126-6136(2006).
RN   [58]
RP   FUNCTION.
RX   PubMed=16617102; DOI=10.1073/pnas.0601989103;
RA   Gururaj A.E., Singh R.R., Rayala S.K., Holm C., den Hollander P., Zhang H.,
RA   Balasenthil S., Talukder A.H., Landberg G., Kumar R.;
RT   "MTA1, a transcriptional activator of breast cancer amplified sequence 3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6670-6675(2006).
RN   [59]
RP   ERRATUM OF PUBMED:16617102.
RA   Gururaj A.E., Singh R.R., Rayala S.K., Holm C., den Hollander P., Zhang H.,
RA   Balasenthil S., Talukder A.H., Landberg G., Kumar R.;
RL   Proc. Natl. Acad. Sci. U.S.A. 110:4147-4148(2013).
RN   [60]
RP   INTERACTION WITH PBXIP1.
RX   PubMed=17043237; DOI=10.1073/pnas.0607445103;
RA   Manavathi B., Acconcia F., Rayala S.K., Kumar R.;
RT   "An inherent role of microtubule network in the action of nuclear
RT   receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15981-15986(2006).
RN   [61]
RP   INTERACTION WITH MAP1S.
RX   PubMed=17658481; DOI=10.1016/j.bbrc.2007.06.179;
RA   Eriksson M., Samuelsson H., Samuelsson E.-B., Liu L., McKeehan W.L.,
RA   Benedikz E., Sundstroem E.;
RT   "The NMDAR subunit NR3A interacts with microtubule-associated protein 1S in
RT   the brain.";
RL   Biochem. Biophys. Res. Commun. 361:127-132(2007).
RN   [62]
RP   INTERACTION WITH CUEDC2.
RX   PubMed=17347654; DOI=10.1038/sj.emboj.7601602;
RA   Zhang P.-J., Zhao J., Li H.-Y., Man J.-H., He K., Zhou T., Pan X.,
RA   Li A.-L., Gong W.-L., Jin B.-F., Xia Q., Yu M., Shen B.-F., Zhang X.-M.;
RT   "CUE domain containing 2 regulates degradation of progesterone receptor by
RT   ubiquitin-proteasome.";
RL   EMBO J. 26:1831-1842(2007).
RN   [63]
RP   INTERACTION WITH MACROD1.
RX   PubMed=17914104; DOI=10.1677/erc-06-0082;
RA   Han W.-D., Zhao Y.-L., Meng Y.G., Zang L., Wu Z.-Q., Li Q., Si Y.-L.,
RA   Huang K., Ba J.-M., Morinaga H., Nomura M., Mu Y.-M.;
RT   "Estrogenically regulated LRP16 interacts with estrogen receptor alpha and
RT   enhances the receptor's transcriptional activity.";
RL   Endocr. Relat. Cancer 14:741-753(2007).
RN   [64]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH KIF18A.
RX   PubMed=17006958; DOI=10.1002/jcb.21000;
RA   Luboshits G., Benayahu D.;
RT   "MS-KIF18A, a kinesin, is associated with estrogen receptor.";
RL   J. Cell. Biochem. 100:693-702(2007).
RN   [65]
RP   INTERACTION WITH PRMT2.
RX   PubMed=17587566; DOI=10.1016/j.jsbmb.2007.05.006;
RA   Meyer R., Wolf S.S., Obendorf M.;
RT   "PRMT2, a member of the protein arginine methyltransferase family, is a
RT   coactivator of the androgen receptor.";
RL   J. Steroid Biochem. Mol. Biol. 107:1-14(2007).
RN   [66]
RP   INTERACTION WITH BCAS3.
RX   PubMed=17505058; DOI=10.1210/me.2006-0514;
RA   Gururaj A.E., Peng S., Vadlamudi R.K., Kumar R.;
RT   "Estrogen induces expression of BCAS3, a novel estrogen receptor-alpha
RT   coactivator, through proline-, glutamic acid-, and leucine-rich protein-1
RT   (PELP1).";
RL   Mol. Endocrinol. 21:1847-1860(2007).
RN   [67]
RP   INTERACTION WITH UIMC1.
RX   PubMed=17311814; DOI=10.1093/nar/gkl1112;
RA   Yan J., Kim Y.S., Yang X.-P., Albers M., Koegl M., Jetten A.M.;
RT   "Ubiquitin-interaction motifs of RAP80 are critical in its regulation of
RT   estrogen receptor alpha.";
RL   Nucleic Acids Res. 35:1673-1686(2007).
RN   [68]
RP   INTERACTION WITH ATAD2.
RX   PubMed=17998543; DOI=10.1073/pnas.0705814104;
RA   Zou J.X., Revenko A.S., Li L.B., Gemo A.T., Chen H.-W.;
RT   "ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is
RT   required for coregulator occupancy and chromatin modification.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:18067-18072(2007).
RN   [69]
RP   FUNCTION IN ASSOCIATION WITH AP-1.
RX   PubMed=18247370; DOI=10.1002/jcp.21379;
RA   Lambertini E., Tavanti E., Torreggiani E., Penolazzi L., Gambari R.,
RA   Piva R.;
RT   "ERalpha and AP-1 interact in vivo with a specific sequence of the F
RT   promoter of the human ERalpha gene in osteoblasts.";
RL   J. Cell. Physiol. 216:101-110(2008).
RN   [70]
RP   METHYLATION AT ARG-260 BY PRMT1, MUTAGENESIS OF ARG-260, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH PI3KR1/2; SRC AND PTK2/FAK1.
RX   PubMed=18657504; DOI=10.1016/j.molcel.2008.05.025;
RA   Le Romancer M., Treilleux I., Leconte N., Robin-Lespinasse Y., Sentis S.,
RA   Bouchekioua-Bouzaghou K., Goddard S., Gobert-Gosse S., Corbo L.;
RT   "Regulation of estrogen rapid signaling through arginine methylation by
RT   PRMT1.";
RL   Mol. Cell 31:212-221(2008).
RN   [71]
RP   FUNCTION IN NF-KAPPA-B TRANSREPRESSION, AND INTERACTION WITH RELA.
RX   PubMed=17932106; DOI=10.1210/me.2007-0324;
RA   Nettles K.W., Gil G., Nowak J., Metivier R., Sharma V.B., Greene G.L.;
RT   "CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression
RT   by the estrogen receptor.";
RL   Mol. Endocrinol. 22:263-272(2008).
RN   [72]
RP   FUNCTION.
RX   PubMed=17922032; DOI=10.1038/sj.onc.1210839;
RA   Molli P.R., Singh R.R., Lee S.W., Kumar R.;
RT   "MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene.";
RL   Oncogene 27:1971-1980(2008).
RN   [73]
RP   INTERACTION WITH CCDC62.
RX   PubMed=18563714; DOI=10.1002/pros.20774;
RA   Chen M., Ni J., Zhang Y., Muyan M., Yeh S.;
RT   "ERAP75 functions as a coactivator to enhance estrogen receptor alpha
RT   transactivation in prostate stromal cells.";
RL   Prostate 68:1273-1282(2008).
RN   [74]
RP   INTERACTION WITH SH2D4A AND PLCG.
RX   PubMed=19712589; DOI=10.5483/bmbrep.2009.42.8.516;
RA   Li T., Li W., Lu J., Liu H., Li Y., Zhao Y.;
RT   "SH2D4A regulates cell proliferation via the ERalpha/PLC-gamma/PKC
RT   pathway.";
RL   BMB Rep. 42:516-522(2009).
RN   [75]
RP   INTERACTION WITH LDB1 AND RLIM.
RX   PubMed=19117995; DOI=10.1158/0008-5472.can-08-1630;
RA   Johnsen S.A., Guengoer C., Prenzel T., Riethdorf S., Riethdorf L.,
RA   Taniguchi-Ishigaki N., Rau T., Tursun B., Furlow J.D., Sauter G.,
RA   Scheffner M., Pantel K., Gannon F., Bach I.;
RT   "Regulation of estrogen-dependent transcription by the LIM cofactors CLIM
RT   and RLIM in breast cancer.";
RL   Cancer Res. 69:128-136(2009).
RN   [76]
RP   INTERACTION WITH DNAAF4.
RX   PubMed=19423554; DOI=10.1093/hmg/ddp215;
RA   Massinen S., Tammimies K., Tapia-Paez I., Matsson H., Hokkanen M.E.,
RA   Soederberg O., Landegren U., Castren E., Gustafsson J.A., Treuter E.,
RA   Kere J.;
RT   "Functional interaction of DYX1C1 with estrogen receptors suggests
RT   involvement of hormonal pathways in dyslexia.";
RL   Hum. Mol. Genet. 18:2802-2812(2009).
RN   [77]
RP   FUNCTION IN MUTUAL TRANSREPRESSION WITH NF-KAPPA-B, AND INTERACTION WITH
RP   NFKB1 AND RELA.
RX   PubMed=19350539; DOI=10.1002/jcb.22141;
RA   Gionet N., Jansson D., Mader S., Pratt M.A.;
RT   "NF-kappaB and estrogen receptor alpha interactions: Differential function
RT   in estrogen receptor-negative and -positive hormone-independent breast
RT   cancer cells.";
RL   J. Cell. Biochem. 107:448-459(2009).
RN   [78]
RP   UBIQUITINATION, AND INTERACTION WITH OTUB1.
RX   PubMed=19383985; DOI=10.1074/jbc.m109.007484;
RA   Stanisic V., Malovannaya A., Qin J., Lonard D.M., O'Malley B.W.;
RT   "OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1)
RT   deubiquitinates estrogen receptor (ER) alpha and affects ERalpha
RT   transcriptional activity.";
RL   J. Biol. Chem. 284:16135-16145(2009).
RN   [79]
RP   PHOSPHORYLATION BY CSNK1D/CK1, AND INTERACTION WITH CSNK1D.
RX   PubMed=19339517; DOI=10.1093/nar/gkp136;
RA   Giamas G., Castellano L., Feng Q., Knippschild U., Jacob J., Thomas R.S.,
RA   Coombes R.C., Smith C.L., Jiao L.R., Stebbing J.;
RT   "CK1delta modulates the transcriptional activity of ERalpha via AIB1 in an
RT   estrogen-dependent manner and regulates ERalpha-AIB1 interactions.";
RL   Nucleic Acids Res. 37:3110-3123(2009).
RN   [80]
RP   INTERACTION WITH DDX17.
RX   PubMed=19718048; DOI=10.1038/onc.2009.261;
RA   Wortham N.C., Ahamed E., Nicol S.M., Thomas R.S., Periyasamy M., Jiang J.,
RA   Ochocka A.M., Shousha S., Huson L., Bray S.E., Coombes R.C., Ali S.,
RA   Fuller-Pace F.V.;
RT   "The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent
RT   transcription and cell growth, and is associated with improved survival in
RT   ERalpha-positive breast cancer.";
RL   Oncogene 28:4053-4064(2009).
RN   [81]
RP   INTERACTION WITH KIF18A.
RX   PubMed=19636373; DOI=10.1371/journal.pone.0006407;
RA   Zusev M., Benayahu D.;
RT   "The regulation of MS-KIF18A expression and cross talk with estrogen
RT   receptor.";
RL   PLoS ONE 4:E6407-E6407(2009).
RN   [82]
RP   INTERACTION WITH TACC1.
RX   PubMed=20078863; DOI=10.1186/1471-2199-11-3;
RA   Guyot R., Vincent S., Bertin J., Samarut J., Ravel-Chapuis P.;
RT   "The transforming acidic coiled coil (TACC1) protein modulates the
RT   transcriptional activity of the nuclear receptors TR and RAR.";
RL   BMC Mol. Biol. 11:3-3(2010).
RN   [83]
RP   FUNCTION, INTERACTION WITH CCAR2, AND SUBCELLULAR LOCATION.
RX   PubMed=20074560; DOI=10.1016/j.bbrc.2010.01.025;
RA   Koyama S., Wada-Hiraike O., Nakagawa S., Tanikawa M., Hiraike H.,
RA   Miyamoto Y., Sone K., Oda K., Fukuhara H., Nakagawa K., Kato S., Yano T.,
RA   Taketani Y.;
RT   "Repression of estrogen receptor beta function by putative tumor suppressor
RT   DBC1.";
RL   Biochem. Biophys. Res. Commun. 392:357-362(2010).
RN   [84]
RP   FUNCTION IN SYNERGISM WITH NF-KAPPA-B.
RX   PubMed=20705611; DOI=10.1074/jbc.m110.155309;
RA   Pradhan M., Bembinster L.A., Baumgarten S.C., Frasor J.;
RT   "Proinflammatory cytokines enhance estrogen-dependent expression of the
RT   multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B
RT   cooperativity at adjacent response elements.";
RL   J. Biol. Chem. 285:31100-31106(2010).
RN   [85]
RP   INTERACTION WITH ZFHX3.
RX   PubMed=20720010; DOI=10.1074/jbc.m110.128330;
RA   Dong X.Y., Sun X., Guo P., Li Q., Sasahara M., Ishii Y., Dong J.T.;
RT   "ATBF1 inhibits estrogen receptor (ER) function by selectively competing
RT   with AIB1 for binding to the ER in ER-positive breast cancer cells.";
RL   J. Biol. Chem. 285:32801-32809(2010).
RN   [86]
RP   INTERACTION WITH ESRRB.
RX   PubMed=19755138; DOI=10.1016/j.mce.2009.09.007;
RA   Bombail V., Collins F., Brown P., Saunders P.T.;
RT   "Modulation of ER alpha transcriptional activity by the orphan nuclear
RT   receptor ERR beta and evidence for differential effects of long- and short-
RT   form splice variants.";
RL   Mol. Cell. Endocrinol. 314:53-61(2010).
RN   [87]
RP   INTERACTION WITH SAV1 AND STK3/MST2.
RX   PubMed=21104395; DOI=10.1007/s00109-010-0698-y;
RA   Park Y., Park J., Lee Y., Lim W., Oh B.C., Shin C., Kim W., Lee Y.;
RT   "Mammalian MST2 kinase and human Salvador activate and reduce estrogen
RT   receptor alpha in the absence of ligand.";
RL   J. Mol. Med. 89:181-191(2011).
RN   [88]
RP   FUNCTION (ISOFORM 3), SUBCELLULAR LOCATION (ISOFORM 3), TOPOLOGY (ISOFORM
RP   3), AND MUTAGENESIS OF ILE-386.
RX   PubMed=21937726; DOI=10.1091/mbc.e11-05-0416;
RA   Kim K.H., Toomre D., Bender J.R.;
RT   "Splice isoform estrogen receptors as integral transmembrane proteins.";
RL   Mol. Biol. Cell 22:4415-4423(2011).
RN   [89]
RP   FUNCTION IN ERE-INDEPENDENT SIGNALING.
RX   PubMed=21330404; DOI=10.1210/me.2010-0425;
RA   Heldring N., Isaacs G.D., Diehl A.G., Sun M., Cheung E., Ranish J.A.,
RA   Kraus W.L.;
RT   "Multiple sequence-specific DNA-binding proteins mediate estrogen receptor
RT   signaling through a tethering pathway.";
RL   Mol. Endocrinol. 25:564-574(2011).
RN   [90]
RP   INTERACTION WITH LMTK3, PHOSPHORYLATION, AND UBIQUITINATION.
RX   PubMed=21602804; DOI=10.1038/nm.2351;
RA   Giamas G., Filipovic A., Jacob J., Messier W., Zhang H., Yang D., Zhang W.,
RA   Shifa B.A., Photiou A., Tralau-Stewart C., Castellano L., Green A.R.,
RA   Coombes R.C., Ellis I.O., Ali S., Lenz H.J., Stebbing J.;
RT   "Kinome screening for regulators of the estrogen receptor identifies LMTK3
RT   as a new therapeutic target in breast cancer.";
RL   Nat. Med. 17:715-719(2011).
RN   [91]
RP   SUBCELLULAR LOCATION, AND PALMITOYLATION.
RX   PubMed=22031296; DOI=10.1091/mbc.e11-07-0638;
RA   Pedram A., Razandi M., Deschenes R.J., Levin E.R.;
RT   "DHHC-7 and -21 are palmitoylacyltransferases for sex steroid receptors.";
RL   Mol. Biol. Cell 23:188-199(2012).
RN   [92]
RP   FUNCTION IN SYNERGISM WITH NF-KAPPA-B.
RX   PubMed=22083956; DOI=10.1128/mcb.05869-11;
RA   Pradhan M., Baumgarten S.C., Bembinster L.A., Frasor J.;
RT   "CBP mediates NF-kappaB-dependent histone acetylation and estrogen receptor
RT   recruitment to an estrogen response element in the BIRC3 promoter.";
RL   Mol. Cell. Biol. 32:569-575(2012).
RN   [93]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH CLOCK.
RX   PubMed=23160374; DOI=10.1038/onc.2012.518;
RA   Li S., Wang M., Ao X., Chang A.K., Yang C., Zhao F., Bi H., Liu Y.,
RA   Xiao L., Wu H.;
RT   "CLOCK is a substrate of SUMO and sumoylation of CLOCK upregulates the
RT   transcriptional activity of estrogen receptor-alpha.";
RL   Oncogene 32:4883-4891(2013).
RN   [94]
RP   INTERACTION WITH SFR1.
RX   PubMed=23874500; DOI=10.1371/journal.pone.0068075;
RA   Feng Y., Singleton D., Guo C., Gardner A., Pakala S., Kumar R., Jensen E.,
RA   Zhang J., Khan S.;
RT   "DNA homologous recombination factor SFR1 physically and functionally
RT   interacts with estrogen receptor alpha.";
RL   PLoS ONE 8:E68075-E68075(2013).
RN   [95]
RP   INTERACTION WITH TRIP4.
RX   PubMed=25219498; DOI=10.1016/j.molcel.2014.08.007;
RA   Yoo H.M., Kang S.H., Kim J.Y., Lee J.E., Seong M.W., Lee S.W., Ka S.H.,
RA   Sou Y.S., Komatsu M., Tanaka K., Lee S.T., Noh D.Y., Baek S.H., Jeon Y.J.,
RA   Chung C.H.;
RT   "Modification of ASC1 by UFM1 is crucial for ERalpha transactivation and
RT   breast cancer development.";
RL   Mol. Cell 56:261-274(2014).
RN   [96]
RP   METHYLATION AT ARG-260, DEMETHYLATION AT ARG-260, AND SUBCELLULAR LOCATION.
RX   PubMed=24498420; DOI=10.1371/journal.pone.0087982;
RA   Poulard C., Rambaud J., Hussein N., Corbo L., Le Romancer M.;
RT   "JMJD6 regulates ERalpha methylation on arginine.";
RL   PLoS ONE 9:E87982-E87982(2014).
RN   [97]
RP   INTERACTION WITH DCAF13; LATS1 AND DCAF1, AND UBIQUITINATION.
RX   PubMed=28068668; DOI=10.1038/nature20829;
RA   Britschgi A., Duss S., Kim S., Couto J.P., Brinkhaus H., Koren S.,
RA   De Silva D., Mertz K.D., Kaup D., Varga Z., Voshol H., Vissieres A.,
RA   Leroy C., Roloff T., Stadler M.B., Scheel C.H., Miraglia L.J., Orth A.P.,
RA   Bonamy G.M., Reddy V.A., Bentires-Alj M.;
RT   "The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk
RT   with ERalpha.";
RL   Nature 541:541-545(2017).
RN   [98]
RP   STRUCTURE BY NMR OF 180-262.
RX   PubMed=2247153; DOI=10.1038/348458a0;
RA   Schwabe J.W.E., Neuhaus D., Rhodes D.;
RT   "Solution structure of the DNA-binding domain of the oestrogen receptor.";
RL   Nature 348:458-461(1990).
RN   [99]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 180-262.
RX   PubMed=8221895; DOI=10.1016/0092-8674(93)90390-c;
RA   Schwabe J.W.E., Chapman L., Finch J.T., Rhodes D.;
RT   "The crystal structure of the estrogen receptor DNA-binding domain bound to
RT   DNA: how receptors discriminate between their response elements.";
RL   Cell 75:567-578(1993).
RN   [100]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 305-548.
RX   PubMed=9338790; DOI=10.1038/39645;
RA   Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T.,
RA   Engstroem O., Oehman L., Greene G.L., Gustafsson J.-A., Carlquist M.;
RT   "Molecular basis of agonism and antagonism in the oestrogen receptor.";
RL   Nature 389:753-758(1997).
RN   [101]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 306-544.
RX   PubMed=9600906; DOI=10.1073/pnas.95.11.5998;
RA   Tanenbaum D.M., Wang Y., Williams S.P., Sigler P.B.;
RT   "Crystallographic comparison of the estrogen and progesterone receptor's
RT   ligand binding domains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:5998-6003(1998).
RN   [102]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 294-554.
RX   PubMed=9875847; DOI=10.1016/s0092-8674(00)81717-1;
RA   Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A.,
RA   Greene G.L.;
RT   "The structural basis of estrogen receptor/coactivator recognition and the
RT   antagonism of this interaction by tamoxifen.";
RL   Cell 95:927-937(1998).
RN   [103]
RP   3D-STRUCTURE MODELING OF 311-547.
RX   PubMed=9619507; DOI=10.1080/07391102.1998.10508206;
RA   Maalouf G.J., Xu W., Smith T., Mohr S.C.;
RT   "Homology model for the ligand-binding domain of the human estrogen
RT   receptor.";
RL   J. Biomol. Struct. Dyn. 15:841-850(1998).
RN   [104]
RP   VARIANT VAL-400.
RX   PubMed=2792078; DOI=10.1002/j.1460-2075.1989.tb03604.x;
RA   Tora L., Mullick A., Metzger D., Ponglikitmongkol M., Park I., Chambon P.;
RT   "The cloned human oestrogen receptor contains a mutation which alters its
RT   hormone binding properties.";
RL   EMBO J. 8:1981-1986(1989).
RN   [105]
RP   VARIANT CYS-160.
RX   PubMed=9195227;
RX   DOI=10.1002/(sici)1098-1004(1997)9:6<531::aid-humu6>3.0.co;2-4;
RA   Anderson T.I., Wooster R., Laake K., Collins N., Warren W., Skrede M.,
RA   Eeles R., Tveit K.M., Johnston S.R.D., Dowsett M., Olsen A.O., Moeller P.,
RA   Stratton M.R., Boerresen-Dale A.-L.;
RT   "Screening for ESR mutations in breast and ovarian cancer patients.";
RL   Hum. Mutat. 9:531-536(1997).
RN   [106]
RP   INVOLVEMENT IN BMD.
RX   PubMed=10942433; DOI=10.1093/hmg/9.13.2043;
RA   Becherini L., Gennari L., Masi L., Mansani R., Massart F., Morelli A.,
RA   Falchetti A., Gonnelli S., Fiorelli G., Tanini A., Brandi M.L.;
RT   "Evidence of a linkage disequilibrium between polymorphisms in the human
RT   estrogen receptor alpha gene and their relationship to bone mass variation
RT   in postmenopausal Italian women.";
RL   Hum. Mol. Genet. 9:2043-2050(2000).
RN   [107]
RP   INTERACTION WITH GPER1.
RX   PubMed=19749156; DOI=10.1210/me.2009-0120;
RA   Vivacqua A., Lappano R., De Marco P., Sisci D., Aquila S., De Amicis F.,
RA   Fuqua S.A., Ando S., Maggiolini M.;
RT   "G protein-coupled receptor 30 expression is up-regulated by EGF and TGF
RT   alpha in estrogen receptor alpha-positive cancer cells.";
RL   Mol. Endocrinol. 23:1815-1826(2009).
RN   [108]
RP   VARIANTS TYR-6 AND ILE-264.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S.,
RA   Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M.,
RA   Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by expression
RT   profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
RN   [109]
RP   VARIANT ESTRR HIS-375, AND CHARACTERIZATION OF VARIANT ESTRR HIS-375.
RX   PubMed=23841731; DOI=10.1056/nejmoa1303611;
RA   Quaynor S.D., Stradtman E.W. Jr., Kim H.G., Shen Y., Chorich L.P.,
RA   Schreihofer D.A., Layman L.C.;
RT   "Delayed puberty and estrogen resistance in a woman with estrogen receptor
RT   alpha variant.";
RL   N. Engl. J. Med. 369:164-171(2013).
RN   [110]
RP   VARIANT ESTRR HIS-394, AND CHARACTERIZATION OF VARIANT ESTRR HIS-394.
RX   PubMed=27754803; DOI=10.1210/jc.2016-2749;
RA   Bernard V., Kherra S., Francou B., Fagart J., Viengchareun S., Guechot J.,
RA   Ladjouze A., Guiochon-Mantel A., Korach K.S., Binart N., Lombes M.,
RA   Christin-Maitre S.;
RT   "Familial multiplicity of estrogen insensitivity associated with a loss-of-
RT   function ESR1 mutation.";
RL   J. Clin. Endocrinol. Metab. 102:93-99(2017).
CC   -!- FUNCTION: Nuclear hormone receptor. The steroid hormones and their
CC       receptors are involved in the regulation of eukaryotic gene expression
CC       and affect cellular proliferation and differentiation in target
CC       tissues. Ligand-dependent nuclear transactivation involves either
CC       direct homodimer binding to a palindromic estrogen response element
CC       (ERE) sequence or association with other DNA-binding transcription
CC       factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-
CC       independent signaling. Ligand binding induces a conformational change
CC       allowing subsequent or combinatorial association with multiprotein
CC       coactivator complexes through LXXLL motifs of their respective
CC       components. Mutual transrepression occurs between the estrogen receptor
CC       (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-
CC       B DNA-binding activity and inhibits NF-kappa-B-mediated transcription
CC       from the IL6 promoter and displace RELA/p65 and associated coregulators
CC       from the promoter. Recruited to the NF-kappa-B response element of the
CC       CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B
CC       components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act
CC       synergistically with NF-kappa-B to activate transcription involving
CC       respective recruitment adjacent response elements; the function
CC       involves CREBBP. Can activate the transcriptional activity of TFF1.
CC       Also mediates membrane-initiated estrogen signaling involving various
CC       kinase cascades. Isoform 3 is involved in activation of NOS3 and
CC       endothelial nitric oxide production. Isoforms lacking one or several
CC       functional domains are thought to modulate transcriptional activity by
CC       competitive ligand or DNA binding and/or heterodimerization with the
CC       full-length receptor. Essential for MTA1-mediated transcriptional
CC       regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit
CC       isoform 1. {ECO:0000269|PubMed:10681512, ECO:0000269|PubMed:10816575,
CC       ECO:0000269|PubMed:11477071, ECO:0000269|PubMed:11682626,
CC       ECO:0000269|PubMed:14764652, ECO:0000269|PubMed:15078875,
CC       ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:16043358,
CC       ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:16684779,
CC       ECO:0000269|PubMed:17922032, ECO:0000269|PubMed:17932106,
CC       ECO:0000269|PubMed:18247370, ECO:0000269|PubMed:19350539,
CC       ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20705611,
CC       ECO:0000269|PubMed:21330404, ECO:0000269|PubMed:22083956,
CC       ECO:0000269|PubMed:7651415, ECO:0000269|PubMed:9328340}.
CC   -!- SUBUNIT: Binds DNA as a homodimer. Can form a heterodimer with ESR2.
CC       Isoform 3 can probably homodimerize or heterodimerize with isoform 1
CC       and ESR2. Interacts with FOXC2, MAP1S, SLC30A9, UBE1C and NCOA3
CC       coactivator (By similarity). Interacts with EP300; the interaction is
CC       estrogen-dependent and enhanced by CITED1. Interacts with CITED1; the
CC       interaction is estrogen-dependent. Interacts with NCOA5 and NCOA6
CC       coactivators. Interacts with NCOA7; the interaction is a ligand-
CC       inducible. Interacts with PHB2, PELP1 and UBE1C. Interacts with AKAP13.
CC       Interacts with CUEDC2. Interacts with KDM5A. Interacts with SMARD1.
CC       Interacts with HEXIM1. Interacts with PBXIP1. Interaction with MUC1 is
CC       stimulated by 7 beta-estradiol (E2) and enhances ERS1-mediated
CC       transcription. Interacts with DNTTIP2, FAM120B and UIMC1. Interacts
CC       with isoform 4 of TXNRD1. Interacts with KMT2D/MLL2. Interacts with
CC       ATAD2 and this interaction is enhanced by estradiol. Interacts with
CC       KIF18A and LDB1. Interacts with RLIM (via C-terminus). Interacts with
CC       MACROD1. Interacts with SH2D4A and PLCG. Interaction with SH2D4A blocks
CC       binding to PLCG and inhibits estrogen-induced cell proliferation.
CC       Interacts with DYNLL1. Interacts with CCDC62 in the presence of
CC       estradiol/E2; this interaction seems to enhance the transcription of
CC       target genes. Interacts with NR2C1; the interaction prevents
CC       homodimerization of ESR1 and suppresses its transcriptional activity
CC       and cell growth. Interacts with DNAAF4. Interacts with PRMT2. Interacts
CC       with PI3KR1 or PI3KR2, SRC and PTK2/FAK1. Interacts with RBFOX2.
CC       Interacts with STK3/MST2 only in the presence of SAV1 and vice-versa.
CC       Binds to CSNK1D. Interacts with NCOA2; NCOA2 can interact with ESR1 AF-
CC       1 and AF-2 domains simultaneously and mediate their transcriptional
CC       synergy. Interacts with DDX5. Interacts with NCOA1; the interaction
CC       seems to require a self-association of N-terminal and C-terminal
CC       regions. Interacts with ZNF366, DDX17, NFKB1, RELA, SP1 and SP3.
CC       Interacts with NRIP1 (By similarity). Interacts with GPER1; the
CC       interaction occurs in an estrogen-dependent manner. Interacts with
CC       CLOCK and the interaction is stimulated by estrogen. Interacts with
CC       BCAS3. Interacts with TRIP4 (ufmylated); estrogen dependent. Interacts
CC       with LMTK3; the interaction phosphorylates ESR1 (in vitro) and protects
CC       it against proteasomal degradation. Interacts with CCAR2 (via N-
CC       terminus) in a ligand-independent manner. Interacts with ZFHX3.
CC       Interacts with SFR1 in a ligand-dependent and -independent manner
CC       (PubMed:23874500). Interacts with DCAF13, LATS1 and DCAF1; regulates
CC       ESR1 ubiquitination and ubiquitin-mediated proteasomal degradation
CC       (PubMed:28068668). Interacts (via DNA-binding domain) with POU4F2 (C-
CC       terminus); this interaction increases the estrogen receptor ESR1
CC       transcriptional activity in a DNA- and ligand 17-beta-estradiol-
CC       independent manner (By similarity). Interacts with ESRRB isoform 1
CC       (PubMed:19755138). Interacts with UBE3A and WBP2 (PubMed:16772533).
CC       Interacts with GTF2B (PubMed:1517211). Interacts with RBM39 (By
CC       similarity). In the absence of hormonal ligand, interacts with TACC1
CC       (PubMed:20078863). {ECO:0000250, ECO:0000250|UniProtKB:P19785,
CC       ECO:0000269|PubMed:10359819, ECO:0000269|PubMed:10409727,
CC       ECO:0000269|PubMed:10567404, ECO:0000269|PubMed:10681512,
CC       ECO:0000269|PubMed:10816575, ECO:0000269|PubMed:10970861,
CC       ECO:0000269|PubMed:11113208, ECO:0000269|PubMed:11265755,
CC       ECO:0000269|PubMed:11358960, ECO:0000269|PubMed:11477071,
CC       ECO:0000269|PubMed:11581164, ECO:0000269|PubMed:11682626,
CC       ECO:0000269|PubMed:11875103, ECO:0000269|PubMed:11971969,
CC       ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12093804,
CC       ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12554772,
CC       ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:15047147,
CC       ECO:0000269|PubMed:1517211, ECO:0000269|PubMed:15199063,
CC       ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:15940264,
CC       ECO:0000269|PubMed:16427018, ECO:0000269|PubMed:16603732,
CC       ECO:0000269|PubMed:16772533, ECO:0000269|PubMed:17006958,
CC       ECO:0000269|PubMed:17043237, ECO:0000269|PubMed:17085477,
CC       ECO:0000269|PubMed:17311814, ECO:0000269|PubMed:17347654,
CC       ECO:0000269|PubMed:17505058, ECO:0000269|PubMed:17587566,
CC       ECO:0000269|PubMed:17658481, ECO:0000269|PubMed:17914104,
CC       ECO:0000269|PubMed:17932106, ECO:0000269|PubMed:17998543,
CC       ECO:0000269|PubMed:18563714, ECO:0000269|PubMed:18657504,
CC       ECO:0000269|PubMed:19117995, ECO:0000269|PubMed:19339517,
CC       ECO:0000269|PubMed:19350539, ECO:0000269|PubMed:19383985,
CC       ECO:0000269|PubMed:19423554, ECO:0000269|PubMed:19636373,
CC       ECO:0000269|PubMed:19712589, ECO:0000269|PubMed:19718048,
CC       ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:19755138,
CC       ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20078863,
CC       ECO:0000269|PubMed:20720010, ECO:0000269|PubMed:21104395,
CC       ECO:0000269|PubMed:21602804, ECO:0000269|PubMed:23160374,
CC       ECO:0000269|PubMed:23874500, ECO:0000269|PubMed:25219498,
CC       ECO:0000269|PubMed:28068668, ECO:0000269|PubMed:9328340,
CC       ECO:0000269|PubMed:9627117}.
CC   -!- INTERACTION:
CC       P03372; P03372; NbExp=11; IntAct=EBI-78473, EBI-78473;
CC       P03372-1; P03372-1; NbExp=4; IntAct=EBI-15606245, EBI-15606245;
CC       P03372; Q12802: AKAP13; NbExp=3; IntAct=EBI-78473, EBI-1373806;
CC       P03372; Q03989: ARID5A; NbExp=9; IntAct=EBI-78473, EBI-948603;
CC       P03372; Q9Y294: ASF1A; NbExp=4; IntAct=EBI-78473, EBI-749553;
CC       P03372; Q8IXJ9: ASXL1; NbExp=2; IntAct=EBI-78473, EBI-1646500;
CC       P03372; P59598: Asxl1; Xeno; NbExp=2; IntAct=EBI-78473, EBI-5743705;
CC       P03372; Q6PL18: ATAD2; NbExp=5; IntAct=EBI-78473, EBI-6598454;
CC       P03372; P18846: ATF1; NbExp=3; IntAct=EBI-78473, EBI-852794;
CC       P03372; P62952: BLCAP; NbExp=2; IntAct=EBI-78473, EBI-3895726;
CC       P03372; P38398: BRCA1; NbExp=14; IntAct=EBI-78473, EBI-349905;
CC       P03372; P20290-2: BTF3; NbExp=5; IntAct=EBI-78473, EBI-1054703;
CC       P03372; Q86Y37: CACUL1; NbExp=5; IntAct=EBI-78473, EBI-8168227;
CC       P03372; P29279: CCN2; NbExp=7; IntAct=EBI-78473, EBI-2835375;
CC       P03372; P17676: CEBPB; NbExp=2; IntAct=EBI-78473, EBI-969696;
CC       P03372; Q99966: CITED1; NbExp=3; IntAct=EBI-78473, EBI-2624951;
CC       P03372; Q9H467: CUEDC2; NbExp=2; IntAct=EBI-78473, EBI-1248228;
CC       P03372; Q9NV06: DCAF13; NbExp=2; IntAct=EBI-78473, EBI-7402939;
CC       P03372; O00429: DNM1L; NbExp=2; IntAct=EBI-78473, EBI-724571;
CC       P03372; O60869: EDF1; NbExp=3; IntAct=EBI-78473, EBI-781301;
CC       P03372; P00533: EGFR; NbExp=2; IntAct=EBI-78473, EBI-297353;
CC       P03372-4; P00533: EGFR; NbExp=4; IntAct=EBI-4309277, EBI-297353;
CC       P03372; Q09472: EP300; NbExp=2; IntAct=EBI-78473, EBI-447295;
CC       P03372-1; Q92731: ESR2; NbExp=5; IntAct=EBI-15606245, EBI-78505;
CC       P03372; Q12778: FOXO1; NbExp=2; IntAct=EBI-78473, EBI-1108782;
CC       P03372; O43524: FOXO3; NbExp=7; IntAct=EBI-78473, EBI-1644164;
CC       P03372; Q9Y3R0: GRIP1; NbExp=2; IntAct=EBI-78473, EBI-5349621;
CC       P03372; O00165: HAX1; NbExp=2; IntAct=EBI-78473, EBI-357001;
CC       P03372; Q6NYC1: JMJD6; NbExp=8; IntAct=EBI-78473, EBI-8464037;
CC       P03372; P05627: Jun; Xeno; NbExp=6; IntAct=EBI-78473, EBI-764369;
CC       P03372-1; Q92993: KAT5; NbExp=3; IntAct=EBI-15606245, EBI-399080;
CC       P03372; O15054: KDM6B; NbExp=2; IntAct=EBI-78473, EBI-2831260;
CC       P03372; O14686: KMT2D; NbExp=3; IntAct=EBI-78473, EBI-996065;
CC       P03372; O95835: LATS1; NbExp=2; IntAct=EBI-78473, EBI-444209;
CC       P03372; Q96Q04: LMTK3; NbExp=3; IntAct=EBI-78473, EBI-720814;
CC       P03372; Q9BQ69: MACROD1; NbExp=6; IntAct=EBI-78473, EBI-5324932;
CC       P03372; Q00987: MDM2; NbExp=2; IntAct=EBI-78473, EBI-389668;
CC       P03372; Q15648: MED1; NbExp=3; IntAct=EBI-78473, EBI-394459;
CC       P03372; P60660: MYL6; NbExp=3; IntAct=EBI-78473, EBI-300817;
CC       P03372; Q15788: NCOA1; NbExp=8; IntAct=EBI-78473, EBI-455189;
CC       P03372; Q15596: NCOA2; NbExp=5; IntAct=EBI-78473, EBI-81236;
CC       P03372; Q9Y6Q9: NCOA3; NbExp=4; IntAct=EBI-78473, EBI-81196;
CC       P03372; Q9JLI4: Ncoa6; Xeno; NbExp=2; IntAct=EBI-78473, EBI-286271;
CC       P03372; Q60974: Ncor1; Xeno; NbExp=2; IntAct=EBI-78473, EBI-349004;
CC       P03372; Q9UN36: NDRG2; NbExp=2; IntAct=EBI-78473, EBI-3895741;
CC       P03372; PRO_0000030311 [P19838]: NFKB1; NbExp=3; IntAct=EBI-78473, EBI-697771;
CC       P03372; Q96RI1-3: NR1H4; NbExp=2; IntAct=EBI-78473, EBI-10921781;
CC       P03372; Q9BZ95: NSD3; NbExp=3; IntAct=EBI-78473, EBI-3390132;
CC       P03372; Q9BTK6: PAGR1; NbExp=5; IntAct=EBI-78473, EBI-2372223;
CC       P03372; Q96AQ6-1: PBXIP1; NbExp=3; IntAct=EBI-78473, EBI-15606280;
CC       P03372-1; Q96AQ6-1: PBXIP1; NbExp=5; IntAct=EBI-15606245, EBI-15606280;
CC       P03372; P62962: Pfn1; Xeno; NbExp=3; IntAct=EBI-78473, EBI-647096;
CC       P03372; P06401: PGR; NbExp=20; IntAct=EBI-78473, EBI-78539;
CC       P03372; P06401-1: PGR; NbExp=4; IntAct=EBI-78473, EBI-12590474;
CC       P03372; Q99623: PHB2; NbExp=4; IntAct=EBI-78473, EBI-358348;
CC       P03372; P27986: PIK3R1; NbExp=7; IntAct=EBI-78473, EBI-79464;
CC       P03372; P36873: PPP1CC; NbExp=3; IntAct=EBI-78473, EBI-356283;
CC       P03372; P53041: PPP5C; NbExp=4; IntAct=EBI-78473, EBI-716663;
CC       P03372; P55345: PRMT2; NbExp=9; IntAct=EBI-78473, EBI-78458;
CC       P03372; P60763: RAC3; NbExp=5; IntAct=EBI-78473, EBI-767084;
CC       P03372; O43251: RBFOX2; NbExp=4; IntAct=EBI-78473, EBI-746056;
CC       P03372; Q04206: RELA; NbExp=9; IntAct=EBI-78473, EBI-73886;
CC       P03372; Q14151: SAFB2; NbExp=2; IntAct=EBI-78473, EBI-352869;
CC       P03372; Q96HI0: SENP5; NbExp=2; IntAct=EBI-78473, EBI-3895753;
CC       P03372-4; P29353: SHC1; NbExp=2; IntAct=EBI-4309277, EBI-78835;
CC       P03372; P08047: SP1; NbExp=2; IntAct=EBI-78473, EBI-298336;
CC       P03372; Q02447: SP3; NbExp=4; IntAct=EBI-78473, EBI-348158;
CC       P03372; P00523: SRC; Xeno; NbExp=2; IntAct=EBI-78473, EBI-848039;
CC       P03372; P12931: SRC; NbExp=12; IntAct=EBI-78473, EBI-621482;
CC       P03372-4; P12931: SRC; NbExp=2; IntAct=EBI-4309277, EBI-621482;
CC       P03372; O15164: TRIM24; NbExp=3; IntAct=EBI-78473, EBI-2130378;
CC       P03372; Q16881-4: TXNRD1; NbExp=4; IntAct=EBI-78473, EBI-9080335;
CC       P03372; Q9UBK9: UXT; NbExp=2; IntAct=EBI-78473, EBI-357355;
CC       P03372; Q8N895: ZNF366; NbExp=6; IntAct=EBI-78473, EBI-2813661;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00407, ECO:0000269|PubMed:12682286,
CC       ECO:0000269|PubMed:20074560}. Cytoplasm {ECO:0000269|PubMed:12682286,
CC       ECO:0000269|PubMed:24498420}. Cell membrane
CC       {ECO:0000269|PubMed:12682286}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:12682286}; Cytoplasmic side
CC       {ECO:0000269|PubMed:12682286}. Note=A minor fraction is associated with
CC       the inner membrane.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. Cytoplasm. Cell membrane;
CC       Peripheral membrane protein; Cytoplasmic side. Cell membrane; Single-
CC       pass type I membrane protein. Note=Associated with the inner membrane
CC       via palmitoylation (Probable). At least a subset exists as a
CC       transmembrane protein with a N-terminal extracellular domain.
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Nucleus. Golgi apparatus. Cell membrane.
CC       Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatus where
CC       most probably palmitoylation occurs. Associated with the plasma
CC       membrane when palmitoylated.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long, hER-alpha66, ER66;
CC         IsoId=P03372-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P03372-2; Sequence=VSP_003680;
CC       Name=3; Synonyms=hER-alpha46, ER46;
CC         IsoId=P03372-3; Sequence=VSP_042460;
CC       Name=4; Synonyms=hER-alpha36, ER36;
CC         IsoId=P03372-4; Sequence=VSP_042460, VSP_042461;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Isoform 3 is not expressed in the
CC       pituitary gland. {ECO:0000269|PubMed:10970861}.
CC   -!- DOMAIN: Composed of three domains: a modulating N-terminal domain, a
CC       DNA-binding domain and a C-terminal ligand-binding domain. The
CC       modulating domain, also known as A/B or AF-1 domain has a ligand-
CC       independent transactivation function. The C-terminus contains a ligand-
CC       dependent transactivation domain, also known as E/F or AF-2 domain
CC       which overlaps with the ligand binding domain. AF-1 and AF-2 activate
CC       transcription independently and synergistically and act in a
CC       promoter- and cell-specific manner. AF-1 seems to provide the major
CC       transactivation function in differentiated cells.
CC   -!- PTM: Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylation probably
CC       enhances transcriptional activity. Self-association induces
CC       phosphorylation. Dephosphorylation at Ser-118 by PPP5C inhibits its
CC       transactivation activity. Phosphorylated by LMTK3 in vitro.
CC       {ECO:0000269|PubMed:10428798, ECO:0000269|PubMed:14764652,
CC       ECO:0000269|PubMed:19339517, ECO:0000269|PubMed:21602804,
CC       ECO:0000269|PubMed:7476978, ECO:0000269|PubMed:7539106,
CC       ECO:0000269|PubMed:7838153}.
CC   -!- PTM: Glycosylated; contains N-acetylglucosamine, probably O-linked.
CC       {ECO:0000269|PubMed:8999954}.
CC   -!- PTM: Ubiquitinated; regulated by LATS1 via DCAF1 it leads to ESR1
CC       proteasomal degradation (PubMed:21602804, PubMed:28068668).
CC       Deubiquitinated by OTUB1 (PubMed:19383985).
CC       {ECO:0000269|PubMed:19383985, ECO:0000269|PubMed:21602804,
CC       ECO:0000269|PubMed:28068668}.
CC   -!- PTM: Dimethylated by PRMT1 at Arg-260. The methylation may favor
CC       cytoplasmic localization (PubMed:18657504, PubMed:24498420).
CC       Demethylated by JMJD6 at Arg-260 (PubMed:24498420).
CC       {ECO:0000269|PubMed:18657504, ECO:0000269|PubMed:24498420}.
CC   -!- PTM: Palmitoylated (isoform 3). Not biotinylated (isoform 3).
CC       {ECO:0000269|PubMed:22031296}.
CC   -!- PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required
CC       for plasma membrane targeting and for rapid intracellular signaling via
CC       ERK and AKT kinases and cAMP generation, but not for signaling mediated
CC       by the nuclear hormone receptor. {ECO:0000269|PubMed:22031296}.
CC   -!- POLYMORPHISM: Genetic variations in ESR1 are correlated with bone
CC       mineral density (BMD). Low BMD is a risk factor for osteoporotic
CC       fracture. Osteoporosis is characterized by reduced bone mineral
CC       density, disruption of bone microarchitecture, and the alteration of
CC       the amount and variety of non-collagenous proteins in bone.
CC       Osteoporotic bones are more at risk of fracture.
CC       {ECO:0000269|PubMed:10942433}.
CC   -!- DISEASE: Estrogen resistance (ESTRR) [MIM:615363]: A disorder
CC       characterized by partial or complete resistance to estrogens, in the
CC       presence of elevated estrogen serum levels. Clinical features include
CC       absence of the pubertal growth spurt, delayed bone maturation, unfused
CC       epiphyses, reduced bone mineral density, osteoporosis, continued growth
CC       into adulthood and very tall adult stature. Glucose intolerance,
CC       hyperinsulinemia and lipid abnormalities may also be present.
CC       {ECO:0000269|PubMed:23841731, ECO:0000269|PubMed:27754803}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Selective estrogen receptor modulators (SERMs), such as
CC       tamoxifen, raloxifene, toremifene, lasofoxifene, clomifene, femarelle
CC       and ormeloxifene, have tissue selective agonistic and antagonistic
CC       effects on the estrogen receptor (ER). They interfere with the ER
CC       association with coactivators or corepressors, mainly involving the AF-
CC       2 domain.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform
CC       3. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB00115.1; Type=Miscellaneous discrepancy; Note=contains an in-frame duplication of exons 6 and 7.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/esr1/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Estrogen receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Estrogen_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X03635; CAA27284.1; -; mRNA.
DR   EMBL; M12674; AAA52399.1; -; mRNA.
DR   EMBL; U47678; AAB00115.1; ALT_SEQ; mRNA.
DR   EMBL; AY425004; AAQ91815.1; -; Genomic_DNA.
DR   EMBL; BX640939; CAE45969.1; -; mRNA.
DR   EMBL; AL049821; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL078582; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356311; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590993; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW47740.1; -; Genomic_DNA.
DR   EMBL; BC128573; AAI28574.1; -; mRNA.
DR   EMBL; BC128574; AAI28575.1; -; mRNA.
DR   EMBL; AH008151; AAD52984.1; -; Genomic_DNA.
DR   EMBL; X73067; CAA51528.1; -; mRNA.
DR   EMBL; Z75126; CAA99436.1; -; mRNA.
DR   CCDS; CCDS5234.1; -. [P03372-1]
DR   PIR; S64737; S64737.
DR   RefSeq; NP_000116.2; NM_000125.3. [P03372-1]
DR   RefSeq; NP_001116212.1; NM_001122740.1. [P03372-1]
DR   RefSeq; NP_001116213.1; NM_001122741.1. [P03372-1]
DR   RefSeq; NP_001116214.1; NM_001122742.1. [P03372-1]
DR   RefSeq; NP_001278159.1; NM_001291230.1.
DR   RefSeq; NP_001278170.1; NM_001291241.1.
DR   RefSeq; NP_001315029.1; NM_001328100.1.
DR   RefSeq; XP_006715438.1; XM_006715375.3. [P03372-3]
DR   RefSeq; XP_011533845.1; XM_011535543.2. [P03372-1]
DR   RefSeq; XP_011533846.1; XM_011535544.2. [P03372-1]
DR   RefSeq; XP_011533847.1; XM_011535545.2. [P03372-1]
DR   RefSeq; XP_016865865.1; XM_017010376.1. [P03372-1]
DR   RefSeq; XP_016865866.1; XM_017010377.1. [P03372-1]
DR   RefSeq; XP_016865867.1; XM_017010378.1. [P03372-1]
DR   RefSeq; XP_016865868.1; XM_017010379.1. [P03372-1]
DR   RefSeq; XP_016865869.1; XM_017010380.1. [P03372-1]
DR   RefSeq; XP_016865870.1; XM_017010381.1. [P03372-1]
DR   PDB; 1A52; X-ray; 2.80 A; A/B=297-554.
DR   PDB; 1AKF; Model; -; A=309-547.
DR   PDB; 1ERE; X-ray; 3.10 A; A/B/C/D/E/F=301-553.
DR   PDB; 1ERR; X-ray; 2.60 A; A/B=301-553.
DR   PDB; 1G50; X-ray; 2.90 A; A/B/C=304-550.
DR   PDB; 1GWQ; X-ray; 2.45 A; A/B=301-548.
DR   PDB; 1GWR; X-ray; 2.40 A; A/B=305-549.
DR   PDB; 1HCP; NMR; -; A=180-254.
DR   PDB; 1HCQ; X-ray; 2.40 A; A/B/E/F=180-262.
DR   PDB; 1L2I; X-ray; 1.95 A; A/B=297-554.
DR   PDB; 1PCG; X-ray; 2.70 A; A/B=304-547.
DR   PDB; 1QKT; X-ray; 2.20 A; A=304-551.
DR   PDB; 1QKU; X-ray; 3.20 A; A/B/C=301-550.
DR   PDB; 1R5K; X-ray; 2.70 A; A/B/C=297-554.
DR   PDB; 1SJ0; X-ray; 1.90 A; A=307-554.
DR   PDB; 1UOM; X-ray; 2.28 A; A=301-553.
DR   PDB; 1X7E; X-ray; 2.80 A; A/B=305-549.
DR   PDB; 1X7R; X-ray; 2.00 A; A=305-549.
DR   PDB; 1XP1; X-ray; 1.80 A; A=307-554.
DR   PDB; 1XP6; X-ray; 1.70 A; A=307-554.
DR   PDB; 1XP9; X-ray; 1.80 A; A=307-554.
DR   PDB; 1XPC; X-ray; 1.60 A; A=307-554.
DR   PDB; 1XQC; X-ray; 2.05 A; A/B/C/D=301-553.
DR   PDB; 1YIM; X-ray; 1.90 A; A=307-554.
DR   PDB; 1YIN; X-ray; 2.20 A; A=307-554.
DR   PDB; 1ZKY; X-ray; 2.25 A; A/B=298-554.
DR   PDB; 2AYR; X-ray; 1.90 A; A=304-551.
DR   PDB; 2B1V; X-ray; 1.80 A; A/B=298-554.
DR   PDB; 2B1Z; X-ray; 1.78 A; A/B=298-554.
DR   PDB; 2B23; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 2BJ4; X-ray; 2.00 A; A/B=305-533.
DR   PDB; 2FAI; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 2G44; X-ray; 2.65 A; A/B=298-554.
DR   PDB; 2G5O; X-ray; 2.30 A; A/B=298-554.
DR   PDB; 2I0J; X-ray; 2.90 A; A/B/C/D=304-547.
DR   PDB; 2IOG; X-ray; 1.60 A; A=309-554.
DR   PDB; 2IOK; X-ray; 2.40 A; A/B=301-554.
DR   PDB; 2JF9; X-ray; 2.10 A; A/B/C=304-533.
DR   PDB; 2JFA; X-ray; 2.55 A; A/B=304-533.
DR   PDB; 2LLO; NMR; -; B=287-305.
DR   PDB; 2LLQ; NMR; -; B=287-305.
DR   PDB; 2OCF; X-ray; 2.95 A; A=298-595.
DR   PDB; 2OUZ; X-ray; 2.00 A; A=301-553.
DR   PDB; 2P15; X-ray; 1.94 A; A/B=298-554.
DR   PDB; 2POG; X-ray; 1.84 A; A/B=304-551.
DR   PDB; 2Q6J; X-ray; 2.70 A; A/B=298-554.
DR   PDB; 2Q70; X-ray; 1.95 A; A/B=304-551.
DR   PDB; 2QA6; X-ray; 2.60 A; A/B=298-554.
DR   PDB; 2QA8; X-ray; 1.85 A; A/B=298-554.
DR   PDB; 2QAB; X-ray; 1.89 A; A/B=298-554.
DR   PDB; 2QE4; X-ray; 2.40 A; A/B=304-551.
DR   PDB; 2QGT; X-ray; 2.15 A; A/B=298-554.
DR   PDB; 2QGW; X-ray; 2.39 A; A/B=298-554.
DR   PDB; 2QH6; X-ray; 2.70 A; A/B=298-554.
DR   PDB; 2QR9; X-ray; 2.00 A; A/B=298-554.
DR   PDB; 2QSE; X-ray; 1.85 A; A/B=298-554.
DR   PDB; 2QXM; X-ray; 2.30 A; A/B=298-554.
DR   PDB; 2QXS; X-ray; 1.70 A; A/B=298-554.
DR   PDB; 2QZO; X-ray; 1.72 A; A/B=298-554.
DR   PDB; 2R6W; X-ray; 2.00 A; A/B=304-551.
DR   PDB; 2R6Y; X-ray; 2.00 A; A/B=304-551.
DR   PDB; 2YAT; X-ray; 2.60 A; A=301-551.
DR   PDB; 2YJA; X-ray; 1.82 A; B=299-551.
DR   PDB; 3CBM; X-ray; 1.69 A; B=298-307.
DR   PDB; 3CBO; X-ray; 1.65 A; B=298-307.
DR   PDB; 3CBP; X-ray; 1.42 A; B=298-307.
DR   PDB; 3DT3; X-ray; 2.40 A; A/B=299-551.
DR   PDB; 3ERD; X-ray; 2.03 A; A/B=297-554.
DR   PDB; 3ERT; X-ray; 1.90 A; A=297-554.
DR   PDB; 3HLV; X-ray; 3.00 A; A/B=298-550.
DR   PDB; 3HM1; X-ray; 2.33 A; A/B=298-550.
DR   PDB; 3L03; X-ray; 1.90 A; A/B=298-550.
DR   PDB; 3OS8; X-ray; 2.03 A; A/B/C/D=299-553.
DR   PDB; 3OS9; X-ray; 2.30 A; A/B/C/D=299-553.
DR   PDB; 3OSA; X-ray; 2.30 A; A/B/C/D=299-553.
DR   PDB; 3Q95; X-ray; 2.05 A; A/B=298-554.
DR   PDB; 3UU7; X-ray; 2.20 A; A/B=302-552.
DR   PDB; 3UUA; X-ray; 2.05 A; A/B=302-552.
DR   PDB; 3UUC; X-ray; 2.10 A; A/B/C/D=302-552.
DR   PDB; 3UUD; X-ray; 1.60 A; A/B=302-552.
DR   PDB; 4AA6; X-ray; 2.60 A; A/B/E/F=182-252.
DR   PDB; 4DMA; X-ray; 2.30 A; A/B=303-549.
DR   PDB; 4IU7; X-ray; 2.29 A; A/B=303-549.
DR   PDB; 4IUI; X-ray; 2.30 A; A/B=303-549.
DR   PDB; 4IV2; X-ray; 2.14 A; A/B=303-549.
DR   PDB; 4IV4; X-ray; 2.30 A; A/B=303-549.
DR   PDB; 4IVW; X-ray; 2.06 A; A/B=303-549.
DR   PDB; 4IVY; X-ray; 1.95 A; A/B=303-549.
DR   PDB; 4IW6; X-ray; 1.98 A; A/B=303-549.
DR   PDB; 4IW8; X-ray; 2.04 A; A/B=303-549.
DR   PDB; 4IWC; X-ray; 2.24 A; A/B=303-549.
DR   PDB; 4IWF; X-ray; 1.93 A; A/B=303-549.
DR   PDB; 4JC3; X-ray; 2.05 A; B=585-595.
DR   PDB; 4JDD; X-ray; 2.10 A; B=585-595.
DR   PDB; 4MG5; X-ray; 2.05 A; A/B=302-552.
DR   PDB; 4MG6; X-ray; 2.10 A; A/B=302-552.
DR   PDB; 4MG7; X-ray; 2.15 A; A/B=302-552.
DR   PDB; 4MG8; X-ray; 1.85 A; A/B=302-552.
DR   PDB; 4MG9; X-ray; 2.00 A; A/B=302-552.
DR   PDB; 4MGA; X-ray; 1.80 A; A/B=302-552.
DR   PDB; 4MGB; X-ray; 1.85 A; A/B=302-552.
DR   PDB; 4MGC; X-ray; 2.15 A; A/B=302-552.
DR   PDB; 4MGD; X-ray; 1.90 A; A/B=302-552.
DR   PDB; 4O6F; X-ray; 2.82 A; B=261-271.
DR   PDB; 4PP6; X-ray; 2.20 A; A/B=305-548.
DR   PDB; 4PPP; X-ray; 2.69 A; A/B=305-548.
DR   PDB; 4PPS; X-ray; 1.93 A; A/B=305-548.
DR   PDB; 4PXM; X-ray; 1.90 A; A/B=299-554.
DR   PDB; 4Q13; X-ray; 2.24 A; A/B=299-554.
DR   PDB; 4Q50; X-ray; 3.07 A; A/B/C/D/E/F/G/H=299-554.
DR   PDB; 4TUZ; X-ray; 1.90 A; A/B=302-552.
DR   PDB; 4TV1; X-ray; 1.85 A; A/B=302-552.
DR   PDB; 4XI3; X-ray; 2.49 A; A/B/C/D=306-548.
DR   PDB; 4ZN7; X-ray; 1.93 A; A/B=301-559.
DR   PDB; 4ZN9; X-ray; 2.21 A; A/B=301-559.
DR   PDB; 4ZNH; X-ray; 1.93 A; A/B=301-559.
DR   PDB; 4ZNS; X-ray; 1.86 A; A/B=301-559.
DR   PDB; 4ZNT; X-ray; 1.90 A; A/B=301-559.
DR   PDB; 4ZNU; X-ray; 2.40 A; A/B=301-559.
DR   PDB; 4ZNV; X-ray; 1.77 A; A/B=301-559.
DR   PDB; 4ZNW; X-ray; 2.31 A; A/B=301-559.
DR   PDB; 5AAU; X-ray; 1.90 A; A/B=307-554.
DR   PDB; 5AAV; X-ray; 1.95 A; A=307-554, B=306-554.
DR   PDB; 5ACC; X-ray; 1.88 A; A=307-554.
DR   PDB; 5AK2; X-ray; 2.19 A; A/B=307-554.
DR   PDB; 5DI7; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DID; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DIE; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DIG; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DK9; X-ray; 2.28 A; A/B=298-554.
DR   PDB; 5DKB; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5DKE; X-ray; 2.60 A; A/B=298-554.
DR   PDB; 5DKG; X-ray; 2.15 A; A/B=298-554.
DR   PDB; 5DKS; X-ray; 2.60 A; A/B=298-554.
DR   PDB; 5DL4; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 5DLR; X-ray; 2.26 A; A/B=298-554.
DR   PDB; 5DMC; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5DMF; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5DP0; X-ray; 2.38 A; A/B=298-554.
DR   PDB; 5DRJ; X-ray; 2.07 A; A/B=298-554.
DR   PDB; 5DRM; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DTV; X-ray; 2.29 A; A/B=298-554.
DR   PDB; 5DU5; X-ray; 2.19 A; A/B=298-554.
DR   PDB; 5DUE; X-ray; 2.09 A; A/B=298-554.
DR   PDB; 5DUG; X-ray; 2.25 A; A/B=298-554.
DR   PDB; 5DUH; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DVS; X-ray; 2.28 A; A/B=298-554.
DR   PDB; 5DVV; X-ray; 2.50 A; A/B=298-554.
DR   PDB; 5DWE; X-ray; 1.92 A; A/B=298-554.
DR   PDB; 5DWG; X-ray; 2.30 A; A/B=298-554.
DR   PDB; 5DWI; X-ray; 2.43 A; A/B=298-554.
DR   PDB; 5DWJ; X-ray; 2.00 A; A/B=298-554.
DR   PDB; 5DX3; X-ray; 2.09 A; A/B=297-554.
DR   PDB; 5DXB; X-ray; 2.08 A; A/B=297-554.
DR   PDB; 5DXE; X-ray; 1.50 A; A/B=297-554.
DR   PDB; 5DXG; X-ray; 1.86 A; A/B=297-554.
DR   PDB; 5DXK; X-ray; 2.23 A; A/B=298-554.
DR   PDB; 5DXM; X-ray; 2.37 A; A/B=298-554.
DR   PDB; 5DXP; X-ray; 2.20 A; A/B=298-554.
DR   PDB; 5DXQ; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5DXR; X-ray; 2.28 A; A/B=298-554.
DR   PDB; 5DY8; X-ray; 2.03 A; A/B=298-554.
DR   PDB; 5DYB; X-ray; 2.27 A; A/B=298-554.
DR   PDB; 5DYD; X-ray; 2.48 A; A/B=298-554.
DR   PDB; 5DZ0; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DZ1; X-ray; 2.20 A; A/B=298-554.
DR   PDB; 5DZ3; X-ray; 2.15 A; A/B=298-554.
DR   PDB; 5DZH; X-ray; 2.11 A; A/B=298-554.
DR   PDB; 5DZI; X-ray; 1.90 A; A/B=298-554.
DR   PDB; 5E0W; X-ray; 2.00 A; A/B=298-554.
DR   PDB; 5E0X; X-ray; 2.01 A; A/B=298-554.
DR   PDB; 5E14; X-ray; 2.22 A; A/B=298-554.
DR   PDB; 5E15; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 5E19; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5E1C; X-ray; 1.98 A; A/B=298-554.
DR   PDB; 5EGV; X-ray; 2.86 A; A/B=298-554.
DR   PDB; 5EHJ; X-ray; 2.50 A; A/B=298-554.
DR   PDB; 5EI1; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5EIT; X-ray; 2.68 A; A/B=298-554.
DR   PDB; 5FQP; X-ray; 1.88 A; A=307-554.
DR   PDB; 5FQR; X-ray; 1.88 A; A=307-554.
DR   PDB; 5FQS; X-ray; 1.94 A; A=307-554.
DR   PDB; 5FQT; X-ray; 1.99 A; A=307-554.
DR   PDB; 5FQV; X-ray; 1.74 A; A=307-554.
DR   PDB; 5GS4; X-ray; 2.40 A; A=305-547.
DR   PDB; 5GTR; X-ray; 2.80 A; A=305-547.
DR   PDB; 5HYR; X-ray; 2.27 A; A/B=302-559.
DR   PDB; 5JMM; X-ray; 2.10 A; A/B=302-552.
DR   PDB; 5KCC; X-ray; 2.39 A; A/B=298-554, A/B=304-549.
DR   PDB; 5KCD; X-ray; 1.82 A; A/B=298-554, A/B=305-549.
DR   PDB; 5KCE; X-ray; 1.85 A; A/B=298-554, A/B=303-549.
DR   PDB; 5KCF; X-ray; 2.07 A; A/B=298-554, A/B=303-549.
DR   PDB; 5KCT; X-ray; 1.60 A; A/B=298-554, A/B=303-548.
DR   PDB; 5KCU; X-ray; 2.03 A; A/B=298-554, A/B=303-548.
DR   PDB; 5KCW; X-ray; 1.91 A; A/B=303-549, A/B=298-554.
DR   PDB; 5KD9; X-ray; 1.78 A; A/B=298-554, A/B=303-549.
DR   PDB; 5KR9; X-ray; 2.25 A; A/B=298-554.
DR   PDB; 5KRA; X-ray; 2.40 A; A/B/E/F=298-554.
DR   PDB; 5KRC; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5KRF; X-ray; 2.19 A; A/B=298-554.
DR   PDB; 5KRH; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5KRI; X-ray; 2.25 A; A/B=298-554.
DR   PDB; 5KRJ; X-ray; 2.70 A; A/B=298-554.
DR   PDB; 5KRK; X-ray; 2.39 A; A/B=298-554.
DR   PDB; 5KRL; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5KRM; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5KRO; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 5N10; X-ray; 1.60 A; C/D/F=584-595.
DR   PDB; 5T0X; NMR; -; B/C=287-305.
DR   PDB; 5T1Z; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 5T92; X-ray; 2.22 A; A/B=301-553.
DR   PDB; 5T97; X-ray; 3.00 A; A/B=301-553.
DR   PDB; 5TLD; X-ray; 2.38 A; A/B=298-554.
DR   PDB; 5TLF; X-ray; 2.20 A; A/B=298-554.
DR   PDB; 5TLG; X-ray; 2.23 A; A/B=298-554.
DR   PDB; 5TLL; X-ray; 2.42 A; A/B=298-554.
DR   PDB; 5TLM; X-ray; 2.50 A; A/B=298-554.
DR   PDB; 5TLO; X-ray; 2.28 A; A/B=298-554.
DR   PDB; 5TLP; X-ray; 2.08 A; A/B=298-554.
DR   PDB; 5TLT; X-ray; 1.90 A; A/B=298-554.
DR   PDB; 5TLU; X-ray; 2.22 A; A/B=298-554.
DR   PDB; 5TLV; X-ray; 2.32 A; A/B=298-554.
DR   PDB; 5TLX; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 5TLY; X-ray; 2.14 A; A/B=298-554.
DR   PDB; 5TM1; X-ray; 2.23 A; A/B=298-554.
DR   PDB; 5TM2; X-ray; 2.60 A; A/B=298-554.
DR   PDB; 5TM3; X-ray; 2.19 A; A/B=298-554.
DR   PDB; 5TM4; X-ray; 2.25 A; A/B=298-554.
DR   PDB; 5TM5; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5TM6; X-ray; 2.54 A; A/B=298-554.
DR   PDB; 5TM7; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5TM8; X-ray; 1.99 A; A/B=298-554.
DR   PDB; 5TM9; X-ray; 2.50 A; A/B=298-554.
DR   PDB; 5TML; X-ray; 2.25 A; A/B=298-554.
DR   PDB; 5TMM; X-ray; 2.20 A; A/B=298-554.
DR   PDB; 5TMO; X-ray; 2.17 A; A/B=298-554.
DR   PDB; 5TMQ; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5TMR; X-ray; 2.30 A; A/B=298-554.
DR   PDB; 5TMS; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5TMT; X-ray; 2.05 A; A/B=298-554.
DR   PDB; 5TMU; X-ray; 2.43 A; A/B=298-554.
DR   PDB; 5TMV; X-ray; 2.38 A; A/B=298-554.
DR   PDB; 5TMW; X-ray; 2.29 A; A/B=298-554.
DR   PDB; 5TMZ; X-ray; 2.21 A; A/B=298-554.
DR   PDB; 5TN1; X-ray; 2.06 A; A/B=298-554.
DR   PDB; 5TN3; X-ray; 2.54 A; A/B=298-554.
DR   PDB; 5TN4; X-ray; 1.86 A; A/B=298-554.
DR   PDB; 5TN5; X-ray; 1.89 A; A/B=298-554.
DR   PDB; 5TN6; X-ray; 2.09 A; A/B=298-554.
DR   PDB; 5TN7; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5TN8; X-ray; 2.65 A; A/B=298-554.
DR   PDB; 5TN9; X-ray; 2.25 A; A/B/C/D=298-554.
DR   PDB; 5TNB; X-ray; 2.08 A; A/B/C/D=298-554.
DR   PDB; 5U2B; X-ray; 2.22 A; A/B/C/D/E/F=298-554.
DR   PDB; 5U2D; X-ray; 1.86 A; A/B=298-554.
DR   PDB; 5UFW; X-ray; 1.58 A; A/B=306-554.
DR   PDB; 5UFX; X-ray; 1.55 A; A/B=306-554.
DR   PDB; 5W9C; X-ray; 1.80 A; A/B/C/D=306-554.
DR   PDB; 5W9D; X-ray; 1.65 A; A/B=306-554.
DR   PDB; 5WGD; X-ray; 1.80 A; A/B=297-554.
DR   PDB; 5WGQ; X-ray; 2.30 A; A/B=297-554.
DR   PDB; 6B0F; X-ray; 2.86 A; A/B=301-553.
DR   PDB; 6C42; X-ray; 2.00 A; A/B=307-554.
DR   PDB; 6CBZ; X-ray; 1.65 A; A/B=305-554.
DR   PDB; 6CHW; X-ray; 1.89 A; A=306-551.
DR   PDB; 6CHZ; X-ray; 1.68 A; A=307-554.
DR   PDB; 6CZN; X-ray; 2.50 A; A/B=298-554.
DR   PDB; 6D0F; X-ray; 2.50 A; A/B=305-554.
DR   PDB; 6DF6; X-ray; 2.50 A; A/B/C/D=298-553.
DR   PDB; 6DFN; X-ray; 2.10 A; A/B/C/D=298-553.
DR   PDB; 6HHP; X-ray; 1.80 A; B=588-595.
DR   PDB; 6HKB; X-ray; 1.70 A; B=588-595.
DR   PDB; 6HKF; X-ray; 1.80 A; B=588-595.
DR   PDB; 6HMU; X-ray; 1.20 A; B=588-595.
DR   PDB; 6IAR; X-ray; 1.84 A; A=307-547.
DR   PDB; 6OWC; X-ray; 1.85 A; A/B=298-554.
DR   PDB; 6PET; X-ray; 2.20 A; A/B/C/D=298-553.
DR   PDB; 6PFM; X-ray; 2.84 A; A/D=298-553.
DR   PDB; 6PIT; X-ray; 2.25 A; A/B=297-554.
DR   PDB; 6PSJ; X-ray; 1.80 A; A/B=307-554.
DR   PDB; 6SBO; X-ray; 1.48 A; A/B=297-554.
DR   PDB; 6SQ0; X-ray; 1.77 A; A/B=307-554.
DR   PDB; 6SUO; X-ray; 1.74 A; A/B=307-554.
DR   PDB; 6V87; X-ray; 2.40 A; A/B=307-554.
DR   PDB; 6V8T; X-ray; 2.10 A; A/B=307-554.
DR   PDBsum; 1A52; -.
DR   PDBsum; 1AKF; -.
DR   PDBsum; 1ERE; -.
DR   PDBsum; 1ERR; -.
DR   PDBsum; 1G50; -.
DR   PDBsum; 1GWQ; -.
DR   PDBsum; 1GWR; -.
DR   PDBsum; 1HCP; -.
DR   PDBsum; 1HCQ; -.
DR   PDBsum; 1L2I; -.
DR   PDBsum; 1PCG; -.
DR   PDBsum; 1QKT; -.
DR   PDBsum; 1QKU; -.
DR   PDBsum; 1R5K; -.
DR   PDBsum; 1SJ0; -.
DR   PDBsum; 1UOM; -.
DR   PDBsum; 1X7E; -.
DR   PDBsum; 1X7R; -.
DR   PDBsum; 1XP1; -.
DR   PDBsum; 1XP6; -.
DR   PDBsum; 1XP9; -.
DR   PDBsum; 1XPC; -.
DR   PDBsum; 1XQC; -.
DR   PDBsum; 1YIM; -.
DR   PDBsum; 1YIN; -.
DR   PDBsum; 1ZKY; -.
DR   PDBsum; 2AYR; -.
DR   PDBsum; 2B1V; -.
DR   PDBsum; 2B1Z; -.
DR   PDBsum; 2B23; -.
DR   PDBsum; 2BJ4; -.
DR   PDBsum; 2FAI; -.
DR   PDBsum; 2G44; -.
DR   PDBsum; 2G5O; -.
DR   PDBsum; 2I0J; -.
DR   PDBsum; 2IOG; -.
DR   PDBsum; 2IOK; -.
DR   PDBsum; 2JF9; -.
DR   PDBsum; 2JFA; -.
DR   PDBsum; 2LLO; -.
DR   PDBsum; 2LLQ; -.
DR   PDBsum; 2OCF; -.
DR   PDBsum; 2OUZ; -.
DR   PDBsum; 2P15; -.
DR   PDBsum; 2POG; -.
DR   PDBsum; 2Q6J; -.
DR   PDBsum; 2Q70; -.
DR   PDBsum; 2QA6; -.
DR   PDBsum; 2QA8; -.
DR   PDBsum; 2QAB; -.
DR   PDBsum; 2QE4; -.
DR   PDBsum; 2QGT; -.
DR   PDBsum; 2QGW; -.
DR   PDBsum; 2QH6; -.
DR   PDBsum; 2QR9; -.
DR   PDBsum; 2QSE; -.
DR   PDBsum; 2QXM; -.
DR   PDBsum; 2QXS; -.
DR   PDBsum; 2QZO; -.
DR   PDBsum; 2R6W; -.
DR   PDBsum; 2R6Y; -.
DR   PDBsum; 2YAT; -.
DR   PDBsum; 2YJA; -.
DR   PDBsum; 3CBM; -.
DR   PDBsum; 3CBO; -.
DR   PDBsum; 3CBP; -.
DR   PDBsum; 3DT3; -.
DR   PDBsum; 3ERD; -.
DR   PDBsum; 3ERT; -.
DR   PDBsum; 3HLV; -.
DR   PDBsum; 3HM1; -.
DR   PDBsum; 3L03; -.
DR   PDBsum; 3OS8; -.
DR   PDBsum; 3OS9; -.
DR   PDBsum; 3OSA; -.
DR   PDBsum; 3Q95; -.
DR   PDBsum; 3UU7; -.
DR   PDBsum; 3UUA; -.
DR   PDBsum; 3UUC; -.
DR   PDBsum; 3UUD; -.
DR   PDBsum; 4AA6; -.
DR   PDBsum; 4DMA; -.
DR   PDBsum; 4IU7; -.
DR   PDBsum; 4IUI; -.
DR   PDBsum; 4IV2; -.
DR   PDBsum; 4IV4; -.
DR   PDBsum; 4IVW; -.
DR   PDBsum; 4IVY; -.
DR   PDBsum; 4IW6; -.
DR   PDBsum; 4IW8; -.
DR   PDBsum; 4IWC; -.
DR   PDBsum; 4IWF; -.
DR   PDBsum; 4JC3; -.
DR   PDBsum; 4JDD; -.
DR   PDBsum; 4MG5; -.
DR   PDBsum; 4MG6; -.
DR   PDBsum; 4MG7; -.
DR   PDBsum; 4MG8; -.
DR   PDBsum; 4MG9; -.
DR   PDBsum; 4MGA; -.
DR   PDBsum; 4MGB; -.
DR   PDBsum; 4MGC; -.
DR   PDBsum; 4MGD; -.
DR   PDBsum; 4O6F; -.
DR   PDBsum; 4PP6; -.
DR   PDBsum; 4PPP; -.
DR   PDBsum; 4PPS; -.
DR   PDBsum; 4PXM; -.
DR   PDBsum; 4Q13; -.
DR   PDBsum; 4Q50; -.
DR   PDBsum; 4TUZ; -.
DR   PDBsum; 4TV1; -.
DR   PDBsum; 4XI3; -.
DR   PDBsum; 4ZN7; -.
DR   PDBsum; 4ZN9; -.
DR   PDBsum; 4ZNH; -.
DR   PDBsum; 4ZNS; -.
DR   PDBsum; 4ZNT; -.
DR   PDBsum; 4ZNU; -.
DR   PDBsum; 4ZNV; -.
DR   PDBsum; 4ZNW; -.
DR   PDBsum; 5AAU; -.
DR   PDBsum; 5AAV; -.
DR   PDBsum; 5ACC; -.
DR   PDBsum; 5AK2; -.
DR   PDBsum; 5DI7; -.
DR   PDBsum; 5DID; -.
DR   PDBsum; 5DIE; -.
DR   PDBsum; 5DIG; -.
DR   PDBsum; 5DK9; -.
DR   PDBsum; 5DKB; -.
DR   PDBsum; 5DKE; -.
DR   PDBsum; 5DKG; -.
DR   PDBsum; 5DKS; -.
DR   PDBsum; 5DL4; -.
DR   PDBsum; 5DLR; -.
DR   PDBsum; 5DMC; -.
DR   PDBsum; 5DMF; -.
DR   PDBsum; 5DP0; -.
DR   PDBsum; 5DRJ; -.
DR   PDBsum; 5DRM; -.
DR   PDBsum; 5DTV; -.
DR   PDBsum; 5DU5; -.
DR   PDBsum; 5DUE; -.
DR   PDBsum; 5DUG; -.
DR   PDBsum; 5DUH; -.
DR   PDBsum; 5DVS; -.
DR   PDBsum; 5DVV; -.
DR   PDBsum; 5DWE; -.
DR   PDBsum; 5DWG; -.
DR   PDBsum; 5DWI; -.
DR   PDBsum; 5DWJ; -.
DR   PDBsum; 5DX3; -.
DR   PDBsum; 5DXB; -.
DR   PDBsum; 5DXE; -.
DR   PDBsum; 5DXG; -.
DR   PDBsum; 5DXK; -.
DR   PDBsum; 5DXM; -.
DR   PDBsum; 5DXP; -.
DR   PDBsum; 5DXQ; -.
DR   PDBsum; 5DXR; -.
DR   PDBsum; 5DY8; -.
DR   PDBsum; 5DYB; -.
DR   PDBsum; 5DYD; -.
DR   PDBsum; 5DZ0; -.
DR   PDBsum; 5DZ1; -.
DR   PDBsum; 5DZ3; -.
DR   PDBsum; 5DZH; -.
DR   PDBsum; 5DZI; -.
DR   PDBsum; 5E0W; -.
DR   PDBsum; 5E0X; -.
DR   PDBsum; 5E14; -.
DR   PDBsum; 5E15; -.
DR   PDBsum; 5E19; -.
DR   PDBsum; 5E1C; -.
DR   PDBsum; 5EGV; -.
DR   PDBsum; 5EHJ; -.
DR   PDBsum; 5EI1; -.
DR   PDBsum; 5EIT; -.
DR   PDBsum; 5FQP; -.
DR   PDBsum; 5FQR; -.
DR   PDBsum; 5FQS; -.
DR   PDBsum; 5FQT; -.
DR   PDBsum; 5FQV; -.
DR   PDBsum; 5GS4; -.
DR   PDBsum; 5GTR; -.
DR   PDBsum; 5HYR; -.
DR   PDBsum; 5JMM; -.
DR   PDBsum; 5KCC; -.
DR   PDBsum; 5KCD; -.
DR   PDBsum; 5KCE; -.
DR   PDBsum; 5KCF; -.
DR   PDBsum; 5KCT; -.
DR   PDBsum; 5KCU; -.
DR   PDBsum; 5KCW; -.
DR   PDBsum; 5KD9; -.
DR   PDBsum; 5KR9; -.
DR   PDBsum; 5KRA; -.
DR   PDBsum; 5KRC; -.
DR   PDBsum; 5KRF; -.
DR   PDBsum; 5KRH; -.
DR   PDBsum; 5KRI; -.
DR   PDBsum; 5KRJ; -.
DR   PDBsum; 5KRK; -.
DR   PDBsum; 5KRL; -.
DR   PDBsum; 5KRM; -.
DR   PDBsum; 5KRO; -.
DR   PDBsum; 5N10; -.
DR   PDBsum; 5T0X; -.
DR   PDBsum; 5T1Z; -.
DR   PDBsum; 5T92; -.
DR   PDBsum; 5T97; -.
DR   PDBsum; 5TLD; -.
DR   PDBsum; 5TLF; -.
DR   PDBsum; 5TLG; -.
DR   PDBsum; 5TLL; -.
DR   PDBsum; 5TLM; -.
DR   PDBsum; 5TLO; -.
DR   PDBsum; 5TLP; -.
DR   PDBsum; 5TLT; -.
DR   PDBsum; 5TLU; -.
DR   PDBsum; 5TLV; -.
DR   PDBsum; 5TLX; -.
DR   PDBsum; 5TLY; -.
DR   PDBsum; 5TM1; -.
DR   PDBsum; 5TM2; -.
DR   PDBsum; 5TM3; -.
DR   PDBsum; 5TM4; -.
DR   PDBsum; 5TM5; -.
DR   PDBsum; 5TM6; -.
DR   PDBsum; 5TM7; -.
DR   PDBsum; 5TM8; -.
DR   PDBsum; 5TM9; -.
DR   PDBsum; 5TML; -.
DR   PDBsum; 5TMM; -.
DR   PDBsum; 5TMO; -.
DR   PDBsum; 5TMQ; -.
DR   PDBsum; 5TMR; -.
DR   PDBsum; 5TMS; -.
DR   PDBsum; 5TMT; -.
DR   PDBsum; 5TMU; -.
DR   PDBsum; 5TMV; -.
DR   PDBsum; 5TMW; -.
DR   PDBsum; 5TMZ; -.
DR   PDBsum; 5TN1; -.
DR   PDBsum; 5TN3; -.
DR   PDBsum; 5TN4; -.
DR   PDBsum; 5TN5; -.
DR   PDBsum; 5TN6; -.
DR   PDBsum; 5TN7; -.
DR   PDBsum; 5TN8; -.
DR   PDBsum; 5TN9; -.
DR   PDBsum; 5TNB; -.
DR   PDBsum; 5U2B; -.
DR   PDBsum; 5U2D; -.
DR   PDBsum; 5UFW; -.
DR   PDBsum; 5UFX; -.
DR   PDBsum; 5W9C; -.
DR   PDBsum; 5W9D; -.
DR   PDBsum; 5WGD; -.
DR   PDBsum; 5WGQ; -.
DR   PDBsum; 6B0F; -.
DR   PDBsum; 6C42; -.
DR   PDBsum; 6CBZ; -.
DR   PDBsum; 6CHW; -.
DR   PDBsum; 6CHZ; -.
DR   PDBsum; 6CZN; -.
DR   PDBsum; 6D0F; -.
DR   PDBsum; 6DF6; -.
DR   PDBsum; 6DFN; -.
DR   PDBsum; 6HHP; -.
DR   PDBsum; 6HKB; -.
DR   PDBsum; 6HKF; -.
DR   PDBsum; 6HMU; -.
DR   PDBsum; 6IAR; -.
DR   PDBsum; 6OWC; -.
DR   PDBsum; 6PET; -.
DR   PDBsum; 6PFM; -.
DR   PDBsum; 6PIT; -.
DR   PDBsum; 6PSJ; -.
DR   PDBsum; 6SBO; -.
DR   PDBsum; 6SQ0; -.
DR   PDBsum; 6SUO; -.
DR   PDBsum; 6V87; -.
DR   PDBsum; 6V8T; -.
DR   SMR; P03372; -.
DR   BioGrid; 108403; 749.
DR   CORUM; P03372; -.
DR   DIP; DIP-5965N; -.
DR   ELM; P03372; -.
DR   IntAct; P03372; 1901.
DR   MINT; P03372; -.
DR   STRING; 9606.ENSP00000405330; -.
DR   BindingDB; P03372; -.
DR   ChEMBL; CHEMBL206; -.
DR   DrugBank; DB07567; (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL.
DR   DrugBank; DB07638; (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL.
DR   DrugBank; DB08737; (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL.
DR   DrugBank; DB08020; (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL.
DR   DrugBank; DB07678; (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL.
DR   DrugBank; DB07707; (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL.
DR   DrugBank; DB03802; 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol.
DR   DrugBank; DB06871; 17-METHYL-17-ALPHA-DIHYDROEQUILENIN.
DR   DrugBank; DB08773; 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol.
DR   DrugBank; DB08398; 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine.
DR   DrugBank; DB13869; 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol.
DR   DrugBank; DB04471; 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol.
DR   DrugBank; DB07708; 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL.
DR   DrugBank; DB07712; 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL.
DR   DrugBank; DB06898; 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol.
DR   DrugBank; DB08048; 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL.
DR   DrugBank; DB08595; 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL.
DR   DrugBank; DB07195; 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL.
DR   DrugBank; DB07086; 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL.
DR   DrugBank; DB07087; 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL.
DR   DrugBank; DB08047; 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol.
DR   DrugBank; DB06927; [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE.
DR   DrugBank; DB04468; Afimoxifene.
DR   DrugBank; DB01431; Allylestrenol.
DR   DrugBank; DB05233; AP1081.
DR   DrugBank; DB06249; Arzoxifene.
DR   DrugBank; DB06401; Bazedoxifene.
DR   DrugBank; DB01878; Benzophenone.
DR   DrugBank; DB06732; beta-Naphthoflavone.
DR   DrugBank; DB05882; CHF 4227.
DR   DrugBank; DB00269; Chlorotrianisene.
DR   DrugBank; DB00882; Clomifene.
DR   DrugBank; DB02715; Compound 18.
DR   DrugBank; DB02615; Compound 19.
DR   DrugBank; DB03742; Compound 4-D.
DR   DrugBank; DB00286; Conjugated estrogens.
DR   DrugBank; DB05487; Custirsen.
DR   DrugBank; DB01406; Danazol.
DR   DrugBank; DB00304; Desogestrel.
DR   DrugBank; DB00890; Dienestrol.
DR   DrugBank; DB08320; DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE.
DR   DrugBank; DB00255; Diethylstilbestrol.
DR   DrugBank; DB07932; dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate.
DR   DrugBank; DB00841; Dobutamine.
DR   DrugBank; DB06374; Elacestrant.
DR   DrugBank; DB11219; Enzacamene.
DR   DrugBank; DB02187; Equilin.
DR   DrugBank; DB07933; Erteberel.
DR   DrugBank; DB00783; Estradiol.
DR   DrugBank; DB13952; Estradiol acetate.
DR   DrugBank; DB13953; Estradiol benzoate.
DR   DrugBank; DB13954; Estradiol cypionate.
DR   DrugBank; DB13955; Estradiol dienanthate.
DR   DrugBank; DB13956; Estradiol valerate.
DR   DrugBank; DB01196; Estramustine.
DR   DrugBank; DB04573; Estriol.
DR   DrugBank; DB14641; Estriol tripropionate.
DR   DrugBank; DB00655; Estrone.
DR   DrugBank; DB04574; Estrone sulfate.
DR   DrugBank; DB00977; Ethinylestradiol.
DR   DrugBank; DB00823; Ethynodiol diacetate.
DR   DrugBank; DB00294; Etonogestrel.
DR   DrugBank; DB09086; Eugenol.
DR   DrugBank; DB01185; Fluoxymesterone.
DR   DrugBank; DB00947; Fulvestrant.
DR   DrugBank; DB01645; Genistein.
DR   DrugBank; DB11619; Gestrinone.
DR   DrugBank; DB00756; Hexachlorophene.
DR   DrugBank; DB07931; Hexestrol.
DR   DrugBank; DB11064; Homosalate.
DR   DrugBank; DB06202; Lasofoxifene.
DR   DrugBank; DB00367; Levonorgestrel.
DR   DrugBank; DB00431; Lindane.
DR   DrugBank; DB00603; Medroxyprogesterone acetate.
DR   DrugBank; DB01065; Melatonin.
DR   DrugBank; DB01357; Mestranol.
DR   DrugBank; DB06710; Methyltestosterone.
DR   DrugBank; DB00648; Mitotane.
DR   DrugBank; DB07991; N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE.
DR   DrugBank; DB01183; Naloxone.
DR   DrugBank; DB03467; Naringenin.
DR   DrugBank; DB09371; Norethynodrel.
DR   DrugBank; DB00957; Norgestimate.
DR   DrugBank; DB05662; NP-50301.
DR   DrugBank; DB09535; Octocrylene.
DR   DrugBank; DB04938; Ospemifene.
DR   DrugBank; DB01428; Oxybenzone.
DR   DrugBank; DB04930; Permethrin.
DR   DrugBank; DB04824; Phenolphthalein.
DR   DrugBank; DB02746; Phthalic Acid.
DR   DrugBank; DB09369; Polyestradiol phosphate.
DR   DrugBank; DB01708; Prasterone.
DR   DrugBank; DB00396; Progesterone.
DR   DrugBank; DB12450; Propyl Gallate.
DR   DrugBank; DB02757; Pyrazole.
DR   DrugBank; DB04216; Quercetin.
DR   DrugBank; DB04575; Quinestrol.
DR   DrugBank; DB11541; Ractopamine.
DR   DrugBank; DB00481; Raloxifene.
DR   DrugBank; DB02709; Resveratrol.
DR   DrugBank; DB02901; Stanolone.
DR   DrugBank; DB13951; Stanolone acetate.
DR   DrugBank; DB09317; Synthetic Conjugated Estrogens, A.
DR   DrugBank; DB09318; Synthetic Conjugated Estrogens, B.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB05966; TAS-108.
DR   DrugBank; DB00624; Testosterone.
DR   DrugBank; DB13943; Testosterone cypionate.
DR   DrugBank; DB13944; Testosterone enanthate.
DR   DrugBank; DB13946; Testosterone undecanoate.
DR   DrugBank; DB09070; Tibolone.
DR   DrugBank; DB00539; Toremifene.
DR   DrugBank; DB01108; Trilostane.
DR   DrugBank; DB11478; Zeranol.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugCentral; P03372; -.
DR   GuidetoPHARMACOLOGY; 620; -.
DR   SwissLipids; SLP:000001568; -.
DR   MoonDB; P03372; Predicted.
DR   GlyConnect; 144; -.
DR   iPTMnet; P03372; -.
DR   PhosphoSitePlus; P03372; -.
DR   SwissPalm; P03372; -.
DR   UniCarbKB; P03372; -.
DR   BioMuta; ESR1; -.
DR   DMDM; 544257; -.
DR   CPTAC; CPTAC-1241; -.
DR   CPTAC; CPTAC-145; -.
DR   EPD; P03372; -.
DR   jPOST; P03372; -.
DR   MassIVE; P03372; -.
DR   PaxDb; P03372; -.
DR   PeptideAtlas; P03372; -.
DR   PRIDE; P03372; -.
DR   ProteomicsDB; 51607; -. [P03372-1]
DR   ProteomicsDB; 51608; -. [P03372-2]
DR   ProteomicsDB; 51609; -. [P03372-3]
DR   ProteomicsDB; 51610; -. [P03372-4]
DR   ABCD; P03372; -.
DR   Antibodypedia; 739; 3921 antibodies.
DR   DNASU; 2099; -.
DR   Ensembl; ENST00000206249; ENSP00000206249; ENSG00000091831. [P03372-1]
DR   Ensembl; ENST00000338799; ENSP00000342630; ENSG00000091831. [P03372-1]
DR   Ensembl; ENST00000440973; ENSP00000405330; ENSG00000091831. [P03372-1]
DR   Ensembl; ENST00000443427; ENSP00000387500; ENSG00000091831. [P03372-1]
DR   GeneID; 2099; -.
DR   KEGG; hsa:2099; -.
DR   UCSC; uc003qom.5; human. [P03372-1]
DR   CTD; 2099; -.
DR   DisGeNET; 2099; -.
DR   GeneCards; ESR1; -.
DR   HGNC; HGNC:3467; ESR1.
DR   HPA; ENSG00000091831; Tissue enhanced (cervix, uterine, endometrium).
DR   MalaCards; ESR1; -.
DR   MIM; 133430; gene.
DR   MIM; 615363; phenotype.
DR   neXtProt; NX_P03372; -.
DR   OpenTargets; ENSG00000091831; -.
DR   Orphanet; 785; Estrogen resistance syndrome.
DR   PharmGKB; PA156; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   eggNOG; ENOG410XRZC; LUCA.
DR   GeneTree; ENSGT00940000158133; -.
DR   InParanoid; P03372; -.
DR   KO; K08550; -.
DR   OMA; TMEPLHD; -.
DR   OrthoDB; 487299at2759; -.
DR   PhylomeDB; P03372; -.
DR   TreeFam; TF323751; -.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-383280; Nuclear Receptor transcription pathway.
DR   Reactome; R-HSA-4090294; SUMOylation of intracellular receptors.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors.
DR   Reactome; R-HSA-8931987; RUNX1 regulates estrogen receptor mediated transcription.
DR   Reactome; R-HSA-8939211; ESR-mediated signaling.
DR   Reactome; R-HSA-8939256; RUNX1 regulates transcription of genes involved in WNT signaling.
DR   Reactome; R-HSA-8939902; Regulation of RUNX2 expression and activity.
DR   Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling.
DR   Reactome; R-HSA-9018519; Estrogen-dependent gene expression.
DR   SignaLink; P03372; -.
DR   SIGNOR; P03372; -.
DR   ChiTaRS; ESR1; human.
DR   EvolutionaryTrace; P03372; -.
DR   GeneWiki; Estrogen_receptor_alpha; -.
DR   GenomeRNAi; 2099; -.
DR   Pharos; P03372; Tclin.
DR   PRO; PR:P03372; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P03372; protein.
DR   Bgee; ENSG00000091831; Expressed in endometrium and 151 other tissues.
DR   ExpressionAtlas; P03372; baseline and differential.
DR   Genevisible; P03372; HS.
DR   GO; GO:0005623; C:cell; IEA:GOC.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IMP:CAFA.
DR   GO; GO:0097550; C:transcriptional preinitiation complex; IDA:CAFA.
DR   GO; GO:0035327; C:transcriptionally active chromatin; IDA:UniProtKB.
DR   GO; GO:0051117; F:ATPase binding; IDA:MGI.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; NAS:BHF-UCL.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0030284; F:estrogen receptor activity; IDA:BHF-UCL.
DR   GO; GO:0030331; F:estrogen receptor binding; IPI:CAFA.
DR   GO; GO:0034056; F:estrogen response element binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0030235; F:nitric-oxide synthase regulator activity; NAS:UniProtKB.
DR   GO; GO:0004879; F:nuclear receptor activity; IDA:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0005496; F:steroid binding; ISS:UniProtKB.
DR   GO; GO:0017025; F:TBP-class protein binding; IPI:CAFA.
DR   GO; GO:0001093; F:TFIIB-class transcription factor binding; IPI:CAFA.
DR   GO; GO:0001223; F:transcription coactivator binding; IPI:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0008209; P:androgen metabolic process; IEA:Ensembl.
DR   GO; GO:0001547; P:antral ovarian follicle growth; IEA:Ensembl.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:BHF-UCL.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IEA:Ensembl.
DR   GO; GO:0006338; P:chromatin remodeling; NAS:UniProtKB.
DR   GO; GO:0002064; P:epithelial cell development; IEA:Ensembl.
DR   GO; GO:0060750; P:epithelial cell proliferation involved in mammary gland duct elongation; IEA:Ensembl.
DR   GO; GO:0030520; P:intracellular estrogen receptor signaling pathway; IDA:CAFA.
DR   GO; GO:0030518; P:intracellular steroid hormone receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0060749; P:mammary gland alveolus development; IEA:Ensembl.
DR   GO; GO:0060745; P:mammary gland branching involved in pregnancy; IEA:Ensembl.
DR   GO; GO:0043433; P:negative regulation of DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:1903799; P:negative regulation of production of miRNAs involved in gene silencing by miRNA; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISS:UniProtKB.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IDA:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; ISS:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; TAS:Reactome.
DR   GO; GO:0045899; P:positive regulation of RNA polymerase II transcriptional preinitiation complex assembly; IDA:CAFA.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; IEA:Ensembl.
DR   GO; GO:0060523; P:prostate epithelial cord elongation; IEA:Ensembl.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0071168; P:protein localization to chromatin; IMP:BHF-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0060687; P:regulation of branching involved in prostate gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0050727; P:regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0034121; P:regulation of toll-like receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0030111; P:regulation of Wnt signaling pathway; TAS:Reactome.
DR   GO; GO:0032355; P:response to estradiol; IDA:BHF-UCL.
DR   GO; GO:0043627; P:response to estrogen; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0048863; P:stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0006351; P:transcription, DNA-templated; TAS:ProtInc.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   GO; GO:0060068; P:vagina development; IEA:Ensembl.
DR   DisProt; DP00074; -.
DR   Gene3D; 1.10.565.10; -; 1.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR024178; Oest_rcpt/oest-rel_rcp.
DR   InterPro; IPR001292; Oestr_rcpt.
DR   InterPro; IPR024736; Oestrogen-typ_rcpt_final_C_dom.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF12743; ESR1_C; 1.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF02159; Oest_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PIRSF; PIRSF500101; ER-a; 1.
DR   PIRSF; PIRSF002527; ER-like_NR; 1.
DR   PRINTS; PR00543; OESTROGENR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative promoter usage; Alternative splicing;
KW   Cell membrane; Cytoplasm; Direct protein sequencing; Disease mutation;
KW   DNA-binding; Glycoprotein; Golgi apparatus; Lipid-binding; Lipoprotein;
KW   Membrane; Metal-binding; Methylation; Nucleus; Palmitate; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Steroid-binding; Transcription;
KW   Transcription regulation; Transmembrane; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..595
FT                   /note="Estrogen receptor"
FT                   /id="PRO_0000053618"
FT   DOMAIN          311..547
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01189"
FT   DNA_BIND        185..250
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         185..205
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         221..245
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   REGION          1..184
FT                   /note="Modulating (transactivation AF-1); mediates
FT                   interaction with MACROD1"
FT                   /evidence="ECO:0000269|PubMed:17914104"
FT   REGION          35..174
FT                   /note="Interaction with DDX5; self-association"
FT   REGION          35..47
FT                   /note="Required for interaction with NCOA1"
FT   REGION          185..310
FT                   /note="Mediates interaction with DNTTIP2"
FT                   /evidence="ECO:0000269|PubMed:15047147"
FT   REGION          251..310
FT                   /note="Hinge"
FT   REGION          262..595
FT                   /note="Interaction with AKAP13"
FT                   /evidence="ECO:0000269|PubMed:9627117"
FT   REGION          264..595
FT                   /note="Self-association"
FT   REGION          311..595
FT                   /note="Transactivation AF-2"
FT   MOD_RES         104
FT                   /note="Phosphoserine; by CDK2"
FT                   /evidence="ECO:0000269|PubMed:10428798"
FT   MOD_RES         106
FT                   /note="Phosphoserine; by CDK2"
FT                   /evidence="ECO:0000269|PubMed:10428798"
FT   MOD_RES         118
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:14764652"
FT   MOD_RES         167
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:7838153"
FT   MOD_RES         260
FT                   /note="Asymmetric dimethylarginine; by PRMT1"
FT                   /evidence="ECO:0000269|PubMed:18657504,
FT                   ECO:0000269|PubMed:24498420"
FT   MOD_RES         537
FT                   /note="Phosphotyrosine; by Tyr-kinases"
FT                   /evidence="ECO:0000269|PubMed:7539106"
FT   LIPID           447
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        10
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..173
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:16165085,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_042460"
FT   VAR_SEQ         255..366
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:3753802"
FT                   /id="VSP_003680"
FT   VAR_SEQ         458..595
FT                   /note="VYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLL
FT                   ILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGASVEETDQSHL
FT                   ATAGSTSSHSLQKYYITGEAEGFPATV -> FTISHVEAKKRILNLHPKIFGNKWFPRV
FT                   (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:16165085,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_042461"
FT   VARIANT         6
FT                   /note="H -> Y (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs139960913)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033028"
FT   VARIANT         77
FT                   /note="G -> S (in dbSNP:rs9340773)"
FT                   /id="VAR_018905"
FT   VARIANT         160
FT                   /note="G -> C (in dbSNP:rs149308960)"
FT                   /evidence="ECO:0000269|PubMed:9195227"
FT                   /id="VAR_004671"
FT   VARIANT         264
FT                   /note="M -> I (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033029"
FT   VARIANT         375
FT                   /note="Q -> H (in ESTRR; results in highly reduced
FT                   activity; dbSNP:rs397509428)"
FT                   /evidence="ECO:0000269|PubMed:23841731"
FT                   /id="VAR_070072"
FT   VARIANT         394
FT                   /note="R -> H (in ESTRR; highly decreased estrogen receptor
FT                   activity; dbSNP:rs1131692059)"
FT                   /evidence="ECO:0000269|PubMed:27754803"
FT                   /id="VAR_078516"
FT   VARIANT         400
FT                   /note="G -> V (destabilizes the receptor and decreases its
FT                   affinity for estradiol at 25 degrees Celsius, but not at 4
FT                   degrees Celsius)"
FT                   /evidence="ECO:0000269|PubMed:2792078,
FT                   ECO:0000269|PubMed:3753802, ECO:0000269|PubMed:3754034"
FT                   /id="VAR_004673"
FT   VARIANT         411
FT                   /note="D -> RNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGV
FT                   YTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHM
FT                   (in a 80 kDa form found in a breast cancer line; contains
FT                   an in-frame duplication of exons 6 and 7)"
FT                   /id="VAR_010143"
FT   MUTAGEN         39
FT                   /note="L->P: Impairs AF-1 transactivation."
FT                   /evidence="ECO:0000269|PubMed:11075817"
FT   MUTAGEN         43
FT                   /note="Y->P: Impairs AF-1 transactivation."
FT                   /evidence="ECO:0000269|PubMed:11075817"
FT   MUTAGEN         104
FT                   /note="S->A: Loss of cyclin A-dependent induction of
FT                   transcriptional activation."
FT   MUTAGEN         106
FT                   /note="S->A: Loss of cyclin A-dependent induction of
FT                   transcriptional activation."
FT   MUTAGEN         118
FT                   /note="S->A: Decreases phosphorylation and transactivation
FT                   activity. Abolishes AF-1 transactivation. Insensitive to
FT                   PPP5C inhibition of transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:10409727,
FT                   ECO:0000269|PubMed:14764652"
FT   MUTAGEN         118
FT                   /note="S->E: Enhances transactivation activity. Enhances
FT                   interaction with DDX5. Insensitive to PPP5C inhibition of
FT                   transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:10409727,
FT                   ECO:0000269|PubMed:14764652"
FT   MUTAGEN         260
FT                   /note="R->A,K: Loss of methylation."
FT                   /evidence="ECO:0000269|PubMed:18657504"
FT   MUTAGEN         364
FT                   /note="V->E: Has higher transcriptional activity in the
FT                   absence of wild type ER. Inhibits transcriptional activity
FT                   when coexpressed with the wild type receptor."
FT                   /evidence="ECO:0000269|PubMed:8961262"
FT   MUTAGEN         386
FT                   /note="I->C: Loss of transmembrane localization, no effect
FT                   on peripheral membrane localization. Impairs activation of
FT                   estrogen-induced activation of NOS3 and production of
FT                   nitric oxide. No effect on binding to ERES."
FT                   /evidence="ECO:0000269|PubMed:21937726"
FT   MUTAGEN         447
FT                   /note="C->A: Loss of hormone binding capacity and
FT                   temperature-sensitive loss in DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:1577818"
FT   MUTAGEN         539
FT                   /note="L->A: Abolishes interaction with NCOA1, NCOA2 and
FT                   NCOA3."
FT                   /evidence="ECO:0000269|PubMed:12554772"
FT   CONFLICT        452
FT                   /note="I -> L (in Ref. 5; CAE45969)"
FT                   /evidence="ECO:0000305"
FT   TURN            186..188
FT                   /evidence="ECO:0000244|PDB:1HCQ"
FT   STRAND          189..191
FT                   /evidence="ECO:0000244|PDB:1HCP"
FT   STRAND          194..196
FT                   /evidence="ECO:0000244|PDB:1HCQ"
FT   STRAND          199..201
FT                   /evidence="ECO:0000244|PDB:1HCQ"
FT   HELIX           203..213
FT                   /evidence="ECO:0000244|PDB:1HCQ"
FT   STRAND          222..225
FT                   /evidence="ECO:0000244|PDB:1HCQ"
FT   TURN            231..236
FT                   /evidence="ECO:0000244|PDB:1HCQ"
FT   HELIX           238..248
FT                   /evidence="ECO:0000244|PDB:1HCQ"
FT   HELIX           288..291
FT                   /evidence="ECO:0000244|PDB:2LLO"
FT   HELIX           302..304
FT                   /evidence="ECO:0000244|PDB:3Q95"
FT   HELIX           307..309
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   HELIX           312..322
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   STRAND          330..332
FT                   /evidence="ECO:0000244|PDB:2YJA"
FT   STRAND          334..336
FT                   /evidence="ECO:0000244|PDB:2QZO"
FT   HELIX           339..363
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   HELIX           367..369
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   HELIX           372..395
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   STRAND          396..398
FT                   /evidence="ECO:0000244|PDB:2QE4"
FT   STRAND          401..405
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   STRAND          408..411
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   HELIX           412..417
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   STRAND          418..420
FT                   /evidence="ECO:0000244|PDB:5KCW"
FT   HELIX           421..438
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   HELIX           442..455
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   HELIX           458..460
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   HELIX           466..492
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   HELIX           497..527
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   STRAND          528..530
FT                   /evidence="ECO:0000244|PDB:1XPC"
FT   STRAND          531..533
FT                   /evidence="ECO:0000244|PDB:2OUZ"
FT   HELIX           537..544
FT                   /evidence="ECO:0000244|PDB:6SBO"
FT   HELIX           547..549
FT                   /evidence="ECO:0000244|PDB:6SUO"
FT   HELIX           588..590
FT                   /evidence="ECO:0000244|PDB:5N10"
SQ   SEQUENCE   595 AA;  66216 MW;  5455C57AB0CCCAA7 CRC64;
     MTMTLHTKAS GMALLHQIQG NELEPLNRPQ LKIPLERPLG EVYLDSSKPA VYNYPEGAAY
     EFNAAAAANA QVYGQTGLPY GPGSEAAAFG SNGLGGFPPL NSVSPSPLML LHPPPQLSPF
     LQPHGQQVPY YLENEPSGYT VREAGPPAFY RPNSDNRRQG GRERLASTND KGSMAMESAK
     ETRYCAVCND YASGYHYGVW SCEGCKAFFK RSIQGHNDYM CPATNQCTID KNRRKSCQAC
     RLRKCYEVGM MKGGIRKDRR GGRMLKHKRQ RDDGEGRGEV GSAGDMRAAN LWPSPLMIKR
     SKKNSLALSL TADQMVSALL DAEPPILYSE YDPTRPFSEA SMMGLLTNLA DRELVHMINW
     AKRVPGFVDL TLHDQVHLLE CAWLEILMIG LVWRSMEHPG KLLFAPNLLL DRNQGKCVEG
     MVEIFDMLLA TSSRFRMMNL QGEEFVCLKS IILLNSGVYT FLSSTLKSLE EKDHIHRVLD
     KITDTLIHLM AKAGLTLQQQ HQRLAQLLLI LSHIRHMSNK GMEHLYSMKC KNVVPLYDLL
     LEMLDAHRLH APTSRGGASV EETDQSHLAT AGSTSSHSLQ KYYITGEAEG FPATV
//
ID   Q9UBT1_HUMAN            Unreviewed;        23 AA.
AC   Q9UBT1;
DT   01-MAY-2000, integrated into UniProtKB/TrEMBL.
DT   01-MAY-2000, sequence version 1.
DT   11-DEC-2019, entry version 91.
DE   SubName: Full=Estrogen receptor {ECO:0000313|EMBL:AAC51875.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAC51875.1};
RN   [1] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=3754034; DOI=10.1038/320134a0;
RA   Green S., Walter P., Kumar V., Krust A., Bornert J.M., Argos P.,
RA   Chambon P.;
RT   "Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-
RT   A.";
RL   Nature 320:134-139(1986).
RN   [2] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=3753802; DOI=10.1126/science.3753802;
RA   Greene G.L., Gilna P., Waterfield M., Baker A., Hort Y., Shine J.;
RT   "Sequence and expression of human estrogen receptor complementary DNA.";
RL   Science 231:1150-1154(1986).
RN   [3] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=2015052;
RA   Keaveney M., Klug J., Dawson M.T., Nestor P.V., Neilan J.G., Forde R.C.,
RA   Gannon F.;
RT   "Evidence for a previously unidentified upstream exon in the human
RT   oestrogen receptor gene.";
RL   J. Mol. Endocrinol. 6:111-115(1991).
RN   [4] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=1567414; DOI=10.1016/S0006-291X(05)80289-X;
RA   Piva R., Gambari R., Zorzato F., Kumar L., del Senno L.;
RT   "Analysis of upstream sequences of the human estrogen receptor gene.";
RL   Biochem. Biophys. Res. Commun. 183:996-1002(1992).
RN   [5] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=1476547;
RA   Keaveney M., Klug J., Gannon F.;
RT   "Sequence analysis of the 5' flanking region of the human estrogen receptor
RT   gene.";
RL   DNA Seq. 2:347-358(1992).
RN   [6] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=8240974; DOI=10.1016/0960-0760(93)90179-Z;
RA   Piva R., Bianchi N., Aguiari G.L., Gambari R., del Senno L.;
RT   "Sequencing of an RNA transcript of the human estrogen receptor gene:
RT   evidence for a new transcriptional event.";
RL   J. Steroid Biochem. Mol. Biol. 46:531-538(1993).
RN   [7] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=8647321; DOI=10.1016/0303-7207(95)03716-0;
RA   Grandien K.;
RT   "Determination of transcription start sites in the human estrogen receptor
RT   gene and identification of a novel, tissue-specific, estrogen receptor-mRNA
RT   isoform.";
RL   Mol. Cell. Endocrinol. 116:207-212(1996).
RN   [8] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=9393949; DOI=10.1016/S0960-0760(97)00029-0;
RA   Thompson D.A., McPherson L.A., Carmeci C., deConinck E.C., Weigel R.J.;
RT   "Identification of two estrogen receptor transcripts with novel 5' exons
RT   isolated from a MCF7 cDNA library.";
RL   J. Steroid Biochem. Mol. Biol. 62:143-153(1997).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U68067; AAC51874.1; -; mRNA.
DR   EMBL; U68068; AAC51875.1; -; mRNA.
DR   RefSeq; NP_001116212.1; NM_001122740.1.
DR   DNASU; 2099; -.
DR   GeneID; 2099; -.
DR   CTD; 2099; -.
DR   PharmGKB; PA156; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   eggNOG; ENOG410XRZC; LUCA.
DR   GenomeRNAi; 2099; -.
PE   2: Evidence at transcript level;
KW   Receptor {ECO:0000313|EMBL:AAC51875.1}.
FT   NON_TER         23
FT                   /evidence="ECO:0000313|EMBL:AAC51875.1"
SQ   SEQUENCE   23 AA;  2526 MW;  4A678094301081FD CRC64;
     MTMTLHTKAS GMALLHQIQG NEL
//
ID   FOXO1_HUMAN             Reviewed;         655 AA.
AC   Q12778; O43523; Q5VYC7; Q6NSK6;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   22-APR-2020, entry version 211.
DE   RecName: Full=Forkhead box protein O1;
DE   AltName: Full=Forkhead box protein O1A;
DE   AltName: Full=Forkhead in rhabdomyosarcoma;
GN   Name=FOXO1; Synonyms=FKHR, FOXO1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHROMOSOMAL TRANSLOCATION WITH PAX3.
RX   PubMed=8275086; DOI=10.1038/ng1193-230;
RA   Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S., Rauscher F.J. III,
RA   Emanuel B.S., Rovera G., Barr F.G.;
RT   "Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar
RT   rhabdomyosarcoma.";
RL   Nat. Genet. 5:230-235(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Rhabdomyosarcoma;
RX   PubMed=9479491; DOI=10.1006/geno.1997.5122;
RA   Anderson M.J., Viars C.S., Czekay S., Cavenee W.K., Arden K.C.;
RT   "Cloning and characterization of three human forkhead genes that comprise
RT   an FKHR-like gene subfamily.";
RL   Genomics 47:187-199(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   CHROMOSOMAL TRANSLOCATION WITH PAX7.
RX   PubMed=8187070;
RA   Davis R.J., D'Cruz C.M., Lovell M.A., Biegel J.A., Barr F.G.;
RT   "Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in
RT   alveolar rhabdomyosarcoma.";
RL   Cancer Res. 54:2869-2872(1994).
RN   [7]
RP   PHOSPHORYLATION AT THR-24; SER-256 AND SER-319.
RX   PubMed=10358075; DOI=10.1074/jbc.274.24.17179;
RA   Rena G., Guo S., Cichy S.C., Unterman T.G., Cohen P.;
RT   "Phosphorylation of the transcription factor forkhead family member FKHR by
RT   protein kinase B.";
RL   J. Biol. Chem. 274:17179-17183(1999).
RN   [8]
RP   DNA-BINDING, PHOSPHORYLATION AT SER-256, AND FUNCTION.
RX   PubMed=10358076; DOI=10.1074/jbc.274.24.17184;
RA   Guo S., Rena G., Cichy S., He X., Cohen P., Unterman T.;
RT   "Phosphorylation of serine 256 by protein kinase B disrupts transactivation
RT   by FKHR and mediates effects of insulin on insulin-like growth factor-
RT   binding protein-1 promoter activity through a conserved insulin response
RT   sequence.";
RL   J. Biol. Chem. 274:17184-17192(1999).
RN   [9]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-329, AND MUTAGENESIS OF
RP   SER-329.
RX   PubMed=11311120; DOI=10.1042/bj3550597;
RA   Woods Y.L., Rena G., Morrice N., Barthel A., Becker W., Guo S.,
RA   Unterman T.G., Cohen P.;
RT   "The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329
RT   in vitro, a novel in vivo phosphorylation site.";
RL   Biochem. J. 355:597-607(2001).
RN   [10]
RP   INTERACTION WITH YWHAG AND YWHAZ, PHOSPHORYLATION AT THR-24; SER-256 AND
RP   SER-319, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-24; SER-256 AND
RP   SER-319.
RX   PubMed=11237865; DOI=10.1042/0264-6021:3540605;
RA   Rena G., Prescott A.R., Guo S., Cohen P., Unterman T.G.;
RT   "Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in
RT   regulating 14-3-3 binding, transactivation and nuclear targetting.";
RL   Biochem. J. 354:605-612(2001).
RN   [11]
RP   PHOSPHORYLATION AT THR-24; SER-256; SER-319; SER-322; SER-325 AND SER-329.
RX   PubMed=11980723; DOI=10.1093/emboj/21.9.2263;
RA   Rena G., Woods Y.L., Prescott A.R., Peggie M., Unterman T.G.,
RA   Williams M.R., Cohen P.;
RT   "Two novel phosphorylation sites on FKHR that are critical for its nuclear
RT   exclusion.";
RL   EMBO J. 21:2263-2271(2002).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-24; SER-256 AND
RP   SER-319.
RX   PubMed=12228231; DOI=10.1074/jbc.m208063200;
RA   Zhang X., Gan L., Pan H., Guo S., He X., Olson S.T., Mesecar A., Adam S.,
RA   Unterman T.G.;
RT   "Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1)
RT   by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic
RT   shuttling and DNA binding.";
RL   J. Biol. Chem. 277:45276-45284(2002).
RN   [13]
RP   INTERACTION WITH CREBBP AND SIRT1, ACETYLATION, DEACETYLATION, AND
RP   FUNCTION.
RX   PubMed=15220471; DOI=10.1073/pnas.0400593101;
RA   Daitoku H., Hatta M., Matsuzaki H., Aratani S., Ohshima T., Miyagishi M.,
RA   Nakajima T., Fukamizu A.;
RT   "Silent information regulator 2 potentiates Foxo1-mediated transcription
RT   through its deacetylase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:10042-10047(2004).
RN   [14]
RP   INTERACTION WITH EP300, ACETYLATION, SUBCELLULAR LOCATION, PHOSPHORYLATION,
RP   AND FUNCTION.
RX   PubMed=15890677; DOI=10.1210/me.2004-0292;
RA   Perrot V., Rechler M.M.;
RT   "The coactivator p300 directly acetylates the forkhead transcription factor
RT   Foxo1 and stimulates Foxo1-induced transcription.";
RL   Mol. Endocrinol. 19:2283-2298(2005).
RN   [15]
RP   INTERACTION WITH SKP2, UBIQUITINATION, AND MUTAGENESIS OF SER-256.
RX   PubMed=15668399; DOI=10.1073/pnas.0406789102;
RA   Huang H., Regan K.M., Wang F., Wang D., Smith D.I., van Deursen J.M.,
RA   Tindall D.J.;
RT   "Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated
RT   degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1649-1654(2005).
RN   [16]
RP   INTERACTION WITH PRMT1.
RX   PubMed=18951090; DOI=10.1016/j.molcel.2008.09.013;
RA   Yamagata K., Daitoku H., Takahashi Y., Namiki K., Hisatake K., Kako K.,
RA   Mukai H., Kasuya Y., Fukamizu A.;
RT   "Arginine methylation of FOXO transcription factors inhibits their
RT   phosphorylation by Akt.";
RL   Mol. Cell 32:221-231(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   FUNCTION, PHOSPHORYLATION AT SER-249 BY CDK1, INTERACTION WITH CDK1 AND
RP   14-3-3 PROTEINS, AND MUTAGENESIS OF SER-249.
RX   PubMed=18356527; DOI=10.1126/science.1152337;
RA   Yuan Z., Becker E.B.E., Merlo P., Yamada T., DiBacco S., Konishi Y.,
RA   Schaefer E.M., Bonni A.;
RT   "Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons.";
RL   Science 319:1665-1668(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   PHOSPHORYLATION AT SER-212, SUBCELLULAR LOCATION, FUNCTION, AND MUTAGENESIS
RP   OF SER-212.
RX   PubMed=19221179; DOI=10.1074/jbc.m900461200;
RA   Yuan Z., Lehtinen M.K., Merlo P., Villen J., Gygi S., Bonni A.;
RT   "Regulation of neuronal cell death by MST1-FOXO1 signaling.";
RL   J. Biol. Chem. 284:11285-11292(2009).
RN   [21]
RP   ACETYLATION AT LYS-262; LYS-265 AND LYS-274, DEACETYLATION BY SIRT2,
RP   FUNCTION IN AUTOPHAGY, AND INTERACTION WITH SIRT2 AND ATG7.
RX   PubMed=20543840; DOI=10.1038/ncb2069;
RA   Zhao Y., Yang J., Liao W., Liu X., Zhang H., Wang S., Wang D., Feng J.,
RA   Yu L., Zhu W.G.;
RT   "Cytosolic FoxO1 is essential for the induction of autophagy and tumour
RT   suppressor activity.";
RL   Nat. Cell Biol. 12:665-675(2010).
RN   [22]
RP   INDUCTION.
RX   PubMed=20668652; DOI=10.1371/journal.pone.0011786;
RA   Goitre L., Balzac F., Degani S., Degan P., Marchi S., Pinton P.,
RA   Retta S.F.;
RT   "KRIT1 regulates the homeostasis of intracellular reactive oxygen
RT   species.";
RL   PLoS ONE 5:E11786-E11786(2010).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-212.
RX   PubMed=21245099; DOI=10.1158/0008-5472.can-10-2203;
RA   Valis K., Prochazka L., Boura E., Chladova J., Obsil T., Rohlena J.,
RA   Truksa J., Dong L.F., Ralph S.J., Neuzil J.;
RT   "Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a
RT   FoxO1-dependent manner.";
RL   Cancer Res. 71:946-954(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 151-266, DNA-BINDING,
RP   PHOSPHORYLATION AT SER-212; SER-218; SER-234 AND SER-235, ACETYLATION,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF SER-249.
RX   PubMed=18786403; DOI=10.1016/j.str.2008.06.013;
RA   Brent M.M., Anand R., Marmorstein R.;
RT   "Structural basis for DNA recognition by FoxO1 and its regulation by
RT   posttranslational modification.";
RL   Structure 16:1407-1416(2008).
CC   -!- FUNCTION: Transcription factor that is the main target of insulin
CC       signaling and regulates metabolic homeostasis in response to oxidative
CC       stress. Binds to the insulin response element (IRE) with consensus
CC       sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding
CC       element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3'. Activity
CC       suppressed by insulin. Main regulator of redox balance and osteoblast
CC       numbers and controls bone mass. Orchestrates the endocrine function of
CC       the skeleton in regulating glucose metabolism. Acts synergistically
CC       with ATF4 to suppress osteocalcin/BGLAP activity, increasing glucose
CC       levels and triggering glucose intolerance and insulin insensitivity.
CC       Also suppresses the transcriptional activity of RUNX2, an upstream
CC       activator of osteocalcin/BGLAP. In hepatocytes, promotes
CC       gluconeogenesis by acting together with PPARGC1A and CEBPA to activate
CC       the expression of genes such as IGFBP1, G6PC and PCK1. Important
CC       regulator of cell death acting downstream of CDK1, PKB/AKT1 and
CC       STK4/MST1. Promotes neural cell death. Mediates insulin action on
CC       adipose tissue. Regulates the expression of adipogenic genes such as
CC       PPARG during preadipocyte differentiation and, adipocyte size and
CC       adipose tissue-specific gene expression in response to excessive
CC       calorie intake. Regulates the transcriptional activity of GADD45A and
CC       repair of nitric oxide-damaged DNA in beta-cells. Required for the
CC       autophagic cell death induction in response to starvation or oxidative
CC       stress in a transcription-independent manner. Mediates the function of
CC       MLIP in cardiomyocytes hypertrophy and cardiac remodeling (By
CC       similarity). {ECO:0000250|UniProtKB:G3V7R4,
CC       ECO:0000250|UniProtKB:Q9R1E0, ECO:0000269|PubMed:10358076,
CC       ECO:0000269|PubMed:12228231, ECO:0000269|PubMed:15220471,
CC       ECO:0000269|PubMed:15890677, ECO:0000269|PubMed:18356527,
CC       ECO:0000269|PubMed:19221179, ECO:0000269|PubMed:20543840,
CC       ECO:0000269|PubMed:21245099}.
CC   -!- SUBUNIT: Interacts with LRPPRC. Interacts with RUNX2; the interaction
CC       inhibits RUNX2 transcriptional activity and mediates the IGF1/insulin-
CC       dependent BGLAP expression in osteoblasts Interacts with PPP2R1A; the
CC       interaction regulates the dephosphorylation of FOXO1 at Thr-24 and Ser-
CC       256 leading to its nuclear import. Interacts (acetylated form) with
CC       PPARG. Interacts with XBP1 isoform 2; this interaction is direct and
CC       leads to FOXO1 ubiquitination and degradation via the proteasome
CC       pathway (By similarity). Interacts with NLK. Interacts with SIRT1; the
CC       interaction results in the deacetylation of FOXO1 leading to activation
CC       of FOXO1-mediated transcription of genes involved in DNA repair and
CC       stress resistance. Binds to CDK1. Interacts with the 14-3-3 proteins,
CC       YWHAG and YWHAZ; the interactions require insulin-stimulated
CC       phosphorylation on Thr-24, promote nuclear exit and loss of
CC       transcriptional activity. Interacts with SKP2; the interaction
CC       ubiquitinates FOXO1 leading to its proteosomal degradation. The
CC       interaction requires the presence of KRIT1. Interacts (via the C-
CC       terminal half) with ATF4 (via its DNA-binding domain); the interaction
CC       occurs in osteoblasts, regulates glucose homeostasis via suppression of
CC       beta-cell proliferation and subsequent decrease in insulin production.
CC       Interacts with PRMT1; the interaction methylates FOXO1, prevents
CC       PKB/AKT1 phosphorylation and retains FOXO1 in the nucleus. Interacts
CC       with EP300 and CREBBP; the interactions acetylate FOXO1. Interacts with
CC       SIRT2; the interaction is disrupted in response to oxidative stress or
CC       serum deprivation, leading to increased level of acetylated FOXO1,
CC       which promotes stress-induced autophagy by stimulating E1-like
CC       activating enzyme ATG7. Interacts (acetylated form) with ATG7; the
CC       interaction is increased in response to oxidative stress or serum
CC       deprivation and promotes the autophagic process leading to cell death.
CC       Interacts (via the Fork-head domain) with CEBPA; the interaction
CC       increases when FOXO1 is deacetylated. Interacts with WDFY2. Forms a
CC       complex with WDFY2 and AKT1 (By similarity). Interacts with CRY1 (By
CC       similarity). {ECO:0000250|UniProtKB:Q9R1E0,
CC       ECO:0000269|PubMed:11237865, ECO:0000269|PubMed:15220471,
CC       ECO:0000269|PubMed:15668399, ECO:0000269|PubMed:15890677,
CC       ECO:0000269|PubMed:18356527, ECO:0000269|PubMed:18951090,
CC       ECO:0000269|PubMed:20543840}.
CC   -!- INTERACTION:
CC       Q12778; P31749: AKT1; NbExp=2; IntAct=EBI-1108782, EBI-296087;
CC       Q12778; P14635: CCNB1; NbExp=2; IntAct=EBI-1108782, EBI-495332;
CC       Q12778; P06493: CDK1; NbExp=5; IntAct=EBI-1108782, EBI-444308;
CC       Q12778; Q92793: CREBBP; NbExp=3; IntAct=EBI-1108782, EBI-81215;
CC       Q12778; P03372: ESR1; NbExp=2; IntAct=EBI-1108782, EBI-78473;
CC       Q12778; P14921-3: ETS1; NbExp=2; IntAct=EBI-1108782, EBI-21403286;
CC       Q12778; Q14192: FHL2; NbExp=8; IntAct=EBI-1108782, EBI-701903;
CC       Q12778; Q01105: SET; NbExp=5; IntAct=EBI-1108782, EBI-1053182;
CC       Q12778; Q96EB6: SIRT1; NbExp=4; IntAct=EBI-1108782, EBI-1802965;
CC       Q12778; Q923E4: Sirt1; Xeno; NbExp=2; IntAct=EBI-1108782, EBI-1802585;
CC       Q12778; P63104: YWHAZ; NbExp=3; IntAct=EBI-1108782, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9R1E0}. Nucleus
CC       {ECO:0000250|UniProtKB:Q9R1E0}. Note=Shuttles between the cytoplasm and
CC       nucleus. Largely nuclear in unstimulated cells. In osteoblasts,
CC       colocalizes with ATF4 and RUNX2 in the nucleus (By similarity).
CC       Insulin-induced phosphorylation at Ser-256 by PKB/AKT1 leads, via
CC       stimulation of Thr-24 phosphorylation, to binding of 14-3-3 proteins
CC       and nuclear export to the cytoplasm where it is degraded by the
CC       ubiquitin-proteosomal pathway. Phosphorylation at Ser-249 by CDK1
CC       disrupts binding of 14-3-3 proteins and promotes nuclear accumulation.
CC       Phosphorylation by NLK results in nuclear export. Translocates to the
CC       nucleus upon oxidative stress-induced phosphorylation at Ser-212 by
CC       STK4/MST1. SGK1-mediated phosphorylation also results in nuclear
CC       translocation. Retained in the nucleus under stress stimuli including
CC       oxidative stress, nutrient deprivation or nitric oxide. Retained in the
CC       nucleus on methylation. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:9479491}.
CC   -!- INDUCTION: Expression is regulated by KRIT1. Levels of expression also
CC       regulated by FOXC1 which binds to a conserved element in the FOXO1
CC       promoter. {ECO:0000269|PubMed:20668652}.
CC   -!- PTM: Phosphorylation by NLK promotes nuclear export and inhibits the
CC       transcriptional activity. In response to growth factors,
CC       phosphorylation on Thr-24, Ser-256 and Ser-322 by PKB/AKT1 promotes
CC       nuclear export and inactivation of transactivational activity.
CC       Phosphorylation on Thr-24 is required for binding 14-3-3 proteins.
CC       Phosphorylation of Ser-256 decreases DNA-binding activity and promotes
CC       the phosphorylation of Thr-24 and Ser-319, permitting phosphorylation
CC       of Ser-322 and Ser-325, probably by CDK1, leading to nuclear exclusion
CC       and loss of function. Stress signals, such as response to oxygen or
CC       nitric oxide, attenuate the PKB/AKT1-mediated phosphorylation leading
CC       to nuclear retention. Phosphorylation of Ser-329 is independent of IGF1
CC       and leads to reduced function. Dephosphorylated on Thr-24 and Ser-256
CC       by PP2A in beta-cells under oxidative stress leading to nuclear
CC       retention (By similarity). Phosphorylation of Ser-249 by CDK1 disrupts
CC       binding of 14-3-3 proteins leading to nuclear accumulation and has no
CC       effect on DNA-binding nor transcriptional activity. Phosphorylation by
CC       STK4/MST1 on Ser-212, upon oxidative stress, inhibits binding to 14-3-3
CC       proteins and nuclear export. {ECO:0000250, ECO:0000269|PubMed:10358075,
CC       ECO:0000269|PubMed:10358076, ECO:0000269|PubMed:11237865,
CC       ECO:0000269|PubMed:11311120, ECO:0000269|PubMed:11980723,
CC       ECO:0000269|PubMed:18356527, ECO:0000269|PubMed:18786403,
CC       ECO:0000269|PubMed:19221179, ECO:0000269|PubMed:21245099}.
CC   -!- PTM: Acetylated. Acetylation at Lys-262, Lys-265 and Lys-274 are
CC       necessary for autophagic cell death induction. Deacetylated by SIRT2 in
CC       response to oxidative stress or serum deprivation, thereby negatively
CC       regulating FOXO1-mediated autophagic cell death.
CC       {ECO:0000269|PubMed:20543840}.
CC   -!- PTM: Ubiquitinated by SKP2. Ubiquitination leads to proteasomal
CC       degradation. {ECO:0000269|PubMed:15668399}.
CC   -!- PTM: Methylation inhibits AKT1-mediated phosphorylation at Ser-256 and
CC       is increased by oxidative stress. {ECO:0000250}.
CC   -!- PTM: Once in the nucleus, acetylated by CREBBP/EP300. Acetylation
CC       diminishes the interaction with target DNA and attenuates the
CC       transcriptional activity. It increases the phosphorylation at Ser-256.
CC       Deacetylation by SIRT1 results in reactivation of the transcriptional
CC       activity. Oxidative stress by hydrogen peroxide treatment appears to
CC       promote deacetylation and uncoupling of insulin-induced
CC       phosphorylation. By contrast, resveratrol acts independently of
CC       acetylation. {ECO:0000269|PubMed:10358075, ECO:0000269|PubMed:10358076,
CC       ECO:0000269|PubMed:11237865, ECO:0000269|PubMed:11980723}.
CC   -!- DISEASE: Rhabdomyosarcoma 2 (RMS2) [MIM:268220]: A form of
CC       rhabdomyosarcoma, a highly malignant tumor of striated muscle derived
CC       from primitive mesenchymal cells and exhibiting differentiation along
CC       rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently
CC       occurring soft tissue sarcomas and the most common in children. It
CC       occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal
CC       rhabdomyosarcomas. Note=The gene represented in this entry may be
CC       involved in disease pathogenesis. Chromosomal aberrations involving
CC       FOXO1 are found in rhabdomyosarcoma. Translocation (2;13)(q35;q14) with
CC       PAX3 and translocation t(1;13)(p36;q14) with PAX7. The resulting
CC       protein is a transcriptional activator.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FOXO1ID83ch13q14.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U02310; AAA03629.1; -; mRNA.
DR   EMBL; AF032885; AAC39591.1; -; mRNA.
DR   EMBL; BT007455; AAP36123.1; -; mRNA.
DR   EMBL; AL355132; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL133318; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC021981; AAH21981.1; -; mRNA.
DR   EMBL; BC070065; AAH70065.3; -; mRNA.
DR   CCDS; CCDS9371.1; -.
DR   PIR; S40521; S40521.
DR   RefSeq; NP_002006.2; NM_002015.3.
DR   PDB; 3CO6; X-ray; 2.10 A; C=151-249.
DR   PDB; 3CO7; X-ray; 2.91 A; C/F=151-266.
DR   PDB; 3COA; X-ray; 2.20 A; C/F=151-266.
DR   PDB; 4LG0; X-ray; 2.19 A; A=143-270.
DR   PDB; 5DUI; X-ray; 2.31 A; A/B=151-259.
DR   PDB; 6QVW; NMR; -; A=159-272.
DR   PDB; 6QZR; X-ray; 2.30 A; J/M/N/O/P/R/T/U=19-29.
DR   PDB; 6QZS; X-ray; 1.90 A; C/P=251-262.
DR   PDBsum; 3CO6; -.
DR   PDBsum; 3CO7; -.
DR   PDBsum; 3COA; -.
DR   PDBsum; 4LG0; -.
DR   PDBsum; 5DUI; -.
DR   PDBsum; 6QVW; -.
DR   PDBsum; 6QZR; -.
DR   PDBsum; 6QZS; -.
DR   SMR; Q12778; -.
DR   BioGrid; 108597; 66.
DR   CORUM; Q12778; -.
DR   DIP; DIP-35654N; -.
DR   IntAct; Q12778; 37.
DR   MINT; Q12778; -.
DR   STRING; 9606.ENSP00000368880; -.
DR   BindingDB; Q12778; -.
DR   ChEMBL; CHEMBL5294; -.
DR   iPTMnet; Q12778; -.
DR   PhosphoSitePlus; Q12778; -.
DR   BioMuta; FOXO1; -.
DR   DMDM; 116241368; -.
DR   CPTAC; CPTAC-1323; -.
DR   EPD; Q12778; -.
DR   jPOST; Q12778; -.
DR   MassIVE; Q12778; -.
DR   MaxQB; Q12778; -.
DR   PaxDb; Q12778; -.
DR   PeptideAtlas; Q12778; -.
DR   PRIDE; Q12778; -.
DR   ProteomicsDB; 58922; -.
DR   Antibodypedia; 645; 2021 antibodies.
DR   DNASU; 2308; -.
DR   Ensembl; ENST00000379561; ENSP00000368880; ENSG00000150907.
DR   GeneID; 2308; -.
DR   KEGG; hsa:2308; -.
DR   UCSC; uc001uxl.5; human.
DR   CTD; 2308; -.
DR   DisGeNET; 2308; -.
DR   GeneCards; FOXO1; -.
DR   HGNC; HGNC:3819; FOXO1.
DR   HPA; ENSG00000150907; Tissue enhanced (skeletal).
DR   MalaCards; FOXO1; -.
DR   MIM; 136533; gene.
DR   MIM; 268220; phenotype.
DR   neXtProt; NX_Q12778; -.
DR   OpenTargets; ENSG00000150907; -.
DR   Orphanet; 99756; Alveolar rhabdomyosarcoma.
DR   PharmGKB; PA28237; -.
DR   eggNOG; KOG2294; Eukaryota.
DR   eggNOG; COG5025; LUCA.
DR   GeneTree; ENSGT00940000161558; -.
DR   HOGENOM; CLU_023456_1_1_1; -.
DR   InParanoid; Q12778; -.
DR   KO; K07201; -.
DR   OMA; YSKWPGS; -.
DR   OrthoDB; 1160384at2759; -.
DR   PhylomeDB; Q12778; -.
DR   TreeFam; TF315583; -.
DR   Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-HSA-210745; Regulation of gene expression in beta cells.
DR   Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors.
DR   Reactome; R-HSA-9614657; FOXO-mediated transcription of cell death genes.
DR   Reactome; R-HSA-9615017; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes.
DR   Reactome; R-HSA-9617629; Regulation of FOXO transcriptional activity by acetylation.
DR   Reactome; R-HSA-9617828; FOXO-mediated transcription of cell cycle genes.
DR   SignaLink; Q12778; -.
DR   SIGNOR; Q12778; -.
DR   ChiTaRS; FOXO1; human.
DR   EvolutionaryTrace; Q12778; -.
DR   GeneWiki; FOXO1; -.
DR   GenomeRNAi; 2308; -.
DR   Pharos; Q12778; Tbio.
DR   PRO; PR:Q12778; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; Q12778; protein.
DR   Bgee; ENSG00000150907; Expressed in female gonad and 243 other tissues.
DR   Genevisible; Q12778; HS.
DR   GO; GO:0005623; C:cell; IEA:GOC.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IBA:GO_Central.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; ISS:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001223; F:transcription coactivator binding; IEA:Ensembl.
DR   GO; GO:0008134; F:transcription factor binding; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0001568; P:blood vessel development; IEA:Ensembl.
DR   GO; GO:0001678; P:cellular glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0070417; P:cellular response to cold; ISS:UniProtKB.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; ISS:UniProtKB.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0071455; P:cellular response to hyperoxia; IDA:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:UniProtKB.
DR   GO; GO:0071732; P:cellular response to nitric oxide; ISS:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISS:UniProtKB.
DR   GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0070166; P:enamel mineralization; IEA:Ensembl.
DR   GO; GO:0031018; P:endocrine pancreas development; TAS:Reactome.
DR   GO; GO:0097009; P:energy homeostasis; ISS:UniProtKB.
DR   GO; GO:0045444; P:fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; IBA:GO_Central.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:1903243; P:negative regulation of cardiac muscle hypertrophy in response to stress; ISS:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0032873; P:negative regulation of stress-activated MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0045722; P:positive regulation of gluconeogenesis; IEA:Ensembl.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006473; P:protein acetylation; ISS:UniProtKB.
DR   GO; GO:2000177; P:regulation of neural precursor cell proliferation; IEA:Ensembl.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:1902617; P:response to fluoride; IEA:Ensembl.
DR   GO; GO:0001659; P:temperature homeostasis; ISS:UniProtKB.
DR   CDD; cd00059; FH; 1.
DR   DisProt; DP01132; -.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR032067; FOXO-TAD.
DR   InterPro; IPR032068; FOXO_KIX-bd.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF00250; Forkhead; 1.
DR   Pfam; PF16676; FOXO-TAD; 1.
DR   Pfam; PF16675; FOXO_KIX_bdg; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Apoptosis; Autophagy;
KW   Chromosomal rearrangement; Cytoplasm; Differentiation; DNA-binding;
KW   Methylation; Nucleus; Phosphoprotein; Proto-oncogene; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..655
FT                   /note="Forkhead box protein O1"
FT                   /id="PRO_0000091872"
FT   DNA_BIND        159..235
FT                   /note="Fork-head"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00089"
FT   REGION          211..218
FT                   /note="DNA-binding"
FT   REGION          234..237
FT                   /note="DNA-binding"
FT   REGION          283..563
FT                   /note="Sufficient for interaction with NLK"
FT                   /evidence="ECO:0000250"
FT   REGION          363..459
FT                   /note="Required for interaction with RUNX2"
FT                   /evidence="ECO:0000250"
FT   MOTIF           251..253
FT                   /note="Nuclear localization signal"
FT   MOTIF           462..466
FT                   /note="Required for interaction with SIRT1"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        91..102
FT                   /note="Poly-Ala"
FT   COMPBIAS        120..130
FT                   /note="Poly-Pro"
FT   COMPBIAS        152..155
FT                   /note="Poly-Ser"
FT   SITE            158
FT                   /note="DNA-binding"
FT   SITE            165
FT                   /note="DNA-binding"
FT   SITE            225
FT                   /note="DNA-binding"
FT   MOD_RES         24
FT                   /note="Phosphothreonine; by PKB/AKT1 or PKB/AKT2 and SGK1"
FT                   /evidence="ECO:0000269|PubMed:10358075,
FT                   ECO:0000269|PubMed:11237865, ECO:0000269|PubMed:11980723"
FT   MOD_RES         212
FT                   /note="Phosphoserine; by STK4/MST1"
FT                   /evidence="ECO:0000269|PubMed:18786403,
FT                   ECO:0000269|PubMed:19221179, ECO:0000269|PubMed:21245099"
FT   MOD_RES         218
FT                   /note="Phosphoserine; by STK4/MST1"
FT                   /evidence="ECO:0000269|PubMed:18786403"
FT   MOD_RES         234
FT                   /note="Phosphoserine; by STK4/MST1"
FT                   /evidence="ECO:0000269|PubMed:18786403"
FT   MOD_RES         235
FT                   /note="Phosphoserine; by STK4/MST1"
FT                   /evidence="ECO:0000269|PubMed:18786403"
FT   MOD_RES         245
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   MOD_RES         248
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   MOD_RES         249
FT                   /note="Phosphoserine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:18356527"
FT   MOD_RES         251
FT                   /note="Omega-N-methylarginine; by PRMT1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   MOD_RES         253
FT                   /note="Omega-N-methylarginine; by PRMT1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   MOD_RES         256
FT                   /note="Phosphoserine; by PKB/AKT1 and SGK1"
FT                   /evidence="ECO:0000269|PubMed:10358075,
FT                   ECO:0000269|PubMed:10358076, ECO:0000269|PubMed:11237865,
FT                   ECO:0000269|PubMed:11980723"
FT   MOD_RES         262
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20543840"
FT   MOD_RES         265
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20543840"
FT   MOD_RES         274
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20543840"
FT   MOD_RES         287
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:21406692"
FT   MOD_RES         298
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   MOD_RES         319
FT                   /note="Phosphoserine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:10358075,
FT                   ECO:0000269|PubMed:11237865, ECO:0000269|PubMed:11980723"
FT   MOD_RES         322
FT                   /note="Phosphoserine; by CK1 and SGK1"
FT                   /evidence="ECO:0000269|PubMed:11980723"
FT   MOD_RES         325
FT                   /note="Phosphoserine; by CK1"
FT                   /evidence="ECO:0000269|PubMed:11980723"
FT   MOD_RES         329
FT                   /note="Phosphoserine; by DYRK1A"
FT                   /evidence="ECO:0000269|PubMed:11311120,
FT                   ECO:0000269|PubMed:11980723"
FT   MOD_RES         333
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   MUTAGEN         24
FT                   /note="T->A: Abolishes PKB/AKT1-mediated phosphorylation
FT                   but does not prevent phosphorylation of Ser-256 or Ser-319.
FT                   Also inhibits binding of 14-3-3 proteins. Nuclear in
FT                   unstimulated cells, and little export to cytoplasm on IGF1
FT                   stimulation. Inhibits the PKB/AKT1-mediated activity
FT                   towards other substrates but does not block the IGF1-
FT                   activated 'T-308' of phosphorylation of PKB/AKT1; when
FT                   associated with A-256 and A-319. Targeted to the nucleus
FT                   and enhances transactivation; when associated with A-319."
FT                   /evidence="ECO:0000269|PubMed:11237865,
FT                   ECO:0000269|PubMed:12228231"
FT   MUTAGEN         212
FT                   /note="S->A: Abolishes STK4/MST1-mediated phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19221179"
FT   MUTAGEN         245
FT                   /note="K->A: Disrupts DNA-binding; when associated with A-
FT                   248."
FT   MUTAGEN         248
FT                   /note="K->A: Disrupts DNA-binding; when associated with A-
FT                   245."
FT   MUTAGEN         249
FT                   /note="S->A: Impaired phosphorylation by CDK1."
FT                   /evidence="ECO:0000269|PubMed:18356527,
FT                   ECO:0000269|PubMed:18786403"
FT   MUTAGEN         249
FT                   /note="S->E: No effect on DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:18356527,
FT                   ECO:0000269|PubMed:18786403"
FT   MUTAGEN         251..253
FT                   /note="RRR->SAS: No targeting to the nucleus and disruption
FT                   of DNA-binding."
FT   MUTAGEN         256
FT                   /note="S->A: Completely abolishes PKB/AKT1-mediated
FT                   phosphorylation at all three sites, and inhibits binding of
FT                   14-3-3 proteins. Inhibits the PKB/AKT1-mediated activity
FT                   towards other substrates but does not block the IGF1-
FT                   activated 'T-308' of phosphorylation of PKB/AKT1; when
FT                   associated with or without A-24 and A-319. Nuclear in
FT                   unstimulated cells, and little export to cytoplasm on IGF1
FT                   stimulation. Abolishes the ability of IGF1 to suppress
FT                   transactivation. Prevents T-24 and S-319 phosphorylation.
FT                   Enhances transactivation; when associated with A-24 and A-
FT                   319."
FT                   /evidence="ECO:0000269|PubMed:11237865,
FT                   ECO:0000269|PubMed:12228231, ECO:0000269|PubMed:15668399"
FT   MUTAGEN         256
FT                   /note="S->D: Reduces DNA binding, promotes nuclear
FT                   exclusion and partially promotes T-24 and S-319
FT                   phosphorylation. Reduces DNA binding, does not promote
FT                   nuclear exclusion but reduces transactivation; when
FT                   associated with A-24 and A-319."
FT                   /evidence="ECO:0000269|PubMed:11237865,
FT                   ECO:0000269|PubMed:12228231, ECO:0000269|PubMed:15668399"
FT   MUTAGEN         262
FT                   /note="K->R: Inhibits interaction with ATG7 and FOXO1-
FT                   acetylation-induced autophagic cell death; when associated
FT                   with R-265 and R-274."
FT   MUTAGEN         265
FT                   /note="K->R: Inhibits interaction with ATG7 and FOXO1-
FT                   acetylation-induced autophagic cell death; when associated
FT                   with R-262 and R-274."
FT   MUTAGEN         274
FT                   /note="K->R: Inhibits interaction with ATG7 and FOXO1-
FT                   acetylation-induced autophagic cell death; when associated
FT                   with R-262 and R-265."
FT   MUTAGEN         319
FT                   /note="S->A: Abolishes PKB/AKT1-mediated phosphorylation
FT                   but does not prevent phosphorylation of Ser-24 or Ser-256.
FT                   Inhibits the PKB/AKT1-mediated activity towards other
FT                   substrates but does not block the IGF1-activated 'T-308' of
FT                   phosphorylation of PKB/AKT1; when associated with A-24 and
FT                   A-256. Targeted to the nucleus and enhances
FT                   transactivation; when associated with A-24."
FT                   /evidence="ECO:0000269|PubMed:11237865,
FT                   ECO:0000269|PubMed:12228231"
FT   MUTAGEN         329
FT                   /note="S->A: Targeted to the nucleus and enhances
FT                   transactivation."
FT                   /evidence="ECO:0000269|PubMed:11311120"
FT   CONFLICT        131
FT                   /note="L -> V (in Ref. 1; AAA03629)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        343
FT                   /note="V -> M (in Ref. 5; AAH70065)"
FT                   /evidence="ECO:0000305"
FT   STRAND          156..158
FT                   /evidence="ECO:0000244|PDB:3CO6"
FT   HELIX           165..175
FT                   /evidence="ECO:0000244|PDB:3CO6"
FT   STRAND          176..181
FT                   /evidence="ECO:0000244|PDB:5DUI"
FT   HELIX           183..193
FT                   /evidence="ECO:0000244|PDB:3CO6"
FT   HELIX           195..197
FT                   /evidence="ECO:0000244|PDB:3CO6"
FT   HELIX           203..219
FT                   /evidence="ECO:0000244|PDB:3CO6"
FT   STRAND          223..226
FT                   /evidence="ECO:0000244|PDB:3CO6"
FT   TURN            230..232
FT                   /evidence="ECO:0000244|PDB:3CO6"
FT   STRAND          236..239
FT                   /evidence="ECO:0000244|PDB:3CO6"
SQ   SEQUENCE   655 AA;  69662 MW;  6DEF6C994BDFDBAB CRC64;
     MAEAPQVVEI DPDFEPLPRP RSCTWPLPRP EFSQSNSATS SPAPSGSAAA NPDAAAGLPS
     ASAAAVSADF MSNLSLLEES EDFPQAPGSV AAAVAAAAAA AATGGLCGDF QGPEAGCLHP
     APPQPPPPGP LSQHPPVPPA AAGPLAGQPR KSSSSRRNAW GNLSYADLIT KAIESSAEKR
     LTLSQIYEWM VKSVPYFKDK GDSNSSAGWK NSIRHNLSLH SKFIRVQNEG TGKSSWWMLN
     PEGGKSGKSP RRRAASMDNN SKFAKSRSRA AKKKASLQSG QEGAGDSPGS QFSKWPASPG
     SHSNDDFDNW STFRPRTSSN ASTISGRLSP IMTEQDDLGE GDVHSMVYPP SAAKMASTLP
     SLSEISNPEN MENLLDNLNL LSSPTSLTVS TQSSPGTMMQ QTPCYSFAPP NTSLNSPSPN
     YQKYTYGQSS MSPLPQMPIQ TLQDNKSSYG GMSQYNCAPG LLKELLTSDS PPHNDIMTPV
     DPGVAQPNSR VLGQNVMMGP NSVMSTYGSQ ASHNKMMNPS SHTHPGHAQQ TSAVNGRPLP
     HTVSTMPHTS GMNRLTQVKT PVQVPLPHPM QMSALGGYSS VSSCNGYGRM GLLHQEKLPS
     DLDGMFIERL DCDMESIIRN DLMDGDTLDF NFDNVLPNQS FPHSVKTTTH SWVSG
//
ID   FOXO3_HUMAN             Reviewed;         673 AA.
AC   O43524; B4DVZ6; E1P5E6; O15171; Q5T2I7; Q9BZ04;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   22-APR-2020, entry version 216.
DE   RecName: Full=Forkhead box protein O3 {ECO:0000305};
DE   AltName: Full=AF6q21 protein {ECO:0000303|PubMed:9345057};
DE   AltName: Full=Forkhead in rhabdomyosarcoma-like 1 {ECO:0000303|PubMed:9479491};
GN   Name=FOXO3 {ECO:0000312|HGNC:HGNC:3821};
GN   Synonyms=FKHRL1 {ECO:0000303|PubMed:9479491},
GN   FOXO3A {ECO:0000303|PubMed:11154281};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Rhabdomyosarcoma;
RX   PubMed=9479491; DOI=10.1006/geno.1997.5122;
RA   Anderson M.J., Viars C.S., Czekay S., Cavenee W.K., Arden K.C.;
RT   "Cloning and characterization of three human forkhead genes that comprise
RT   an FKHR-like gene subfamily.";
RL   Genomics 47:187-199(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Stomach;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 1-383 (ISOFORM 1), AND
RP   INVOLVEMENT IN SECONDARY ACUTE LEUKEMIAS.
RX   PubMed=9345057;
RA   Hillion J., Le Coniat M., Jonveaux P., Berger R., Bernard O.A.;
RT   "AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a
RT   forkhead transcriptional factor subfamily.";
RL   Blood 90:3714-3719(1997).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-32; SER-253 AND
RP   SER-315, AND MUTAGENESIS OF THR-32; SER-253 AND SER-315.
RX   PubMed=10102273; DOI=10.1016/s0092-8674(00)80595-4;
RA   Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S.,
RA   Anderson M.J., Arden K.C., Blenis J., Greenberg M.E.;
RT   "Akt promotes cell survival by phosphorylating and inhibiting a Forkhead
RT   transcription factor.";
RL   Cell 96:857-868(1999).
RN   [8]
RP   PHOSPHORYLATION AT SER-315.
RX   PubMed=11154281; DOI=10.1128/mcb.21.3.952-965.2001;
RA   Brunet A., Park J., Tran H., Hu L.S., Hemmings B.A., Greenberg M.E.;
RT   "Protein kinase SGK mediates survival signals by phosphorylating the
RT   forkhead transcription factor FKHRL1 (FOXO3a).";
RL   Mol. Cell. Biol. 21:952-965(2001).
RN   [9]
RP   INTERACTION WITH CHUK AND IKBKB, REGION, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION AT SER-644, AND MUTAGENESIS OF SER-644.
RX   PubMed=15084260; DOI=10.1016/s0092-8674(04)00302-2;
RA   Hu M.C., Lee D.F., Xia W., Golfman L.S., Ou-Yang F., Yang J.Y., Zou Y.,
RA   Bao S., Hanada N., Saso H., Kobayashi R., Hung M.C.;
RT   "IkappaB kinase promotes tumorigenesis through inhibition of forkhead
RT   FOXO3a.";
RL   Cell 117:225-237(2004).
RN   [10]
RP   FUNCTION, PHOSPHORYLATION AT SER-209, INTERACTION WITH STK4/MST1 AND YWHAB,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-209.
RX   PubMed=16751106; DOI=10.1016/j.cell.2006.03.046;
RA   Lehtinen M.K., Yuan Z., Boag P.R., Yang Y., Villen J., Becker E.B.E.,
RA   DiBacco S., de la Iglesia N., Gygi S.P., Blackwell T.K., Bonni A.;
RT   "A conserved MST-FOXO signaling pathway mediates oxidative-stress responses
RT   and extends life span.";
RL   Cell 125:987-1001(2006).
RN   [11]
RP   PHOSPHORYLATION AT THR-179; SER-399; SER-413; SER-555; SER-588 AND SER-626,
RP   MUTAGENESIS OF THR-179; SER-399; SER-413; SER-555; SER-588 AND SER-626, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=17711846; DOI=10.1074/jbc.m705325200;
RA   Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P., Gygi S.P.,
RA   Brunet A.;
RT   "The energy sensor AMP-activated protein kinase directly regulates the
RT   mammalian FOXO3 transcription factor.";
RL   J. Biol. Chem. 282:30107-30119(2007).
RN   [12]
RP   INTERACTION WITH PIM1, AND PHOSPHORYLATION.
RX   PubMed=18593906; DOI=10.1158/0008-5472.can-08-0634;
RA   Morishita D., Katayama R., Sekimizu K., Tsuruo T., Fujita N.;
RT   "Pim kinases promote cell cycle progression by phosphorylating and down-
RT   regulating p27Kip1 at the transcriptional and posttranscriptional levels.";
RL   Cancer Res. 68:5076-5085(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-421, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280 AND SER-284, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   INTERACTION WITH NUPR1.
RX   PubMed=20181828; DOI=10.1091/mbc.e09-09-0818;
RA   Kong D.K., Georgescu S.P., Cano C., Aronovitz M.J., Iovanna J.L.,
RA   Patten R.D., Kyriakis J.M., Goruppi S.;
RT   "Deficiency of the transcriptional regulator p8 results in increased
RT   autophagy and apoptosis, and causes impaired heart function.";
RL   Mol. Biol. Cell 21:1335-1349(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, DNA-BINDING, AND PHOSPHORYLATION AT
RP   SER-215; SER-253; SER-551 AND SER-555.
RX   PubMed=21329882; DOI=10.1016/j.molcel.2011.01.023;
RA   Kress T.R., Cannell I.G., Brenkman A.B., Samans B., Gaestel M., Roepman P.,
RA   Burgering B.M., Bushell M., Rosenwald A., Eilers M.;
RT   "The MK5/PRAK kinase and Myc form a negative feedback loop that is
RT   disrupted during colorectal tumorigenesis.";
RL   Mol. Cell 41:445-457(2011).
RN   [20]
RP   METHYLATION AT LYS-46; LYS-149; LYS-230; LYS-262; LYS-271; LYS-290 AND
RP   LYS-419, AND MUTAGENESIS OF LYS-269; LYS-270 AND LYS-271.
RX   PubMed=22820736; DOI=10.18632/aging.100471;
RA   Calnan D.R., Webb A.E., White J.L., Stowe T.R., Goswami T., Shi X.,
RA   Espejo A., Bedford M.T., Gozani O., Gygi S.P., Brunet A.;
RT   "Methylation by Set9 modulates FoxO3 stability and transcriptional
RT   activity.";
RL   Aging (Albany NY) 4:462-479(2012).
RN   [21]
RP   INTERACTION WITH IKBKB, AND SUBCELLULAR LOCATION.
RX   PubMed=22313691; DOI=10.1016/j.cellsig.2012.01.012;
RA   Tezil T., Bodur C., Kutuk O., Basaga H.;
RT   "IKK-beta mediates chemoresistance by sequestering FOXO3; a critical factor
RT   for cell survival and death.";
RL   Cell. Signal. 24:1361-1368(2012).
RN   [22]
RP   ACETYLATION, DEACETYLATION BY SIRT2, INTERACTION WITH SKP2, UBIQUITINATION
RP   BY SKP2, AND MUTAGENESIS OF LYS-242; LYS-259; LYS-290 AND LYS-569.
RX   PubMed=21841822; DOI=10.1038/onc.2011.347;
RA   Wang F., Chan C.H., Chen K., Guan X., Lin H.K., Tong Q.;
RT   "Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3
RT   ubiquitination and degradation.";
RL   Oncogene 31:1546-1557(2012).
RN   [23]
RP   INTERACTION WITH DDIT3, AND SUBCELLULAR LOCATION.
RX   PubMed=22761832; DOI=10.1371/journal.pone.0039586;
RA   Ghosh A.P., Klocke B.J., Ballestas M.E., Roth K.A.;
RT   "CHOP potentially co-operates with FOXO3a in neuronal cells to regulate
RT   PUMA and BIM expression in response to ER stress.";
RL   PLoS ONE 7:E39586-E39586(2012).
RN   [24]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH SIRT3 AND POLRMT, SUBCELLULAR
RP   LOCATION, AND ACETYLATION.
RX   PubMed=23283301; DOI=10.1007/s00018-012-1244-6;
RA   Peserico A., Chiacchiera F., Grossi V., Matrone A., Latorre D.,
RA   Simonatto M., Fusella A., Ryall J.G., Finley L.W., Haigis M.C., Villani G.,
RA   Puri P.L., Sartorelli V., Simone C.;
RT   "A novel AMPK-dependent FoxO3A-SIRT3 intramitochondrial complex sensing
RT   glucose levels.";
RL   Cell. Mol. Life Sci. 70:2015-2029(2013).
RN   [25]
RP   PHOSPHORYLATION AT SER-299, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23805378; DOI=10.7554/elife.00518;
RA   Tao L., Xie Q., Ding Y.H., Li S.T., Peng S., Zhang Y.P., Tan D., Yuan Z.,
RA   Dong M.Q.;
RT   "CAMKII and Calcineurin regulate the lifespan of Caenorhabditis elegans
RT   through the FOXO transcription factor DAF-16.";
RL   Elife 2:E00518-E00518(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280; SER-284; SER-299;
RP   SER-311; SER-413 AND SER-551, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   IDENTIFICATION IN A COMPLEX WITH SIRT3; TFAM AND POLRMT, SUBCELLULAR
RP   LOCATION, PROTEOLYTIC CLEAVAGE, PHOSPHORYLATION AT SER-30, NUCLEAR
RP   LOCALIZATION SIGNAL, AND MUTAGENESIS OF 2-ALA--SER-30; 2-ALA--ARG-148;
RP   SER-12; SER-30; 80-GLY--PRO-108 AND 241-LYS--LYS-271.
RX   PubMed=29445193; DOI=10.1038/s41419-018-0336-0;
RA   Celestini V., Tezil T., Russo L., Fasano C., Sanese P., Forte G.,
RA   Peserico A., Lepore Signorile M., Longo G., De Rasmo D., Signorile A.,
RA   Gadaleta R.M., Scialpi N., Terao M., Garattini E., Cocco T., Villani G.,
RA   Moschetta A., Grossi V., Simone C.;
RT   "Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells
RT   undergoing metabolic stress and chemotherapy.";
RL   Cell Death Dis. 9:231-231(2018).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 158-253 IN COMPLEX WITH DNA,
RP   MUTAGENESIS OF LYS-242 AND LYS-245, AND NUCLEAR LOCALIZATION SIGNAL.
RX   PubMed=17940099; DOI=10.1093/nar/gkm703;
RA   Tsai K.-L., Sun Y.-J., Huang C.-Y., Yang J.-Y., Hung M.-C., Hsiao C.-D.;
RT   "Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects
RT   of post-translational modification.";
RL   Nucleic Acids Res. 35:6984-6994(2007).
CC   -!- FUNCTION: Transcriptional activator that recognizes and binds to the
CC       DNA sequence 5'-[AG]TAAA[TC]A-3' and regulates different processes,
CC       such as apoptosis and autophagy (PubMed:10102273, PubMed:16751106,
CC       PubMed:21329882). Acts as a positive regulator of autophagy in skeletal
CC       muscle: in starved cells, enters the nucleus following
CC       dephosphorylation and binds the promoters of autophagy genes, such as
CC       GABARAP1L, MAP1LC3B and ATG12, thereby activating their expression,
CC       resulting in proteolysis of skeletal muscle proteins (By similarity).
CC       Triggers apoptosis in the absence of survival factors, including
CC       neuronal cell death upon oxidative stress (PubMed:10102273,
CC       PubMed:16751106). Participates in post-transcriptional regulation of
CC       MYC: following phosphorylation by MAPKAPK5, promotes induction of miR-
CC       34b and miR-34c expression, 2 post-transcriptional regulators of MYC
CC       that bind to the 3'UTR of MYC transcript and prevent its translation
CC       (PubMed:21329882). In response to metabolic stress, translocates into
CC       the mitochondria where it promotes mtDNA transcription
CC       (PubMed:23283301). {ECO:0000250|UniProtKB:Q9WVH4,
CC       ECO:0000269|PubMed:10102273, ECO:0000269|PubMed:16751106,
CC       ECO:0000269|PubMed:21329882, ECO:0000269|PubMed:23283301}.
CC   -!- SUBUNIT: Upon metabolic stress, forms a complex composed of FOXO3,
CC       SIRT3 and mitochondrial RNA polymerase POLRMT; the complex is recruited
CC       to mtDNA in a SIRT3-dependent manner (PubMed:23283301). Also forms a
CC       complex composed of FOXO3, SIRT3, TFAM and POLRMT (PubMed:29445193).
CC       Interacts with SIRT2; the interaction occurs independently of SIRT2
CC       deacetylase activity (By similarity). Interacts with YWHAB/14-3-3-beta
CC       and YWHAZ/14-3-3-zeta, which are required for cytosolic sequestration
CC       (PubMed:16751106). Upon oxidative stress, interacts with STK4/MST1,
CC       which disrupts interaction with YWHAB/14-3-3-beta and leads to nuclear
CC       translocation (PubMed:16751106). Interacts with PIM1 (PubMed:18593906).
CC       Interacts with DDIT3/CHOP (PubMed:22761832). Interacts (deacetylated
CC       form) with SKP2 (PubMed:21841822). Interacts with CHUK and IKBKB
CC       (PubMed:15084260, PubMed:22313691). Interacts with CAMK2A, CAMK2B and
CC       calcineurin A (By similarity). Interacts FOXO3; this interaction
CC       represses FOXO3 transactivation (PubMed:20181828).
CC       {ECO:0000250|UniProtKB:Q9WVH4, ECO:0000269|PubMed:15084260,
CC       ECO:0000269|PubMed:16751106, ECO:0000269|PubMed:18593906,
CC       ECO:0000269|PubMed:20181828, ECO:0000269|PubMed:21841822,
CC       ECO:0000269|PubMed:22313691, ECO:0000269|PubMed:22761832,
CC       ECO:0000269|PubMed:23283301, ECO:0000269|PubMed:29445193}.
CC   -!- INTERACTION:
CC       O43524; P31749: AKT1; NbExp=3; IntAct=EBI-1644164, EBI-296087;
CC       O43524; Q92974: ARHGEF2; NbExp=2; IntAct=EBI-1644164, EBI-302405;
CC       O43524; P30260: CDC27; NbExp=2; IntAct=EBI-1644164, EBI-994813;
CC       O43524; Q92793: CREBBP; NbExp=3; IntAct=EBI-1644164, EBI-81215;
CC       O43524; P03372: ESR1; NbExp=7; IntAct=EBI-1644164, EBI-78473;
CC       O43524; Q92731: ESR2; NbExp=4; IntAct=EBI-1644164, EBI-78505;
CC       O43524; Q60987: Foxg1; Xeno; NbExp=5; IntAct=EBI-1644164, EBI-11166131;
CC       O43524; P85037: FOXK1; NbExp=2; IntAct=EBI-1644164, EBI-2509974;
CC       O43524; Q08050: FOXM1; NbExp=2; IntAct=EBI-1644164, EBI-866480;
CC       O43524; P51610: HCFC1; NbExp=2; IntAct=EBI-1644164, EBI-396176;
CC       O43524; P01106: MYC; NbExp=3; IntAct=EBI-1644164, EBI-447544;
CC       O43524; P11309-1: PIM1; NbExp=2; IntAct=EBI-1644164, EBI-1018629;
CC       O43524; Q96T60: PNKP; NbExp=2; IntAct=EBI-1644164, EBI-1045072;
CC       O43524; P06400: RB1; NbExp=2; IntAct=EBI-1644164, EBI-491274;
CC       O43524; P28749: RBL1; NbExp=3; IntAct=EBI-1644164, EBI-971402;
CC       O43524; Q96EB6: SIRT1; NbExp=5; IntAct=EBI-1644164, EBI-1802965;
CC       O43524; P84022: SMAD3; NbExp=5; IntAct=EBI-1644164, EBI-347161;
CC       O43524; Q13485: SMAD4; NbExp=9; IntAct=EBI-1644164, EBI-347263;
CC       O43524; O75529: TAF5L; NbExp=2; IntAct=EBI-1644164, EBI-1785876;
CC       O43524; P04637: TP53; NbExp=2; IntAct=EBI-1644164, EBI-366083;
CC       O43524; P63104: YWHAZ; NbExp=3; IntAct=EBI-1644164, EBI-347088;
CC       O43524; P63101: Ywhaz; Xeno; NbExp=2; IntAct=EBI-1644164, EBI-354751;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:10102273,
CC       ECO:0000269|PubMed:15084260, ECO:0000269|PubMed:16751106,
CC       ECO:0000269|PubMed:17711846, ECO:0000269|PubMed:21329882,
CC       ECO:0000269|PubMed:22313691, ECO:0000269|PubMed:22761832,
CC       ECO:0000269|PubMed:23283301}. Nucleus {ECO:0000269|PubMed:10102273,
CC       ECO:0000269|PubMed:15084260, ECO:0000269|PubMed:16751106,
CC       ECO:0000269|PubMed:17711846, ECO:0000269|PubMed:21329882,
CC       ECO:0000269|PubMed:22313691, ECO:0000269|PubMed:22761832,
CC       ECO:0000269|PubMed:23283301, ECO:0000269|PubMed:29445193}.
CC       Mitochondrion matrix {ECO:0000269|PubMed:23283301,
CC       ECO:0000269|PubMed:29445193}. Mitochondrion outer membrane
CC       {ECO:0000269|PubMed:29445193}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:29445193}; Cytoplasmic side
CC       {ECO:0000269|PubMed:29445193}. Note=Retention in the cytoplasm
CC       contributes to its inactivation (PubMed:10102273, PubMed:15084260,
CC       PubMed:16751106). Translocates to the nucleus upon oxidative stress and
CC       in the absence of survival factors (PubMed:10102273, PubMed:16751106).
CC       Translocates from the cytosol to the nucleus following
CC       dephosphorylation in response to autophagy-inducing stimuli (By
CC       similarity). Translocates in a AMPK-dependent manner into the
CC       mitochondrion in response to metabolic stress (PubMed:23283301,
CC       PubMed:29445193). {ECO:0000250|UniProtKB:Q9WVH4,
CC       ECO:0000269|PubMed:10102273, ECO:0000269|PubMed:15084260,
CC       ECO:0000269|PubMed:16751106, ECO:0000269|PubMed:23283301,
CC       ECO:0000269|PubMed:29445193}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O43524-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43524-2; Sequence=VSP_056225;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:9479491}.
CC   -!- PTM: In the presence of survival factors such as IGF-1, phosphorylated
CC       on Thr-32 and Ser-253 by AKT1/PKB (PubMed:10102273). This
CC       phosphorylated form then interacts with 14-3-3 proteins and is retained
CC       in the cytoplasm (PubMed:10102273). Survival factor withdrawal induces
CC       dephosphorylation and promotes translocation to the nucleus where the
CC       dephosphorylated protein induces transcription of target genes and
CC       triggers apoptosis (PubMed:10102273). Although AKT1/PKB doesn't appear
CC       to phosphorylate Ser-315 directly, it may activate other kinases that
CC       trigger phosphorylation at this residue (PubMed:10102273,
CC       PubMed:11154281). Phosphorylated by STK4/MST1 on Ser-209 upon oxidative
CC       stress, which leads to dissociation from YWHAB/14-3-3-beta and nuclear
CC       translocation (PubMed:16751106). Phosphorylated by PIM1
CC       (PubMed:18593906). Phosphorylation by AMPK leads to the activation of
CC       transcriptional activity without affecting subcellular localization
CC       (PubMed:17711846). In response to metabolic stress, phosphorylated by
CC       AMPK on Ser-30 which mediates FOXO3 mitochondrial translocation
CC       (PubMed:29445193). Phosphorylation by MAPKAPK5 promotes nuclear
CC       localization and DNA-binding, leading to induction of miR-34b and miR-
CC       34c expression, 2 post-transcriptional regulators of MYC that bind to
CC       the 3'UTR of MYC transcript and prevent its translation
CC       (PubMed:21329882). Phosphorylated by CHUK/IKKA and IKBKB/IKKB
CC       (PubMed:15084260). TNF-induced inactivation of FOXO3 requires its
CC       phosphorylation at Ser-644 by IKBKB/IKKB which promotes FOXO3 retention
CC       in the cytoplasm, polyubiquitination and ubiquitin-mediated proteasomal
CC       degradation (PubMed:15084260). May be dephosphorylated by calcineurin A
CC       on Ser-299 which abolishes FOXO3 transcriptional activity (By
CC       similarity). In cancer cells, ERK mediated-phosphorylation of Ser-12 is
CC       required for mitochondrial translocation of FOXO3 in response to
CC       metabolic stress or chemotherapeutic agents (PubMed:29445193).
CC       {ECO:0000250|UniProtKB:Q9WVH4, ECO:0000269|PubMed:10102273,
CC       ECO:0000269|PubMed:11154281, ECO:0000269|PubMed:15084260,
CC       ECO:0000269|PubMed:16751106, ECO:0000269|PubMed:17711846,
CC       ECO:0000269|PubMed:18593906, ECO:0000269|PubMed:21329882,
CC       ECO:0000269|PubMed:29445193}.
CC   -!- PTM: Deacetylation by SIRT1 or SIRT2 stimulates interaction of FOXO3
CC       with SKP2 and facilitates SCF(SKP2)-mediated FOXO3 ubiquitination and
CC       proteasomal degradation (PubMed:21841822). Deacetylation by SIRT2
CC       stimulates FOXO3-mediated transcriptional activity in response to
CC       oxidative stress (By similarity). Deacetylated by SIRT3
CC       (PubMed:23283301). Deacetylation by SIRT3 stimulates FOXO3-mediated
CC       mtDNA transcriptional activity in response to metabolic stress
CC       (PubMed:23283301). {ECO:0000250|UniProtKB:Q9WVH4,
CC       ECO:0000269|PubMed:21841822, ECO:0000269|PubMed:23283301}.
CC   -!- PTM: Heavily methylated by SET9 which decreases stability, while
CC       moderately increasing transcriptional activity. The main methylation
CC       site is Lys-271. Methylation doesn't affect subcellular location.
CC       {ECO:0000269|PubMed:22820736}.
CC   -!- PTM: Polyubiquitinated. Ubiquitinated by a SCF complex containing SKP2,
CC       leading to proteasomal degradation. {ECO:0000269|PubMed:21841822}.
CC   -!- PTM: The N-terminus is cleaved following import into the mitochondrion.
CC       {ECO:0000269|PubMed:29445193}.
CC   -!- DISEASE: Note=A chromosomal aberration involving FOXO3 is found in
CC       secondary acute leukemias. Translocation t(6;11)(q21;q23) with
CC       KMT2A/MLL1.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AF6q21ID125.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF032886; AAC39592.1; -; mRNA.
DR   EMBL; AK301304; BAG62858.1; -; mRNA.
DR   EMBL; AL096818; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL391646; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL365509; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW48373.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48374.1; -; Genomic_DNA.
DR   EMBL; BC020227; AAH20227.1; -; mRNA.
DR   EMBL; BC021224; AAH21224.1; -; mRNA.
DR   EMBL; BC068552; AAH68552.1; -; mRNA.
DR   EMBL; AJ001589; CAA04860.1; -; mRNA.
DR   EMBL; AJ001590; CAA04861.1; -; Genomic_DNA.
DR   CCDS; CCDS5068.1; -. [O43524-1]
DR   RefSeq; NP_001446.1; NM_001455.3. [O43524-1]
DR   RefSeq; NP_963853.1; NM_201559.2. [O43524-1]
DR   RefSeq; XP_005266925.1; XM_005266868.3. [O43524-2]
DR   RefSeq; XP_011533930.1; XM_011535628.2. [O43524-2]
DR   RefSeq; XP_011533931.1; XM_011535629.2. [O43524-2]
DR   RefSeq; XP_016866075.1; XM_017010586.1. [O43524-2]
DR   PDB; 2K86; NMR; -; A=151-251.
DR   PDB; 2LQH; NMR; -; B=461-483.
DR   PDB; 2LQI; NMR; -; B=461-483.
DR   PDB; 2UZK; X-ray; 2.70 A; A/C=158-253.
DR   PDB; 6MNL; NMR; -; A=237-252.
DR   PDBsum; 2K86; -.
DR   PDBsum; 2LQH; -.
DR   PDBsum; 2LQI; -.
DR   PDBsum; 2UZK; -.
DR   PDBsum; 6MNL; -.
DR   SMR; O43524; -.
DR   BioGrid; 108598; 73.
DR   ComplexPortal; CPX-1123; FOXO3-MYC complex.
DR   ComplexPortal; CPX-1147; FOXO3-YWHAZ complex.
DR   CORUM; O43524; -.
DR   DIP; DIP-29723N; -.
DR   IntAct; O43524; 51.
DR   MINT; O43524; -.
DR   STRING; 9606.ENSP00000385824; -.
DR   BindingDB; O43524; -.
DR   ChEMBL; CHEMBL5778; -.
DR   GlyConnect; 1253; -.
DR   iPTMnet; O43524; -.
DR   PhosphoSitePlus; O43524; -.
DR   BioMuta; FOXO3; -.
DR   EPD; O43524; -.
DR   jPOST; O43524; -.
DR   MassIVE; O43524; -.
DR   MaxQB; O43524; -.
DR   PaxDb; O43524; -.
DR   PeptideAtlas; O43524; -.
DR   PRIDE; O43524; -.
DR   ProteomicsDB; 49029; -. [O43524-1]
DR   ProteomicsDB; 5304; -.
DR   Antibodypedia; 3419; 1110 antibodies.
DR   DNASU; 2309; -.
DR   Ensembl; ENST00000343882; ENSP00000339527; ENSG00000118689. [O43524-1]
DR   Ensembl; ENST00000406360; ENSP00000385824; ENSG00000118689. [O43524-1]
DR   Ensembl; ENST00000540898; ENSP00000446316; ENSG00000118689. [O43524-2]
DR   GeneID; 2309; -.
DR   KEGG; hsa:2309; -.
DR   UCSC; uc003psk.3; human. [O43524-1]
DR   CTD; 2309; -.
DR   DisGeNET; 2309; -.
DR   GeneCards; FOXO3; -.
DR   HGNC; HGNC:3821; FOXO3.
DR   HPA; ENSG00000118689; Low tissue specificity.
DR   MIM; 602681; gene.
DR   neXtProt; NX_O43524; -.
DR   OpenTargets; ENSG00000118689; -.
DR   PharmGKB; PA28239; -.
DR   eggNOG; KOG2294; Eukaryota.
DR   eggNOG; COG5025; LUCA.
DR   GeneTree; ENSGT00940000159826; -.
DR   HOGENOM; CLU_023456_1_0_1; -.
DR   InParanoid; O43524; -.
DR   KO; K09408; -.
DR   OMA; NSRRNIM; -.
DR   OrthoDB; 1160384at2759; -.
DR   PhylomeDB; O43524; -.
DR   TreeFam; TF315583; -.
DR   Reactome; R-HSA-1181150; Signaling by NODAL.
DR   Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-8862803; Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models.
DR   Reactome; R-HSA-8952158; RUNX3 regulates BCL2L11 (BIM) transcription.
DR   Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors.
DR   Reactome; R-HSA-9614657; FOXO-mediated transcription of cell death genes.
DR   Reactome; R-HSA-9615017; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes.
DR   Reactome; R-HSA-9617629; Regulation of FOXO transcriptional activity by acetylation.
DR   Reactome; R-HSA-9617828; FOXO-mediated transcription of cell cycle genes.
DR   Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling.
DR   SignaLink; O43524; -.
DR   SIGNOR; O43524; -.
DR   ChiTaRS; FOXO3; human.
DR   EvolutionaryTrace; O43524; -.
DR   GeneWiki; FOXO3; -.
DR   GenomeRNAi; 2309; -.
DR   Pharos; O43524; Tbio.
DR   PRO; PR:O43524; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; O43524; protein.
DR   Bgee; ENSG00000118689; Expressed in trabecular bone tissue and 235 other tissues.
DR   Genevisible; O43524; HS.
DR   GO; GO:0005623; C:cell; IEA:GOC.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:FlyBase.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0031490; F:chromatin DNA binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:MGI.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:BHF-UCL.
DR   GO; GO:0034246; F:mitochondrial sequence-specific DNA-binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001221; F:transcription cofactor binding; IEA:Ensembl.
DR   GO; GO:0008134; F:transcription factor binding; IBA:GO_Central.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0001547; P:antral ovarian follicle growth; IEA:Ensembl.
DR   GO; GO:0048854; P:brain morphogenesis; IEA:Ensembl.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; IEA:Ensembl.
DR   GO; GO:0071386; P:cellular response to corticosterone stimulus; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISS:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0042593; P:glucose homeostasis; IBA:GO_Central.
DR   GO; GO:0001544; P:initiation of primordial ovarian follicle growth; IEA:Ensembl.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0006390; P:mitochondrial transcription; IMP:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0001556; P:oocyte maturation; IEA:Ensembl.
DR   GO; GO:0001542; P:ovulation from ovarian follicle; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0010508; P:positive regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IDA:MGI.
DR   GO; GO:1901300; P:positive regulation of hydrogen peroxide-mediated programmed cell death; IEA:Ensembl.
DR   GO; GO:0014737; P:positive regulation of muscle atrophy; ISS:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IMP:UniProtKB.
DR   GO; GO:1903428; P:positive regulation of reactive oxygen species biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:2000177; P:regulation of neural precursor cell proliferation; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0006417; P:regulation of translation; IDA:UniProtKB.
DR   GO; GO:0071548; P:response to dexamethasone; IEA:Ensembl.
DR   GO; GO:0042594; P:response to starvation; ISS:UniProtKB.
DR   GO; GO:1990785; P:response to water-immersion restraint stress; IEA:Ensembl.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IMP:UniProtKB.
DR   CDD; cd00059; FH; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR032067; FOXO-TAD.
DR   InterPro; IPR032068; FOXO_KIX-bd.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF00250; Forkhead; 1.
DR   Pfam; PF16676; FOXO-TAD; 1.
DR   Pfam; PF16675; FOXO_KIX_bdg; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Apoptosis;
KW   Chromosomal rearrangement; Cytoplasm; DNA-binding; Membrane; Methylation;
KW   Mitochondrion; Mitochondrion outer membrane; Nucleus; Phosphoprotein;
KW   Proto-oncogene; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..673
FT                   /note="Forkhead box protein O3"
FT                   /id="PRO_0000091874"
FT   DNA_BIND        157..251
FT                   /note="Fork-head"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00089"
FT   REGION          80..108
FT                   /note="Required for mitochondrial import"
FT                   /evidence="ECO:0000269|PubMed:23283301"
FT   REGION          300..673
FT                   /note="Mediates interaction with CHUK/IKKA and IKBKB/IKKB"
FT                   /evidence="ECO:0000269|PubMed:15084260"
FT   MOTIF           242..259
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000269|PubMed:17940099,
FT                   ECO:0000269|PubMed:29445193"
FT   MOD_RES         30
FT                   /note="Phosphoserine; by AMPK"
FT                   /evidence="ECO:0000269|PubMed:29445193"
FT   MOD_RES         32
FT                   /note="Phosphothreonine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:10102273"
FT   MOD_RES         46
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:22820736"
FT   MOD_RES         149
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:22820736"
FT   MOD_RES         179
FT                   /note="Phosphothreonine; by AMPK"
FT                   /evidence="ECO:0000269|PubMed:17711846"
FT   MOD_RES         209
FT                   /note="Phosphoserine; by STK4/MST1"
FT                   /evidence="ECO:0000269|PubMed:16751106"
FT   MOD_RES         215
FT                   /note="Phosphoserine; by MAPKAPK5"
FT                   /evidence="ECO:0000269|PubMed:21329882"
FT   MOD_RES         230
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:22820736"
FT   MOD_RES         242
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WVH4"
FT   MOD_RES         253
FT                   /note="Phosphoserine; by PKB/AKT1 and MAPKAPK5"
FT                   /evidence="ECO:0000269|PubMed:10102273,
FT                   ECO:0000269|PubMed:21329882"
FT   MOD_RES         262
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:22820736"
FT   MOD_RES         271
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:22820736"
FT   MOD_RES         280
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:23186163"
FT   MOD_RES         284
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         290
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:22820736"
FT   MOD_RES         294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WVH4"
FT   MOD_RES         299
FT                   /note="Phosphoserine; by CaMK2A"
FT                   /evidence="ECO:0000244|PubMed:23186163,
FT                   ECO:0000269|PubMed:23805378"
FT   MOD_RES         311
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         315
FT                   /note="Phosphoserine; by SGK1"
FT                   /evidence="ECO:0000269|PubMed:10102273,
FT                   ECO:0000269|PubMed:11154281"
FT   MOD_RES         399
FT                   /note="Phosphoserine; by AMPK"
FT                   /evidence="ECO:0000269|PubMed:17711846"
FT   MOD_RES         413
FT                   /note="Phosphoserine; by AMPK"
FT                   /evidence="ECO:0000244|PubMed:23186163,
FT                   ECO:0000269|PubMed:17711846"
FT   MOD_RES         419
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:22820736"
FT   MOD_RES         421
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18220336"
FT   MOD_RES         551
FT                   /note="Phosphoserine; by MAPKAPK5"
FT                   /evidence="ECO:0000244|PubMed:23186163,
FT                   ECO:0000269|PubMed:21329882"
FT   MOD_RES         555
FT                   /note="Phosphoserine; by AMPK and MAPKAPK5"
FT                   /evidence="ECO:0000269|PubMed:17711846,
FT                   ECO:0000269|PubMed:21329882"
FT   MOD_RES         588
FT                   /note="Phosphoserine; by AMPK"
FT                   /evidence="ECO:0000269|PubMed:17711846"
FT   MOD_RES         626
FT                   /note="Phosphoserine; by AMPK"
FT                   /evidence="ECO:0000269|PubMed:17711846"
FT   MOD_RES         644
FT                   /note="Phosphoserine; by IKKB"
FT                   /evidence="ECO:0000269|PubMed:15084260"
FT   VAR_SEQ         1..220
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056225"
FT   MUTAGEN         2..148
FT                   /note="Missing: Loss of localization to the mitochondrion
FT                   outer membrane and loss of translocation into the
FT                   mitochondrion following metabolic stress."
FT                   /evidence="ECO:0000269|PubMed:29445193"
FT   MUTAGEN         2..30
FT                   /note="Missing: Loss of translocation into the
FT                   mitochondrion following metabolic stress."
FT                   /evidence="ECO:0000269|PubMed:29445193"
FT   MUTAGEN         12
FT                   /note="S->A: In normal cells, no defect in mitochondrion
FT                   import following metabolic stress. In cancer cells,
FT                   defective mitochondrion import following metabolic stress
FT                   and abolition of ERK-mediated phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:29445193"
FT   MUTAGEN         30
FT                   /note="S->A: Abolishes phosphorylation. Loss of
FT                   localization to the mitochondrion outer membrane and loss
FT                   of translocation into the mitochondrion following metabolic
FT                   stress."
FT                   /evidence="ECO:0000269|PubMed:29445193"
FT   MUTAGEN         32
FT                   /note="T->A: Abolishes YWHAZ-binding; when associated with
FT                   A-253. Exclusively nuclear, induces transcription and
FT                   promotes apoptosis; when associated with A-253 and A-315."
FT                   /evidence="ECO:0000269|PubMed:10102273"
FT   MUTAGEN         80..108
FT                   /note="Missing: Loss of translocation into the
FT                   mitochondrion following metabolic stress."
FT                   /evidence="ECO:0000269|PubMed:29445193"
FT   MUTAGEN         179
FT                   /note="T->A: Decreased phosphorylation by AMPK and impaired
FT                   ability to transactivate a reporter gene; when associated
FT                   with A-399; A-413; A-555; A-588 and A-626."
FT                   /evidence="ECO:0000269|PubMed:17711846"
FT   MUTAGEN         209
FT                   /note="S->A: Impairs nuclear translocation upon oxidative
FT                   stress."
FT                   /evidence="ECO:0000269|PubMed:16751106"
FT   MUTAGEN         242..271
FT                   /note="Missing: Loss of nuclear import."
FT                   /evidence="ECO:0000269|PubMed:29445193"
FT   MUTAGEN         242
FT                   /note="K->A: Slightly decreases DNA affinity."
FT                   /evidence="ECO:0000269|PubMed:17940099,
FT                   ECO:0000269|PubMed:21841822"
FT   MUTAGEN         242
FT                   /note="K->R: Reduces acetylation, increases interaction
FT                   with SKP2 and inhibits FOXO3 ubiquitination and
FT                   degradation; when associated with R-259; R-290 and R-569."
FT                   /evidence="ECO:0000269|PubMed:17940099,
FT                   ECO:0000269|PubMed:21841822"
FT   MUTAGEN         245
FT                   /note="K->A: Decreases DNA affinity."
FT                   /evidence="ECO:0000269|PubMed:17940099"
FT   MUTAGEN         253
FT                   /note="S->A: Abolishes YWHAZ-binding; when associated with
FT                   A-32. Exclusively nuclear, induces transcription and
FT                   promotes apoptosis; when associated with A-32 and A-315."
FT                   /evidence="ECO:0000269|PubMed:10102273"
FT   MUTAGEN         259
FT                   /note="K->R: Reduces acetylation, increases interaction
FT                   with SKP2 and inhibits FOXO3 ubiquitination and
FT                   degradation; when associated with R-242; R-290 and R-569."
FT                   /evidence="ECO:0000269|PubMed:21841822"
FT   MUTAGEN         269
FT                   /note="K->R: Methylation levels similar to wild-type; when
FT                   associated with ARG-270."
FT                   /evidence="ECO:0000269|PubMed:22820736"
FT   MUTAGEN         270
FT                   /note="K->R: Methylation levels similar to wild-type; when
FT                   associated with ARG-269."
FT                   /evidence="ECO:0000269|PubMed:22820736"
FT   MUTAGEN         271
FT                   /note="K->R: Methylation levels strongly reduced."
FT                   /evidence="ECO:0000269|PubMed:22820736"
FT   MUTAGEN         290
FT                   /note="K->R: Reduces acetylation, increases interaction
FT                   with SKP2 and inhibits FOXO3 ubiquitination and
FT                   degradation; when associated with R-242; R-259 and R-569."
FT                   /evidence="ECO:0000269|PubMed:21841822"
FT   MUTAGEN         315
FT                   /note="S->A: No effect on YWHAZ-binding. Promotes nuclear
FT                   translocation. Exclusively nuclear, induces transcription
FT                   and promotes apoptosis; when associated with A-32 and A-
FT                   253."
FT                   /evidence="ECO:0000269|PubMed:10102273"
FT   MUTAGEN         399
FT                   /note="S->A: Decreased phosphorylation by AMPK and impaired
FT                   ability to transactivate a reporter gene; when associated
FT                   with A-179; A-413; A-555; A-588 and A-626."
FT                   /evidence="ECO:0000269|PubMed:17711846"
FT   MUTAGEN         413
FT                   /note="S->A: Decreased phosphorylation by AMPK and impaired
FT                   ability to transactivate a reporter gene; when associated
FT                   with A-179; A-399; A-555; A-588 and A-626."
FT                   /evidence="ECO:0000269|PubMed:17711846"
FT   MUTAGEN         555
FT                   /note="S->A: Decreased phosphorylation by AMPK and impaired
FT                   ability to transactivate a reporter gene; when associated
FT                   with A-179; A-399; A-413; A-588 and A-626."
FT                   /evidence="ECO:0000269|PubMed:17711846"
FT   MUTAGEN         569
FT                   /note="K->R: Reduces acetylation, increases interaction
FT                   with SKP2 and inhibits FOXO3 ubiquitination and
FT                   degradation; when associated with R-242; R-259 and R-290."
FT                   /evidence="ECO:0000269|PubMed:21841822"
FT   MUTAGEN         588
FT                   /note="S->A: Decreased phosphorylation by AMPK and impaired
FT                   ability to transactivate a reporter gene; when associated
FT                   with A-179; A-399; A-413; A-555 and A-626."
FT                   /evidence="ECO:0000269|PubMed:17711846"
FT   MUTAGEN         626
FT                   /note="S->A: Decreased phosphorylation by AMPK and impaired
FT                   ability to transactivate a reporter gene; when associated
FT                   with A-179; A-399; A-413; A-555 and A-588."
FT                   /evidence="ECO:0000269|PubMed:17711846"
FT   MUTAGEN         644
FT                   /note="S->A: Loss of phosphorylation by IKKB."
FT                   /evidence="ECO:0000269|PubMed:15084260"
FT   CONFLICT        156..163
FT                   /note="AWGNLSYA -> WGKPVYS (in Ref. 6; CAA04860)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        238..246
FT                   /note="PDGGKSGKA -> LMGEERKT (in Ref. 6; CAA04860)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        253
FT                   /note="S -> T (in Ref. 6; CAA04860)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        271
FT                   /note="Missing (in Ref. 6; CAA04860)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        292..330
FT                   /note="PGSPTSRSSDELDAWTDFRSRTNSNASTVSGRLSPIMAS -> AWQPHVNAA
FT                   VMSWMRGRTSVHAPILTPAQSVAACRPSWQV (in Ref. 6; CAA04860)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        345..361
FT                   /note="PMLYSSSASLSPSVSKP -> AHALQHVSQPVTFSKQA (in Ref. 6;
FT                   CAA04860)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        367
FT                   /note="P -> R (in Ref. 6; CAA04860)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        371
FT                   /note="D -> E (in Ref. 6; CAA04860)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        382..383
FT                   /note="LT -> AD (in Ref. 6; CAA04860)"
FT                   /evidence="ECO:0000305"
FT   TURN            156..158
FT                   /evidence="ECO:0000244|PDB:2K86"
FT   HELIX           162..169
FT                   /evidence="ECO:0000244|PDB:2UZK"
FT   STRAND          172..176
FT                   /evidence="ECO:0000244|PDB:2UZK"
FT   HELIX           180..189
FT                   /evidence="ECO:0000244|PDB:2UZK"
FT   STRAND          198..200
FT                   /evidence="ECO:0000244|PDB:2UZK"
FT   HELIX           206..216
FT                   /evidence="ECO:0000244|PDB:2UZK"
FT   STRAND          217..229
FT                   /evidence="ECO:0000244|PDB:2UZK"
FT   STRAND          233..236
FT                   /evidence="ECO:0000244|PDB:2UZK"
FT   STRAND          238..240
FT                   /evidence="ECO:0000244|PDB:2K86"
FT   STRAND          463..465
FT                   /evidence="ECO:0000244|PDB:2LQH"
FT   HELIX           468..477
FT                   /evidence="ECO:0000244|PDB:2LQH"
FT   TURN            478..480
FT                   /evidence="ECO:0000244|PDB:2LQH"
SQ   SEQUENCE   673 AA;  71277 MW;  E5B4E830665A9982 CRC64;
     MAEAPASPAP LSPLEVELDP EFEPQSRPRS CTWPLQRPEL QASPAKPSGE TAADSMIPEE
     EDDEDDEDGG GRAGSAMAIG GGGGSGTLGS GLLLEDSARV LAPGGQDPGS GPATAAGGLS
     GGTQALLQPQ QPLPPPQPGA AGGSGQPRKC SSRRNAWGNL SYADLITRAI ESSPDKRLTL
     SQIYEWMVRC VPYFKDKGDS NSSAGWKNSI RHNLSLHSRF MRVQNEGTGK SSWWIINPDG
     GKSGKAPRRR AVSMDNSNKY TKSRGRAAKK KAALQTAPES ADDSPSQLSK WPGSPTSRSS
     DELDAWTDFR SRTNSNASTV SGRLSPIMAS TELDEVQDDD APLSPMLYSS SASLSPSVSK
     PCTVELPRLT DMAGTMNLND GLTENLMDDL LDNITLPPSQ PSPTGGLMQR SSSFPYTTKG
     SGLGSPTSSF NSTVFGPSSL NSLRQSPMQT IQENKPATFS SMSHYGNQTL QDLLTSDSLS
     HSDVMMTQSD PLMSQASTAV SAQNSRRNVM LRNDPMMSFA AQPNQGSLVN QNLLHHQHQT
     QGALGGSRAL SNSVSNMGLS ESSSLGSAKH QQQSPVSQSM QTLSDSLSGS SLYSTSANLP
     VMGHEKFPSD LDLDMFNGSL ECDMESIIRS ELMDADGLDF NFDSLISTQN VVGLNVGNFT
     GAKQASSQSW VPG
//
ID   FOXO4_HUMAN             Reviewed;         505 AA.
AC   P98177; B7WPJ7; O43821; Q13720; Q3KPF1; Q8TDK9;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   25-JUL-2006, sequence version 5.
DT   22-APR-2020, entry version 200.
DE   RecName: Full=Forkhead box protein O4;
DE   AltName: Full=Fork head domain transcription factor AFX1;
GN   Name=FOXO4; Synonyms=AFX, AFX1, MLLT7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=9341872; DOI=10.1007/s004390050553;
RA   Peters U., Haberhausen G., Kostrzewa M., Nolte D., Mueller U.;
RT   "AFX1 and p54nrb: fine mapping, genomic structure, and exclusion as
RT   candidate genes of X-linked dystonia parkinsonism.";
RL   Hum. Genet. 100:569-572(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9010221; DOI=10.1038/sj.onc.1200814;
RA   Borkhardt A., Repp R., Haas O.A., Leis T., Harbott J., Kreuder J.,
RA   Hammermann J., Henn T., Lampert F.;
RT   "Cloning and characterization of AFX, the gene that fuses to MLL in acute
RT   leukemias with a t(X;11)(q13;q23).";
RL   Oncogene 14:195-202(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ZETA).
RX   PubMed=11779849; DOI=10.1074/jbc.m106091200;
RA   Yang Z., Whelan J., Babb R., Bowen B.R.;
RT   "An mRNA splice variant of the AFX gene with altered transcriptional
RT   activity.";
RL   J. Biol. Chem. 277:8068-8075(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CHROMOSOMAL TRANSLOCATION.
RC   TISSUE=Bone marrow;
RX   PubMed=7529552; DOI=10.1002/gcc.2870110203;
RA   Parry P., Wei Y., Evans G.;
RT   "Cloning and characterization of the t(X;11) breakpoint from a leukemic
RT   cell line identify a new member of the forkhead gene family.";
RL   Genes Chromosomes Cancer 11:79-84(1994).
RN   [8]
RP   FUNCTION, PHOSPHORYLATION AT SER-197 AND SER-262, AND MUTAGENESIS OF
RP   SER-197 AND SER-262.
RX   PubMed=10217147; DOI=10.1038/19328;
RA   Kops G.J.P.L., de Ruiter N.D., De Vries-Smits A.M.M., Powell D.R.,
RA   Bos J.L., Burgering B.M.T.;
RT   "Direct control of the forkhead transcription factor AFX by protein kinase
RT   B.";
RL   Nature 398:630-634(1999).
RN   [9]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-197 AND SER-262, AND
RP   MUTAGENESIS OF THR-32; SER-197 AND SER-262.
RX   PubMed=10518537; DOI=10.1073/pnas.96.21.11836;
RA   Takaishi H., Konishi H., Matsuzaki H., Ono Y., Shirai Y., Saito N.,
RA   Kitamura T., Ogawa W., Kasuga M., Kikkawa U., Nishizuka Y.;
RT   "Regulation of nuclear translocation of forkhead transcription factor AFX
RT   by protein kinase B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:11836-11841(1999).
RN   [10]
RP   FUNCTION.
RX   PubMed=10783894; DOI=10.1038/35008115;
RA   Medema R.H., Kops G.J.P.L., Bos J.L., Burgering B.M.T.;
RT   "AFX-like forkhead transcription factors mediate cell-cycle regulation by
RT   Ras and PKB through p27kip1.";
RL   Nature 404:782-787(2000).
RN   [11]
RP   FUNCTION.
RX   PubMed=12761217; DOI=10.1074/jbc.m302042200;
RA   Tang T.T.-L., Lasky L.A.;
RT   "The forkhead transcription factor FOXO4 induces the down-regulation of
RT   hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent
RT   mechanism.";
RL   J. Biol. Chem. 278:30125-30135(2003).
RN   [12]
RP   FUNCTION, INTERACTION WITH CREBBP AND SIRT1, AND ACETYLATION.
RX   PubMed=15126506; DOI=10.1074/jbc.m401138200;
RA   van der Horst A., Tertoolen L.G.J., de Vries-Smits L.M.M., Frye R.A.,
RA   Medema R.H., Burgering B.M.T.;
RT   "FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity
RT   protein hSir2(SIRT1).";
RL   J. Biol. Chem. 279:28873-28879(2004).
RN   [13]
RP   INTERACTION WITH YWHAZ, AND SUBCELLULAR LOCATION.
RX   PubMed=16114898; DOI=10.1021/bi050618r;
RA   Obsilova V., Vecer J., Herman P., Pabianova A., Sulc M., Teisinger J.,
RA   Boura E., Obsil T.;
RT   "14-3-3 protein interacts with nuclear localization sequence of forkhead
RT   transcription factor FoxO4.";
RL   Biochemistry 44:11608-11617(2005).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH MYOCD AND SRF.
RX   PubMed=16054032; DOI=10.1016/j.devcel.2005.05.017;
RA   Liu Z.-P., Wang Z., Yanagisawa H., Olson E.N.;
RT   "Phenotypic modulation of smooth muscle cells through interaction of Foxo4
RT   and myocardin.";
RL   Dev. Cell 9:261-270(2005).
RN   [15]
RP   PHOSPHORYLATION AT THR-32; SER-197 AND SER-262, AND MUTAGENESIS OF THR-32;
RP   SER-197 AND SER-262.
RX   PubMed=16272144; DOI=10.1093/jb/mvi146;
RA   Matsuzaki H., Ichino A., Hayashi T., Yamamoto T., Kikkawa U.;
RT   "Regulation of intracellular localization and transcriptional activity of
RT   FOXO4 by protein kinase B through phosphorylation at the motif sites
RT   conserved among the FOXO family.";
RL   J. Biochem. 138:485-491(2005).
RN   [16]
RP   PHARMACEUTICAL USE.
RX   PubMed=15688030; DOI=10.1038/sj.onc.1208352;
RA   Yang H., Zhao R., Yang H.-Y., Lee M.-H.;
RT   "Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1
RT   stability, and suppresses HER2-mediated tumorigenicity.";
RL   Oncogene 24:1924-1935(2005).
RN   [17]
RP   FUNCTION, INTERACTION WITH USP7, UBIQUITINATION, DEUBIQUITINATION BY USP7,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=16964248; DOI=10.1038/ncb1469;
RA   van der Horst A., de Vries-Smits A.M., Brenkman A.B., van Triest M.H.,
RA   van den Broek N., Colland F., Maurice M.M., Burgering B.M.;
RT   "FOXO4 transcriptional activity is regulated by monoubiquitination and
RT   USP7/HAUSP.";
RL   Nat. Cell Biol. 8:1064-1073(2006).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH NLK; CTNNB1 AND CREBBP.
RX   PubMed=20874444; DOI=10.1089/ars.2010.3243;
RA   Szypowska A.A., de Ruiter H., Meijer L.A.T., Smits L.M.M.,
RA   Burgering B.M.T.;
RT   "Oxidative stress-dependent regulation of Forkhead box O4 activity by nemo-
RT   like kinase.";
RL   Antioxid. Redox Signal. 14:563-578(2011).
RN   [19]
RP   FUNCTION, AND MUTAGENESIS OF THR-32; SER-197 AND SER-262.
RX   PubMed=22972301; DOI=10.1038/nature11468;
RA   Vilchez D., Boyer L., Morantte I., Lutz M., Merkwirth C., Joyce D.,
RA   Spencer B., Page L., Masliah E., Berggren W.T., Gage F.H., Dillin A.;
RT   "Increased proteasome activity in human embryonic stem cells is regulated
RT   by PSMD11.";
RL   Nature 489:304-308(2012).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   STRUCTURE BY NMR OF 86-211.
RX   PubMed=10921784; DOI=10.1023/a:1008358816478;
RA   Weigelt J., Climent I., Dahlman-Wright K., Wikstrom M.;
RT   "1H, 13C and 15N resonance assignments of the DNA binding domain of the
RT   human forkhead transcription factor AFX.";
RL   J. Biomol. NMR 17:181-182(2000).
RN   [22]
RP   STRUCTURE BY NMR OF 86-211.
RX   PubMed=11352721; DOI=10.1021/bi001663w;
RA   Weigelt J., Climent I., Dahlman-Wright K., Wikstrom M.;
RT   "Solution structure of the DNA binding domain of the human forkhead
RT   transcription factor AFX (FOXO4).";
RL   Biochemistry 40:5861-5869(2001).
CC   -!- FUNCTION: Transcription factor involved in the regulation of the
CC       insulin signaling pathway. Binds to insulin-response elements (IREs)
CC       and can activate transcription of IGFBP1. Down-regulates expression of
CC       HIF1A and suppresses hypoxia-induced transcriptional activation of
CC       HIF1A-modulated genes. Also involved in negative regulation of the cell
CC       cycle. Involved in increased proteasome activity in embryonic stem
CC       cells (ESCs) by activating expression of PSMD11 in ESCs, leading to
CC       enhanced assembly of the 26S proteasome, followed by higher proteasome
CC       activity. {ECO:0000269|PubMed:10217147, ECO:0000269|PubMed:10783894,
CC       ECO:0000269|PubMed:12761217, ECO:0000269|PubMed:15126506,
CC       ECO:0000269|PubMed:16054032, ECO:0000269|PubMed:16964248,
CC       ECO:0000269|PubMed:20874444, ECO:0000269|PubMed:22972301}.
CC   -!- SUBUNIT: Interacts with CREBBP/CBP, CTNNB1, MYOCD, SIRT1, SRF and
CC       YWHAZ. Acetylated by CREBBP/CBP and deacetylated by SIRT1. Binding of
CC       YWHAZ inhibits DNA-binding. Interacts with USP7; the interaction is
CC       enhanced in presence of hydrogen peroxide and occurs independently of
CC       TP53. Interacts with NLK, and this inhibits monoubiquitination and
CC       transcriptional activity. Interacts with FOXK1; the interaction
CC       inhibits MEF2C transactivation activity (By similarity).
CC       {ECO:0000250|UniProtKB:Q9WVH3, ECO:0000269|PubMed:15126506,
CC       ECO:0000269|PubMed:16054032, ECO:0000269|PubMed:16114898,
CC       ECO:0000269|PubMed:16964248, ECO:0000269|PubMed:20874444}.
CC   -!- INTERACTION:
CC       P98177; P98177; NbExp=2; IntAct=EBI-4481939, EBI-4481939;
CC       P98177; Q04864: REL; NbExp=3; IntAct=EBI-4481939, EBI-307352;
CC       P98177; P31947: SFN; NbExp=3; IntAct=EBI-4481939, EBI-476295;
CC       P98177; Q96EB6: SIRT1; NbExp=3; IntAct=EBI-4481939, EBI-1802965;
CC       P98177; Q13485: SMAD4; NbExp=2; IntAct=EBI-4481939, EBI-347263;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=When phosphorylated,
CC       translocated from nucleus to cytoplasm. Dephosphorylation triggers
CC       nuclear translocation. Monoubiquitination increases nuclear
CC       localization. When deubiquitinated, translocated from nucleus to
CC       cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=FOXO4a;
CC         IsoId=P98177-1; Sequence=Displayed;
CC       Name=Zeta; Synonyms=AFXzeta, FOXO4b;
CC         IsoId=P98177-2; Sequence=VSP_001552;
CC   -!- TISSUE SPECIFICITY: Heart, brain, placenta, lung, liver, skeletal
CC       muscle, kidney and pancreas. Isoform zeta is most abundant in the
CC       liver, kidney, and pancreas.
CC   -!- PTM: Acetylation by CREBBP/CBP, which is induced by peroxidase stress,
CC       inhibits transcriptional activity. Deacetylation by SIRT1 is NAD-
CC       dependent and stimulates transcriptional activity.
CC       {ECO:0000269|PubMed:15126506}.
CC   -!- PTM: Phosphorylation by PKB/AKT1 inhibits transcriptional activity and
CC       is responsible for cytoplasmic localization. May be phosphorylated at
CC       multiple sites by NLK. {ECO:0000269|PubMed:10217147,
CC       ECO:0000269|PubMed:10518537, ECO:0000269|PubMed:16272144}.
CC   -!- PTM: Monoubiquitinated; monoubiquitination is induced by oxidative
CC       stress and reduced by deacetylase inhibitors; results in its
CC       relocalization to the nucleus and its increased transcriptional
CC       activity. Deubiquitinated by USP7; deubiquitination is induced by
CC       oxidative stress; enhances its interaction with USP7 and consequently,
CC       deubiquitination; increases its translocation to the cytoplasm and
CC       inhibits its transcriptional activity. Hydrogene-peroxide-induced
CC       ubiquitination and USP7-mediated deubiquitination have no major effect
CC       on its protein stability. {ECO:0000269|PubMed:16964248}.
CC   -!- DISEASE: Note=A chromosomal aberration involving FOXO4 is found in
CC       acute leukemias. Translocation t(X;11)(q13;q23) with KMT2A/MLL1. The
CC       result is a rogue activator protein.
CC   -!- PHARMACEUTICAL: A constitutively active FOXO4 mutant where
CC       phosphorylation sites Thr-32, Ser-197 and Ser-262 have been mutated to
CC       alanine may have therapeutic potential in ERBB2/HER2-overexpressing
CC       cancers as it inhibits ERBB2-mediated cell survival, transformation and
CC       tumorigenicity.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AFX1ID57.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y11284; CAA72156.1; -; Genomic_DNA.
DR   EMBL; Y11285; CAA72156.1; JOINED; Genomic_DNA.
DR   EMBL; Y11286; CAA72156.1; JOINED; Genomic_DNA.
DR   EMBL; X93996; CAA63819.1; -; mRNA.
DR   EMBL; AF384029; AAL85197.1; -; mRNA.
DR   EMBL; AL590764; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471132; EAX05321.1; -; Genomic_DNA.
DR   EMBL; BC106761; AAI06762.1; -; mRNA.
DR   EMBL; U10072; AAA82171.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS43969.1; -. [P98177-1]
DR   CCDS; CCDS55440.1; -. [P98177-2]
DR   PIR; I38654; I38654.
DR   RefSeq; NP_001164402.1; NM_001170931.1. [P98177-2]
DR   RefSeq; NP_005929.2; NM_005938.3. [P98177-1]
DR   PDB; 1E17; NMR; -; A=86-211.
DR   PDB; 3L2C; X-ray; 1.87 A; A=86-187.
DR   PDBsum; 1E17; -.
DR   PDBsum; 3L2C; -.
DR   SMR; P98177; -.
DR   BioGrid; 110449; 20.
DR   CORUM; P98177; -.
DR   IntAct; P98177; 16.
DR   MINT; P98177; -.
DR   STRING; 9606.ENSP00000363377; -.
DR   iPTMnet; P98177; -.
DR   PhosphoSitePlus; P98177; -.
DR   BioMuta; FOXO4; -.
DR   DMDM; 110825720; -.
DR   EPD; P98177; -.
DR   jPOST; P98177; -.
DR   MassIVE; P98177; -.
DR   MaxQB; P98177; -.
DR   PaxDb; P98177; -.
DR   PeptideAtlas; P98177; -.
DR   PRIDE; P98177; -.
DR   ProteomicsDB; 57814; -. [P98177-1]
DR   ProteomicsDB; 57815; -. [P98177-2]
DR   Antibodypedia; 6096; 946 antibodies.
DR   Ensembl; ENST00000341558; ENSP00000342209; ENSG00000184481. [P98177-2]
DR   Ensembl; ENST00000374259; ENSP00000363377; ENSG00000184481. [P98177-1]
DR   GeneID; 4303; -.
DR   KEGG; hsa:4303; -.
DR   UCSC; uc004dys.3; human. [P98177-1]
DR   CTD; 4303; -.
DR   DisGeNET; 4303; -.
DR   GeneCards; FOXO4; -.
DR   HGNC; HGNC:7139; FOXO4.
DR   HPA; ENSG00000184481; Tissue enhanced (placenta).
DR   MIM; 300033; gene.
DR   neXtProt; NX_P98177; -.
DR   OpenTargets; ENSG00000184481; -.
DR   PharmGKB; PA162388882; -.
DR   eggNOG; KOG2294; Eukaryota.
DR   eggNOG; COG5025; LUCA.
DR   GeneTree; ENSGT00940000159334; -.
DR   HOGENOM; CLU_023456_1_1_1; -.
DR   InParanoid; P98177; -.
DR   KO; K12358; -.
DR   OMA; MMTQVDP; -.
DR   OrthoDB; 1160384at2759; -.
DR   PhylomeDB; P98177; -.
DR   TreeFam; TF315583; -.
DR   Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors.
DR   Reactome; R-HSA-9614657; FOXO-mediated transcription of cell death genes.
DR   Reactome; R-HSA-9615017; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes.
DR   Reactome; R-HSA-9617629; Regulation of FOXO transcriptional activity by acetylation.
DR   Reactome; R-HSA-9617828; FOXO-mediated transcription of cell cycle genes.
DR   SignaLink; P98177; -.
DR   SIGNOR; P98177; -.
DR   ChiTaRS; FOXO4; human.
DR   EvolutionaryTrace; P98177; -.
DR   GeneWiki; FOXO4; -.
DR   GenomeRNAi; 4303; -.
DR   Pharos; P98177; Tbio.
DR   PRO; PR:P98177; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P98177; protein.
DR   Bgee; ENSG00000184481; Expressed in placenta and 229 other tissues.
DR   Genevisible; P98177; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IEA:Ensembl.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; IBA:GO_Central.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007095; P:mitotic G2 DNA damage checkpoint; IEA:Ensembl.
DR   GO; GO:0007517; P:muscle organ development; IEA:UniProtKB-KW.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0070317; P:negative regulation of G0 to G1 transition; IDA:UniProtKB.
DR   GO; GO:0051151; P:negative regulation of smooth muscle cell differentiation; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:1990785; P:response to water-immersion restraint stress; IEA:Ensembl.
DR   GO; GO:0048863; P:stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:ProtInc.
DR   CDD; cd00059; FH; 1.
DR   DisProt; DP01788; -.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR032067; FOXO-TAD.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF00250; Forkhead; 1.
DR   Pfam; PF16676; FOXO-TAD; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Cell cycle;
KW   Chromosomal rearrangement; Cytoplasm; Developmental protein;
KW   Differentiation; DNA-binding; Myogenesis; Nucleus; Pharmaceutical;
KW   Phosphoprotein; Proto-oncogene; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..505
FT                   /note="Forkhead box protein O4"
FT                   /id="PRO_0000091875"
FT   DNA_BIND        100..188
FT                   /note="Fork-head"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00089"
FT   MOD_RES         32
FT                   /note="Phosphothreonine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:16272144"
FT   MOD_RES         197
FT                   /note="Phosphoserine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:10217147,
FT                   ECO:0000269|PubMed:10518537, ECO:0000269|PubMed:16272144"
FT   MOD_RES         262
FT                   /note="Phosphoserine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:10217147,
FT                   ECO:0000269|PubMed:10518537, ECO:0000269|PubMed:16272144"
FT   VAR_SEQ         58..112
FT                   /note="Missing (in isoform Zeta)"
FT                   /evidence="ECO:0000303|PubMed:11779849"
FT                   /id="VSP_001552"
FT   MUTAGEN         32
FT                   /note="T->A: Abolishes phosphorylation. Protein is located
FT                   mainly in nucleus and shows increased transcriptional
FT                   activity. Increased transcriptional and proteasome
FT                   activities in embryonic stem cells; when associated with A-
FT                   197 and A-262."
FT                   /evidence="ECO:0000269|PubMed:10518537,
FT                   ECO:0000269|PubMed:16272144, ECO:0000269|PubMed:22972301"
FT   MUTAGEN         197
FT                   /note="S->A: Abolishes phosphorylation. Protein is located
FT                   mainly in nucleus and shows increased transcriptional
FT                   activity. Increased transcriptional and proteasome
FT                   activities in embryonic stem cells; when associated with A-
FT                   32 and A-262."
FT                   /evidence="ECO:0000269|PubMed:10217147,
FT                   ECO:0000269|PubMed:10518537, ECO:0000269|PubMed:16272144,
FT                   ECO:0000269|PubMed:22972301"
FT   MUTAGEN         262
FT                   /note="S->A: Abolishes phosphorylation. No effect on
FT                   cellular location or transcriptional activity. Increased
FT                   transcriptional and proteasome activities in embryonic stem
FT                   cells; when associated with A-32 and A-197."
FT                   /evidence="ECO:0000269|PubMed:10217147,
FT                   ECO:0000269|PubMed:10518537, ECO:0000269|PubMed:16272144,
FT                   ECO:0000269|PubMed:22972301"
FT   CONFLICT        1..11
FT                   /note="MDPGNENSATE -> MRIQPQK (in Ref. 2; CAA63819)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        25..34
FT                   /note="QSRPRSCTWP -> RAVPLLHLA (in Ref. 1; CAA72156)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        74
FT                   /note="P -> S (in Ref. 2; CAA63819)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        79
FT                   /note="G -> A (in Ref. 1; CAA72156)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        109
FT                   /note="L -> F (in Ref. 2; CAA63819)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        422
FT                   /note="P -> R (in Ref. 2; CAA63819 and 3; AAL85197)"
FT                   /evidence="ECO:0000305"
FT   HELIX           106..116
FT                   /evidence="ECO:0000244|PDB:3L2C"
FT   STRAND          117..119
FT                   /evidence="ECO:0000244|PDB:1E17"
FT   HELIX           124..134
FT                   /evidence="ECO:0000244|PDB:3L2C"
FT   HELIX           136..138
FT                   /evidence="ECO:0000244|PDB:3L2C"
FT   HELIX           139..142
FT                   /evidence="ECO:0000244|PDB:1E17"
FT   HELIX           149..160
FT                   /evidence="ECO:0000244|PDB:3L2C"
FT   STRAND          164..167
FT                   /evidence="ECO:0000244|PDB:3L2C"
FT   TURN            170..172
FT                   /evidence="ECO:0000244|PDB:1E17"
FT   STRAND          173..175
FT                   /evidence="ECO:0000244|PDB:1E17"
FT   STRAND          177..180
FT                   /evidence="ECO:0000244|PDB:3L2C"
SQ   SEQUENCE   505 AA;  53684 MW;  0C71C8E2167CEE68 CRC64;
     MDPGNENSAT EAAAIIDLDP DFEPQSRPRS CTWPLPRPEI ANQPSEPPEV EPDLGEKVHT
     EGRSEPILLP SRLPEPAGGP QPGILGAVTG PRKGGSRRNA WGNQSYAELI SQAIESAPEK
     RLTLAQIYEW MVRTVPYFKD KGDSNSSAGW KNSIRHNLSL HSKFIKVHNE ATGKSSWWML
     NPEGGKSGKA PRRRAASMDS SSKLLRGRSK APKKKPSVLP APPEGATPTS PVGHFAKWSG
     SPCSRNREEA DMWTTFRPRS SSNASSVSTR LSPLRPESEV LAEEIPASVS SYAGGVPPTL
     NEGLELLDGL NLTSSHSLLS RSGLSGFSLQ HPGVTGPLHT YSSSLFSPAE GPLSAGEGCF
     SSSQALEALL TSDTPPPPAD VLMTQVDPIL SQAPTLLLLG GLPSSSKLAT GVGLCPKPLE
     APGPSSLVPT LSMIAPPPVM ASAPIPKALG TPVLTPPTEA ASQDRMPQDL DLDMYMENLE
     CDMDNIISDL MDEGEGLDFN FEPDP
//
ID   HXA11_HUMAN             Reviewed;         313 AA.
AC   P31270; A4D190;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   21-FEB-2001, sequence version 2.
DT   22-APR-2020, entry version 184.
DE   RecName: Full=Homeobox protein Hox-A11;
DE   AltName: Full=Homeobox protein Hox-1I;
GN   Name=HOXA11; Synonyms=HOX1I;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9745033; DOI=10.1007/s003359900870;
RA   Potter S.S., Branford W.W.;
RT   "Evolutionary conservation and tissue-specific processing of hoxa 11
RT   antisense transcripts.";
RL   Mamm. Genome 9:799-806(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Mi X., Winters J.L., Stevens D.B., Fleischman R.A.;
RL   Submitted (DEC-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE OF 241-306.
RX   PubMed=2574852; DOI=10.1093/nar/17.24.10385;
RA   Acampora D., D'Esposito M., Faiella A., Pannese M., Migliaccio E.,
RA   Morelli F., Stornaiuolo A., Nigro V., Simeone A., Boncinelli E.;
RT   "The human HOX gene family.";
RL   Nucleic Acids Res. 17:10385-10402(1989).
RN   [8]
RP   INVOLVEMENT IN RUSAT1.
RX   PubMed=11101832; DOI=10.1038/82511;
RA   Thompson A.A., Nguyen L.T.;
RT   "Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated
RT   with HOXA11 mutation.";
RL   Nat. Genet. 26:397-398(2000).
CC   -!- FUNCTION: Sequence-specific transcription factor which is part of a
CC       developmental regulatory system that provides cells with specific
CC       positional identities on the anterior-posterior axis.
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- DISEASE: Radioulnar synostosis with amegakaryocytic thrombocytopenia 1
CC       (RUSAT1) [MIM:605432]: The syndrome consists of an unusual association
CC       of bone marrow failure and skeletal defects. Patients have the same
CC       skeletal defects, the proximal fusion of the radius and ulna, resulting
CC       in extremely limited pronation and supination of the forearm. Some
CC       patients have also symptomatic thrombocytopenia, with bruising and
CC       bleeding problems since birth, necessitating correction by bone marrow
CC       or umbilical-cord stem-cell transplantation.
CC       {ECO:0000269|PubMed:11101832}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the Abd-B homeobox family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HOXA11ID40847ch7p15.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF071164; AAC80455.1; -; Genomic_DNA.
DR   EMBL; AF039307; AAB94761.1; -; Genomic_DNA.
DR   EMBL; AC004080; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236948; EAL24220.1; -; Genomic_DNA.
DR   EMBL; CH471073; EAW93888.1; -; Genomic_DNA.
DR   EMBL; BC040948; AAH40948.1; -; mRNA.
DR   CCDS; CCDS5411.1; -.
DR   PIR; S14931; S14931.
DR   RefSeq; NP_005514.1; NM_005523.5.
DR   SMR; P31270; -.
DR   BioGrid; 109447; 5.
DR   IntAct; P31270; 1.
DR   STRING; 9606.ENSP00000006015; -.
DR   iPTMnet; P31270; -.
DR   PhosphoSitePlus; P31270; -.
DR   BioMuta; HOXA11; -.
DR   DMDM; 13124744; -.
DR   jPOST; P31270; -.
DR   MassIVE; P31270; -.
DR   MaxQB; P31270; -.
DR   PaxDb; P31270; -.
DR   PeptideAtlas; P31270; -.
DR   PRIDE; P31270; -.
DR   ProteomicsDB; 54771; -.
DR   Antibodypedia; 12408; 350 antibodies.
DR   DNASU; 3207; -.
DR   Ensembl; ENST00000006015; ENSP00000006015; ENSG00000005073.
DR   GeneID; 3207; -.
DR   KEGG; hsa:3207; -.
DR   UCSC; uc003syx.4; human.
DR   CTD; 3207; -.
DR   DisGeNET; 3207; -.
DR   GeneCards; HOXA11; -.
DR   HGNC; HGNC:5101; HOXA11.
DR   HPA; ENSG00000005073; Tissue enhanced (cervix, uterine, endometrium, smooth muscle).
DR   MalaCards; HOXA11; -.
DR   MIM; 142958; gene.
DR   MIM; 605432; phenotype.
DR   neXtProt; NX_P31270; -.
DR   OpenTargets; ENSG00000005073; -.
DR   Orphanet; 71289; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome.
DR   PharmGKB; PA29378; -.
DR   eggNOG; KOG0487; Eukaryota.
DR   eggNOG; ENOG4111FJP; LUCA.
DR   GeneTree; ENSGT00940000158311; -.
DR   HOGENOM; CLU_079662_0_0_1; -.
DR   InParanoid; P31270; -.
DR   KO; K21951; -.
DR   OMA; YETAYGN; -.
DR   OrthoDB; 976319at2759; -.
DR   PhylomeDB; P31270; -.
DR   TreeFam; TF350668; -.
DR   SignaLink; P31270; -.
DR   SIGNOR; P31270; -.
DR   GeneWiki; HOXA11; -.
DR   GenomeRNAi; 3207; -.
DR   Pharos; P31270; Tbio.
DR   PRO; PR:P31270; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P31270; protein.
DR   Bgee; ENSG00000005073; Expressed in myometrium and 67 other tissues.
DR   ExpressionAtlas; P31270; baseline and differential.
DR   Genevisible; P31270; HS.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0032991; C:protein-containing complex; ISS:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; ISS:UniProtKB.
DR   GO; GO:0005667; C:transcription factor complex; ISS:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISM:NTNU_SB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060351; P:cartilage development involved in endochondral bone morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048589; P:developmental growth; ISS:UniProtKB.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; ISS:UniProtKB.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060272; P:embryonic skeletal joint morphogenesis; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0007501; P:mesodermal cell fate specification; ISS:UniProtKB.
DR   GO; GO:0001656; P:metanephros development; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; ISS:UniProtKB.
DR   GO; GO:0001759; P:organ induction; IEA:Ensembl.
DR   GO; GO:0010720; P:positive regulation of cell development; ISS:UniProtKB.
DR   GO; GO:0032332; P:positive regulation of chondrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IEA:Ensembl.
DR   GO; GO:0007338; P:single fertilization; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; ISS:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   CDD; cd00086; homeodomain; 1.
DR   InterPro; IPR021918; DUF3528.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR017970; Homeobox_CS.
DR   InterPro; IPR001356; Homeobox_dom.
DR   InterPro; IPR020479; Homeobox_metazoa.
DR   Pfam; PF12045; DUF3528; 1.
DR   Pfam; PF00046; Homeodomain; 1.
DR   PRINTS; PR00024; HOMEOBOX.
DR   SMART; SM00389; HOX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00027; HOMEOBOX_1; 1.
DR   PROSITE; PS50071; HOMEOBOX_2; 1.
PE   2: Evidence at transcript level;
KW   Developmental protein; DNA-binding; Homeobox; Nucleus; Reference proteome;
KW   Transcription; Transcription regulation.
FT   CHAIN           1..313
FT                   /note="Homeobox protein Hox-A11"
FT                   /id="PRO_0000200095"
FT   DNA_BIND        241..300
FT                   /note="Homeobox"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00108"
FT   COMPBIAS        177..183
FT                   /note="Poly-Ala"
FT   COMPBIAS        195..199
FT                   /note="Poly-Gly"
FT   COMPBIAS        204..207
FT                   /note="Poly-Ala"
FT   COMPBIAS        212..215
FT                   /note="Poly-Arg"
FT   COMPBIAS        218..221
FT                   /note="Poly-Ser"
SQ   SEQUENCE   313 AA;  34486 MW;  B345B987816AB9FB CRC64;
     MDFDERGPCS SNMYLPSCTY YVSGPDFSSL PSFLPQTPSS RPMTYSYSSN LPQVQPVREV
     TFREYAIEPA TKWHPRGNLA HCYSAEELVH RDCLQAPSAA GVPGDVLAKS SANVYHHPTP
     AVSSNFYSTV GRNGVLPQAF DQFFETAYGT PENLASSDYP GDKSAEKGPP AATATSAAAA
     AAATGAPATS SSDSGGGGGC RETAAAAEEK ERRRRPESSS SPESSSGHTE DKAGGSSGQR
     TRKKRCPYTK YQIRELEREF FFSVYINKEK RLQLSRMLNL TDRQVKIWFQ NRRMKEKKIN
     RDRLQYYSAN PLL
//
ID   HXA9_HUMAN              Reviewed;         272 AA.
AC   P31269; O43369; O43429; Q99820;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1999, sequence version 4.
DT   22-APR-2020, entry version 198.
DE   RecName: Full=Homeobox protein Hox-A9;
DE   AltName: Full=Homeobox protein Hox-1G;
GN   Name=HOXA9; Synonyms=HOX1G;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Bone marrow;
RA   Rozenfeld S., Sauvageau G., Largman C.;
RL   Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9880515; DOI=10.1074/jbc.274.3.1415;
RA   Patel C.V., Sharangpani R., Bandyopadhyay S., DiCorleto P.E.;
RT   "Endothelial cells express a novel, tumor necrosis factor-alpha-regulated
RT   variant of HOXA9.";
RL   J. Biol. Chem. 274:1415-1422(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 195-272, AND CHROMOSOMAL TRANSLOCATION WITH
RP   NUP98.
RX   PubMed=8563754; DOI=10.1038/ng0296-159;
RA   Borrow J., Shearman A.M., Stanton V.P., Becher R., Collins T.,
RA   Williams A.J., Dube I., Katz F., Kwong Y.L., Morris C., Ohyashiki K.,
RA   Toyama K., Rowley J., Housman D.E.;
RT   "The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the
RT   genes for nucleoporin NUP98 and class I homeoprotein HOXA9.";
RL   Nat. Genet. 12:159-167(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE OF 206-271.
RX   PubMed=2574852; DOI=10.1093/nar/17.24.10385;
RA   Acampora D., D'Esposito M., Faiella A., Pannese M., Migliaccio E.,
RA   Morelli F., Stornaiuolo A., Nigro V., Simeone A., Boncinelli E.;
RT   "The human HOX gene family.";
RL   Nucleic Acids Res. 17:10385-10402(1989).
RN   [8]
RP   CHROMOSOMAL TRANSLOCATION WITH MSI2.
RX   PubMed=12649177;
RA   Barbouti A., Hoeglund M., Johansson B., Lassen C., Nilsson P.-G.,
RA   Hagemeijer A., Mitelman F., Fioretos T.;
RT   "A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently
RT   rearranged at disease progression of chronic myeloid leukemia and forms a
RT   fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23).";
RL   Cancer Res. 63:1202-1206(2003).
RN   [9]
RP   FUNCTION, INTERACTION WITH PRMT5, METHYLATION AT ARG-140, MUTAGENESIS OF
RP   ARG-140, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22269951; DOI=10.1128/mcb.05977-11;
RA   Bandyopadhyay S., Harris D.P., Adams G.N., Lause G.E., McHugh A.,
RA   Tillmaand E.G., Money A., Willard B., Fox P.L., Dicorleto P.E.;
RT   "HOXA9 methylation by PRMT5 is essential for endothelial cell expression of
RT   leukocyte adhesion molecules.";
RL   Mol. Cell. Biol. 32:1202-1213(2012).
CC   -!- FUNCTION: Sequence-specific transcription factor which is part of a
CC       developmental regulatory system that provides cells with specific
CC       positional identities on the anterior-posterior axis. Required for
CC       induction of E-selectin and VCAM-1, on the endothelial cells surface at
CC       sites of inflammation. {ECO:0000269|PubMed:22269951}.
CC   -!- SUBUNIT: Transiently interacts with PRMT5 in TNF-alpha stimulated
CC       endothelial cells. {ECO:0000269|PubMed:22269951}.
CC   -!- INTERACTION:
CC       P31269; Q9BYQ3: KRTAP9-3; NbExp=3; IntAct=EBI-742314, EBI-1043191;
CC       P31269; O14744: PRMT5; NbExp=4; IntAct=EBI-742314, EBI-351098;
CC       P31269; Q15654: TRIP6; NbExp=4; IntAct=EBI-742314, EBI-742327;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- PTM: Methylated on Arg-140 by PRMT5; methylation is critical for E-
CC       selectin induction. {ECO:0000269|PubMed:22269951}.
CC   -!- DISEASE: Note=A chromosomal aberration involving HOXA9 is found in a
CC       form of acute myeloid leukemia. Translocation t(7;11)(p15;p15) with
CC       NUP98.
CC   -!- DISEASE: Note=A chromosomal aberration involving HOXA9 may contribute
CC       to disease progression in chronic myeloid leukemia. Translocation
CC       t(7;17)(p15;q23) with MSI2.
CC   -!- SIMILARITY: Belongs to the Abd-B homeobox family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC50364.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HOXA9ID61.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U82759; AAB40867.1; -; mRNA.
DR   EMBL; AF010258; AAD08713.1; -; Genomic_DNA.
DR   EMBL; BT006990; AAP35636.1; -; mRNA.
DR   EMBL; AC004080; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC006537; AAH06537.1; -; mRNA.
DR   EMBL; BC010023; AAH10023.1; -; mRNA.
DR   EMBL; U41813; AAC50364.1; ALT_INIT; mRNA.
DR   CCDS; CCDS5409.1; -.
DR   PIR; S14929; S14929.
DR   RefSeq; NP_689952.1; NM_152739.3.
DR   SMR; P31269; -.
DR   BioGrid; 109445; 18.
DR   CORUM; P31269; -.
DR   IntAct; P31269; 8.
DR   MINT; P31269; -.
DR   STRING; 9606.ENSP00000343619; -.
DR   iPTMnet; P31269; -.
DR   PhosphoSitePlus; P31269; -.
DR   BioMuta; HOXA9; -.
DR   DMDM; 6166219; -.
DR   EPD; P31269; -.
DR   jPOST; P31269; -.
DR   MassIVE; P31269; -.
DR   MaxQB; P31269; -.
DR   PaxDb; P31269; -.
DR   PeptideAtlas; P31269; -.
DR   PRIDE; P31269; -.
DR   ProteomicsDB; 54770; -.
DR   Antibodypedia; 12395; 329 antibodies.
DR   DNASU; 3205; -.
DR   Ensembl; ENST00000343483; ENSP00000343619; ENSG00000078399.
DR   GeneID; 3205; -.
DR   KEGG; hsa:3205; -.
DR   UCSC; uc003syt.4; human.
DR   CTD; 3205; -.
DR   DisGeNET; 3205; -.
DR   GeneCards; HOXA9; -.
DR   HGNC; HGNC:5109; HOXA9.
DR   HPA; ENSG00000078399; Tissue enhanced (kidney).
DR   MIM; 142956; gene.
DR   neXtProt; NX_P31269; -.
DR   OpenTargets; ENSG00000078399; -.
DR   PharmGKB; PA29386; -.
DR   eggNOG; KOG0487; Eukaryota.
DR   eggNOG; ENOG4111FJP; LUCA.
DR   GeneTree; ENSGT00940000161864; -.
DR   HOGENOM; CLU_071854_0_0_1; -.
DR   InParanoid; P31269; -.
DR   KO; K21950; -.
DR   OMA; WSHVPAQ; -.
DR   OrthoDB; 976319at2759; -.
DR   PhylomeDB; P31269; -.
DR   TreeFam; TF317819; -.
DR   SignaLink; P31269; -.
DR   SIGNOR; P31269; -.
DR   GeneWiki; HOXA9; -.
DR   GenomeRNAi; 3205; -.
DR   Pharos; P31269; Tbio.
DR   PRO; PR:P31269; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P31269; protein.
DR   Bgee; ENSG00000078399; Expressed in metanephros and 148 other tissues.
DR   ExpressionAtlas; P31269; baseline and differential.
DR   Genevisible; P31269; HS.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:LIFEdb.
DR   GO; GO:0005667; C:transcription factor complex; IEA:Ensembl.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IBA:GO_Central.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IBA:GO_Central.
DR   GO; GO:0060216; P:definitive hemopoiesis; IEA:Ensembl.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0048704; P:embryonic skeletal system morphogenesis; IBA:GO_Central.
DR   GO; GO:0042118; P:endothelial cell activation; IMP:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0030879; P:mammary gland development; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0045638; P:negative regulation of myeloid cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IBA:GO_Central.
DR   GO; GO:0007338; P:single fertilization; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:InterPro.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   CDD; cd00086; homeodomain; 1.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR017970; Homeobox_CS.
DR   InterPro; IPR001356; Homeobox_dom.
DR   InterPro; IPR020479; Homeobox_metazoa.
DR   InterPro; IPR006711; Hox9_activation_N.
DR   InterPro; IPR017112; HXA9/HXB9/HXC9.
DR   Pfam; PF00046; Homeodomain; 1.
DR   Pfam; PF04617; Hox9_act; 1.
DR   PIRSF; PIRSF037109; Homeobox_Hox9; 1.
DR   PRINTS; PR00024; HOMEOBOX.
DR   SMART; SM00389; HOX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00027; HOMEOBOX_1; 1.
DR   PROSITE; PS50071; HOMEOBOX_2; 1.
PE   1: Evidence at protein level;
KW   Chromosomal rearrangement; Developmental protein; DNA-binding; Homeobox;
KW   Methylation; Nucleus; Proto-oncogene; Reference proteome; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..272
FT                   /note="Homeobox protein Hox-A9"
FT                   /id="PRO_0000200081"
FT   DNA_BIND        206..265
FT                   /note="Homeobox"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00108"
FT   SITE            163..164
FT                   /note="Breakpoint for translocation to form MSI2/HOXA9
FT                   fusion protein"
FT   MOD_RES         140
FT                   /note="Symmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:22269951"
FT   MUTAGEN         140
FT                   /note="R->A: Results in loss of methylation."
FT                   /evidence="ECO:0000269|PubMed:22269951"
FT   CONFLICT        64
FT                   /note="G -> V (in Ref. 1; AAB40867)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        67
FT                   /note="W -> R (in Ref. 2; AAD08713)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        80
FT                   /note="Missing (in Ref. 1; AAB40867)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        243
FT                   /note="L -> F (in Ref. 1; AAB40867)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   272 AA;  30172 MW;  823A1A22BB07A881 CRC64;
     MATTGALGNY YVDSFLLGAD AADELSVGRY APGTLGQPPR QAATLAEHPD FSPCSFQSKA
     TVFGASWNPV HAAGANAVPA AVYHHHHHHP YVHPQAPVAA AAPDGRYMRS WLEPTPGALS
     FAGLPSSRPY GIKPEPLSAR RGDCPTLDTH TLSLTDYACG SPPVDREKQP SEGAFSENNA
     ENESGGDKPP IDPNNPAANW LHARSTRKKR CPYTKHQTLE LEKEFLFNMY LTRDRRYEVA
     RLLNLTERQV KIWFQNRRMK MKKINKDRAK DE
//
ID   IRF4_HUMAN              Reviewed;         451 AA.
AC   Q15306; Q5VUI7; Q99660;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   22-APR-2020, entry version 199.
DE   RecName: Full=Interferon regulatory factor 4;
DE            Short=IRF-4;
DE   AltName: Full=Lymphocyte-specific interferon regulatory factor;
DE            Short=LSIRF;
DE   AltName: Full=Multiple myeloma oncogene 1;
DE   AltName: Full=NF-EM5;
GN   Name=IRF4; Synonyms=MUM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Spleen;
RX   PubMed=8921401; DOI=10.1006/geno.1996.0547;
RA   Grossman A., Mittrucker H.W., Nicholl J., Suzuki A., Chung S., Antonio L.,
RA   Sugga S., Sutherland G.R., Siderovski D.P., Mak T.W.;
RT   "Cloning of human lymphocyte-specific interferon regulatory factor
RT   (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25.";
RL   Genomics 37:229-233(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INVOLVEMENT IN MULTIPLE
RP   MYELOMA.
RC   TISSUE=Spleen;
RX   PubMed=9326949; DOI=10.1038/ng1097-226;
RA   Iida S., Rao P.H., Butler M., Corradini P., Boccadoro M., Klein B.,
RA   Chaganti R.S.K., Dalla-Favera R.;
RT   "Deregulation of MUM1/IRF4 by chromosomal translocation in multiple
RT   myeloma.";
RL   Nat. Genet. 17:226-230(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH SPIB.
RX   PubMed=10196196; DOI=10.1074/jbc.274.16.11115;
RA   Rao S., Matsumura A., Yoon J., Simon M.C.;
RT   "SPI-B activates transcription via a unique proline, serine, and threonine
RT   domain and exhibits DNA binding affinity differences from PU.1.";
RL   J. Biol. Chem. 274:11115-11124(1999).
RN   [6]
RP   INTERACTION WITH DEF6.
RC   TISSUE=Lymph node;
RX   PubMed=12651066; DOI=10.1016/s0198-8859(03)00024-7;
RA   Gupta S., Lee A.E., Hu C., Fanzo J.C., Goldberg I., Cattoretti G.,
RA   Pernis A.B.;
RT   "Molecular cloning of IBP, a SWAP-70 homologous GEF, which is highly
RT   expressed in the immune system.";
RL   Hum. Immunol. 64:389-401(2003).
RN   [7]
RP   POLYMORPHISM.
RX   PubMed=18483556; DOI=10.1371/journal.pgen.1000074;
RA   Han J., Kraft P., Nan H., Guo Q., Chen C., Qureshi A., Hankinson S.E.,
RA   Hu F.B., Duffy D.L., Zhao Z.Z., Martin N.G., Montgomery G.W., Hayward N.K.,
RA   Thomas G., Hoover R.N., Chanock S., Hunter D.J.;
RT   "A genome-wide association study identifies novel alleles associated with
RT   hair color and skin pigmentation.";
RL   PLoS Genet. 4:E1000074-E1000074(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   POLYMORPHISM.
RX   PubMed=24267888; DOI=10.1016/j.cell.2013.10.022;
RA   Praetorius C., Grill C., Stacey S.N., Metcalf A.M., Gorkin D.U.,
RA   Robinson K.C., Van Otterloo E., Kim R.S., Bergsteinsdottir K.,
RA   Ogmundsdottir M.H., Magnusdottir E., Mishra P.J., Davis S.R., Guo T.,
RA   Zaidi M.R., Helgason A.S., Sigurdsson M.I., Meltzer P.S., Merlino G.,
RA   Petit V., Larue L., Loftus S.K., Adams D.R., Sobhiafshar U., Emre N.C.,
RA   Pavan W.J., Cornell R., Smith A.G., McCallion A.S., Fisher D.E.,
RA   Stefansson K., Sturm R.A., Steingrimsson E.;
RT   "A polymorphism in IRF4 affects human pigmentation through a tyrosinase-
RT   dependent MITF/TFAP2A pathway.";
RL   Cell 155:1022-1033(2013).
RN   [10]
RP   STRUCTURE BY NMR OF 22-130.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the IRF domain of human interferon regulator factor
RT   4.";
RL   Submitted (OCT-2006) to the PDB data bank.
CC   -!- FUNCTION: Transcriptional activator. Binds to the interferon-stimulated
CC       response element (ISRE) of the MHC class I promoter. Binds the
CC       immunoglobulin lambda light chain enhancer, together with PU.1.
CC       Probably plays a role in ISRE-targeted signal transduction mechanisms
CC       specific to lymphoid cells. Involved in CD8(+) dendritic cell
CC       differentiation by forming a complex with the BATF-JUNB heterodimer in
CC       immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-
CC       3'), an immune-specific regulatory element, followed by cooperative
CC       binding of BATF and IRF4 and activation of genes (By similarity).
CC       {ECO:0000250|UniProtKB:Q64287}.
CC   -!- SUBUNIT: Interacts with the BATF-JUNB heterodimer. Interacts with BATF
CC       (via bZIP domain); the interaction is direct (By similarity). Interacts
CC       with SPIB and DEF6. Directly interacts with NLRP3 in the nucleus of Th2
CC       cells; this interaction enhances IRF4 ability to bind to the IL4
CC       promoter and is required for optimal IRF4-dependent IL4 transcription
CC       (By similarity). {ECO:0000250, ECO:0000250|UniProtKB:Q64287,
CC       ECO:0000269|PubMed:10196196, ECO:0000269|PubMed:12651066}.
CC   -!- INTERACTION:
CC       Q15306; O95163: ELP1; NbExp=2; IntAct=EBI-751345, EBI-347559;
CC       Q15306; Q8TF65: GIPC2; NbExp=5; IntAct=EBI-751345, EBI-712067;
CC       Q15306; P51617: IRAK1; NbExp=2; IntAct=EBI-751345, EBI-358664;
CC       Q15306; Q86UE8: TLK2; NbExp=2; IntAct=EBI-751345, EBI-1047967;
CC       Q15306; Q7Z6J9: TSEN54; NbExp=3; IntAct=EBI-751345, EBI-2559824;
CC       Q15306; Q9H6S0: YTHDC2; NbExp=2; IntAct=EBI-751345, EBI-1057466;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q15306-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15306-2; Sequence=VSP_002755;
CC   -!- TISSUE SPECIFICITY: Lymphoid cells.
CC   -!- INDUCTION: Not induced by interferons.
CC   -!- PTM: Phosphorylation by ROCK2 regulates IL-17 and IL-21 production.
CC       {ECO:0000250}.
CC   -!- POLYMORPHISM: Genetic variants in IRF4 define the skin/hair/eye
CC       pigmentation variation locus 8 (SHEP8) [MIM:611724]. Hair, eye and skin
CC       pigmentation are among the most visible examples of human phenotypic
CC       variation, with a broad normal range that is subject to substantial
CC       geographic stratification. In the case of skin, individuals tend to
CC       have lighter pigmentation with increasing distance from the equator. By
CC       contrast, the majority of variation in human eye and hair color is
CC       found among individuals of European ancestry, with most other human
CC       populations fixed for brown eyes and black hair.
CC       {ECO:0000269|PubMed:18483556, ECO:0000269|PubMed:24267888}.
CC   -!- DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor of
CC       plasma cells usually arising in the bone marrow and characterized by
CC       diffuse involvement of the skeletal system, hyperglobulinemia, Bence-
CC       Jones proteinuria and anemia. Complications of multiple myeloma are
CC       bone pain, hypercalcemia, renal failure and spinal cord compression.
CC       The aberrant antibodies that are produced lead to impaired humoral
CC       immunity and patients have a high prevalence of infection. Amyloidosis
CC       may develop in some patients. Multiple myeloma is part of a spectrum of
CC       diseases ranging from monoclonal gammopathy of unknown significance
CC       (MGUS) to plasma cell leukemia. {ECO:0000269|PubMed:9326949}. Note=The
CC       gene represented in this entry may be involved in disease pathogenesis.
CC       A chromosomal aberration involving IRF4 has been found in multiple
CC       myeloma. Translocation t(6;14)(p25;q32) with the IgH locus.
CC   -!- SIMILARITY: Belongs to the IRF family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00840}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/IRF4ID231ch6p25.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U52682; AAC50779.1; -; mRNA.
DR   EMBL; U63738; AAB37258.1; -; mRNA.
DR   EMBL; AL365272; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL589962; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015752; AAH15752.1; -; mRNA.
DR   CCDS; CCDS4469.1; -. [Q15306-1]
DR   RefSeq; NP_001182215.1; NM_001195286.1. [Q15306-2]
DR   RefSeq; NP_002451.2; NM_002460.3. [Q15306-1]
DR   PDB; 2DLL; NMR; -; A=23-130.
DR   PDBsum; 2DLL; -.
DR   SMR; Q15306; -.
DR   BioGrid; 109870; 26.
DR   IntAct; Q15306; 13.
DR   STRING; 9606.ENSP00000370343; -.
DR   iPTMnet; Q15306; -.
DR   PhosphoSitePlus; Q15306; -.
DR   BioMuta; IRF4; -.
DR   DMDM; 2497445; -.
DR   jPOST; Q15306; -.
DR   MassIVE; Q15306; -.
DR   MaxQB; Q15306; -.
DR   PaxDb; Q15306; -.
DR   PeptideAtlas; Q15306; -.
DR   PRIDE; Q15306; -.
DR   ProteomicsDB; 60524; -. [Q15306-1]
DR   ProteomicsDB; 60525; -. [Q15306-2]
DR   Antibodypedia; 1057; 644 antibodies.
DR   DNASU; 3662; -.
DR   Ensembl; ENST00000380956; ENSP00000370343; ENSG00000137265. [Q15306-1]
DR   GeneID; 3662; -.
DR   KEGG; hsa:3662; -.
DR   UCSC; uc003msz.5; human. [Q15306-1]
DR   CTD; 3662; -.
DR   DisGeNET; 3662; -.
DR   GeneCards; IRF4; -.
DR   HGNC; HGNC:6119; IRF4.
DR   HPA; ENSG00000137265; Tissue enhanced (lymphoid).
DR   MalaCards; IRF4; -.
DR   MIM; 254500; phenotype.
DR   MIM; 601900; gene.
DR   MIM; 611724; phenotype.
DR   neXtProt; NX_Q15306; -.
DR   OpenTargets; ENSG00000137265; -.
DR   PharmGKB; PA29918; -.
DR   eggNOG; ENOG410IES5; Eukaryota.
DR   eggNOG; ENOG411023V; LUCA.
DR   GeneTree; ENSGT00940000159059; -.
DR   InParanoid; Q15306; -.
DR   KO; K09445; -.
DR   OMA; EQPHPEI; -.
DR   OrthoDB; 648909at2759; -.
DR   PhylomeDB; Q15306; -.
DR   TreeFam; TF328512; -.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   SIGNOR; Q15306; -.
DR   ChiTaRS; IRF4; human.
DR   EvolutionaryTrace; Q15306; -.
DR   GeneWiki; IRF4; -.
DR   GenomeRNAi; 3662; -.
DR   Pharos; Q15306; Tbio.
DR   PRO; PR:Q15306; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q15306; protein.
DR   Bgee; ENSG00000137265; Expressed in endocervix and 115 other tissues.
DR   ExpressionAtlas; Q15306; baseline and differential.
DR   Genevisible; Q15306; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0000788; C:nuclear nucleosome; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; NAS:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0042832; P:defense response to protozoan; ISS:UniProtKB.
DR   GO; GO:0043966; P:histone H3 acetylation; IEA:Ensembl.
DR   GO; GO:0043967; P:histone H4 acetylation; IEA:Ensembl.
DR   GO; GO:0002376; P:immune system process; IBA:GO_Central.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0043388; P:positive regulation of DNA binding; IEA:Ensembl.
DR   GO; GO:0045082; P:positive regulation of interleukin-10 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045368; P:positive regulation of interleukin-13 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045086; P:positive regulation of interleukin-2 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045404; P:positive regulation of interleukin-4 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0045622; P:regulation of T-helper cell differentiation; NAS:UniProtKB.
DR   GO; GO:0042110; P:T cell activation; NAS:UniProtKB.
DR   GO; GO:0072540; P:T-helper 17 cell lineage commitment; ISS:UniProtKB.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   CDD; cd00103; IRF; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   Gene3D; 2.60.200.10; -; 1.
DR   InterPro; IPR019817; Interferon_reg_fac_CS.
DR   InterPro; IPR001346; Interferon_reg_fact_DNA-bd_dom.
DR   InterPro; IPR019471; Interferon_reg_factor-3.
DR   InterPro; IPR017855; SMAD-like_dom_sf.
DR   InterPro; IPR008984; SMAD_FHA_dom_sf.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR11949; PTHR11949; 1.
DR   Pfam; PF00605; IRF; 1.
DR   Pfam; PF10401; IRF-3; 1.
DR   PRINTS; PR00267; INTFRNREGFCT.
DR   SMART; SM00348; IRF; 1.
DR   SMART; SM01243; IRF-3; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   SUPFAM; SSF49879; SSF49879; 1.
DR   PROSITE; PS00601; IRF_1; 1.
DR   PROSITE; PS51507; IRF_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Chromosomal rearrangement;
KW   DNA-binding; Nucleus; Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..451
FT                   /note="Interferon regulatory factor 4"
FT                   /id="PRO_0000154556"
FT   DNA_BIND        21..129
FT                   /note="IRF tryptophan pentad repeat"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00840"
FT   MOD_RES         447
FT                   /note="Phosphoserine; by ROCK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q64287"
FT   MOD_RES         448
FT                   /note="Phosphoserine; by ROCK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q64287"
FT   VAR_SEQ         165
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8921401"
FT                   /id="VSP_002755"
FT   CONFLICT        300
FT                   /note="Q -> H (in Ref. 2; AAB37258)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        306
FT                   /note="K -> N (in Ref. 2; AAB37258)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        333
FT                   /note="R -> T (in Ref. 2; AAB37258)"
FT                   /evidence="ECO:0000305"
FT   HELIX           24..34
FT                   /evidence="ECO:0000244|PDB:2DLL"
FT   STRAND          37..39
FT                   /evidence="ECO:0000244|PDB:2DLL"
FT   STRAND          41..47
FT                   /evidence="ECO:0000244|PDB:2DLL"
FT   STRAND          49..53
FT                   /evidence="ECO:0000244|PDB:2DLL"
FT   STRAND          60..62
FT                   /evidence="ECO:0000244|PDB:2DLL"
FT   HELIX           64..67
FT                   /evidence="ECO:0000244|PDB:2DLL"
FT   HELIX           69..78
FT                   /evidence="ECO:0000244|PDB:2DLL"
FT   HELIX           90..103
FT                   /evidence="ECO:0000244|PDB:2DLL"
FT   STRAND          107..109
FT                   /evidence="ECO:0000244|PDB:2DLL"
FT   TURN            111..113
FT                   /evidence="ECO:0000244|PDB:2DLL"
FT   STRAND          115..120
FT                   /evidence="ECO:0000244|PDB:2DLL"
FT   STRAND          122..127
FT                   /evidence="ECO:0000244|PDB:2DLL"
SQ   SEQUENCE   451 AA;  51772 MW;  17CD1327C6F5BFFA CRC64;
     MNLEGGGRGG EFGMSAVSCG NGKLRQWLID QIDSGKYPGL VWENEEKSIF RIPWKHAGKQ
     DYNREEDAAL FKAWALFKGK FREGIDKPDP PTWKTRLRCA LNKSNDFEEL VERSQLDISD
     PYKVYRIVPE GAKKGAKQLT LEDPQMSMSH PYTMTTPYPS LPAQQVHNYM MPPLDRSWRD
     YVPDQPHPEI PYQCPMTFGP RGHHWQGPAC ENGCQVTGTF YACAPPESQA PGVPTEPSIR
     SAEALAFSDC RLHICLYYRE ILVKELTTSS PEGCRISHGH TYDASNLDQV LFPYPEDNGQ
     RKNIEKLLSH LERGVVLWMA PDGLYAKRLC QSRIYWDGPL ALCNDRPNKL ERDQTCKLFD
     TQQFLSELQA FAHHGRSLPR FQVTLCFGEE FPDPQRQRKL ITAHVEPLLA RQLYYFAQQN
     SGHFLRGYDL PEHISNPEDY HRSIRHSSIQ E
//
ID   A0A087WVL2_HUMAN        Unreviewed;       881 AA.
AC   A0A087WVL2;
DT   05-JUN-2019, integrated into UniProtKB/TrEMBL.
DT   05-JUN-2019, sequence version 1.
DT   22-APR-2020, entry version 8.
DE   SubName: Full=Myocardin-related transcription factor A {ECO:0000313|Ensembl:ENSP00000479510};
GN   Name=MRTFA {ECO:0000313|Ensembl:ENSP00000479510};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000479510, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000479510, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA   Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA   Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA   Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA   Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA   Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA   Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA   Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA   Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA   Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA   Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA   Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA   Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA   Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA   Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA   Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA   Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA   Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA   Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA   Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA   Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA   Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA   Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA   Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA   Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA   Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA   Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA   McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA   Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA   Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA   Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA   Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [2] {ECO:0000213|PubMed:17081983}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [3] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [4] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [5] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [6] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [7] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [8] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9] {ECO:0000213|PubMed:24275569}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10] {ECO:0000313|Ensembl:ENSP00000479510}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (SEP-2014) to UniProtKB.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL022238; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL031594; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF457470; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z86090; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001269590.1; NM_001282661.1.
DR   Antibodypedia; 26780; 313 antibodies.
DR   Ensembl; ENST00000618196; ENSP00000479510; ENSG00000196588.
DR   GeneID; 57591; -.
DR   CTD; 57591; -.
DR   HGNC; HGNC:14334; MRTFA.
DR   OpenTargets; ENSG00000196588; -.
DR   GeneTree; ENSGT00950000182979; -.
DR   ChiTaRS; SMARCA4; human.
DR   GenomeRNAi; 57591; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   ExpressionAtlas; A0A087WVL2; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0003785; F:actin monomer binding; IEA:InterPro.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:InterPro.
DR   GO; GO:0010735; P:positive regulation of transcription via serum response element binding; IEA:InterPro.
DR   Gene3D; 1.10.720.30; -; 1.
DR   InterPro; IPR029992; MRTF-A.
DR   InterPro; IPR004018; RPEL_repeat.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   PANTHER; PTHR22793:SF6; PTHR22793:SF6; 2.
DR   Pfam; PF02755; RPEL; 2.
DR   Pfam; PF02037; SAP; 1.
DR   SMART; SM00707; RPEL; 2.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51073; RPEL; 2.
DR   PROSITE; PS50800; SAP; 1.
PE   1: Evidence at protein level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Proteomics identification {ECO:0000213|EPD:A0A087WVL2,
KW   ECO:0000213|MaxQB:A0A087WVL2, ECO:0000213|PeptideAtlas:A0A087WVL2,
KW   ECO:0000213|ProteomicsDB:A0A087WVL2};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   REPEAT          24..49
FT                   /note="RPEL"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00401"
FT   REPEAT          68..93
FT                   /note="RPEL"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00401"
FT   DOMAIN          297..331
FT                   /note="SAP"
FT                   /evidence="ECO:0000259|PROSITE:PS50800"
FT   REGION          110..209
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          240..294
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          394..426
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          508..527
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          624..696
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          713..766
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          56..76
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        110..140
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        149..167
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        255..290
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        624..640
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        682..696
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        746..760
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   881 AA;  93588 MW;  86844F800009AC00 CRC64;
     MPPLKSPAAF HEQRRSLERA RTEDYLKRKI RSRPERSELV RMHILEETSA EPSLQAKQLK
     LKRARLADDL NEKIAQRPGP MELVEKNILP VESSLKEAII VGQVNYPKVA DSSSFDEDSS
     DALSPEQPAS HESQGSVPSP LEARVSEPLL SATSASPTQQ SQPKSASEKS QRSKKAKELK
     PKVKKLKYHQ YIPPDQKQDR GAPPMDSSYA KILQQQQLFL QLQILNQQQQ QHHNYQAILP
     APPKSAGEAL GSSGTPPVRS LSTTNSSSSS GAPGPCGLAR QNSTSLTGKP GALPANLDDM
     KVAELKQELK LRSLPVSGTK TELIERLRAY QDQISPVPGA PKAPAATSIL HKAGEVVVAF
     PAARLSTGPA LVAAGLAPAE VVVATVASSG VVKFGSTGST PPVSPTPSER SLLSTGDENS
     TPGDTFGEMV TSPLTQLTLQ ASPLQILVKE EGPRAGSCCL SPGGRAELEG RDKDQMLQEK
     DKQIEALTRM LRQKQQLVER LKLQLEQEKR AQQPAPAPAP LGTPVKQENS FSSCQLSQQP
     LGPAHPFNPS LAAPATNHID PCAVAPGPPS VVVKQEALQP EPEPVPAPQL LLGPQGPSLI
     KGVAPPTLIT DSTGTHLVLT VTNKNADSPG LSSGSPQQPS SQPGSPAPAP SAQMDLEHPL
     QPLFGTPTSL LKKEPPGYEE AMSQQPKQQE NGSSSQQMDD LFDILIQSGE ISADFKEPPS
     LPGKEKPSPK TVCGSPLAAQ PSPSAELPQA APPPPGSPSL PGRLEDFLES STGLPLLTSG
     HDGPEPLSLI DDLHSQMLSS TAILDHPPSP MDTSELHFVP EPSSTMGLDL ADGHLDSMDW
     LELSSGGPVL SLAPLSTTAP SLFSTDFLDG HDLQLHWDSC L
//
ID   A4FUJ8_HUMAN            Unreviewed;       798 AA.
AC   A4FUJ8;
DT   17-APR-2007, integrated into UniProtKB/TrEMBL.
DT   17-APR-2007, sequence version 1.
DT   11-DEC-2019, entry version 74.
DE   SubName: Full=MKL1 protein {ECO:0000313|EMBL:AAI15040.1};
GN   Name=MKL1 {ECO:0000313|EMBL:AAI15040.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAI15040.1};
RN   [1] {ECO:0000313|EMBL:AAI15040.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph {ECO:0000313|EMBL:AAI15040.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC115039; AAI15040.1; -; mRNA.
DR   RefSeq; NP_001269589.1; NM_001282660.1.
DR   RefSeq; NP_001269590.1; NM_001282661.1.
DR   RefSeq; NP_001269591.1; NM_001282662.1.
DR   RefSeq; NP_001305068.1; NM_001318139.1.
DR   RefSeq; NP_065882.1; NM_020831.4.
DR   IntAct; A4FUJ8; 2.
DR   MaxQB; A4FUJ8; -.
DR   PeptideAtlas; A4FUJ8; -.
DR   PRIDE; A4FUJ8; -.
DR   GeneID; 57591; -.
DR   KEGG; hsa:57591; -.
DR   CTD; 57591; -.
DR   eggNOG; ENOG410IFJX; Eukaryota.
DR   eggNOG; ENOG41101AM; LUCA.
DR   KO; K22525; -.
DR   OrthoDB; 190145at2759; -.
DR   ChiTaRS; MKL1; human.
DR   GenomeRNAi; 57591; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0003785; F:actin monomer binding; IEA:InterPro.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:InterPro.
DR   GO; GO:0010735; P:positive regulation of transcription via serum response element binding; IEA:InterPro.
DR   Gene3D; 1.10.720.30; -; 1.
DR   InterPro; IPR029992; MRTF-A.
DR   InterPro; IPR004018; RPEL_repeat.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   PANTHER; PTHR22793:SF6; PTHR22793:SF6; 1.
DR   Pfam; PF02755; RPEL; 2.
DR   Pfam; PF02037; SAP; 1.
DR   SMART; SM00707; RPEL; 2.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51073; RPEL; 2.
DR   PROSITE; PS50800; SAP; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   REPEAT          24..49
FT                   /note="RPEL"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00401"
FT   REPEAT          68..93
FT                   /note="RPEL"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00401"
FT   DOMAIN          347..381
FT                   /note="SAP"
FT                   /evidence="ECO:0000259|PROSITE:PS50800"
FT   REGION          110..256
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          290..344
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          444..476
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          558..577
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          674..747
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          56..76
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        110..140
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        149..165
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        178..192
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        193..217
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        305..340
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        674..690
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        732..747
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   798 AA;  85046 MW;  55B8CF6F845F873C CRC64;
     MPPLKSPAAF HEQRRSLERA RTEDYLKRKI RSRPERSELV RMHILEETSA EPSLQAKQLK
     LKRARLADDL NEKIAQRPGP MELVEKNILP VESSLKEAII VGQVNYPKVA DSSSFDEDSS
     DALSPEQPAS HESQGSVPSP LEARVSEPLL SATSASPTQV VSQLPMGRDS REMLFLAEQP
     PLPPPPLLPP SLTNGTTIPT AKSTPTLIKQ SQPKSASEKS QRSKKAKELK PKVKKLKYHQ
     YIPPDQKQDR GAPPMDSSYA KILQQQQLFL QLQILNQQQQ QHHNYQAILP APPKSAGEAL
     GSSGTPPVRS LSTTNSSSSS GAPGPCGLAR QNSTSLTGKP GALPANLDDM KVAELKQELK
     LRSLPVSGTK TELIERLRAY QDQISPVPGA PKAPAATSIL HKAGEVVVAF PAARLSTGPA
     LVAAGLAPAE VVVATVASSG VVKFGSTGST PPVSPTPSER SLLSTGDENS TPGDTFGEMV
     TSPLTQLTLQ ASPLQILVKE EGPRAGSCCL SPGGRAELEG RDKDQMLQEK DKQIEALTRM
     LRQKQQLVER LKLQLEQEKR AQQPAPAPAP LGTPVKQENS FSSCQLSQQP LGPAHPFNPS
     LAAPATNHID PCAVAPGPPS VVVKQEALQP EPEPVPAPQL LLGPQGPGLI KGVAPPTLIT
     DSTGTHLVLT VTNKNADSPG LSSGSPQQPS SQPGSPAPAP SAQMDLEHPL QPLFGTPTSL
     LKKEPPGYEE AMSQQPKQQE NGSSSQQMDD LFDILIQSGG NPRNFSRFQG AAIPAREGEA
     IPEDSLWVPP GSTAITFC
//
ID   E7ER32_HUMAN            Unreviewed;       798 AA.
AC   E7ER32;
DT   08-MAR-2011, integrated into UniProtKB/TrEMBL.
DT   28-JUN-2011, sequence version 2.
DT   22-APR-2020, entry version 73.
DE   SubName: Full=Myocardin-related transcription factor A {ECO:0000313|Ensembl:ENSP00000379861};
GN   Name=MRTFA {ECO:0000313|Ensembl:ENSP00000379861};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000379861, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000379861, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA   Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA   Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA   Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA   Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA   Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA   Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA   Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA   Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA   Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA   Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA   Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA   Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA   Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA   Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA   Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA   Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA   Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA   Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA   Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA   Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA   Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA   Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA   Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA   Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA   Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA   Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA   McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA   Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA   Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA   Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA   Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [2] {ECO:0000213|PubMed:17081983}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [3] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [4] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [5] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [6] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [7] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [8] {ECO:0000313|Ensembl:ENSP00000379861}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
RN   [9] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10] {ECO:0000213|PubMed:24275569}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL022238; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL031594; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF457470; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z86090; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001269591.1; NM_001282662.1.
DR   jPOST; E7ER32; -.
DR   MaxQB; E7ER32; -.
DR   PeptideAtlas; E7ER32; -.
DR   PRIDE; E7ER32; -.
DR   ProteomicsDB; 17704; -.
DR   Antibodypedia; 26780; 313 antibodies.
DR   Ensembl; ENST00000396617; ENSP00000379861; ENSG00000196588.
DR   GeneID; 57591; -.
DR   UCSC; uc010gye.3; human.
DR   CTD; 57591; -.
DR   EuPathDB; HostDB:ENSG00000196588.14; -.
DR   HGNC; HGNC:14334; MRTFA.
DR   OpenTargets; ENSG00000196588; -.
DR   eggNOG; ENOG410IFJX; Eukaryota.
DR   eggNOG; ENOG41101AM; LUCA.
DR   GeneTree; ENSGT00950000182979; -.
DR   ChiTaRS; SMARCA4; human.
DR   GenomeRNAi; 57591; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000196588; Expressed in blood and 204 other tissues.
DR   ExpressionAtlas; E7ER32; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003785; F:actin monomer binding; IEA:InterPro.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:InterPro.
DR   GO; GO:0010735; P:positive regulation of transcription via serum response element binding; IEA:InterPro.
DR   Gene3D; 1.10.720.30; -; 1.
DR   InterPro; IPR029992; MRTF-A.
DR   InterPro; IPR004018; RPEL_repeat.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   PANTHER; PTHR22793:SF6; PTHR22793:SF6; 1.
DR   Pfam; PF02755; RPEL; 2.
DR   Pfam; PF02037; SAP; 1.
DR   SMART; SM00707; RPEL; 2.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51073; RPEL; 2.
DR   PROSITE; PS50800; SAP; 1.
PE   1: Evidence at protein level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Proteomics identification {ECO:0000213|EPD:E7ER32,
KW   ECO:0000213|MaxQB:E7ER32, ECO:0000213|PeptideAtlas:E7ER32,
KW   ECO:0000213|ProteomicsDB:E7ER32};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   REPEAT          24..49
FT                   /note="RPEL"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00401"
FT   REPEAT          68..93
FT                   /note="RPEL"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00401"
FT   DOMAIN          347..381
FT                   /note="SAP"
FT                   /evidence="ECO:0000259|PROSITE:PS50800"
FT   REGION          110..256
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          290..344
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          444..476
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          558..577
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          674..746
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          56..76
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        110..140
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        149..165
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        178..192
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        193..217
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        305..340
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        674..690
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        732..746
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   798 AA;  85077 MW;  85399B6F911EDCA7 CRC64;
     MPPLKSPAAF HEQRRSLERA RTEDYLKRKI RSRPERSELV RMHILEETSA EPSLQAKQLK
     LKRARLADDL NEKIAQRPGP MELVEKNILP VESSLKEAII VGQVNYPKVA DSSSFDEDSS
     DALSPEQPAS HESQGSVPSP LEARVSEPLL SATSASPTQV VSQLPMGRDS REMLFLAEQP
     PLPPPPLLPP SLTNGTTIPT AKSTPTLIKQ SQPKSASEKS QRSKKAKELK PKVKKLKYHQ
     YIPPDQKQDR GAPPMDSSYA KILQQQQLFL QLQILNQQQQ QHHNYQAILP APPKSAGEAL
     GSSGTPPVRS LSTTNSSSSS GAPGPCGLAR QNSTSLTGKP GALPANLDDM KVAELKQELK
     LRSLPVSGTK TELIERLRAY QDQISPVPGA PKAPAATSIL HKAGEVVVAF PAARLSTGPA
     LVAAGLAPAE VVVATVASSG VVKFGSTGST PPVSPTPSER SLLSTGDENS TPGDTFGEMV
     TSPLTQLTLQ ASPLQILVKE EGPRAGSCCL SPGGRAELEG RDKDQMLQEK DKQIEALTRM
     LRQKQQLVER LKLQLEQEKR AQQPAPAPAP LGTPVKQENS FSSCQLSQQP LGPAHPFNPS
     LAAPATNHID PCAVAPGPPS VVVKQEALQP EPEPVPAPQL LLGPQGPSLI KGVAPPTLIT
     DSTGTHLVLT VTNKNADSPG LSSGSPQQPS SQPGSPAPAP SAQMDLEHPL QPLFGTPTSL
     LKKEPPGYEE AMSQQPKQQE NGSSSQQMDD LFDILIQSGG NPRNFSRFQG AAIPAREGEA
     IPEDSLWVPP GSTAITFC
//
ID   MRTFA_HUMAN             Reviewed;         931 AA.
AC   Q969V6; Q8TCL1; Q96SC5; Q96SC6; Q9P2B0;
DT   27-JUN-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   22-APR-2020, entry version 178.
DE   RecName: Full=Myocardin-related transcription factor A {ECO:0000305};
DE            Short=MRTF-A {ECO:0000305};
DE   AltName: Full=MKL/myocardin-like protein 1 {ECO:0000303|PubMed:11431691};
DE   AltName: Full=Megakaryoblastic leukemia 1 protein {ECO:0000303|PubMed:11431691};
DE   AltName: Full=Megakaryocytic acute leukemia protein {ECO:0000250|UniProtKB:Q8K4J6};
GN   Name=MRTFA {ECO:0000312|HGNC:HGNC:14334};
GN   Synonyms=KIAA1438 {ECO:0000303|PubMed:10718198},
GN   MAL {ECO:0000250|UniProtKB:Q8K4J6}, MKL1 {ECO:0000303|PubMed:11431691};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHROMOSOMAL TRANSLOCATION WITH RBM15.
RX   PubMed=11431691; DOI=10.1038/90054;
RA   Ma Z., Morris S.W., Valentine V., Li M., Herbrick J.-A., Cui X., Bouman D.,
RA   Li Y., Mehta P.K., Nizetic D., Kaneko Y., Chan G.C.F., Chan L.C.,
RA   Squire J., Scherer S.W., Hitzler J.K.;
RT   "Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of
RT   acute megakaryoblastic leukemia.";
RL   Nat. Genet. 28:220-221(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHROMOSOMAL TRANSLOCATION WITH RBM15, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Blood;
RX   PubMed=11344311; DOI=10.1073/pnas.101001498;
RA   Mercher T., Coniat M.B.-L., Monni R., Mauchauffe M., Khac F.N., Gressin L.,
RA   Mugneret F., Leblanc T., Dastugue N., Berger R., Bernard O.A.;
RT   "Involvement of a human gene related to the Drosophila spen gene in the
RT   recurrent t(1;22) translocation of acute megakaryocytic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:5776-5779(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI. The
RT   complete sequences of 150 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [4]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLY-648.
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA   Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA   Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA   Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA   Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA   Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA   Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA   Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA   Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA   Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA   Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA   Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA   Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA   Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA   Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA   Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA   Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA   Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA   Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA   Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA   Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA   Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA   Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA   Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA   Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA   Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA   Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA   McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA   Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA   Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA   Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA   Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 195-931, AND VARIANT GLY-648.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   INTERACTION WITH MRTFB AND SRF.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=14565952; DOI=10.1074/jbc.m305679200;
RA   Selvaraj A., Prywes R.;
RT   "Megakaryoblastic leukemia-1/2, a transcriptional co-activator of serum
RT   response factor, is required for skeletal myogenic differentiation.";
RL   J. Biol. Chem. 278:41977-41987(2003).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-305 AND THR-450, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   INTERACTION WITH SCAI AND SRF, AND SUBCELLULAR LOCATION.
RX   PubMed=19350017; DOI=10.1038/ncb1862;
RA   Brandt D.T., Baarlink C., Kitzing T.M., Kremmer E., Ivaska J., Nollau P.,
RA   Grosse R.;
RT   "SCAI acts as a suppressor of cancer cell invasion through the
RT   transcriptional control of beta1-integrin.";
RL   Nat. Cell Biol. 11:557-568(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-450 AND SER-454, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6; THR-450 AND SER-454, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-156; SER-333; SER-385 AND
RP   THR-450, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=24440334; DOI=10.1016/j.cell.2013.12.035;
RA   Lundquist M.R., Storaska A.J., Liu T.C., Larsen S.D., Evans T.,
RA   Neubig R.R., Jaffrey S.R.;
RT   "Redox modification of nuclear actin by MICAL-2 regulates SRF signaling.";
RL   Cell 156:563-576(2014).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-385, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   STRUCTURE BY NMR OF 336-396.
RG   Northeast structural genomics consortium (NESG);
RT   "Northeast structural genomics consortium target HR4547E.";
RL   Submitted (JUN-2010) to the PDB data bank.
CC   -!- FUNCTION: Transcription coactivator that associates with the serum
CC       response factor (SRF) transcription factor to control expression of
CC       genes regulating the cytoskeleton during development, morphogenesis and
CC       cell migration. The SRF-MRTFA complex activity responds to Rho GTPase-
CC       induced changes in cellular globular actin (G-actin) concentration,
CC       thereby coupling cytoskeletal gene expression to cytoskeletal dynamics.
CC       MRTFA binds G-actin via its RPEL repeats, regulating activity of the
CC       MRTFA-SRF complex. Activity is also regulated by filamentous actin (F-
CC       actin) in the nucleus. {ECO:0000250|UniProtKB:Q8K4J6}.
CC   -!- SUBUNIT: Interacts with SRF, forming the SRF-MRTFA nuclear complex
CC       which binds the 5'-CArG-3' consensus motif (CArG box) on DNA via SRF
CC       (PubMed:14565952, PubMed:19350017). Interacts (via RPEL repeats) with
CC       globular actin (G-actin), thereby regulating its subcellular location
CC       and activity of the complex formed with SRF (PubMed:19350017). Either
CC       forms a trivalent (by binding three G-actin monomers) or pentavalent
CC       (by binding five G-actin monomers) complex with G-actin (By
CC       similarity). Forms a nuclear ternary complex with SCAI and SRF, leading
CC       to suppress MRTFA-induced SRF transcriptional activity
CC       (PubMed:19350017). Interacts with beta-actin (ACTB); interaction with
CC       ACTB prevents interaction with SCAI (By similarity). Interacts with
CC       MRTFB (PubMed:14565952). {ECO:0000250|UniProtKB:Q8K4J6,
CC       ECO:0000269|PubMed:14565952, ECO:0000269|PubMed:19350017}.
CC   -!- INTERACTION:
CC       Q969V6; P11831: SRF; NbExp=2; IntAct=EBI-493122, EBI-493034;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:24440334}. Nucleus
CC       {ECO:0000269|PubMed:19350017, ECO:0000269|PubMed:24440334}.
CC       Note=Subcellular location is tightly regulated by actin both in
CC       cytoplasm and nucleus: high levels of G-actin in the nucleus observed
CC       during serum deprivation lead to low levels of nuclear MRTFA, while
CC       reduced levels of nuclear G-actin result in accumulation of MRTFA in
CC       the nucleus (By similarity). G-actin-binding in the cytoplasm inhibits
CC       nuclear import by masking the nuclear localization signal (NLS) (By
CC       similarity). In contrast, binding to nuclear globular actin (G-actin)
CC       promotes nuclear export to the cytoplasm (By similarity). Nuclear
CC       localization is regulated by MICAL2, which mediates depolymerization of
CC       nuclear actin, which decreases nuclear G-actin pool, thereby promoting
CC       retention of MRTFA in the nucleus and subsequent formation of an active
CC       complex with SRF (PubMed:24440334). {ECO:0000250|UniProtKB:Q8K4J6,
CC       ECO:0000269|PubMed:24440334}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, has been detected in lung,
CC       placenta, small intestine, liver, kidney, spleen, thymus, colon,
CC       muscle, heart and brain. {ECO:0000269|PubMed:11344311}.
CC   -!- DOMAIN: The N-terminal region is required for nuclear localization and
CC       the C-terminal region mediates transcriptional activity.
CC       {ECO:0000250|UniProtKB:Q8K4J6}.
CC   -!- DOMAIN: The RPEL repeats mediate binding to globular actin (G-actin);
CC       each RPEL repeat-binding to one G-actin monomer. In addition, each
CC       intervening spacer sequence region can bind one G-actin monomer, to
CC       reach a pentavalent complex. {ECO:0000250|UniProtKB:Q8K4J6}.
CC   -!- PTM: Phosphorylation at Ser-6 by Erk inhibits binding of globular actin
CC       (G-actin), unmasking the nuclear localization signal (NLS) and
CC       promoting nuclear import. {ECO:0000250|UniProtKB:Q8K4J6}.
CC   -!- DISEASE: Note=A chromosomal aberration involving MRTFA may be a cause
CC       of acute megakaryoblastic leukemia. Translocation t(1;22)(p13;q13) with
CC       RBM15 (PubMed:11431691, PubMed:11344311). Although both reciprocal
CC       fusion transcripts are detected in acute megakaryoblastic leukemia
CC       (AMKL, FAB-M7), the RBM15-MRTFA chimeric protein has all the putative
CC       functional domains encoded by each gene and is the candidate oncogene
CC       (PubMed:11431691, PubMed:11344311). {ECO:0000269|PubMed:11344311,
CC       ECO:0000269|PubMed:11431691}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAK56920.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA92676.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAC38828.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAC38829.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MALID352.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ297257; CAC38826.1; -; mRNA.
DR   EMBL; AF364035; AAK56920.1; ALT_INIT; mRNA.
DR   EMBL; CR456522; CAG30408.1; -; mRNA.
DR   EMBL; AJ297258; CAC38827.1; -; mRNA.
DR   EMBL; AF368061; AAK54721.1; -; mRNA.
DR   EMBL; AJ303089; CAC38828.1; ALT_INIT; mRNA.
DR   EMBL; AJ303090; CAC38829.1; ALT_INIT; mRNA.
DR   EMBL; AB037859; BAA92676.2; ALT_INIT; mRNA.
DR   EMBL; AL022238; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL713710; CAD28507.2; -; mRNA.
DR   CCDS; CCDS14003.1; -.
DR   RefSeq; NP_001269589.1; NM_001282660.1.
DR   RefSeq; NP_001269590.1; NM_001282661.1.
DR   RefSeq; NP_065882.1; NM_020831.4.
DR   RefSeq; XP_005261751.1; XM_005261694.1.
DR   PDB; 2KVU; NMR; -; A=336-396.
DR   PDB; 2KW9; NMR; -; A=336-396.
DR   PDBsum; 2KVU; -.
DR   PDBsum; 2KW9; -.
DR   SMR; Q969V6; -.
DR   BioGrid; 121642; 26.
DR   IntAct; Q969V6; 15.
DR   MINT; Q969V6; -.
DR   STRING; 9606.ENSP00000347847; -.
DR   DrugBank; DB08080; LATRUNCULIN B.
DR   iPTMnet; Q969V6; -.
DR   PhosphoSitePlus; Q969V6; -.
DR   BioMuta; MKL1; -.
DR   DMDM; 32363202; -.
DR   EPD; Q969V6; -.
DR   jPOST; Q969V6; -.
DR   MassIVE; Q969V6; -.
DR   MaxQB; Q969V6; -.
DR   PaxDb; Q969V6; -.
DR   PeptideAtlas; Q969V6; -.
DR   PRIDE; Q969V6; -.
DR   ProteomicsDB; 75854; -.
DR   Antibodypedia; 26780; 313 antibodies.
DR   DNASU; 57591; -.
DR   Ensembl; ENST00000407029; ENSP00000385835; ENSG00000196588.
DR   GeneID; 57591; -.
DR   KEGG; hsa:57591; -.
DR   UCSC; uc003ayv.3; human.
DR   CTD; 57591; -.
DR   DisGeNET; 57591; -.
DR   GeneCards; MRTFA; -.
DR   HGNC; HGNC:14334; MRTFA.
DR   HPA; ENSG00000196588; Low tissue specificity.
DR   MalaCards; MRTFA; -.
DR   MIM; 606078; gene.
DR   neXtProt; NX_Q969V6; -.
DR   OpenTargets; ENSG00000196588; -.
DR   Orphanet; 402023; Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13).
DR   PharmGKB; PA30827; -.
DR   eggNOG; ENOG410IFJX; Eukaryota.
DR   eggNOG; ENOG41101AM; LUCA.
DR   GeneTree; ENSGT00950000182979; -.
DR   InParanoid; Q969V6; -.
DR   KO; K22525; -.
DR   PhylomeDB; Q969V6; -.
DR   TreeFam; TF326024; -.
DR   Reactome; R-HSA-3899300; SUMOylation of transcription cofactors.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   SIGNOR; Q969V6; -.
DR   ChiTaRS; SMARCA4; human.
DR   EvolutionaryTrace; Q969V6; -.
DR   GeneWiki; MKL1; -.
DR   GenomeRNAi; 57591; -.
DR   Pharos; Q969V6; Tbio.
DR   PRO; PR:Q969V6; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; Q969V6; protein.
DR   Bgee; ENSG00000196588; Expressed in blood and 204 other tissues.
DR   ExpressionAtlas; Q969V6; baseline and differential.
DR   Genevisible; Q969V6; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IDA:UniProtKB.
DR   GO; GO:0003785; F:actin monomer binding; ISS:UniProtKB.
DR   GO; GO:0043522; F:leucine zipper domain binding; IPI:BHF-UCL.
DR   GO; GO:0003713; F:transcription coactivator activity; ISS:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0010735; P:positive regulation of transcription via serum response element binding; IDA:UniProtKB.
DR   GO; GO:0051145; P:smooth muscle cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0044319; P:wound healing, spreading of cells; IDA:CACAO.
DR   Gene3D; 1.10.720.30; -; 1.
DR   InterPro; IPR029992; MRTF-A.
DR   InterPro; IPR004018; RPEL_repeat.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   PANTHER; PTHR22793:SF6; PTHR22793:SF6; 1.
DR   Pfam; PF02755; RPEL; 2.
DR   Pfam; PF02037; SAP; 1.
DR   SMART; SM00707; RPEL; 2.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51073; RPEL; 2.
DR   PROSITE; PS50800; SAP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Actin-binding; Chromosomal rearrangement; Coiled coil;
KW   Cytoplasm; Nucleus; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Reference proteome; Repeat; Transcription; Transcription regulation.
FT   CHAIN           1..931
FT                   /note="Myocardin-related transcription factor A"
FT                   /id="PRO_0000126625"
FT   REPEAT          24..49
FT                   /note="RPEL 1"
FT   REPEAT          68..93
FT                   /note="RPEL 2"
FT   DOMAIN          347..381
FT                   /note="SAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00186"
FT   REGION          1..256
FT                   /note="Mediates interaction with SCAI and ACTB"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   REGION          6..23
FT                   /note="Intervening spacer sequence 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   REGION          50..67
FT                   /note="Intervening spacer sequence 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   COILED          515..563
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        264..286
FT                   /note="Gln-rich"
FT   COMPBIAS        564..811
FT                   /note="Pro-rich"
FT   SITE            3..4
FT                   /note="Breakpoint for translocation to form RBM15-MRTFA"
FT                   /evidence="ECO:0000269|PubMed:11431691"
FT   MOD_RES         6
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983,
FT                   ECO:0000244|PubMed:21406692"
FT   MOD_RES         124
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         139
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         156
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         305
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         310
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         312
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         313
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         317
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         320
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         333
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         385
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163,
FT                   ECO:0000244|PubMed:24275569"
FT   MOD_RES         446
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         447
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         449
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         450
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         454
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:21406692"
FT   MOD_RES         456
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         458
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         482
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         492
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         507
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         511
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         685
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         691
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         695
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         792
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         807
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   MOD_RES         859
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4J6"
FT   VARIANT         648
FT                   /note="S -> G (in dbSNP:rs878756)"
FT                   /evidence="ECO:0000269|PubMed:15461802,
FT                   ECO:0000269|PubMed:17974005"
FT                   /id="VAR_021409"
FT   TURN            345..349
FT                   /evidence="ECO:0000244|PDB:2KVU"
FT   HELIX           352..361
FT                   /evidence="ECO:0000244|PDB:2KVU"
FT   HELIX           370..382
FT                   /evidence="ECO:0000244|PDB:2KVU"
FT   STRAND          388..390
FT                   /evidence="ECO:0000244|PDB:2KVU"
FT   STRAND          392..394
FT                   /evidence="ECO:0000244|PDB:2KW9"
SQ   SEQUENCE   931 AA;  98919 MW;  6EDE5E2C56D89609 CRC64;
     MPPLKSPAAF HEQRRSLERA RTEDYLKRKI RSRPERSELV RMHILEETSA EPSLQAKQLK
     LKRARLADDL NEKIAQRPGP MELVEKNILP VESSLKEAII VGQVNYPKVA DSSSFDEDSS
     DALSPEQPAS HESQGSVPSP LEARVSEPLL SATSASPTQV VSQLPMGRDS REMLFLAEQP
     PLPPPPLLPP SLTNGTTIPT AKSTPTLIKQ SQPKSASEKS QRSKKAKELK PKVKKLKYHQ
     YIPPDQKQDR GAPPMDSSYA KILQQQQLFL QLQILNQQQQ QHHNYQAILP APPKSAGEAL
     GSSGTPPVRS LSTTNSSSSS GAPGPCGLAR QNSTSLTGKP GALPANLDDM KVAELKQELK
     LRSLPVSGTK TELIERLRAY QDQISPVPGA PKAPAATSIL HKAGEVVVAF PAARLSTGPA
     LVAAGLAPAE VVVATVASSG VVKFGSTGST PPVSPTPSER SLLSTGDENS TPGDTFGEMV
     TSPLTQLTLQ ASPLQILVKE EGPRAGSCCL SPGGRAELEG RDKDQMLQEK DKQIEALTRM
     LRQKQQLVER LKLQLEQEKR AQQPAPAPAP LGTPVKQENS FSSCQLSQQP LGPAHPFNPS
     LAAPATNHID PCAVAPGPPS VVVKQEALQP EPEPVPAPQL LLGPQGPSLI KGVAPPTLIT
     DSTGTHLVLT VTNKNADSPG LSSGSPQQPS SQPGSPAPAP SAQMDLEHPL QPLFGTPTSL
     LKKEPPGYEE AMSQQPKQQE NGSSSQQMDD LFDILIQSGE ISADFKEPPS LPGKEKPSPK
     TVCGSPLAAQ PSPSAELPQA APPPPGSPSL PGRLEDFLES STGLPLLTSG HDGPEPLSLI
     DDLHSQMLSS TAILDHPPSP MDTSELHFVP EPSSTMGLDL ADGHLDSMDW LELSSGGPVL
     SLAPLSTTAP SLFSTDFLDG HDLQLHWDSC L
//
ID   W0Z7M9_HUMAN            Unreviewed;       966 AA.
AC   W0Z7M9;
DT   19-MAR-2014, integrated into UniProtKB/TrEMBL.
DT   19-MAR-2014, sequence version 1.
DT   22-APR-2020, entry version 58.
DE   SubName: Full=Mkl1 variant 1 Mkl1_S {ECO:0000313|EMBL:CDJ79779.1};
DE   SubName: Full=Myocardin-related transcription factor A {ECO:0000313|Ensembl:ENSP00000498671};
GN   Name=MRTFA {ECO:0000313|Ensembl:ENSP00000498671};
GN   Synonyms=mkl1 {ECO:0000313|EMBL:CDJ79779.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:CDJ79779.1};
RN   [1] {ECO:0000313|Ensembl:ENSP00000498671, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA   Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA   Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA   Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA   Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA   Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA   Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA   Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA   Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA   Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA   Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA   Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA   Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA   Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA   Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA   Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA   Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA   Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA   Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA   Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA   Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA   Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA   Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA   Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA   Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA   Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA   Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA   McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA   Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA   Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA   Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA   Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [2] {ECO:0000213|PubMed:17081983}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [3] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [4] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [5] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [6] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [7] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [8] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9] {ECO:0000313|EMBL:CDJ79779.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Brain {ECO:0000313|EMBL:CDJ79779.1};
RA   Scharenberg M.A., Pippenger B.E., Sack R., Zingg D., Schenk S.,
RA   Ferralli J., Martin I., Chiquet-Ehrismann R.;
RT   "TGF-beta-induced differentiation into myofibroblasts involves specific
RT   regulation of two MKL1 isoforms.";
RL   Submitted (OCT-2013) to the EMBL/GenBank/DDBJ databases.
RN   [10] {ECO:0000213|PubMed:24275569}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11] {ECO:0000313|Ensembl:ENSP00000498671}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (APR-2019) to UniProtKB.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL022238; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL031594; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF457470; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z86090; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; HG764171; CDJ79779.1; -; mRNA.
DR   RefSeq; NP_001305068.1; NM_001318139.1.
DR   Antibodypedia; 26780; 313 antibodies.
DR   Ensembl; ENST00000652095; ENSP00000498671; ENSG00000196588.
DR   GeneID; 57591; -.
DR   UCSC; uc032qph.2; human.
DR   CTD; 57591; -.
DR   EuPathDB; HostDB:ENSG00000196588.14; -.
DR   HGNC; HGNC:14334; MRTFA.
DR   OpenTargets; ENSG00000196588; -.
DR   eggNOG; ENOG410IFJX; Eukaryota.
DR   eggNOG; ENOG41101AM; LUCA.
DR   GeneTree; ENSGT00950000182979; -.
DR   OMA; PMDSRIC; -.
DR   OrthoDB; 190145at2759; -.
DR   ChiTaRS; SMARCA4; human.
DR   GenomeRNAi; 57591; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000196588; Expressed in blood and 204 other tissues.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003785; F:actin monomer binding; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:Ensembl.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0031175; P:neuron projection development; IEA:Ensembl.
DR   GO; GO:0010735; P:positive regulation of transcription via serum response element binding; IEA:Ensembl.
DR   Gene3D; 1.10.720.30; -; 1.
DR   InterPro; IPR029992; MRTF-A.
DR   InterPro; IPR004018; RPEL_repeat.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   PANTHER; PTHR22793:SF6; PTHR22793:SF6; 1.
DR   Pfam; PF02755; RPEL; 3.
DR   Pfam; PF02037; SAP; 1.
DR   SMART; SM00707; RPEL; 3.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51073; RPEL; 3.
DR   PROSITE; PS50800; SAP; 1.
PE   1: Evidence at protein level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Proteomics identification {ECO:0000213|EPD:W0Z7M9,
KW   ECO:0000213|MaxQB:W0Z7M9, ECO:0000213|PeptideAtlas:W0Z7M9,
KW   ECO:0000213|ProteomicsDB:W0Z7M9};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   REPEAT          15..40
FT                   /note="RPEL"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00401"
FT   REPEAT          59..84
FT                   /note="RPEL"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00401"
FT   REPEAT          103..128
FT                   /note="RPEL"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00401"
FT   DOMAIN          382..416
FT                   /note="SAP"
FT                   /evidence="ECO:0000259|PROSITE:PS50800"
FT   REGION          145..176
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          212..291
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          325..379
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          479..511
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          593..628
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          709..781
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          798..851
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          91..111
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        145..175
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        213..227
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        228..252
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        340..375
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        610..628
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        709..725
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        767..781
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        831..845
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   966 AA;  103002 MW;  375B00BFFC7536B4 CRC64;
     MTLLEPEMLM MAVQSVLQLK LQQRRTREEL VSQGIMPPLK SPAAFHEQRR SLERARTEDY
     LKRKIRSRPE RSELVRMHIL EETSAEPSLQ AKQLKLKRAR LADDLNEKIA QRPGPMELVE
     KNILPVESSL KEAIIVGQVN YPKVADSSSF DEDSSDALSP EQPASHESQG SVPSPLEARV
     SEPLLSATSA SPTQVVSQLP MGRDSREMLF LAEQPPLPPP PLLPPSLTNG TTIPTAKSTP
     TLIKQSQPKS ASEKSQRSKK AKELKPKVKK LKYHQYIPPD QKQDRGAPPM DSSYAKILQQ
     QQLFLQLQIL NQQQQQHHNY QAILPAPPKS AGEALGSSGT PPVRSLSTTN SSSSSGAPGP
     CGLARQNSTS LTGKPGALPA NLDDMKVAEL KQELKLRSLP VSGTKTELIE RLRAYQDQIS
     PVPGAPKAPA ATSILHKAGE VVVAFPAARL STGPALVAAG LAPAEVVVAT VASSGVVKFG
     STGSTPPVSP TPSERSLLST GDENSTPGDT FGEMVTSPLT QLTLQASPLQ ILVKEEGPRA
     GSCCLSPGGR AELEGRDKDQ MLQEKDKQIE ALTRMLRQKQ QLVERLKLQL EQEKRAQQPA
     PAPAPLGTPV KQENSFSSCQ LSQQPLGPAH PFNPSLAAPA TNHIDPCAVA PGPPSVVVKQ
     EALQPEPEPV PAPQLLLGPQ GPSLIKGVAP PTLITDSTGT HLVLTVTNKN ADSPGLSSGS
     PQQPSSQPGS PAPAPSAQMD LEHPLQPLFG TPTSLLKKEP PGYEEAMSQQ PKQQENGSSS
     QQMDDLFDIL IQSGEISADF KEPPSLPGKE KPSPKTVCGS PLAAQPSPSA ELPQAAPPPP
     GSPSLPGRLE DFLESSTGLP LLTSGHDGPE PLSLIDDLHS QMLSSTAILD HPPSPMDTSE
     LHFVPEPSST MGLDLADGHL DSMDWLELSS GGPVLSLAPL STTAPSLFST DFLDGHDLQL
     HWDSCL
//
ID   NFKB2_HUMAN             Reviewed;         900 AA.
AC   Q00653; A8K9D9; D3DR83; Q04860; Q9BU75; Q9H471; Q9H472;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 4.
DT   22-APR-2020, entry version 239.
DE   RecName: Full=Nuclear factor NF-kappa-B p100 subunit;
DE   AltName: Full=DNA-binding factor KBF2;
DE   AltName: Full=H2TF1;
DE   AltName: Full=Lymphocyte translocation chromosome 10 protein;
DE   AltName: Full=Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2;
DE   AltName: Full=Oncogene Lyt-10;
DE            Short=Lyt10;
DE   Contains:
DE     RecName: Full=Nuclear factor NF-kappa-B p52 subunit;
GN   Name=NFKB2; Synonyms=LYT10;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Leukemia;
RX   PubMed=1876189; DOI=10.1038/352733a0;
RA   Schmid R.M., Perkins N.D., Duckett C.S., Andrews P.C., Nabel G.J.;
RT   "Cloning of an NF-kappa B subunit which stimulates HIV transcription in
RT   synergy with p65.";
RL   Nature 352:733-736(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1531086; DOI=10.1128/mcb.12.2.685;
RA   Bours V., Burd P.R., Brown K., Villalobos J., Park S., Ryseck R.P.,
RA   Bravo R., Kelly K., Siebenlist U.;
RT   "A novel mitogen-inducible gene product related to p50/p105-NF-kappa B
RT   participates in transactivation through a kappa B site.";
RL   Mol. Cell. Biol. 12:685-695(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHROMOSOMAL TRANSLOCATION, AND P80HT
RP   GENERATION.
RX   PubMed=8036016;
RA   Thakur S., Lin H.C., Tseng W.T., Kumar S., Bravo R., Foss F., Gelinas C.,
RA   Rabson A.B.;
RT   "Rearrangement and altered expression of the NFKB-2 gene in human cutaneous
RT   T-lymphoma cells.";
RL   Oncogene 9:2335-2344(1994).
RN   [4]
RP   SEQUENCE REVISION.
RA   Rabson A.B.;
RL   Submitted (FEB-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-14; ARG-351 AND
RP   ARG-452.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-220.
RX   PubMed=7969113; DOI=10.1128/mcb.14.12.7695;
RA   Liptay S., Schmid R.M., Nabel E.G., Nabel G.J.;
RT   "Transcriptional regulation of NF-kappa B2: evidence for kappa B-mediated
RT   positive and negative autoregulation.";
RL   Mol. Cell. Biol. 14:7695-7703(1994).
RN   [12]
RP   PROTEIN SEQUENCE OF 459-470; 580-597 AND 636-647 (ISOFORM 1).
RX   PubMed=8360178;
RA   Potter D.A., Larson C.J., Eckes P., Schmid R.M., Nabel G.J., Verdine G.L.,
RA   Sharp P.A.;
RT   "Purification of the major histocompatibility complex class I transcription
RT   factor H2TF1. The full-length product of the nfkb2 gene.";
RL   J. Biol. Chem. 268:18882-18890(1993).
RN   [13]
RP   IDENTIFICATION IN A COMPLEX WITH BCL3.
RX   PubMed=8453667; DOI=10.1016/0092-8674(93)90401-b;
RA   Bours V., Franzoso G., Azarenko V., Park S., Kanno T., Brown K.,
RA   Siebenlist U.;
RT   "The oncoprotein Bcl-3 directly transactivates through kappa B motifs via
RT   association with DNA-binding p50B homodimers.";
RL   Cell 72:729-739(1993).
RN   [14]
RP   FUNCTION, AND IDENTIFICATION IN THE NF-KAPPA-B RELB-P52 COMPLEX.
RX   PubMed=7925301; DOI=10.1002/j.1460-2075.1994.tb06782.x;
RA   Dobrzanski P., Ryseck R.P., Bravo R.;
RT   "Differential interactions of Rel-NF-kappa B complexes with I kappa B alpha
RT   determine pools of constitutive and inducible NF-kappa B activity.";
RL   EMBO J. 13:4608-4616(1994).
RN   [15]
RP   IDENTIFICATION IN THE NF-KAPPA-B P52-C-REL COMPLEX, AND IDENTIFICATION IN
RP   THE NF-KAPPA-B P65-P52 COMPLEX.
RX   PubMed=8152812;
RA   Beg A.A., Baldwin A.S. Jr.;
RT   "Activation of multiple NF-kappa B/Rel DNA-binding complexes by tumor
RT   necrosis factor.";
RL   Oncogene 9:1487-1492(1994).
RN   [16]
RP   INTERACTION WITH NFKBIE.
RX   PubMed=9315679; DOI=10.1128/mcb.17.10.6184;
RA   Li Z., Nabel G.J.;
RT   "A new member of the IkappaB protein family, IkappaB epsilon, inhibits RelA
RT   (p65)-mediated NF-kappaB transcription.";
RL   Mol. Cell. Biol. 17:6184-6190(1997).
RN   [17]
RP   COTRANSLATIONAL FOLDING/PROCESSING OF P100, AND GENERATION OF P52/P100.
RX   PubMed=10597218; DOI=10.1038/sj.onc.1203022;
RA   Heusch M., Lin L., Geleziunas R., Greene W.C.;
RT   "The generation of nfkb2 p52: mechanism and efficiency.";
RL   Oncogene 18:6201-6208(1999).
RN   [18]
RP   PHOSPHORYLATION AT SER-713; SER-715 AND SER-717, MUTAGENESIS, DIMERIZATION,
RP   AND PROTEOLYTIC PROCESSING OF P100.
RX   PubMed=8887665; DOI=10.1128/mcb.16.11.6363;
RA   Betts J.C., Nabel G.J.;
RT   "Differential regulation of NF-kappaB2(p100) processing and control by
RT   amino-terminal sequences.";
RL   Mol. Cell. Biol. 16:6363-6371(1996).
RN   [19]
RP   PHOSPHORYLATION AT SER-866 AND SER-870, MUTAGENESIS OF SER-866 AND SER-870,
RP   AND PROTEOLYTIC PROCESSING OF P100.
RX   PubMed=11239468; DOI=10.1016/s1097-2765(01)00187-3;
RA   Xiao G., Harhaj E.W., Sun S.-C.;
RT   "NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100.";
RL   Mol. Cell 7:401-409(2001).
RN   [20]
RP   CHROMOSOMAL TRANSLOCATION WITH IGHA1.
RX   PubMed=1760839; DOI=10.1016/0092-8674(91)90285-7;
RA   Neri A., Chang C.C., Lombardi L., Salina M., Corradini P., Maiolo A.T.,
RA   Chaganti R.S., Dalla-Favera R.;
RT   "B cell lymphoma-associated chromosomal translocation involves candidate
RT   oncogene lyt-10, homologous to NF-kappa B p50.";
RL   Cell 67:1075-1087(1991).
RN   [21]
RP   CHROMOSOMAL ABERRATIONS, AND GENERATION OF LB40 AND EB308.
RX   PubMed=7949142;
RA   Migliazza A., Lombardi L., Rocchi M., Trecca D., Chang C.-C., Antonacci R.,
RA   Fracchiolla N.S., Ciana P., Maiolo A.T., Neri A.;
RT   "Heterogeneous chromosomal aberrations generate 3' truncations of the
RT   NFKB2/lyt-10 gene in lymphoid malignancies.";
RL   Blood 84:3850-3860(1994).
RN   [22]
RP   CHARACTERIZATION OF THE TWO PROMOTER REGIONS.
RX   PubMed=7541912; DOI=10.1093/nar/23.12.2328;
RA   Lombardi L., Ciana P., Cappellini C., Trecca D., Guerrini L., Migliazza A.,
RA   Maiolo A.T., Neri A.;
RT   "Structural and functional characterization of the promoter regions of the
RT   NFKB2 gene.";
RL   Nucleic Acids Res. 23:2328-2336(1995).
RN   [23]
RP   INTERACTION WITH MEN1.
RX   PubMed=11526476; DOI=10.1038/sj.onc.1204529;
RA   Heppner C., Bilimoria K.Y., Agarwal S.K., Kester M., Whitty L.J.,
RA   Guru S.C., Chandrasekharappa S.C., Collins F.S., Spiegel A.M., Marx S.J.,
RA   Burns A.L.;
RT   "The tumor suppressor protein menin interacts with NF-kappaB proteins and
RT   inhibits NF-kappaB-mediated transactivation.";
RL   Oncogene 20:4917-4925(2001).
RN   [24]
RP   UBIQUITINATION AT LYS-855.
RX   PubMed=14676825; DOI=10.1038/sj.onc.1207366;
RA   Amir R.E., Haecker H., Karin M., Ciechanover A.;
RT   "Mechanism of processing of the NF-kappa B2 p100 precursor: identification
RT   of the specific polyubiquitin chain-anchoring lysine residue and analysis
RT   of the role of NEDD8-modification on the SCF(beta-TrCP) ubiquitin ligase.";
RL   Oncogene 23:2540-2547(2004).
RN   [25]
RP   IDENTIFICATION IN THE NF-KAPPA-B P65-P52 COMPLEX.
RX   PubMed=16477006; DOI=10.1073/pnas.0511096103;
RA   Song Y.J., Jen K.Y., Soni V., Kieff E., Cahir-McFarland E.;
RT   "IL-1 receptor-associated kinase 1 is critical for latent membrane protein
RT   1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:2689-2694(2006).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-429, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-161 AND SER-812, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 37-327.
RX   PubMed=9384586; DOI=10.1093/emboj/16.23.7078;
RA   Cramer P., Larson C.J., Verdine G.L., Mueller C.W.;
RT   "Structure of the human NF-kappaB p52 homodimer-DNA complex at 2.1-A
RT   resolution.";
RL   EMBO J. 16:7078-7090(1997).
RN   [32]
RP   STRUCTURE BY NMR OF 764-859.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the death domain of nuclear factor NF-kappa-B
RT   p100.";
RL   Submitted (DEC-2006) to the PDB data bank.
RN   [33]
RP   INVOLVEMENT IN CVID10.
RX   PubMed=24140114; DOI=10.1016/j.ajhg.2013.09.009;
RA   Chen K., Coonrod E.M., Kumanovics A., Franks Z.F., Durtschi J.D.,
RA   Margraf R.L., Wu W., Heikal N.M., Augustine N.H., Ridge P.G., Hill H.R.,
RA   Jorde L.B., Weyrich A.S., Zimmerman G.A., Gundlapalli A.V., Bohnsack J.F.,
RA   Voelkerding K.V.;
RT   "Germline mutations in NFKB2 implicate the noncanonical NF-kappaB pathway
RT   in the pathogenesis of common variable immunodeficiency.";
RL   Am. J. Hum. Genet. 93:812-824(2013).
RN   [34]
RP   VARIANTS CVID10 GLY-865 AND VAL-867.
RX   PubMed=25524009; DOI=10.1186/s12881-014-0139-9;
RA   Brue T., Quentien M.H., Khetchoumian K., Bensa M., Capo-Chichi J.M.,
RA   Delemer B., Balsalobre A., Nassif C., Papadimitriou D.T., Pagnier A.,
RA   Hasselmann C., Patry L., Schwartzentruber J., Souchon P.F., Takayasu S.,
RA   Enjalbert A., Van Vliet G., Majewski J., Drouin J., Samuels M.E.;
RT   "Mutations in NFKB2 and potential genetic heterogeneity in patients with
RT   DAVID syndrome, having variable endocrine and immune deficiencies.";
RL   BMC Med. Genet. 15:139-139(2014).
CC   -!- FUNCTION: NF-kappa-B is a pleiotropic transcription factor present in
CC       almost all cell types and is the endpoint of a series of signal
CC       transduction events that are initiated by a vast array of stimuli
CC       related to many biological processes such as inflammation, immunity,
CC       differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B
CC       is a homo- or heterodimeric complex formed by the Rel-like domain-
CC       containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and
CC       NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target
CC       genes and the individual dimers have distinct preferences for different
CC       kappa-B sites that they can bind with distinguishable affinity and
CC       specificity. Different dimer combinations act as transcriptional
CC       activators or repressors, respectively. NF-kappa-B is controlled by
CC       various mechanisms of post-translational modification and subcellular
CC       compartmentalization as well as by interactions with other cofactors or
CC       corepressors. NF-kappa-B complexes are held in the cytoplasm in an
CC       inactive state complexed with members of the NF-kappa-B inhibitor (I-
CC       kappa-B) family. In a conventional activation pathway, I-kappa-B is
CC       phosphorylated by I-kappa-B kinases (IKKs) in response to different
CC       activators, subsequently degraded thus liberating the active NF-kappa-B
CC       complex which translocates to the nucleus. In a non-canonical
CC       activation pathway, the MAP3K14-activated CHUK/IKKA homodimer
CC       phosphorylates NFKB2/p100 associated with RelB, inducing its
CC       proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B
CC       RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a
CC       transcriptional activator. The NF-kappa-B p52-p52 homodimer is a
CC       transcriptional repressor. NFKB2 appears to have dual functions such as
CC       cytoplasmic retention of attached NF-kappa-B proteins by p100 and
CC       generation of p52 by a cotranslational processing. The proteasome-
CC       mediated process ensures the production of both p52 and p100 and
CC       preserves their independent function. p52 binds to the kappa-B
CC       consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of
CC       genes involved in immune response and acute phase reactions. p52 and
CC       p100 are respectively the minor and major form; the processing of p100
CC       being relatively poor. Isoform p49 is a subunit of the NF-kappa-B
CC       protein complex, which stimulates the HIV enhancer in synergy with p65.
CC       In concert with RELB, regulates the circadian clock by repressing the
CC       transcriptional activator activity of the CLOCK-ARNTL/BMAL1
CC       heterodimer. {ECO:0000269|PubMed:7925301}.
CC   -!- SUBUNIT: Component of the NF-kappa-B RelB-p52 complex. Homodimer;
CC       component of the NF-kappa-B p52-p52 complex. Component of the NF-kappa-
CC       B p65-p52 complex. Component of the NF-kappa-B p52-c-Rel complex.
CC       NFKB2/p52 interacts with NFKBIE. Component of a complex consisting of
CC       the NF-kappa-B p50-p50 homodimer and BCL3. Directly interacts with
CC       MEN1. {ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:16477006,
CC       ECO:0000269|PubMed:7925301, ECO:0000269|PubMed:8152812,
CC       ECO:0000269|PubMed:8453667, ECO:0000269|PubMed:9315679}.
CC   -!- INTERACTION:
CC       Q00653; P41279: MAP3K8; NbExp=2; IntAct=EBI-307326, EBI-354900;
CC       PRO_0000030322; O00255-2: MEN1; NbExp=3; IntAct=EBI-9869360, EBI-9869387;
CC       Q00653; P19838: NFKB1; NbExp=6; IntAct=EBI-307326, EBI-300010;
CC       Q00653; P25963: NFKBIA; NbExp=2; IntAct=EBI-307326, EBI-307386;
CC       Q00653; Q04864: REL; NbExp=2; IntAct=EBI-307326, EBI-307352;
CC       Q00653; Q01201: RELB; NbExp=2; IntAct=EBI-307326, EBI-357837;
CC       Q00653; P63165: SUMO1; NbExp=2; IntAct=EBI-307326, EBI-80140;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but also found
CC       in the cytoplasm in an inactive form complexed to an inhibitor (I-
CC       kappa-B).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=p100;
CC         IsoId=Q00653-1; Sequence=Displayed;
CC       Name=3; Synonyms=p49;
CC         IsoId=Q00653-3; Sequence=VSP_040082, VSP_040083;
CC       Name=4;
CC         IsoId=Q00653-4; Sequence=VSP_040084;
CC   -!- DOMAIN: The C-terminus of p100 might be involved in cytoplasmic
CC       retention, inhibition of DNA-binding by p52 homodimers, and/or
CC       transcription activation. {ECO:0000250}.
CC   -!- DOMAIN: The glycine-rich region (GRR) appears to be a critical element
CC       in the generation of p52.
CC   -!- PTM: While translation occurs, the particular unfolded structure after
CC       the GRR repeat promotes the generation of p52 making it an acceptable
CC       substrate for the proteasome. This process is known as cotranslational
CC       processing. The processed form is active and the unprocessed form acts
CC       as an inhibitor (I kappa B-like), being able to form cytosolic
CC       complexes with NF-kappa B, trapping it in the cytoplasm. Complete
CC       folding of the region downstream of the GRR repeat precludes
CC       processing.
CC   -!- PTM: Subsequent to MAP3K14-dependent serine phosphorylation, p100
CC       polyubiquitination occurs then triggering its proteasome-dependent
CC       processing. {ECO:0000269|PubMed:11239468, ECO:0000269|PubMed:14676825,
CC       ECO:0000269|PubMed:8887665}.
CC   -!- PTM: Constitutive processing is tightly suppressed by its C-terminal
CC       processing inhibitory domain, named PID, which contains the death
CC       domain.
CC   -!- DISEASE: Note=A chromosomal aberration involving NFKB2 is found in a
CC       case of B-cell non Hodgkin lymphoma (B-NHL). Translocation
CC       t(10;14)(q24;q32) with IGHA1. The resulting oncogene is also called
CC       Lyt-10C alpha variant.
CC   -!- DISEASE: Note=A chromosomal aberration involving NFKB2 is found in a
CC       cutaneous T-cell leukemia (C-TCL) cell line. This rearrangement
CC       produces the p80HT gene which codes for a truncated 80 kDa protein
CC       (p80HT).
CC   -!- DISEASE: Note=In B-cell leukemia (B-CLL) cell line, LB40 and EB308, can
CC       be found after heterogeneous chromosomal aberrations, such as internal
CC       deletions.
CC   -!- DISEASE: Immunodeficiency, common variable, 10 (CVID10) [MIM:615577]: A
CC       primary immunodeficiency characterized by childhood-onset of recurrent
CC       infections, hypogammaglobulinemia, and decreased numbers of memory and
CC       marginal zone B-cells. Some patients may develop autoimmune features
CC       and have circulating autoantibodies. An unusual feature is central
CC       adrenal insufficiency. {ECO:0000269|PubMed:24140114,
CC       ECO:0000269|PubMed:25524009}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA43715.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- SEQUENCE CAUTION: [Isoform 3]:
CC       Sequence=CAA43716.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NFKB2ID362.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/nfkb2/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X61498; CAA43715.1; ALT_FRAME; mRNA.
DR   EMBL; X61499; CAA43716.1; ALT_FRAME; mRNA.
DR   EMBL; S76638; AAB21124.1; -; mRNA.
DR   EMBL; U09609; AAA21462.2; -; mRNA.
DR   EMBL; BT009769; AAP88771.1; -; mRNA.
DR   EMBL; AK292654; BAF85343.1; -; mRNA.
DR   EMBL; AY865619; AAW56071.1; -; Genomic_DNA.
DR   EMBL; AL121928; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW49700.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49701.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49702.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49704.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49706.1; -; Genomic_DNA.
DR   EMBL; BC002844; AAH02844.1; -; mRNA.
DR   EMBL; U20816; AAA68171.1; -; Genomic_DNA.
DR   CCDS; CCDS41564.1; -. [Q00653-1]
DR   CCDS; CCDS41565.1; -. [Q00653-4]
DR   PIR; A42024; A42024.
DR   PIR; A57034; A57034.
DR   PIR; I38609; I38609.
DR   PIR; S17233; S17233.
DR   RefSeq; NP_001070962.1; NM_001077494.3. [Q00653-1]
DR   RefSeq; NP_001248332.1; NM_001261403.2. [Q00653-4]
DR   RefSeq; NP_001275653.1; NM_001288724.1. [Q00653-4]
DR   RefSeq; NP_001309863.1; NM_001322934.1. [Q00653-1]
DR   RefSeq; NP_001309864.1; NM_001322935.1.
DR   RefSeq; NP_002493.3; NM_002502.5. [Q00653-4]
DR   PDB; 1A3Q; X-ray; 2.10 A; A/B=37-327.
DR   PDB; 2D96; NMR; -; A=766-859.
DR   PDB; 3DO7; X-ray; 3.05 A; B=37-329.
DR   PDB; 4OT9; X-ray; 3.35 A; A=407-765.
DR   PDB; 5ZMC; X-ray; 2.99 A; A=35-329.
DR   PDBsum; 1A3Q; -.
DR   PDBsum; 2D96; -.
DR   PDBsum; 3DO7; -.
DR   PDBsum; 4OT9; -.
DR   PDBsum; 5ZMC; -.
DR   SMR; Q00653; -.
DR   BioGrid; 110858; 64.
DR   CORUM; Q00653; -.
DR   DIP; DIP-24239N; -.
DR   DIP; DIP-27535N; -.
DR   IntAct; Q00653; 45.
DR   MINT; Q00653; -.
DR   STRING; 9606.ENSP00000358983; -.
DR   ChEMBL; CHEMBL3003; -.
DR   DrugBank; DB05767; Andrographolide.
DR   DrugBank; DB05487; Custirsen.
DR   DrugBank; DB00843; Donepezil.
DR   DrugBank; DB13961; Fish oil.
DR   DrugBank; DB01296; Glucosamine.
DR   DrugBank; DB13751; Glycyrrhizic acid.
DR   DrugBank; DB05212; HE3286.
DR   DrugBank; DB05559; NF-kappaB Decoy.
DR   DrugBank; DB05464; NOX-700.
DR   DrugBank; DB05451; P54.
DR   DrugBank; DB14059; SC-236.
DR   DrugBank; DB05471; SGN-30.
DR   DrugCentral; Q00653; -.
DR   CarbonylDB; Q00653; -.
DR   iPTMnet; Q00653; -.
DR   PhosphoSitePlus; Q00653; -.
DR   SwissPalm; Q00653; -.
DR   BioMuta; NFKB2; -.
DR   DMDM; 116242678; -.
DR   CPTAC; CPTAC-721; -.
DR   EPD; Q00653; -.
DR   jPOST; Q00653; -.
DR   MassIVE; Q00653; -.
DR   MaxQB; Q00653; -.
DR   PaxDb; Q00653; -.
DR   PeptideAtlas; Q00653; -.
DR   PRIDE; Q00653; -.
DR   ProteomicsDB; 57866; -. [Q00653-1]
DR   ProteomicsDB; 57867; -. [Q00653-3]
DR   ProteomicsDB; 57868; -. [Q00653-4]
DR   ABCD; Q00653; -.
DR   Antibodypedia; 1322; 933 antibodies.
DR   DNASU; 4791; -.
DR   Ensembl; ENST00000189444; ENSP00000189444; ENSG00000077150. [Q00653-4]
DR   Ensembl; ENST00000369966; ENSP00000358983; ENSG00000077150. [Q00653-1]
DR   Ensembl; ENST00000428099; ENSP00000410256; ENSG00000077150. [Q00653-4]
DR   Ensembl; ENST00000652277; ENSP00000498308; ENSG00000077150. [Q00653-4]
DR   Ensembl; ENST00000661543; ENSP00000499294; ENSG00000077150. [Q00653-1]
DR   GeneID; 4791; -.
DR   KEGG; hsa:4791; -.
DR   UCSC; uc001kva.4; human. [Q00653-1]
DR   CTD; 4791; -.
DR   DisGeNET; 4791; -.
DR   GeneCards; NFKB2; -.
DR   HGNC; HGNC:7795; NFKB2.
DR   HPA; ENSG00000077150; Low tissue specificity.
DR   MalaCards; NFKB2; -.
DR   MIM; 164012; gene.
DR   MIM; 615577; phenotype.
DR   neXtProt; NX_Q00653; -.
DR   OpenTargets; ENSG00000077150; -.
DR   Orphanet; 1572; Common variable immunodeficiency.
DR   Orphanet; 293978; Deficiency in anterior pituitary function-variable immunodeficiency syndrome.
DR   PharmGKB; PA31600; -.
DR   eggNOG; KOG0504; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   GeneTree; ENSGT00940000160968; -.
DR   HOGENOM; CLU_004343_1_1_1; -.
DR   InParanoid; Q00653; -.
DR   KO; K04469; -.
DR   OMA; VIYHAPH; -.
DR   OrthoDB; 916931at2759; -.
DR   PhylomeDB; Q00653; -.
DR   TreeFam; TF325632; -.
DR   Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-HSA-3134963; DEx/H-box helicases activate type I IFN and inflammatory cytokines production.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-HSA-448706; Interleukin-1 processing.
DR   Reactome; R-HSA-4755510; SUMOylation of immune response proteins.
DR   Reactome; R-HSA-5603029; IkBA variant leads to EDA-ID.
DR   Reactome; R-HSA-5607761; Dectin-1 mediated noncanonical NF-kB signaling.
DR   Reactome; R-HSA-5676590; NIK-->noncanonical NF-kB signaling.
DR   Reactome; R-HSA-844456; The NLRP3 inflammasome.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   SIGNOR; Q00653; -.
DR   ChiTaRS; NFKB2; human.
DR   EvolutionaryTrace; Q00653; -.
DR   GeneWiki; NFKB2; -.
DR   GenomeRNAi; 4791; -.
DR   Pharos; Q00653; Tchem.
DR   PRO; PR:Q00653; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q00653; protein.
DR   Bgee; ENSG00000077150; Expressed in left lobe of thyroid gland and 169 other tissues.
DR   ExpressionAtlas; Q00653; baseline and differential.
DR   Genevisible; Q00653; HS.
DR   GO; GO:0033257; C:Bcl3/NF-kappaB2 complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0033256; C:I-kappaB/NF-kappaB complex; IBA:GO_Central.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0003713; F:transcription coactivator activity; TAS:ProtInc.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; IEA:Ensembl.
DR   GO; GO:0002268; P:follicular dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0002467; P:germinal center formation; IEA:Ensembl.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0038061; P:NIK/NF-kappaB signaling; IBA:GO_Central.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; TAS:Reactome.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0034097; P:response to cytokine; IBA:GO_Central.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR   CDD; cd01177; IPT_NFkappaB; 1.
DR   Gene3D; 1.25.40.20; -; 1.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 2.60.40.340; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002909; IPT_dom.
DR   InterPro; IPR033926; IPT_NFkappaB.
DR   InterPro; IPR000451; NFkB/Dor.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR030492; RHD_CS.
DR   InterPro; IPR032397; RHD_dimer.
DR   InterPro; IPR011539; RHD_DNA_bind_dom.
DR   InterPro; IPR037059; RHD_DNA_bind_dom_sf.
DR   PANTHER; PTHR24169; PTHR24169; 1.
DR   Pfam; PF12796; Ank_2; 2.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF16179; RHD_dimer; 1.
DR   Pfam; PF00554; RHD_DNA_bind; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   PRINTS; PR00057; NFKBTNSCPFCT.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00429; IPT; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   SUPFAM; SSF81296; SSF81296; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 5.
DR   PROSITE; PS01204; REL_1; 1.
DR   PROSITE; PS50254; REL_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; ANK repeat;
KW   Biological rhythms; Chromosomal rearrangement; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; DNA-binding; Isopeptide bond;
KW   Nucleus; Phosphoprotein; Polymorphism; Proto-oncogene; Reference proteome;
KW   Repeat; Repressor; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN           1..900
FT                   /note="Nuclear factor NF-kappa-B p100 subunit"
FT                   /id="PRO_0000030321"
FT   CHAIN           1..454
FT                   /note="Nuclear factor NF-kappa-B p52 subunit"
FT                   /id="PRO_0000030322"
FT   DOMAIN          38..343
FT                   /note="RHD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00265"
FT   REPEAT          487..519
FT                   /note="ANK 1"
FT   REPEAT          526..555
FT                   /note="ANK 2"
FT   REPEAT          559..591
FT                   /note="ANK 3"
FT   REPEAT          599..628
FT                   /note="ANK 4"
FT   REPEAT          633..663
FT                   /note="ANK 5"
FT   REPEAT          667..696
FT                   /note="ANK 6"
FT   REPEAT          729..758
FT                   /note="ANK 7"
FT   DOMAIN          764..851
FT                   /note="Death"
FT   REGION          346..377
FT                   /note="GRR"
FT   MOTIF           337..341
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        350..400
FT                   /note="Gly-rich"
FT   SITE            454..455
FT                   /note="Cleavage (when cotranslationally processed)"
FT   SITE            490..491
FT                   /note="Breakpoint for translocation to form NFKB2-IGHA1
FT                   oncogene"
FT   MOD_RES         23
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         161
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         429
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         713
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:8887665"
FT   MOD_RES         715
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:8887665"
FT   MOD_RES         717
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:8887665"
FT   MOD_RES         812
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         866
FT                   /note="Phosphoserine; by MAP3K14"
FT                   /evidence="ECO:0000269|PubMed:11239468"
FT   MOD_RES         870
FT                   /note="Phosphoserine; by MAP3K14"
FT                   /evidence="ECO:0000269|PubMed:11239468"
FT   CROSSLNK        855
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:14676825"
FT   VAR_SEQ         374..428
FT                   /note="GSLGFFPSSLAYSPYQSGAGPMGCYPGGGGGAQMAATVPSRDSGEEAAEPSA
FT                   PSR -> EGVLMEGGVKVREAVEEKNLGEAGRGLHACNPALWEAKAGRLPEIRSSRPAW
FT                   PTA (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1876189"
FT                   /id="VSP_040082"
FT   VAR_SEQ         429..900
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1876189"
FT                   /id="VSP_040083"
FT   VAR_SEQ         860
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:1876189,
FT                   ECO:0000303|Ref.5"
FT                   /id="VSP_040084"
FT   VARIANT         14
FT                   /note="E -> K (in dbSNP:rs45581936)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_022223"
FT   VARIANT         351
FT                   /note="G -> R (in dbSNP:rs45580031)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_022224"
FT   VARIANT         392
FT                   /note="A -> G (in dbSNP:rs11574848)"
FT                   /id="VAR_051781"
FT   VARIANT         452
FT                   /note="G -> R (in dbSNP:rs45471103)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_022225"
FT   VARIANT         618..900
FT                   /note="Missing (in truncated form EB308)"
FT                   /id="VAR_018452"
FT   VARIANT         667..669
FT                   /note="AGN -> SAS (in truncated form p80HT)"
FT                   /id="VAR_006909"
FT   VARIANT         670..900
FT                   /note="Missing (in truncated form p80HT)"
FT                   /id="VAR_006910"
FT   VARIANT         703..900
FT                   /note="Missing (in truncated form LB40)"
FT                   /id="VAR_018453"
FT   VARIANT         865
FT                   /note="D -> G (in CVID10; unknown pathological
FT                   significance; de novo mutation; dbSNP:rs727502787)"
FT                   /evidence="ECO:0000269|PubMed:25524009"
FT                   /id="VAR_074035"
FT   VARIANT         867
FT                   /note="A -> V (in CVID10; unknown pathological
FT                   significance; de novo mutation; dbSNP:rs727502788)"
FT                   /evidence="ECO:0000269|PubMed:25524009"
FT                   /id="VAR_074036"
FT   MUTAGEN         247..249
FT                   /note="YLL->AAA: Two-fold reduction in heterodimerization
FT                   with RelA."
FT                   /evidence="ECO:0000269|PubMed:8887665"
FT   MUTAGEN         399
FT                   /note="P->A: No change in cleavage rate or products."
FT                   /evidence="ECO:0000269|PubMed:8887665"
FT   MUTAGEN         404
FT                   /note="G->A: No change in cleavage rate or products."
FT                   /evidence="ECO:0000269|PubMed:8887665"
FT   MUTAGEN         405
FT                   /note="A->P: No change in cleavage rate or products."
FT                   /evidence="ECO:0000269|PubMed:8887665"
FT   MUTAGEN         406
FT                   /note="Q->N: No change in cleavage rate or products."
FT                   /evidence="ECO:0000269|PubMed:8887665"
FT   MUTAGEN         713
FT                   /note="S->G: Loss of phosphorylation; when associated with
FT                   A-715 and A-717."
FT                   /evidence="ECO:0000269|PubMed:8887665"
FT   MUTAGEN         715
FT                   /note="S->A: Loss of phosphorylation; when associated with
FT                   G-713 and A-717."
FT                   /evidence="ECO:0000269|PubMed:8887665"
FT   MUTAGEN         717
FT                   /note="S->A: Loss of phosphorylation; when associated with
FT                   G-713 and A-715."
FT                   /evidence="ECO:0000269|PubMed:8887665"
FT   MUTAGEN         866
FT                   /note="S->A: Decrease in MAP3K14-induced phosphorylation;
FT                   no inducible processing occurs; when associated with A-
FT                   869."
FT                   /evidence="ECO:0000269|PubMed:11239468"
FT   MUTAGEN         870
FT                   /note="S->A: Decrease in MAP3K14-induced phosphorylation;
FT                   no inducible processing occurs; when associated with A-
FT                   865."
FT                   /evidence="ECO:0000269|PubMed:11239468"
FT   CONFLICT        144
FT                   /note="K -> E (in Ref. 2; AAB21124)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        213
FT                   /note="I -> T (in Ref. 1; CAA43715/CAA43716 and 11;
FT                   AAA68171)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        396
FT                   /note="G -> R (in Ref. 1; CAA43715)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        433..434
FT                   /note="EP -> DA (in Ref. 2; AAB21124)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        459
FT                   /note="R -> K (in Ref. 12; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        465
FT                   /note="G -> C (in Ref. 1; CAA43715)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        470
FT                   /note="A -> R (in Ref. 1; CAA43715 and 2; AAB21124)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        741
FT                   /note="K -> L (in Ref. 1; CAA43715)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        860
FT                   /note="A -> T (in Ref. 2; AAB21124)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        876
FT                   /note="E -> K (in Ref. 2; AAB21124)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        891
FT                   /note="C -> S (in Ref. 1; CAA43715)"
FT                   /evidence="ECO:0000305"
FT   STRAND          39..44
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          48..51
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   TURN            56..58
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          79..83
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          87..96
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          98..101
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          106..111
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          116..118
FT                   /evidence="ECO:0000244|PDB:3DO7"
FT   STRAND          120..124
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          130..132
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          136..140
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   TURN            143..145
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   HELIX           146..158
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   TURN            159..161
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   HELIX           168..182
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          189..198
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          205..207
FT                   /evidence="ECO:0000244|PDB:3DO7"
FT   STRAND          217..219
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          220..222
FT                   /evidence="ECO:0000244|PDB:3DO7"
FT   TURN            223..225
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          230..234
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          236..239
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          240..242
FT                   /evidence="ECO:0000244|PDB:3DO7"
FT   STRAND          245..252
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   TURN            255..257
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          258..264
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          266..268
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          270..273
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   HELIX           278..280
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   TURN            283..285
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          286..290
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          303..311
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   TURN            312..314
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   STRAND          321..326
FT                   /evidence="ECO:0000244|PDB:1A3Q"
FT   HELIX           439..467
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           470..475
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           476..480
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           491..497
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           501..512
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   TURN            513..515
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           519..521
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           530..536
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           540..548
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           563..567
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           575..582
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           586..588
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   TURN            589..593
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   TURN            597..599
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           603..609
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           613..621
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   TURN            631..633
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           637..643
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           647..654
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   TURN            655..657
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           671..678
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           681..689
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   TURN            733..735
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           740..751
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   STRAND          752..754
FT                   /evidence="ECO:0000244|PDB:4OT9"
FT   HELIX           772..782
FT                   /evidence="ECO:0000244|PDB:2D96"
FT   STRAND          783..786
FT                   /evidence="ECO:0000244|PDB:2D96"
FT   HELIX           791..798
FT                   /evidence="ECO:0000244|PDB:2D96"
FT   HELIX           801..808
FT                   /evidence="ECO:0000244|PDB:2D96"
FT   HELIX           813..823
FT                   /evidence="ECO:0000244|PDB:2D96"
FT   HELIX           828..838
FT                   /evidence="ECO:0000244|PDB:2D96"
FT   HELIX           841..848
FT                   /evidence="ECO:0000244|PDB:2D96"
SQ   SEQUENCE   900 AA;  96749 MW;  6BAD7038834783CA CRC64;
     MESCYNPGLD GIIEYDDFKL NSSIVEPKEP APETADGPYL VIVEQPKQRG FRFRYGCEGP
     SHGGLPGASS EKGRKTYPTV KICNYEGPAK IEVDLVTHSD PPRAHAHSLV GKQCSELGIC
     AVSVGPKDMT AQFNNLGVLH VTKKNMMGTM IQKLQRQRLR SRPQGLTEAE QRELEQEAKE
     LKKVMDLSIV RLRFSAFLRA SDGSFSLPLK PVISQPIHDS KSPGASNLKI SRMDKTAGSV
     RGGDEVYLLC DKVQKDDIEV RFYEDDENGW QAFGDFSPTD VHKQYAIVFR TPPYHKMKIE
     RPVTVFLQLK RKRGGDVSDS KQFTYYPLVE DKEEVQRKRR KALPTFSQPF GGGSHMGGGS
     GGAAGGYGGA GGGGSLGFFP SSLAYSPYQS GAGPMGCYPG GGGGAQMAAT VPSRDSGEEA
     AEPSAPSRTP QCEPQAPEML QRAREYNARL FGLAQRSARA LLDYGVTADA RALLAGQRHL
     LTAQDENGDT PLHLAIIHGQ TSVIEQIVYV IHHAQDLGVV NLTNHLHQTP LHLAVITGQT
     SVVSFLLRVG ADPALLDRHG DSAMHLALRA GAGAPELLRA LLQSGAPAVP QLLHMPDFEG
     LYPVHLAVRA RSPECLDLLV DSGAEVEATE RQGGRTALHL ATEMEELGLV THLVTKLRAN
     VNARTFAGNT PLHLAAGLGY PTLTRLLLKA GADIHAENEE PLCPLPSPPT SDSDSDSEGP
     EKDTRSSFRG HTPLDLTCST KVKTLLLNAA QNTMEPPLTP PSPAGPGLSL GDTALQNLEQ
     LLDGPEAQGS WAELAERLGL RSLVDTYRQT TSPSGSLLRS YELAGGDLAG LLEALSDMGL
     EEGVRLLRGP ETRDKLPSTA EVKEDSAYGS QSVEQEAEKL GPPPEPPGGL CHGHPQPQVH
//
ID   NOTC1_HUMAN             Reviewed;        2555 AA.
AC   P46531; Q59ED8; Q5SXM3;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 4.
DT   22-APR-2020, entry version 237.
DE   RecName: Full=Neurogenic locus notch homolog protein 1;
DE            Short=Notch 1;
DE            Short=hN1;
DE   AltName: Full=Translocation-associated notch protein TAN-1;
DE   Contains:
DE     RecName: Full=Notch 1 extracellular truncation;
DE              Short=NEXT;
DE   Contains:
DE     RecName: Full=Notch 1 intracellular domain;
DE              Short=NICD;
DE   Flags: Precursor;
GN   Name=NOTCH1; Synonyms=TAN1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Mann R.S., Blaumueller C.M., Zagouras P.;
RT   "Complete human notch 1 (hN1) cDNA sequence.";
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-2443.
RX   PubMed=1831692; DOI=10.1016/0092-8674(91)90111-b;
RA   Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D.,
RA   Sklar J.;
RT   "TAN-1, the human homolog of the Drosophila notch gene, is broken by
RT   chromosomal translocations in T lymphoblastic neoplasms.";
RL   Cell 66:649-661(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 489-2555.
RC   TISSUE=Aortic endothelium;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   PROTEIN SEQUENCE OF 1947-1962, INTERACTION WITH HIF1AN, HYDROXYLATION AT
RP   ASN-1955, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17573339; DOI=10.1074/jbc.m704102200;
RA   Coleman M.L., McDonough M.A., Hewitson K.S., Coles C., Mecinovic J.,
RA   Edelmann M., Cook K.M., Cockman M.E., Lancaster D.E., Kessler B.M.,
RA   Oldham N.J., Ratcliffe P.J., Schofield C.J.;
RT   "Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor
RT   inhibiting hypoxia-inducible factor.";
RL   J. Biol. Chem. 282:24027-24038(2007).
RN   [6]
RP   IDENTIFICATION OF LIGANDS.
RX   PubMed=10079256; DOI=10.1016/s0002-9440(10)65325-4;
RA   Gray G.E., Mann R.S., Mitsiadis E., Henrique D., Carcangiu M.-L., Banks A.,
RA   Leiman J., Ward D., Ish-Horowitz D., Artavanis-Tsakonas S.;
RT   "Human ligands of the Notch receptor.";
RL   Am. J. Pathol. 154:785-794(1999).
RN   [7]
RP   INTERACTION WITH DTX1.
RX   PubMed=9590294; DOI=10.1038/ng0598-74;
RA   Matsuno K., Eastman D., Mitsiades T., Quinn A.M., Carcanciu M.L.,
RA   Ordentlich P., Kadesch T., Artavanis-Tsakonas S.;
RT   "Human deltex is a conserved regulator of Notch signalling.";
RL   Nat. Genet. 19:74-78(1998).
RN   [8]
RP   INTERACTION WITH SNW1.
RX   PubMed=10713164; DOI=10.1128/mcb.20.7.2400-2410.2000;
RA   Zhou S., Fujimuro M., Hsieh J.J., Chen L., Miyamoto A., Weinmaster G.,
RA   Hayward S.D.;
RT   "SKIP, a CBF1-associated protein, interacts with the ankyrin repeat domain
RT   of NotchIC To facilitate NotchIC function.";
RL   Mol. Cell. Biol. 20:2400-2410(2000).
RN   [9]
RP   INTERACTION WITH MAML1.
RX   PubMed=11101851; DOI=10.1038/82644;
RA   Wu L., Aster J.C., Blacklow S.C., Lake R., Artavanis-Tsakonas S.,
RA   Griffin J.D.;
RT   "MAML1, a human homologue of Drosophila mastermind, is a transcriptional
RT   co-activator for NOTCH receptors.";
RL   Nat. Genet. 26:484-489(2000).
RN   [10]
RP   INTERACTION WITH MAML2 AND MAML3.
RX   PubMed=12370315; DOI=10.1128/mcb.22.21.7688-7700.2002;
RA   Wu L., Sun T., Kobayashi K., Gao P., Griffin J.D.;
RT   "Identification of a family of mastermind-like transcriptional coactivators
RT   for mammalian notch receptors.";
RL   Mol. Cell. Biol. 22:7688-7700(2002).
RN   [11]
RP   INTERACTION WITH CCN3.
RX   PubMed=12050162; DOI=10.1074/jbc.m203727200;
RA   Sakamoto K., Yamaguchi S., Ando R., Miyawaki A., Kabasawa Y., Takagi M.,
RA   Li C.L., Perbal B., Katsube K.;
RT   "The nephroblastoma overexpressed gene (NOV/ccn3) protein associates with
RT   Notch1 extracellular domain and inhibits myoblast differentiation via Notch
RT   signaling pathway.";
RL   J. Biol. Chem. 277:29399-29405(2002).
RN   [12]
RP   INVOLVEMENT IN AOVD1.
RX   PubMed=16025100; DOI=10.1038/nature03940;
RA   Garg V., Muth A.N., Ransom J.F., Schluterman M.K., Barnes R., King I.N.,
RA   Grossfeld P.D., Srivastava D.;
RT   "Mutations in NOTCH1 cause aortic valve disease.";
RL   Nature 437:270-274(2005).
RN   [13]
RP   UBIQUITINATION BY ITCH.
RX   PubMed=18628966; DOI=10.1371/journal.pone.0002735;
RA   Chastagner P., Israel A., Brou C.;
RT   "AIP4/Itch regulates Notch receptor degradation in the absence of ligand.";
RL   PLoS ONE 3:E2735-E2735(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   FUNCTION.
RX   PubMed=20616313; DOI=10.1161/circresaha.110.217257;
RA   Brutsch R., Liebler S.S., Wustehube J., Bartol A., Herberich S.E.,
RA   Adam M.G., Telzerow A., Augustin H.G., Fischer A.;
RT   "Integrin cytoplasmic domain-associated protein-1 attenuates sprouting
RT   angiogenesis.";
RL   Circ. Res. 107:592-601(2010).
RN   [16]
RP   INTERACTION WITH SNAI1 AND MDM2A.
RX   PubMed=22128911; DOI=10.1186/1741-7007-9-83;
RA   Lim S.O., Kim H.S., Quan X., Ahn S.M., Kim H., Hsieh D., Seong J.K.,
RA   Jung G.;
RT   "Notch1 binds and induces degradation of Snail in hepatocellular
RT   carcinoma.";
RL   BMC Biol. 9:83-83(2011).
RN   [17]
RP   INTERACTION WITH AAK1.
RX   PubMed=21464124; DOI=10.1074/jbc.m110.190769;
RA   Gupta-Rossi N., Ortica S., Meas-Yedid V., Heuss S., Moretti J.,
RA   Olivo-Marin J.C., Israel A.;
RT   "The adaptor-associated kinase 1, AAK1, is a positive regulator of the
RT   Notch pathway.";
RL   J. Biol. Chem. 286:18720-18730(2011).
RN   [18]
RP   INTERACTION WITH SGK1 AND FBXW7.
RX   PubMed=21147854; DOI=10.1242/jcs.073924;
RA   Mo J.S., Ann E.J., Yoon J.H., Jung J., Choi Y.H., Kim H.Y., Ahn J.S.,
RA   Kim S.M., Kim M.Y., Hong J.A., Seo M.S., Lang F., Choi E.J., Park H.S.;
RT   "Serum- and glucocorticoid-inducible kinase 1 (SGK1) controls Notch1
RT   signaling by downregulation of protein stability through Fbw7 ubiquitin
RT   ligase.";
RL   J. Cell Sci. 124:100-112(2011).
RN   [19]
RP   INTERACTION WITH SNW1.
RX   PubMed=21245387; DOI=10.1128/mcb.00360-10;
RA   Vasquez-Del Carpio R., Kaplan F.M., Weaver K.L., VanWye J.D.,
RA   Alves-Guerra M.C., Robbins D.J., Capobianco A.J.;
RT   "Assembly of a Notch transcriptional activation complex requires
RT   multimerization.";
RL   Mol. Cell. Biol. 31:1396-1408(2011).
RN   [20]
RP   UBIQUITINATION BY ITCH.
RX   PubMed=23886940; DOI=10.1242/jcs.130500;
RA   Puca L., Chastagner P., Meas-Yedid V., Israel A., Brou C.;
RT   "Alpha-arrestin 1 (ARRDC1) and beta-arrestins cooperate to mediate Notch
RT   degradation in mammals.";
RL   J. Cell Sci. 126:4457-4468(2013).
RN   [21]
RP   GLYCOSYLATION AT THR-232; THR-1402 AND THR-1725, AND PROTEOLYTIC
RP   PROCESSING.
RX   PubMed=24226769; DOI=10.1038/nature12723;
RA   Boskovski M.T., Yuan S., Pedersen N.B., Goth C.K., Makova S., Clausen H.,
RA   Brueckner M., Khokha M.K.;
RT   "The heterotaxy gene GALNT11 glycosylates Notch to orchestrate cilia type
RT   and laterality.";
RL   Nature 504:456-459(2013).
RN   [22]
RP   ANKYRIN REPEATS.
RX   PubMed=25547411; DOI=10.1186/s12859-014-0440-9;
RA   Chakrabarty B., Parekh N.;
RT   "Identifying tandem Ankyrin repeats in protein structures.";
RL   BMC Bioinformatics 15:6599-6599(2014).
RN   [23]
RP   INTERACTION WITH ZMIZ1.
RX   PubMed=26522984; DOI=10.1016/j.immuni.2015.10.007;
RA   Pinnell N., Yan R., Cho H.J., Keeley T., Murai M.J., Liu Y., Alarcon A.S.,
RA   Qin J., Wang Q., Kuick R., Elenitoba-Johnson K.S., Maillard I.,
RA   Samuelson L.C., Cierpicki T., Chiang M.Y.;
RT   "The PIAS-like coactivator Zmiz1 is a direct and selective cofactor of
RT   Notch1 in T cell development and leukemia.";
RL   Immunity 43:870-883(2015).
RN   [24]
RP   GLYCOSYLATION AT SER-435.
RX   PubMed=30127001; DOI=10.1073/pnas.1804005115;
RA   Takeuchi H., Schneider M., Williamson D.B., Ito A., Takeuchi M.,
RA   Handford P.A., Haltiwanger R.S.;
RT   "Two novel protein O-glucosyltransferases that modify sites distinct from
RT   POGLUT1 and affect Notch trafficking and signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:E8395-E8402(2018).
RN   [25]
RP   STRUCTURE BY NMR OF 1446-1480 IN COMPLEX WITH CALCIUM IONS, AND DISULFIDE
RP   BONDS.
RX   PubMed=12795601; DOI=10.1021/bi034156y;
RA   Vardar D., North C.L., Sanchez-Irizarry C., Aster J.C., Blacklow S.C.;
RT   "Nuclear magnetic resonance structure of a prototype Lin12-Notch repeat
RT   module from human Notch1.";
RL   Biochemistry 42:7061-7067(2003).
RN   [26]
RP   STRUCTURE BY NMR OF 411-526.
RX   PubMed=15576031; DOI=10.1016/j.str.2004.09.012;
RA   Hambleton S., Valeyev N.V., Muranyi A., Knott V., Werner J.M.,
RA   McMichael A.J., Handford P.A., Downing A.K.;
RT   "Structural and functional properties of the human notch-1 ligand binding
RT   region.";
RL   Structure 12:2173-2183(2004).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 1872-2114.
RX   PubMed=16011479; DOI=10.1042/bj20050515;
RA   Ehebauer M.T., Chirgadze D.Y., Hayward P., Martinez Arias A.,
RA   Blundell T.L.;
RT   "High-resolution crystal structure of the human Notch 1 ankyrin domain.";
RL   Biochem. J. 392:13-20(2005).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 1872-2126 IN COMPLEX WITH RBPSUH
RP   AND MAML1.
RX   PubMed=16530044; DOI=10.1016/j.cell.2005.12.037;
RA   Nam Y., Sliz P., Song L., Aster J.C., Blacklow S.C.;
RT   "Structural basis for cooperativity in recruitment of MAML coactivators to
RT   Notch transcription complexes.";
RL   Cell 124:973-983(2006).
RN   [29]
RP   STRUCTURE BY NMR OF 1721-1771, AND TOPOLOGY.
RX   PubMed=28439555; DOI=10.1126/sciadv.1602794;
RA   Deatherage C.L., Lu Z., Kroncke B.M., Ma S., Smith J.A., Voehler M.W.,
RA   McFeeters R.L., Sanders C.R.;
RT   "Structural and biochemical differences between the Notch and the amyloid
RT   precursor protein transmembrane domains.";
RL   Sci. Adv. 3:E1602794-E1602794(2017).
RN   [30]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.70 ANGSTROMS) OF 1721-1821 IN COMPLEX
RP   WITH GAMMA-SECRETASE, SUBUNIT, TOPOLOGY, INTERACTION WITH PSEN1,
RP   PROTEOLYTIC CLEAVAGE BY PSEN1, DOMAIN, AND MUTAGENESIS OF PRO-1728 AND
RP   1755-LEU--ARG-1761.
RX   PubMed=30598546; DOI=10.1038/s41586-018-0813-8;
RA   Yang G., Zhou R., Zhou Q., Guo X., Yan C., Ke M., Lei J., Shi Y.;
RT   "Structural basis of Notch recognition by human gamma-secretase.";
RL   Nature 565:192-197(2019).
RN   [31]
RP   INVOLVEMENT IN AOS5, AND VARIANTS AOS5 ARG-429; TYR-1496 AND ASN-1989.
RX   PubMed=25132448; DOI=10.1016/j.ajhg.2014.07.011;
RA   Stittrich A.B., Lehman A., Bodian D.L., Ashworth J., Zong Z., Li H.,
RA   Lam P., Khromykh A., Iyer R.K., Vockley J.G., Baveja R., Silva E.S.,
RA   Dixon J., Leon E.L., Solomon B.D., Glusman G., Niederhuber J.E.,
RA   Roach J.C., Patel M.S.;
RT   "Mutations in NOTCH1 cause Adams-Oliver syndrome.";
RL   Am. J. Hum. Genet. 95:275-284(2014).
CC   -!- FUNCTION: Functions as a receptor for membrane-bound ligands Jagged-1
CC       (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate
CC       determination. Upon ligand activation through the released notch
CC       intracellular domain (NICD) it forms a transcriptional activator
CC       complex with RBPJ/RBPSUH and activates genes of the enhancer of split
CC       locus. Affects the implementation of differentiation, proliferation and
CC       apoptotic programs. Involved in angiogenesis; negatively regulates
CC       endothelial cell proliferation and migration and angiogenic sprouting.
CC       Involved in the maturation of both CD4(+) and CD8(+) cells in the
CC       thymus. Important for follicular differentiation and possibly cell fate
CC       selection within the follicle. During cerebellar development, functions
CC       as a receptor for neuronal DNER and is involved in the differentiation
CC       of Bergmann glia. Represses neuronal and myogenic differentiation. May
CC       play an essential role in postimplantation development, probably in
CC       some aspect of cell specification and/or differentiation. May be
CC       involved in mesoderm development, somite formation and neurogenesis.
CC       May enhance HIF1A function by sequestering HIF1AN away from HIF1A.
CC       Required for the THBS4 function in regulating protective astrogenesis
CC       from the subventricular zone (SVZ) niche after injury. Involved in
CC       determination of left/right symmetry by modulating the balance between
CC       motile and immotile (sensory) cilia at the left-right organiser (LRO).
CC       {ECO:0000269|PubMed:20616313}.
CC   -!- SUBUNIT: Heterodimer of a C-terminal fragment N(TM) and an N-terminal
CC       fragment N(EC) which are probably linked by disulfide bonds. Interacts
CC       with DNER, DTX1, DTX2 and RBPJ/RBPSUH. Also interacts with MAML1, MAML2
CC       and MAML3 which act as transcriptional coactivators for NOTCH1
CC       (PubMed:11101851, PubMed:12370315). The NOTCH1 intracellular domain
CC       interacts with SNW1; the interaction involves multimerized NOTCH1 NICD
CC       and is implicated in a formation of an intermediate preactivation
CC       complex which associates with DNA-bound CBF-1/RBPJ (PubMed:10713164).
CC       The activated membrane-bound form interacts with AAK1 which promotes
CC       NOTCH1 stabilization. Forms a trimeric complex with FBXW7 and SGK1.
CC       Interacts with HIF1AN. HIF1AN negatively regulates the function of
CC       notch intracellular domain (NICD), accelerating myogenic
CC       differentiation (PubMed:17573339). Interacts (via NICD) with SNAI1 (via
CC       zinc fingers); the interaction induces SNAI1 degradation via MDM2-
CC       mediated ubiquitination and inhibits SNAI1-induced cell invasion.
CC       Interacts (via NICD) with MDM2A. Interacts (via NICD) with BCL6; the
CC       interaction decreases MAML1 recruitment by NOTCH1 NICD on target genes
CC       DNA and inhibits NOTCH1 transcractivation activity. Interacts with
CC       THBS4 (By similarity). Interacts (via the EGF-like repeat region) with
CC       CCN3 (via CTCK domain) (PubMed:12050162). Interacts (via EGF-like
CC       domains) with DLL4 (via N-terminal DSL and MNNL domains) (By
CC       similarity). Interacts with ZMIZ1. Interacts (via NICD domain) with
CC       MEGF10 (via the cytoplasmic domain). Interacts with DLL1 and JAG1 (By
CC       similarity). Interacts (via NICD domain) with PRAG1 (By similarity).
CC       Forms a complex with PRAG1, N1ICD and MAML1, in a MAML1-dependent
CC       manner (By similarity). Interacts (via transmembrane region) with
CC       PSEN1; the interaction is direct (PubMed:30598546).
CC       {ECO:0000250|UniProtKB:Q01705, ECO:0000250|UniProtKB:Q07008,
CC       ECO:0000269|PubMed:10713164, ECO:0000269|PubMed:11101851,
CC       ECO:0000269|PubMed:12050162, ECO:0000269|PubMed:12370315,
CC       ECO:0000269|PubMed:17573339, ECO:0000269|PubMed:26522984,
CC       ECO:0000269|PubMed:30598546, ECO:0000269|PubMed:9590294}.
CC   -!- INTERACTION:
CC       P46531; Q13315: ATM; NbExp=8; IntAct=EBI-636374, EBI-495465;
CC       P46531; Q969H0: FBXW7; NbExp=10; IntAct=EBI-636374, EBI-359574;
CC       P46531; Q16665: HIF1A; NbExp=2; IntAct=EBI-636374, EBI-447269;
CC       P46531; P78504: JAG1; NbExp=6; IntAct=EBI-636374, EBI-2847071;
CC       P46531; O60341: KDM1A; NbExp=8; IntAct=EBI-636374, EBI-710124;
CC       P46531; Q8N423: LILRB2; NbExp=8; IntAct=EBI-636374, EBI-2816428;
CC       P46531; Q92585: MAML1; NbExp=14; IntAct=EBI-636374, EBI-908250;
CC       P46531; P19838: NFKB1; NbExp=2; IntAct=EBI-636374, EBI-300010;
CC       P46531; Q13526: PIN1; NbExp=9; IntAct=EBI-636374, EBI-714158;
CC       P46531; Q06330: RBPJ; NbExp=12; IntAct=EBI-636374, EBI-632552;
CC       P46531; Q06330-6: RBPJ; NbExp=6; IntAct=EBI-636374, EBI-12599287;
CC       P46531; Q13573: SNW1; NbExp=3; IntAct=EBI-636374, EBI-632715;
CC       P46531; P98170: XIAP; NbExp=4; IntAct=EBI-636374, EBI-517127;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:Q01705};
CC       Single-pass type I membrane protein {ECO:0000305|PubMed:30598546}.
CC   -!- SUBCELLULAR LOCATION: [Notch 1 intracellular domain]: Nucleus
CC       {ECO:0000250|UniProtKB:Q01705}. Note=Following proteolytical processing
CC       NICD is translocated to the nucleus. Nuclear location may require
CC       MEGF10. {ECO:0000250|UniProtKB:Q01705}.
CC   -!- TISSUE SPECIFICITY: In fetal tissues most abundant in spleen, brain
CC       stem and lung. Also present in most adult tissues where it is found
CC       mainly in lymphoid tissues.
CC   -!- DOMAIN: Interaction with PSEN1 causes partial unwinding of the
CC       transmembrane helix, facilitating access to the scissile peptide bond.
CC       {ECO:0000269|PubMed:30598546}.
CC   -!- PTM: Synthesized in the endoplasmic reticulum as an inactive form which
CC       is proteolytically cleaved by a furin-like convertase in the trans-
CC       Golgi network before it reaches the plasma membrane to yield an active,
CC       ligand-accessible form (By similarity). Cleavage results in a C-
CC       terminal fragment N(TM) and a N-terminal fragment N(EC). Following
CC       ligand binding, it is cleaved by ADAM17 to yield a membrane-associated
CC       intermediate fragment called notch extracellular truncation (NEXT)
CC       (PubMed:24226769). Following endocytosis, this fragment is then cleaved
CC       by one of the catalytic subunits of gamma-secretase (PSEN1 or PSEN2),
CC       to release a Notch-derived peptide containing the intracellular domain
CC       (NICD) from the membrane (PubMed:30598546).
CC       {ECO:0000250|UniProtKB:Q01705, ECO:0000269|PubMed:24226769,
CC       ECO:0000269|PubMed:30598546}.
CC   -!- PTM: Phosphorylated. {ECO:0000250}.
CC   -!- PTM: O-glycosylated on the EGF-like domains (PubMed:24226769). O-
CC       glucosylated at Ser-435 by KDELC1 and KDELC2 (PubMed:30127001).
CC       Contains both O-linked fucose and O-linked glucose in the EGF-like
CC       domains 11, 12 and 13, which are interacting with the residues on DLL4
CC       (By similarity). O-linked glycosylation by GALNT11 is involved in
CC       determination of left/right symmetry: glycosylation promotes activation
CC       of NOTCH1, possibly by promoting cleavage by ADAM17, modulating the
CC       balance between motile and immotile (sensory) cilia at the left-right
CC       organiser (LRO) (PubMed:24226769). MFNG-, RFNG- and LFNG-mediated
CC       modification of O-fucose residues at specific EGF-like domains results
CC       in inhibition of its activation by JAG1 and enhancement of its
CC       activation by DLL1 via an increased binding to DLL1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q01705, ECO:0000250|UniProtKB:Q07008,
CC       ECO:0000269|PubMed:24226769, ECO:0000269|PubMed:30127001}.
CC   -!- PTM: Ubiquitinated. Undergoes 'Lys-29'-linked polyubiquitination by
CC       ITCH; promotes the lysosomal degradation of non-activated internalized
CC       NOTCH1 (PubMed:18628966, PubMed:23886940). Monoubiquitination at Lys-
CC       1759 is required for activation by gamma-secretase cleavage, it
CC       promotes interaction with AAK1, which stabilizes it. Deubiquitination
CC       by EIF3F is necessary for nuclear import of activated Notch
CC       (PubMed:24226769). {ECO:0000269|PubMed:18628966,
CC       ECO:0000269|PubMed:23886940, ECO:0000269|PubMed:24226769}.
CC   -!- PTM: Hydroxylated at Asn-1955 by HIF1AN. Hydroxylated at Asn-2022 by
CC       HIF1AN (By similarity). Hydroxylation reduces affinity for HI1AN and
CC       may thus indirectly modulate negative regulation of NICD (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Aortic valve disease 1 (AOVD1) [MIM:109730]: A common defect
CC       in the aortic valve in which two rather than three leaflets are
CC       present. It is often associated with aortic valve calcification,
CC       stenosis and insufficiency. In extreme cases, the blood flow may be so
CC       restricted that the left ventricle fails to grow, resulting in
CC       hypoplastic left heart syndrome. {ECO:0000269|PubMed:16025100}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Adams-Oliver syndrome 5 (AOS5) [MIM:616028]: A form of Adams-
CC       Oliver syndrome, a disorder characterized by the congenital absence of
CC       skin (aplasia cutis congenita) in combination with transverse limb
CC       defects. Aplasia cutis congenita can be located anywhere on the body,
CC       but in the vast majority of the cases, it is present on the posterior
CC       parietal region where it is often associated with an underlying defect
CC       of the parietal bones. Limb abnormalities are typically limb truncation
CC       defects affecting the distal phalanges or entire digits (true
CC       ectrodactyly). Only rarely, metatarsals/metacarpals or more proximal
CC       limb structures are also affected. Apart from transverse limb defects,
CC       syndactyly, most commonly of second and third toes, can also be
CC       observed. The clinical features are highly variable and can also
CC       include cardiovascular malformations, brain abnormalities and vascular
CC       defects such as cutis marmorata and dilated scalp veins.
CC       {ECO:0000269|PubMed:25132448}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the NOTCH family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NOTCH1ID30ch9q34.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF308602; AAG33848.1; -; mRNA.
DR   EMBL; AL592301; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL354671; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M73980; AAA60614.1; -; mRNA.
DR   EMBL; AB209873; BAD93110.1; -; mRNA.
DR   CCDS; CCDS43905.1; -.
DR   PIR; A40043; A40043.
DR   RefSeq; NP_060087.3; NM_017617.4.
DR   PDB; 1PB5; NMR; -; A=1446-1480.
DR   PDB; 1TOZ; NMR; -; A=411-526.
DR   PDB; 1YYH; X-ray; 1.90 A; A/B=1872-2114.
DR   PDB; 2F8X; X-ray; 3.25 A; K=1872-2126.
DR   PDB; 2F8Y; X-ray; 1.55 A; A/B=1905-2126.
DR   PDB; 2HE0; X-ray; 1.90 A; A/B=1872-2114.
DR   PDB; 2VJ3; X-ray; 2.60 A; A=411-526.
DR   PDB; 3ETO; X-ray; 2.00 A; A/B=1446-1733.
DR   PDB; 3I08; X-ray; 3.20 A; A/C=1446-1664, B/D=1665-1733.
DR   PDB; 3L95; X-ray; 2.19 A; X/Y=1448-1728.
DR   PDB; 3NBN; X-ray; 3.45 A; B/E=1872-2126.
DR   PDB; 3V79; X-ray; 3.85 A; K=1872-2126, R=1759-1777.
DR   PDB; 4CUD; X-ray; 1.85 A; A=411-526.
DR   PDB; 4CUE; X-ray; 3.00 A; A=411-526.
DR   PDB; 4CUF; X-ray; 2.29 A; A=411-526.
DR   PDB; 4D0E; X-ray; 1.61 A; A=411-526.
DR   PDB; 4D0F; X-ray; 2.80 A; A=411-526.
DR   PDB; 5FM9; X-ray; 2.92 A; A=140-294.
DR   PDB; 5FMA; X-ray; 2.46 A; A/B=142-294.
DR   PDB; 5KZO; NMR; -; A=1721-1771.
DR   PDB; 5L0R; X-ray; 1.50 A; B=452-491.
DR   PDB; 5UB5; X-ray; 2.09 A; B=452-491.
DR   PDB; 6IDF; EM; 2.70 A; E=1721-1821.
DR   PDB; 6PY8; X-ray; 3.75 A; F/K=1759-2127.
DR   PDBsum; 1PB5; -.
DR   PDBsum; 1TOZ; -.
DR   PDBsum; 1YYH; -.
DR   PDBsum; 2F8X; -.
DR   PDBsum; 2F8Y; -.
DR   PDBsum; 2HE0; -.
DR   PDBsum; 2VJ3; -.
DR   PDBsum; 3ETO; -.
DR   PDBsum; 3I08; -.
DR   PDBsum; 3L95; -.
DR   PDBsum; 3NBN; -.
DR   PDBsum; 3V79; -.
DR   PDBsum; 4CUD; -.
DR   PDBsum; 4CUE; -.
DR   PDBsum; 4CUF; -.
DR   PDBsum; 4D0E; -.
DR   PDBsum; 4D0F; -.
DR   PDBsum; 5FM9; -.
DR   PDBsum; 5FMA; -.
DR   PDBsum; 5KZO; -.
DR   PDBsum; 5L0R; -.
DR   PDBsum; 5UB5; -.
DR   PDBsum; 6IDF; -.
DR   PDBsum; 6PY8; -.
DR   SMR; P46531; -.
DR   BioGrid; 110913; 232.
DR   CORUM; P46531; -.
DR   DIP; DIP-29919N; -.
DR   IntAct; P46531; 155.
DR   MINT; P46531; -.
DR   STRING; 9606.ENSP00000277541; -.
DR   BindingDB; P46531; -.
DR   ChEMBL; CHEMBL2146346; -.
DR   TCDB; 9.B.87.1.12; the selenoprotein p receptor (selp-receptor) family.
DR   iPTMnet; P46531; -.
DR   PhosphoSitePlus; P46531; -.
DR   BioMuta; NOTCH1; -.
DR   DMDM; 206729936; -.
DR   EPD; P46531; -.
DR   jPOST; P46531; -.
DR   MassIVE; P46531; -.
DR   MaxQB; P46531; -.
DR   PaxDb; P46531; -.
DR   PeptideAtlas; P46531; -.
DR   PRIDE; P46531; -.
DR   ProteomicsDB; 55742; -.
DR   ABCD; P46531; -.
DR   Antibodypedia; 8424; 1273 antibodies.
DR   Ensembl; ENST00000651671; ENSP00000498587; ENSG00000148400.
DR   GeneID; 4851; -.
DR   KEGG; hsa:4851; -.
DR   UCSC; uc004chz.4; human.
DR   CTD; 4851; -.
DR   DisGeNET; 4851; -.
DR   GeneCards; NOTCH1; -.
DR   GeneReviews; NOTCH1; -.
DR   HGNC; HGNC:7881; NOTCH1.
DR   HPA; ENSG00000148400; Low tissue specificity.
DR   MalaCards; NOTCH1; -.
DR   MIM; 109730; phenotype.
DR   MIM; 190198; gene.
DR   MIM; 616028; phenotype.
DR   neXtProt; NX_P46531; -.
DR   OpenTargets; ENSG00000148400; -.
DR   Orphanet; 974; Adams-Oliver syndrome.
DR   Orphanet; 402075; Familial bicuspid aortic valve.
DR   PharmGKB; PA31683; -.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   GeneTree; ENSGT00940000157157; -.
DR   HOGENOM; CLU_000576_2_0_1; -.
DR   InParanoid; P46531; -.
DR   KO; K02599; -.
DR   OMA; NEGSCLD; -.
DR   OrthoDB; 7525at2759; -.
DR   PhylomeDB; P46531; -.
DR   TreeFam; TF351641; -.
DR   Reactome; R-HSA-1912399; Pre-NOTCH Processing in the Endoplasmic Reticulum.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-HSA-210744; Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2122948; Activated NOTCH1 Transmits Signal to the Nucleus.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2644607; Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling.
DR   Reactome; R-HSA-2660826; Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant.
DR   Reactome; R-HSA-2691232; Constitutive Signaling by NOTCH1 HD Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-5083630; Defective LFNG causes SCDO3.
DR   Reactome; R-HSA-8941856; RUNX3 regulates NOTCH signaling.
DR   Reactome; R-HSA-9013508; NOTCH3 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-9013695; NOTCH4 Intracellular Domain Regulates Transcription.
DR   SignaLink; P46531; -.
DR   SIGNOR; P46531; -.
DR   ChiTaRS; NOTCH1; human.
DR   EvolutionaryTrace; P46531; -.
DR   GeneWiki; Notch-1; -.
DR   GenomeRNAi; 4851; -.
DR   Pharos; P46531; Tchem.
DR   PRO; PR:P46531; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; P46531; protein.
DR   Bgee; ENSG00000148400; Expressed in visceral pleura and 218 other tissues.
DR   Genevisible; P46531; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0005912; C:adherens junction; ISS:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0002193; C:MAML1-RBP-Jkappa- ICN1 complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISS:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; ISS:UniProtKB.
DR   GO; GO:0004857; F:enzyme inhibitor activity; ISS:UniProtKB.
DR   GO; GO:0005112; F:Notch binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IEA:Ensembl.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0003180; P:aortic valve morphogenesis; IMP:BHF-UCL.
DR   GO; GO:1902263; P:apoptotic process involved in embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0060842; P:arterial endothelial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0048708; P:astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0003162; P:atrioventricular node development; IEA:Ensembl.
DR   GO; GO:0003181; P:atrioventricular valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0009912; P:auditory receptor cell fate commitment; IEA:Ensembl.
DR   GO; GO:0007409; P:axonogenesis; IEA:Ensembl.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IEA:Ensembl.
DR   GO; GO:0003209; P:cardiac atrium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003207; P:cardiac chamber formation; ISS:BHF-UCL.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0055008; P:cardiac muscle tissue morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003213; P:cardiac right atrium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003219; P:cardiac right ventricle formation; IEA:Ensembl.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060948; P:cardiac vascular smooth muscle cell development; ISS:BHF-UCL.
DR   GO; GO:0003208; P:cardiac ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:0021515; P:cell differentiation in spinal cord; IEA:Ensembl.
DR   GO; GO:0001708; P:cell fate specification; IEA:Ensembl.
DR   GO; GO:0003273; P:cell migration involved in endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IDA:BHF-UCL.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0060271; P:cilium assembly; ISS:UniProtKB.
DR   GO; GO:0072044; P:collecting duct development; IEA:Ensembl.
DR   GO; GO:0007386; P:compartment pattern specification; IEA:Ensembl.
DR   GO; GO:0060982; P:coronary artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003182; P:coronary sinus valve morphogenesis; IEA:Ensembl.
DR   GO; GO:0003169; P:coronary vein morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007368; P:determination of left/right symmetry; ISS:BHF-UCL.
DR   GO; GO:0072017; P:distal tubule development; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0060956; P:endocardial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003157; P:endocardium development; ISS:BHF-UCL.
DR   GO; GO:0003160; P:endocardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007492; P:endoderm development; IEA:Ensembl.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0003198; P:epithelial to mesenchymal transition involved in endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0007440; P:foregut morphogenesis; IEA:Ensembl.
DR   GO; GO:0072144; P:glomerular mesangial cell development; IEA:Ensembl.
DR   GO; GO:0003241; P:growth involved in heart morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IMP:DFLAT.
DR   GO; GO:0001947; P:heart looping; ISS:BHF-UCL.
DR   GO; GO:0061384; P:heart trabecula morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; ISS:BHF-UCL.
DR   GO; GO:0006959; P:humoral immune response; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0072602; P:interleukin-4 secretion; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0070986; P:left/right axis specification; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0014031; P:mesenchymal cell development; ISS:BHF-UCL.
DR   GO; GO:0003192; P:mitral valve formation; IMP:BHF-UCL.
DR   GO; GO:2000811; P:negative regulation of anoikis; IMP:BHF-UCL.
DR   GO; GO:0070168; P:negative regulation of biomineral tissue development; ISS:BHF-UCL.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0045955; P:negative regulation of calcium ion-dependent exocytosis; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0010614; P:negative regulation of cardiac muscle hypertrophy; ISS:BHF-UCL.
DR   GO; GO:0043086; P:negative regulation of catalytic activity; ISS:UniProtKB.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0003252; P:negative regulation of cell proliferation involved in heart valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; IDA:BHF-UCL.
DR   GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:2001027; P:negative regulation of endothelial cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0003332; P:negative regulation of extracellular matrix constituent secretion; ISS:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0060253; P:negative regulation of glial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045967; P:negative regulation of growth rate; IDA:UniProtKB.
DR   GO; GO:0045608; P:negative regulation of inner ear auditory receptor cell differentiation; IEA:Ensembl.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; IMP:UniProtKB.
DR   GO; GO:0010832; P:negative regulation of myotube differentiation; ISS:UniProtKB.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; ISS:UniProtKB.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0030279; P:negative regulation of ossification; ISS:BHF-UCL.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; ISS:BHF-UCL.
DR   GO; GO:0046533; P:negative regulation of photoreceptor cell differentiation; IEA:Ensembl.
DR   GO; GO:2000974; P:negative regulation of pro-B cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000737; P:negative regulation of stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:BHF-UCL.
DR   GO; GO:0021915; P:neural tube development; IEA:Ensembl.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IEP:UniProtKB.
DR   GO; GO:0061314; P:Notch signaling involved in heart development; IMP:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0003270; P:Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003344; P:pericardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:1903849; P:positive regulation of aorta morphogenesis; IEA:Ensembl.
DR   GO; GO:1902339; P:positive regulation of apoptotic process involved in morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048711; P:positive regulation of astrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0062043; P:positive regulation of cardiac epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:BHF-UCL.
DR   GO; GO:0045618; P:positive regulation of keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0007221; P:positive regulation of transcription of Notch receptor target; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IEA:Ensembl.
DR   GO; GO:0060740; P:prostate gland epithelium morphogenesis; IEA:Ensembl.
DR   GO; GO:0003184; P:pulmonary valve morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0060768; P:regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:1901201; P:regulation of extracellular matrix assembly; ISS:BHF-UCL.
DR   GO; GO:0014807; P:regulation of somitogenesis; IEA:Ensembl.
DR   GO; GO:0003256; P:regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:UniProtKB.
DR   GO; GO:0031960; P:response to corticosteroid; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0032495; P:response to muramyl dipeptide; IEA:Ensembl.
DR   GO; GO:0060528; P:secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development; IEA:Ensembl.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0048103; P:somatic stem cell division; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0002040; P:sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0042246; P:tissue regeneration; IEA:Ensembl.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0035148; P:tube formation; IMP:UniProtKB.
DR   GO; GO:0060979; P:vasculogenesis involved in coronary vascular morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060843; P:venous endothelial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; ISS:BHF-UCL.
DR   DisProt; DP01104; -.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR024600; DUF3454_notch.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR008297; Notch.
DR   InterPro; IPR035993; Notch-like_dom_sf.
DR   InterPro; IPR022362; Notch_1.
DR   InterPro; IPR000800; Notch_dom.
DR   InterPro; IPR010660; Notch_NOD_dom.
DR   InterPro; IPR011656; Notch_NODP_dom.
DR   Pfam; PF12796; Ank_2; 2.
DR   Pfam; PF11936; DUF3454; 1.
DR   Pfam; PF00008; EGF; 25.
DR   Pfam; PF07645; EGF_CA; 4.
DR   Pfam; PF12661; hEGF; 2.
DR   Pfam; PF06816; NOD; 1.
DR   Pfam; PF07684; NODP; 1.
DR   Pfam; PF00066; Notch; 3.
DR   PIRSF; PIRSF002279; Notch; 1.
DR   PRINTS; PR01452; LNOTCHREPEAT.
DR   PRINTS; PR01984; NOTCH1.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM01334; DUF3454; 1.
DR   SMART; SM00181; EGF; 36.
DR   SMART; SM00179; EGF_CA; 33.
DR   SMART; SM00004; NL; 3.
DR   SMART; SM01338; NOD; 1.
DR   SMART; SM01339; NODP; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF57184; SSF57184; 6.
DR   SUPFAM; SSF90193; SSF90193; 3.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 22.
DR   PROSITE; PS00022; EGF_1; 35.
DR   PROSITE; PS01186; EGF_2; 27.
DR   PROSITE; PS50026; EGF_3; 36.
DR   PROSITE; PS01187; EGF_CA; 20.
DR   PROSITE; PS50258; LNR; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Angiogenesis; ANK repeat; Calcium; Cell membrane;
KW   Developmental protein; Differentiation; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; EGF-like domain; Glycoprotein;
KW   Hydroxylation; Isopeptide bond; Membrane; Metal-binding;
KW   Notch signaling pathway; Nucleus; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Signal; Transcription;
KW   Transcription regulation; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..2555
FT                   /note="Neurogenic locus notch homolog protein 1"
FT                   /id="PRO_0000007674"
FT   CHAIN           1721..2555
FT                   /note="Notch 1 extracellular truncation"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000007675"
FT   CHAIN           1754..2555
FT                   /note="Notch 1 intracellular domain"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000007676"
FT   TOPO_DOM        19..1735
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:28439555,
FT                   ECO:0000305|PubMed:30598546"
FT   TRANSMEM        1736..1756
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:28439555,
FT                   ECO:0000269|PubMed:30598546"
FT   TOPO_DOM        1757..2555
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:28439555,
FT                   ECO:0000305|PubMed:30598546"
FT   DOMAIN          20..58
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          59..99
FT                   /note="EGF-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          102..139
FT                   /note="EGF-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          140..176
FT                   /note="EGF-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          178..216
FT                   /note="EGF-like 5; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          218..255
FT                   /note="EGF-like 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          257..293
FT                   /note="EGF-like 7; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          295..333
FT                   /note="EGF-like 8; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          335..371
FT                   /note="EGF-like 9; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          372..410
FT                   /note="EGF-like 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          412..450
FT                   /note="EGF-like 11; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          452..488
FT                   /note="EGF-like 12; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          490..526
FT                   /note="EGF-like 13; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          528..564
FT                   /note="EGF-like 14; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          566..601
FT                   /note="EGF-like 15; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          603..639
FT                   /note="EGF-like 16; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          641..676
FT                   /note="EGF-like 17; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          678..714
FT                   /note="EGF-like 18; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          716..751
FT                   /note="EGF-like 19; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          753..789
FT                   /note="EGF-like 20"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          791..827
FT                   /note="EGF-like 21; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          829..867
FT                   /note="EGF-like 22"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          869..905
FT                   /note="EGF-like 23; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          907..943
FT                   /note="EGF-like 24"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          945..981
FT                   /note="EGF-like 25; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          983..1019
FT                   /note="EGF-like 26"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1021..1057
FT                   /note="EGF-like 27"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1059..1095
FT                   /note="EGF-like 28"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1097..1143
FT                   /note="EGF-like 29"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          1145..1181
FT                   /note="EGF-like 30"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1183..1219
FT                   /note="EGF-like 31; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1221..1265
FT                   /note="EGF-like 32; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1267..1305
FT                   /note="EGF-like 33"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1307..1346
FT                   /note="EGF-like 34"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1348..1384
FT                   /note="EGF-like 35"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1387..1426
FT                   /note="EGF-like 36"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   REPEAT          1449..1489
FT                   /note="LNR 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00525"
FT   REPEAT          1490..1531
FT                   /note="LNR 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00525"
FT   REPEAT          1532..1571
FT                   /note="LNR 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00525"
FT   REPEAT          1927..1956
FT                   /note="ANK 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1960..1990
FT                   /note="ANK 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1994..2023
FT                   /note="ANK 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          2027..2056
FT                   /note="ANK 4"
FT                   /evidence="ECO:0000255"
FT   REPEAT          2060..2089
FT                   /note="ANK 5"
FT                   /evidence="ECO:0000255"
FT   REPEAT          2095..2122
FT                   /note="ANK 6"
FT   REGION          420..421
FT                   /note="Interaction with DLL4"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   REGION          448..452
FT                   /note="Interaction with DLL4"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   REGION          1728..1760
FT                   /note="Interaction with PSEN1"
FT                   /evidence="ECO:0000269|PubMed:30598546"
FT   REGION          1947..1955
FT                   /note="HIF1AN-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          2014..2022
FT                   /note="HIF1AN-binding"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        1575..1578
FT                   /note="Poly-Val"
FT   COMPBIAS        1661..1664
FT                   /note="Poly-Arg"
FT   COMPBIAS        1728..1731
FT                   /note="Poly-Pro"
FT   COMPBIAS        1740..1743
FT                   /note="Poly-Ala"
FT   COMPBIAS        1901..1904
FT                   /note="Poly-Glu"
FT   COMPBIAS        2259..2262
FT                   /note="Poly-Gly"
FT   COMPBIAS        2403..2406
FT                   /note="Poly-Gln"
FT   COMPBIAS        2410..2417
FT                   /note="Poly-Pro"
FT   COMPBIAS        2521..2524
FT                   /note="Poly-Ser"
FT   METAL           432
FT                   /note="Calcium 1; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   METAL           435
FT                   /note="Calcium 1; via amide nitrogen"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   METAL           452
FT                   /note="Calcium 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   METAL           453
FT                   /note="Calcium 2; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   METAL           455
FT                   /note="Calcium 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   METAL           469
FT                   /note="Calcium 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   METAL           470
FT                   /note="Calcium 2; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   METAL           490
FT                   /note="Calcium 3"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   METAL           491
FT                   /note="Calcium 3; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   METAL           493
FT                   /note="Calcium 3"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   METAL           507
FT                   /note="Calcium 3"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   METAL           508
FT                   /note="Calcium 3; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   METAL           1457
FT                   /note="Calcium 4; via carbonyl oxygen"
FT   METAL           1460
FT                   /note="Calcium 4"
FT   METAL           1475
FT                   /note="Calcium 4"
FT   METAL           1478
FT                   /note="Calcium 4"
FT   SITE            469
FT                   /note="Interaction with DLL4"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   SITE            1664..1665
FT                   /note="Cleavage; by furin-like protease"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   SITE            1710..1711
FT                   /note="Cleavage; by ADAM17"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   MOD_RES         1861
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   MOD_RES         1955
FT                   /note="(3S)-3-hydroxyasparagine; by HIF1AN; partial"
FT                   /evidence="ECO:0000269|PubMed:17573339"
FT   MOD_RES         2022
FT                   /note="(3S)-3-hydroxyasparagine; by HIF1AN"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        41
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        65
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        73
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        116
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        146
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        194
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        232
FT                   /note="O-linked (Fuc...) threonine; alternate"
FT                   /evidence="ECO:0000269|PubMed:24226769"
FT   CARBOHYD        232
FT                   /note="O-linked (GalNAc...) threonine; alternate"
FT                   /evidence="ECO:0000269|PubMed:24226769"
FT   CARBOHYD        311
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        341
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        349
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        378
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        435
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000269|PubMed:30127001"
FT   CARBOHYD        458
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   CARBOHYD        466
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   CARBOHYD        496
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   CARBOHYD        534
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        609
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        617
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        647
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        692
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        722
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        759
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        767
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        784
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        797
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        805
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        921
FT                   /note="O-linked (Fuc) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        951
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        959
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        997
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        1027
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        1035
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        1065
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        1159
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        1179
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1189
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        1197
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        1241
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1273
FT                   /note="O-linked (Glc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        1362
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        1379
FT                   /note="O-linked (GlcNAc...) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   CARBOHYD        1402
FT                   /note="O-linked (Fuc...) threonine; alternate"
FT                   /evidence="ECO:0000269|PubMed:24226769"
FT   CARBOHYD        1402
FT                   /note="O-linked (GalNAc...) threonine; alternate"
FT                   /evidence="ECO:0000269|PubMed:24226769"
FT   CARBOHYD        1489
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1587
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1725
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:24226769"
FT   DISULFID        24..37
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        31..46
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        48..57
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        63..74
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        68..87
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        89..98
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        106..117
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        111..127
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        129..138
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        144..155
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        149..164
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        166..175
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        182..195
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        189..204
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        206..215
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        222..233
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        227..243
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        245..254
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        261..272
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        266..281
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        283..292
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        299..312
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        306..321
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        323..332
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        339..350
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        344..359
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        361..370
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        376..387
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        381..398
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        400..409
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        416..429
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   DISULFID        423..438
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   DISULFID        440..449
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   DISULFID        456..467
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   DISULFID        461..476
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   DISULFID        478..487
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   DISULFID        494..505
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   DISULFID        499..514
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   DISULFID        516..525
FT                   /evidence="ECO:0000250|UniProtKB:Q07008"
FT   DISULFID        532..543
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        537..552
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        554..563
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        570..580
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        575..589
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        591..600
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        607..618
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        612..627
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        629..638
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        645..655
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        650..664
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        666..675
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        682..693
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        687..702
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        704..713
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        720..730
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        725..739
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        741..750
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        757..768
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        762..777
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        779..788
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        795..806
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        800..815
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        817..826
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        833..844
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        838..855
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        857..866
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        873..884
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        878..893
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        895..904
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        911..922
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        916..931
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        933..942
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        949..960
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        954..969
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        971..980
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        987..998
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        992..1007
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1009..1018
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1025..1036
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1030..1045
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1047..1056
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1063..1074
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1068..1083
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1085..1094
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1101..1122
FT                   /evidence="ECO:0000305"
FT   DISULFID        1116..1131
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1133..1142
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1149..1160
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1154..1169
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1171..1180
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1187..1198
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1192..1207
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1209..1218
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1238..1253
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1255..1264
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1271..1284
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1276..1293
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1295..1304
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1311..1322
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1316..1334
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1336..1345
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1352..1363
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1357..1372
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1374..1383
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1391..1403
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1397..1414
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1416..1425
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1449..1472
FT                   /evidence="ECO:0000269|PubMed:12795601"
FT   DISULFID        1454..1467
FT                   /evidence="ECO:0000269|PubMed:12795601"
FT   DISULFID        1463..1479
FT                   /evidence="ECO:0000269|PubMed:12795601"
FT   DISULFID        1490..1514
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00525"
FT   DISULFID        1496..1509
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00525"
FT   DISULFID        1505..1521
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00525"
FT   DISULFID        1536..1549
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00525"
FT   DISULFID        1545..1561
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00525"
FT   CROSSLNK        1759
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT   VARIANT         300
FT                   /note="Q -> R (in dbSNP:rs11574885)"
FT                   /id="VAR_034898"
FT   VARIANT         429
FT                   /note="C -> R (in AOS5; dbSNP:rs587777736)"
FT                   /evidence="ECO:0000269|PubMed:25132448"
FT                   /id="VAR_071960"
FT   VARIANT         879
FT                   /note="R -> W (in dbSNP:rs11574895)"
FT                   /id="VAR_048990"
FT   VARIANT         1496
FT                   /note="C -> Y (in AOS5; dbSNP:rs587781259)"
FT                   /evidence="ECO:0000269|PubMed:25132448"
FT                   /id="VAR_071961"
FT   VARIANT         1671
FT                   /note="V -> I (in dbSNP:rs2229968)"
FT                   /id="VAR_046618"
FT   VARIANT         1989
FT                   /note="D -> N (in AOS5; dbSNP:rs587777734)"
FT                   /evidence="ECO:0000269|PubMed:25132448"
FT                   /id="VAR_071962"
FT   MUTAGEN         1728
FT                   /note="P->C: Formation of an artifactual disulfide bond
FT                   with PSEN1."
FT                   /evidence="ECO:0000269|PubMed:30598546"
FT   MUTAGEN         1755..1761
FT                   /note="Missing: Loss of proteolytic cleavage by gamma-
FT                   secretase."
FT                   /evidence="ECO:0000269|PubMed:30598546"
FT   CONFLICT        187
FT                   /note="G -> R (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        282
FT                   /note="R -> P (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        477
FT                   /note="I -> M (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        614..615
FT                   /note="HG -> LR (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        621
FT                   /note="R -> P (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        677
FT                   /note="I -> S (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        775
FT                   /note="Y -> I (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        803
FT                   /note="Q -> K (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        860..862
FT                   /note="GWQ -> AGAK (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1021
FT                   /note="D -> V (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1028
FT                   /note="Q -> R (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1032
FT                   /note="H -> L (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1040..1043
FT                   /note="CGSY -> RGLH (in Ref. 1; AAG33848 and 3; AAA60614)"
FT                   /evidence="ECO:0000305"
FT   HELIX           143..146
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          154..157
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          162..165
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          170..175
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   HELIX           181..184
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   TURN            190..192
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          194..198
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          201..205
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          210..212
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          232..235
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          237..239
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          241..244
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          249..254
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          271..274
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          279..282
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   STRAND          289..292
FT                   /evidence="ECO:0000244|PDB:5FMA"
FT   HELIX           415..417
FT                   /evidence="ECO:0000244|PDB:4D0E"
FT   STRAND          418..420
FT                   /evidence="ECO:0000244|PDB:4D0E"
FT   STRAND          422..424
FT                   /evidence="ECO:0000244|PDB:4D0E"
FT   STRAND          428..432
FT                   /evidence="ECO:0000244|PDB:4D0E"
FT   STRAND          435..439
FT                   /evidence="ECO:0000244|PDB:4D0E"
FT   STRAND          444..446
FT                   /evidence="ECO:0000244|PDB:4D0E"
FT   HELIX           455..458
FT                   /evidence="ECO:0000244|PDB:5L0R"
FT   STRAND          466..470
FT                   /evidence="ECO:0000244|PDB:5L0R"
FT   STRAND          473..477
FT                   /evidence="ECO:0000244|PDB:5L0R"
FT   STRAND          482..484
FT                   /evidence="ECO:0000244|PDB:5L0R"
FT   TURN            493..496
FT                   /evidence="ECO:0000244|PDB:4D0E"
FT   TURN            500..502
FT                   /evidence="ECO:0000244|PDB:2VJ3"
FT   STRAND          504..507
FT                   /evidence="ECO:0000244|PDB:4D0E"
FT   STRAND          512..515
FT                   /evidence="ECO:0000244|PDB:4D0E"
FT   STRAND          520..522
FT                   /evidence="ECO:0000244|PDB:4D0E"
FT   HELIX           1448..1450
FT                   /evidence="ECO:0000244|PDB:3L95"
FT   HELIX           1452..1457
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   STRAND          1460..1462
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1465..1467
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1470..1472
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1473..1476
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   TURN            1477..1482
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   TURN            1486..1489
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1492..1494
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1496..1498
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   TURN            1499..1501
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   STRAND          1502..1504
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1507..1509
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1512..1519
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   TURN            1530..1532
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1533..1539
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   STRAND          1542..1544
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1547..1549
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1552..1559
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   STRAND          1563..1565
FT                   /evidence="ECO:0000244|PDB:3L95"
FT   STRAND          1571..1580
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1582..1587
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1589..1600
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   STRAND          1602..1606
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   STRAND          1616..1620
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   STRAND          1672..1681
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1685..1688
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   HELIX           1696..1708
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   STRAND          1714..1716
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   STRAND          1718..1724
FT                   /evidence="ECO:0000244|PDB:3ETO"
FT   STRAND          1733..1735
FT                   /evidence="ECO:0000244|PDB:6IDF"
FT   HELIX           1736..1741
FT                   /evidence="ECO:0000244|PDB:6IDF"
FT   HELIX           1743..1746
FT                   /evidence="ECO:0000244|PDB:6IDF"
FT   TURN            1747..1752
FT                   /evidence="ECO:0000244|PDB:6IDF"
FT   STRAND          1755..1760
FT                   /evidence="ECO:0000244|PDB:6IDF"
FT   STRAND          1767..1769
FT                   /evidence="ECO:0000244|PDB:5KZO"
FT   HELIX           1884..1890
FT                   /evidence="ECO:0000244|PDB:2F8X"
FT   HELIX           1909..1914
FT                   /evidence="ECO:0000244|PDB:2F8X"
FT   TURN            1925..1927
FT                   /evidence="ECO:0000244|PDB:2F8Y"
FT   HELIX           1931..1937
FT                   /evidence="ECO:0000244|PDB:2F8Y"
FT   HELIX           1941..1949
FT                   /evidence="ECO:0000244|PDB:2F8Y"
FT   HELIX           1964..1970
FT                   /evidence="ECO:0000244|PDB:2F8Y"
FT   HELIX           1974..1982
FT                   /evidence="ECO:0000244|PDB:2F8Y"
FT   STRAND          1983..1985
FT                   /evidence="ECO:0000244|PDB:2F8X"
FT   HELIX           1998..2005
FT                   /evidence="ECO:0000244|PDB:2F8Y"
FT   HELIX           2008..2016
FT                   /evidence="ECO:0000244|PDB:2F8Y"
FT   HELIX           2031..2037
FT                   /evidence="ECO:0000244|PDB:2F8Y"
FT   HELIX           2041..2049
FT                   /evidence="ECO:0000244|PDB:2F8Y"
FT   HELIX           2064..2071
FT                   /evidence="ECO:0000244|PDB:2F8Y"
FT   HELIX           2074..2082
FT                   /evidence="ECO:0000244|PDB:2F8Y"
FT   HELIX           2097..2103
FT                   /evidence="ECO:0000244|PDB:2F8Y"
FT   HELIX           2107..2115
FT                   /evidence="ECO:0000244|PDB:2F8Y"
SQ   SEQUENCE   2555 AA;  272505 MW;  E173C872D195F028 CRC64;
     MPPLLAPLLC LALLPALAAR GPRCSQPGET CLNGGKCEAA NGTEACVCGG AFVGPRCQDP
     NPCLSTPCKN AGTCHVVDRR GVADYACSCA LGFSGPLCLT PLDNACLTNP CRNGGTCDLL
     TLTEYKCRCP PGWSGKSCQQ ADPCASNPCA NGGQCLPFEA SYICHCPPSF HGPTCRQDVN
     ECGQKPGLCR HGGTCHNEVG SYRCVCRATH TGPNCERPYV PCSPSPCQNG GTCRPTGDVT
     HECACLPGFT GQNCEENIDD CPGNNCKNGG ACVDGVNTYN CRCPPEWTGQ YCTEDVDECQ
     LMPNACQNGG TCHNTHGGYN CVCVNGWTGE DCSENIDDCA SAACFHGATC HDRVASFYCE
     CPHGRTGLLC HLNDACISNP CNEGSNCDTN PVNGKAICTC PSGYTGPACS QDVDECSLGA
     NPCEHAGKCI NTLGSFECQC LQGYTGPRCE IDVNECVSNP CQNDATCLDQ IGEFQCICMP
     GYEGVHCEVN TDECASSPCL HNGRCLDKIN EFQCECPTGF TGHLCQYDVD ECASTPCKNG
     AKCLDGPNTY TCVCTEGYTG THCEVDIDEC DPDPCHYGSC KDGVATFTCL CRPGYTGHHC
     ETNINECSSQ PCRHGGTCQD RDNAYLCFCL KGTTGPNCEI NLDDCASSPC DSGTCLDKID
     GYECACEPGY TGSMCNINID ECAGNPCHNG GTCEDGINGF TCRCPEGYHD PTCLSEVNEC
     NSNPCVHGAC RDSLNGYKCD CDPGWSGTNC DINNNECESN PCVNGGTCKD MTSGYVCTCR
     EGFSGPNCQT NINECASNPC LNQGTCIDDV AGYKCNCLLP YTGATCEVVL APCAPSPCRN
     GGECRQSEDY ESFSCVCPTG WQGQTCEVDI NECVLSPCRH GASCQNTHGG YRCHCQAGYS
     GRNCETDIDD CRPNPCHNGG SCTDGINTAF CDCLPGFRGT FCEEDINECA SDPCRNGANC
     TDCVDSYTCT CPAGFSGIHC ENNTPDCTES SCFNGGTCVD GINSFTCLCP PGFTGSYCQH
     DVNECDSQPC LHGGTCQDGC GSYRCTCPQG YTGPNCQNLV HWCDSSPCKN GGKCWQTHTQ
     YRCECPSGWT GLYCDVPSVS CEVAAQRQGV DVARLCQHGG LCVDAGNTHH CRCQAGYTGS
     YCEDLVDECS PSPCQNGATC TDYLGGYSCK CVAGYHGVNC SEEIDECLSH PCQNGGTCLD
     LPNTYKCSCP RGTQGVHCEI NVDDCNPPVD PVSRSPKCFN NGTCVDQVGG YSCTCPPGFV
     GERCEGDVNE CLSNPCDARG TQNCVQRVND FHCECRAGHT GRRCESVING CKGKPCKNGG
     TCAVASNTAR GFICKCPAGF EGATCENDAR TCGSLRCLNG GTCISGPRSP TCLCLGPFTG
     PECQFPASSP CLGGNPCYNQ GTCEPTSESP FYRCLCPAKF NGLLCHILDY SFGGGAGRDI
     PPPLIEEACE LPECQEDAGN KVCSLQCNNH ACGWDGGDCS LNFNDPWKNC TQSLQCWKYF
     SDGHCDSQCN SAGCLFDGFD CQRAEGQCNP LYDQYCKDHF SDGHCDQGCN SAECEWDGLD
     CAEHVPERLA AGTLVVVVLM PPEQLRNSSF HFLRELSRVL HTNVVFKRDA HGQQMIFPYY
     GREEELRKHP IKRAAEGWAA PDALLGQVKA SLLPGGSEGG RRRRELDPMD VRGSIVYLEI
     DNRQCVQASS QCFQSATDVA AFLGALASLG SLNIPYKIEA VQSETVEPPP PAQLHFMYVA
     AAAFVLLFFV GCGVLLSRKR RRQHGQLWFP EGFKVSEASK KKRREPLGED SVGLKPLKNA
     SDGALMDDNQ NEWGDEDLET KKFRFEEPVV LPDLDDQTDH RQWTQQHLDA ADLRMSAMAP
     TPPQGEVDAD CMDVNVRGPD GFTPLMIASC SGGGLETGNS EEEEDAPAVI SDFIYQGASL
     HNQTDRTGET ALHLAARYSR SDAAKRLLEA SADANIQDNM GRTPLHAAVS ADAQGVFQIL
     IRNRATDLDA RMHDGTTPLI LAARLAVEGM LEDLINSHAD VNAVDDLGKS ALHWAAAVNN
     VDAAVVLLKN GANKDMQNNR EETPLFLAAR EGSYETAKVL LDHFANRDIT DHMDRLPRDI
     AQERMHHDIV RLLDEYNLVR SPQLHGAPLG GTPTLSPPLC SPNGYLGSLK PGVQGKKVRK
     PSSKGLACGS KEAKDLKARR KKSQDGKGCL LDSSGMLSPV DSLESPHGYL SDVASPPLLP
     SPFQQSPSVP LNHLPGMPDT HLGIGHLNVA AKPEMAALGG GGRLAFETGP PRLSHLPVAS
     GTSTVLGSSS GGALNFTVGG STSLNGQCEW LSRLQSGMVP NQYNPLRGSV APGPLSTQAP
     SLQHGMVGPL HSSLAASALS QMMSYQGLPS TRLATQPHLV QTQQVQPQNL QMQQQNLQPA
     NIQQQQSLQP PPPPPQPHLG VSSAASGHLG RSFLSGEPSQ ADVQPLGPSS LAVHTILPQE
     SPALPTSLPS SLVPPVTAAQ FLTPPSQHSY SSPVDNTPSH QLQVPEHPFL TPSPESPDQW
     SSSSPHSNVS DWSEGVSSPP TSMQSQIARI PEAFK
//
ID   NTRK1_HUMAN             Reviewed;         796 AA.
AC   P04629; B2R6T5; B7ZM34; P08119; Q15655; Q15656; Q5D056; Q5VZS2; Q7Z5C3;
AC   Q9UIU7;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   02-MAY-2006, sequence version 4.
DT   22-APR-2020, entry version 252.
DE   RecName: Full=High affinity nerve growth factor receptor;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:2927393};
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 1;
DE   AltName: Full=TRK1-transforming tyrosine kinase protein;
DE   AltName: Full=Tropomyosin-related kinase A;
DE   AltName: Full=Tyrosine kinase receptor;
DE   AltName: Full=Tyrosine kinase receptor A;
DE            Short=Trk-A;
DE   AltName: Full=gp140trk {ECO:0000303|PubMed:2927393};
DE   AltName: Full=p140-TrkA;
DE   Flags: Precursor;
GN   Name=NTRK1;
GN   Synonyms=MTC, TRK {ECO:0000303|PubMed:2927393},
GN   TRKA {ECO:0000303|PubMed:9290260};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKA-I), CATALYTIC ACTIVITY,
RP   PHOSPHORYLATION, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Colon;
RX   PubMed=2927393; DOI=10.1128/mcb.9.1.24;
RA   Martin-Zanca D., Oskam R., Mitra G., Copeland T.D., Barbacid M.;
RT   "Molecular and biochemical characterization of the human trk proto-
RT   oncogene.";
RL   Mol. Cell. Biol. 9:24-33(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=7823156; DOI=10.1523/jneurosci.15-01-00477.1995;
RA   Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P.,
RA   Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.;
RT   "Human trks: molecular cloning, tissue distribution, and expression of
RT   extracellular domain immunoadhesins.";
RL   J. Neurosci. 15:477-491(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9290260; DOI=10.1007/bf02766957;
RA   Indo Y., Mardy S., Tsuruta M., Karim M.A., Matsuda I.;
RT   "Structure and organization of the human TRKA gene encoding a high affinity
RT   receptor for nerve growth factor.";
RL   Jpn. J. Hum. Genet. 42:343-351(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKA-II), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 1-175 (ISOFORM 3).
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS TRKA-I AND TRKA-II).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-71.
RX   PubMed=15870692; DOI=10.1038/sj.onc.1208697;
RA   Fujimoto M., Kitazawa R., Maeda S., Kitazawa S.;
RT   "Methylation adjacent to negatively regulating AP-1 site reactivates TrkA
RT   gene expression during cancer progression.";
RL   Oncogene 24:5108-5118(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796, AND CHROMOSOMAL TRANSLOCATION WITH
RP   TPM3.
RX   PubMed=2869410; DOI=10.1038/319743a0;
RA   Martin-Zanca D., Hughes S.H., Barbacid M.;
RT   "A human oncogene formed by the fusion of truncated tropomyosin and protein
RT   tyrosine kinase sequences.";
RL   Nature 319:743-748(1986).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796.
RX   PubMed=2966065; DOI=10.1002/j.1460-2075.1988.tb02794.x;
RA   Kozma S.C., Redmond S.M.S., Saurer S.M., Groner B., Hynes N.E.;
RT   "Activation of the receptor kinase domain of the trk oncogene by
RT   recombination with two different cellular sequences.";
RL   EMBO J. 7:147-154(1988).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796, AND CHROMOSOMAL TRANSLOCATION WITH
RP   TFG.
RX   PubMed=7565764; DOI=10.1128/mcb.15.11.6118;
RA   Greco A., Mariani C., Miranda C., Lupas A., Pagliardini S., Pomati M.,
RA   Pierotti M.A.;
RT   "The DNA rearrangement that generates the TRK-T3 oncogene involves a novel
RT   gene on chromosome 3 whose product has a potential coiled-coil domain.";
RL   Mol. Cell. Biol. 15:6118-6127(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 486-796, AND CHROMOSOMAL REARRANGEMENT WITH
RP   TPR.
RX   PubMed=1532241;
RA   Greco A., Pierotti M.A., Bongarzone I., Pagliardini S., Lanzi C.,
RA   Della Porta G.;
RT   "TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in
RT   human papillary thyroid carcinomas.";
RL   Oncogene 7:237-242(1992).
RN   [12]
RP   FUNCTION AS RECEPTOR FOR NGF.
RX   PubMed=1850821; DOI=10.1038/350678a0;
RA   Hempstead B.L., Martin-Zanca D., Kaplan D.R., Parada L.F., Chao M.V.;
RT   "High-affinity NGF binding requires coexpression of the trk proto-oncogene
RT   and the low-affinity NGF receptor.";
RL   Nature 350:678-683(1991).
RN   [13]
RP   FUNCTION IN NGF SIGNALING, AND IDENTIFICATION AS THE HIGH AFFINITY NGF
RP   RECEPTOR.
RX   PubMed=1849459; DOI=10.1016/0092-8674(91)90419-y;
RA   Klein R., Jing S., Nanduri V., O'Rourke E., Barbacid M.;
RT   "The trk proto-oncogene encodes a receptor for nerve growth factor.";
RL   Cell 65:189-197(1991).
RN   [14]
RP   FUNCTION, SUBUNIT, CATALYTIC ACTIVITY, PHOSPHORYLATION, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LYS-544.
RX   PubMed=1281417; DOI=10.1016/0896-6273(92)90066-m;
RA   Jing S., Tapley P., Barbacid M.;
RT   "Nerve growth factor mediates signal transduction through trk homodimer
RT   receptors.";
RL   Neuron 9:1067-1079(1992).
RN   [15]
RP   ALTERNATIVE SPLICING (ISOFORMS TRKA-I AND TRKA-II), FUNCTION IN CELL
RP   SURVIVAL, NGF-BINDING, PHOSPHORYLATION, AND TISSUE SPECIFICITY.
RX   PubMed=8325889;
RA   Barker P.A., Lomen-Hoerth C., Gensch E.M., Meakin S.O., Glass D.J.,
RA   Shooter E.M.;
RT   "Tissue-specific alternative splicing generates two isoforms of the trkA
RT   receptor.";
RL   J. Biol. Chem. 268:15150-15157(1993).
RN   [16]
RP   PHOSPHORYLATION AT TYR-791, INTERACTION WITH PLCG1, AND MUTAGENESIS OF
RP   TYR-791.
RX   PubMed=7510697;
RA   Loeb D.M., Stephens R.M., Copeland T.D., Kaplan D.R., Greene L.A.;
RT   "A Trk nerve growth factor (NGF) receptor point mutation affecting
RT   interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin
RT   induction but not neurite outgrowth.";
RL   J. Biol. Chem. 269:8901-8910(1994).
RN   [17]
RP   FUNCTION IN NEURONAL DIFFERENTIATION, FUNCTION IN PHOSPHORYLATION OF SHC1
RP   AND PLCG1, INTERACTION WITH SHC1, MUTAGENESIS OF TYR-496; LYS-544 AND
RP   TYR-791, AND PHOSPHORYLATION AT TYR-496; TYR-676; TYR-680; TYR-681 AND
RP   TYR-791.
RX   PubMed=8155326; DOI=10.1016/0896-6273(94)90223-2;
RA   Stephens R.M., Loeb D.M., Copeland T.D., Pawson T., Greene L.A.,
RA   Kaplan D.R.;
RT   "Trk receptors use redundant signal transduction pathways involving SHC and
RT   PLC-gamma 1 to mediate NGF responses.";
RL   Neuron 12:691-705(1994).
RN   [18]
RP   FUNCTION IN NF-KAPPA-B ACTIVATION, AND INTERACTION WITH SQSTM1.
RX   PubMed=11244088; DOI=10.1074/jbc.c000869200;
RA   Wooten M.W., Seibenhener M.L., Mamidipudi V., Diaz-Meco M.T., Barker P.A.,
RA   Moscat J.;
RT   "The atypical protein kinase C-interacting protein p62 is a scaffold for
RT   NF-kappaB activation by nerve growth factor.";
RL   J. Biol. Chem. 276:7709-7712(2001).
RN   [19]
RP   FUNCTION IN NEURONAL CELL PROLIFERATION AND DIFFERENTIATION, FUNCTION IN
RP   SIGNALING CASCADE ACTIVATION, NGF-BINDING, SUBCELLULAR LOCATION,
RP   ALTERNATIVE SPLICING (ISOFORM TRKA-III), CHARACTERIZATION OF ISOFORM
RP   TRKA-III, PHOSPHORYLATION AT TYR-496; TYR-680; TYR-681 AND TYR-791,
RP   INTERACTION WITH FRS2; GRB2; PIK3R1; PLCG1; SHC1, GLYCOSYLATION, TISSUE
RP   SPECIFICITY, AND INDUCTION BY HYPOXIA.
RX   PubMed=15488758; DOI=10.1016/j.ccr.2004.09.011;
RA   Tacconelli A., Farina A.R., Cappabianca L., Desantis G., Tessitore A.,
RA   Vetuschi A., Sferra R., Rucci N., Argenti B., Screpanti I., Gulino A.,
RA   Mackay A.R.;
RT   "TrkA alternative splicing: a regulated tumor-promoting switch in human
RT   neuroblastoma.";
RL   Cancer Cell 6:347-360(2004).
RN   [20]
RP   INTERACTION WITH SORT1, AND ACTIVITY REGULATION.
RX   PubMed=21102451; DOI=10.1038/nn.2689;
RA   Vaegter C.B., Jansen P., Fjorback A.W., Glerup S., Skeldal S., Kjolby M.,
RA   Richner M., Erdmann B., Nyengaard J.R., Tessarollo L., Lewin G.R.,
RA   Willnow T.E., Chao M.V., Nykjaer A.;
RT   "Sortilin associates with Trk receptors to enhance anterograde transport
RT   and neurotrophin signaling.";
RL   Nat. Neurosci. 14:54-61(2011).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH NGF.
RX   PubMed=22649032; DOI=10.1096/fj.12-207316;
RA   Tong Q., Wang F., Zhou H.Z., Sun H.L., Song H., Shu Y.Y., Gong Y.,
RA   Zhang W.T., Cai T.X., Yang F.Q., Tang J., Jiang T.;
RT   "Structural and functional insights into lipid-bound nerve growth
RT   factors.";
RL   FASEB J. 26:3811-3821(2012).
RN   [22]
RP   INTERACTION WITH GGA3, AND MUTAGENESIS OF 540-LEU-VAL-541; LYS-544 AND
RP   610-LEU-LEU-611.
RX   PubMed=26446845; DOI=10.1091/mbc.e15-02-0087;
RA   Li X., Lavigne P., Lavoie C.;
RT   "GGA3 mediates TrkA endocytic recycling to promote sustained Akt
RT   phosphorylation and cell survival.";
RL   Mol. Biol. Cell 26:4412-4426(2015).
RN   [23]
RP   FUNCTION, UBIQUITINATION BY NEDD4L, AND INTERACTION WITH USP36.
RX   PubMed=27445338; DOI=10.1074/jbc.m116.722637;
RA   Anta B., Martin-Rodriguez C., Gomis-Perez C., Calvo L., Lopez-Benito S.,
RA   Calderon-Garcia A.A., Vicente-Garcia C., Villarroel A., Arevalo J.C.;
RT   "Ubiquitin-specific Protease 36 (USP36) Controls Neuronal Precursor Cell-
RT   expressed Developmentally Down-regulated 4-2 (Nedd4-2) Actions over the
RT   Neurotrophin Receptor TrkA and Potassium Voltage-gated Channels 7.2/3
RT   (Kv7.2/3).";
RL   J. Biol. Chem. 291:19132-19145(2016).
RN   [24]
RP   PHOSPHORYLATION, VARIANTS CIPA 235-SER--GLY-796 DEL; ASN-596 AND TYR-674,
RP   AND CHARACTERIZATION OF VARIANTS CIPA 235-SER--GLY-796 DEL AND ASN-596.
RX   PubMed=28177573; DOI=10.1111/jns.12205;
RA   Nam T.S., Li W., Yoon S., Eom G.H., Kim M.K., Jung S.T., Choi S.Y.;
RT   "Novel NTRK1 mutations associated with congenital insensitivity to pain
RT   with anhidrosis verified by functional studies.";
RL   J. Peripher. Nerv. Syst. 22:92-99(2017).
RN   [25]
RP   STRUCTURE BY NMR OF 489-500.
RX   PubMed=8524391; DOI=10.1038/378584a0;
RA   Zhou M.-M., Ravichandran K.S., Olejniczak E.F., Petros A.M., Meadows R.P.,
RA   Sattler M., Harlan J.E., Wade W.S., Burakoff S.J., Fesik S.W.;
RT   "Structure and ligand recognition of the phosphotyrosine binding domain of
RT   Shc.";
RL   Nature 378:584-592(1995).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 278-386, AND DISULFIDE BONDS.
RX   PubMed=10388563; DOI=10.1006/jmbi.1999.2816;
RA   Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M., Reilly D.,
RA   Bass S.H., de Vos A.M.;
RT   "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and
RT   TrkC.";
RL   J. Mol. Biol. 290:149-159(1999).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 282-382 IN COMPLEX WITH NGF,
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=10490030; DOI=10.1038/43705;
RA   Wiesmann C., Ultsch M.H., Bass S.H., de Vos A.M.;
RT   "Crystal structure of nerve growth factor in complex with the ligand-
RT   binding domain of the TrkA receptor.";
RL   Nature 401:184-188(1999).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 36-382 IN COMPLEX WITH NGF,
RP   HOMODIMERIZATION, SUBUNIT, SUBCELLULAR LOCATION, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-95; ASN-121; ASN-188; ASN-262; ASN-281 AND ASN-358.
RX   PubMed=17196528; DOI=10.1016/j.neuron.2006.09.034;
RA   Wehrman T., He X., Raab B., Dukipatti A., Blau H., Garcia K.C.;
RT   "Structural and mechanistic insights into nerve growth factor interactions
RT   with the TrkA and p75 receptors.";
RL   Neuron 53:25-38(2007).
RN   [29]
RP   VARIANT CIPA ARG-577.
RX   PubMed=8696348; DOI=10.1038/ng0896-485;
RA   Indo Y., Tsuruta M., Hayashida Y., Karim M.A., Ohta K., Kawano T.,
RA   Mitsubuchi H., Tonoki H., Awaya Y., Matsuda I.;
RT   "Mutations in the TRKA/NGF receptor gene in patients with congenital
RT   insensitivity to pain with anhidrosis.";
RL   Nat. Genet. 13:485-488(1996).
RN   [30]
RP   VARIANT CIPA PRO-780.
RX   PubMed=10090906; DOI=10.1086/302319;
RA   Greco A., Villa R., Tubino B., Romano L., Penso D., Pierotti M.A.;
RT   "A novel NTRK1 mutation associated with congenital insensitivity to pain
RT   with anhidrosis.";
RL   Am. J. Hum. Genet. 64:1207-1210(1999).
RN   [31]
RP   VARIANTS CIPA PRO-213; TRP-649 AND SER-714, AND VARIANTS SER-85; TYR-604
RP   AND VAL-613.
RX   PubMed=10330344; DOI=10.1086/302422;
RA   Mardy S., Miura Y., Endo F., Matsuda I., Sztriha L., Frossard P., Moosa A.,
RA   Ismail E.A.R., Macaya A., Andria G., Toscano E., Gibson W., Graham G.E.,
RA   Indo Y.;
RT   "Congenital insensitivity to pain with anhidrosis: novel mutations in the
RT   TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth
RT   factor.";
RL   Am. J. Hum. Genet. 64:1570-1579(1999).
RN   [32]
RP   VARIANTS TYR-604; VAL-613 AND GLN-780.
RX   PubMed=10443680; DOI=10.1210/jcem.84.8.5901;
RA   Gimm O., Greco A., Hoang-Vu C., Dralle H., Pierotti M.A., Eng C.;
RT   "Mutation analysis reveals novel sequence variants in NTRK1 in sporadic
RT   human medullary thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 84:2784-2787(1999).
RN   [33]
RP   VARIANT CIPA VAL-587.
RX   PubMed=10233776; DOI=10.1046/j.1523-1747.1999.00569.x;
RA   Yotsumoto S., Setoyama M., Hozumi H., Mizoguchi S., Fukumaru S.,
RA   Kobayashi K., Saheki T., Kanzaki T.;
RT   "A novel point mutation affecting the tyrosine kinase domain of the TRKA
RT   gene in a family with congenital insensitivity to pain with anhidrosis.";
RL   J. Invest. Dermatol. 112:810-814(1999).
RN   [34]
RP   VARIANTS TYR-604 AND VAL-613.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [35]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [36]
RP   VARIANT CIPA LEU-695, AND VARIANT VAL-613.
RC   TISSUE=Peripheral blood;
RX   PubMed=10861667;
RX   DOI=10.1002/1096-8628(20000619)92:5<353::aid-ajmg12>3.0.co;2-c;
RA   Shatzky S., Moses S., Levy J., Pinsk V., Hershkovitz E., Herzog L.,
RA   Shorer Z., Luder A., Parvari R.;
RT   "Congenital insensitivity to pain with anhidrosis (CIPA) in Israeli-
RT   Bedouins: genetic heterogeneity, novel mutations in the TRKA/NGF receptor
RT   gene, clinical findings, and results of nerve conduction studies.";
RL   Am. J. Med. Genet. 92:353-360(2000).
RN   [37]
RP   VARIANTS CIPA PRO-93; ARG-522; ARG-577; CYS-654 AND TYR-674.
RX   PubMed=10982191; DOI=10.1007/s004390051018;
RA   Miura Y., Mardy S., Awaya Y., Nihei K., Endo F., Matsuda I., Indo Y.;
RT   "Mutation and polymorphism analysis of the TRKA (NTRK1) gene encoding a
RT   high-affinity receptor for nerve growth factor in congenital insensitivity
RT   to pain with anhidrosis (CIPA) families.";
RL   Hum. Genet. 106:116-124(2000).
RN   [38]
RP   VARIANT CIPA ARG-577.
RX   PubMed=10567924;
RX   DOI=10.1002/(sici)1097-4652(200001)182:1<127::aid-jcp14>3.0.co;2-0;
RA   Greco A., Villa R., Fusetti L., Orlandi R., Pierotti M.A.;
RT   "The Gly571Arg mutation, associated with the autonomic and sensory disorder
RT   congenital insensitivity to pain with anhidrosis, causes the inactivation
RT   of the NTRK1/nerve growth factor receptor.";
RL   J. Cell. Physiol. 182:127-133(2000).
RN   [39]
RP   VARIANT CIPA CYS-359, AND VARIANTS TYR-604 AND VAL-613.
RX   PubMed=11310631; DOI=10.1002/ana.103;
RA   Houlden H., King R.H., Hashemi-Nejad A., Wood N.W., Mathias C.J.,
RA   Reilly M., Thomas P.K.;
RT   "A novel TRK A (NTRK1) mutation associated with hereditary sensory and
RT   autonomic neuropathy type V.";
RL   Ann. Neurol. 49:521-525(2001).
RN   [40]
RP   CHARACTERIZATION OF VARIANTS CIPA PRO-93; PRO-213; ARG-522; ARG-577;
RP   TRP-649; CYS-654 AND SER-714, AND CHARACTERIZATION OF VARIANTS SER-85;
RP   TYR-604; VAL-613 AND TYR-674.
RX   PubMed=11159935; DOI=10.1093/hmg/10.3.179;
RA   Mardy S., Miura Y., Endo F., Matsuda I., Indo Y.;
RT   "Congenital insensitivity to pain with anhidrosis (CIPA): effect of TRKA
RT   (NTRK1) missense mutations on autophosphorylation of the receptor tyrosine
RT   kinase for nerve growth factor.";
RL   Hum. Mol. Genet. 10:179-188(2001).
RN   [41]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-80; VAL-107; MET-237; GLY-238; GLY-260;
RP   GLN-444; CYS-452; THR-566; TYR-604; VAL-613; GLN-780 AND ILE-790.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [42]
RP   VARIANTS CIPA SER-572 AND ARG-717.
RX   PubMed=18077166; DOI=10.1016/j.nmd.2007.10.005;
RA   Huehne K., Zweier C., Raab K., Odent S., Bonnaure-Mallet M., Sixou J.L.,
RA   Landrieu P., Goizet C., Sarlangue J., Baumann M., Eggermann T., Rauch A.,
RA   Ruppert S., Stettner G.M., Rautenstrauss B.;
RT   "Novel missense, insertion and deletion mutations in the neurotrophic
RT   tyrosine kinase receptor type 1 gene (NTRK1) associated with congenital
RT   insensitivity to pain with anhidrosis.";
RL   Neuromuscul. Disord. 18:159-166(2008).
RN   [43]
RP   VARIANTS CIPA LYS-492 AND CYS-654, AND VARIANT TRP-6.
RX   PubMed=22302274; DOI=10.1007/s00415-011-6397-y;
RA   Davidson G.L., Murphy S.M., Polke J.M., Laura M., Salih M.A., Muntoni F.,
RA   Blake J., Brandner S., Davies N., Horvath R., Price S., Donaghy M.,
RA   Roberts M., Foulds N., Ramdharry G., Soler D., Lunn M.P., Manji H.,
RA   Davis M.B., Houlden H., Reilly M.M.;
RT   "Frequency of mutations in the genes associated with hereditary sensory and
RT   autonomic neuropathy in a UK cohort.";
RL   J. Neurol. 259:1673-1685(2012).
RN   [44]
RP   VARIANTS CIPA ASP-110; 146-SER--GLY-796 DEL; 176-GLN--GLY-796 DEL;
RP   476-LEU--GLY-796 DEL; GLN-649 AND PRO-700.
RX   PubMed=28328124; DOI=10.1002/ajmg.a.38120;
RA   Altassan R., Saud H.A., Masoodi T.A., Dosssari H.A., Khalifa O.,
RA   Al-Zaidan H., Sakati N., Rhabeeni Z., Al-Hassnan Z., Binamer Y.,
RA   Alhashemi N., Wade W., Al-Zayed Z., Al-Sayed M., Al-Muhaizea M.A.,
RA   Meyer B., Al-Owain M., Wakil S.M.;
RT   "Exome sequencing identifies novel NTRK1 mutations in patients with HSAN-IV
RT   phenotype.";
RL   Am. J. Med. Genet. A 173:1009-1016(2017).
RN   [45]
RP   VARIANTS CIPA GLU-517; GLU-522; PRO-657; THR-699; SER-752; SER-763 AND
RP   CYS-771, CHARACTERIZATION OF VARIANTS CIPA GLU-517; GLU-522; PRO-657;
RP   THR-699; SER-752; SER-763 AND CYS-771, GLYCOSYLATION, SUBCELLULAR LOCATION,
RP   AUTOPHOSPHORYLATION AFTER NGF STIMULATION, AND FUNCTION.
RX   PubMed=27676246; DOI=10.1002/humu.23123;
RA   Shaikh S.S., Chen Y.C., Halsall S.A., Nahorski M.S., Omoto K., Young G.T.,
RA   Phelan A., Woods C.G.;
RT   "A comprehensive functional analysis of NTRK1 missense mutations causing
RT   hereditary sensory and autonomic neuropathy type IV (HSAN IV).";
RL   Hum. Mutat. 38:55-63(2017).
CC   -!- FUNCTION: Receptor tyrosine kinase involved in the development and the
CC       maturation of the central and peripheral nervous systems through
CC       regulation of proliferation, differentiation and survival of
CC       sympathetic and nervous neurons. High affinity receptor for NGF which
CC       is its primary ligand (PubMed:1850821, PubMed:1849459, PubMed:1281417,
CC       PubMed:8325889, PubMed:15488758, PubMed:22649032, PubMed:17196528,
CC       PubMed:27445338). Can also bind and be activated by NTF3/neurotrophin-
CC       3. However, NTF3 only supports axonal extension through NTRK1 but has
CC       no effect on neuron survival (By similarity). Upon dimeric NGF ligand-
CC       binding, undergoes homodimerization, autophosphorylation and activation
CC       (PubMed:1281417). Recruits, phosphorylates and/or activates several
CC       downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that
CC       regulate distinct overlapping signaling cascades driving cell survival
CC       and differentiation. Through SHC1 and FRS2 activates a GRB2-Ras-MAPK
CC       cascade that regulates cell differentiation and survival. Through PLCG1
CC       controls NF-Kappa-B activation and the transcription of genes involved
CC       in cell survival. Through SHC1 and SH2B1 controls a Ras-PI3 kinase-AKT1
CC       signaling cascade that is also regulating survival. In absence of
CC       ligand and activation, may promote cell death, making the survival of
CC       neurons dependent on trophic factors. {ECO:0000250|UniProtKB:P35739,
CC       ECO:0000250|UniProtKB:Q3UFB7, ECO:0000269|PubMed:11244088,
CC       ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:17196528, ECO:0000269|PubMed:1849459,
CC       ECO:0000269|PubMed:1850821, ECO:0000269|PubMed:22649032,
CC       ECO:0000269|PubMed:27445338, ECO:0000269|PubMed:27676246,
CC       ECO:0000269|PubMed:8155326, ECO:0000269|PubMed:8325889}.
CC   -!- FUNCTION: [Isoform TrkA-III]: Resistant to NGF, it constitutively
CC       activates AKT1 and NF-kappa-B and is unable to activate the Ras-MAPK
CC       signaling cascade. Antagonizes the anti-proliferative NGF-NTRK1
CC       signaling that promotes neuronal precursors differentiation. Isoform
CC       TrkA-III promotes angiogenesis and has oncogenic activity when
CC       overexpressed. {ECO:0000269|PubMed:15488758}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:2927393};
CC   -!- ACTIVITY REGULATION: The pro-survival signaling effect of NTRK1 in
CC       neurons requires its endocytosis into signaling early endosomes and its
CC       retrograde axonal transport. This is regulated by different proteins
CC       including CFL1, RAC1 and SORT1. NTF3 is unable to induce this signaling
CC       probably due to the lability of the NTF3-NTRK1 complex in endosomes.
CC       SH2D1A inhibits the autophosphorylation of the receptor, and alters the
CC       recruitment and activation of downstream effectors and signaling
CC       cascades (By similarity). Regulated by NGFR (By similarity).
CC       {ECO:0000250|UniProtKB:Q3UFB7}.
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures. Homodimerization is
CC       induced by binding of a NGF dimer (PubMed:1281417, PubMed:10490030,
CC       PubMed:17196528). Interacts with SQSTM1; bridges NTRK1 to NGFR
CC       (PubMed:11244088). Forms a ternary complex with NGFR and KIDINS220;
CC       this complex is affected by the expression levels of KIDINS220 and an
CC       increase in KIDINS220 expression leads to a decreased association of
CC       NGFR and NTRK1 (By similarity). Interacts with SH2D1A; regulates NTRK1
CC       (By similarity). Interacts (phosphorylated upon activation by NGF) with
CC       SHC1; mediates SHC1 phosphorylation and activation (PubMed:8155326,
CC       PubMed:15488758). Interacts (phosphorylated upon activation by NGF)
CC       with PLCG1; mediates PLCG1 phosphorylation and activation
CC       (PubMed:7510697, PubMed:15488758). Interacts (phosphorylated) with
CC       SH2B1 and SH2B2 (By similarity). Interacts with GRB2 (PubMed:15488758).
CC       Interacts with PIK3R1 (PubMed:15488758). Interacts with FRS2
CC       (PubMed:15488758). Interacts with SORT1; may regulate NTRK1 anterograde
CC       axonal transport (PubMed:21102451). Interacts with RAB7A (By
CC       similarity). Found in a complex, at least composed of KIDINS220, MAGI2,
CC       NTRK1 and RAPGEF2; the complex is mainly formed at late endosomes in a
CC       nerve growth factor (NGF)-dependent manner (By similarity). Interacts
CC       with RAPGEF2; the interaction is strengthened after NGF stimulation (By
CC       similarity). Interacts with PTPRS (By similarity). Interacts with
CC       USP36; USP36 does not deubiquitinate NTRK1 (PubMed:27445338). Interacts
CC       with GGA3 (PubMed:26446845). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P35739, ECO:0000269|PubMed:10490030,
CC       ECO:0000269|PubMed:11244088, ECO:0000269|PubMed:1281417,
CC       ECO:0000269|PubMed:15488758, ECO:0000269|PubMed:17196528,
CC       ECO:0000269|PubMed:21102451, ECO:0000269|PubMed:22649032,
CC       ECO:0000269|PubMed:26446845, ECO:0000269|PubMed:27445338,
CC       ECO:0000269|PubMed:7510697, ECO:0000269|PubMed:8155326,
CC       ECO:0000269|PubMed:8325889}.
CC   -!- INTERACTION:
CC       P04629; P04629; NbExp=3; IntAct=EBI-1028226, EBI-1028226;
CC       P04629; P05067-4: APP; NbExp=7; IntAct=EBI-1028226, EBI-302641;
CC       P04629; P22681: CBL; NbExp=2; IntAct=EBI-1028226, EBI-518228;
CC       P04629; P01138: NGF; NbExp=3; IntAct=EBI-1028226, EBI-1028250;
CC       P04629; PRO_0000019600 [P01138]: NGF; NbExp=2; IntAct=EBI-1028226, EBI-9249861;
CC       P04629; Q8K4V6: Pirb; Xeno; NbExp=2; IntAct=EBI-1028226, EBI-8602514;
CC       P04629; P18031: PTPN1; NbExp=2; IntAct=EBI-1028226, EBI-968788;
CC       P04629; Q99523: SORT1; NbExp=3; IntAct=EBI-1028226, EBI-1057058;
CC       P04629; Q13501: SQSTM1; NbExp=2; IntAct=EBI-1028226, EBI-307104;
CC       P04629; O75385: ULK1; NbExp=2; IntAct=EBI-1028226, EBI-908831;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1281417,
CC       ECO:0000269|PubMed:15488758, ECO:0000269|PubMed:17196528,
CC       ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:2927393}; Single-pass
CC       type I membrane protein {ECO:0000269|PubMed:1281417,
CC       ECO:0000269|PubMed:15488758}. Early endosome membrane
CC       {ECO:0000250|UniProtKB:P35739}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P35739}. Late endosome membrane
CC       {ECO:0000250|UniProtKB:P35739}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P35739}. Recycling endosome membrane
CC       {ECO:0000250|UniProtKB:P35739}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P35739}. Note=Rapidly internalized after NGF
CC       binding (PubMed:1281417). Internalized to endosomes upon binding of NGF
CC       or NTF3 and further transported to the cell body via a retrograde
CC       axonal transport. Localized at cell membrane and early endosomes before
CC       nerve growth factor (NGF) stimulation. Recruited to late endosomes
CC       after NGF stimulation. Colocalized with RAPGEF2 at late endosomes.
CC       {ECO:0000250|UniProtKB:P35739, ECO:0000269|PubMed:1281417}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=TrkA-I and TrkA-II isoforms have similar biological
CC         properties but are differentially expressed.;
CC       Name=TrkA-II; Synonyms=TrkAII;
CC         IsoId=P04629-1; Sequence=Displayed;
CC       Name=TrkA-I; Synonyms=TrkAI;
CC         IsoId=P04629-2; Sequence=VSP_002899;
CC       Name=3;
CC         IsoId=P04629-3; Sequence=VSP_041905, VSP_002899;
CC       Name=TrkA-III; Synonyms=TrkAIII;
CC         IsoId=P04629-4; Sequence=VSP_042152, VSP_002899;
CC   -!- TISSUE SPECIFICITY: Isoform TrkA-I is found in most non-neuronal
CC       tissues. Isoform TrkA-II is primarily expressed in neuronal cells.
CC       TrkA-III is specifically expressed by pluripotent neural stem and
CC       neural crest progenitors. {ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:8325889}.
CC   -!- INDUCTION: Isoform TrkA-III is up-regulated upon hypoxia in cells
CC       normally expressing it. {ECO:0000269|PubMed:15488758}.
CC   -!- DOMAIN: The transmembrane domain mediates interaction with KIDINS220.
CC       {ECO:0000250|UniProtKB:P35739}.
CC   -!- DOMAIN: The extracellular domain mediates interaction with NGFR.
CC       {ECO:0000250|UniProtKB:P35739}.
CC   -!- PTM: Ligand-mediated autophosphorylation (PubMed:2927393,
CC       PubMed:1281417, PubMed:15488758, PubMed:7510697, PubMed:8155326,
CC       PubMed:8325889, PubMed:27676246, PubMed:28177573). Interaction with
CC       SQSTM1 is phosphotyrosine-dependent. Autophosphorylation at Tyr-496
CC       mediates interaction and phosphorylation of SHC1 (PubMed:15488758,
CC       PubMed:7510697, PubMed:8155326, PubMed:8325889).
CC       {ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:28177573,
CC       ECO:0000269|PubMed:2927393, ECO:0000269|PubMed:7510697,
CC       ECO:0000269|PubMed:8155326, ECO:0000269|PubMed:8325889}.
CC   -!- PTM: N-glycosylated (PubMed:2927393). Isoform TrkA-I and isoform TrkA-
CC       II are N-glycosylated. {ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:17196528, ECO:0000269|PubMed:27676246,
CC       ECO:0000269|PubMed:2927393}.
CC   -!- PTM: Ubiquitinated (PubMed:27445338). Undergoes polyubiquitination upon
CC       activation; regulated by NGFR (PubMed:27445338). Ubiquitination by
CC       NEDD4L leads to degradation (PubMed:27445338). Ubiquitination regulates
CC       the internalization of the receptor (By similarity).
CC       {ECO:0000250|UniProtKB:Q3UFB7, ECO:0000269|PubMed:27445338}.
CC   -!- DISEASE: Congenital insensitivity to pain with anhidrosis (CIPA)
CC       [MIM:256800]: Characterized by a congenital insensitivity to pain,
CC       anhidrosis (absence of sweating), absence of reaction to noxious
CC       stimuli, self-mutilating behavior, and mental retardation. This rare
CC       autosomal recessive disorder is also known as congenital sensory
CC       neuropathy with anhidrosis or hereditary sensory and autonomic
CC       neuropathy type IV or familial dysautonomia type II.
CC       {ECO:0000269|PubMed:10090906, ECO:0000269|PubMed:10233776,
CC       ECO:0000269|PubMed:10330344, ECO:0000269|PubMed:10567924,
CC       ECO:0000269|PubMed:10861667, ECO:0000269|PubMed:10982191,
CC       ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:11310631,
CC       ECO:0000269|PubMed:18077166, ECO:0000269|PubMed:22302274,
CC       ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:28177573,
CC       ECO:0000269|PubMed:28328124, ECO:0000269|PubMed:8696348}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=Chromosomal aberrations involving NTRK1 are found in
CC       papillary thyroid carcinomas (PTCs) (PubMed:2869410, PubMed:7565764,
CC       PubMed:1532241). Translocation t(1;3)(q21;q11) with TFG generates the
CC       TRKT3 (TRK-T3) transcript by fusing TFG to the 3'-end of NTRK1
CC       (PubMed:7565764). A rearrangement with TPM3 generates the TRK
CC       transcript by fusing TPM3 to the 3'-end of NTRK1 (PubMed:2869410). An
CC       intrachromosomal rearrangement that links the protein kinase domain of
CC       NTRK1 to the 5'-end of the TPR gene forms the fusion protein TRK-T1.
CC       TRK-T1 is a 55 kDa protein reacting with antibodies against the C-
CC       terminus of the NTRK1 protein (PubMed:1532241).
CC       {ECO:0000269|PubMed:1532241, ECO:0000269|PubMed:2869410,
CC       ECO:0000269|PubMed:7565764}.
CC   -!- MISCELLANEOUS: Trk also stands for tropomyosin-related kinase since it
CC       was first isolated as an oncogenic protein which was the result of a
CC       fusion between the tropomyosin gene TPM3 and NTRK1.
CC   -!- MISCELLANEOUS: [Isoform TrkA-II]: Major isoform.
CC   -!- MISCELLANEOUS: [Isoform TrkA-I]: Has enhanced responsiveness to NTF3
CC       neurotrophin. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform TrkA-III]: Constitutively active. Does not bind
CC       NGF and does not interact with GRB2 and FRS2. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA27243.1; Type=Erroneous termination; Note=Truncated C-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA27243.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=CAA27243.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA29888.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA44719.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA59936.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M23102; AAA36770.1; -; mRNA.
DR   EMBL; AB019488; BAA34355.1; -; Genomic_DNA.
DR   EMBL; AK312704; BAG35582.1; -; mRNA.
DR   EMBL; DB265639; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AL158169; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC062580; AAH62580.1; -; mRNA.
DR   EMBL; BC136554; AAI36555.1; -; mRNA.
DR   EMBL; BC144239; AAI44240.1; -; mRNA.
DR   EMBL; AY321513; AAP88292.1; -; Genomic_DNA.
DR   EMBL; X03541; CAA27243.1; ALT_SEQ; mRNA.
DR   EMBL; X06704; CAA29888.1; ALT_SEQ; mRNA.
DR   EMBL; X85960; CAA59936.1; ALT_SEQ; mRNA.
DR   EMBL; X62947; CAA44719.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS1161.1; -. [P04629-1]
DR   CCDS; CCDS30890.1; -. [P04629-3]
DR   CCDS; CCDS30891.1; -. [P04629-2]
DR   PIR; A30124; TVHUTT.
DR   PIR; S23741; S23741.
DR   RefSeq; NP_001007793.1; NM_001007792.1. [P04629-3]
DR   RefSeq; NP_001012331.1; NM_001012331.1. [P04629-2]
DR   RefSeq; NP_002520.2; NM_002529.3. [P04629-1]
DR   PDB; 1HE7; X-ray; 2.00 A; A=285-413.
DR   PDB; 1SHC; NMR; -; B=489-500.
DR   PDB; 1WWA; X-ray; 2.50 A; X/Y=278-386.
DR   PDB; 1WWW; X-ray; 2.20 A; X/Y=282-382.
DR   PDB; 2IFG; X-ray; 3.40 A; A/B=36-382.
DR   PDB; 2N90; NMR; -; A/B=410-447.
DR   PDB; 4AOJ; X-ray; 2.75 A; A/B/C=473-796.
DR   PDB; 4CRP; NMR; -; A=282-383.
DR   PDB; 4F0I; X-ray; 2.30 A; A/B=498-796.
DR   PDB; 4GT5; X-ray; 2.40 A; A=498-796.
DR   PDB; 4PMM; X-ray; 2.00 A; A=501-787.
DR   PDB; 4PMP; X-ray; 1.80 A; A=501-787.
DR   PDB; 4PMS; X-ray; 2.80 A; A=501-787.
DR   PDB; 4PMT; X-ray; 2.10 A; A=501-787.
DR   PDB; 4YNE; X-ray; 2.02 A; A=502-796.
DR   PDB; 4YPS; X-ray; 2.10 A; A=502-796.
DR   PDB; 5H3Q; X-ray; 2.10 A; A=473-796.
DR   PDB; 5I8A; X-ray; 2.33 A; A=498-787.
DR   PDB; 5JFS; X-ray; 2.07 A; A=502-796.
DR   PDB; 5JFV; X-ray; 1.59 A; A=502-796.
DR   PDB; 5JFW; X-ray; 1.52 A; A=502-796.
DR   PDB; 5JFX; X-ray; 1.63 A; A=502-796.
DR   PDB; 5KMI; X-ray; 1.87 A; A=474-796.
DR   PDB; 5KMJ; X-ray; 2.04 A; A=474-796.
DR   PDB; 5KMK; X-ray; 2.24 A; A=474-796.
DR   PDB; 5KML; X-ray; 2.01 A; A=474-796.
DR   PDB; 5KMM; X-ray; 2.12 A; A=474-796.
DR   PDB; 5KMN; X-ray; 2.14 A; A=474-796.
DR   PDB; 5KMO; X-ray; 2.67 A; A=474-796.
DR   PDB; 5KVT; X-ray; 2.45 A; A=501-787.
DR   PDB; 5WR7; X-ray; 2.76 A; A=489-792.
DR   PDB; 6D1Y; X-ray; 1.93 A; A=479-796.
DR   PDB; 6D1Z; X-ray; 1.87 A; A=479-796.
DR   PDB; 6D20; X-ray; 1.94 A; A=479-796.
DR   PDB; 6D22; X-ray; 2.46 A; A=502-796.
DR   PDB; 6DKB; X-ray; 2.68 A; A=479-796.
DR   PDB; 6DKG; X-ray; 2.53 A; A=479-796.
DR   PDB; 6DKI; X-ray; 2.11 A; A=479-796.
DR   PDB; 6DKW; X-ray; 2.91 A; A/B=502-796.
DR   PDB; 6IQN; X-ray; 2.54 A; A/B=502-796.
DR   PDB; 6J5L; X-ray; 2.30 A; A=502-796.
DR   PDB; 6NPT; X-ray; 2.19 A; A=491-795.
DR   PDB; 6NSP; X-ray; 2.31 A; A=500-796.
DR   PDB; 6NSS; X-ray; 1.97 A; A=485-795.
DR   PDB; 6PL1; X-ray; 2.03 A; A=485-795.
DR   PDB; 6PL2; X-ray; 2.59 A; A=485-795.
DR   PDB; 6PL3; X-ray; 3.00 A; A=485-795.
DR   PDBsum; 1HE7; -.
DR   PDBsum; 1SHC; -.
DR   PDBsum; 1WWA; -.
DR   PDBsum; 1WWW; -.
DR   PDBsum; 2IFG; -.
DR   PDBsum; 2N90; -.
DR   PDBsum; 4AOJ; -.
DR   PDBsum; 4CRP; -.
DR   PDBsum; 4F0I; -.
DR   PDBsum; 4GT5; -.
DR   PDBsum; 4PMM; -.
DR   PDBsum; 4PMP; -.
DR   PDBsum; 4PMS; -.
DR   PDBsum; 4PMT; -.
DR   PDBsum; 4YNE; -.
DR   PDBsum; 4YPS; -.
DR   PDBsum; 5H3Q; -.
DR   PDBsum; 5I8A; -.
DR   PDBsum; 5JFS; -.
DR   PDBsum; 5JFV; -.
DR   PDBsum; 5JFW; -.
DR   PDBsum; 5JFX; -.
DR   PDBsum; 5KMI; -.
DR   PDBsum; 5KMJ; -.
DR   PDBsum; 5KMK; -.
DR   PDBsum; 5KML; -.
DR   PDBsum; 5KMM; -.
DR   PDBsum; 5KMN; -.
DR   PDBsum; 5KMO; -.
DR   PDBsum; 5KVT; -.
DR   PDBsum; 5WR7; -.
DR   PDBsum; 6D1Y; -.
DR   PDBsum; 6D1Z; -.
DR   PDBsum; 6D20; -.
DR   PDBsum; 6D22; -.
DR   PDBsum; 6DKB; -.
DR   PDBsum; 6DKG; -.
DR   PDBsum; 6DKI; -.
DR   PDBsum; 6DKW; -.
DR   PDBsum; 6IQN; -.
DR   PDBsum; 6J5L; -.
DR   PDBsum; 6NPT; -.
DR   PDBsum; 6NSP; -.
DR   PDBsum; 6NSS; -.
DR   PDBsum; 6PL1; -.
DR   PDBsum; 6PL2; -.
DR   PDBsum; 6PL3; -.
DR   SMR; P04629; -.
DR   BioGrid; 110969; 1960.
DR   CORUM; P04629; -.
DR   DIP; DIP-5714N; -.
DR   ELM; P04629; -.
DR   IntAct; P04629; 30.
DR   MINT; P04629; -.
DR   STRING; 9606.ENSP00000431418; -.
DR   BindingDB; P04629; -.
DR   ChEMBL; CHEMBL2815; -.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB13926; Cenegermin.
DR   DrugBank; DB11986; Entrectinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB14723; Larotrectinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugCentral; P04629; -.
DR   GuidetoPHARMACOLOGY; 1817; -.
DR   iPTMnet; P04629; -.
DR   PhosphoSitePlus; P04629; -.
DR   BioMuta; NTRK1; -.
DR   DMDM; 94730402; -.
DR   jPOST; P04629; -.
DR   MassIVE; P04629; -.
DR   PaxDb; P04629; -.
DR   PeptideAtlas; P04629; -.
DR   PRIDE; P04629; -.
DR   ProteomicsDB; 51723; -. [P04629-1]
DR   ProteomicsDB; 51724; -. [P04629-2]
DR   ProteomicsDB; 51725; -. [P04629-3]
DR   ProteomicsDB; 51726; -. [P04629-4]
DR   ABCD; P04629; -.
DR   Antibodypedia; 3896; 1500 antibodies.
DR   Ensembl; ENST00000368196; ENSP00000357179; ENSG00000198400. [P04629-2]
DR   Ensembl; ENST00000392302; ENSP00000376120; ENSG00000198400. [P04629-3]
DR   Ensembl; ENST00000524377; ENSP00000431418; ENSG00000198400. [P04629-1]
DR   GeneID; 4914; -.
DR   KEGG; hsa:4914; -.
DR   UCSC; uc001fqf.2; human. [P04629-1]
DR   CTD; 4914; -.
DR   DisGeNET; 4914; -.
DR   GeneCards; NTRK1; -.
DR   GeneReviews; NTRK1; -.
DR   HGNC; HGNC:8031; NTRK1.
DR   HPA; ENSG00000198400; Group enriched (adrenal gland, blood, brain).
DR   MalaCards; NTRK1; -.
DR   MIM; 164970; gene.
DR   MIM; 191315; gene.
DR   MIM; 256800; phenotype.
DR   neXtProt; NX_P04629; -.
DR   OpenTargets; ENSG00000198400; -.
DR   Orphanet; 146; Differentiated thyroid carcinoma.
DR   Orphanet; 99361; Familial medullary thyroid carcinoma.
DR   Orphanet; 642; Hereditary sensory and autonomic neuropathy type 4.
DR   Orphanet; 64752; Hereditary sensory and autonomic neuropathy type 5.
DR   PharmGKB; PA31817; -.
DR   eggNOG; ENOG410IMMI; Eukaryota.
DR   eggNOG; ENOG410XTGG; LUCA.
DR   GeneTree; ENSGT00940000159412; -.
DR   HOGENOM; CLU_000288_74_1_1; -.
DR   InParanoid; P04629; -.
DR   KO; K03176; -.
DR   OMA; QCLEPNG; -.
DR   OrthoDB; 295510at2759; -.
DR   PhylomeDB; P04629; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-167021; PLC-gamma1 signalling.
DR   Reactome; R-HSA-167044; Signalling to RAS.
DR   Reactome; R-HSA-170968; Frs2-mediated activation. [P04629-1]
DR   Reactome; R-HSA-170984; ARMS-mediated activation.
DR   Reactome; R-HSA-177504; Retrograde neurotrophin signalling.
DR   Reactome; R-HSA-187024; NGF-independant TRKA activation.
DR   Reactome; R-HSA-187042; TRKA activation by NGF. [P04629-1]
DR   Reactome; R-HSA-187706; Signalling to p38 via RIT and RIN.
DR   Reactome; R-HSA-198203; PI3K/AKT activation.
DR   Reactome; R-HSA-198745; Signalling to STAT3.
DR   SignaLink; P04629; -.
DR   SIGNOR; P04629; -.
DR   ChiTaRS; NTRK1; human.
DR   EvolutionaryTrace; P04629; -.
DR   GenomeRNAi; 4914; -.
DR   Pharos; P04629; Tclin.
DR   PRO; PR:P04629; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P04629; protein.
DR   Bgee; ENSG00000198400; Expressed in adenohypophysis and 91 other tissues.
DR   ExpressionAtlas; P04629; baseline and differential.
DR   Genevisible; P04629; HS.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; ISS:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005770; C:late endosome; ISS:UniProtKB.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0032991; C:protein-containing complex; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0055038; C:recycling endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019900; F:kinase binding; IEA:Ensembl.
DR   GO; GO:0048406; F:nerve growth factor binding; IDA:UniProtKB.
DR   GO; GO:0010465; F:nerve growth factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0043121; F:neurotrophin binding; IBA:GO_Central.
DR   GO; GO:0005166; F:neurotrophin p75 receptor binding; IEA:Ensembl.
DR   GO; GO:0005030; F:neurotrophin receptor activity; IBA:GO_Central.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0060385; P:axonogenesis involved in innervation; ISS:UniProtKB.
DR   GO; GO:0030183; P:B cell differentiation; IEA:Ensembl.
DR   GO; GO:0061368; P:behavioral response to formalin induced pain; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IMP:UniProtKB.
DR   GO; GO:0071316; P:cellular response to nicotine; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ARUK-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0038180; P:nerve growth factor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; IBA:GO_Central.
DR   GO; GO:0048666; P:neuron development; IDA:MGI.
DR   GO; GO:0031175; P:neuron projection development; IDA:MGI.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0021553; P:olfactory nerve development; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:MGI.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IBA:GO_Central.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0010623; P:programmed cell death involved in cell development; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0051896; P:regulation of protein kinase B signaling; IBA:GO_Central.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0051599; P:response to hydrostatic pressure; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0009314; P:response to radiation; IEA:Ensembl.
DR   GO; GO:0060009; P:Sertoli cell development; IEA:Ensembl.
DR   GO; GO:0048485; P:sympathetic nervous system development; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR031635; NTRK_C2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR040665; TrkA_TMD.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR020461; Tyr_kinase_neurotrophic_rcpt_1.
DR   InterPro; IPR020777; Tyr_kinase_NGF_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF16920; TPKR_C2; 1.
DR   Pfam; PF18613; TrkA_TMD; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01940; NTKRECEPTOR1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chromosomal rearrangement; Developmental protein; Differentiation;
KW   Disease mutation; Disulfide bond; Endosome; Glycoprotein;
KW   Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane; Neurogenesis;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Proto-oncogene; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..32
FT                   /evidence="ECO:0000255"
FT   CHAIN           33..796
FT                   /note="High affinity nerve growth factor receptor"
FT                   /id="PRO_0000016724"
FT   TOPO_DOM        33..423
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        424..439
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        440..796
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REPEAT          90..113
FT                   /note="LRR 1"
FT   REPEAT          116..137
FT                   /note="LRR 2"
FT   DOMAIN          148..193
FT                   /note="LRRCT"
FT   DOMAIN          194..283
FT                   /note="Ig-like C2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DOMAIN          299..365
FT                   /note="Ig-like C2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DOMAIN          510..781
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         516..524
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          469..490
FT                   /note="Interaction with SQSTM1"
FT                   /evidence="ECO:0000250"
FT   MOTIF           537..541
FT                   /note="DXXLL"
FT                   /evidence="ECO:0000269|PubMed:26446845"
FT   MOTIF           607..611
FT                   /note="DXXLL"
FT                   /evidence="ECO:0000269|PubMed:26446845"
FT   ACT_SITE        650
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         544
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            398..399
FT                   /note="Breakpoint for translocation to form TRK and TRK-T3"
FT   SITE            486
FT                   /note="Breakpoint for translocation to form TRK-T1"
FT   SITE            496
FT                   /note="Interaction with SHC1"
FT   SITE            791
FT                   /note="Interaction with PLCG1"
FT   MOD_RES         496
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15488758,
FT                   ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:8155326"
FT   MOD_RES         676
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8155326"
FT   MOD_RES         680
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15488758,
FT                   ECO:0000269|PubMed:8155326"
FT   MOD_RES         681
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15488758,
FT                   ECO:0000269|PubMed:8155326"
FT   MOD_RES         791
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15488758,
FT                   ECO:0000269|PubMed:7510697, ECO:0000269|PubMed:8155326"
FT   CARBOHYD        67
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        95
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17196528"
FT   CARBOHYD        121
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17196528"
FT   CARBOHYD        188
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000244|PDB:2IFG,
FT                   ECO:0000269|PubMed:17196528"
FT   CARBOHYD        202
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        253
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        262
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000244|PDB:2IFG,
FT                   ECO:0000269|PubMed:17196528"
FT   CARBOHYD        281
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000244|PDB:2IFG,
FT                   ECO:0000269|PubMed:17196528"
FT   CARBOHYD        318
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        323
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        338
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        358
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000244|PDB:2IFG,
FT                   ECO:0000269|PubMed:17196528"
FT   CARBOHYD        401
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        36..41
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   DISULFID        40..50
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   DISULFID        154..191
FT                   /evidence="ECO:0000244|PDB:2IFG, ECO:0000255|PROSITE-
FT                   ProRule:PRU00114, ECO:0000269|PubMed:17196528"
FT   DISULFID        215..265
FT                   /evidence="ECO:0000244|PDB:2IFG, ECO:0000255|PROSITE-
FT                   ProRule:PRU00114, ECO:0000269|PubMed:17196528"
FT   DISULFID        300..345
FT                   /evidence="ECO:0000244|PDB:1HE7, ECO:0000244|PDB:1WWA,
FT                   ECO:0000244|PDB:1WWW, ECO:0000244|PDB:2IFG,
FT                   ECO:0000244|PDB:4CRP"
FT   VAR_SEQ         1..71
FT                   /note="MLRGGRRGQLGWHSWAAGPGSLLAWLILASAGAAPCPDACCPHGSSGLRCTR
FT                   DGALDSLHHLPGAENLTEL -> MKEAALICLAPSVPPILTVKSWDTMQLRAARSRCTN
FT                   LLAAS (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_041905"
FT   VAR_SEQ         192..284
FT                   /note="GVPTLKVQVPNASVDVGDDVLLRCQVEGRGLEQAGWILTELEQSATVMKSGG
FT                   LPSLGLTLANVTSDLNRKNVTCWAENDVGRAEVSVQVNVSF -> V (in isoform
FT                   TrkA-III)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_042152"
FT   VAR_SEQ         393..398
FT                   /note="Missing (in isoform TrkA-I, isoform 3 and isoform
FT                   TrkA-III)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:2927393"
FT                   /id="VSP_002899"
FT   VARIANT         6
FT                   /note="R -> W (in dbSNP:rs201472270)"
FT                   /evidence="ECO:0000269|PubMed:22302274"
FT                   /id="VAR_068480"
FT   VARIANT         18
FT                   /note="G -> E (in dbSNP:rs1007211)"
FT                   /id="VAR_049714"
FT   VARIANT         80
FT                   /note="Q -> R (in dbSNP:rs55891455)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041461"
FT   VARIANT         85
FT                   /note="R -> S (in dbSNP:rs543320028)"
FT                   /evidence="ECO:0000269|PubMed:10330344,
FT                   ECO:0000269|PubMed:11159935"
FT                   /id="VAR_009623"
FT   VARIANT         93
FT                   /note="L -> P (in CIPA; aberrantly processed; shows
FT                   diminished autophosphorylation in neuronal cells)"
FT                   /evidence="ECO:0000269|PubMed:10982191,
FT                   ECO:0000269|PubMed:11159935"
FT                   /id="VAR_009624"
FT   VARIANT         107
FT                   /note="A -> V (in an ovarian serous carcinoma sample;
FT                   somatic mutation; dbSNP:rs540521894)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041462"
FT   VARIANT         110
FT                   /note="A -> D (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:28328124"
FT                   /id="VAR_079399"
FT   VARIANT         146..796
FT                   /note="Missing (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:28328124"
FT                   /id="VAR_079400"
FT   VARIANT         176..796
FT                   /note="Missing (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:28328124"
FT                   /id="VAR_079401"
FT   VARIANT         213
FT                   /note="L -> P (in CIPA; aberrantly processed; shows
FT                   diminished autophosphorylation in neuronal cells;
FT                   dbSNP:rs747711259)"
FT                   /evidence="ECO:0000269|PubMed:10330344,
FT                   ECO:0000269|PubMed:11159935"
FT                   /id="VAR_009625"
FT   VARIANT         235..796
FT                   /note="Missing (in CIPA; loss of protein)"
FT                   /evidence="ECO:0000269|PubMed:28177573"
FT                   /id="VAR_079402"
FT   VARIANT         237
FT                   /note="T -> M (in dbSNP:rs55909005)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041463"
FT   VARIANT         238
FT                   /note="V -> G (in dbSNP:rs56000394)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041464"
FT   VARIANT         260
FT                   /note="R -> G (in dbSNP:rs35116695)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041465"
FT   VARIANT         359
FT                   /note="Y -> C (in CIPA; dbSNP:rs121964869)"
FT                   /evidence="ECO:0000269|PubMed:11310631"
FT                   /id="VAR_068481"
FT   VARIANT         444
FT                   /note="R -> Q (in dbSNP:rs56320207)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041466"
FT   VARIANT         452
FT                   /note="R -> C (in dbSNP:rs34900547)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041467"
FT   VARIANT         476..796
FT                   /note="Missing (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:28328124"
FT                   /id="VAR_079403"
FT   VARIANT         492
FT                   /note="E -> K (in CIPA; dbSNP:rs144901788)"
FT                   /evidence="ECO:0000269|PubMed:22302274"
FT                   /id="VAR_068482"
FT   VARIANT         517
FT                   /note="G -> E (in CIPA; following transfection in
FT                   neuroblastoma cells and NGF treatment, small decrease in
FT                   the percentage of cells differentiated into neuronal
FT                   phenotype, but in differentiated cells, the average neurite
FT                   length is comparable to wild-type; no effect on N-
FT                   glycosylation, subcellular location, nor on basal and NGF-
FT                   induced autophosphorylation; loss of NGF-stimulated calcium
FT                   flux; dbSNP:rs606231467)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077472"
FT   VARIANT         522
FT                   /note="G -> E (in CIPA; no effect on N-glycosylation, nor
FT                   on subcellular location; reduced basal autophosphorylation
FT                   and complete loss of NGF-induced autophosphorylation; loss
FT                   of NGF-stimulated calcium flux)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077473"
FT   VARIANT         522
FT                   /note="G -> R (in CIPA; processed as wild-type but shows
FT                   significantly diminished autophosphorylation in both
FT                   neuronal and non-neuronal cells)"
FT                   /evidence="ECO:0000269|PubMed:10982191,
FT                   ECO:0000269|PubMed:11159935"
FT                   /id="VAR_009626"
FT   VARIANT         566
FT                   /note="M -> T (in dbSNP:rs55892037)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041468"
FT   VARIANT         572
FT                   /note="I -> S (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:18077166"
FT                   /id="VAR_077474"
FT   VARIANT         577
FT                   /note="G -> R (in CIPA; loss of function; processed as
FT                   wild-type but shows significantly diminished
FT                   autophosphorylation in both neuronal and non-neuronal
FT                   cells; dbSNP:rs121964866)"
FT                   /evidence="ECO:0000269|PubMed:10567924,
FT                   ECO:0000269|PubMed:10982191, ECO:0000269|PubMed:11159935,
FT                   ECO:0000269|PubMed:8696348"
FT                   /id="VAR_004103"
FT   VARIANT         587
FT                   /note="M -> V (in CIPA; dbSNP:rs121964870)"
FT                   /evidence="ECO:0000269|PubMed:10233776"
FT                   /id="VAR_009627"
FT   VARIANT         596
FT                   /note="D -> N (in CIPA; abolishes autophosphorylation)"
FT                   /evidence="ECO:0000269|PubMed:28177573"
FT                   /id="VAR_079404"
FT   VARIANT         604
FT                   /note="H -> Y (in dbSNP:rs6336)"
FT                   /evidence="ECO:0000269|PubMed:10330344,
FT                   ECO:0000269|PubMed:10391209, ECO:0000269|PubMed:10443680,
FT                   ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:11310631,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_009628"
FT   VARIANT         613
FT                   /note="G -> V (in dbSNP:rs6339)"
FT                   /evidence="ECO:0000269|PubMed:10330344,
FT                   ECO:0000269|PubMed:10391209, ECO:0000269|PubMed:10443680,
FT                   ECO:0000269|PubMed:10861667, ECO:0000269|PubMed:11159935,
FT                   ECO:0000269|PubMed:11310631, ECO:0000269|PubMed:17344846"
FT                   /id="VAR_009629"
FT   VARIANT         649
FT                   /note="R -> Q (in CIPA; dbSNP:rs786205449)"
FT                   /evidence="ECO:0000269|PubMed:28328124"
FT                   /id="VAR_079405"
FT   VARIANT         649
FT                   /note="R -> W (in CIPA; processed as wild-type but shows
FT                   significantly diminished autophosphorylation in both
FT                   neuronal and non-neuronal cells; dbSNP:rs369353892)"
FT                   /evidence="ECO:0000269|PubMed:10330344,
FT                   ECO:0000269|PubMed:11159935"
FT                   /id="VAR_009630"
FT   VARIANT         654
FT                   /note="R -> C (in CIPA; processed as wild-type but shows
FT                   significantly diminished autophosphorylation in both
FT                   neuronal and non-neuronal cells; dbSNP:rs764992664)"
FT                   /evidence="ECO:0000269|PubMed:10982191,
FT                   ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:22302274"
FT                   /id="VAR_009631"
FT   VARIANT         657
FT                   /note="L -> P (in CIPA; following transfection in
FT                   neuroblastoma cells and NGF treatment, loss of
FT                   differentiation into neuronal phenotype; partially
FT                   decreased N-glycosylation; reduced expression at the plasma
FT                   membrane; reduced basal autophosphorylation and complete
FT                   loss of NGF-induced autophosphorylation; loss of NGF-
FT                   stimulated calcium flux)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077475"
FT   VARIANT         674
FT                   /note="D -> Y (in CIPA; might impair the function of the
FT                   enzyme without compromising autophosphorylation;
FT                   dbSNP:rs80356677)"
FT                   /evidence="ECO:0000269|PubMed:10982191,
FT                   ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:28177573"
FT                   /id="VAR_009632"
FT   VARIANT         695
FT                   /note="P -> L (in CIPA; dbSNP:rs121964868)"
FT                   /evidence="ECO:0000269|PubMed:10861667"
FT                   /id="VAR_009633"
FT   VARIANT         699
FT                   /note="I -> T (in CIPA; partially decreased N-
FT                   glycosylation; reduced expression at the plasma membrane;
FT                   reduced basal autophosphorylation and complete loss of NGF-
FT                   induced autophosphorylation; loss of NGF-stimulated calcium
FT                   flux)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077476"
FT   VARIANT         700
FT                   /note="L -> P (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:28328124"
FT                   /id="VAR_079406"
FT   VARIANT         714
FT                   /note="G -> S (in CIPA; processed as wild-type but shows
FT                   significantly diminished autophosphorylation in both
FT                   neuronal and non-neuronal cells; dbSNP:rs770727871)"
FT                   /evidence="ECO:0000269|PubMed:10330344,
FT                   ECO:0000269|PubMed:11159935"
FT                   /id="VAR_009634"
FT   VARIANT         717
FT                   /note="L -> R (in CIPA; found in a compound heterozygote
FT                   also carrying an premature stop codon at position 558)"
FT                   /evidence="ECO:0000269|PubMed:18077166"
FT                   /id="VAR_077477"
FT   VARIANT         752
FT                   /note="C -> S (in CIPA; unknown pathological significance;
FT                   following transfection in neuroblastoma cells and NGF
FT                   treatment, no effect on neurite outgrowth, nor neurite
FT                   length; no effect on N-glycosylation, subcellular location,
FT                   basal and NGF-induced autophosphorylation, nor on NGF-
FT                   stimulated calcium flux)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077478"
FT   VARIANT         763
FT                   /note="C -> S (in CIPA; following transfection in
FT                   neuroblastoma cells and NGF treatment, decreased percentage
FT                   of cells differentiated into neuronal phenotype and reduced
FT                   neurite length compared with wild-type; slightly decreased
FT                   N-glycosylation; reduced expression at the plasma membrane;
FT                   reduced basal and NGF-induced autophosphorylation; small
FT                   reduction in NGF-stimulated calcium flux)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077479"
FT   VARIANT         771
FT                   /note="R -> C (in CIPA; partially decreased N-
FT                   glycosylation; reduced expression at the plasma membrane;
FT                   reduced basal autophosphorylation and complete loss of NGF-
FT                   induced autophosphorylation; loss of NGF-stimulated calcium
FT                   flux; dbSNP:rs1324983370)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077480"
FT   VARIANT         780
FT                   /note="R -> P (in CIPA; loss of function;
FT                   dbSNP:rs35669708)"
FT                   /evidence="ECO:0000269|PubMed:10090906"
FT                   /id="VAR_009635"
FT   VARIANT         780
FT                   /note="R -> Q (in dbSNP:rs35669708)"
FT                   /evidence="ECO:0000269|PubMed:10443680,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_009636"
FT   VARIANT         790
FT                   /note="V -> I (in dbSNP:rs55948542)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041469"
FT   MUTAGEN         496
FT                   /note="Y->F: Loss of interaction with SHC1 and altered
FT                   phosphorylation of SHC1. Altered neurite outgrowth and
FT                   altered activation of the MAPK pathway; when associated
FT                   with F-791."
FT                   /evidence="ECO:0000269|PubMed:8155326"
FT   MUTAGEN         540..541
FT                   /note="LV->AA: Abolishes interaction with GGA3."
FT                   /evidence="ECO:0000269|PubMed:26446845"
FT   MUTAGEN         544
FT                   /note="K->A: No effect on interaction with GGA3."
FT                   /evidence="ECO:0000269|PubMed:26446845"
FT   MUTAGEN         544
FT                   /note="K->N: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:1281417,
FT                   ECO:0000269|PubMed:8155326"
FT   MUTAGEN         610..611
FT                   /note="LL->AA: No effect on interaction with GGA3."
FT                   /evidence="ECO:0000269|PubMed:26446845"
FT   MUTAGEN         791
FT                   /note="Y->F: Loss of interaction with PLCG1 and altered
FT                   phosphorylation of PLCG1. Altered neurite outgrowth and
FT                   altered activation of the MAPK pathway; when associated
FT                   with F-496."
FT                   /evidence="ECO:0000269|PubMed:7510697,
FT                   ECO:0000269|PubMed:8155326"
FT   CONFLICT        263
FT                   /note="V -> L (in Ref. 1; AAA36770)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        300
FT                   /note="C -> S (in Ref. 1; AAA36770)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        529
FT                   /note="C -> S (in Ref. 10; CAA59936)"
FT                   /evidence="ECO:0000305"
FT   STRAND          38..40
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          43..46
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   TURN            57..61
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          69..72
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   HELIX           84..86
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          94..97
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   HELIX           110..112
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          119..121
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   TURN            133..135
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          142..144
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   HELIX           154..156
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   HELIX           157..164
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   HELIX           171..173
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          178..181
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          195..199
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          211..218
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          227..230
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          234..238
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          244..253
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   TURN            257..260
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          263..265
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          276..278
FT                   /evidence="ECO:0000244|PDB:2IFG"
FT   STRAND          284..290
FT                   /evidence="ECO:0000244|PDB:1WWW"
FT   STRAND          298..305
FT                   /evidence="ECO:0000244|PDB:1HE7"
FT   STRAND          312..317
FT                   /evidence="ECO:0000244|PDB:1HE7"
FT   STRAND          326..333
FT                   /evidence="ECO:0000244|PDB:1HE7"
FT   STRAND          342..350
FT                   /evidence="ECO:0000244|PDB:1HE7"
FT   HELIX           353..355
FT                   /evidence="ECO:0000244|PDB:1HE7"
FT   STRAND          357..365
FT                   /evidence="ECO:0000244|PDB:1HE7"
FT   STRAND          368..376
FT                   /evidence="ECO:0000244|PDB:1HE7"
FT   HELIX           418..441
FT                   /evidence="ECO:0000244|PDB:2N90"
FT   STRAND          476..478
FT                   /evidence="ECO:0000244|PDB:5KML"
FT   HELIX           490..492
FT                   /evidence="ECO:0000244|PDB:5KMI"
FT   TURN            494..496
FT                   /evidence="ECO:0000244|PDB:1SHC"
FT   HELIX           507..509
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   STRAND          510..517
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   STRAND          520..522
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   STRAND          524..533
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   TURN            534..536
FT                   /evidence="ECO:0000244|PDB:5KMI"
FT   STRAND          537..545
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   HELIX           552..566
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   STRAND          575..579
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   STRAND          581..584
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   STRAND          586..590
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   HELIX           597..603
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   STRAND          605..607
FT                   /evidence="ECO:0000244|PDB:4F0I"
FT   HELIX           608..611
FT                   /evidence="ECO:0000244|PDB:4PMP"
FT   STRAND          615..617
FT                   /evidence="ECO:0000244|PDB:6NSS"
FT   STRAND          619..621
FT                   /evidence="ECO:0000244|PDB:5KMI"
FT   HELIX           624..643
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   STRAND          646..648
FT                   /evidence="ECO:0000244|PDB:5KML"
FT   HELIX           653..655
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   STRAND          656..659
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   HELIX           660..662
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   STRAND          663..666
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   HELIX           672..675
FT                   /evidence="ECO:0000244|PDB:5KMI"
FT   HELIX           677..679
FT                   /evidence="ECO:0000244|PDB:4PMP"
FT   STRAND          680..683
FT                   /evidence="ECO:0000244|PDB:5KMI"
FT   TURN            684..686
FT                   /evidence="ECO:0000244|PDB:5KMI"
FT   STRAND          687..689
FT                   /evidence="ECO:0000244|PDB:5KMI"
FT   HELIX           691..693
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   HELIX           696..701
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   HELIX           706..721
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   TURN            722..724
FT                   /evidence="ECO:0000244|PDB:5JFV"
FT   TURN            727..730
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   HELIX           733..742
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   HELIX           754..763
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   HELIX           768..770
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   HELIX           774..786
FT                   /evidence="ECO:0000244|PDB:5JFW"
FT   HELIX           789..793
FT                   /evidence="ECO:0000244|PDB:5KMI"
SQ   SEQUENCE   796 AA;  87497 MW;  6C15C721E336B601 CRC64;
     MLRGGRRGQL GWHSWAAGPG SLLAWLILAS AGAAPCPDAC CPHGSSGLRC TRDGALDSLH
     HLPGAENLTE LYIENQQHLQ HLELRDLRGL GELRNLTIVK SGLRFVAPDA FHFTPRLSRL
     NLSFNALESL SWKTVQGLSL QELVLSGNPL HCSCALRWLQ RWEEEGLGGV PEQKLQCHGQ
     GPLAHMPNAS CGVPTLKVQV PNASVDVGDD VLLRCQVEGR GLEQAGWILT ELEQSATVMK
     SGGLPSLGLT LANVTSDLNR KNVTCWAEND VGRAEVSVQV NVSFPASVQL HTAVEMHHWC
     IPFSVDGQPA PSLRWLFNGS VLNETSFIFT EFLEPAANET VRHGCLRLNQ PTHVNNGNYT
     LLAANPFGQA SASIMAAFMD NPFEFNPEDP IPVSFSPVDT NSTSGDPVEK KDETPFGVSV
     AVGLAVFACL FLSTLLLVLN KCGRRNKFGI NRPAVLAPED GLAMSLHFMT LGGSSLSPTE
     GKGSGLQGHI IENPQYFSDA CVHHIKRRDI VLKWELGEGA FGKVFLAECH NLLPEQDKML
     VAVKALKEAS ESARQDFQRE AELLTMLQHQ HIVRFFGVCT EGRPLLMVFE YMRHGDLNRF
     LRSHGPDAKL LAGGEDVAPG PLGLGQLLAV ASQVAAGMVY LAGLHFVHRD LATRNCLVGQ
     GLVVKIGDFG MSRDIYSTDY YRVGGRTMLP IRWMPPESIL YRKFTTESDV WSFGVVLWEI
     FTYGKQPWYQ LSNTEAIDCI TQGRELERPR ACPPEVYAIM RGCWQREPQQ RHSIKDVHAR
     LQALAQAPPV YLDVLG
//
ID   X5DR71_HUMAN            Unreviewed;       790 AA.
AC   X5DR71;
DT   11-JUN-2014, integrated into UniProtKB/TrEMBL.
DT   11-JUN-2014, sequence version 1.
DT   22-APR-2020, entry version 43.
DE   RecName: Full=Tyrosine-protein kinase receptor {ECO:0000256|RuleBase:RU000312};
DE            EC=2.7.10.1 {ECO:0000256|RuleBase:RU000312};
DE   Flags: Fragment;
GN   Name=NTRK1 {ECO:0000313|EMBL:AHW56542.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AHW56542.1};
RN   [1] {ECO:0000313|EMBL:AHW56542.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Adult whole brain {ECO:0000313|EMBL:AHW56542.1};
RX   PubMed=24722188;
RA   Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L., Broly M.,
RA   Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S., Tasan M., Lemmens I.,
RA   Kuang X., Zhao N., Malhotra D., Michaelson J.J., Vacic V., Calderwood M.A.,
RA   Roth F.P., Tavernier J., Horvath S., Salehi-Ashtiani K., Korkin D.,
RA   Sebat J., Hill D.E., Hao T., Vidal M., Iakoucheva L.M.;
RT   "Protein interaction network of alternatively spliced isoforms from brain
RT   links genetic risk factors for autism.";
RL   Nat. Commun. 5:3650-3650(2014).
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000256|RuleBase:RU000312,
CC         ECO:0000256|SAAS:SAAS01124082};
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily.
CC       {ECO:0000256|RuleBase:RU000312}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; KJ534902; AHW56542.1; -; mRNA.
DR   RefSeq; NP_001012331.1; NM_001012331.1.
DR   SMR; X5DR71; -.
DR   PRIDE; X5DR71; -.
DR   Antibodypedia; 3896; 1500 antibodies.
DR   GeneID; 4914; -.
DR   UCSC; uc001fqi.2; human.
DR   CTD; 4914; -.
DR   EuPathDB; HostDB:ENSG00000198400.11; -.
DR   eggNOG; ENOG410IMMI; Eukaryota.
DR   eggNOG; ENOG410XTGG; LUCA.
DR   HOGENOM; CLU_000288_74_1_1; -.
DR   ChiTaRS; NTRK1; human.
DR   GenomeRNAi; 4914; -.
DR   Bgee; ENSG00000198400; Expressed in adenohypophysis and 91 other tissues.
DR   ExpressionAtlas; X5DR71; baseline and differential.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:InterPro.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005030; F:neurotrophin receptor activity; IEA:InterPro.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IEA:InterPro.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR031635; NTRK_C2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR040665; TrkA_TMD.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR020461; Tyr_kinase_neurotrophic_rcpt_1.
DR   InterPro; IPR020777; Tyr_kinase_NGF_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF16920; TPKR_C2; 1.
DR   Pfam; PF18613; TrkA_TMD; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01940; NTKRECEPTOR1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding {ECO:0000256|PIRSR:PIRSR620777-51,
KW   ECO:0000256|SAAS:SAAS00600564};
KW   Disulfide bond {ECO:0000256|SAAS:SAAS01010727};
KW   Immunoglobulin domain {ECO:0000256|SAAS:SAAS00941986};
KW   Kinase {ECO:0000313|EMBL:AHW56542.1};
KW   Leucine-rich repeat {ECO:0000256|SAAS:SAAS00488662};
KW   Membrane {ECO:0000256|SAAS:SAAS00602683, ECO:0000256|SAM:Phobius};
KW   Nucleotide-binding {ECO:0000256|PIRSR:PIRSR620777-51,
KW   ECO:0000256|SAAS:SAAS00600564};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU000312};
KW   Receptor {ECO:0000256|RuleBase:RU000312, ECO:0000256|SAAS:SAAS00600436,
KW   ECO:0000313|EMBL:AHW56542.1}; Signal {ECO:0000256|SAM:SignalP};
KW   Transferase {ECO:0000313|EMBL:AHW56542.1};
KW   Transmembrane {ECO:0000256|SAAS:SAAS00602683, ECO:0000256|SAM:Phobius};
KW   Transmembrane helix {ECO:0000256|SAAS:SAAS00602683,
KW   ECO:0000256|SAM:Phobius}.
FT   SIGNAL          1..33
FT                   /evidence="ECO:0000256|SAM:SignalP"
FT   CHAIN           34..790
FT                   /note="Tyrosine-protein kinase receptor"
FT                   /evidence="ECO:0000256|SAM:SignalP"
FT                   /id="PRO_5004955970"
FT   TRANSMEM        410..433
FT                   /note="Helical"
FT                   /evidence="ECO:0000256|SAM:Phobius"
FT   DOMAIN          194..283
FT                   /note="Ig-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50835"
FT   DOMAIN          504..775
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000259|PROSITE:PS50011"
FT   NP_BIND         510..518
FT                   /note="ATP"
FT                   /evidence="ECO:0000256|PIRSR:PIRSR620777-51"
FT   ACT_SITE        644
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000256|PIRSR:PIRSR620777-50"
FT   BINDING         538
FT                   /note="ATP"
FT                   /evidence="ECO:0000256|PIRSR:PIRSR620777-51"
FT   SITE            490
FT                   /note="Interaction with SHC1"
FT                   /evidence="ECO:0000256|PIRSR:PIRSR620777-52"
FT   SITE            785
FT                   /note="Interaction with PLC-gamma-1"
FT                   /evidence="ECO:0000256|PIRSR:PIRSR620777-52"
FT   NON_TER         790
FT                   /evidence="ECO:0000313|EMBL:AHW56542.1"
SQ   SEQUENCE   790 AA;  86880 MW;  25F05BADA8A2A50C CRC64;
     MLRGGRRGQL GWHSWAAGPG SLLAWLILAS AGAAPCPDAC CPHGSSGLRC TRDGALDSLH
     HLPGAENLTE LYIENQQHLQ HLELRDLRGL GELRNLTIVK SGLRFVAPDA FHFTPRLSRL
     NLSFNALESL SWKTVQGLSL QELVLSGNPL HCSCALRWLQ RWEEEGLGGV PEQKLQCHGQ
     GPLAHMPNAS CGVPTLKVQV PNASVDVGDD VLLRCQVEGR GLEQAGWILT ELEQSATVMK
     SGGLPSLGLT LANVTSDLNR KNVTCWAEND VGRAEVSVQV NVSFPASVQL HTAVEMHHWC
     IPFSVDGQPA PSLRWLFNGS VLNETSFIFT EFLEPAANET VRHGCLRLNQ PTHVNNGNYT
     LLAANPFGQA SASIMAAFMD NPFEFNPEDP IPDTNSTSGD PVEKKDETPF GVSVAVGLAV
     FACLFLSTLL LVLNKCGRRN KFGINRPAVL APEDGLAMSL HFMTLGGSSL SPTEGKGSGL
     QGHIIENPQY FSDACVHHIK RRDIVLKWEL GEGAFGKVFL AECHNLLPEQ DKMLVAVKAL
     KEASESARQD FQREAELLTM LQHQHIVRFF GVCTEGRPLL MVFEYMRHGD LNRFLRSHGP
     DAKLLAGGED VAPGPLGLGQ LLAVASQVAA GMVYLAGLHF VHRDLATRNC LVGQGLVVKI
     GDFGMSRDIY STDYYRVGGR TMLPIRWMPP ESILYRKFTT ESDVWSFGVV LWEIFTYGKQ
     PWYQLSNTEA IDCITQGREL ERPRACPPEV YAIMRGCWQR EPQQRHSIKD VHARLQALAQ
     APPVYLDVLG
//
ID   C0KTE5_HUMAN            Unreviewed;       136 AA.
AC   C0KTE5;
DT   05-MAY-2009, integrated into UniProtKB/TrEMBL.
DT   05-MAY-2009, sequence version 1.
DT   22-APR-2020, entry version 52.
DE   SubName: Full=B cell specific activator protein variant delta 8/9 {ECO:0000313|EMBL:ACM91593.1};
DE   Flags: Fragment;
GN   Name=PAX5 {ECO:0000313|EMBL:ACM91593.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:ACM91593.1};
RN   [1] {ECO:0000313|EMBL:ACM91593.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=19725825; DOI=10.1111/j.1365-2141.2009.07859.x;
RA   Arseneau J.R., Laflamme M., Lewis S.M., Maicas E., Ouellette R.J.;
RT   "Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-
RT   cells.";
RL   Br. J. Haematol. 147:328-338(2009).
RN   [2] {ECO:0000313|EMBL:ACM91593.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Arseneau J.-R., Laflamme M., Lewis S.M., Maicas E., Ouellette R.J.;
RL   Submitted (JAN-2009) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; FJ626410; ACM91593.1; -; mRNA.
DR   RefSeq; NP_001267480.1; NM_001280551.1.
DR   PeptideAtlas; C0KTE5; -.
DR   PRIDE; C0KTE5; -.
DR   GeneID; 5079; -.
DR   CTD; 5079; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   eggNOG; ENOG410ZT0S; LUCA.
DR   ChiTaRS; PAX5; human.
DR   GenomeRNAi; 5079; -.
PE   2: Evidence at transcript level;
FT   REGION          1..26
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:ACM91593.1"
SQ   SEQUENCE   136 AA;  14857 MW;  1429D7ED040BFD00 CRC64;
     DTNKRKRDEG IQESPVPNGH SLPGRDFLRK QMRGDLFTQQ QLEVLDRVFE RQHYSDIFTT
     TEPIKPEQTT EYSAMASLAG GLDDMKANLA SPTPADIGSS VPGPQSYPIV TGSPYYYSAA
     ARGAAPPAAA TAYDRH
//
ID   C0KTF5_HUMAN            Unreviewed;        26 AA.
AC   C0KTF5;
DT   05-MAY-2009, integrated into UniProtKB/TrEMBL.
DT   05-MAY-2009, sequence version 1.
DT   22-APR-2020, entry version 23.
DE   SubName: Full=B cell specific activator protein variant A delta 2/8/9 {ECO:0000313|EMBL:ACM91603.1};
GN   Name=PAX5 {ECO:0000313|EMBL:ACM91603.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:ACM91603.1};
RN   [1] {ECO:0000313|EMBL:ACM91603.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=19725825; DOI=10.1111/j.1365-2141.2009.07859.x;
RA   Arseneau J.R., Laflamme M., Lewis S.M., Maicas E., Ouellette R.J.;
RT   "Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-
RT   cells.";
RL   Br. J. Haematol. 147:328-338(2009).
RN   [2] {ECO:0000313|EMBL:ACM91603.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Arseneau J.-R., Laflamme M., Lewis S.M., Maicas E., Ouellette R.J.;
RL   Submitted (JAN-2009) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; FJ626420; ACM91603.1; -; mRNA.
DR   RefSeq; NP_001267480.1; NM_001280551.1.
DR   GeneID; 5079; -.
DR   CTD; 5079; -.
DR   ChiTaRS; PAX5; human.
DR   GenomeRNAi; 5079; -.
PE   2: Evidence at transcript level;
FT   REGION          1..26
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        8..26
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   26 AA;  2939 MW;  2A72F22CE9512382 CRC64;
     MDLEKNYPTP RTSRTGIMRQ EASSLG
//
ID   E7EQT0_HUMAN            Unreviewed;       324 AA.
AC   E7EQT0;
DT   08-MAR-2011, integrated into UniProtKB/TrEMBL.
DT   08-MAR-2011, sequence version 1.
DT   22-APR-2020, entry version 74.
DE   SubName: Full=Paired box protein Pax-5 {ECO:0000313|Ensembl:ENSP00000429637};
GN   Name=PAX5 {ECO:0000313|Ensembl:ENSP00000429637};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000429637, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000429637, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [2] {ECO:0000313|Ensembl:ENSP00000429637}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|SAAS:SAAS00117811}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL161781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450267; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001267478.1; NM_001280549.1.
DR   SMR; E7EQT0; -.
DR   MaxQB; E7EQT0; -.
DR   PeptideAtlas; E7EQT0; -.
DR   PRIDE; E7EQT0; -.
DR   ProteomicsDB; 17640; -.
DR   Antibodypedia; 3668; 881 antibodies.
DR   Ensembl; ENST00000523241; ENSP00000429637; ENSG00000196092.
DR   GeneID; 5079; -.
DR   UCSC; uc010mlr.3; human.
DR   CTD; 5079; -.
DR   EuPathDB; HostDB:ENSG00000196092.12; -.
DR   HGNC; HGNC:8619; PAX5.
DR   OpenTargets; ENSG00000196092; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   eggNOG; ENOG410ZT0S; LUCA.
DR   GeneTree; ENSGT00940000159636; -.
DR   ChiTaRS; PAX5; human.
DR   GenomeRNAi; 5079; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000196092; Expressed in buccal mucosa cell and 111 other tissues.
DR   ExpressionAtlas; E7EQT0; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0007275; P:multicellular organism development; IEA:UniProtKB-KW.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:InterPro.
DR   CDD; cd00131; PAX; 1.
DR   Gene3D; 1.10.10.10; -; 2.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR001523; Paired_dom.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   Pfam; PF00292; PAX; 1.
DR   PRINTS; PR00027; PAIREDBOX.
DR   SMART; SM00351; PAX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00034; PAIRED_1; 1.
DR   PROSITE; PS51057; PAIRED_2; 1.
PE   1: Evidence at protein level;
KW   Developmental protein {ECO:0000256|SAAS:SAAS00476581};
KW   DNA-binding {ECO:0000256|SAAS:SAAS00476599};
KW   Nucleus {ECO:0000256|SAAS:SAAS00476573};
KW   Paired box {ECO:0000256|SAAS:SAAS00476583};
KW   Proteomics identification {ECO:0000213|MaxQB:E7EQT0,
KW   ECO:0000213|PeptideAtlas:E7EQT0, ECO:0000213|ProteomicsDB:E7EQT0};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|SAAS:SAAS00476577};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS00476577}.
FT   DOMAIN          16..142
FT                   /note="Paired"
FT                   /evidence="ECO:0000259|PROSITE:PS51057"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          169..218
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          298..324
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        169..192
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   324 AA;  35269 MW;  58AE4FF245B8B979 CRC64;
     MDLEKNYPTP RTSRTGHGGV NQLGGVFVNG RPLPDVVRQR IVELAHQGVR PCDISRQLRV
     SHGCVSKILG RYYETGSIKP GVIGGSKPKV ATPKVVEKIA EYKRQNPTMF AWEIRDRLLA
     ERVCDNDTVP SVSSINRIIR TKVQQPPNQP VPASSHSIVS TGSVTQVSSV STDSAGSSYS
     ISGILGITSP SADTNKRKRD EGIQESPVPN GHSLPGRDFL RKQMRGDLFT QQQLEVLDRV
     FERQHYSDIF TTTEPIKPEQ GVSFPGVPTA TLSIPRTTTP GGSPTRGCLA PPTIIALPPE
     EPPHLQPPLP MTVTDPWSQA GTKH
//
ID   E7ERK2_HUMAN            Unreviewed;       283 AA.
AC   E7ERK2;
DT   08-MAR-2011, integrated into UniProtKB/TrEMBL.
DT   08-MAR-2011, sequence version 1.
DT   22-APR-2020, entry version 72.
DE   SubName: Full=Paired box protein Pax-5 {ECO:0000313|Ensembl:ENSP00000429359};
GN   Name=PAX5 {ECO:0000313|Ensembl:ENSP00000429359};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000429359, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000429359, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [2] {ECO:0000313|Ensembl:ENSP00000429359}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
RN   [3] {ECO:0000313|Ensembl:ENSP00000498443}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (APR-2019) to UniProtKB.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL161781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450267; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001267485.1; NM_001280556.1.
DR   ProteomicsDB; 17800; -.
DR   Antibodypedia; 3668; 881 antibodies.
DR   Ensembl; ENST00000522003; ENSP00000429359; ENSG00000196092.
DR   Ensembl; ENST00000651550; ENSP00000498443; ENSG00000196092.
DR   GeneID; 5079; -.
DR   UCSC; uc011lqa.3; human.
DR   CTD; 5079; -.
DR   EuPathDB; HostDB:ENSG00000196092.12; -.
DR   HGNC; HGNC:8619; PAX5.
DR   OpenTargets; ENSG00000196092; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   eggNOG; ENOG410ZT0S; LUCA.
DR   GeneTree; ENSGT00940000159636; -.
DR   ChiTaRS; PAX5; human.
DR   GenomeRNAi; 5079; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000196092; Expressed in buccal mucosa cell and 111 other tissues.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003677; F:DNA binding; IEA:InterPro.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:InterPro.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR001523; Paired_dom.
DR   InterPro; IPR022130; Pax2_C.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   Pfam; PF00292; PAX; 1.
DR   Pfam; PF12403; Pax2_C; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS51057; PAIRED_2; 1.
PE   1: Evidence at protein level;
KW   Proteomics identification {ECO:0000213|MaxQB:E7ERK2,
KW   ECO:0000213|PeptideAtlas:E7ERK2, ECO:0000213|ProteomicsDB:E7ERK2};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   DOMAIN          1..34
FT                   /note="Paired"
FT                   /evidence="ECO:0000259|PROSITE:PS51057"
FT   REGION          78..110
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   283 AA;  30321 MW;  20828150572E66D5 CRC64;
     MFAWEIRDRL LAERVCDNDT VPSVSSINRI IRTKVQQPPN QPVPASSHSI VSTGSVTQVS
     SVSTDSAGSS YSISGILGIT SPSADTNKRK RDEGIQESPV PNGHSLPGRD FLRKQMRGDL
     FTQQQLEVLD RVFERQHYSD IFTTTEPIKP EQTTEYSAMA SLAGGLDDMK ANLASPTPAD
     IGSSVPGPQS YPIVTGRDLA STTLPGYPPH VPPAGQGSYS APTLTGMVPG SEFSGSPYSH
     PQYSSYNDSW RFPNPGLLGS PYYYSAAARG AAPPAAATAY DRH
//
ID   E7ERW5_HUMAN            Unreviewed;       295 AA.
AC   E7ERW5;
DT   08-MAR-2011, integrated into UniProtKB/TrEMBL.
DT   08-MAR-2011, sequence version 1.
DT   22-APR-2020, entry version 73.
DE   SubName: Full=Paired box protein Pax-5 {ECO:0000313|Ensembl:ENSP00000429291};
GN   Name=PAX5 {ECO:0000313|Ensembl:ENSP00000429291};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000429291, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000429291, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [2] {ECO:0000313|Ensembl:ENSP00000429291}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|SAAS:SAAS00117811}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL161781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450267; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001267479.1; NM_001280550.1.
DR   SMR; E7ERW5; -.
DR   MaxQB; E7ERW5; -.
DR   PeptideAtlas; E7ERW5; -.
DR   PRIDE; E7ERW5; -.
DR   ProteomicsDB; 17865; -.
DR   Antibodypedia; 3668; 881 antibodies.
DR   Ensembl; ENST00000520154; ENSP00000429291; ENSG00000196092.
DR   GeneID; 5079; -.
DR   UCSC; uc010mls.3; human.
DR   CTD; 5079; -.
DR   EuPathDB; HostDB:ENSG00000196092.12; -.
DR   HGNC; HGNC:8619; PAX5.
DR   OpenTargets; ENSG00000196092; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   eggNOG; ENOG410ZT0S; LUCA.
DR   GeneTree; ENSGT00940000159636; -.
DR   ChiTaRS; PAX5; human.
DR   GenomeRNAi; 5079; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000196092; Expressed in buccal mucosa cell and 111 other tissues.
DR   ExpressionAtlas; E7ERW5; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0007275; P:multicellular organism development; IEA:UniProtKB-KW.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:InterPro.
DR   CDD; cd00131; PAX; 1.
DR   Gene3D; 1.10.10.10; -; 2.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR001523; Paired_dom.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   Pfam; PF00292; PAX; 1.
DR   PRINTS; PR00027; PAIREDBOX.
DR   SMART; SM00351; PAX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00034; PAIRED_1; 1.
DR   PROSITE; PS51057; PAIRED_2; 1.
PE   1: Evidence at protein level;
KW   Developmental protein {ECO:0000256|SAAS:SAAS00476581};
KW   DNA-binding {ECO:0000256|SAAS:SAAS00476599};
KW   Nucleus {ECO:0000256|SAAS:SAAS00476573};
KW   Paired box {ECO:0000256|SAAS:SAAS00476583};
KW   Proteomics identification {ECO:0000213|MaxQB:E7ERW5,
KW   ECO:0000213|PeptideAtlas:E7ERW5, ECO:0000213|ProteomicsDB:E7ERW5};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|SAAS:SAAS00476577};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS00476577}.
FT   DOMAIN          16..142
FT                   /note="Paired"
FT                   /evidence="ECO:0000259|PROSITE:PS51057"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          169..218
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          254..295
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        169..192
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        262..281
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   295 AA;  32459 MW;  7BE055066EE14208 CRC64;
     MDLEKNYPTP RTSRTGHGGV NQLGGVFVNG RPLPDVVRQR IVELAHQGVR PCDISRQLRV
     SHGCVSKILG RYYETGSIKP GVIGGSKPKV ATPKVVEKIA EYKRQNPTMF AWEIRDRLLA
     ERVCDNDTVP SVSSINRIIR TKVQQPPNQP VPASSHSIVS TGSVTQVSSV STDSAGSSYS
     ISGILGITSP SADTNKRKRD EGIQESPVPN GHSLPGRDFL RKQMRGDLFT QQQLEVLDRV
     FERQHYSDIF TTTEPIKPEQ APPTIIALPP EEPPHLQPPL PMTVTDPWSQ AGTKH
//
ID   E7ES87_HUMAN            Unreviewed;       220 AA.
AC   E7ES87;
DT   08-MAR-2011, integrated into UniProtKB/TrEMBL.
DT   08-MAR-2011, sequence version 1.
DT   22-APR-2020, entry version 72.
DE   SubName: Full=Paired box protein Pax-5 {ECO:0000313|Ensembl:ENSP00000429197};
GN   Name=PAX5 {ECO:0000313|Ensembl:ENSP00000429197};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000429197, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000429197, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [2] {ECO:0000313|Ensembl:ENSP00000429197}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL161781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450267; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001267480.1; NM_001280551.1.
DR   SMR; E7ES87; -.
DR   MaxQB; E7ES87; -.
DR   PeptideAtlas; E7ES87; -.
DR   PRIDE; E7ES87; -.
DR   ProteomicsDB; 17934; -.
DR   Antibodypedia; 3668; 881 antibodies.
DR   Ensembl; ENST00000523145; ENSP00000429197; ENSG00000196092.
DR   GeneID; 5079; -.
DR   UCSC; uc011lpy.3; human.
DR   CTD; 5079; -.
DR   EuPathDB; HostDB:ENSG00000196092.12; -.
DR   HGNC; HGNC:8619; PAX5.
DR   OpenTargets; ENSG00000196092; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   eggNOG; ENOG410ZT0S; LUCA.
DR   GeneTree; ENSGT00940000159636; -.
DR   HOGENOM; CLU_019281_4_2_1; -.
DR   ChiTaRS; PAX5; human.
DR   GenomeRNAi; 5079; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000196092; Expressed in buccal mucosa cell and 111 other tissues.
DR   ExpressionAtlas; E7ES87; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003677; F:DNA binding; IEA:InterPro.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:InterPro.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR001523; Paired_dom.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   Pfam; PF00292; PAX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS51057; PAIRED_2; 1.
PE   1: Evidence at protein level;
KW   Proteomics identification {ECO:0000213|MaxQB:E7ES87,
KW   ECO:0000213|PeptideAtlas:E7ES87, ECO:0000213|ProteomicsDB:E7ES87};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   DOMAIN          1..34
FT                   /note="Paired"
FT                   /evidence="ECO:0000259|PROSITE:PS51057"
FT   REGION          78..110
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   220 AA;  23685 MW;  74A33883A0719337 CRC64;
     MFAWEIRDRL LAERVCDNDT VPSVSSINRI IRTKVQQPPN QPVPASSHSI VSTGSVTQVS
     SVSTDSAGSS YSISGILGIT SPSADTNKRK RDEGIQESPV PNGHSLPGRD FLRKQMRGDL
     FTQQQLEVLD RVFERQHYSD IFTTTEPIKP EQTTEYSAMA SLAGGLDDMK ANLASPTPAD
     IGSSVPGPQS YPIVTGSPYY YSAAARGAAP PAAATAYDRH
//
ID   PAX5_HUMAN              Reviewed;         391 AA.
AC   Q02548; A3QVP6; A3QVP7; A3QVP8; C0KTF6; C0KTF7; C0KTF8; C0KTF9; C0KTG0;
AC   O75933; Q5SFM2; Q6S728; Q6S729; Q6S730; Q6S731; Q6S732;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   22-APR-2020, entry version 188.
DE   RecName: Full=Paired box protein Pax-5;
DE   AltName: Full=B-cell-specific transcription factor;
DE            Short=BSAP;
GN   Name=PAX5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1516825; DOI=10.1101/gad.6.9.1589;
RA   Adams B., Doerfler P., Aguzzi A., Kozmik Z., Urbanek P., Maurer-Fogy I.,
RA   Busslinger M.;
RT   "Pax-5 encodes the transcription factor BSAP and is expressed in B
RT   lymphocytes, the developing CNS, and adult testis.";
RL   Genes Dev. 6:1589-1607(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5 AND 6), AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=15385562; DOI=10.1074/jbc.m407171200;
RA   Robichaud G.A., Nardini M., Laflamme M., Cuperlovic-Culf M.,
RA   Ouellette R.J.;
RT   "Human Pax-5 C-terminal isoforms possess distinct transactivation
RT   properties and are differentially modulated in normal and malignant B
RT   cells.";
RL   J. Biol. Chem. 279:49956-49963(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 7; 8; 9; 10 AND 11).
RX   PubMed=19725825; DOI=10.1111/j.1365-2141.2009.07859.x;
RA   Arseneau J.R., Laflamme M., Lewis S.M., Maicas E., Ouellette R.J.;
RT   "Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-
RT   cells.";
RL   Br. J. Haematol. 147:328-338(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Livingston R.J., Shaffer T., McFarland I., Nguyen C.P., Stanaway I.B.,
RA   Rajkumar N., Johnson E.J., da Ponte S.H., Willa H., Ahearn M.O.,
RA   Bertucci C., Acklestad J., Carroll A., Swanson J., Gildersleeve H.I.,
RA   Nickerson D.A.;
RL   Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-333 (ISOFORM 1), CHROMOSOMAL TRANSLOCATION
RP   WITH ZNF521, CHROMOSOMAL TRANSLOCATION WITH FOXP1, AND CHROMOSOMAL
RP   TRANSLOCATION WITH ETV6.
RX   PubMed=17344859; DOI=10.1038/nature05690;
RA   Mullighan C.G., Goorha S., Radtke I., Miller C.B., Coustan-Smith E.,
RA   Dalton J.D., Girtman K., Mathew S., Ma J., Pounds S.B., Su X., Pui C.-H.,
RA   Relling M.V., Evans W.E., Shurtleff S.A., Downing J.R.;
RT   "Genome-wide analysis of genetic alterations in acute lymphoblastic
RT   leukaemia.";
RL   Nature 446:758-764(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 62-197.
RX   PubMed=9742255; DOI=10.1093/nar/26.19.4497;
RA   Verkoczy L.K., Berinstein N.L.;
RT   "Isolation of genes negatively or positively co-expressed with human
RT   recombination activating gene 1 (RAG1) by differential display PCR (DD RT-
RT   PCR).";
RL   Nucleic Acids Res. 26:4497-4507(1998).
RN   [9]
RP   INTERACTION WITH TLE4.
RX   PubMed=10811620; DOI=10.1093/emboj/19.10.2292;
RA   Eberhard D., Jimenez G., Heavey B., Busslinger M.;
RT   "Transcriptional repression by Pax5 (BSAP) through interaction with
RT   corepressors of the Groucho family.";
RL   EMBO J. 19:2292-2303(2000).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 1-149 IN COMPLEX WITH MOUSE ETS1
RP   AND DNA.
RX   PubMed=11779502; DOI=10.1016/s1097-2765(01)00410-5;
RA   Garvie C.W., Hagman J., Wolberger C.;
RT   "Structural studies of Ets-1/Pax5 complex formation on DNA.";
RL   Mol. Cell 8:1267-1276(2001).
RN   [11]
RP   VARIANT ALL3 SER-183, VARIANTS ARG-24; GLY-26; GLN-34; VAL-53; GLY-59;
RP   ASN-66; ARG-75; ARG-80; THR-139; ILE-151; VAL-183; LEU-213; THR-301 AND
RP   VAL-338, AND CHARACTERIZATION OF VARIANT ALL3 SER-183.
RX   PubMed=24013638; DOI=10.1038/ng.2754;
RA   Shah S., Schrader K.A., Waanders E., Timms A.E., Vijai J., Miething C.,
RA   Wechsler J., Yang J., Hayes J., Klein R.J., Zhang J., Wei L., Wu G.,
RA   Rusch M., Nagahawatte P., Ma J., Chen S.C., Song G., Cheng J., Meyers P.,
RA   Bhojwani D., Jhanwar S., Maslak P., Fleisher M., Littman J., Offit L.,
RA   Rau-Murthy R., Fleischut M.H., Corines M., Murali R., Gao X.,
RA   Manschreck C., Kitzing T., Murty V.V., Raimondi S.C., Kuiper R.P.,
RA   Simons A., Schiffman J.D., Onel K., Plon S.E., Wheeler D.A., Ritter D.,
RA   Ziegler D.S., Tucker K., Sutton R., Chenevix-Trench G., Li J.,
RA   Huntsman D.G., Hansford S., Senz J., Walsh T., Lee M., Hahn C.N.,
RA   Roberts K.G., King M.C., Lo S.M., Levine R.L., Viale A., Socci N.D.,
RA   Nathanson K.L., Scott H.S., Daly M., Lipkin S.M., Lowe S.W., Downing J.R.,
RA   Altshuler D., Sandlund J.T., Horwitz M.S., Mullighan C.G., Offit K.;
RT   "A recurrent germline PAX5 mutation confers susceptibility to pre-B cell
RT   acute lymphoblastic leukemia.";
RL   Nat. Genet. 45:1226-1231(2013).
CC   -!- FUNCTION: May play an important role in B-cell differentiation as well
CC       as neural development and spermatogenesis. Involved in the regulation
CC       of the CD19 gene, a B-lymphoid-specific target gene.
CC   -!- SUBUNIT: Interacts with DAXX (By similarity). Binds DNA as a monomer.
CC       Binds TLE4. Interacts with ETS1, altering its DNA-binding properties.
CC       {ECO:0000250, ECO:0000269|PubMed:10811620,
CC       ECO:0000269|PubMed:11779502}.
CC   -!- INTERACTION:
CC       Q02548; Q8WYK0: ACOT12; NbExp=3; IntAct=EBI-296331, EBI-11954993;
CC       Q02548; O75934: BCAS2; NbExp=3; IntAct=EBI-296331, EBI-1050106;
CC       Q02548; Q9NX04: C1orf109; NbExp=3; IntAct=EBI-296331, EBI-8643161;
CC       Q02548; P24863: CCNC; NbExp=3; IntAct=EBI-296331, EBI-395261;
CC       Q02548; Q00526: CDK3; NbExp=3; IntAct=EBI-296331, EBI-1245761;
CC       Q02548; Q96Q77: CIB3; NbExp=3; IntAct=EBI-296331, EBI-10292696;
CC       Q02548; P61024: CKS1B; NbExp=3; IntAct=EBI-296331, EBI-456371;
CC       Q02548; P68400: CSNK2A1; NbExp=3; IntAct=EBI-296331, EBI-347804;
CC       Q02548; Q8TB03: CXorf38; NbExp=3; IntAct=EBI-296331, EBI-12024320;
CC       Q02548; Q86UW9: DTX2; NbExp=3; IntAct=EBI-296331, EBI-740376;
CC       Q02548; P23142-4: FBLN1; NbExp=3; IntAct=EBI-296331, EBI-11956479;
CC       Q02548; Q9P2W3: GNG13; NbExp=3; IntAct=EBI-296331, EBI-11427343;
CC       Q02548; Q6ISB3: GRHL2; NbExp=3; IntAct=EBI-296331, EBI-10219092;
CC       Q02548; O14964: HGS; NbExp=3; IntAct=EBI-296331, EBI-740220;
CC       Q02548; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-296331, EBI-2549423;
CC       Q02548; O15347: HMGB3; NbExp=3; IntAct=EBI-296331, EBI-2214136;
CC       Q02548; P31273: HOXC8; NbExp=3; IntAct=EBI-296331, EBI-1752118;
CC       Q02548; Q2WGJ6: KLHL38; NbExp=3; IntAct=EBI-296331, EBI-6426443;
CC       Q02548; PRO_0000390949 [Q03164]: KMT2A; NbExp=2; IntAct=EBI-296331, EBI-2610266;
CC       Q02548; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-296331, EBI-10171774;
CC       Q02548; Q9BYQ3: KRTAP9-3; NbExp=3; IntAct=EBI-296331, EBI-1043191;
CC       Q02548; Q6P4E2: LARP4; NbExp=3; IntAct=EBI-296331, EBI-12079790;
CC       Q02548; Q5SW96: LDLRAP1; NbExp=3; IntAct=EBI-296331, EBI-747813;
CC       Q02548; Q17RB8: LONRF1; NbExp=3; IntAct=EBI-296331, EBI-2341787;
CC       Q02548; P45984: MAPK9; NbExp=3; IntAct=EBI-296331, EBI-713568;
CC       Q02548; Q969S2: NEIL2; NbExp=3; IntAct=EBI-296331, EBI-10281234;
CC       Q02548; Q13952-2: NFYC; NbExp=3; IntAct=EBI-296331, EBI-11956831;
CC       Q02548; Q96IV0: NGLY1; NbExp=3; IntAct=EBI-296331, EBI-6165879;
CC       Q02548; Q9UJX0: OSGIN1; NbExp=3; IntAct=EBI-296331, EBI-9057006;
CC       Q02548; Q96PV4: PNMA5; NbExp=3; IntAct=EBI-296331, EBI-10171633;
CC       Q02548; P43351: RAD52; NbExp=3; IntAct=EBI-296331, EBI-706448;
CC       Q02548; Q9UBE0: SAE1; NbExp=3; IntAct=EBI-296331, EBI-743154;
CC       Q02548; Q9UDX3: SEC14L4; NbExp=3; IntAct=EBI-296331, EBI-10320311;
CC       Q02548; Q99469: STAC; NbExp=3; IntAct=EBI-296331, EBI-2652799;
CC       Q02548; Q86UE8: TLK2; NbExp=3; IntAct=EBI-296331, EBI-1047967;
CC       Q02548; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-296331, EBI-10180829;
CC       Q02548; Q14CS0: UBXN2B; NbExp=3; IntAct=EBI-296331, EBI-1993619;
CC       Q02548; O94888: UBXN7; NbExp=3; IntAct=EBI-296331, EBI-1993627;
CC       Q02548; Q9UJ78-2: ZMYM5; NbExp=3; IntAct=EBI-296331, EBI-17634549;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC       Name=1;
CC         IsoId=Q02548-1; Sequence=Displayed;
CC       Name=2; Synonyms=delta9;
CC         IsoId=Q02548-2; Sequence=VSP_044121;
CC       Name=3; Synonyms=delta78;
CC         IsoId=Q02548-3; Sequence=VSP_044117, VSP_044118, VSP_044120;
CC       Name=4; Synonyms=delta789;
CC         IsoId=Q02548-4; Sequence=VSP_044116, VSP_044120;
CC       Name=5; Synonyms=delta8;
CC         IsoId=Q02548-5; Sequence=VSP_044115;
CC       Name=6; Synonyms=delta7;
CC         IsoId=Q02548-6; Sequence=VSP_044119;
CC       Name=7;
CC         IsoId=Q02548-7; Sequence=VSP_047830;
CC       Name=8;
CC         IsoId=Q02548-8; Sequence=VSP_047828;
CC       Name=9;
CC         IsoId=Q02548-9; Sequence=VSP_047828, VSP_044121;
CC       Name=10;
CC         IsoId=Q02548-10; Sequence=VSP_047827, VSP_047831;
CC       Name=11;
CC         IsoId=Q02548-11; Sequence=VSP_047829, VSP_047832;
CC   -!- DEVELOPMENTAL STAGE: Expressed at early B-cell differentiation, in the
CC       developing CNS and in adult testis.
CC   -!- PTM: O-glycosylated. {ECO:0000305}.
CC   -!- DISEASE: Note=A chromosomal aberration involving PAX5 is a cause of
CC       acute lymphoblastic leukemia. Translocation t(9;18)(p13;q11.2) with
CC       ZNF521. Translocation t(9;3)(p13;p14.1) with FOXP1. Translocation
CC       t(9;12)(p13;p13) with ETV6. {ECO:0000269|PubMed:17344859}.
CC   -!- DISEASE: Leukemia, acute lymphoblastic, 3 (ALL3) [MIM:613065]: A
CC       subtype of acute leukemia, a cancer of the white blood cells. Acute
CC       lymphoblastic anemia is a malignant disease of bone marrow and the most
CC       common malignancy diagnosed in children. The malignant cells are
CC       lymphoid precursor cells (lymphoblasts) that are arrested in an early
CC       stage of development. The lymphoblasts replace the normal marrow
CC       elements, resulting in a marked decrease in the production of normal
CC       blood cells. Consequently, anemia, thrombocytopenia, and neutropenia
CC       occur to varying degrees. The lymphoblasts also proliferate in organs
CC       other than the marrow, particularly the liver, spleen, and lymphnodes.
CC       {ECO:0000269|PubMed:24013638}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PAX5ID62.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M96944; AAA58397.1; -; mRNA.
DR   EMBL; AY463952; AAR27590.1; -; mRNA.
DR   EMBL; AY463953; AAR27591.1; -; mRNA.
DR   EMBL; AY463954; AAR27592.1; -; mRNA.
DR   EMBL; AY463955; AAR27593.1; -; mRNA.
DR   EMBL; AY463956; AAR27594.1; -; mRNA.
DR   EMBL; AY463957; AAR27595.1; -; mRNA.
DR   EMBL; FJ626421; ACM91604.1; -; mRNA.
DR   EMBL; FJ626422; ACM91605.1; -; mRNA.
DR   EMBL; FJ626423; ACM91606.1; -; mRNA.
DR   EMBL; FJ626424; ACM91607.1; -; mRNA.
DR   EMBL; FJ626425; ACM91608.1; -; mRNA.
DR   EMBL; EF064717; ABK41900.1; -; Genomic_DNA.
DR   EMBL; AL161781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450267; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471071; EAW58294.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58295.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58296.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58297.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58298.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58299.1; -; Genomic_DNA.
DR   EMBL; DQ841178; ABI30005.1; ALT_TERM; mRNA.
DR   EMBL; DQ845345; ABI33104.1; ALT_TERM; mRNA.
DR   EMBL; DQ845346; ABI33105.1; ALT_TERM; mRNA.
DR   EMBL; AF080573; AAC35286.1; -; mRNA.
DR   CCDS; CCDS65041.1; -. [Q02548-10]
DR   CCDS; CCDS65042.1; -. [Q02548-9]
DR   CCDS; CCDS65043.1; -. [Q02548-8]
DR   CCDS; CCDS65044.1; -. [Q02548-4]
DR   CCDS; CCDS65045.1; -. [Q02548-3]
DR   CCDS; CCDS65046.1; -. [Q02548-7]
DR   CCDS; CCDS65047.1; -. [Q02548-6]
DR   CCDS; CCDS65048.1; -. [Q02548-2]
DR   CCDS; CCDS6607.1; -. [Q02548-1]
DR   PIR; A44063; A44063.
DR   RefSeq; NP_001267476.1; NM_001280547.1. [Q02548-6]
DR   RefSeq; NP_001267477.1; NM_001280548.1. [Q02548-2]
DR   RefSeq; NP_001267478.1; NM_001280549.1.
DR   RefSeq; NP_001267479.1; NM_001280550.1.
DR   RefSeq; NP_001267481.1; NM_001280552.1. [Q02548-7]
DR   RefSeq; NP_001267482.1; NM_001280553.1. [Q02548-9]
DR   RefSeq; NP_001267483.1; NM_001280554.1. [Q02548-8]
DR   RefSeq; NP_001267484.1; NM_001280555.1. [Q02548-10]
DR   RefSeq; NP_001267485.1; NM_001280556.1.
DR   RefSeq; NP_057953.1; NM_016734.2. [Q02548-1]
DR   PDB; 1K78; X-ray; 2.25 A; A/E/I=1-149.
DR   PDB; 1MDM; X-ray; 2.80 A; A=1-149.
DR   PDBsum; 1K78; -.
DR   PDBsum; 1MDM; -.
DR   SMR; Q02548; -.
DR   BioGrid; 111113; 12.
DR   ELM; Q02548; -.
DR   IntAct; Q02548; 43.
DR   STRING; 9606.ENSP00000350844; -.
DR   iPTMnet; Q02548; -.
DR   PhosphoSitePlus; Q02548; -.
DR   BioMuta; PAX5; -.
DR   DMDM; 417449; -.
DR   MassIVE; Q02548; -.
DR   PaxDb; Q02548; -.
DR   PeptideAtlas; Q02548; -.
DR   PRIDE; Q02548; -.
DR   ProteomicsDB; 58109; -. [Q02548-1]
DR   ProteomicsDB; 67344; -.
DR   ProteomicsDB; 67345; -.
DR   ProteomicsDB; 67346; -.
DR   ProteomicsDB; 7578; -.
DR   ProteomicsDB; 7579; -.
DR   ProteomicsDB; 7580; -.
DR   ProteomicsDB; 7581; -.
DR   ProteomicsDB; 7582; -.
DR   Antibodypedia; 3668; 881 antibodies.
DR   DNASU; 5079; -.
DR   Ensembl; ENST00000358127; ENSP00000350844; ENSG00000196092. [Q02548-1]
DR   Ensembl; ENST00000377840; ENSP00000367071; ENSG00000196092. [Q02548-5]
DR   Ensembl; ENST00000377847; ENSP00000367078; ENSG00000196092. [Q02548-7]
DR   Ensembl; ENST00000377852; ENSP00000367083; ENSG00000196092. [Q02548-6]
DR   Ensembl; ENST00000377853; ENSP00000367084; ENSG00000196092. [Q02548-2]
DR   Ensembl; ENST00000414447; ENSP00000412188; ENSG00000196092. [Q02548-8]
DR   Ensembl; ENST00000446742; ENSP00000404687; ENSG00000196092. [Q02548-10]
DR   Ensembl; ENST00000520281; ENSP00000430773; ENSG00000196092. [Q02548-9]
DR   Ensembl; ENST00000523493; ENSP00000431038; ENSG00000196092. [Q02548-11]
DR   GeneID; 5079; -.
DR   KEGG; hsa:5079; -.
DR   UCSC; uc003zzo.3; human. [Q02548-1]
DR   CTD; 5079; -.
DR   DisGeNET; 5079; -.
DR   GeneCards; PAX5; -.
DR   HGNC; HGNC:8619; PAX5.
DR   HPA; ENSG00000196092; Tissue enhanced (blood, lymphoid tissue).
DR   MalaCards; PAX5; -.
DR   MIM; 167414; gene.
DR   MIM; 613065; phenotype.
DR   neXtProt; NX_Q02548; -.
DR   OpenTargets; ENSG00000196092; -.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA32959; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   eggNOG; ENOG410ZT0S; LUCA.
DR   GeneTree; ENSGT00940000159636; -.
DR   HOGENOM; CLU_019281_1_3_1; -.
DR   InParanoid; Q02548; -.
DR   KO; K09383; -.
DR   OMA; QPSCPIQ; -.
DR   OrthoDB; 592933at2759; -.
DR   PhylomeDB; Q02548; -.
DR   TreeFam; TF315397; -.
DR   Reactome; R-HSA-8939245; RUNX1 regulates transcription of genes involved in BCR signaling.
DR   SignaLink; Q02548; -.
DR   SIGNOR; Q02548; -.
DR   ChiTaRS; PAX5; human.
DR   EvolutionaryTrace; Q02548; -.
DR   GeneWiki; PAX5; -.
DR   GenomeRNAi; 5079; -.
DR   Pharos; Q02548; Tbio.
DR   PRO; PR:Q02548; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q02548; protein.
DR   Bgee; ENSG00000196092; Expressed in buccal mucosa cell and 111 other tissues.
DR   ExpressionAtlas; Q02548; baseline and differential.
DR   Genevisible; Q02548; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0030534; P:adult behavior; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IEA:Ensembl.
DR   GO; GO:0006959; P:humoral immune response; TAS:ProtInc.
DR   GO; GO:0021670; P:lateral ventricle development; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0051573; P:negative regulation of histone H3-K9 methylation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0050855; P:regulation of B cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:ProtInc.
DR   CDD; cd00131; PAX; 1.
DR   DisProt; DP00969; -.
DR   Gene3D; 1.10.10.10; -; 2.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR001523; Paired_dom.
DR   InterPro; IPR022130; Pax2_C.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   Pfam; PF00292; PAX; 1.
DR   Pfam; PF12403; Pax2_C; 1.
DR   PRINTS; PR00027; PAIREDBOX.
DR   SMART; SM00351; PAX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00034; PAIRED_1; 1.
DR   PROSITE; PS51057; PAIRED_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosomal rearrangement;
KW   Developmental protein; Differentiation; Disease mutation; DNA-binding;
KW   Glycoprotein; Neurogenesis; Nucleus; Paired box; Polymorphism;
KW   Proto-oncogene; Reference proteome; Spermatogenesis; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..391
FT                   /note="Paired box protein Pax-5"
FT                   /id="PRO_0000050183"
FT   DNA_BIND        16..142
FT                   /note="Paired"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00381"
FT   REGION          19..75
FT                   /note="PAI subdomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00381"
FT   REGION          94..142
FT                   /note="RED subdomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00381"
FT   SITE            158..159
FT                   /note="Breakpoint for translocation to form PAX5-ETV6"
FT   SITE            260..261
FT                   /note="Breakpoint for translocation to form PAX5-FOXP1"
FT   SITE            303..304
FT                   /note="Breakpoint for translocation to form PAX5-ZNF521"
FT   VAR_SEQ         71..136
FT                   /note="Missing (in isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:19725825"
FT                   /id="VSP_047827"
FT   VAR_SEQ         159..201
FT                   /note="Missing (in isoform 8 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:19725825"
FT                   /id="VSP_047828"
FT   VAR_SEQ         261..391
FT                   /note="TTEYSAMASLAGGLDDMKANLASPTPADIGSSVPGPQSYPIVTGRDLASTTL
FT                   PGYPPHVPPAGQGSYSAPTLTGMVPGSEFSGSPYSHPQYSSYNDSWRFPNPGLLGSPYY
FT                   YSAAARGAAPPAAATAYDRH -> AVTWRARPSPGTLHTSPPLDRAATQHRR (in
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15385562"
FT                   /id="VSP_044115"
FT   VAR_SEQ         261..315
FT                   /note="TTEYSAMASLAGGLDDMKANLASPTPADIGSSVPGPQSYPIVTGRDLASTTL
FT                   PGY -> APPIIIALPPEE (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15385562"
FT                   /id="VSP_044116"
FT   VAR_SEQ         261..307
FT                   /note="TTEYSAMASLAGGLDDMKANLASPTPADIGSSVPGPQSYPIVTGRDL -> W
FT                   CPVLMRQYLVQPQAVLFQAVTWRARPSPGTLHTSPPLDRAATQHRR (in isoform
FT                   11)"
FT                   /evidence="ECO:0000303|PubMed:19725825"
FT                   /id="VSP_047829"
FT   VAR_SEQ         261..282
FT                   /note="TTEYSAMASLAGGLDDMKANLA -> GVSFPGVPTATLSIPRTTTPGG (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15385562"
FT                   /id="VSP_044117"
FT   VAR_SEQ         286..315
FT                   /note="PADIGSSVPGPQSYPIVTGRDLASTTLPGY -> RGCLAPPIIIALPPEE
FT                   (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15385562"
FT                   /id="VSP_044118"
FT   VAR_SEQ         304..366
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:19725825"
FT                   /id="VSP_047830"
FT   VAR_SEQ         304..337
FT                   /note="Missing (in isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:19725825"
FT                   /id="VSP_047831"
FT   VAR_SEQ         305..349
FT                   /note="RDLASTTLPGYPPHVPPAGQGSYSAPTLTGMVPGSEFSGSPYSHP -> SEF
FT                   SGSPYSHP (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15385562"
FT                   /id="VSP_044119"
FT   VAR_SEQ         308..391
FT                   /note="Missing (in isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:19725825"
FT                   /id="VSP_047832"
FT   VAR_SEQ         319..391
FT                   /note="VPPAGQGSYSAPTLTGMVPGSEFSGSPYSHPQYSSYNDSWRFPNPGLLGSPY
FT                   YYSAAARGAAPPAAATAYDRH -> LQPPLPMTVTDPWSQAGTKH (in isoform 3
FT                   and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15385562"
FT                   /id="VSP_044120"
FT   VAR_SEQ         338..366
FT                   /note="Missing (in isoform 2 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:15385562,
FT                   ECO:0000303|PubMed:19725825"
FT                   /id="VSP_044121"
FT   VARIANT         24
FT                   /note="G -> R (in dbSNP:rs868494257)"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070672"
FT   VARIANT         26
FT                   /note="V -> G (in dbSNP:rs926053251)"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070673"
FT   VARIANT         34
FT                   /note="P -> Q"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070674"
FT   VARIANT         53
FT                   /note="D -> V"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070675"
FT   VARIANT         59
FT                   /note="R -> G"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070676"
FT   VARIANT         66
FT                   /note="S -> N"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070677"
FT   VARIANT         75
FT                   /note="T -> R"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070678"
FT   VARIANT         80
FT                   /note="P -> R"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070679"
FT   VARIANT         139
FT                   /note="I -> T"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070680"
FT   VARIANT         151
FT                   /note="V -> I (in dbSNP:rs115889954)"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070681"
FT   VARIANT         183
FT                   /note="G -> S (in ALL3; confers susceptibility to ALL3;
FT                   reduced transcription factor activity; dbSNP:rs398123063)"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070682"
FT   VARIANT         183
FT                   /note="G -> V"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070683"
FT   VARIANT         213
FT                   /note="S -> L (in dbSNP:rs137870876)"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070684"
FT   VARIANT         301
FT                   /note="I -> T (in dbSNP:rs372989600)"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070685"
FT   VARIANT         322
FT                   /note="A -> T (in dbSNP:rs34810717)"
FT                   /id="VAR_034370"
FT   VARIANT         338
FT                   /note="G -> V"
FT                   /evidence="ECO:0000269|PubMed:24013638"
FT                   /id="VAR_070686"
FT   CONFLICT        99
FT                   /note="I -> F (in Ref. 8; AAC35286)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        141..143
FT                   /note="TKV -> PKL (in Ref. 8; AAC35286)"
FT                   /evidence="ECO:0000305"
FT   HELIX           35..46
FT                   /evidence="ECO:0000244|PDB:1K78"
FT   HELIX           51..58
FT                   /evidence="ECO:0000244|PDB:1K78"
FT   HELIX           62..75
FT                   /evidence="ECO:0000244|PDB:1K78"
FT   STRAND          89..91
FT                   /evidence="ECO:0000244|PDB:1K78"
FT   HELIX           93..105
FT                   /evidence="ECO:0000244|PDB:1K78"
FT   HELIX           111..120
FT                   /evidence="ECO:0000244|PDB:1K78"
FT   TURN            126..128
FT                   /evidence="ECO:0000244|PDB:1K78"
FT   HELIX           132..140
FT                   /evidence="ECO:0000244|PDB:1K78"
SQ   SEQUENCE   391 AA;  42149 MW;  DB37E6EACD9F993A CRC64;
     MDLEKNYPTP RTSRTGHGGV NQLGGVFVNG RPLPDVVRQR IVELAHQGVR PCDISRQLRV
     SHGCVSKILG RYYETGSIKP GVIGGSKPKV ATPKVVEKIA EYKRQNPTMF AWEIRDRLLA
     ERVCDNDTVP SVSSINRIIR TKVQQPPNQP VPASSHSIVS TGSVTQVSSV STDSAGSSYS
     ISGILGITSP SADTNKRKRD EGIQESPVPN GHSLPGRDFL RKQMRGDLFT QQQLEVLDRV
     FERQHYSDIF TTTEPIKPEQ TTEYSAMASL AGGLDDMKAN LASPTPADIG SSVPGPQSYP
     IVTGRDLAST TLPGYPPHVP PAGQGSYSAP TLTGMVPGSE FSGSPYSHPQ YSSYNDSWRF
     PNPGLLGSPY YYSAAARGAA PPAAATAYDR H
//
ID   B2R5T5_HUMAN            Unreviewed;       381 AA.
AC   B2R5T5;
DT   01-JUL-2008, integrated into UniProtKB/TrEMBL.
DT   01-JUL-2008, sequence version 1.
DT   22-APR-2020, entry version 108.
DE   SubName: Full=Epididymis secretory sperm binding protein {ECO:0000313|EMBL:ADO22565.1};
DE   SubName: Full=Protein kinase, cAMP-dependent, regulatory, type I, alpha (Tissue specific extinguisher 1), isoform CRA_a {ECO:0000313|EMBL:EAW89060.1};
DE   SubName: Full=cDNA FLJ40261 fis, clone TESTI2025609, highly similar to cAMP-dependent protein kinase type I-alpha regulatory subunit {ECO:0000313|EMBL:BAG53489.1};
DE   SubName: Full=cDNA, FLJ92612, Homo sapiens protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) (PRKAR1A), mRNA {ECO:0000313|EMBL:BAG35232.1};
GN   Name=PRKAR1A {ECO:0000313|EMBL:EAW89060.1};
GN   ORFNames=hCG_28462 {ECO:0000313|EMBL:EAW89060.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG35232.1};
RN   [1] {ECO:0000313|EMBL:EAW89060.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:BAG53489.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Testis {ECO:0000313|EMBL:BAG53489.1};
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M.,
RA   Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S.,
RA   Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S.,
RA   Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H.,
RA   Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M.,
RA   Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M.,
RA   Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y.,
RA   Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N.,
RA   Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S.,
RA   Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T.,
RA   Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M.,
RA   Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y.,
RA   Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y.,
RA   Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T.,
RA   Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3] {ECO:0000313|EMBL:EAW89060.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4] {ECO:0000313|EMBL:BAG35232.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Cerebellum {ECO:0000313|EMBL:BAG35232.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Kaida T., Tsuchiya K., Iida Y.,
RA   Takayama Y., Murakawa K., Kanehori K., Andoh T., Kagawa N., Sato R.,
RA   Kawamura Y., Tanaka S., Kisu Y., Sugano S., Goshima N., Nomura N.,
RA   Isogai T.;
RT   "NEDO functional analysis of protein and research application project.";
RL   Submitted (JAN-2008) to the EMBL/GenBank/DDBJ databases.
RN   [5] {ECO:0000313|EMBL:ADO22565.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Hoernsten L., Su C., Osbourn A.E., Hellman U., Wernstedt C., Oliw E.H.;
RL   Submitted (SEP-2009) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; GQ901048; ADO22565.1; -; mRNA.
DR   EMBL; AK312307; BAG35232.1; -; mRNA.
DR   EMBL; AK097580; BAG53489.1; -; mRNA.
DR   EMBL; CH471099; EAW89060.1; -; Genomic_DNA.
DR   EMBL; CH471099; EAW89061.1; -; Genomic_DNA.
DR   EMBL; CH471099; EAW89062.1; -; Genomic_DNA.
DR   EMBL; CH471099; EAW89063.1; -; Genomic_DNA.
DR   EMBL; CH471099; EAW89065.1; -; Genomic_DNA.
DR   RefSeq; NP_001263218.1; NM_001276289.1.
DR   RefSeq; NP_001265362.1; NM_001278433.1.
DR   RefSeq; NP_002725.1; NM_002734.4.
DR   RefSeq; NP_997636.1; NM_212471.2.
DR   RefSeq; NP_997637.1; NM_212472.2.
DR   RefSeq; XP_011523285.1; XM_011524983.2.
DR   RefSeq; XP_011523286.1; XM_011524984.2.
DR   RefSeq; XP_011523287.1; XM_011524985.2.
DR   Antibodypedia; 31783; 351 antibodies.
DR   DNASU; 5573; -.
DR   GeneID; 5573; -.
DR   KEGG; hsa:5573; -.
DR   CTD; 5573; -.
DR   EuPathDB; HostDB:ENSG00000108946.14; -.
DR   PharmGKB; PA33754; -.
DR   eggNOG; KOG1113; Eukaryota.
DR   eggNOG; COG0664; LUCA.
DR   HOGENOM; CLU_018310_1_0_1; -.
DR   KO; K04739; -.
DR   OMA; IVQLCTV; -.
DR   OrthoDB; 1047290at2759; -.
DR   ChiTaRS; PRKAR1A; human.
DR   GenomeRNAi; 5573; -.
DR   Bgee; ENSG00000108946; Expressed in substantia nigra and 238 other tissues.
DR   GO; GO:0005952; C:cAMP-dependent protein kinase complex; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0030552; F:cAMP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008603; F:cAMP-dependent protein kinase regulator activity; IEA:Ensembl.
DR   GO; GO:0016301; F:kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0007143; P:female meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0001707; P:mesoderm formation; IEA:Ensembl.
DR   GO; GO:0045835; P:negative regulation of meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IEA:Ensembl.
DR   GO; GO:0045214; P:sarcomere organization; IEA:Ensembl.
DR   CDD; cd00038; CAP_ED; 2.
DR   Gene3D; 2.60.120.10; -; 2.
DR   InterPro; IPR012198; cAMP_dep_PK_reg_su.
DR   InterPro; IPR003117; cAMP_dep_PK_reg_su_I/II_a/b.
DR   InterPro; IPR018490; cNMP-bd-like.
DR   InterPro; IPR018488; cNMP-bd_CS.
DR   InterPro; IPR000595; cNMP-bd_dom.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   Pfam; PF00027; cNMP_binding; 2.
DR   Pfam; PF02197; RIIa; 1.
DR   PIRSF; PIRSF000548; PK_regulatory; 1.
DR   SMART; SM00100; cNMP; 2.
DR   SMART; SM00394; RIIa; 1.
DR   SUPFAM; SSF51206; SSF51206; 2.
DR   PROSITE; PS00888; CNMP_BINDING_1; 2.
DR   PROSITE; PS00889; CNMP_BINDING_2; 2.
DR   PROSITE; PS50042; CNMP_BINDING_3; 2.
PE   2: Evidence at transcript level;
KW   cAMP {ECO:0000256|PIRSR:PIRSR000548-1};
KW   cAMP-binding {ECO:0000256|PIRSR:PIRSR000548-1};
KW   Kinase {ECO:0000313|EMBL:BAG35232.1};
KW   Nucleotide-binding {ECO:0000256|PIRSR:PIRSR000548-1};
KW   Transferase {ECO:0000313|EMBL:BAG35232.1}.
FT   DOMAIN          137..252
FT                   /note="Cyclic nucleotide-binding"
FT                   /evidence="ECO:0000259|PROSITE:PS50042"
FT   DOMAIN          255..376
FT                   /note="Cyclic nucleotide-binding"
FT                   /evidence="ECO:0000259|PROSITE:PS50042"
FT   REGION          64..96
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         202
FT                   /note="cAMP 1"
FT                   /evidence="ECO:0000256|PIRSR:PIRSR000548-1"
FT   BINDING         211
FT                   /note="cAMP 1"
FT                   /evidence="ECO:0000256|PIRSR:PIRSR000548-1"
FT   BINDING         326
FT                   /note="cAMP 2"
FT                   /evidence="ECO:0000256|PIRSR:PIRSR000548-1"
FT   BINDING         335
FT                   /note="cAMP 2"
FT                   /evidence="ECO:0000256|PIRSR:PIRSR000548-1"
SQ   SEQUENCE   381 AA;  42982 MW;  2D04F08CE8857A6D CRC64;
     MESGSTAASE EARSLRECEL YVQKHNIQAL LKDSIVQLCT ARPERPMAFL REYFERLEKE
     EAKQIQNLQK AGTRTDSRED EISPPPPNPV VKGRRRRGAI SAEVYTEEDA ASYVRKVIPK
     DYKTMAALAK AIEKNVLFSH LDDNERSDIF DAMFSVSFIA GETVIQQGDE GDNFYVIDQG
     ETDVYVNNEW ATSVGEGGSF GELALIYGTP RAATVKAKTN VKLWGIDRDS YRRILMGSTL
     RKRKMYEEFL SKVSILESLD KWERLTVADA LEPVQFEDGQ KIVVQGEPGD EFFIILEGSA
     AVLQRRSENE EFVEVGRLGP SDYFGEIALL MNRPRAATVV ARGPLKCVKL DRPRFERVLG
     PCSDILKRNI QQYNSFVSLS V
//
ID   KAP0_HUMAN              Reviewed;         381 AA.
AC   P10644; K7ER48; Q567S7;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   22-APR-2020, entry version 230.
DE   RecName: Full=cAMP-dependent protein kinase type I-alpha regulatory subunit;
DE   AltName: Full=Tissue-specific extinguisher 1;
DE            Short=TSE1;
GN   Name=PRKAR1A; Synonyms=PKR1, PRKAR1, TSE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=3426618; DOI=10.1016/0006-291x(87)90499-2;
RA   Sandberg M., Tasken K., Oeyen O., Hansson V., Jahnsen T.;
RT   "Molecular cloning, cDNA structure and deduced amino acid sequence for a
RT   type I regulatory subunit of cAMP-dependent protein kinase from human
RT   testis.";
RL   Biochem. Biophys. Res. Commun. 149:939-945(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=2310396; DOI=10.1016/0006-291x(90)91768-n;
RA   Sandberg M., Skalhegg B., Jahnsen T.;
RT   "The two mRNA forms for the type I alpha regulatory subunit of cAMP-
RT   dependent protein kinase from human testis are due to the use of different
RT   polyadenylation site signals.";
RL   Biochem. Biophys. Res. Commun. 167:323-330(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1889088; DOI=10.1016/0092-8674(91)90433-y;
RA   Jones K.W., Shapero M.H., Chevrette M., Fournier R.E.;
RT   "Subtractive hybridization cloning of a tissue-specific extinguisher: TSE1
RT   encodes a regulatory subunit of protein kinase A.";
RL   Cell 66:861-872(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=8977401; DOI=10.1210/endo.138.1.4864;
RA   Solberg R., Sandberg M., Natarajan V., Torjesen P.A., Hansson V.,
RA   Jahnsen T., Tasken K.;
RT   "The human gene for the regulatory subunit RI alpha of cyclic adenosine 3',
RT   5'-monophosphate-dependent protein kinase: two distinct promoters provide
RT   differential regulation of alternately spliced messenger ribonucleic
RT   acids.";
RL   Endocrinology 138:169-181(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-13, AND ACETYLATION AT MET-1.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [8]
RP   INVOLVEMENT IN PPNAD1.
RX   PubMed=12213893; DOI=10.1210/jc.2002-020592;
RA   Groussin L., Jullian E., Perlemoine K., Louvel A., Leheup B., Luton J.P.,
RA   Bertagna X., Bertherat J.;
RT   "Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic
RT   primary pigmented nodular adrenocortical disease.";
RL   J. Clin. Endocrinol. Metab. 87:4324-4329(2002).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [10]
RP   INTERACTION WITH RFC2.
RX   PubMed=15655353;
RA   Gupte R.S., Weng Y., Liu L., Lee M.Y.;
RT   "The second subunit of the replication factor C complex (RFC40) and the
RT   regulatory subunit (RIalpha) of protein kinase A form a protein complex
RT   promoting cell survival.";
RL   Cell Cycle 4:323-329(2005).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH PRKX.
RX   PubMed=16491121; DOI=10.1038/sj.onc.1209436;
RA   Glesne D., Huberman E.;
RT   "Smad6 is a protein kinase X phosphorylation substrate and is required for
RT   HL-60 cell differentiation.";
RL   Oncogene 25:4086-4098(2006).
RN   [13]
RP   INTERACTION WITH AICDA.
RX   PubMed=16387847; DOI=10.1073/pnas.0509969103;
RA   Pasqualucci L., Kitaura Y., Gu H., Dalla-Favera R.;
RT   "PKA-mediated phosphorylation regulates the function of activation-induced
RT   deaminase (AID) in B cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:395-400(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using sequential
RT   IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT   and fractionation of phosphopeptides with strong anion exchange
RT   chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   INTERACTION WITH RARA, AND FUNCTION.
RX   PubMed=20215566; DOI=10.1210/en.2009-1338;
RA   Santos N.C., Kim K.H.;
RT   "Activity of retinoic acid receptor-alpha is directly regulated at its
RT   protein kinase A sites in response to follicle-stimulating hormone
RT   signaling.";
RL   Endocrinology 151:2361-2372(2010).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   INVOLVEMENT IN ACRDYS1, AND MUTAGENESIS OF TYR-373.
RX   PubMed=21651393; DOI=10.1056/nejmoa1012717;
RA   Linglart A., Menguy C., Couvineau A., Auzan C., Gunes Y., Cancel M.,
RA   Motte E., Pinto G., Chanson P., Bougneres P., Clauser E., Silve C.;
RT   "Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance.";
RL   N. Engl. J. Med. 364:2218-2226(2011).
RN   [26]
RP   INTERACTION WITH PJA2.
RX   PubMed=21423175; DOI=10.1038/ncb2209;
RA   Lignitto L., Carlucci A., Sepe M., Stefan E., Cuomo O., Nistico R.,
RA   Scorziello A., Savoia C., Garbi C., Annunziato L., Feliciello A.;
RT   "Control of PKA stability and signalling by the RING ligase praja2.";
RL   Nat. Cell Biol. 13:412-422(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [28]
RP   INVOLVEMENT IN CNC1.
RX   PubMed=22785148; DOI=10.1507/endocrj.ej12-0040;
RA   Tung S.C., Hwang D.Y., Yang J.W., Chen W.J., Lee C.T.;
RT   "An unusual presentation of Carney complex with diffuse primary pigmented
RT   nodular adrenocortical disease on one adrenal gland and a nonpigmented
RT   adrenocortical adenoma and focal primary pigmented nodular adrenocortical
RT   disease on the other.";
RL   Endocr. J. 59:823-830(2012).
RN   [29]
RP   INTERACTION WITH C2ORF88/SMAKAP, AND SUBCELLULAR LOCATION.
RX   PubMed=23115245; DOI=10.1074/jbc.m112.395970;
RA   Burgers P.P., Ma Y., Margarucci L., Mackey M., van der Heyden M.A.,
RA   Ellisman M., Scholten A., Taylor S.S., Heck A.J.;
RT   "A small novel A-kinase anchoring protein (AKAP) that localizes
RT   specifically protein kinase A-regulatory subunit I (PKA-RI) to the plasma
RT   membrane.";
RL   J. Biol. Chem. 287:43789-43797(2012).
RN   [30]
RP   INVOLVEMENT IN CNC1.
RX   PubMed=23323113; DOI=10.4132/koreanjpathol.2012.46.6.595;
RA   Park K.U., Kim H.S., Lee S.K., Jung W.W., Park Y.K.;
RT   "Novel Mutation in PRKAR1A in Carney Complex.";
RL   Korean J. Pathol. 46:595-600(2012).
RN   [31]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-75; SER-77 AND SER-83, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   VARIANT CNC1 CYS-74.
RX   PubMed=15371594; DOI=10.1073/pnas.0405535101;
RA   Veugelers M., Wilkes D., Burton K., McDermott D.A., Song Y.,
RA   Goldstein M.M., La Perle K., Vaughan C.J., O'Hagan A., Bennett K.R.,
RA   Meyer B.J., Legius E., Karttunen M., Norio R., Kaariainen H., Lavyne M.,
RA   Neau J.-P., Richter G., Kirali K., Farnsworth A., Stapleton K., Morelli P.,
RA   Takanashi Y., Bamforth J.-S., Eitelberger F., Noszian I., Manfroi W.,
RA   Powers J., Mochizuki Y., Imai T., Ko G.T.C., Driscoll D.A., Goldmuntz E.,
RA   Edelberg J.M., Collins A., Eccles D., Irvine A.D., McKnight G.S.,
RA   Basson C.T.;
RT   "Comparative PRKAR1A genotype-phenotype analyses in humans with Carney
RT   complex and prkar1a haploinsufficient mice.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:14222-14227(2004).
RN   [36]
RP   VARIANTS CNC1 ASN-9; SER-146; TYR-183; ASP-213 AND TRP-289, AND
RP   CHARACTERIZATION OF VARIANTS CNC1 ASN-9; CYS-74; SER-146; TYR-183; ASP-213
RP   AND TRP-289.
RX   PubMed=18241045; DOI=10.1002/humu.20688;
RA   Greene E.L., Horvath A.D., Nesterova M., Giatzakis C., Bossis I.,
RA   Stratakis C.A.;
RT   "In vitro functional studies of naturally occurring pathogenic PRKAR1A
RT   mutations that are not subject to nonsense mRNA decay.";
RL   Hum. Mutat. 29:633-639(2008).
RN   [37]
RP   VARIANT ACRDYS1 HIS-373.
RX   PubMed=22464250; DOI=10.1016/j.ajhg.2012.03.003;
RA   Michot C., Le Goff C., Goldenberg A., Abhyankar A., Klein C., Kinning E.,
RA   Guerrot A.M., Flahaut P., Duncombe A., Baujat G., Lyonnet S.,
RA   Thalassinos C., Nitschke P., Casanova J.L., Le Merrer M., Munnich A.,
RA   Cormier-Daire V.;
RT   "Exome sequencing identifies PDE4D mutations as another cause of
RT   acrodysostosis.";
RL   Am. J. Hum. Genet. 90:740-745(2012).
RN   [38]
RP   VARIANTS ACRDYS1 THR-327 AND PRO-335.
RX   PubMed=22464252; DOI=10.1016/j.ajhg.2012.03.004;
RA   Lee H., Graham J.M. Jr., Rimoin D.L., Lachman R.S., Krejci P.,
RA   Tompson S.W., Nelson S.F., Krakow D., Cohn D.H.;
RT   "Exome sequencing identifies PDE4D mutations in acrodysostosis.";
RL   Am. J. Hum. Genet. 90:746-751(2012).
RN   [39]
RP   VARIANTS ACRDYS1 ARG-285; GLU-289; VAL-328 AND LEU-335.
RX   PubMed=23043190; DOI=10.1210/jc.2012-2326;
RA   Linglart A., Fryssira H., Hiort O., Holterhus P.M., Perez de Nanclares G.,
RA   Argente J., Heinrichs C., Kuechler A., Mantovani G., Leheup B., Wicart P.,
RA   Chassot V., Schmidt D., Rubio-Cabezas O., Richter-Unruh A., Berrade S.,
RA   Pereda A., Boros E., Munoz-Calvo M.T., Castori M., Gunes Y., Bertrand G.,
RA   Bougneres P., Clauser E., Silve C.;
RT   "PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct
RT   syndromes with or without GPCR-signaling hormone resistance.";
RL   J. Clin. Endocrinol. Metab. 97:E2328-E2338(2012).
RN   [40]
RP   VARIANT ACRDYS1 ALA-239, AND CHARACTERIZATION OF VARIANT ACRDYS1 ALA-239.
RX   PubMed=22723333; DOI=10.1210/jc.2012-1369;
RA   Nagasaki K., Iida T., Sato H., Ogawa Y., Kikuchi T., Saitoh A., Ogata T.,
RA   Fukami M.;
RT   "PRKAR1A mutation affecting cAMP-mediated G protein-coupled receptor
RT   signaling in a patient with acrodysostosis and hormone resistance.";
RL   J. Clin. Endocrinol. Metab. 97:E1808-E1813(2012).
RN   [41]
RP   VARIANTS ACRDYS1 THR-213 AND CYS-373, AND VARIANT ASN-227.
RX   PubMed=23425300; DOI=10.1111/cge.12106;
RA   Muhn F., Klopocki E., Graul-Neumann L., Uhrig S., Colley A., Castori M.,
RA   Lankes E., Henn W., Gruber-Sedlmayr U., Seifert W., Horn D.;
RT   "Novel mutations of the PRKAR1A gene in patients with acrodysostosis.";
RL   Clin. Genet. 84:531-538(2013).
RN   [42]
RP   VARIANT ACRDYS1 CYS-175, CHARACTERIZATION OF VARIANTS ACRDYS1 CYS-175;
RP   THR-213; ARG-285; GLU-289; VAL-328 AND LEU-335, CHARACTERIZATION OF
RP   VARIANTS CNC1 ASP-213 AND TRP-289, AND FUNCTION.
RX   PubMed=26405036; DOI=10.1074/jbc.m115.656553;
RA   Rhayem Y., Le Stunff C., Abdel Khalek W., Auzan C., Bertherat J.,
RA   Linglart A., Couvineau A., Silve C., Clauser E.;
RT   "Functional characterization of PRKAR1A mutations reveals a unique
RT   molecular mechanism causing acrodysostosis but multiple mechanisms causing
RT   carney complex.";
RL   J. Biol. Chem. 290:27816-27828(2015).
CC   -!- FUNCTION: Regulatory subunit of the cAMP-dependent protein kinases
CC       involved in cAMP signaling in cells. {ECO:0000269|PubMed:16491121,
CC       ECO:0000269|PubMed:20215566, ECO:0000269|PubMed:26405036}.
CC   -!- SUBUNIT: The inactive holoenzyme is composed of two regulatory chains
CC       and two catalytic chains. Activation by cAMP releases the two active
CC       catalytic monomers and the regulatory dimer. PRKAR1A also interacts
CC       with RFC2; the complex may be involved in cell survival. Interacts with
CC       AKAP4. Interacts with RARA; the interaction occurs in the presence of
CC       cAMP or FSH and regulates RARA transcriptional activity. Interacts with
CC       the phosphorylated form of PJA2. Interacts with CBFA2T3 (By
CC       similarity). Interacts with PRKX; regulates this cAMP-dependent protein
CC       kinase. Interacts with C2orf88/smAKAP; this interaction may target
CC       PRKAR1A to the plasma membrane. Interacts with AICDA. {ECO:0000250,
CC       ECO:0000269|PubMed:15655353, ECO:0000269|PubMed:16387847,
CC       ECO:0000269|PubMed:16491121, ECO:0000269|PubMed:20215566,
CC       ECO:0000269|PubMed:21423175, ECO:0000269|PubMed:23115245}.
CC   -!- INTERACTION:
CC       P10644; P03259-2; Xeno; NbExp=5; IntAct=EBI-476431, EBI-7225021;
CC       P10644; Q9GZX7: AICDA; NbExp=5; IntAct=EBI-476431, EBI-3834328;
CC       P10644; P24588: AKAP5; NbExp=3; IntAct=EBI-476431, EBI-703640;
CC       P10644; O43687-2: AKAP7; NbExp=3; IntAct=EBI-476431, EBI-10185182;
CC       P10644; Q9H6J7-2: C11orf49; NbExp=3; IntAct=EBI-476431, EBI-13328871;
CC       P10644; Q9BSF0: C2orf88; NbExp=9; IntAct=EBI-476431, EBI-744298;
CC       P10644; Q86Y01: DTX1; NbExp=3; IntAct=EBI-476431, EBI-1755174;
CC       P10644; P0C7A2-2: FAM153B; NbExp=3; IntAct=EBI-476431, EBI-12940382;
CC       P10644; Q9H0R8: GABARAPL1; NbExp=2; IntAct=EBI-476431, EBI-746969;
CC       P10644; Q9H8W4: PLEKHF2; NbExp=3; IntAct=EBI-476431, EBI-742388;
CC       P10644; P17612: PRKACA; NbExp=11; IntAct=EBI-476431, EBI-476586;
CC       P10644; P31321: PRKAR1B; NbExp=6; IntAct=EBI-476431, EBI-2805516;
CC       P10644; P51817: PRKX; NbExp=2; IntAct=EBI-476431, EBI-4302903;
CC       P10644; P35250: RFC2; NbExp=7; IntAct=EBI-476431, EBI-476409;
CC       P10644; Q86UC2: RSPH3; NbExp=3; IntAct=EBI-476431, EBI-6873025;
CC       P10644; Q01105: SET; NbExp=2; IntAct=EBI-476431, EBI-1053182;
CC       P10644; Q8N0X7: SPART; NbExp=3; IntAct=EBI-476431, EBI-2643803;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23115245}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P10644-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P10644-2; Sequence=VSP_054833, VSP_054834;
CC   -!- TISSUE SPECIFICITY: Four types of regulatory chains are found: I-alpha,
CC       I-beta, II-alpha, and II-beta. Their expression varies among tissues
CC       and is in some cases constitutive and in others inducible.
CC   -!- PTM: The pseudophosphorylation site binds to the substrate-binding
CC       region of the catalytic chain, resulting in the inhibition of its
CC       activity.
CC   -!- DISEASE: Carney complex 1 (CNC1) [MIM:160980]: CNC is a multiple
CC       neoplasia syndrome characterized by spotty skin pigmentation, cardiac
CC       and other myxomas, endocrine tumors, and psammomatous melanotic
CC       schwannomas. {ECO:0000269|PubMed:15371594, ECO:0000269|PubMed:18241045,
CC       ECO:0000269|PubMed:22785148, ECO:0000269|PubMed:23323113,
CC       ECO:0000269|PubMed:26405036}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Intracardiac myxoma (INTMYX) [MIM:255960]: Inheritance is
CC       autosomal recessive. Note=The disease is caused by mutations affecting
CC       the gene represented in this entry.
CC   -!- DISEASE: Primary pigmented nodular adrenocortical disease 1 (PPNAD1)
CC       [MIM:610489]: A rare bilateral adrenal defect causing ACTH-independent
CC       Cushing syndrome. Macroscopic appearance of the adrenals is
CC       characteristic with small pigmented micronodules observed in the
CC       cortex. Clinical manifestations of Cushing syndrome include facial and
CC       truncal obesity, abdominal striae, muscular weakness, osteoporosis,
CC       arterial hypertension, diabetes. PPNAD1 is most often diagnosed in
CC       patients with Carney complex, a multiple neoplasia syndrome. However it
CC       can also be observed in patients without other manifestations.
CC       {ECO:0000269|PubMed:12213893}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Acrodysostosis 1, with or without hormone resistance (ACRDYS1)
CC       [MIM:101800]: A form of skeletal dysplasia characterized by short
CC       stature, severe brachydactyly, facial dysostosis, and nasal hypoplasia.
CC       Affected individuals often have advanced bone age and obesity.
CC       Laboratory studies show resistance to multiple hormones, including
CC       parathyroid, thyrotropin, calcitonin, growth hormone-releasing hormone,
CC       and gonadotropin. However, not all patients show endocrine
CC       abnormalities. {ECO:0000269|PubMed:21651393,
CC       ECO:0000269|PubMed:22464250, ECO:0000269|PubMed:22464252,
CC       ECO:0000269|PubMed:22723333, ECO:0000269|PubMed:23043190,
CC       ECO:0000269|PubMed:23425300, ECO:0000269|PubMed:26405036}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the cAMP-dependent kinase regulatory chain
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PRKAR1AID387.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M18468; AAB50922.1; -; mRNA.
DR   EMBL; M33336; AAB50921.1; -; mRNA.
DR   EMBL; S54705; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S54707; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S54709; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S54711; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Y07642; CAA68925.1; -; mRNA.
DR   EMBL; AC079210; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC036285; AAH36285.1; -; mRNA.
DR   EMBL; BC093042; AAH93042.1; -; mRNA.
DR   CCDS; CCDS11678.1; -. [P10644-1]
DR   CCDS; CCDS62307.1; -. [P10644-2]
DR   PIR; A34627; OKHU1R.
DR   RefSeq; NP_001263218.1; NM_001276289.1. [P10644-1]
DR   RefSeq; NP_001263219.1; NM_001276290.1. [P10644-2]
DR   RefSeq; NP_001265362.1; NM_001278433.1. [P10644-1]
DR   RefSeq; NP_002725.1; NM_002734.4. [P10644-1]
DR   RefSeq; NP_997636.1; NM_212471.2. [P10644-1]
DR   RefSeq; NP_997637.1; NM_212472.2. [P10644-1]
DR   RefSeq; XP_011523285.1; XM_011524983.2.
DR   RefSeq; XP_011523286.1; XM_011524984.2. [P10644-1]
DR   RefSeq; XP_011523287.1; XM_011524985.2.
DR   PDB; 5KJX; X-ray; 1.90 A; A=234-381.
DR   PDB; 5KJY; X-ray; 2.00 A; A=234-381.
DR   PDB; 5KJZ; X-ray; 1.35 A; A=234-381.
DR   PDBsum; 5KJX; -.
DR   PDBsum; 5KJY; -.
DR   PDBsum; 5KJZ; -.
DR   SMR; P10644; -.
DR   BioGrid; 111559; 105.
DR   DIP; DIP-34368N; -.
DR   IntAct; P10644; 182.
DR   MINT; P10644; -.
DR   STRING; 9606.ENSP00000376475; -.
DR   BindingDB; P10644; -.
DR   DrugBank; DB02527; Cyclic adenosine monophosphate.
DR   DrugBank; DB02315; Cyclic GMP.
DR   DrugBank; DB05798; GEM-231.
DR   DrugBank; DB01790; Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate.
DR   GuidetoPHARMACOLOGY; 1472; -.
DR   iPTMnet; P10644; -.
DR   MetOSite; P10644; -.
DR   PhosphoSitePlus; P10644; -.
DR   SwissPalm; P10644; -.
DR   BioMuta; PRKAR1A; -.
DR   DMDM; 125193; -.
DR   OGP; P10644; -.
DR   REPRODUCTION-2DPAGE; IPI00021831; -.
DR   EPD; P10644; -.
DR   jPOST; P10644; -.
DR   MassIVE; P10644; -.
DR   MaxQB; P10644; -.
DR   PaxDb; P10644; -.
DR   PeptideAtlas; P10644; -.
DR   PRIDE; P10644; -.
DR   ProteomicsDB; 52634; -. [P10644-1]
DR   Antibodypedia; 31783; 351 antibodies.
DR   DNASU; 5573; -.
DR   Ensembl; ENST00000358598; ENSP00000351410; ENSG00000108946. [P10644-1]
DR   Ensembl; ENST00000392711; ENSP00000376475; ENSG00000108946. [P10644-1]
DR   Ensembl; ENST00000536854; ENSP00000445625; ENSG00000108946. [P10644-1]
DR   Ensembl; ENST00000586397; ENSP00000466459; ENSG00000108946. [P10644-1]
DR   Ensembl; ENST00000588188; ENSP00000468106; ENSG00000108946. [P10644-2]
DR   Ensembl; ENST00000589228; ENSP00000464977; ENSG00000108946. [P10644-1]
DR   GeneID; 5573; -.
DR   KEGG; hsa:5573; -.
DR   UCSC; uc002jhg.5; human. [P10644-1]
DR   CTD; 5573; -.
DR   DisGeNET; 5573; -.
DR   GeneCards; PRKAR1A; -.
DR   GeneReviews; PRKAR1A; -.
DR   HGNC; HGNC:9388; PRKAR1A.
DR   HPA; ENSG00000108946; Low tissue specificity.
DR   MalaCards; PRKAR1A; -.
DR   MIM; 101800; phenotype.
DR   MIM; 160980; phenotype.
DR   MIM; 188830; gene.
DR   MIM; 255960; phenotype.
DR   MIM; 610489; phenotype.
DR   neXtProt; NX_P10644; -.
DR   OpenTargets; ENSG00000108946; -.
DR   Orphanet; 950; Acrodysostosis.
DR   Orphanet; 280651; Acrodysostosis with multiple hormone resistance.
DR   Orphanet; 520; Acute promyelocytic leukemia.
DR   Orphanet; 1359; Carney complex.
DR   Orphanet; 615; Familial atrial myxoma.
DR   Orphanet; 189439; Primary pigmented nodular adrenocortical disease.
DR   PharmGKB; PA33754; -.
DR   eggNOG; KOG1113; Eukaryota.
DR   eggNOG; COG0664; LUCA.
DR   GeneTree; ENSGT00940000155148; -.
DR   HOGENOM; CLU_018310_1_0_1; -.
DR   InParanoid; P10644; -.
DR   KO; K04739; -.
DR   OMA; IVQLCTV; -.
DR   PhylomeDB; P10644; -.
DR   TreeFam; TF314920; -.
DR   Reactome; R-HSA-163615; PKA activation.
DR   Reactome; R-HSA-164378; PKA activation in glucagon signalling.
DR   Reactome; R-HSA-180024; DARPP-32 events.
DR   Reactome; R-HSA-381676; Glucagon-like Peptide-1 (GLP1) regulates insulin secretion.
DR   Reactome; R-HSA-432040; Vasopressin regulates renal water homeostasis via Aquaporins.
DR   Reactome; R-HSA-442720; CREB1 phosphorylation through the activation of Adenylate Cyclase.
DR   Reactome; R-HSA-5610787; Hedgehog 'off' state.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P10644; -.
DR   SIGNOR; P10644; -.
DR   ChiTaRS; PRKAR1A; human.
DR   GenomeRNAi; 5573; -.
DR   Pharos; P10644; Tbio.
DR   PRO; PR:P10644; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P10644; protein.
DR   Bgee; ENSG00000108946; Expressed in substantia nigra and 238 other tissues.
DR   ExpressionAtlas; P10644; baseline and differential.
DR   Genevisible; P10644; HS.
DR   GO; GO:0005952; C:cAMP-dependent protein kinase complex; IEA:Ensembl.
DR   GO; GO:0097546; C:ciliary base; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0031588; C:nucleotide-activated protein kinase complex; IDA:BHF-UCL.
DR   GO; GO:0044853; C:plasma membrane raft; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0047555; F:3',5'-cyclic-GMP phosphodiesterase activity; IBA:GO_Central.
DR   GO; GO:0030552; F:cAMP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004862; F:cAMP-dependent protein kinase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0008603; F:cAMP-dependent protein kinase regulator activity; IDA:BHF-UCL.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0034236; F:protein kinase A catalytic subunit binding; IPI:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:UniProtKB.
DR   GO; GO:0034199; P:activation of protein kinase A activity; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0071377; P:cellular response to glucagon stimulus; TAS:Reactome.
DR   GO; GO:0019934; P:cGMP-mediated signaling; IBA:GO_Central.
DR   GO; GO:0007143; P:female meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc.
DR   GO; GO:0001707; P:mesoderm formation; IEA:Ensembl.
DR   GO; GO:0046007; P:negative regulation of activated T cell proliferation; IMP:UniProtKB.
DR   GO; GO:2000480; P:negative regulation of cAMP-dependent protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0045835; P:negative regulation of meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:ProtInc.
DR   GO; GO:0003091; P:renal water homeostasis; TAS:Reactome.
DR   GO; GO:0045214; P:sarcomere organization; IEA:Ensembl.
DR   CDD; cd00038; CAP_ED; 2.
DR   Gene3D; 2.60.120.10; -; 2.
DR   InterPro; IPR012198; cAMP_dep_PK_reg_su.
DR   InterPro; IPR003117; cAMP_dep_PK_reg_su_I/II_a/b.
DR   InterPro; IPR018490; cNMP-bd-like.
DR   InterPro; IPR018488; cNMP-bd_CS.
DR   InterPro; IPR000595; cNMP-bd_dom.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   Pfam; PF00027; cNMP_binding; 2.
DR   Pfam; PF02197; RIIa; 1.
DR   PIRSF; PIRSF000548; PK_regulatory; 1.
DR   SMART; SM00100; cNMP; 2.
DR   SMART; SM00394; RIIa; 1.
DR   SUPFAM; SSF51206; SSF51206; 2.
DR   PROSITE; PS00888; CNMP_BINDING_1; 2.
DR   PROSITE; PS00889; CNMP_BINDING_2; 2.
DR   PROSITE; PS50042; CNMP_BINDING_3; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; cAMP; cAMP-binding;
KW   Cell membrane; Cushing syndrome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Repeat.
FT   CHAIN           1..381
FT                   /note="cAMP-dependent protein kinase type I-alpha
FT                   regulatory subunit"
FT                   /id="PRO_0000205377"
FT   NP_BIND         137..254
FT                   /note="cAMP 1"
FT   NP_BIND         255..381
FT                   /note="cAMP 2"
FT   REGION          1..136
FT                   /note="Dimerization and phosphorylation"
FT   MOTIF           96..100
FT                   /note="Pseudophosphorylation motif"
FT   BINDING         202
FT                   /note="cAMP 1"
FT   BINDING         211
FT                   /note="cAMP 1"
FT   BINDING         326
FT                   /note="cAMP 2"
FT   BINDING         335
FT                   /note="cAMP 2"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000244|PubMed:19413330,
FT                   ECO:0000244|PubMed:22223895, ECO:0000244|PubMed:22814378,
FT                   ECO:0000269|PubMed:12665801"
FT   MOD_RES         3
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09456"
FT   MOD_RES         75
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         77
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         83
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983,
FT                   ECO:0000244|PubMed:18318008, ECO:0000244|PubMed:18691976,
FT                   ECO:0000244|PubMed:19367720, ECO:0000244|PubMed:19369195,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:23186163,
FT                   ECO:0000244|PubMed:24275569"
FT   MOD_RES         101
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9DBC7"
FT   MOD_RES         258
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09456"
FT   DISULFID        18
FT                   /note="Interchain (with C-39)"
FT                   /evidence="ECO:0000250"
FT   DISULFID        39
FT                   /note="Interchain (with C-18)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         326..337
FT                   /note="EIALLMNRPRAA -> HLIISRRSIPLG (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_054833"
FT   VAR_SEQ         338..381
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_054834"
FT   VARIANT         9
FT                   /note="S -> N (in CNC1; exhibits increased PKA activity
FT                   which is attributed to decreased binding to cAMP and/or the
FT                   catalytic subunit)"
FT                   /evidence="ECO:0000269|PubMed:18241045"
FT                   /id="VAR_046894"
FT   VARIANT         74
FT                   /note="R -> C (in CNC1; exhibits increased PKA activity
FT                   which is attributed to decreased binding to cAMP and/or the
FT                   catalytic subunit; dbSNP:rs137853303)"
FT                   /evidence="ECO:0000269|PubMed:15371594,
FT                   ECO:0000269|PubMed:18241045"
FT                   /id="VAR_046895"
FT   VARIANT         146
FT                   /note="R -> S (in CNC1; exhibits increased PKA activity
FT                   which is attributed to decreased binding to cAMP and/or the
FT                   catalytic subunit)"
FT                   /evidence="ECO:0000269|PubMed:18241045"
FT                   /id="VAR_046896"
FT   VARIANT         175
FT                   /note="Y -> C (in ACRDYS1; reduces PKA activity; decreases
FT                   cAMP binding)"
FT                   /evidence="ECO:0000269|PubMed:26405036"
FT                   /id="VAR_075533"
FT   VARIANT         183
FT                   /note="D -> Y (in CNC1; exhibits increased PKA activity
FT                   which is attributed to decreased binding to cAMP and/or the
FT                   catalytic subunit)"
FT                   /evidence="ECO:0000269|PubMed:18241045"
FT                   /id="VAR_046897"
FT   VARIANT         213
FT                   /note="A -> D (in CNC1; exhibits increased PKA activity
FT                   which is attributed to decreased binding to cAMP and/or the
FT                   catalytic subunit; reduces protein degradation;
FT                   dbSNP:rs281864786)"
FT                   /evidence="ECO:0000269|PubMed:18241045,
FT                   ECO:0000269|PubMed:26405036"
FT                   /id="VAR_046898"
FT   VARIANT         213
FT                   /note="A -> T (in ACRDYS1; reduces PKA activity; decreases
FT                   cAMP binding; reduces protein degradation)"
FT                   /evidence="ECO:0000269|PubMed:23425300,
FT                   ECO:0000269|PubMed:26405036"
FT                   /id="VAR_069456"
FT   VARIANT         227
FT                   /note="D -> N"
FT                   /evidence="ECO:0000269|PubMed:23425300"
FT                   /id="VAR_069457"
FT   VARIANT         239
FT                   /note="T -> A (in ACRDYS1; impairs response of PKA to c-
FT                   AMP)"
FT                   /evidence="ECO:0000269|PubMed:22723333"
FT                   /id="VAR_069458"
FT   VARIANT         285
FT                   /note="Q -> R (in ACRDYS1; reduces PKA activity; decreases
FT                   cAMP binding; dbSNP:rs1555814719)"
FT                   /evidence="ECO:0000269|PubMed:23043190,
FT                   ECO:0000269|PubMed:26405036"
FT                   /id="VAR_069459"
FT   VARIANT         289
FT                   /note="G -> E (in ACRDYS1; reduces PKA activity; decreases
FT                   cAMP binding; reduces protein degradation)"
FT                   /evidence="ECO:0000269|PubMed:23043190,
FT                   ECO:0000269|PubMed:26405036"
FT                   /id="VAR_069460"
FT   VARIANT         289
FT                   /note="G -> W (in CNC1; exhibits increased PKA activity
FT                   which is attributed to decreased binding to cAMP and/or the
FT                   catalytic subunit; accelerates protein degradation)"
FT                   /evidence="ECO:0000269|PubMed:18241045,
FT                   ECO:0000269|PubMed:26405036"
FT                   /id="VAR_046899"
FT   VARIANT         327
FT                   /note="I -> T (in ACRDYS1; dbSNP:rs387906695)"
FT                   /evidence="ECO:0000269|PubMed:22464252"
FT                   /id="VAR_069461"
FT   VARIANT         328
FT                   /note="A -> V (in ACRDYS1; disrupts cAMP binding)"
FT                   /evidence="ECO:0000269|PubMed:23043190,
FT                   ECO:0000269|PubMed:26405036"
FT                   /id="VAR_069462"
FT   VARIANT         335
FT                   /note="R -> L (in ACRDYS1; disrupts cAMP binding)"
FT                   /evidence="ECO:0000269|PubMed:23043190,
FT                   ECO:0000269|PubMed:26405036"
FT                   /id="VAR_069464"
FT   VARIANT         335
FT                   /note="R -> P (in ACRDYS1; dbSNP:rs387906694)"
FT                   /evidence="ECO:0000269|PubMed:22464252"
FT                   /id="VAR_069463"
FT   VARIANT         373
FT                   /note="Y -> C (in ACRDYS1)"
FT                   /evidence="ECO:0000269|PubMed:23425300"
FT                   /id="VAR_069465"
FT   VARIANT         373
FT                   /note="Y -> H (in ACRDYS1; dbSNP:rs387906693)"
FT                   /evidence="ECO:0000269|PubMed:22464250"
FT                   /id="VAR_068241"
FT   MUTAGEN         373
FT                   /note="Y->A: Impairs response of PKA to c-AMP."
FT                   /evidence="ECO:0000269|PubMed:21651393"
FT   HELIX           237..250
FT                   /evidence="ECO:0000244|PDB:5KJZ"
FT   HELIX           254..256
FT                   /evidence="ECO:0000244|PDB:5KJZ"
FT   HELIX           261..270
FT                   /evidence="ECO:0000244|PDB:5KJZ"
FT   STRAND          272..276
FT                   /evidence="ECO:0000244|PDB:5KJZ"
FT   STRAND          281..283
FT                   /evidence="ECO:0000244|PDB:5KJZ"
FT   STRAND          291..304
FT                   /evidence="ECO:0000244|PDB:5KJZ"
FT   STRAND          313..318
FT                   /evidence="ECO:0000244|PDB:5KJZ"
FT   HELIX           326..330
FT                   /evidence="ECO:0000244|PDB:5KJZ"
FT   STRAND          336..351
FT                   /evidence="ECO:0000244|PDB:5KJZ"
FT   HELIX           352..358
FT                   /evidence="ECO:0000244|PDB:5KJZ"
FT   HELIX           360..362
FT                   /evidence="ECO:0000244|PDB:5KJZ"
FT   HELIX           363..370
FT                   /evidence="ECO:0000244|PDB:5KJZ"
FT   TURN            371..376
FT                   /evidence="ECO:0000244|PDB:5KJZ"
SQ   SEQUENCE   381 AA;  42982 MW;  2D04F08CE8857A6D CRC64;
     MESGSTAASE EARSLRECEL YVQKHNIQAL LKDSIVQLCT ARPERPMAFL REYFERLEKE
     EAKQIQNLQK AGTRTDSRED EISPPPPNPV VKGRRRRGAI SAEVYTEEDA ASYVRKVIPK
     DYKTMAALAK AIEKNVLFSH LDDNERSDIF DAMFSVSFIA GETVIQQGDE GDNFYVIDQG
     ETDVYVNNEW ATSVGEGGSF GELALIYGTP RAATVKAKTN VKLWGIDRDS YRRILMGSTL
     RKRKMYEEFL SKVSILESLD KWERLTVADA LEPVQFEDGQ KIVVQGEPGD EFFIILEGSA
     AVLQRRSENE EFVEVGRLGP SDYFGEIALL MNRPRAATVV ARGPLKCVKL DRPRFERVLG
     PCSDILKRNI QQYNSFVSLS V
//
ID   RUNX1_HUMAN             Reviewed;         453 AA.
AC   Q01196; A8MV94; B2RMS4; D3DSG1; O60472; O60473; O76047; O76089; Q13081;
AC   Q13755; Q13756; Q13757; Q13758; Q13759; Q15341; Q15343; Q16122; Q16284;
AC   Q16285; Q16286; Q16346; Q16347; Q92479;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 3.
DT   22-APR-2020, entry version 238.
DE   RecName: Full=Runt-related transcription factor 1;
DE   AltName: Full=Acute myeloid leukemia 1 protein;
DE   AltName: Full=Core-binding factor subunit alpha-2;
DE            Short=CBF-alpha-2;
DE   AltName: Full=Oncogene AML-1;
DE   AltName: Full=Polyomavirus enhancer-binding protein 2 alpha B subunit;
DE            Short=PEA2-alpha B;
DE            Short=PEBP2-alpha B;
DE   AltName: Full=SL3-3 enhancer factor 1 alpha B subunit;
DE   AltName: Full=SL3/AKV core-binding factor alpha B subunit;
GN   Name=RUNX1; Synonyms=AML1, CBFA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Ahn M.-Y., Bae S.C., Zhang Y.W., Shigesada K., Ito Y.;
RL   Submitted (SEP-1994) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM AML-1C).
RC   TISSUE=Leukocyte;
RX   PubMed=1720541; DOI=10.1073/pnas.88.23.10431;
RA   Miyoshi H., Shimizu K., Kozu T., Maseki N., Kaneko Y., Ohki M.;
RT   "t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are
RT   clustered within a limited region of a single gene, AML1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10431-10434(1991).
RN   [3]
RP   ALTERNATIVE PRODUCTS, AND CHROMOSOMAL TRANSLOCATION WITH EAP.
RX   PubMed=7533526; DOI=10.1002/gcc.2870110405;
RA   Sacchi N., Nisson P.E., Watkins P.C., Faustinella F., Wijsman J.,
RA   Hagemeijer A.;
RT   "AML1 fusion transcripts in t(3;21) positive leukemia: evidence of
RT   molecular heterogeneity and usage of splicing sites frequently involved in
RT   the generation of normal AML1 transcripts.";
RL   Genes Chromosomes Cancer 11:226-236(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM AML-1E), AND CHROMOSOMAL TRANSLOCATION
RP   WITH ETO.
RX   PubMed=8490181;
RA   Nucifora G., Birn D.J., Espinosa R. III, Erickson P., Lebeau M.M.,
RA   Roulston D., McKeithan T.W., Drabkin H., Rowley J.D.;
RT   "Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia
RT   and in chronic myeloid leukemia in blast crisis.";
RL   Blood 81:2728-2734(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM AML-1A).
RC   TISSUE=Monocyte;
RX   PubMed=7835892; DOI=10.1006/geno.1994.1519;
RA   Levanon D., Negreanu V., Bernstein Y., Bar-Am I., Avivi L., Groner Y.;
RT   "AML1, AML2, and AML3, the human members of the runt domain gene-family:
RT   cDNA structure, expression, and chromosomal localization.";
RL   Genomics 23:425-432(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS AML-1B; AML-1A; AML-1G AND AML-1L).
RX   PubMed=7651838; DOI=10.1093/nar/23.14.2762;
RA   Miyoshi H., Ohira M., Shimizu K., Mitani K., Hirai H., Imai T.,
RA   Yokoyama K., Soeda E., Ohki M.;
RT   "Alternative splicing and genomic structure of the AML1 gene involved in
RT   acute myeloid leukemia.";
RL   Nucleic Acids Res. 23:2762-2769(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM AML-1G).
RC   TISSUE=B-cell;
RX   PubMed=7891692; DOI=10.1128/mcb.15.4.1974;
RA   Meyers S., Lenny N., Hiebert S.W.;
RT   "The t(8;21) fusion protein interferes with AML-1B-dependent
RT   transcriptional activation.";
RL   Mol. Cell. Biol. 15:1974-1982(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM AML-1L), AND FUNCTION (ISOFORM AML-1L).
RX   PubMed=9199349; DOI=10.1128/mcb.17.7.4133;
RA   Zhang Y.-W., Bae S.-C., Huang G., Fu Y.-X., Lu J., Ahn M.-Y., Kanno Y.,
RA   Kanno T., Ito Y.;
RT   "A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB
RT   protein interferes with transactivation and blocks granulocytic
RT   differentiation of 32Dcl3 myeloid cells.";
RL   Mol. Cell. Biol. 17:4133-4145(1997).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.-S.,
RA   Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y., Soeda E., Ohki M.,
RA   Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A., Menzel U.,
RA   Delabar J., Kumpf K., Lehmann R., Patterson D., Reichwald K., Rump A.,
RA   Schillhabel M., Schudy A., Zimmermann W., Rosenthal A., Kudoh J.,
RA   Shibuya K., Kawasaki K., Asakawa S., Shintani A., Sasaki T., Nagamine K.,
RA   Mitsuyama S., Antonarakis S.E., Minoshima S., Shimizu N., Nordsiek G.,
RA   Hornischer K., Brandt P., Scharfe M., Schoen O., Desario A., Reichelt J.,
RA   Kauer G., Bloecker H., Ramser J., Beck A., Klages S., Hennig S.,
RA   Riesselmann L., Dagand E., Wehrmeyer S., Borzym K., Gardiner K.,
RA   Nizetic D., Francis F., Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM AML-1G).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-177, AND CHROMOSOMAL TRANSLOCATION WITH
RP   MECOM IN CHRONIC MYELOCYTIC LEUKEMIA.
RX   PubMed=8313895; DOI=10.1002/j.1460-2075.1994.tb06288.x;
RA   Mitani K., Ogawa S., Tanaka T., Miyoshi H., Kurokawa M., Mano H.,
RA   Yazaki Y., Ohki M., Hirai H.;
RT   "Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes
RT   blastic crisis in chronic myelocytic leukemia.";
RL   EMBO J. 13:504-510(1994).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-90 (ISOFORMS AML-1H AND AML-1I).
RX   PubMed=8700862; DOI=10.1073/pnas.93.5.1935;
RA   Ghozi M.C., Bernstein Y., Negreanu V., Levanon D., Groner Y.;
RT   "Expression of the human acute myeloid leukemia gene AML1 is regulated by
RT   two promoter regions.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:1935-1940(1996).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 440-453, AND ALTERNATIVE
RP   SPLICING.
RC   TISSUE=Monocyte;
RX   PubMed=8634147; DOI=10.1089/dna.1996.15.175;
RA   Levanon D., Bernstein Y., Negreanu V., Ghozi M.C., Bar-Am I., Aloya R.,
RA   Goldenberg D., Lotem J., Groner Y.;
RT   "A large variety of alternatively spliced and differentially expressed
RT   mRNAs are encoded by the human acute myeloid leukemia gene AML1.";
RL   DNA Cell Biol. 15:175-185(1996).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-19, AND ALTERNATIVE SPLICING
RP   (ISOFORM AML-1G).
RA   Blechschmidt K., Rump A., Nordsiek G., Drescher B., Weber J., Rosenthal A.;
RT   "Sequencing and analysis of 960 kb between AML1 and CBR1 on chromosome
RT   21q22.2.";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   SIMILARITY TO RUNT.
RX   PubMed=1560822; DOI=10.1038/356484b0;
RA   Daga A., Tighe J.E., Calabi F.;
RT   "Leukaemia/Drosophila homology.";
RL   Nature 356:484-484(1992).
RN   [17]
RP   ENHANCER CORE BINDING SEQUENCE.
RX   PubMed=8413232; DOI=10.1128/mcb.13.10.6336;
RA   Meyers S., Downing J.R., Hiebert S.W.;
RT   "Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO)
RT   as sequence-specific DNA-binding proteins: the runt homology domain is
RT   required for DNA binding and protein-protein interactions.";
RL   Mol. Cell. Biol. 13:6336-6345(1993).
RN   [18]
RP   INTERACTION WITH ALYREF/THOC4.
RX   PubMed=9119228; DOI=10.1101/gad.11.5.640;
RA   Bruhn L., Munnerlyn A., Grosschedl R.;
RT   "ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for
RT   TCRalpha enhancer function.";
RL   Genes Dev. 11:640-653(1997).
RN   [19]
RP   CHROMOSOMAL TRANSLOCATION WITH CBFA2T3.
RX   PubMed=9596646;
RA   Gamou T., Kitamura E., Hosoda F., Shimuzu K., Hayashi Y., Nagase T.,
RA   Yokoyama Y., Ohki M.;
RT   "The partner gene of AML1 in t(16;21) myeloid malignancies is a novel
RT   member of the MTG8(ETO) family.";
RL   Blood 91:4028-4037(1998).
RN   [20]
RP   INTERACTION WITH TLE1.
RX   PubMed=9751710; DOI=10.1073/pnas.95.20.11590;
RA   Levanon D., Goldstein R.E., Bernstein Y., Tang H., Goldenberg D.,
RA   Stifani S., Paroush Z., Groner Y.;
RT   "Transcriptional repression by AML1 and LEF-1 is mediated by the
RT   TLE/Groucho corepressors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:11590-11595(1998).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH ELF1; ELF2; ELF4 AND SPI1.
RX   PubMed=10207087; DOI=10.1128/mcb.19.5.3635;
RA   Mao S., Frank R.C., Zhang J., Miyazaki Y., Nimer S.D.;
RT   "Functional and physical interactions between AML1 proteins and an ETS
RT   protein, MEF: implications for the pathogenesis of t(8;21)-positive
RT   leukemias.";
RL   Mol. Cell. Biol. 19:3635-3644(1999).
RN   [22]
RP   INTERACTION WITH KAT6A, AND PHOSPHORYLATION.
RX   PubMed=11742995; DOI=10.1093/emboj/20.24.7184;
RA   Kitabayashi I., Aikawa Y., Nguyen L.A., Yokoyama A., Ohki M.;
RT   "Activation of AML1-mediated transcription by MOZ and inhibition by the
RT   MOZ-CBP fusion protein.";
RL   EMBO J. 20:7184-7196(2001).
RN   [23]
RP   INTERACTION WITH KAT6B, AND FUNCTION.
RX   PubMed=11965546; DOI=10.1038/sj.onc.1205367;
RA   Pelletier N., Champagne N., Stifani S., Yang X.-J.;
RT   "MOZ and MORF histone acetyltransferases interact with the Runt-domain
RT   transcription factor Runx2.";
RL   Oncogene 21:2729-2740(2002).
RN   [24]
RP   INTERACTION WITH SUV39H1, AND METHYLATION.
RX   PubMed=12917624; DOI=10.1038/sj.onc.1206600;
RA   Chakraborty S., Sinha K.K., Senyuk V., Nucifora G.;
RT   "SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is
RT   methylated in vivo.";
RL   Oncogene 22:5229-5237(2003).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH ELF2.
RX   PubMed=14970218; DOI=10.1074/jbc.m309074200;
RA   Cho J.-Y., Akbarali Y., Zerbini L.F., Gu X., Boltax J., Wang Y.,
RA   Oettgen P., Zhang D.-E., Libermann T.A.;
RT   "Isoforms of the Ets transcription factor NERF/ELF-2 physically interact
RT   with AML1 and mediate opposing effects on AML1-mediated transcription of
RT   the B cell-specific blk gene.";
RL   J. Biol. Chem. 279:19512-19522(2004).
RN   [26]
RP   INTERACTION WITH SUV39H1.
RX   PubMed=16652147; DOI=10.1038/sj.onc.1209591;
RA   Reed-Inderbitzin E., Moreno-Miralles I., Vanden-Eynden S.K., Xie J.,
RA   Lutterbach B., Durst-Goodwin K.L., Luce K.S., Irvin B.J., Cleary M.L.,
RA   Brandt S.J., Hiebert S.W.;
RT   "RUNX1 associates with histone deacetylases and SUV39H1 to repress
RT   transcription.";
RL   Oncogene 25:5777-5786(2006).
RN   [27]
RP   FUNCTION IN MYELOID DIFFERENTIATION, AND INTERACTION WITH CDK6.
RX   PubMed=17431401; DOI=10.1038/sj.emboj.7601675;
RA   Fujimoto T., Anderson K., Jacobsen S.E., Nishikawa S.I., Nerlov C.;
RT   "Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding
RT   and Runx1-C/EBPalpha interaction.";
RL   EMBO J. 26:2361-2370(2007).
RN   [28]
RP   CHROMOSOMAL TRANSLOCATION WITH MACROD1.
RX   PubMed=17532767; DOI=10.1111/j.1600-0609.2007.00858.x;
RA   Imagama S., Abe A., Suzuki M., Hayakawa F., Katsumi A., Emi N., Kiyoi H.,
RA   Naoe T.;
RT   "LRP16 is fused to RUNX1 in monocytic leukemia cell line with
RT   t(11;21)(q13;q22).";
RL   Eur. J. Haematol. 79:25-31(2007).
RN   [29]
RP   FUNCTION, AND INTERACTION WITH FOXP3.
RX   PubMed=17377532; DOI=10.1038/nature05673;
RA   Ono M., Yaguchi H., Ohkura N., Kitabayashi I., Nagamura Y., Nomura T.,
RA   Miyachi Y., Tsukada T., Sakaguchi S.;
RT   "Foxp3 controls regulatory T-cell function by interacting with
RT   AML1/Runx1.";
RL   Nature 446:685-689(2007).
RN   [30]
RP   PHOSPHORYLATION AT SER-249; THR-273 AND SER-276 BY HIPK2, VARIANT GLN-174,
RP   AND MUTAGENESIS OF SER-67; LYS-83; GLY-108; SER-249; THR-273 AND SER-276.
RX   PubMed=18695000; DOI=10.1182/blood-2008-01-134122;
RA   Wee H.-J., Voon D.C.-C., Bae S.-C., Ito Y.;
RT   "PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2:
RT   implications for leukemogenesis.";
RL   Blood 112:3777-3787(2008).
RN   [31]
RP   INTERACTION WITH YAP1.
RX   PubMed=18280240; DOI=10.1016/j.molcel.2007.12.022;
RA   Levy D., Adamovich Y., Reuven N., Shaul Y.;
RT   "Yap1 phosphorylation by c-Abl is a critical step in selective activation
RT   of proapoptotic genes in response to DNA damage.";
RL   Mol. Cell 29:350-361(2008).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-14 AND SER-21, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [33]
RP   INTERACTION WITH CBFB, AND MUTAGENESIS OF MET-106; ALA-107 AND SER-140.
RX   PubMed=19202074; DOI=10.1073/pnas.0810558106;
RA   Kwok C., Zeisig B.B., Qiu J., Dong S., So C.W.;
RT   "Transforming activity of AML1-ETO is independent of CBFbeta and ETO
RT   interaction but requires formation of homo-oligomeric complexes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:2853-2858(2009).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-14; SER-249; SER-266; SER-268
RP   AND SER-276, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [35]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-24 AND LYS-43, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [36]
RP   CHROMOSOMAL TRANSLOCATION WITH CBFA2T2.
RX   PubMed=20520637; DOI=10.1038/leu.2010.106;
RA   Guastadisegni M.C., Lonoce A., Impera L., Di Terlizzi F., Fugazza G.,
RA   Aliano S., Grasso R., Cluzeau T., Raynaud S., Rocchi M., Storlazzi C.T.;
RT   "CBFA2T2 and C20orf112: two novel fusion partners of RUNX1 in acute myeloid
RT   leukemia.";
RL   Leukemia 24:1516-1519(2010).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-14; SER-21; SER-193; SER-212
RP   AND THR-296, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-212 AND SER-435, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [39]
RP   INDUCTION.
RX   PubMed=25134913; DOI=10.1007/s00018-014-1704-2;
RA   Lu B., Sun X., Chen Y., Jin Q., Liang Q., Liu S., Li Y., Zhou Y., Li W.,
RA   Huang Z.;
RT   "Novel function of PITH domain-containing 1 as an activator of internal
RT   ribosomal entry site to enhance RUNX1 expression and promote megakaryocyte
RT   differentiation.";
RL   Cell. Mol. Life Sci. 72:821-832(2015).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 59-173 IN COMPLEX WITH CBFB.
RX   PubMed=10856244; DOI=10.1093/emboj/19.12.3004;
RA   Warren A.J., Bravo J., Williams R.L., Rabbitts T.H.;
RT   "Structural basis for the heterodimeric interaction between the acute
RT   leukaemia-associated transcription factors AML1 and CBFbeta.";
RL   EMBO J. 19:3004-3015(2000).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 54-243 IN COMPLEX WITH CBFB AND
RP   DNA, AND MUTAGENESIS OF ARG-80; LYS-83; THR-84; ARG-135; ARG-139; ARG-142;
RP   LYS-167; THR-169; ASP-171; ARG-174 AND ARG-177.
RX   PubMed=11276260; DOI=10.1038/86264;
RA   Bravo J., Li Z., Speck N.A., Warren A.J.;
RT   "The leukemia-associated AML1 (Runx1) -- CBF beta complex functions as a
RT   DNA-induced molecular clamp.";
RL   Nat. Struct. Biol. 8:371-378(2001).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 61-174 IN COMPLEX WITH DNA.
RX   PubMed=12377125; DOI=10.1016/s0969-2126(02)00853-5;
RA   Bartfeld D., Shimon L., Couture G.C., Rabinovich D., Frolow F., Levanon D.,
RA   Groner Y., Shakked Z.;
RT   "DNA recognition by the RUNX1 transcription factor is mediated by an
RT   allosteric transition in the RUNT domain and by DNA bending.";
RL   Structure 10:1395-1407(2002).
RN   [43]
RP   STRUCTURE BY NMR OF 53-178, AND MUTAGENESIS OF ALA-107 AND GLY-108.
RX   PubMed=10404214; DOI=10.1038/10658;
RA   Nagata T., Gupta V., Sorce D., Kim W.-Y., Sali A., Chait B.T.,
RA   Shigesada K., Ito Y., Werner M.H.;
RT   "Immunoglobulin motif DNA recognition and heterodimerization of the
RT   PEBP2/CBF Runt domain.";
RL   Nat. Struct. Biol. 6:615-619(1999).
RN   [44]
RP   STRUCTURE BY NMR OF 61-175 IN COMPLEX WITH DNA.
RX   PubMed=10545320; DOI=10.1016/s0969-2126(00)80058-1;
RA   Berardi M.J., Sun C., Zehr M., Abildgaard F., Peng J., Speck N.A.,
RA   Bushweller J.H.;
RT   "The Ig fold of the core binding factor alpha Runt domain is a member of a
RT   family of structurally and functionally related Ig-fold DNA-binding
RT   domains.";
RL   Structure 7:1247-1256(1999).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 46-185, AND CHLORIDE-BINDING.
RX   PubMed=12217689; DOI=10.1016/s0022-2836(02)00702-7;
RA   Baeckstroem S., Wolf-Watz M., Grundstroem C., Haerd T., Grundstroem T.,
RA   Sauer U.H.;
RT   "The RUNX1 Runt domain at 1.25A resolution: a structural switch and
RT   specifically bound chloride ions modulate DNA binding.";
RL   J. Mol. Biol. 322:259-272(2002).
RN   [46]
RP   REVIEW ON AML1 TRANSLOCATIONS.
RX   PubMed=7795214;
RA   Nucifora G., Rowley J.D.;
RT   "AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid
RT   leukemia.";
RL   Blood 86:1-14(1995).
RN   [47]
RP   CHROMOSOMAL TRANSLOCATION WITH MTG8/ETO IN AML-M2.
RX   PubMed=1423235; DOI=10.1016/0165-4608(92)90384-k;
RA   Nisson P.E., Watkins P.C., Sacchi N.;
RT   "Transcriptionally active chimeric gene derived from the fusion of the AML1
RT   gene and a novel gene on chromosome 8 in t(8;21) leukemic cells.";
RL   Cancer Genet. Cytogenet. 63:81-88(1992).
RN   [48]
RP   CHROMOSOMAL TRANSLOCATION WITH MTG8/ETO IN AML-M2.
RX   PubMed=8353289;
RA   Kozu T., Miyoshi H., Shimizu K., Maseki N., Kaneko Y., Asou H., Kamada N.,
RA   Ohki M.;
RT   "Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute
RT   myeloid leukemia detected by reverse transcription polymerase chain
RT   reaction.";
RL   Blood 82:1270-1276(1993).
RN   [49]
RP   CHROMOSOMAL TRANSLOCATION WITH MTG8/ETO IN AML-M2.
RX   PubMed=8334990; DOI=10.1002/j.1460-2075.1993.tb05933.x;
RA   Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y.,
RA   Kamada N., Ohki M.;
RT   "The t(8;21) translocation in acute myeloid leukemia results in production
RT   of an AML1-MTG8 fusion transcript.";
RL   EMBO J. 12:2715-2721(1993).
RN   [50]
RP   CHROMOSOMAL TRANSLOCATION WITH EAP IN MYELODYSPLASIA.
RC   TISSUE=Peripheral blood;
RX   PubMed=8395054; DOI=10.1073/pnas.90.16.7784;
RA   Nucifora G., Begy C.R., Erickson P., Drabkin H.A., Rowley J.D.;
RT   "The 3;21 translocation in myelodysplasia results in a fusion transcript
RT   between the AML1 gene and the gene for EAP, a highly conserved protein
RT   associated with the Epstein-Barr virus small RNA EBER 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:7784-7788(1993).
RN   [51]
RP   CHROMOSOMAL TRANSLOCATION WITH MTG8/ETO IN AML-M2.
RX   PubMed=7919324;
RA   Tighe J.E., Calabi F.;
RT   "Alternative, out-of-frame runt/MTG8 transcripts are encoded by the
RT   derivative (8) chromosome in the t(8;21) of acute myeloid leukemia M2.";
RL   Blood 84:2115-2121(1994).
RN   [52]
RP   CHROMOSOMAL TRANSLOCATION WITH TEL IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).
RX   PubMed=7780150;
RA   Romana S.P., Mauchauffe M., le Coniat M., Chumakov I., le Paslier D.,
RA   Berger R., Bernard O.A.;
RT   "The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene
RT   fusion.";
RL   Blood 85:3662-3670(1995).
RN   [53]
RP   CHROMOSOMAL TRANSLOCATION WITH MTG8/ETO IN AML-M2.
RX   PubMed=7541640; DOI=10.1002/gcc.2870130105;
RA   Era T., Asou N., Kunisada T., Yamasaki H., Asou H., Kamada N.,
RA   Nishikawa S., Yamaguchi K., Takatsuki K.;
RT   "Identification of two transcripts of AML1/ETO-fused gene in t(8;21)
RT   leukemic cells and expression of wild-type ETO gene in hematopoietic
RT   cells.";
RL   Genes Chromosomes Cancer 13:25-33(1995).
RN   [54]
RP   CHROMOSOMAL TRANSLOCATION WITH TEL IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).
RX   PubMed=7761424; DOI=10.1073/pnas.92.11.4917;
RA   Golub T.R., Barker G.F., Bohlander S.K., Hiebert S.W., Ward D.C.,
RA   Bray-Ward P., Morgan E., Raimondi S.C., Rowley J.D., Gilliland D.G.;
RT   "Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute
RT   lymphoblastic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:4917-4921(1995).
RN   [55]
RP   VARIANTS FPDMM GLN-139 AND GLN-174.
RX   PubMed=10508512; DOI=10.1038/13793;
RA   Song W.-J., Sullivan M.G., Legare R.D., Hutchings S., Tan X., Kufrin D.,
RA   Ratajczak J., Resende I.C., Haworth C., Hock R., Loh M., Felix C.,
RA   Roy D.-C., Busque L., Kurnit D., Willman C., Gewirtz A.M., Speck N.A.,
RA   Bushweller J.H., Li F.P., Gardiner K., Poncz M., Maris J.M.,
RA   Gilliland D.G.;
RT   "Haploinsufficiency of CBFA2 causes familial thrombocytopenia with
RT   propensity to develop acute myelogenous leukaemia.";
RL   Nat. Genet. 23:166-175(1999).
RN   [56]
RP   CHROMOSOMAL REARRANGEMENT.
RX   PubMed=18925961; DOI=10.1186/1471-2407-8-299;
RA   Gelsi-Boyer V., Trouplin V., Adelaide J., Aceto N., Remy V., Pinson S.,
RA   Houdayer C., Arnoulet C., Sainty D., Bentires-Alj M., Olschwang S., Vey N.,
RA   Mozziconacci M.-J., Birnbaum D., Chaffanet M.;
RT   "Genome profiling of chronic myelomonocytic leukemia: frequent alterations
RT   of RAS and RUNX1 genes.";
RL   BMC Cancer 8:299-299(2008).
RN   [57]
RP   INTERACTION WITH DPF2.
RX   PubMed=28533407; DOI=10.1073/pnas.1700328114;
RA   Huber F.M., Greenblatt S.M., Davenport A.M., Martinez C., Xu Y., Vu L.P.,
RA   Nimer S.D., Hoelz A.;
RT   "Histone-binding of DPF2 mediates its repressive role in myeloid
RT   differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:6016-6021(2017).
CC   -!- FUNCTION: Forms the heterodimeric complex core-binding factor (CBF)
CC       with CBFB. RUNX members modulate the transcription of their target
CC       genes through recognizing the core consensus binding sequence 5'-
CC       TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory
CC       regions via their runt domain, while CBFB is a non-DNA-binding
CC       regulatory subunit that allosterically enhances the sequence-specific
CC       DNA-binding capacity of RUNX. The heterodimers bind to the core site of
CC       a number of enhancers and promoters, including murine leukemia virus,
CC       polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF
CC       promoters (Probable). Essential for the development of normal
CC       hematopoiesis (PubMed:17431401). Acts synergistically with ELF4 to
CC       transactivate the IL-3 promoter and with ELF2 to transactivate the BLK
CC       promoter (PubMed:10207087, PubMed:14970218). Inhibits KAT6B-dependent
CC       transcriptional activation (By similarity). Involved in lineage
CC       commitment of immature T cell precursors. CBF complexes repress ZBTB7B
CC       transcription factor during cytotoxic (CD8+) T cell development. They
CC       bind to RUNX-binding sequence within the ZBTB7B locus acting as
CC       transcriptional silencer and allowing for cytotoxic T cell
CC       differentiation. CBF complexes binding to the transcriptional silencer
CC       is essential for recruitment of nuclear protein complexes that catalyze
CC       epigenetic modifications to establish epigenetic ZBTB7B silencing (By
CC       similarity). Controls the anergy and suppressive function of regulatory
CC       T-cells (Treg) by associating with FOXP3. Activates the expression of
CC       IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and
CC       CTLA4, in conventional T-cells (PubMed:17377532). Positively regulates
CC       the expression of RORC in T-helper 17 cells (By similarity).
CC       {ECO:0000250|UniProtKB:Q03347, ECO:0000269|PubMed:10207087,
CC       ECO:0000269|PubMed:11965546, ECO:0000269|PubMed:14970218,
CC       ECO:0000269|PubMed:17377532, ECO:0000269|PubMed:17431401, ECO:0000305}.
CC   -!- FUNCTION: Isoform AML-1G shows higher binding activities for target
CC       genes and binds TCR-beta-E2 and RAG-1 target site with threefold higher
CC       affinity than other isoforms. It is less effective in the context of
CC       neutrophil terminal differentiation. {ECO:0000250|UniProtKB:Q03347}.
CC   -!- FUNCTION: Isoform AML-1L interferes with the transactivation activity
CC       of RUNX1. {ECO:0000269|PubMed:9199349}.
CC   -!- SUBUNIT: Heterodimer with CBFB. RUNX1 binds DNA as a monomer and
CC       through the Runt domain. DNA-binding is increased by
CC       heterodimerization. Isoform AML-1L can neither bind DNA nor
CC       heterodimerize. Interacts with TLE1 and ALYREF/THOC4 (PubMed:9119228,
CC       PubMed:9751710). Interacts with ELF1, ELF2 and SPI1 (PubMed:10207087).
CC       Interacts via its Runt domain with the ELF4 N-terminal region
CC       (PubMed:10207087). Interaction with ELF2 isoform 2 (NERF-1a) may act to
CC       repress RUNX1-mediated transactivation (PubMed:14970218). Interacts
CC       with KAT6A and KAT6B (PubMed:11742995, PubMed:11965546). Interacts with
CC       SUV39H1, leading to abrogation of transactivating and DNA-binding
CC       properties of RUNX1 (PubMed:12917624, PubMed:16652147). Interacts with
CC       YAP1 (PubMed:18280240). Interacts with HIPK2 (By similarity).
CC       Interaction with CDK6 prevents myeloid differentiation, reducing its
CC       transcription transactivation activity. Found in a complex with PRMT5,
CC       RUNX1 and CBFB. Interacts with FOXP3 (PubMed:17377532). Interacts with
CC       TBX21 (By similarity). Interacts with DPF2 (PubMed:28533407).
CC       {ECO:0000250|UniProtKB:Q03347, ECO:0000269|PubMed:10207087,
CC       ECO:0000269|PubMed:10545320, ECO:0000269|PubMed:10856244,
CC       ECO:0000269|PubMed:11276260, ECO:0000269|PubMed:11742995,
CC       ECO:0000269|PubMed:11965546, ECO:0000269|PubMed:12377125,
CC       ECO:0000269|PubMed:12917624, ECO:0000269|PubMed:14970218,
CC       ECO:0000269|PubMed:16652147, ECO:0000269|PubMed:17377532,
CC       ECO:0000269|PubMed:17431401, ECO:0000269|PubMed:18280240,
CC       ECO:0000269|PubMed:28533407, ECO:0000269|PubMed:9119228,
CC       ECO:0000269|PubMed:9751710}.
CC   -!- INTERACTION:
CC       Q01196-8; O95817: BAG3; NbExp=3; IntAct=EBI-12001422, EBI-747185;
CC       Q01196-8; O95429: BAG4; NbExp=3; IntAct=EBI-12001422, EBI-2949658;
CC       Q01196; Q13951: CBFB; NbExp=3; IntAct=EBI-925904, EBI-718750;
CC       Q01196-8; Q13951: CBFB; NbExp=3; IntAct=EBI-12001422, EBI-718750;
CC       Q01196-8; O75909-2: CCNK; NbExp=3; IntAct=EBI-12001422, EBI-12010594;
CC       Q01196; Q00534: CDK6; NbExp=5; IntAct=EBI-925904, EBI-295663;
CC       Q01196; Q15723: ELF2; NbExp=2; IntAct=EBI-925904, EBI-956941;
CC       Q01196-8; Q8WU58: FAM222B; NbExp=3; IntAct=EBI-12001422, EBI-2807642;
CC       Q01196-8; Q96EF6: FBXO17; NbExp=3; IntAct=EBI-12001422, EBI-2510157;
CC       Q01196-8; Q96CN9: GCC1; NbExp=3; IntAct=EBI-12001422, EBI-746252;
CC       Q01196-1; P16371: gro; Xeno; NbExp=4; IntAct=EBI-925940, EBI-153866;
CC       Q01196-8; O14964: HGS; NbExp=3; IntAct=EBI-12001422, EBI-740220;
CC       Q01196; Q9H2X6: HIPK2; NbExp=4; IntAct=EBI-925904, EBI-348345;
CC       Q01196-8; Q8NI38: NFKBID; NbExp=3; IntAct=EBI-12001422, EBI-10271199;
CC       Q01196-8; Q7RTU3: OLIG3; NbExp=3; IntAct=EBI-12001422, EBI-10225049;
CC       Q01196-8; P09234: SNRPC; NbExp=3; IntAct=EBI-12001422, EBI-766589;
CC       Q01196; P17542: TAL1; NbExp=3; IntAct=EBI-925904, EBI-1753878;
CC       Q01196-8; Q15562-2: TEAD2; NbExp=3; IntAct=EBI-12001422, EBI-9370956;
CC       Q01196-8; Q15561: TEAD4; NbExp=5; IntAct=EBI-12001422, EBI-747736;
CC       Q01196-8; Q96M29: TEKT5; NbExp=3; IntAct=EBI-12001422, EBI-10239812;
CC       Q01196-1; Q04724: TLE1; NbExp=4; IntAct=EBI-925940, EBI-711424;
CC       Q01196-2; Q04724: TLE1; NbExp=3; IntAct=EBI-925944, EBI-711424;
CC       Q01196-8; A5D8V6: VPS37C; NbExp=3; IntAct=EBI-12001422, EBI-2559305;
CC       Q01196; P46937: YAP1; NbExp=3; IntAct=EBI-925904, EBI-1044059;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=AML-1B;
CC         IsoId=Q01196-1; Sequence=Displayed;
CC       Name=AML-1A;
CC         IsoId=Q01196-2; Sequence=VSP_005929;
CC       Name=AML-1C;
CC         IsoId=Q01196-3; Sequence=VSP_005926, VSP_005927;
CC       Name=AML-1E;
CC         IsoId=Q01196-4; Sequence=VSP_005928;
CC       Name=AML-1FA;
CC         IsoId=Q01196-5; Sequence=VSP_005923, VSP_005924;
CC       Name=AML-1FB;
CC         IsoId=Q01196-6; Sequence=VSP_005921, VSP_005922;
CC       Name=AML-1FC;
CC         IsoId=Q01196-7; Sequence=VSP_005920, VSP_005925;
CC       Name=AML-1G;
CC         IsoId=Q01196-8; Sequence=VSP_005917;
CC       Name=AML-1H;
CC         IsoId=Q01196-9; Sequence=VSP_005916;
CC       Name=AML-1I;
CC         IsoId=Q01196-10; Sequence=VSP_005918;
CC       Name=AML-1L; Synonyms=AML1-delta N;
CC         IsoId=Q01196-11; Sequence=VSP_005919;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined except brain and
CC       heart. Highest levels in thymus, bone marrow and peripheral blood.
CC   -!- INDUCTION: Up-regulated by phorbol myristate acetate (PMA).
CC       {ECO:0000269|PubMed:25134913}.
CC   -!- DOMAIN: A proline/serine/threonine rich region at the C-terminus is
CC       necessary for transcriptional activation of target genes.
CC   -!- PTM: Phosphorylated in its C-terminus upon IL-6 treatment.
CC       Phosphorylation enhances interaction with KAT6A.
CC   -!- PTM: Methylated. {ECO:0000269|PubMed:12917624}.
CC   -!- PTM: Phosphorylated in Ser-249 Thr-273 and Ser-276 by HIPK2 when
CC       associated with CBFB and DNA. This phosphorylation promotes subsequent
CC       EP300 phosphorylation. {ECO:0000269|PubMed:18695000}.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause
CC       of M2 type acute myeloid leukemia (AML-M2). Translocation
CC       t(8;21)(q22;q22) with RUNX1T1.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause
CC       of therapy-related myelodysplastic syndrome (T-MDS). Translocation
CC       t(3;21)(q26;q22) with EAP or MECOM.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause
CC       of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22)
CC       with EAP or MECOM.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in
CC       childhood acute lymphoblastic leukemia (ALL). Translocation
CC       t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL
CC       to the alternate 5'-exon of AML-1H.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1 is found in
CC       acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-
CC       RUNX1 fusion protein.
CC   -!- DISEASE: Familial platelet disorder with associated myeloid malignancy
CC       (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by
CC       qualitative and quantitative platelet defects, and propensity to
CC       develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in
CC       therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22)
CC       that forms a RUNX1-CBFA2T3 fusion protein.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause
CC       of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with
CC       USP16.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in
CC       acute myeloid leukemia. Translocation t(20;21)(q11;q22) with CBFA2T2.
CC       {ECO:0000269|PubMed:20520637}.
CC   -!- CAUTION: The fusion of AML1 with EAP in T-MDS induces a change of
CC       reading frame in the latter resulting in 17 AA unrelated to those of
CC       EAP. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC05246.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAC05247.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AML1ID52.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L34598; AAA51720.1; -; mRNA.
DR   EMBL; D43967; BAA07902.1; -; mRNA.
DR   EMBL; D10570; BAA01426.1; -; mRNA.
DR   EMBL; S76345; AAB33729.1; -; mRNA.
DR   EMBL; S76346; AAB33730.1; -; mRNA.
DR   EMBL; S76350; AAB33731.1; -; mRNA.
DR   EMBL; S60998; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X79549; CAA56092.1; -; mRNA.
DR   EMBL; D43968; BAA07903.1; -; mRNA.
DR   EMBL; D43969; BAA07904.1; -; mRNA.
DR   EMBL; U19601; AAB51691.1; -; mRNA.
DR   EMBL; L21756; AAA03086.1; ALT_TERM; mRNA.
DR   EMBL; S69002; AAB29907.1; ALT_TERM; mRNA.
DR   EMBL; D13979; BAA03089.1; -; mRNA.
DR   EMBL; D14822; BAA03559.1; ALT_TERM; mRNA.
DR   EMBL; D14823; BAA03560.1; ALT_TERM; mRNA.
DR   EMBL; S78158; AAB34819.2; ALT_TERM; mRNA.
DR   EMBL; S78159; AAB34820.2; ALT_TERM; mRNA.
DR   EMBL; S50186; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S78496; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S74092; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X90979; CAA62466.1; -; mRNA.
DR   EMBL; X90976; CAA62464.1; -; mRNA.
DR   EMBL; D89790; BAA14022.1; -; mRNA.
DR   EMBL; D89788; BAA14020.1; -; mRNA.
DR   EMBL; D89789; BAA14021.1; -; mRNA.
DR   EMBL; AP000330; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000331; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000332; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000333; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000334; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF015262; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471079; EAX09769.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09770.1; -; Genomic_DNA.
DR   EMBL; BC136380; AAI36381.1; -; mRNA.
DR   EMBL; BC136381; AAI36382.1; -; mRNA.
DR   EMBL; BC144053; AAI44054.1; -; mRNA.
DR   EMBL; AF025841; AAC05246.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF025841; AAC05247.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AJ229043; CAA13070.1; -; Genomic_DNA.
DR   CCDS; CCDS13639.1; -. [Q01196-8]
DR   CCDS; CCDS42922.1; -. [Q01196-1]
DR   CCDS; CCDS46646.1; -. [Q01196-3]
DR   PIR; I39443; I39443.
DR   PIR; S57842; S57842.
DR   RefSeq; NP_001001890.1; NM_001001890.2. [Q01196-1]
DR   RefSeq; NP_001116079.1; NM_001122607.1. [Q01196-3]
DR   RefSeq; NP_001745.2; NM_001754.4. [Q01196-8]
DR   RefSeq; XP_005261125.1; XM_005261068.3. [Q01196-10]
DR   RefSeq; XP_011528068.1; XM_011529766.2. [Q01196-8]
DR   PDB; 1CMO; NMR; -; A=52-178.
DR   PDB; 1CO1; NMR; -; A=61-175.
DR   PDB; 1E50; X-ray; 2.60 A; A/C/E/G/Q/R=50-183.
DR   PDB; 1H9D; X-ray; 2.60 A; A/C=50-183.
DR   PDB; 1LJM; X-ray; 2.50 A; A/B=51-181.
DR   PDBsum; 1CMO; -.
DR   PDBsum; 1CO1; -.
DR   PDBsum; 1E50; -.
DR   PDBsum; 1H9D; -.
DR   PDBsum; 1LJM; -.
DR   SMR; Q01196; -.
DR   BioGrid; 107309; 218.
DR   CORUM; Q01196; -.
DR   DIP; DIP-36773N; -.
DR   ELM; Q01196; -.
DR   IntAct; Q01196; 36.
DR   MINT; Q01196; -.
DR   STRING; 9606.ENSP00000300305; -.
DR   iPTMnet; Q01196; -.
DR   MetOSite; Q01196; -.
DR   PhosphoSitePlus; Q01196; -.
DR   BioMuta; RUNX1; -.
DR   DMDM; 215274205; -.
DR   EPD; Q01196; -.
DR   jPOST; Q01196; -.
DR   MassIVE; Q01196; -.
DR   MaxQB; Q01196; -.
DR   PaxDb; Q01196; -.
DR   PeptideAtlas; Q01196; -.
DR   PRIDE; Q01196; -.
DR   ProteomicsDB; 57927; -. [Q01196-1]
DR   ProteomicsDB; 57928; -. [Q01196-10]
DR   ProteomicsDB; 57929; -. [Q01196-11]
DR   ProteomicsDB; 57930; -. [Q01196-2]
DR   ProteomicsDB; 57931; -. [Q01196-3]
DR   ProteomicsDB; 57932; -. [Q01196-4]
DR   ProteomicsDB; 57933; -. [Q01196-5]
DR   ProteomicsDB; 57934; -. [Q01196-6]
DR   ProteomicsDB; 57935; -. [Q01196-7]
DR   ProteomicsDB; 57936; -. [Q01196-8]
DR   ProteomicsDB; 57937; -. [Q01196-9]
DR   Antibodypedia; 935; 1037 antibodies.
DR   Ensembl; ENST00000300305; ENSP00000300305; ENSG00000159216. [Q01196-8]
DR   Ensembl; ENST00000344691; ENSP00000340690; ENSG00000159216. [Q01196-1]
DR   Ensembl; ENST00000358356; ENSP00000351123; ENSG00000159216. [Q01196-3]
DR   Ensembl; ENST00000437180; ENSP00000409227; ENSG00000159216. [Q01196-8]
DR   GeneID; 861; -.
DR   KEGG; hsa:861; -.
DR   UCSC; uc002yuh.3; human. [Q01196-1]
DR   CTD; 861; -.
DR   DisGeNET; 861; -.
DR   GeneCards; RUNX1; -.
DR   HGNC; HGNC:10471; RUNX1.
DR   HPA; ENSG00000159216; Tissue enhanced (breast, lymphoid tissue).
DR   MalaCards; RUNX1; -.
DR   MIM; 151385; gene.
DR   MIM; 601399; phenotype.
DR   neXtProt; NX_Q01196; -.
DR   OpenTargets; ENSG00000159216; -.
DR   Orphanet; 102724; Acute myeloid leukemia with t(8;21)(q22;q22) translocation.
DR   Orphanet; 521; Chronic myeloid leukemia.
DR   Orphanet; 71290; Familial platelet disorder with associated myeloid malignancy.
DR   Orphanet; 248340; Isolated delta-storage pool disease.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA34884; -.
DR   eggNOG; KOG3982; Eukaryota.
DR   eggNOG; ENOG4111J4Y; LUCA.
DR   GeneTree; ENSGT00940000159255; -.
DR   HOGENOM; CLU_032910_1_0_1; -.
DR   InParanoid; Q01196; -.
DR   KO; K08367; -.
DR   OMA; PRVNHST; -.
DR   OrthoDB; 562214at2759; -.
DR   PhylomeDB; Q01196; -.
DR   TreeFam; TF321496; -.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-549127; Organic cation transport.
DR   Reactome; R-HSA-8877330; RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs).
DR   Reactome; R-HSA-8931987; RUNX1 regulates estrogen receptor mediated transcription.
DR   Reactome; R-HSA-8934593; Regulation of RUNX1 Expression and Activity.
DR   Reactome; R-HSA-8935964; RUNX1 regulates expression of components of tight junctions.
DR   Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function.
DR   Reactome; R-HSA-8939236; RUNX1 regulates transcription of genes involved in differentiation of HSCs.
DR   Reactome; R-HSA-8939242; RUNX1 regulates transcription of genes involved in differentiation of keratinocytes.
DR   Reactome; R-HSA-8939243; RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known.
DR   Reactome; R-HSA-8939245; RUNX1 regulates transcription of genes involved in BCR signaling.
DR   Reactome; R-HSA-8939246; RUNX1 regulates transcription of genes involved in differentiation of myeloid cells.
DR   Reactome; R-HSA-8939247; RUNX1 regulates transcription of genes involved in interleukin signaling.
DR   Reactome; R-HSA-8939256; RUNX1 regulates transcription of genes involved in WNT signaling.
DR   Reactome; R-HSA-8941333; RUNX2 regulates genes involved in differentiation of myeloid cells.
DR   Reactome; R-HSA-8951936; RUNX3 regulates p14-ARF.
DR   Reactome; R-HSA-9018519; Estrogen-dependent gene expression.
DR   Reactome; R-HSA-9616222; Transcriptional regulation of granulopoiesis.
DR   SignaLink; Q01196; -.
DR   SIGNOR; Q01196; -.
DR   ChiTaRS; RUNX1; human.
DR   EvolutionaryTrace; Q01196; -.
DR   GeneWiki; RUNX1; -.
DR   GenomeRNAi; 861; -.
DR   Pharos; Q01196; Tbio.
DR   PRO; PR:Q01196; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   RNAct; Q01196; protein.
DR   Bgee; ENSG00000159216; Expressed in epithelium of mammary gland and 193 other tissues.
DR   ExpressionAtlas; Q01196; baseline and differential.
DR   Genevisible; Q01196; HS.
DR   GO; GO:0016513; C:core-binding factor complex; TAS:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:InterPro.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0008134; F:transcription factor binding; IDA:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0002062; P:chondrocyte differentiation; IBA:GO_Central.
DR   GO; GO:0071425; P:hematopoietic stem cell proliferation; TAS:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; IDA:UniProtKB.
DR   GO; GO:0030099; P:myeloid cell differentiation; IDA:UniProtKB.
DR   GO; GO:0043371; P:negative regulation of CD4-positive, alpha-beta T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; TAS:Reactome.
DR   GO; GO:0030853; P:negative regulation of granulocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0030182; P:neuron differentiation; IBA:GO_Central.
DR   GO; GO:0001503; P:ossification; IBA:GO_Central.
DR   GO; GO:0048935; P:peripheral nervous system neuron development; TAS:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0043378; P:positive regulation of CD8-positive, alpha-beta T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030854; P:positive regulation of granulocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0050855; P:regulation of B cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:2000810; P:regulation of bicellular tight junction assembly; TAS:Reactome.
DR   GO; GO:0045595; P:regulation of cell differentiation; IBA:GO_Central.
DR   GO; GO:0001959; P:regulation of cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; TAS:Reactome.
DR   GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0045616; P:regulation of keratinocyte differentiation; TAS:Reactome.
DR   GO; GO:0045652; P:regulation of megakaryocyte differentiation; TAS:Reactome.
DR   GO; GO:0045637; P:regulation of myeloid cell differentiation; TAS:Reactome.
DR   GO; GO:0045589; P:regulation of regulatory T cell differentiation; TAS:Reactome.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0030111; P:regulation of Wnt signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.770.10; -; 1.
DR   InterPro; IPR000040; AML1_Runt.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR013524; Runt_dom.
DR   InterPro; IPR027384; Runx_central_dom_sf.
DR   InterPro; IPR013711; RunxI_C_dom.
DR   InterPro; IPR016554; TF_Runt-rel_RUNX.
DR   PANTHER; PTHR11950; PTHR11950; 1.
DR   Pfam; PF00853; Runt; 1.
DR   Pfam; PF08504; RunxI; 1.
DR   PIRSF; PIRSF009374; TF_Runt-rel_RUNX; 1.
DR   PRINTS; PR00967; ONCOGENEAML1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS51062; RUNT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Chloride;
KW   Chromosomal rearrangement; Disease mutation; DNA-binding; Methylation;
KW   Nucleus; Phosphoprotein; Polymorphism; Proto-oncogene; Reference proteome;
KW   Repressor; Transcription; Transcription regulation.
FT   CHAIN           1..453
FT                   /note="Runt-related transcription factor 1"
FT                   /id="PRO_0000174655"
FT   DOMAIN          50..178
FT                   /note="Runt"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00399"
FT   REGION          80..84
FT                   /note="Interaction with DNA"
FT   REGION          135..143
FT                   /note="Interaction with DNA"
FT   REGION          168..177
FT                   /note="Interaction with DNA"
FT   REGION          291..371
FT                   /note="Interaction with KAT6A"
FT                   /evidence="ECO:0000269|PubMed:11742995"
FT   REGION          307..400
FT                   /note="Interaction with KAT6B"
FT                   /evidence="ECO:0000250"
FT   REGION          362..402
FT                   /note="Interaction with FOXP3"
FT                   /evidence="ECO:0000269|PubMed:17377532"
FT   COMPBIAS        187..453
FT                   /note="Pro/Ser/Thr-rich"
FT   BINDING         112
FT                   /note="Chloride 1"
FT   BINDING         116
FT                   /note="Chloride 1; via amide nitrogen"
FT   BINDING         139
FT                   /note="Chloride 2"
FT   BINDING         170
FT                   /note="Chloride 2; via amide nitrogen"
FT   SITE            177..178
FT                   /note="Breakpoint for translocation to form AML1-EMV-1 (or
FT                   AML1-EAP) in CML and T-MDS, to form AML1-MTG8 (ETO) in AML-
FT                   M2, to form AML1-CBFA2T3 in therapy-related myeloid
FT                   malignancies, to form AML1-MECOM in CML and to form type I
FT                   MACROD1-RUNX1 fusion protein"
FT   SITE            241..242
FT                   /note="Breakpoint for translocation to form AML1-EAP in T-
FT                   MDS and CML, to form type II MACROD1-RUNX1 fusion protein
FT                   and to form RUNX1-CBFA2T2 in acute myeloid leukemia"
FT                   /evidence="ECO:0000269|PubMed:20520637"
FT   MOD_RES         14
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:23186163"
FT   MOD_RES         21
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         24
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         43
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         193
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         212
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163,
FT                   ECO:0000244|PubMed:24275569"
FT   MOD_RES         249
FT                   /note="Phosphoserine; by HIPK2"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000269|PubMed:18695000"
FT   MOD_RES         266
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         268
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         273
FT                   /note="Phosphothreonine; by HIPK2"
FT                   /evidence="ECO:0000269|PubMed:18695000"
FT   MOD_RES         276
FT                   /note="Phosphoserine; by HIPK2"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000269|PubMed:18695000"
FT   MOD_RES         296
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         435
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   VAR_SEQ         1..105
FT                   /note="Missing (in isoform AML-1L)"
FT                   /evidence="ECO:0000303|PubMed:7651838,
FT                   ECO:0000303|PubMed:9199349"
FT                   /id="VSP_005919"
FT   VAR_SEQ         1..5
FT                   /note="MRIPV -> MASDSIFESFPSYPQCFMRECILGMNPSRDVH (in
FT                   isoform AML-1G)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7651838, ECO:0000303|PubMed:7891692"
FT                   /id="VSP_005917"
FT   VAR_SEQ         1..5
FT                   /note="MRIPV -> MNPSRDVH (in isoform AML-1H)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005916"
FT   VAR_SEQ         1..5
FT                   /note="MRIPV -> MPAAPRGPAQGEAAARTRSR (in isoform AML-1I)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005918"
FT   VAR_SEQ         137..242
FT                   /note="VGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTK
FT                   PGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQD -> V
FT                   DGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHS
FT                   TAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPI (in isoform
FT                   AML-1FC)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005920"
FT   VAR_SEQ         178..224
FT                   /note="RHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRA -> S
FT                   KCIHLGLVHPPGWYTLQAGILRDHVSDSLGSTFPPGGWQAPVKPKS (in isoform
FT                   AML-1FA)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005923"
FT   VAR_SEQ         178..188
FT                   /note="RHRQKLDDQTK -> NSLTWPRYPHI (in isoform AML-1FB)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005921"
FT   VAR_SEQ         189..453
FT                   /note="Missing (in isoform AML-1FB)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005922"
FT   VAR_SEQ         225..453
FT                   /note="Missing (in isoform AML-1FA)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005924"
FT   VAR_SEQ         242..250
FT                   /note="DTRQIQPSP -> EEDTAPWRC (in isoform AML-1C)"
FT                   /evidence="ECO:0000303|PubMed:1720541"
FT                   /id="VSP_005926"
FT   VAR_SEQ         243..453
FT                   /note="Missing (in isoform AML-1FC)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005925"
FT   VAR_SEQ         251..453
FT                   /note="Missing (in isoform AML-1C)"
FT                   /evidence="ECO:0000303|PubMed:1720541"
FT                   /id="VSP_005927"
FT   VAR_SEQ         258..453
FT                   /note="Missing (in isoform AML-1E)"
FT                   /evidence="ECO:0000303|PubMed:8490181"
FT                   /id="VSP_005928"
FT   VAR_SEQ         440..453
FT                   /note="APSARLEEAVWRPY -> GGASCSRQARRDPGPWARTPSWGRGRPTDRISL
FT                   (in isoform AML-1A)"
FT                   /evidence="ECO:0000303|PubMed:7651838,
FT                   ECO:0000303|PubMed:7835892"
FT                   /id="VSP_005929"
FT   VARIANT         139
FT                   /note="R -> Q (in FPDMM; dbSNP:rs1060499616)"
FT                   /evidence="ECO:0000269|PubMed:10508512"
FT                   /id="VAR_012128"
FT   VARIANT         174
FT                   /note="R -> Q (in FPDMM; impaired phosphorylation;
FT                   dbSNP:rs74315450)"
FT                   /evidence="ECO:0000269|PubMed:10508512,
FT                   ECO:0000269|PubMed:18695000"
FT                   /id="VAR_012129"
FT   VARIANT         431
FT                   /note="S -> R (in dbSNP:rs1055308)"
FT                   /id="VAR_013177"
FT   VARIANT         433
FT                   /note="S -> R (in dbSNP:rs1055309)"
FT                   /id="VAR_013178"
FT   MUTAGEN         67
FT                   /note="S->R: Loss of heterodimerization and reduced EP300
FT                   phosphorylation induction."
FT                   /evidence="ECO:0000269|PubMed:18695000"
FT   MUTAGEN         80
FT                   /note="R->A: Strongly reduces DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:11276260"
FT   MUTAGEN         83
FT                   /note="K->A: Strongly reduces DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:11276260,
FT                   ECO:0000269|PubMed:18695000"
FT   MUTAGEN         83
FT                   /note="K->E: Strongly reduces DNA-binding, impaired
FT                   phosphorylation and reduced EP300 phosphorylation
FT                   induction."
FT                   /evidence="ECO:0000269|PubMed:11276260,
FT                   ECO:0000269|PubMed:18695000"
FT   MUTAGEN         84
FT                   /note="T->A: No effect on DNA binding."
FT                   /evidence="ECO:0000269|PubMed:11276260"
FT   MUTAGEN         106
FT                   /note="M->V: Disrupts interaction of AML1-MTG8/ETO with
FT                   CBFB, no effect on AML1-MTG8/ETO-mediated transformation
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19202074"
FT   MUTAGEN         107
FT                   /note="A->T: Loss of heterodimerization. Disrupts
FT                   interactionof AML1-MTG8/ETO with CBFB, no effect on AML1-
FT                   MTG8/ETO-mediated transformation activity."
FT                   /evidence="ECO:0000269|PubMed:10404214,
FT                   ECO:0000269|PubMed:19202074"
FT   MUTAGEN         108
FT                   /note="G->R: Loss of heterodimerization and impaired
FT                   phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:10404214,
FT                   ECO:0000269|PubMed:18695000"
FT   MUTAGEN         135
FT                   /note="R->A: Strongly reduces DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:11276260"
FT   MUTAGEN         139
FT                   /note="R->A: Strongly reduces DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:11276260"
FT   MUTAGEN         140
FT                   /note="S->G: Disrupts AML1-MTG8/ETO DNA-binding, decreases
FT                   AML1-MTG8/ETO transforming activity."
FT                   /evidence="ECO:0000269|PubMed:19202074"
FT   MUTAGEN         142
FT                   /note="R->A: Strongly reduces DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:11276260"
FT   MUTAGEN         145..453
FT                   /note="Missing: No DNA-binding."
FT   MUTAGEN         167
FT                   /note="K->A: Reduces DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:11276260"
FT   MUTAGEN         169
FT                   /note="T->A: Strongly reduces DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:11276260"
FT   MUTAGEN         171
FT                   /note="D->A: Strongly reduces DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:11276260"
FT   MUTAGEN         174
FT                   /note="R->A: Strongly reduces DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:11276260"
FT   MUTAGEN         177
FT                   /note="R->A: Strongly reduces DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:11276260"
FT   MUTAGEN         249
FT                   /note="S->A: Reduced phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:18695000"
FT   MUTAGEN         273
FT                   /note="T->A: Reduced phosphorylation; when associated with
FT                   A-276."
FT                   /evidence="ECO:0000269|PubMed:18695000"
FT   MUTAGEN         276
FT                   /note="S->A: Reduced phosphorylation; when associated with
FT                   A-273."
FT                   /evidence="ECO:0000269|PubMed:18695000"
FT   CONFLICT        412
FT                   /note="S -> F (in Ref. 1; AAA51720)"
FT                   /evidence="ECO:0000305"
FT   HELIX           54..57
FT                   /evidence="ECO:0000244|PDB:1CMO"
FT   STRAND          62..64
FT                   /evidence="ECO:0000244|PDB:1LJM"
FT   STRAND          70..73
FT                   /evidence="ECO:0000244|PDB:1LJM"
FT   STRAND          77..80
FT                   /evidence="ECO:0000244|PDB:1LJM"
FT   STRAND          82..84
FT                   /evidence="ECO:0000244|PDB:1CMO"
FT   STRAND          90..93
FT                   /evidence="ECO:0000244|PDB:1LJM"
FT   STRAND          102..108
FT                   /evidence="ECO:0000244|PDB:1LJM"
FT   STRAND          110..114
FT                   /evidence="ECO:0000244|PDB:1H9D"
FT   STRAND          117..119
FT                   /evidence="ECO:0000244|PDB:1LJM"
FT   STRAND          121..123
FT                   /evidence="ECO:0000244|PDB:1LJM"
FT   STRAND          128..130
FT                   /evidence="ECO:0000244|PDB:1LJM"
FT   STRAND          146..152
FT                   /evidence="ECO:0000244|PDB:1LJM"
FT   STRAND          154..156
FT                   /evidence="ECO:0000244|PDB:1E50"
FT   STRAND          158..161
FT                   /evidence="ECO:0000244|PDB:1LJM"
FT   STRAND          166..171
FT                   /evidence="ECO:0000244|PDB:1LJM"
FT   HELIX           175..177
FT                   /evidence="ECO:0000244|PDB:1CMO"
SQ   SEQUENCE   453 AA;  48737 MW;  4F1F193A7CADDBAB CRC64;
     MRIPVDASTS RRFTPPSTAL SPGKMSEALP LGAPDAGAAL AGKLRSGDRS MVEVLADHPG
     ELVRTDSPNF LCSVLPTHWR CNKTLPIAFK VVALGDVPDG TLVTVMAGND ENYSAELRNA
     TAAMKNQVAR FNDLRFVGRS GRGKSFTLTI TVFTNPPQVA TYHRAIKITV DGPREPRRHR
     QKLDDQTKPG SLSFSERLSE LEQLRRTAMR VSPHHPAPTP NPRASLNHST AFNPQPQSQM
     QDTRQIQPSP PWSYDQSYQY LGSIASPSVH PATPISPGRA SGMTTLSAEL SSRLSTAPDL
     TAFSDPRQFP ALPSISDPRM HYPGAFTYSP TPVTSGIGIG MSAMGSATRY HTYLPPPYPG
     SSQAQGGPFQ ASSPSYHLYY GASAGSYQFS MVGGERSPPR ILPPCTNAST GSALLNPSLP
     NQSDVVEAEG SHSNSPTNMA PSARLEEAVW RPY
//
ID   A0A087WWT6_HUMAN        Unreviewed;       584 AA.
AC   A0A087WWT6;
DT   29-OCT-2014, integrated into UniProtKB/TrEMBL.
DT   29-OCT-2014, sequence version 1.
DT   22-APR-2020, entry version 54.
DE   SubName: Full=Protein CBFA2T1 {ECO:0000313|Ensembl:ENSP00000480500};
DE   SubName: Full=Runt-related transcription factor 1 translocated to, 1 (Cyclin D-related), isoform CRA_c {ECO:0000313|EMBL:EAW91683.1};
GN   Name=RUNX1T1 {ECO:0000313|EMBL:EAW91683.1,
GN   ECO:0000313|Ensembl:ENSP00000480500};
GN   ORFNames=hCG_20715 {ECO:0000313|EMBL:EAW91683.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000480500, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|EMBL:EAW91683.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW91683.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|Ensembl:ENSP00000480500, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Glockner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [4] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [5] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [6] {ECO:0000313|Ensembl:ENSP00000480500}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (SEP-2014) to UniProtKB.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC103680; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104339; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF181450; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458797; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471060; EAW91683.1; -; Genomic_DNA.
DR   RefSeq; NP_001185562.1; NM_001198633.1.
DR   Antibodypedia; 25672; 263 antibodies.
DR   Ensembl; ENST00000615601; ENSP00000480500; ENSG00000079102.
DR   GeneID; 862; -.
DR   UCSC; uc022axu.1; human.
DR   CTD; 862; -.
DR   EuPathDB; HostDB:ENSG00000079102.16; -.
DR   HGNC; HGNC:1535; RUNX1T1.
DR   OpenTargets; ENSG00000079102; -.
DR   eggNOG; ENOG410IG1Z; Eukaryota.
DR   eggNOG; ENOG410XR30; LUCA.
DR   GeneTree; ENSGT00950000183176; -.
DR   ChiTaRS; RUNX1T1; human.
DR   GenomeRNAi; 862; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000079102; Expressed in forebrain and 227 other tissues.
DR   ExpressionAtlas; A0A087WWT6; baseline and differential.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:InterPro.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:InterPro.
DR   Gene3D; 1.20.120.1110; -; 1.
DR   InterPro; IPR013290; CBFA2T1.
DR   InterPro; IPR013289; CBFA2T1/2/3.
DR   InterPro; IPR014896; NHR2.
DR   InterPro; IPR037249; TAFH/NHR1_dom_sf.
DR   InterPro; IPR003894; TAFH_NHR1.
DR   InterPro; IPR002893; Znf_MYND.
DR   PANTHER; PTHR10379; PTHR10379; 1.
DR   PANTHER; PTHR10379:SF5; PTHR10379:SF5; 1.
DR   Pfam; PF08788; NHR2; 1.
DR   Pfam; PF07531; TAFH; 1.
DR   Pfam; PF01753; zf-MYND; 1.
DR   PRINTS; PR01875; ETOFAMILY.
DR   PRINTS; PR01876; MTG8PROTEIN.
DR   SMART; SM00549; TAFH; 1.
DR   SUPFAM; SSF158553; SSF158553; 1.
DR   PROSITE; PS51119; TAFH; 1.
DR   PROSITE; PS01360; ZF_MYND_1; 1.
DR   PROSITE; PS50865; ZF_MYND_2; 1.
PE   1: Evidence at protein level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00299494};
KW   Proteomics identification {ECO:0000213|PeptideAtlas:A0A087WWT6,
KW   ECO:0000213|ProteomicsDB:A0A087WWT6};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00134, ECO:0000256|SAAS:SAAS00299494};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00299494}.
FT   DOMAIN          100..195
FT                   /note="TAFH"
FT                   /evidence="ECO:0000259|PROSITE:PS51119"
FT   DOMAIN          495..531
FT                   /note="MYND-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50865"
FT   REGION          1..94
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          210..278
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          381..403
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          537..584
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          434..476
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        10..31
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        45..94
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        215..243
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        250..267
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   584 AA;  65085 MW;  581085B1DF3AB0BA CRC64;
     MVGLSGPVQY RTEKHSTMPD SPVDVKTQSR LTPPTMPPPP TTQGAPRTSS FTPTTLTNGT
     SHSPTALNGA PSPPNGFSNG PSSSSSSSLA NQQLPPACGA RQLSKLKRFL TTLQQFGNDI
     SPEIGERVRT LVLGLVNSTL TIEEFHSKLQ EATNFPLRPF VIPFLKANLP LLQRELLHCA
     RLAKQNPAQY LAQHEQLLLD ASTTSPVDSS ELLLDVNENG KRRTPDRTKE NGFDREPLHS
     EHPSKRPCTI SPGQRYSPNN GLSYQPNGLP HPTPPPPQHY RLDDMAIAHH YRDSYRHPSH
     RDLRDRNRPM GLHGTRQEEM IDHRLTDREW AEEWKHLDHL LNCIMDMVEK TRRSLTVLRR
     CQEADREELN YWIRRYSDAE DLKKGGGSSS SHSRQQSPVN PDPVALDAHR EFLHRPASGY
     VPEEIWKKAE EAVNEVKRQA MTELQKAVSE AERKAHDMIT TERAKMERTV AEAKRQAAED
     ALAVINQQED SSESCWNCGR KASETCSGCN TARYCGSFCQ HKDWEKHHHI CGQTLQAQQQ
     GDTPAVSSSV TPNSGAGSPM DTPPAATPRS TTPGTPSTIE TTPR
//
ID   A0A0A0MSU1_HUMAN        Unreviewed;       663 AA.
AC   A0A0A0MSU1;
DT   07-JAN-2015, integrated into UniProtKB/TrEMBL.
DT   07-JAN-2015, sequence version 1.
DT   22-APR-2020, entry version 48.
DE   SubName: Full=Protein CBFA2T1 {ECO:0000313|Ensembl:ENSP00000402257};
GN   Name=RUNX1T1 {ECO:0000313|Ensembl:ENSP00000402257};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000402257, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000402257, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Glockner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [2] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [3] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [4] {ECO:0000313|Ensembl:ENSP00000402257}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (NOV-2014) to UniProtKB.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC103680; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104339; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF181450; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458797; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001185608.1; NM_001198679.1.
DR   jPOST; A0A0A0MSU1; -.
DR   PRIDE; A0A0A0MSU1; -.
DR   Antibodypedia; 25672; 263 antibodies.
DR   Ensembl; ENST00000436581; ENSP00000402257; ENSG00000079102.
DR   GeneID; 862; -.
DR   UCSC; uc022axs.1; human.
DR   CTD; 862; -.
DR   EuPathDB; HostDB:ENSG00000079102.16; -.
DR   HGNC; HGNC:1535; RUNX1T1.
DR   OpenTargets; ENSG00000079102; -.
DR   GeneTree; ENSGT00950000183176; -.
DR   OMA; HQRPQRN; -.
DR   OrthoDB; 334242at2759; -.
DR   ChiTaRS; RUNX1T1; human.
DR   GenomeRNAi; 862; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000079102; Expressed in forebrain and 227 other tissues.
DR   ExpressionAtlas; A0A0A0MSU1; baseline and differential.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:InterPro.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:InterPro.
DR   Gene3D; 1.20.120.1110; -; 1.
DR   InterPro; IPR013290; CBFA2T1.
DR   InterPro; IPR013289; CBFA2T1/2/3.
DR   InterPro; IPR014896; NHR2.
DR   InterPro; IPR037249; TAFH/NHR1_dom_sf.
DR   InterPro; IPR003894; TAFH_NHR1.
DR   InterPro; IPR002893; Znf_MYND.
DR   PANTHER; PTHR10379; PTHR10379; 1.
DR   PANTHER; PTHR10379:SF5; PTHR10379:SF5; 1.
DR   Pfam; PF08788; NHR2; 1.
DR   Pfam; PF07531; TAFH; 1.
DR   Pfam; PF01753; zf-MYND; 1.
DR   PRINTS; PR01875; ETOFAMILY.
DR   PRINTS; PR01876; MTG8PROTEIN.
DR   SMART; SM00549; TAFH; 1.
DR   SUPFAM; SSF158553; SSF158553; 1.
DR   PROSITE; PS51119; TAFH; 1.
DR   PROSITE; PS01360; ZF_MYND_1; 1.
DR   PROSITE; PS50865; ZF_MYND_2; 1.
PE   1: Evidence at protein level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00299494};
KW   Proteomics identification {ECO:0000213|PeptideAtlas:A0A0A0MSU1,
KW   ECO:0000213|ProteomicsDB:A0A0A0MSU1};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00134, ECO:0000256|SAAS:SAAS00299494};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00299494}.
FT   DOMAIN          179..274
FT                   /note="TAFH"
FT                   /evidence="ECO:0000259|PROSITE:PS51119"
FT   DOMAIN          574..610
FT                   /note="MYND-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50865"
FT   REGION          88..173
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          289..357
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          460..482
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          616..663
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          513..555
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        124..173
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        294..322
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        329..346
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   663 AA;  74192 MW;  E6D792FD9B56D7C9 CRC64;
     MCHPDKAFTS DKLQCVFNEY KAAVWVPPRP RPLSRAPLPE AGGENLHLKI SRVRKRNLPF
     VVWGEEEAST PGLDAISHHL CYPDRTHRDR TEKHSTMPDS PVDVKTQSRL TPPTMPPPPT
     TQGAPRTSSF TPTTLTNGTS HSPTALNGAP SPPNGFSNGP SSSSSSSLAN QQLPPACGAR
     QLSKLKRFLT TLQQFGNDIS PEIGERVRTL VLGLVNSTLT IEEFHSKLQE ATNFPLRPFV
     IPFLKANLPL LQRELLHCAR LAKQNPAQYL AQHEQLLLDA STTSPVDSSE LLLDVNENGK
     RRTPDRTKEN GFDREPLHSE HPSKRPCTIS PGQRYSPNNG LSYQPNGLPH PTPPPPQHYR
     LDDMAIAHHY RDSYRHPSHR DLRDRNRPMG LHGTRQEEMI DHRLTDREWA EEWKHLDHLL
     NCIMDMVEKT RRSLTVLRRC QEADREELNY WIRRYSDAED LKKGGGSSSS HSRQQSPVNP
     DPVALDAHRE FLHRPASGYV PEEIWKKAEE AVNEVKRQAM TELQKAVSEA ERKAHDMITT
     ERAKMERTVA EAKRQAAEDA LAVINQQEDS SESCWNCGRK ASETCSGCNT ARYCGSFCQH
     KDWEKHHHIC GQTLQAQQQG DTPAVSSSVT PNSGAGSPMD TPPAATPRST TPGTPSTIET
     TPR
//
ID   B2R6I9_HUMAN            Unreviewed;       577 AA.
AC   B2R6I9;
DT   01-JUL-2008, integrated into UniProtKB/TrEMBL.
DT   01-JUL-2008, sequence version 1.
DT   22-APR-2020, entry version 73.
DE   SubName: Full=cDNA, FLJ92968, highly similar to Homo sapiens runt-related transcription factor 1; translocated to, 1 (cyclin D-related) (RUNX1T1), transcript variant 1, mRNA {ECO:0000313|EMBL:BAG35486.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG35486.1};
RN   [1] {ECO:0000313|EMBL:BAG35486.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Brain {ECO:0000313|EMBL:BAG35486.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Kaida T., Tsuchiya K., Iida Y.,
RA   Takayama Y., Murakawa K., Kanehori K., Andoh T., Kagawa N., Sato R.,
RA   Kawamura Y., Tanaka S., Kisu Y., Sugano S., Goshima N., Nomura N.,
RA   Isogai T.;
RT   "NEDO functional analysis of protein and research application project.";
RL   Submitted (JAN-2008) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK312592; BAG35486.1; -; mRNA.
DR   RefSeq; NP_001185554.1; NM_001198625.1.
DR   PeptideAtlas; B2R6I9; -.
DR   PRIDE; B2R6I9; -.
DR   DNASU; 862; -.
DR   GeneID; 862; -.
DR   CTD; 862; -.
DR   eggNOG; ENOG410IG1Z; Eukaryota.
DR   eggNOG; ENOG410XR30; LUCA.
DR   GenomeRNAi; 862; -.
DR   Genevisible; B2R6I9; HS.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:InterPro.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:InterPro.
DR   Gene3D; 1.20.120.1110; -; 1.
DR   InterPro; IPR013290; CBFA2T1.
DR   InterPro; IPR013289; CBFA2T1/2/3.
DR   InterPro; IPR014896; NHR2.
DR   InterPro; IPR037249; TAFH/NHR1_dom_sf.
DR   InterPro; IPR003894; TAFH_NHR1.
DR   InterPro; IPR002893; Znf_MYND.
DR   PANTHER; PTHR10379; PTHR10379; 1.
DR   PANTHER; PTHR10379:SF5; PTHR10379:SF5; 1.
DR   Pfam; PF08788; NHR2; 1.
DR   Pfam; PF07531; TAFH; 1.
DR   Pfam; PF01753; zf-MYND; 1.
DR   PRINTS; PR01875; ETOFAMILY.
DR   PRINTS; PR01876; MTG8PROTEIN.
DR   SMART; SM00549; TAFH; 1.
DR   SUPFAM; SSF158553; SSF158553; 1.
DR   PROSITE; PS51119; TAFH; 1.
DR   PROSITE; PS01360; ZF_MYND_1; 1.
DR   PROSITE; PS50865; ZF_MYND_2; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00299494};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00134, ECO:0000256|SAAS:SAAS00299494};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00299494}.
FT   DOMAIN          93..188
FT                   /note="TAFH"
FT                   /evidence="ECO:0000259|PROSITE:PS51119"
FT   DOMAIN          488..524
FT                   /note="MYND-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50865"
FT   REGION          1..87
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          203..271
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          374..396
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          530..577
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          427..469
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        38..87
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        208..236
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        243..260
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   577 AA;  64369 MW;  E2AAB735120EDC07 CRC64;
     MPDRTEKHST MPDSPVDVKT QSRLTPPTMP PPPTTQGAPR TSSFTPTTLT NGTSHSPTAL
     NGAPSPPNGF SNGPSSSSSS SLANQQLPPA CGARQLSKLK RFLTTLQQFG NDISPEIGER
     VRTLVLGLVN STLTIEEFHS KLQEATNFPL RPFVIPFLKA NLPLLQRELL HCARLAKQSP
     AQYLAQHEQL LLDASTTSPV DSSELLLDVN ENGKRRTPDR TKENGFDREP LHSEHPSKRP
     CTISPGQRYS PNNGLSYQPN GLPHPTPPPP QHYRLDDMAI AHHYRDSYRH PSHRDLRDRN
     RPMGLHGTRQ EEMIDHRLTD REWAEEWKHL DHLLNCIMDM VEKTRRSLTV LRRCQEADRE
     ELNYWIRRYS DAEDLKKGGG SSSSHSRQQS PVNPDPVALD AHREFLHRPA SGYVPEEIWK
     KAEEAVNEVK RQAMTELQKA VSEAERKAHD MITTERAKME RTVAEAKRQA AEDALAVINQ
     QEDSSESCWN CGRKASETCS GCNTARYCGS FCQHKDWEKH HHICGQTLQA QQQGDTPAVS
     SSVTPNSGAG SPMDTPPAAT PRSTTPGTPS TIETTPR
//
ID   MTG8_HUMAN              Reviewed;         604 AA.
AC   Q06455; B7Z4P4; E7EPN4; O14784; Q06456; Q14873; Q16239; Q16346; Q16347;
AC   Q6IBL1; Q6NXH1; Q7Z4J5; Q92479; Q9BRZ0;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   22-APR-2020, entry version 205.
DE   RecName: Full=Protein CBFA2T1;
DE   AltName: Full=Cyclin-D-related protein;
DE   AltName: Full=Eight twenty one protein;
DE   AltName: Full=Protein ETO;
DE   AltName: Full=Protein MTG8;
DE   AltName: Full=Zinc finger MYND domain-containing protein 2;
GN   Name=RUNX1T1; Synonyms=AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MTG8B), AND VARIANT AML1-MTG8/ETO
RP   FUSION IN AML-M2.
RC   TISSUE=Fetal brain;
RX   PubMed=8334990; DOI=10.1002/j.1460-2075.1993.tb05933.x;
RA   Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y.,
RA   Kamada N., Ohki M.;
RT   "The t(8;21) translocation in acute myeloid leukemia results in production
RT   of an AML1-MTG8 fusion transcript.";
RL   EMBO J. 12:2715-2721(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM MTG8B), AND ALTERNATIVE
RP   SPLICING (ISOFORMS MTG8A-2 AND MTG8B-2).
RX   PubMed=9661669; DOI=10.1016/s0378-1119(98)00141-3;
RA   Wolford J.K., Prochazka M.;
RT   "Structure and expression of the human MTG8/ETO gene.";
RL   Gene 212:103-109(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM MTG8A).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 31-604.
RX   PubMed=8137293;
RA   Erickson P.F., Robinson M., Owens G., Drabkin H.A.;
RT   "The ETO portion of acute myeloid leukemia t(8;21) fusion transcript
RT   encodes a highly evolutionarily conserved putative transcription factor.";
RL   Cancer Res. 54:1782-1786(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 334-432, AND VARIANT AML1-MTG8/ETO
RP   FUSION.
RX   PubMed=7919324;
RA   Tighe J.E., Calabi F.;
RT   "Alternative, out-of-frame runt/MTG8 transcripts are encoded by the
RT   derivative (8) chromosome in the t(8;21) of acute myeloid leukemia M2.";
RL   Blood 84:2115-2121(1994).
RN   [11]
RP   INTERACTION WITH ATN1, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=10973986; DOI=10.1083/jcb.150.5.939;
RA   Wood J.D., Nucifora F.C. Jr., Duan K., Zhang C., Wang J., Kim Y.,
RA   Schilling G., Sacchi N., Liu J.M., Ross C.A.;
RT   "Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene product,
RT   interacts with ETO/MTG8 in the nuclear matrix and represses
RT   transcription.";
RL   J. Cell Biol. 150:939-948(2000).
RN   [12]
RP   INTERACTION WITH CBFA2T3.
RX   PubMed=12242670; DOI=10.1038/sj.onc.1205882;
RA   Hoogeveen A.T., Rossetti S., Stoyanova V., Schonkeren J., Fenaroli A.,
RA   Schiaffonati L., van Unen L., Sacchi N.;
RT   "The transcriptional corepressor MTG16a contains a novel nucleolar
RT   targeting sequence deranged in t(16; 21)-positive myeloid malignancies.";
RL   Oncogene 21:6703-6712(2002).
RN   [13]
RP   REVIEW.
RX   PubMed=12559562; DOI=10.1016/s0378-1119(02)01172-1;
RA   Davis J.N., McGhee L., Meyers S.;
RT   "The ETO (MTG8) gene family.";
RL   Gene 303:1-10(2003).
RN   [14]
RP   REVIEW.
RX   PubMed=15203199; DOI=10.1016/j.ygeno.2004.02.011;
RA   Rossetti S., Hoogeveen A.T., Sacchi N.;
RT   "The MTG proteins: chromatin repression players with a passion for
RT   networking.";
RL   Genomics 84:1-9(2004).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   SUBUNIT.
RX   PubMed=19202074; DOI=10.1073/pnas.0810558106;
RA   Kwok C., Zeisig B.B., Qiu J., Dong S., So C.W.;
RT   "Transforming activity of AML1-ETO is independent of CBFbeta and ETO
RT   interaction but requires formation of homo-oligomeric complexes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:2853-2858(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41 AND SER-417, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   FUNCTION.
RX   PubMed=23251453; DOI=10.1371/journal.pone.0051205;
RA   Barrett C.W., Smith J.J., Lu L.C., Markham N., Stengel K.R., Short S.P.,
RA   Zhang B., Hunt A.A., Fingleton B.M., Carnahan R.H., Engel M.E., Chen X.,
RA   Beauchamp R.D., Wilson K.T., Hiebert S.W., Reynolds A.B., Williams C.S.;
RT   "Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding
RT   site in target promoters.";
RL   PLoS ONE 7:E51205-E51205(2012).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 335-403, SUBUNIT, NRH2 DOMAIN,
RP   INTERACTION WITH HDAC1; HDAC2; HDAC3; TCF12; NCOR1; NCOR2; SIN3A; CBFA2T2
RP   AND CBFA2T3, AND MUTAGENESIS OF LEU-345; LEU-357; LEU-360; LEU-361;
RP   LEU-375; LEU-378 AND LEU-389.
RX   PubMed=16616331; DOI=10.1016/j.ccr.2006.03.012;
RA   Liu Y., Cheney M.D., Gaudet J.J., Chruszcz M., Lukasik S.M., Sugiyama D.,
RA   Lary J., Cole J., Dauter Z., Minor W., Speck N.A., Bushweller J.H.;
RT   "The tetramer structure of the Nervy homology two domain, NHR2, is critical
RT   for AML1/ETO's activity.";
RL   Cancer Cell 9:249-260(2006).
RN   [20]
RP   STRUCTURE BY NMR OF 120-222, INTERACTION WITH TCF12, FUNCTION, AND
RP   MUTAGENESIS OF LYS-125; LEU-126; ARG-128; PHE-129; ARG-178 AND PHE-184.
RX   PubMed=16803958; DOI=10.1073/pnas.0603463103;
RA   Plevin M.J., Zhang J., Guo C., Roeder R.G., Ikura M.;
RT   "The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via
RT   a paired amphipathic helix-like TBP-associated factor homology domain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10242-10247(2006).
RN   [21]
RP   STRUCTURE BY NMR OF 510-559 IN COMPLEX WITH ZINC IONS AND NCOR2,
RP   MUTAGENESIS OF HIS-547, AND INTERACTION WITH NCOR1 AND NCOR2.
RX   PubMed=17560331; DOI=10.1016/j.ccr.2007.04.010;
RA   Liu Y., Chen W., Gaudet J., Cheney M.D., Roudaia L., Cierpicki T.,
RA   Klet R.C., Hartman K., Laue T.M., Speck N.A., Bushweller J.H.;
RT   "Structural basis for recognition of SMRT/N-CoR by the MYND domain and its
RT   contribution to AML1/ETO's activity.";
RL   Cancer Cell 11:483-497(2007).
RN   [22]
RP   STRUCTURE BY NMR OF 119-225, INTERACTION WITH NCOR1 AND TCF12, MUTAGENESIS
RP   OF PHE-129; PHE-136; GLN-170; THR-173; PHE-175 AND LEU-177, AND DOMAIN.
RX   PubMed=17572682; DOI=10.1038/nsmb1258;
RA   Wei Y., Liu S., Lausen J., Woodrell C., Cho S., Biris N., Kobayashi N.,
RA   Wei Y., Yokoyama S., Werner M.H.;
RT   "A TAF4-homology domain from the corepressor ETO is a docking platform for
RT   positive and negative regulators of transcription.";
RL   Nat. Struct. Mol. Biol. 14:653-661(2007).
RN   [23]
RP   STRUCTURE BY NMR OF 505-551.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of ZF-MYND domain of protein CBFA2TI (protein MTG8).";
RL   Submitted (OCT-2006) to the PDB data bank.
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.91 ANGSTROMS) OF 338-400 IN COMPLEX WITH TCF12,
RP   FUNCTION, SUBUNIT, AND MUTAGENESIS OF LEU-345; 352-GLU-GLU-353; LEU-357;
RP   LEU-360; LEU-361; LEU-375; LEU-378; 379-ARG--CYS-381 AND LEU-389.
RX   PubMed=23812588; DOI=10.1038/nature12287;
RA   Sun X.J., Wang Z., Wang L., Jiang Y., Kost N., Soong T.D., Chen W.Y.,
RA   Tang Z., Nakadai T., Elemento O., Fischle W., Melnick A., Patel D.J.,
RA   Nimer S.D., Roeder R.G.;
RT   "A stable transcription factor complex nucleated by oligomeric AML1-ETO
RT   controls leukaemogenesis.";
RL   Nature 500:93-97(2013).
RN   [25]
RP   VARIANT AML1-MTG8/ETO FUSION IN AML-M2.
RX   PubMed=7541640; DOI=10.1002/gcc.2870130105;
RA   Era T., Asou N., Kunisada T., Yamasaki H., Asou H., Kamada N.,
RA   Nishikawa S., Yamaguchi K., Takatsuki K.;
RT   "Identification of two transcripts of AML1/ETO-fused gene in t(8;21)
RT   leukemic cells and expression of wild-type ETO gene in hematopoietic
RT   cells.";
RL   Genes Chromosomes Cancer 13:25-33(1995).
RN   [26]
RP   VARIANT AML1-MTG8/ETO FUSION IN AML-M2.
RX   PubMed=8353289;
RA   Kozu T., Miyoshi H., Shimizu K., Maseki N., Kaneko Y., Asou H., Kamada N.,
RA   Ohki M.;
RT   "Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute
RT   myeloid leukemia detected by reverse transcription polymerase chain
RT   reaction.";
RL   Blood 82:1270-1276(1993).
RN   [27]
RP   VARIANT AML1-MTG8/ETO FUSION IN AML-M2.
RX   PubMed=1423235; DOI=10.1016/0165-4608(92)90384-k;
RA   Nisson P.E., Watkins P.C., Sacchi N.;
RT   "Transcriptionally active chimeric gene derived from the fusion of the AML1
RT   gene and a novel gene on chromosome 8 in t(8;21) leukemic cells.";
RL   Cancer Genet. Cytogenet. 63:81-88(1992).
RN   [28]
RP   VARIANTS [LARGE SCALE ANALYSIS] TRP-386; TRP-395 AND VAL-471.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Transcriptional corepressor which facilitates transcriptional
CC       repression via its association with DNA-binding transcription factors
CC       and recruitment of other corepressors and histone-modifying enzymes
CC       (PubMed:12559562, PubMed:15203199). Can repress the expression of MMP7
CC       in a ZBTB33-dependent manner (PubMed:23251453). Can repress
CC       transactivation mediated by TCF12 (PubMed:16803958). Acts as a negative
CC       regulator of adipogenesis (By similarity). The AML1-MTG8/ETO fusion
CC       protein frequently found in leukemic cells is involved in
CC       leukemogenesis and contributes to hematopoietic stem/progenitor cell
CC       self-renewal (PubMed:23812588). {ECO:0000250|UniProtKB:Q61909,
CC       ECO:0000269|PubMed:10973986, ECO:0000269|PubMed:16803958,
CC       ECO:0000269|PubMed:23251453, ECO:0000269|PubMed:23812588,
CC       ECO:0000303|PubMed:12559562, ECO:0000303|PubMed:15203199}.
CC   -!- SUBUNIT: Homooligomer. Homotetramerization is mediated by nervy
CC       homology region 2 (NRH2). Can interact with CBFA2T2 and CBFA2T3;
CC       heterotetramerization between members of the CBFA2T family is proposed.
CC       Interacts with TCF12, SIN3A, HDAC1, HDAC2, HDAC3, NCOR1, NCOR2.
CC       Interacts with ATN1 (via its N-terminus); the interaction enhances the
CC       transcriptional repression. AML1-MTG8/ETO fusion protein interacts with
CC       CBFB. AML1-MTG8/ETO is part of a stable transcription factor complex
CC       AETFC in leukemic cells; AETFC formation seems to be involved in
CC       recruitment of EP300. AML1-MTG8/ETO nervy homology region 2-mediated
CC       oligomerization is proposed to be homotypic, required for AML1-
CC       MTG8/ETO-mediated transformation of primary hematopoietic cells and is
CC       required for AML1-MTG8/ETO interaction with TCF12.
CC       {ECO:0000269|PubMed:10973986, ECO:0000269|PubMed:12242670,
CC       ECO:0000269|PubMed:16616331, ECO:0000269|PubMed:16803958,
CC       ECO:0000269|PubMed:17560331, ECO:0000269|PubMed:17572682,
CC       ECO:0000269|PubMed:19202074, ECO:0000269|PubMed:23812588}.
CC   -!- INTERACTION:
CC       Q06455-2; Q7Z783; NbExp=3; IntAct=EBI-11984663, EBI-9088990;
CC       Q06455-2; Q9P2A4: ABI3; NbExp=3; IntAct=EBI-11984663, EBI-742038;
CC       Q06455-4; Q9P2A4: ABI3; NbExp=3; IntAct=EBI-10224192, EBI-742038;
CC       Q06455-2; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-11984663, EBI-10173507;
CC       Q06455-2; Q9BRR9: ARHGAP9; NbExp=3; IntAct=EBI-11984663, EBI-750254;
CC       Q06455-2; Q86V38: ATN1; NbExp=3; IntAct=EBI-11984663, EBI-11954292;
CC       Q06455-2; Q13490: BIRC2; NbExp=3; IntAct=EBI-11984663, EBI-514538;
CC       Q06455-4; Q0VDD7: C19orf57; NbExp=3; IntAct=EBI-10224192, EBI-741210;
CC       Q06455-2; Q8NCU1: CCDC197; NbExp=3; IntAct=EBI-11984663, EBI-750686;
CC       Q06455-2; Q8IYA8: CCDC36; NbExp=3; IntAct=EBI-11984663, EBI-8638439;
CC       Q06455-4; Q8IYA8: CCDC36; NbExp=3; IntAct=EBI-10224192, EBI-8638439;
CC       Q06455-2; Q9UJX2: CDC23; NbExp=3; IntAct=EBI-11984663, EBI-396137;
CC       Q06455-2; Q01850: CDR2; NbExp=3; IntAct=EBI-11984663, EBI-1181367;
CC       Q06455-2; Q9Y592-2: CEP83; NbExp=3; IntAct=EBI-11984663, EBI-11123098;
CC       Q06455-2; Q9Y2V7: COG6; NbExp=3; IntAct=EBI-11984663, EBI-3866319;
CC       Q06455-4; Q8N684: CPSF7; NbExp=3; IntAct=EBI-10224192, EBI-746909;
CC       Q06455-2; Q8N684-3: CPSF7; NbExp=3; IntAct=EBI-11984663, EBI-11523759;
CC       Q06455-4; Q96BA8: CREB3L1; NbExp=3; IntAct=EBI-10224192, EBI-6942903;
CC       Q06455-2; Q05D60: DEUP1; NbExp=3; IntAct=EBI-11984663, EBI-748597;
CC       Q06455-4; Q5JST6: EFHC2; NbExp=3; IntAct=EBI-10224192, EBI-2349927;
CC       Q06455-4; Q12929: EPS8; NbExp=3; IntAct=EBI-10224192, EBI-375576;
CC       Q06455-2; Q96C01: FAM136A; NbExp=3; IntAct=EBI-11984663, EBI-373319;
CC       Q06455-2; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-11984663, EBI-8468186;
CC       Q06455-4; Q14687: GSE1; NbExp=3; IntAct=EBI-10224192, EBI-372619;
CC       Q06455-2; Q9NSC5: HOMER3; NbExp=3; IntAct=EBI-11984663, EBI-748420;
CC       Q06455-4; Q9NSC5: HOMER3; NbExp=3; IntAct=EBI-10224192, EBI-748420;
CC       Q06455-2; P14652: HOXB2; NbExp=3; IntAct=EBI-11984663, EBI-5329558;
CC       Q06455-2; Q6ZU52: KIAA0408; NbExp=5; IntAct=EBI-11984663, EBI-739493;
CC       Q06455-2; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-11984663, EBI-14069005;
CC       Q06455-2; Q9C075: KRT23; NbExp=3; IntAct=EBI-11984663, EBI-3211278;
CC       Q06455-2; Q7Z3Y8: KRT27; NbExp=3; IntAct=EBI-11984663, EBI-3044087;
CC       Q06455-2; Q14525: KRT33B; NbExp=3; IntAct=EBI-11984663, EBI-1049638;
CC       Q06455-2; Q92764: KRT35; NbExp=3; IntAct=EBI-11984663, EBI-1058674;
CC       Q06455-2; Q3SY46: KRTAP13-3; NbExp=3; IntAct=EBI-11984663, EBI-10241252;
CC       Q06455-2; Q3LI70: KRTAP19-6; NbExp=3; IntAct=EBI-11984663, EBI-12805508;
CC       Q06455-2; Q3LI66: KRTAP6-2; NbExp=3; IntAct=EBI-11984663, EBI-11962084;
CC       Q06455-2; Q9UBR4-2: LHX3; NbExp=3; IntAct=EBI-11984663, EBI-12039345;
CC       Q06455-2; O60711: LPXN; NbExp=3; IntAct=EBI-11984663, EBI-744222;
CC       Q06455-4; O60711: LPXN; NbExp=3; IntAct=EBI-10224192, EBI-744222;
CC       Q06455-2; Q9Y250: LZTS1; NbExp=3; IntAct=EBI-11984663, EBI-1216080;
CC       Q06455-4; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-10224192, EBI-741037;
CC       Q06455-4; P50222: MEOX2; NbExp=3; IntAct=EBI-10224192, EBI-748397;
CC       Q06455-2; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-11984663, EBI-16439278;
CC       Q06455-2; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-11984663, EBI-10172526;
CC       Q06455-4; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-10224192, EBI-10172526;
CC       Q06455; O75376: NCOR1; NbExp=5; IntAct=EBI-743342, EBI-347233;
CC       Q06455-2; Q7Z6G3-2: NECAB2; NbExp=3; IntAct=EBI-11984663, EBI-10172876;
CC       Q06455-4; Q7Z6G3-2: NECAB2; NbExp=3; IntAct=EBI-10224192, EBI-10172876;
CC       Q06455-2; O43482: OIP5; NbExp=3; IntAct=EBI-11984663, EBI-536879;
CC       Q06455-2; O75928-2: PIAS2; NbExp=5; IntAct=EBI-11984663, EBI-348567;
CC       Q06455-2; Q9NRY6: PLSCR3; NbExp=3; IntAct=EBI-11984663, EBI-750734;
CC       Q06455-2; Q9GZV8: PRDM14; NbExp=6; IntAct=EBI-11984663, EBI-3957793;
CC       Q06455-4; Q9GZV8: PRDM14; NbExp=3; IntAct=EBI-10224192, EBI-3957793;
CC       Q06455-2; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-11984663, EBI-11320284;
CC       Q06455-2; P31321: PRKAR1B; NbExp=3; IntAct=EBI-11984663, EBI-2805516;
CC       Q06455-2; Q9Y4B4: RAD54L2; NbExp=3; IntAct=EBI-11984663, EBI-948156;
CC       Q06455-2; Q04864-2: REL; NbExp=3; IntAct=EBI-11984663, EBI-10829018;
CC       Q06455-2; P78317: RNF4; NbExp=3; IntAct=EBI-11984663, EBI-2340927;
CC       Q06455-2; Q8WWV3: RTN4IP1; NbExp=3; IntAct=EBI-11984663, EBI-743502;
CC       Q06455; Q9QX47: Son; Xeno; NbExp=4; IntAct=EBI-743342, EBI-643037;
CC       Q06455-2; O60504: SORBS3; NbExp=3; IntAct=EBI-11984663, EBI-741237;
CC       Q06455; P08047: SP1; NbExp=2; IntAct=EBI-743342, EBI-298336;
CC       Q06455-4; Q8NA61: SPERT; NbExp=3; IntAct=EBI-10224192, EBI-741724;
CC       Q06455-2; Q8NA61-2: SPERT; NbExp=3; IntAct=EBI-11984663, EBI-11524851;
CC       Q06455-4; O43597: SPRY2; NbExp=3; IntAct=EBI-10224192, EBI-742487;
CC       Q06455-4; O75558: STX11; NbExp=3; IntAct=EBI-10224192, EBI-714135;
CC       Q06455-2; Q8N0S2: SYCE1; NbExp=3; IntAct=EBI-11984663, EBI-6872807;
CC       Q06455-4; Q99081-3: TCF12; NbExp=2; IntAct=EBI-10224192, EBI-11952764;
CC       Q06455-2; Q969V4: TEKT1; NbExp=3; IntAct=EBI-11984663, EBI-10180409;
CC       Q06455-2; Q9UBB9: TFIP11; NbExp=3; IntAct=EBI-11984663, EBI-1105213;
CC       Q06455-4; Q8IWZ5: TRIM42; NbExp=3; IntAct=EBI-10224192, EBI-5235829;
CC       Q06455-2; Q9BYV2: TRIM54; NbExp=3; IntAct=EBI-11984663, EBI-2130429;
CC       Q06455-2; Q8N1B4: VPS52; NbExp=3; IntAct=EBI-11984663, EBI-2799833;
CC       Q06455-2; Q9Y2W2: WBP11; NbExp=3; IntAct=EBI-11984663, EBI-714455;
CC       Q06455-2; P98170: XIAP; NbExp=3; IntAct=EBI-11984663, EBI-517127;
CC       Q06455-2; P26651: ZFP36; NbExp=3; IntAct=EBI-11984663, EBI-374248;
CC       Q06455-2; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-11984663, EBI-11419867;
CC       Q06455-4; Q5VZL5: ZMYM4; NbExp=3; IntAct=EBI-10224192, EBI-2514659;
CC       Q06455-2; Q6P1L6: ZNF343; NbExp=3; IntAct=EBI-11984663, EBI-10252492;
CC       Q06455-2; Q8N720: ZNF655; NbExp=3; IntAct=EBI-11984663, EBI-625509;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00440,
CC       ECO:0000269|PubMed:10973986}. Note=Colocalizes with ATN1 in discrete
CC       nuclear dots.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=MTG8B;
CC         IsoId=Q06455-1; Sequence=Displayed;
CC       Name=MTG8A;
CC         IsoId=Q06455-2; Sequence=VSP_003327;
CC       Name=3;
CC         IsoId=Q06455-3; Sequence=VSP_044558;
CC       Name=4;
CC         IsoId=Q06455-4; Sequence=VSP_045442;
CC       Name=MTG8B-2;
CC         IsoId=Q06455-5; Sequence=VSP_058512, VSP_058513;
CC       Name=MTG8A-2;
CC         IsoId=Q06455-6; Sequence=VSP_003327, VSP_058512, VSP_058513;
CC   -!- TISSUE SPECIFICITY: Most abundantly expressed in brain. Lower levels in
CC       lung, heart, testis and ovary.
CC   -!- DOMAIN: The TAFH domain mediates interaction with transcription
CC       regulators. {ECO:0000269|PubMed:17572682}.
CC   -!- DOMAIN: Nervy homology region 2 (NHR2) mediates homo- and possibly
CC       heterotypic oligomerization by forming a four-helix bundle tetrameric
CC       structure. {ECO:0000269|PubMed:16616331}.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1T1 is a cause of
CC       acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with
CC       RUNX1/AML1. {ECO:0000269|PubMed:1423235, ECO:0000269|PubMed:7541640,
CC       ECO:0000269|PubMed:8334990, ECO:0000269|PubMed:8353289}.
CC   -!- SIMILARITY: Belongs to the CBFA2T family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH05850.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA03247.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ETOID26.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D14821; BAA03558.1; -; mRNA.
DR   EMBL; D13979; BAA03089.1; ALT_SEQ; mRNA.
DR   EMBL; D14289; BAA03247.1; ALT_INIT; mRNA.
DR   EMBL; AF018282; AAC28932.1; -; Genomic_DNA.
DR   EMBL; AF018271; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018272; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018273; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018274; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018275; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018276; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018277; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018278; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018279; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018281; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018282; AAC28931.1; -; Genomic_DNA.
DR   EMBL; AF018270; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018272; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018273; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018274; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018275; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018276; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018277; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018278; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018279; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018281; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018283; AAC26143.1; -; mRNA.
DR   EMBL; AK297616; BAH12630.1; -; mRNA.
DR   EMBL; BT009871; AAP88873.1; -; mRNA.
DR   EMBL; CR456792; CAG33073.1; -; mRNA.
DR   EMBL; AC103680; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104339; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471060; EAW91685.1; -; Genomic_DNA.
DR   EMBL; BC005850; AAH05850.1; ALT_INIT; mRNA.
DR   EMBL; BC067078; AAH67078.2; -; mRNA.
DR   EMBL; AF181450; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; D43638; BAA07755.1; -; mRNA.
DR   EMBL; X79990; CAA56311.1; -; mRNA.
DR   EMBL; S74096; AAB32126.1; -; Genomic_DNA.
DR   EMBL; S74092; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S78158; AAB34819.2; ALT_SEQ; mRNA.
DR   EMBL; S78159; AAB34820.2; ALT_SEQ; mRNA.
DR   EMBL; D14822; BAA03559.1; ALT_SEQ; mRNA.
DR   EMBL; D14823; BAA03560.1; ALT_SEQ; mRNA.
DR   EMBL; S50186; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS47891.1; -. [Q06455-2]
DR   CCDS; CCDS56544.1; -. [Q06455-3]
DR   CCDS; CCDS6256.1; -. [Q06455-1]
DR   CCDS; CCDS6257.1; -. [Q06455-4]
DR   PIR; A57784; A57784.
DR   PIR; C57784; C57784.
DR   RefSeq; NP_001185554.1; NM_001198625.1. [Q06455-2]
DR   RefSeq; NP_001185555.1; NM_001198626.1. [Q06455-1]
DR   RefSeq; NP_001185556.1; NM_001198627.1. [Q06455-1]
DR   RefSeq; NP_001185557.1; NM_001198628.1. [Q06455-1]
DR   RefSeq; NP_001185558.1; NM_001198629.1. [Q06455-1]
DR   RefSeq; NP_001185559.1; NM_001198630.1. [Q06455-1]
DR   RefSeq; NP_001185560.1; NM_001198631.1. [Q06455-1]
DR   RefSeq; NP_001185561.1; NM_001198632.1. [Q06455-2]
DR   RefSeq; NP_001185562.1; NM_001198633.1.
DR   RefSeq; NP_001185563.1; NM_001198634.1. [Q06455-3]
DR   RefSeq; NP_001185608.1; NM_001198679.1.
DR   RefSeq; NP_004340.1; NM_004349.3. [Q06455-2]
DR   RefSeq; NP_783552.1; NM_175634.2. [Q06455-1]
DR   RefSeq; NP_783553.1; NM_175635.2. [Q06455-4]
DR   RefSeq; NP_783554.1; NM_175636.2. [Q06455-4]
DR   RefSeq; XP_006716739.1; XM_006716676.3. [Q06455-4]
DR   RefSeq; XP_011515653.1; XM_011517351.2. [Q06455-1]
DR   RefSeq; XP_011515654.1; XM_011517352.2. [Q06455-2]
DR   RefSeq; XP_011515655.1; XM_011517353.2. [Q06455-4]
DR   RefSeq; XP_016869420.1; XM_017013931.1.
DR   RefSeq; XP_016869421.1; XM_017013932.1. [Q06455-2]
DR   RefSeq; XP_016869422.1; XM_017013933.1. [Q06455-2]
DR   RefSeq; XP_016869423.1; XM_017013934.1. [Q06455-4]
DR   RefSeq; XP_016869424.1; XM_017013935.1. [Q06455-4]
DR   RefSeq; XP_016869425.1; XM_017013936.1. [Q06455-4]
DR   RefSeq; XP_016869426.1; XM_017013937.1. [Q06455-4]
DR   PDB; 1WQ6; X-ray; 2.00 A; A/B=335-403.
DR   PDB; 2DJ8; NMR; -; A=505-551.
DR   PDB; 2H7B; NMR; -; A=120-222.
DR   PDB; 2KNH; NMR; -; A=119-216.
DR   PDB; 2KYG; NMR; -; C=437-467.
DR   PDB; 2OD1; NMR; -; A=510-559.
DR   PDB; 2ODD; NMR; -; A=510-559.
DR   PDB; 2PP4; NMR; -; A=119-225.
DR   PDB; 4JOL; X-ray; 2.91 A; A/B/C/D=338-400.
DR   PDBsum; 1WQ6; -.
DR   PDBsum; 2DJ8; -.
DR   PDBsum; 2H7B; -.
DR   PDBsum; 2KNH; -.
DR   PDBsum; 2KYG; -.
DR   PDBsum; 2OD1; -.
DR   PDBsum; 2ODD; -.
DR   PDBsum; 2PP4; -.
DR   PDBsum; 4JOL; -.
DR   SMR; Q06455; -.
DR   BioGrid; 107310; 61.
DR   DIP; DIP-29401N; -.
DR   ELM; Q06455; -.
DR   IntAct; Q06455; 85.
DR   MINT; Q06455; -.
DR   STRING; 9606.ENSP00000402257; -.
DR   iPTMnet; Q06455; -.
DR   PhosphoSitePlus; Q06455; -.
DR   BioMuta; RUNX1T1; -.
DR   DMDM; 2498595; -.
DR   jPOST; Q06455; -.
DR   MassIVE; Q06455; -.
DR   MaxQB; Q06455; -.
DR   PaxDb; Q06455; -.
DR   PeptideAtlas; Q06455; -.
DR   PRIDE; Q06455; -.
DR   ProteomicsDB; 17401; -.
DR   ProteomicsDB; 58447; -. [Q06455-1]
DR   ProteomicsDB; 58448; -. [Q06455-2]
DR   ProteomicsDB; 69196; -.
DR   Antibodypedia; 25672; 263 antibodies.
DR   DNASU; 862; -.
DR   Ensembl; ENST00000265814; ENSP00000265814; ENSG00000079102. [Q06455-1]
DR   Ensembl; ENST00000360348; ENSP00000353504; ENSG00000079102. [Q06455-4]
DR   Ensembl; ENST00000396218; ENSP00000379520; ENSG00000079102. [Q06455-2]
DR   Ensembl; ENST00000422361; ENSP00000390137; ENSG00000079102. [Q06455-4]
DR   Ensembl; ENST00000518844; ENSP00000430728; ENSG00000079102. [Q06455-2]
DR   Ensembl; ENST00000520724; ENSP00000428742; ENSG00000079102. [Q06455-3]
DR   Ensembl; ENST00000523629; ENSP00000428543; ENSG00000079102. [Q06455-1]
DR   Ensembl; ENST00000613302; ENSP00000481799; ENSG00000079102. [Q06455-1]
DR   Ensembl; ENST00000613886; ENSP00000478331; ENSG00000079102. [Q06455-2]
DR   Ensembl; ENST00000614812; ENSP00000481315; ENSG00000079102. [Q06455-1]
DR   Ensembl; ENST00000617740; ENSP00000481112; ENSG00000079102. [Q06455-1]
DR   GeneID; 862; -.
DR   KEGG; hsa:862; -.
DR   UCSC; uc003yfc.3; human. [Q06455-1]
DR   CTD; 862; -.
DR   DisGeNET; 862; -.
DR   GeneCards; RUNX1T1; -.
DR   HGNC; HGNC:1535; RUNX1T1.
DR   HPA; ENSG00000079102; Tissue enriched (brain).
DR   MalaCards; RUNX1T1; -.
DR   MIM; 133435; gene.
DR   neXtProt; NX_Q06455; -.
DR   OpenTargets; ENSG00000079102; -.
DR   Orphanet; 102724; Acute myeloid leukemia with t(8;21)(q22;q22) translocation.
DR   PharmGKB; PA26111; -.
DR   eggNOG; ENOG410IG1Z; Eukaryota.
DR   eggNOG; ENOG410XR30; LUCA.
DR   GeneTree; ENSGT00950000183176; -.
DR   HOGENOM; CLU_022077_2_0_1; -.
DR   InParanoid; Q06455; -.
DR   KO; K10053; -.
DR   OrthoDB; 334242at2759; -.
DR   PhylomeDB; Q06455; -.
DR   TreeFam; TF106303; -.
DR   SIGNOR; Q06455; -.
DR   ChiTaRS; RUNX1T1; human.
DR   EvolutionaryTrace; Q06455; -.
DR   GeneWiki; RUNX1T1; -.
DR   GenomeRNAi; 862; -.
DR   Pharos; Q06455; Tbio.
DR   PRO; PR:Q06455; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q06455; protein.
DR   Bgee; ENSG00000079102; Expressed in forebrain and 227 other tissues.
DR   ExpressionAtlas; Q06455; baseline and differential.
DR   Genevisible; Q06455; HS.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003714; F:transcription corepressor activity; IBA:GO_Central.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   Gene3D; 1.20.120.1110; -; 1.
DR   InterPro; IPR013290; CBFA2T1.
DR   InterPro; IPR013289; CBFA2T1/2/3.
DR   InterPro; IPR014896; NHR2.
DR   InterPro; IPR037249; TAFH/NHR1_dom_sf.
DR   InterPro; IPR003894; TAFH_NHR1.
DR   InterPro; IPR002893; Znf_MYND.
DR   PANTHER; PTHR10379; PTHR10379; 1.
DR   PANTHER; PTHR10379:SF5; PTHR10379:SF5; 1.
DR   Pfam; PF08788; NHR2; 1.
DR   Pfam; PF07531; TAFH; 1.
DR   Pfam; PF01753; zf-MYND; 1.
DR   PRINTS; PR01875; ETOFAMILY.
DR   PRINTS; PR01876; MTG8PROTEIN.
DR   SMART; SM00549; TAFH; 1.
DR   SUPFAM; SSF158553; SSF158553; 1.
DR   PROSITE; PS51119; TAFH; 1.
DR   PROSITE; PS01360; ZF_MYND_1; 1.
DR   PROSITE; PS50865; ZF_MYND_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosomal rearrangement; DNA-binding;
KW   Metal-binding; Nucleus; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Reference proteome; Repressor; Transcription; Transcription regulation;
KW   Zinc; Zinc-finger.
FT   CHAIN           1..604
FT                   /note="Protein CBFA2T1"
FT                   /id="PRO_0000218299"
FT   DOMAIN          120..215
FT                   /note="TAFH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00440"
FT   ZN_FING         515..551
FT                   /note="MYND-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00134"
FT   REGION          337..383
FT                   /note="Important for oligomerization"
FT   REGION          337..383
FT                   /note="Nervy homology region 2 (NHR2)"
FT                   /evidence="ECO:0000303|PubMed:12559562"
FT   REGION          443..492
FT                   /note="Nervy homology region 3 (NHR3)"
FT                   /evidence="ECO:0000303|PubMed:12559562"
FT   COMPBIAS        57..60
FT                   /note="Poly-Pro"
FT   COMPBIAS        102..108
FT                   /note="Poly-Ser"
FT   COMPBIAS        290..297
FT                   /note="Poly-Pro"
FT   COMPBIAS        408..413
FT                   /note="Poly-Ser"
FT   SITE            30..31
FT                   /note="Breakpoint for translocation to form AML1-MTG8 in
FT                   AML-M2"
FT                   /evidence="ECO:0000269|PubMed:8334990"
FT   MOD_RES         41
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21406692"
FT   MOD_RES         417
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21406692"
FT   VAR_SEQ         1..37
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4"
FT                   /id="VSP_045442"
FT   VAR_SEQ         1..29
FT                   /note="MISVKRNTWRALSLVIGDCRKKGNFEYCQ -> MCHPDKAFTSDKLQCVFNE
FT                   YKAAVWVPPRPRPLSRAPLPE (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044558"
FT   VAR_SEQ         1..29
FT                   /note="MISVKRNTWRALSLVIGDCRKKGNFEYCQ -> MP (in isoform
FT                   MTG8A and isoform MTG8A-2)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_003327"
FT   VAR_SEQ         427
FT                   /note="D -> G (in isoform MTG8B-2 and isoform MTG8A-2)"
FT                   /evidence="ECO:0000303|PubMed:9661669"
FT                   /id="VSP_058512"
FT   VAR_SEQ         428..604
FT                   /note="Missing (in isoform MTG8B-2 and isoform MTG8A-2)"
FT                   /evidence="ECO:0000303|PubMed:9661669"
FT                   /id="VSP_058513"
FT   VARIANT         386
FT                   /note="R -> W (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs1301792645)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036321"
FT   VARIANT         395
FT                   /note="R -> W (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs1448417558)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036322"
FT   VARIANT         471
FT                   /note="A -> V (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs1462140811)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036323"
FT   MUTAGEN         125
FT                   /note="K->A,D: Loss of interaction with TCF12."
FT                   /evidence="ECO:0000269|PubMed:16803958"
FT   MUTAGEN         126
FT                   /note="L->A: Loss of interaction with TCF12."
FT                   /evidence="ECO:0000269|PubMed:16803958"
FT   MUTAGEN         128
FT                   /note="R->D: Loss of interaction with TCF12."
FT                   /evidence="ECO:0000269|PubMed:16803958"
FT   MUTAGEN         129
FT                   /note="F->A: Loss of interaction with TCF12."
FT                   /evidence="ECO:0000269|PubMed:16803958,
FT                   ECO:0000269|PubMed:17572682"
FT   MUTAGEN         129
FT                   /note="F->K: Abolishes interaction with corepressor."
FT                   /evidence="ECO:0000269|PubMed:16803958,
FT                   ECO:0000269|PubMed:17572682"
FT   MUTAGEN         136
FT                   /note="F->A: Abolishes interaction with corepressor."
FT                   /evidence="ECO:0000269|PubMed:17572682"
FT   MUTAGEN         170
FT                   /note="Q->A: Abolishes interaction with corepressor."
FT                   /evidence="ECO:0000269|PubMed:17572682"
FT   MUTAGEN         173
FT                   /note="T->Q: Abolishes interaction with corepressor."
FT                   /evidence="ECO:0000269|PubMed:17572682"
FT   MUTAGEN         175
FT                   /note="F->A: Abolishes interaction with corepressor."
FT                   /evidence="ECO:0000269|PubMed:17572682"
FT   MUTAGEN         177
FT                   /note="L->A: Abolishes interaction with corepressor."
FT                   /evidence="ECO:0000269|PubMed:17572682"
FT   MUTAGEN         178
FT                   /note="R->A,D: Loss of interaction with TCF12."
FT                   /evidence="ECO:0000269|PubMed:16803958"
FT   MUTAGEN         184
FT                   /note="F->A: Loss of interaction with TCF12."
FT                   /evidence="ECO:0000269|PubMed:16803958"
FT   MUTAGEN         345
FT                   /note="L->E: Disrupts tetramerization, disrupts AML1-
FT                   MTG8/ETO interaction with TCF12, decreases AML1-MTG8/ETO
FT                   interaction with RUNX1T1, CBFA2T3 and CBFA2T2; when
FT                   associated with R-357; R-360; E-361; E-375; R-378 and R-
FT                   389."
FT                   /evidence="ECO:0000269|PubMed:16616331,
FT                   ECO:0000269|PubMed:23812588"
FT   MUTAGEN         352..353
FT                   /note="EE->AA: Decreases interaction with TCF12, no effect
FT                   on oligomerization. Impairs AML1-MTG8/ETO activity in
FT                   hematopoietic stem/progenitor cell self-renewal but no
FT                   effect in inhibiting differentiation; when associated with
FT                   379-A--A-381."
FT                   /evidence="ECO:0000269|PubMed:23812588"
FT   MUTAGEN         357
FT                   /note="L->R: Disrupts tetramerization, disrupts AML1-
FT                   MTG8/ETO interaction with TCF12, decreases AML1-MTG8/ETO
FT                   interaction with RUNX1T1, CBFA2T3 and CBFA2T2; when
FT                   associated with E-345; R-360; E- 61; E-375; R-378 and R-
FT                   389."
FT                   /evidence="ECO:0000269|PubMed:16616331,
FT                   ECO:0000269|PubMed:23812588"
FT   MUTAGEN         360
FT                   /note="L->R: Disrupts tetramerization, disrupts AML1-
FT                   MTG8/ETO interaction with TCF12, decreases AML1-MTG8/ETO
FT                   interaction with RUNX1T1, CBFA2T3 and CBFA2T2; when
FT                   associated with E-345; R-357; E-361; E-375; R-378 and R-
FT                   389."
FT                   /evidence="ECO:0000269|PubMed:16616331,
FT                   ECO:0000269|PubMed:23812588"
FT   MUTAGEN         361
FT                   /note="L->E: Disrupts tetramerization, disrupts AML1-
FT                   MTG8/ETO interaction with TCF12, decreases AML1-MTG8/ETO
FT                   interaction with RUNX1T1, CBFA2T3 and CBFA2T2; when
FT                   associated with E-345; R-357; R-360; E-375; R-378 and R-
FT                   389."
FT                   /evidence="ECO:0000269|PubMed:16616331,
FT                   ECO:0000269|PubMed:23812588"
FT   MUTAGEN         375
FT                   /note="L->E: Disrupts tetramerization, disrupts AML1-
FT                   MTG8/ETO interaction with TCF12, decreases AML1-MTG8/ETO
FT                   interaction with RUNX1T1, CBFA2T3 and CBFA2T2; when
FT                   associated with E-345; R-357; R-360; E-361; R-378 and R-
FT                   389."
FT                   /evidence="ECO:0000269|PubMed:16616331,
FT                   ECO:0000269|PubMed:23812588"
FT   MUTAGEN         378
FT                   /note="L->R: Disrupts tetramerization, disrupts AML1-
FT                   MTG8/ETO interaction with TCF12, decreases AML1-MTG8/ETO
FT                   interaction with RUNX1T1, CBFA2T3 and CBFA2T2 when
FT                   associated with E-345; R-357; R-360; E-361; E-375 and R-
FT                   389."
FT                   /evidence="ECO:0000269|PubMed:16616331,
FT                   ECO:0000269|PubMed:23812588"
FT   MUTAGEN         379..381
FT                   /note="RRC->AAA: Disrupts interaction with TCF12, no effect
FT                   on oligomerization. Impairs AML1-MTG8/ETO activity in
FT                   hematopoietic stem/progenitor cell self-renewal but no
FT                   effect in inhibiting differentiation; when associated with
FT                   352-E-E-353."
FT                   /evidence="ECO:0000269|PubMed:23812588"
FT   MUTAGEN         389
FT                   /note="L->R: Disrupts tetramerization, disrupts AML1-
FT                   MTG8/ETO interaction with TCF12, decreases AML1-MTG8/ETO
FT                   interaction with RUNX1T1, CBFA2T3 and CBFA2T2; when
FT                   associated with E-345; R-357; R-360; E-361; E-375 and R-
FT                   378."
FT                   /evidence="ECO:0000269|PubMed:16616331,
FT                   ECO:0000269|PubMed:23812588"
FT   MUTAGEN         547
FT                   /note="H->A: Causes unfolding of the MYND-type zinc finger
FT                   domain."
FT                   /evidence="ECO:0000269|PubMed:17560331"
FT   CONFLICT        455
FT                   /note="E -> G (in Ref. 3; BAH12630)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        506
FT                   /note="N -> S (in Ref. 3; BAH12630)"
FT                   /evidence="ECO:0000305"
FT   HELIX           121..123
FT                   /evidence="ECO:0000244|PDB:2H7B"
FT   HELIX           125..135
FT                   /evidence="ECO:0000244|PDB:2H7B"
FT   HELIX           137..140
FT                   /evidence="ECO:0000244|PDB:2H7B"
FT   HELIX           142..156
FT                   /evidence="ECO:0000244|PDB:2H7B"
FT   HELIX           162..172
FT                   /evidence="ECO:0000244|PDB:2H7B"
FT   STRAND          173..176
FT                   /evidence="ECO:0000244|PDB:2H7B"
FT   STRAND          179..181
FT                   /evidence="ECO:0000244|PDB:2H7B"
FT   HELIX           182..186
FT                   /evidence="ECO:0000244|PDB:2H7B"
FT   HELIX           189..199
FT                   /evidence="ECO:0000244|PDB:2H7B"
FT   HELIX           200..202
FT                   /evidence="ECO:0000244|PDB:2H7B"
FT   HELIX           209..212
FT                   /evidence="ECO:0000244|PDB:2H7B"
FT   HELIX           347..399
FT                   /evidence="ECO:0000244|PDB:1WQ6"
FT   HELIX           444..465
FT                   /evidence="ECO:0000244|PDB:2KYG"
FT   STRAND          512..514
FT                   /evidence="ECO:0000244|PDB:2ODD"
FT   STRAND          516..518
FT                   /evidence="ECO:0000244|PDB:2DJ8"
FT   STRAND          524..526
FT                   /evidence="ECO:0000244|PDB:2ODD"
FT   TURN            527..529
FT                   /evidence="ECO:0000244|PDB:2DJ8"
FT   STRAND          533..536
FT                   /evidence="ECO:0000244|PDB:2DJ8"
FT   HELIX           537..542
FT                   /evidence="ECO:0000244|PDB:2DJ8"
FT   HELIX           544..547
FT                   /evidence="ECO:0000244|PDB:2DJ8"
FT   TURN            548..550
FT                   /evidence="ECO:0000244|PDB:2DJ8"
SQ   SEQUENCE   604 AA;  67566 MW;  C3D2452F96E65679 CRC64;
     MISVKRNTWR ALSLVIGDCR KKGNFEYCQD RTEKHSTMPD SPVDVKTQSR LTPPTMPPPP
     TTQGAPRTSS FTPTTLTNGT SHSPTALNGA PSPPNGFSNG PSSSSSSSLA NQQLPPACGA
     RQLSKLKRFL TTLQQFGNDI SPEIGERVRT LVLGLVNSTL TIEEFHSKLQ EATNFPLRPF
     VIPFLKANLP LLQRELLHCA RLAKQNPAQY LAQHEQLLLD ASTTSPVDSS ELLLDVNENG
     KRRTPDRTKE NGFDREPLHS EHPSKRPCTI SPGQRYSPNN GLSYQPNGLP HPTPPPPQHY
     RLDDMAIAHH YRDSYRHPSH RDLRDRNRPM GLHGTRQEEM IDHRLTDREW AEEWKHLDHL
     LNCIMDMVEK TRRSLTVLRR CQEADREELN YWIRRYSDAE DLKKGGGSSS SHSRQQSPVN
     PDPVALDAHR EFLHRPASGY VPEEIWKKAE EAVNEVKRQA MTELQKAVSE AERKAHDMIT
     TERAKMERTV AEAKRQAAED ALAVINQQED SSESCWNCGR KASETCSGCN TARYCGSFCQ
     HKDWEKHHHI CGQTLQAQQQ GDTPAVSSSV TPNSGAGSPM DTPPAATPRS TTPGTPSTIE
     TTPR
//
ID   W8FW32_HUMAN            Unreviewed;       567 AA.
AC   W8FW32;
DT   14-MAY-2014, integrated into UniProtKB/TrEMBL.
DT   14-MAY-2014, sequence version 1.
DT   22-APR-2020, entry version 55.
DE   SubName: Full=CBFA2T1 isoform r1t1-7d56 {ECO:0000313|EMBL:AHK05730.1};
DE   SubName: Full=CBFA2T1 isoform r1t1-8a60 {ECO:0000313|EMBL:AHK05734.1};
GN   Name=RUNX1T1 {ECO:0000313|EMBL:AHK05730.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AHK05730.1};
RN   [1] {ECO:0000313|EMBL:AHK05730.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Migas A.A., Mishkova O.A., Ramanouskaya T.V., Ilyushonak I.M.,
RA   Aleinikova O.V., Grinev V.V.;
RT   "RUNX1T1/MTG8/ETO Gene Expression Status in Human t(8;21)(q22;q22)-Positive
RT   Acute Myeloid Leukemia Cells.";
RL   Submitted (NOV-2013) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; KF946514; AHK05730.1; -; mRNA.
DR   EMBL; KF946518; AHK05734.1; -; mRNA.
DR   RefSeq; NP_783553.1; NM_175635.2.
DR   RefSeq; NP_783554.1; NM_175636.2.
DR   RefSeq; XP_006716739.1; XM_006716676.3.
DR   RefSeq; XP_011515655.1; XM_011517353.2.
DR   RefSeq; XP_016869423.1; XM_017013934.1.
DR   RefSeq; XP_016869424.1; XM_017013935.1.
DR   RefSeq; XP_016869425.1; XM_017013936.1.
DR   RefSeq; XP_016869426.1; XM_017013937.1.
DR   Antibodypedia; 25672; 263 antibodies.
DR   GeneID; 862; -.
DR   UCSC; uc003yfb.3; human.
DR   CTD; 862; -.
DR   EuPathDB; HostDB:ENSG00000079102.16; -.
DR   eggNOG; ENOG410IG1Z; Eukaryota.
DR   eggNOG; ENOG410XR30; LUCA.
DR   HOGENOM; CLU_022077_2_0_1; -.
DR   ChiTaRS; RUNX1T1; human.
DR   GenomeRNAi; 862; -.
DR   Bgee; ENSG00000079102; Expressed in forebrain and 227 other tissues.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:InterPro.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:InterPro.
DR   Gene3D; 1.20.120.1110; -; 1.
DR   InterPro; IPR013290; CBFA2T1.
DR   InterPro; IPR013289; CBFA2T1/2/3.
DR   InterPro; IPR014896; NHR2.
DR   InterPro; IPR037249; TAFH/NHR1_dom_sf.
DR   InterPro; IPR003894; TAFH_NHR1.
DR   InterPro; IPR002893; Znf_MYND.
DR   PANTHER; PTHR10379; PTHR10379; 1.
DR   PANTHER; PTHR10379:SF5; PTHR10379:SF5; 1.
DR   Pfam; PF08788; NHR2; 1.
DR   Pfam; PF07531; TAFH; 1.
DR   Pfam; PF01753; zf-MYND; 1.
DR   PRINTS; PR01875; ETOFAMILY.
DR   PRINTS; PR01876; MTG8PROTEIN.
DR   SMART; SM00549; TAFH; 1.
DR   SUPFAM; SSF158553; SSF158553; 1.
DR   PROSITE; PS51119; TAFH; 1.
DR   PROSITE; PS01360; ZF_MYND_1; 1.
DR   PROSITE; PS50865; ZF_MYND_2; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00299494};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00134, ECO:0000256|SAAS:SAAS00299494};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00299494}.
FT   DOMAIN          83..178
FT                   /note="TAFH"
FT                   /evidence="ECO:0000259|PROSITE:PS51119"
FT   DOMAIN          478..514
FT                   /note="MYND-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50865"
FT   REGION          1..77
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          193..261
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          364..386
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          520..567
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          417..459
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        28..77
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        198..226
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        233..250
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   567 AA;  63212 MW;  44AADF2EC7032050 CRC64;
     MPDSPVDVKT QSRLTPPTMP PPPTTQGAPR TSSFTPTTLT NGTSHSPTAL NGAPSPPNGF
     SNGPSSSSSS SLANQQLPPA CGARQLSKLK RFLTTLQQFG NDISPEIGER VRTLVLGLVN
     STLTIEEFHS KLQEATNFPL RPFVIPFLKA NLPLLQRELL HCARLAKQNP AQYLAQHEQL
     LLDASTTSPV DSSELLLDVN ENGKRRTPDR TKENGFDREP LHSEHPSKRP CTISPGQRYS
     PNNGLSYQPN GLPHPTPPPP QHYRLDDMAI AHHYRDSYRH PSHRDLRDRN RPMGLHGTRQ
     EEMIDHRLTD REWAEEWKHL DHLLNCIMDM VEKTRRSLTV LRRCQEADRE ELNYWIRRYS
     DAEDLKKGGG SSSSHSRQQS PVNPDPVALD AHREFLHRPA SGYVPEEIWK KAEEAVNEVK
     RQAMTELQKA VSEAERKAHD MITTERAKME RTVAEAKRQA AEDALAVINQ QEDSSESCWN
     CGRKASETCS GCNTARYCGS FCQHKDWEKH HHICGQTLQA QQQGDTPAVS SSVTPNSGAG
     SPMDTPPAAT PRSTTPGTPS TIETTPR
//
ID   STA5B_HUMAN             Reviewed;         787 AA.
AC   P51692; Q8WWS8;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   16-JAN-2004, sequence version 2.
DT   22-APR-2020, entry version 204.
DE   RecName: Full=Signal transducer and activator of transcription 5B;
GN   Name=STAT5B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=8732682; DOI=10.1210/mend.10.5.8732682;
RA   Silva C.M., Lu H., Day R.N.;
RT   "Characterization and cloning of STAT5 from IM-9 cells and its activation
RT   by growth hormone.";
RL   Mol. Endocrinol. 10:508-518(1996).
RN   [2]
RP   SEQUENCE REVISION TO 628; 717 AND 720.
RA   Silva C.M., Lu H.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8631883; DOI=10.1074/jbc.271.18.10738;
RA   Lin J.-X., Mietz J., Modi W.S., John S., Leonard W.J.;
RT   "Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A
RT   and Stat5B DNA binding activity in COS-7 cells.";
RL   J. Biol. Chem. 271:10738-10744(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=12039059; DOI=10.1016/s0378-1119(02)00421-3;
RA   Ambrosio R., Fimiani G., Monfregola J., Sanzari E., De Felice N.,
RA   Salerno M.C., Pignata C., D'Urso M., Ursini M.V.;
RT   "The structure of human STAT5A and B genes reveals two regions of nearly
RT   identical sequence and an alternative tissue specific STAT5B promoter.";
RL   Gene 285:311-318(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION BY INSR, INTERACTION WITH INSR, AND MUTAGENESIS OF THR-684.
RX   PubMed=9428692; DOI=10.1111/j.1432-1033.1997.0411a.x;
RA   Sawka-Verhelle D., Filloux C., Tartare-Deckert S., Mothe I.,
RA   Van Obberghen E.;
RT   "Identification of Stat 5B as a substrate of the insulin receptor.";
RL   Eur. J. Biochem. 250:411-417(1997).
RN   [7]
RP   INTERACTION WITH NMI.
RX   PubMed=9989503; DOI=10.1016/s0092-8674(00)80965-4;
RA   Zhu M.-H., John S., Berg M., Leonard W.J.;
RT   "Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-
RT   mediated signaling.";
RL   Cell 96:121-130(1999).
RN   [8]
RP   PHOSPHORYLATION AT TYR-699, AND MUTAGENESIS OF TYR-699.
RX   PubMed=12411494; DOI=10.1093/emboj/cdf562;
RA   Klejman A., Schreiner S.J., Nieborowska-Skorska M., Slupianek A.,
RA   Wilson M., Smithgall T.E., Skorski T.;
RT   "The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid
RT   leukemia cells.";
RL   EMBO J. 21:5766-5774(2002).
RN   [9]
RP   CAUTION.
RX   PubMed=11773439; DOI=10.1210/mend.16.1.0761;
RA   Aoki N., Matsuda T.;
RT   "A nuclear protein tyrosine phosphatase TC-PTP is a potential negative
RT   regulator of the PRL-mediated signaling pathway: dephosphorylation and
RT   deactivation of signal transducer and activator of transcription 5a and 5b
RT   by TC-PTP in nucleus.";
RL   Mol. Endocrinol. 16:58-69(2002).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-193, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-193, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-128, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-193, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-90; SER-128 AND SER-193, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   RETRACTION NOTICE OF PUBMED:23186163, AND CAUTION.
RX   PubMed=24319783; DOI=10.1210/me.2013-1264;
RA   Aoki N., Matsuda T.;
RT   "Retraction.";
RL   Mol. Endocrinol. 27:1982-1982(2013).
RN   [18]
RP   INTERACTION WITH NCOA1.
RX   PubMed=12954634; DOI=10.1074/jbc.m303644200;
RA   Litterst C.M., Kliem S., Marilley D., Pfitzner E.;
RT   "NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL
RT   motif in the alpha-helical region of the STAT5 transactivation domain.";
RL   J. Biol. Chem. 278:45340-45351(2003).
RN   [19]
RP   PHOSPHORYLATION IN RESPONSE TO FLT3 SIGNALING.
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric ALL
RT   with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
RN   [20]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [21]
RP   PHOSPHORYLATION BY JAK2.
RX   PubMed=15121872; DOI=10.1128/mcb.24.10.4557-4570.2004;
RA   Kurzer J.H., Argetsinger L.S., Zhou Y.J., Kouadio J.L., O'Shea J.J.,
RA   Carter-Su C.;
RT   "Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation
RT   of JAK2 by SH2-B beta.";
RL   Mol. Cell. Biol. 24:4557-4570(2004).
RN   [22]
RP   INTERACTION WITH SOCS7.
RX   PubMed=15677474; DOI=10.1074/jbc.m411596200;
RA   Martens N., Uzan G., Wery M., Hooghe R., Hooghe-Peters E.L., Gertler A.;
RT   "Suppressor of cytokine signaling 7 inhibits prolactin, growth hormone, and
RT   leptin signaling by interacting with STAT5 or STAT3 and attenuating their
RT   nuclear translocation.";
RL   J. Biol. Chem. 280:13817-13823(2005).
RN   [23]
RP   INVOLVEMENT IN GHII.
RX   PubMed=15827093; DOI=10.1210/jc.2005-0515;
RA   Hwa V., Little B., Adiyaman P., Kofoed E.M., Pratt K.L., Ocal G.,
RA   Berberoglu M., Rosenfeld R.G.;
RT   "Severe growth hormone insensitivity resulting from total absence of signal
RT   transducer and activator of transcription 5b.";
RL   J. Clin. Endocrinol. Metab. 90:4260-4266(2005).
RN   [24]
RP   PHOSPHORYLATION AT TYR-699 BY PTK6.
RX   PubMed=17997837; DOI=10.1186/bcr1794;
RA   Weaver A.M., Silva C.M.;
RT   "Signal transducer and activator of transcription 5b: a new target of
RT   breast tumor kinase/protein tyrosine kinase 6.";
RL   Breast Cancer Res. 9:R79-R79(2007).
RN   [25]
RP   FUNCTION.
RX   PubMed=20702587; DOI=10.1091/mbc.e10-01-0040;
RA   Vignudelli T., Selmi T., Martello A., Parenti S., Grande A., Gemelli C.,
RA   Zanocco-Marani T., Ferrari S.;
RT   "ZFP36L1 negatively regulates erythroid differentiation of CD34+
RT   hematopoietic stem cells by interfering with the Stat5b pathway.";
RL   Mol. Biol. Cell 21:3340-3351(2010).
RN   [26]
RP   INTERACTION WITH CPEB3.
RX   PubMed=20639532; DOI=10.1093/nar/gkq634;
RA   Peng S.C., Lai Y.T., Huang H.Y., Huang H.D., Huang Y.S.;
RT   "A novel role of CPEB3 in regulating EGFR gene transcription via
RT   association with Stat5b in neurons.";
RL   Nucleic Acids Res. 38:7446-7457(2010).
RN   [27]
RP   PHOSPHORYLATION IN RESPONSE TO KIT SIGNALING.
RX   PubMed=21135090; DOI=10.1074/jbc.m110.182642;
RA   Chaix A., Lopez S., Voisset E., Gros L., Dubreuil P., De Sepulveda P.;
RT   "Mechanisms of STAT protein activation by oncogenic KIT mutants in
RT   neoplastic mast cells.";
RL   J. Biol. Chem. 286:5956-5966(2011).
RN   [28]
RP   VARIANT GHII PRO-630.
RX   PubMed=13679528; DOI=10.1056/nejmoa022926;
RA   Kofoed E.M., Hwa V., Little B., Woods K.A., Buckway C.K., Tsubaki J.,
RA   Pratt K.L., Bezrodnik L., Jasper H., Tepper A., Heinrich J.J.,
RA   Rosenfeld R.G.;
RT   "Growth hormone insensitivity associated with a STAT5b mutation.";
RL   N. Engl. J. Med. 349:1139-1147(2003).
RN   [29]
RP   VARIANT GHII SER-646, AND CHARACTERIZATION OF VARIANT GHII SER-646.
RX   PubMed=22419735; DOI=10.1210/jc.2011-2554;
RA   Scaglia P.A., Martinez A.S., Feigerlova E., Bezrodnik L., Gaillard M.I.,
RA   Di Giovanni D., Ballerini M.G., Jasper H.G., Heinrich J.J., Fang P.,
RA   Domene H.M., Rosenfeld R.G., Hwa V.;
RT   "A Novel Missense Mutation in the SH2 Domain of the STAT5B Gene Results in
RT   a transcriptionally inactive STAT5b associated with severe IGF-I
RT   deficiency, immune dysfunction, and lack of pulmonary disease.";
RL   J. Clin. Endocrinol. Metab. 97:E830-839(2012).
CC   -!- FUNCTION: Carries out a dual function: signal transduction and
CC       activation of transcription. Mediates cellular responses to the
CC       cytokine KITLG/SCF and other growth factors. Binds to the GAS element
CC       and activates PRL-induced transcription. Positively regulates
CC       hematopoietic/erythroid differentiation. {ECO:0000269|PubMed:20702587,
CC       ECO:0000269|PubMed:8732682}.
CC   -!- SUBUNIT: Forms a homodimer or a heterodimer with a related family
CC       member. Binds NR3C1 (By similarity). Interacts with NCOA1
CC       (PubMed:12954634). Interacts with NMI (PubMed:9989503). Interacts with
CC       SOCS7 (PubMed:15677474). Interacts (via SH2 domain) with INSR
CC       (PubMed:9428692). Interacts with CPEB3; this inhibits STAT5B-mediated
CC       transcriptional activation (PubMed:20639532).
CC       {ECO:0000250|UniProtKB:P42232, ECO:0000269|PubMed:12954634,
CC       ECO:0000269|PubMed:15677474, ECO:0000269|PubMed:20639532,
CC       ECO:0000269|PubMed:9428692, ECO:0000269|PubMed:9989503}.
CC   -!- INTERACTION:
CC       P51692; P38936: CDKN1A; NbExp=3; IntAct=EBI-1186119, EBI-375077;
CC       P51692; Q13111: CHAF1A; NbExp=3; IntAct=EBI-1186119, EBI-1020839;
CC       P51692; Q96EY1: DNAJA3; NbExp=2; IntAct=EBI-1186119, EBI-356767;
CC       P51692; I6L957: HNRNPA2B1; NbExp=3; IntAct=EBI-1186119, EBI-1642515;
CC       P51692; Q8TCE9: LGALS14; NbExp=3; IntAct=EBI-1186119, EBI-10274069;
CC       P51692; P61968: LMO4; NbExp=3; IntAct=EBI-1186119, EBI-2798728;
CC       P51692; Q71SY5: MED25; NbExp=3; IntAct=EBI-1186119, EBI-394558;
CC       P51692; P82932: MRPS6; NbExp=3; IntAct=EBI-1186119, EBI-716172;
CC       P51692; Q13287: NMI; NbExp=7; IntAct=EBI-1186119, EBI-372942;
CC       P51692; Q92569: PIK3R3; NbExp=3; IntAct=EBI-1186119, EBI-79893;
CC       P51692; Q09028: RBBP4; NbExp=3; IntAct=EBI-1186119, EBI-620823;
CC       P51692; Q99469: STAC; NbExp=3; IntAct=EBI-1186119, EBI-2652799;
CC       P51692; P51687: SUOX; NbExp=3; IntAct=EBI-1186119, EBI-3921347;
CC       P51692; Q96PN8: TSSK3; NbExp=3; IntAct=EBI-1186119, EBI-3918381;
CC       P51692; O75604: USP2; NbExp=3; IntAct=EBI-1186119, EBI-743272;
CC       P51692; Q86VK4-3: ZNF410; NbExp=3; IntAct=EBI-1186119, EBI-11741890;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P42232}. Nucleus
CC       {ECO:0000250|UniProtKB:P42232}. Note=Translocated into the nucleus in
CC       response to phosphorylation. {ECO:0000250}.
CC   -!- PTM: Tyrosine phosphorylated in response to signaling via activated
CC       KIT, resulting in translocation to the nucleus. Tyrosine phosphorylated
CC       in response to signaling via activated FLT3; wild-type FLT3 results in
CC       much weaker phosphorylation than constitutively activated mutant FLT3.
CC       Alternatively, can be phosphorylated by JAK2. Phosphorylation at Tyr-
CC       699 by PTK6 or HCK leads to an increase of its transcriptional
CC       activity. {ECO:0000269|PubMed:12411494, ECO:0000269|PubMed:14504097,
CC       ECO:0000269|PubMed:15121872, ECO:0000269|PubMed:17997837,
CC       ECO:0000269|PubMed:21135090, ECO:0000269|PubMed:9428692}.
CC   -!- DISEASE: Growth hormone insensitivity with immunodeficiency (GHII)
CC       [MIM:245590]: A disease characterized by short stature, growth hormone
CC       deficiency in the presence of normal to elevated circulating
CC       concentrations of growth hormone, resistance to exogeneous growth
CC       hormone therapy, and recurrent infections.
CC       {ECO:0000269|PubMed:13679528, ECO:0000269|PubMed:15827093,
CC       ECO:0000269|PubMed:22419735}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the transcription factor STAT family.
CC       {ECO:0000305}.
CC   -!- CAUTION: It was reported that dephosphorylation on tyrosine residues by
CC       PTPN2 would negatively regulate prolactin signaling pathway
CC       (PubMed:11773439). However, the corresponding article has been
CC       retracted (PubMed:24319783). {ECO:0000269|PubMed:11773439,
CC       ECO:0000303|PubMed:24319783}.
CC   -!- WEB RESOURCE: Name=STAT5Bbase; Note=STAT5B mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/STAT5Bbase/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=STAT5 entry;
CC       URL="https://en.wikipedia.org/wiki/STAT5";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/STAT5BID217ch17q21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U48730; AAC50485.2; -; mRNA.
DR   EMBL; U47686; AAC50491.1; -; mRNA.
DR   EMBL; AJ412888; CAD19638.1; -; Genomic_DNA.
DR   EMBL; AJ412889; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412890; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412891; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412892; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412893; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412894; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412895; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412896; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412897; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412898; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412899; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; BC065227; AAH65227.1; -; mRNA.
DR   CCDS; CCDS11423.1; -.
DR   RefSeq; NP_036580.2; NM_012448.3.
DR   PDB; 6MBW; X-ray; 3.29 A; A/B=136-703.
DR   PDB; 6MBZ; X-ray; 3.21 A; A/B=136-703.
DR   PDBsum; 6MBW; -.
DR   PDBsum; 6MBZ; -.
DR   SMR; P51692; -.
DR   BioGrid; 112654; 63.
DR   CORUM; P51692; -.
DR   IntAct; P51692; 116.
DR   MINT; P51692; -.
DR   STRING; 9606.ENSP00000293328; -.
DR   BindingDB; P51692; -.
DR   ChEMBL; CHEMBL5817; -.
DR   DrugBank; DB01254; Dasatinib.
DR   iPTMnet; P51692; -.
DR   PhosphoSitePlus; P51692; -.
DR   BioMuta; STAT5B; -.
DR   DMDM; 41019536; -.
DR   EPD; P51692; -.
DR   jPOST; P51692; -.
DR   MassIVE; P51692; -.
DR   MaxQB; P51692; -.
DR   PaxDb; P51692; -.
DR   PeptideAtlas; P51692; -.
DR   PRIDE; P51692; -.
DR   ProteomicsDB; 56378; -.
DR   Antibodypedia; 3804; 858 antibodies.
DR   DNASU; 6777; -.
DR   Ensembl; ENST00000293328; ENSP00000293328; ENSG00000173757.
DR   GeneID; 6777; -.
DR   KEGG; hsa:6777; -.
DR   UCSC; uc002hzh.4; human.
DR   CTD; 6777; -.
DR   DisGeNET; 6777; -.
DR   GeneCards; STAT5B; -.
DR   HGNC; HGNC:11367; STAT5B.
DR   HPA; ENSG00000173757; Low tissue specificity.
DR   MalaCards; STAT5B; -.
DR   MIM; 245590; phenotype.
DR   MIM; 604260; gene.
DR   neXtProt; NX_P51692; -.
DR   OpenTargets; ENSG00000173757; -.
DR   Orphanet; 520; Acute promyelocytic leukemia.
DR   Orphanet; 220465; Laron syndrome with immunodeficiency.
DR   PharmGKB; PA36186; -.
DR   eggNOG; KOG3667; Eukaryota.
DR   eggNOG; ENOG410XPN8; LUCA.
DR   GeneTree; ENSGT00950000182688; -.
DR   HOGENOM; CLU_014189_2_2_1; -.
DR   InParanoid; P51692; -.
DR   KO; K11224; -.
DR   OMA; IWLNRQQ; -.
DR   OrthoDB; 327469at2759; -.
DR   PhylomeDB; P51692; -.
DR   TreeFam; TF318648; -.
DR   Reactome; R-HSA-1170546; Prolactin receptor signaling.
DR   Reactome; R-HSA-1266695; Interleukin-7 signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-2586552; Signaling by Leptin.
DR   Reactome; R-HSA-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling.
DR   Reactome; R-HSA-8854691; Interleukin-20 family signaling.
DR   Reactome; R-HSA-8983432; Interleukin-15 signaling.
DR   Reactome; R-HSA-8985947; Interleukin-9 signaling.
DR   Reactome; R-HSA-9020558; Interleukin-2 signaling.
DR   Reactome; R-HSA-9020958; Interleukin-21 signaling.
DR   Reactome; R-HSA-9027283; Erythropoietin activates STAT5.
DR   Reactome; R-HSA-9645135; STAT5 Activation.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   SignaLink; P51692; -.
DR   SIGNOR; P51692; -.
DR   ChiTaRS; STAT5B; human.
DR   GeneWiki; STAT5B; -.
DR   GenomeRNAi; 6777; -.
DR   Pharos; P51692; Tchem.
DR   PRO; PR:P51692; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P51692; protein.
DR   Bgee; ENSG00000173757; Expressed in blood and 233 other tissues.
DR   ExpressionAtlas; P51692; baseline and differential.
DR   Genevisible; P51692; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0035259; F:glucocorticoid receptor binding; IPI:BHF-UCL.
DR   GO; GO:0046983; F:protein dimerization activity; ISS:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IDA:BHF-UCL.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0006952; P:defense response; IBA:GO_Central.
DR   GO; GO:0046543; P:development of secondary female sexual characteristics; IEA:Ensembl.
DR   GO; GO:0046544; P:development of secondary male sexual characteristics; IEA:Ensembl.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0060397; P:growth hormone receptor signaling pathway via JAK-STAT; IDA:BHF-UCL.
DR   GO; GO:0035723; P:interleukin-15-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038110; P:interleukin-2-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038111; P:interleukin-7-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038113; P:interleukin-9-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0019915; P:lipid storage; IEA:Ensembl.
DR   GO; GO:0001553; P:luteinization; IEA:Ensembl.
DR   GO; GO:0097531; P:mast cell migration; IEA:Ensembl.
DR   GO; GO:0001779; P:natural killer cell differentiation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045647; P:negative regulation of erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0048541; P:Peyer's patch development; IEA:Ensembl.
DR   GO; GO:0042104; P:positive regulation of activated T cell proliferation; IEA:Ensembl.
DR   GO; GO:0045579; P:positive regulation of B cell differentiation; IEA:Ensembl.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IDA:UniProtKB.
DR   GO; GO:0045588; P:positive regulation of gamma-delta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0045086; P:positive regulation of interleukin-2 biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0032825; P:positive regulation of natural killer cell differentiation; IEA:Ensembl.
DR   GO; GO:0045954; P:positive regulation of natural killer cell mediated cytotoxicity; IEA:Ensembl.
DR   GO; GO:0032819; P:positive regulation of natural killer cell proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0042448; P:progesterone metabolic process; IEA:Ensembl.
DR   GO; GO:0007259; P:receptor signaling pathway via JAK-STAT; IBA:GO_Central.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IBA:GO_Central.
DR   GO; GO:0030856; P:regulation of epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; ISS:BHF-UCL.
DR   GO; GO:0019218; P:regulation of steroid metabolic process; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:ProtInc.
DR   GO; GO:0032355; P:response to estradiol; IDA:BHF-UCL.
DR   GO; GO:0070670; P:response to interleukin-4; IEA:Ensembl.
DR   GO; GO:0043434; P:response to peptide hormone; IBA:GO_Central.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0043029; P:T cell homeostasis; IEA:Ensembl.
DR   GO; GO:0019530; P:taurine metabolic process; ISS:BHF-UCL.
DR   CDD; cd10420; SH2_STAT5b; 1.
DR   Gene3D; 1.10.532.10; -; 1.
DR   Gene3D; 2.60.40.630; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR001217; STAT.
DR   InterPro; IPR035858; STAT5a/5b.
DR   InterPro; IPR035886; STAT5b_SH2.
DR   InterPro; IPR036535; STAT_N_sf.
DR   InterPro; IPR013800; STAT_TF_alpha.
DR   InterPro; IPR015988; STAT_TF_coiled-coil.
DR   InterPro; IPR013801; STAT_TF_DNA-bd.
DR   InterPro; IPR012345; STAT_TF_DNA-bd_N.
DR   InterPro; IPR013799; STAT_TF_prot_interaction.
DR   PANTHER; PTHR11801; PTHR11801; 1.
DR   PANTHER; PTHR11801:SF47; PTHR11801:SF47; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF01017; STAT_alpha; 1.
DR   Pfam; PF02864; STAT_bind; 1.
DR   Pfam; PF02865; STAT_int; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00964; STAT_int; 1.
DR   SUPFAM; SSF47655; SSF47655; 1.
DR   SUPFAM; SSF48092; SSF48092; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Cytoplasm; Disease mutation; DNA-binding;
KW   Dwarfism; Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   SH2 domain; Transcription; Transcription regulation.
FT   CHAIN           1..787
FT                   /note="Signal transducer and activator of transcription 5B"
FT                   /id="PRO_0000182429"
FT   DOMAIN          589..686
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   REGION          232..321
FT                   /note="Required for interaction with NMI"
FT                   /evidence="ECO:0000269|PubMed:9989503"
FT   MOD_RES         90
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         128
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         193
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:16964243,
FT                   ECO:0000244|PubMed:18691976, ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         682
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P42229"
FT   MOD_RES         699
FT                   /note="Phosphotyrosine; by HCK, JAK and PTK6"
FT                   /evidence="ECO:0000269|PubMed:12411494,
FT                   ECO:0000269|PubMed:17997837"
FT   VARIANT         130
FT                   /note="A -> V (in dbSNP:rs2277619)"
FT                   /id="VAR_052074"
FT   VARIANT         630
FT                   /note="A -> P (in GHII; affects activation by growth
FT                   hormone or interferon-gamma; dbSNP:rs121908501)"
FT                   /evidence="ECO:0000269|PubMed:13679528"
FT                   /id="VAR_018728"
FT   VARIANT         646
FT                   /note="F -> S (in GHII; transcriptionally inactive)"
FT                   /evidence="ECO:0000269|PubMed:22419735"
FT                   /id="VAR_067368"
FT   MUTAGEN         684
FT                   /note="T->A: Abolishes interaction with INSR."
FT                   /evidence="ECO:0000269|PubMed:9428692"
FT   MUTAGEN         699
FT                   /note="Y->F: Abolishes phosphorylation by HCK."
FT                   /evidence="ECO:0000269|PubMed:12411494"
FT   CONFLICT        230
FT                   /note="A -> P (in Ref. 2; AAC50491)"
FT                   /evidence="ECO:0000305"
FT   HELIX           141..182
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           194..249
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           251..262
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   TURN            263..265
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           273..302
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           309..330
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          332..336
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          340..343
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          347..354
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   TURN            355..364
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          368..375
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           376..383
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          400..402
FT                   /evidence="ECO:0000244|PDB:6MBW"
FT   STRAND          404..406
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   TURN            407..410
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          411..421
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   TURN            435..437
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          440..449
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   TURN            451..454
FT                   /evidence="ECO:0000244|PDB:6MBW"
FT   STRAND          456..462
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          468..471
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           472..488
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          500..503
FT                   /evidence="ECO:0000244|PDB:6MBW"
FT   HELIX           504..519
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           527..537
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           545..548
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          552..554
FT                   /evidence="ECO:0000244|PDB:6MBW"
FT   HELIX           555..559
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          564..567
FT                   /evidence="ECO:0000244|PDB:6MBW"
FT   HELIX           569..583
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           586..590
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           600..608
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          614..619
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          621..623
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          627..631
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           636..638
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           648..653
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           656..662
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   STRAND          668..672
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   HELIX           675..679
FT                   /evidence="ECO:0000244|PDB:6MBZ"
FT   TURN            680..682
FT                   /evidence="ECO:0000244|PDB:6MBZ"
SQ   SEQUENCE   787 AA;  89866 MW;  AA2F1CAB20955ACA CRC64;
     MAVWIQAQQL QGEALHQMQA LYGQHFPIEV RHYLSQWIES QAWDSVDLDN PQENIKATQL
     LEGLVQELQK KAEHQVGEDG FLLKIKLGHY ATQLQNTYDR CPMELVRCIR HILYNEQRLV
     REANNGSSPA GSLADAMSQK HLQINQTFEE LRLVTQDTEN ELKKLQQTQE YFIIQYQESL
     RIQAQFGPLA QLSPQERLSR ETALQQKQVS LEAWLQREAQ TLQQYRVELA EKHQKTLQLL
     RKQQTIILDD ELIQWKRRQQ LAGNGGPPEG SLDVLQSWCE KLAEIIWQNR QQIRRAEHLC
     QQLPIPGPVE EMLAEVNATI TDIISALVTS TFIIEKQPPQ VLKTQTKFAA TVRLLVGGKL
     NVHMNPPQVK ATIISEQQAK SLLKNENTRN DYSGEILNNC CVMEYHQATG TLSAHFRNMS
     LKRIKRSDRR GAESVTEEKF TILFESQFSV GGNELVFQVK TLSLPVVVIV HGSQDNNATA
     TVLWDNAFAE PGRVPFAVPD KVLWPQLCEA LNMKFKAEVQ SNRGLTKENL VFLAQKLFNN
     SSSHLEDYSG LSVSWSQFNR ENLPGRNYTF WQWFDGVMEV LKKHLKPHWN DGAILGFVNK
     QQAHDLLINK PDGTFLLRFS DSEIGGITIA WKFDSQERMF WNLMPFTTRD FSIRSLADRL
     GDLNYLIYVF PDRPKDEVYS KYYTPVPCES ATAKAVDGYV KPQIKQVVPE FVNASADAGG
     GSATYMDQAP SPAVCPQAHY NMYPQNPDSV LDTDGDFDLE DTMDVARRVE ELLGRPMDSQ
     WIPHAQS
//
ID   J3QQW9_HUMAN            Unreviewed;       716 AA.
AC   J3QQW9;
DT   03-OCT-2012, integrated into UniProtKB/TrEMBL.
DT   03-OCT-2012, sequence version 1.
DT   22-APR-2020, entry version 59.
DE   SubName: Full=Polycomb protein SUZ12 {ECO:0000313|Ensembl:ENSP00000463936};
GN   Name=SUZ12 {ECO:0000313|Ensembl:ENSP00000463936};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000463936, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000213|PubMed:17081983}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [2] {ECO:0000313|Ensembl:ENSP00000463936, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [3] {ECO:0000213|PubMed:18220336}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.D., Yates J.R.;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [4] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [5] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [6] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [7] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [8] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [9] {ECO:0000313|Ensembl:ENSP00000463936}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (AUG-2012) to UniProtKB.
RN   [10] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11] {ECO:0000213|PubMed:24129315}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24129315;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [12] {ECO:0000213|PubMed:28112733}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC090616; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC129917; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001308136.1; NM_001321207.1.
DR   EPD; J3QQW9; -.
DR   jPOST; J3QQW9; -.
DR   MaxQB; J3QQW9; -.
DR   PeptideAtlas; J3QQW9; -.
DR   PRIDE; J3QQW9; -.
DR   Antibodypedia; 27067; 339 antibodies.
DR   Ensembl; ENST00000580398; ENSP00000463936; ENSG00000178691.
DR   GeneID; 23512; -.
DR   UCSC; uc002hgt.3; human.
DR   CTD; 23512; -.
DR   EuPathDB; HostDB:ENSG00000178691.10; -.
DR   HGNC; HGNC:17101; SUZ12.
DR   OpenTargets; ENSG00000178691; -.
DR   eggNOG; KOG2350; Eukaryota.
DR   eggNOG; ENOG410YJ29; LUCA.
DR   GeneTree; ENSGT00390000012364; -.
DR   HOGENOM; CLU_014678_0_0_1; -.
DR   ChiTaRS; SUZ12; human.
DR   GenomeRNAi; 23512; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000178691; Expressed in female gonad and 235 other tissues.
DR   ExpressionAtlas; J3QQW9; baseline and differential.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   InterPro; IPR019135; Polycomb_protein_VEFS-Box.
DR   Pfam; PF09733; VEFS-Box; 1.
PE   1: Evidence at protein level;
KW   Proteomics identification {ECO:0000213|EPD:J3QQW9,
KW   ECO:0000213|MaxQB:J3QQW9, ECO:0000213|PeptideAtlas:J3QQW9,
KW   ECO:0000213|ProteomicsDB:J3QQW9};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   DOMAIN          524..656
FT                   /note="VEFS-Box"
FT                   /evidence="ECO:0000259|Pfam:PF09733"
FT   REGION          1..23
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          343..376
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          664..716
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        352..376
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        675..716
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   716 AA;  80322 MW;  7DC4178E12AEB8D7 CRC64;
     MAPQKHGGGG GGGSGPSAGS GGGGFGGSAA VAAATASGGK SGGGSCGGGG SYSASSSSSA
     AAAAGAAVLP VKKPKMEHVQ ADHELFLQAF EKPTQIYRFL RTRNLIAPIF LHRTLTYMSH
     RNSRTNIKSL SAHLQLTFTG FFHKNDKPSP NSENEQNSVT LEVLLVKVCH KKRKDVSCPI
     RQVPTGKKQV PLNPDLNQTK PGNFPSLAVS SNEFEPSNSH MVKSYSLLFR VTRPGRREFN
     GMINGETNEN IDVNEELPAR RKRNREDGEK TFVAQMTVFD KNRRLQLLDG EYEVAMQEME
     ECPISKKRAT WETILDGKRL PPFETFSQGP TLQFTLRWTG ETNDKSTAPI AKPLATRNSE
     SLHQENKPGS VKPTQTIAVK ESLTTDLQTR KEKDTPNENR QKLRIFYQFL YNNNTRQQTE
     ARDDLHCPWC TLNCRKLYSL LKHLKLCHSR FIFNYVYHPK GARIDVSINE CYDGSYAGNP
     QDIHRQPGFA FSRNGPVKRT PITHILVCRP KRTKASMSEF LESEDGEVEQ QRTYSSGHNR
     LYFHSDTCLP LRPQEMEVDS EDEKDPEWLR EKTITQIEEF SDVNEGEKEV MKLWNLHVMK
     HGFIADNQMN HACMLFVENY GQKIIKKNLC RNFMLHLVSM HDFNLISIMS IDKAVTKLRE
     MQQKLEKGES ASPANEEITE EQNGTANGFS EINSKEKALE TDSVSGVSKQ SKKQKL
//
ID   SUZ12_HUMAN             Reviewed;         739 AA.
AC   Q15022; Q96BD9;
DT   11-JUL-2003, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   22-APR-2020, entry version 192.
DE   RecName: Full=Polycomb protein SUZ12;
DE   AltName: Full=Chromatin precipitated E2F target 9 protein;
DE            Short=ChET 9 protein;
DE   AltName: Full=Joined to JAZF1 protein;
DE   AltName: Full=Suppressor of zeste 12 protein homolog;
GN   Name=SUZ12; Synonyms=CHET9, JJAZ1, KIAA0160;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-216.
RC   TISSUE=Bone marrow;
RX   PubMed=8590280; DOI=10.1093/dnares/2.4.167;
RA   Nagase T., Seki N., Tanaka A., Ishikawa K., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. IV. The
RT   coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of
RT   cDNA clones from human cell line KG-1.";
RL   DNA Res. 2:167-174(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   DISEASE, AND CHROMOSOMAL TRANSLOCATION WITH JAZF1.
RX   PubMed=11371647; DOI=10.1073/pnas.101132598;
RA   Koontz J.I., Soreng A.L., Nucci M., Kuo F.C., Pauwels P.,
RA   van Den Berghe H., Cin P.D., Fletcher J.A., Sklar J.;
RT   "Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal
RT   tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:6348-6353(2001).
RN   [4]
RP   INDUCTION.
RX   PubMed=11564866; DOI=10.1128/mcb.21.20.6820-6832.2001;
RA   Weinmann A.S., Bartley S.M., Zhang T., Zhang M.Q., Farnham P.J.;
RT   "Use of chromatin immunoprecipitation to clone novel E2F target
RT   promoters.";
RL   Mol. Cell. Biol. 21:6820-6832(2001).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2 COMPLEX
RP   WITH EED; EZH2; RBBP4 AND RBBP7, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2
RP   COMPLEX.
RX   PubMed=12435631; DOI=10.1101/gad.1035902;
RA   Kuzmichev A., Nishioka K., Erdjument-Bromage H., Tempst P., Reinberg D.;
RT   "Histone methyltransferase activity associated with a human multiprotein
RT   complex containing the Enhancer of Zeste protein.";
RL   Genes Dev. 16:2893-2905(2002).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2 COMPLEX
RP   WITH EED; EZH2; RBBP4 AND RBBP7, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2
RP   COMPLEX.
RX   PubMed=12351676; DOI=10.1126/science.1076997;
RA   Cao R., Wang L., Wang H., Xia L., Erdjument-Bromage H., Tempst P.,
RA   Jones R.S., Zhang Y.;
RT   "Role of histone H3 lysine 27 methylation in Polycomb-group silencing.";
RL   Science 298:1039-1043(2002).
RN   [7]
RP   INDUCTION.
RX   PubMed=14532106; DOI=10.1093/emboj/cdg542;
RA   Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K.;
RT   "EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and
RT   amplified in cancer.";
RL   EMBO J. 22:5323-5335(2003).
RN   [8]
RP   FUNCTION, INTERACTION WITH EZH2, METHYLTRANSFERASE ACTIVITY OF THE PRC2
RP   COMPLEX, AND DEVELOPMENTAL STAGE.
RX   PubMed=15385962; DOI=10.1038/sj.emboj.7600402;
RA   Pasini D., Bracken A.P., Jensen M.R., Lazzerini Denchi E., Helin K.;
RT   "Suz12 is essential for mouse development and for EZH2 histone
RT   methyltransferase activity.";
RL   EMBO J. 23:4061-4071(2004).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=15231737; DOI=10.1101/gad.1200204;
RA   Kirmizis A., Bartley S.M., Kuzmichev A., Margueron R., Reinberg D.,
RA   Green R., Farnham P.J.;
RT   "Silencing of human polycomb target genes is associated with methylation of
RT   histone H3 Lys 27.";
RL   Genes Dev. 18:1592-1605(2004).
RN   [10]
RP   CHARACTERIZATION OF THE PRC2 AND PRC3 COMPLEXES INCLUDING EED; EZH2; RBBP4;
RP   RBBP7 AND SUZ12, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 AND PRC3
RP   COMPLEXES.
RX   PubMed=15099518; DOI=10.1016/s1097-2765(04)00185-6;
RA   Kuzmichev A., Jenuwein T., Tempst P., Reinberg D.;
RT   "Different EZH2-containing complexes target methylation of histone H1 or
RT   nucleosomal histone H3.";
RL   Mol. Cell 14:183-193(2004).
RN   [11]
RP   FUNCTION, CHARACTERIZATION OF THE PRC2 COMPLEX INCLUDING AEBP2; EED; EZH2;
RP   RBBP4 AND SUZ12, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=15225548; DOI=10.1016/j.molcel.2004.06.020;
RA   Cao R., Zhang Y.;
RT   "SUZ12 is required for both the histone methyltransferase activity and the
RT   silencing function of the EED-EZH2 complex.";
RL   Mol. Cell 15:57-67(2004).
RN   [12]
RP   CHARACTERIZATION OF THE PRC4 COMPLEX INCLUDING EED; EZH2; RBBP4; RBBP7;
RP   SUZ12 AND SIRT1, METHYLTRANSFERASE ACTIVITY OF THE PRC4 COMPLEX, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=15684044; DOI=10.1073/pnas.0409875102;
RA   Kuzmichev A., Margueron R., Vaquero A., Preissner T.S., Scher M.,
RA   Kirmizis A., Ouyang X., Brockdorff N., Abate-Shen C., Farnham P.J.,
RA   Reinberg D.;
RT   "Composition and histone substrates of polycomb repressive group complexes
RT   change during cellular differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1859-1864(2005).
RN   [13]
RP   INTERACTION WITH EZH2.
RX   PubMed=16224021; DOI=10.1126/science.1118947;
RA   Cha T.-L., Zhou B.P., Xia W., Wu Y., Yang C.-C., Chen C.-T., Ping B.,
RA   Otte A.P., Hung M.-C.;
RT   "Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27
RT   in histone H3.";
RL   Science 310:306-310(2005).
RN   [14]
RP   INTERACTION WITH WDR77.
RX   PubMed=16712789; DOI=10.1016/j.bbrc.2006.05.014;
RA   Furuno K., Masatsugu T., Sonoda M., Sasazuki T., Yamamoto K.;
RT   "Association of Polycomb group SUZ12 with WD-repeat protein MEP50 that
RT   binds to histone H2A selectively in vitro.";
RL   Biochem. Biophys. Res. Commun. 345:1051-1058(2006).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-546, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [16]
RP   FUNCTION.
RX   PubMed=16618801; DOI=10.1101/gad.381706;
RA   Bracken A.P., Dietrich N., Pasini D., Hansen K.H., Helin K.;
RT   "Genome-wide mapping of Polycomb target genes unravels their roles in cell
RT   fate transitions.";
RL   Genes Dev. 20:1123-1136(2006).
RN   [17]
RP   METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX, AND INTERACTION WITH
RP   HISTONE H1.
RX   PubMed=16431907; DOI=10.1074/jbc.m513425200;
RA   Martin C., Cao R., Zhang Y.;
RT   "Substrate preferences of the EZH2 histone methyltransferase complex.";
RL   J. Biol. Chem. 281:8365-8370(2006).
RN   [18]
RP   FUNCTION.
RX   PubMed=17344414; DOI=10.1101/gad.415507;
RA   Bracken A.P., Kleine-Kohlbrecher D., Dietrich N., Pasini D., Gargiulo G.,
RA   Beekman C., Theilgaard-Moench K., Minucci S., Porse B.T., Marine J.-C.,
RA   Hansen K.H., Helin K.;
RT   "The Polycomb group proteins bind throughout the INK4A-ARF locus and are
RT   disassociated in senescent cells.";
RL   Genes Dev. 21:525-530(2007).
RN   [19]
RP   DE NOVO DNA METHYLATION OF PRC2 TARGET GENES.
RX   PubMed=17200670; DOI=10.1038/ng1950;
RA   Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M.,
RA   Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E.,
RA   Bergman Y., Simon I., Cedar H.;
RT   "Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for
RT   de novo methylation in cancer.";
RL   Nat. Genet. 39:232-236(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-546 AND SER-583, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [21]
RP   IDENTIFICATION IN THE PRC2/EED-EZH1 COMPLEX.
RX   PubMed=19026781; DOI=10.1016/j.molcel.2008.11.004;
RA   Margueron R., Li G., Sarma K., Blais A., Zavadil J., Woodcock C.L.,
RA   Dynlacht B.D., Reinberg D.;
RT   "Ezh1 and Ezh2 maintain repressive chromatin through different
RT   mechanisms.";
RL   Mol. Cell 32:503-518(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2 COMPLEX,
RP   AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=18086877; DOI=10.1128/mcb.01589-07;
RA   Cao R., Wang H., He J., Erdjument-Bromage H., Tempst P., Zhang Y.;
RT   "Role of hPHF1 in H3K27 methylation and Hox gene silencing.";
RL   Mol. Cell. Biol. 28:1862-1872(2008).
RN   [23]
RP   FUNCTION, INTERACTION WITH EED AND EZH2, INTERACTION OF THE PRC2 COMPLEX
RP   WITH PHF1, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=18285464; DOI=10.1128/mcb.02017-07;
RA   Sarma K., Margueron R., Ivanov A., Pirrotta V., Reinberg D.;
RT   "Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in
RT   vivo.";
RL   Mol. Cell. Biol. 28:2718-2731(2008).
RN   [24]
RP   SUMOYLATION AT LYS-72; LYS-73 AND LYS-75.
RX   PubMed=18628979; DOI=10.1371/journal.pone.0002704;
RA   Riising E.M., Boggio R., Chiocca S., Helin K., Pasini D.;
RT   "The polycomb repressive complex 2 is a potential target of SUMO
RT   modifications.";
RL   PLoS ONE 3:E2704-E2704(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-546, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   TRANS-SPLICING.
RX   PubMed=18772439; DOI=10.1126/science.1156725;
RA   Li H., Wang J., Mor G., Sklar J.;
RT   "A neoplastic gene fusion mimics trans-splicing of RNAs in normal human
RT   cells.";
RL   Science 321:1357-1361(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-546, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-546, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   INTERACTION WITH CDYL.
RX   PubMed=22009739; DOI=10.1074/jbc.m111.271064;
RA   Zhang Y., Yang X., Gui B., Xie G., Zhang D., Shang Y., Liang J.;
RT   "Corepressor protein CDYL functions as a molecular bridge between polycomb
RT   repressor complex 2 and repressive chromatin mark trimethylated histone
RT   lysine 27.";
RL   J. Biol. Chem. 286:42414-42425(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-546, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20; SER-541; SER-546 AND
RP   SER-726, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [34]
RP   INVOLVEMENT IN DISEASE, VARIANT VAL-610, CHARACTERIZATION OF VARIANT
RP   VAL-610, AND FUNCTION.
RX   PubMed=28229514; DOI=10.1002/humu.23200;
RA   Imagawa E., Higashimoto K., Sakai Y., Numakura C., Okamoto N.,
RA   Matsunaga S., Ryo A., Sato Y., Sanefuji M., Ihara K., Takada Y.,
RA   Nishimura G., Saitsu H., Mizuguchi T., Miyatake S., Nakashima M.,
RA   Miyake N., Soejima H., Matsumoto N.;
RT   "Mutations in genes encoding polycomb repressive complex 2 subunits cause
RT   Weaver syndrome.";
RL   Hum. Mutat. 38:637-648(2017).
RN   [35]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-75; LYS-223 AND LYS-390, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [36]
RP   INTERACTION WITH EZHIP.
RX   PubMed=30923826; DOI=10.1093/neuonc/noz058;
RA   Huebner J.M., Mueller T., Papageorgiou D.N., Mauermann M., Krijgsveld J.,
RA   Russell R.B., Ellison D.W., Pfister S.M., Pajtler K.W., Kool M.;
RT   "EZHIP / CXorf67 mimics K27M mutated oncohistones and functions as an
RT   intrinsic inhibitor of PRC2 function in aggressive posterior fossa
RT   ependymoma.";
RL   Neuro-oncol. 0:0-0(2019).
CC   -!- FUNCTION: Polycomb group (PcG) protein. Component of the PRC2/EED-EZH2
CC       complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of
CC       histone H3, leading to transcriptional repression of the affected
CC       target gene. The PRC2/EED-EZH2 complex may also serve as a recruiting
CC       platform for DNA methyltransferases, thereby linking two epigenetic
CC       repression systems. Genes repressed by the PRC2/EED-EZH2 complex
CC       include HOXC8, HOXA9, MYT1 and CDKN2A. {ECO:0000269|PubMed:15225548,
CC       ECO:0000269|PubMed:15231737, ECO:0000269|PubMed:15385962,
CC       ECO:0000269|PubMed:16618801, ECO:0000269|PubMed:17344414,
CC       ECO:0000269|PubMed:18285464, ECO:0000269|PubMed:28229514}.
CC   -!- SUBUNIT: Component of the PRC2/EED-EZH2 complex, which includes EED,
CC       EZH2, SUZ12, RBBP4 and RBBP7 and possibly AEBP2. The minimum components
CC       required for methyltransferase activity of the PRC2/EED-EZH2 complex
CC       are EED, EZH2 and SUZ12. Component of the PRC2/EED-EZH1 complex, which
CC       includes EED, EZH1, SUZ12, RBBP4 and AEBP2. The PRC2 complex may also
CC       interact with DNMT1, DNMT3A, DNMT3B and PHF1 via the EZH2 subunit and
CC       with SIRT1 via the SUZ12 subunit. Interacts with WDR77. Interacts with
CC       histone H1. Interacts with CDYL. Interacts with ARNTL/BMAL1. Interacts
CC       with EZHIP (via C-terminal region) (PubMed:30923826).
CC       {ECO:0000269|PubMed:12351676, ECO:0000269|PubMed:12435631,
CC       ECO:0000269|PubMed:15385962, ECO:0000269|PubMed:16224021,
CC       ECO:0000269|PubMed:16431907, ECO:0000269|PubMed:16712789,
CC       ECO:0000269|PubMed:18086877, ECO:0000269|PubMed:18285464,
CC       ECO:0000269|PubMed:19026781, ECO:0000269|PubMed:22009739,
CC       ECO:0000269|PubMed:30923826}.
CC   -!- INTERACTION:
CC       Q15022; O75530: EED; NbExp=8; IntAct=EBI-1264675, EBI-923794;
CC       Q15022; Q15910: EZH2; NbExp=22; IntAct=EBI-1264675, EBI-530054;
CC       Q15022; O15379: HDAC3; NbExp=7; IntAct=EBI-1264675, EBI-607682;
CC       Q15022; Q14774: HLX; NbExp=2; IntAct=EBI-1264675, EBI-6678255;
CC       Q15022; Q92833-1: JARID2; NbExp=7; IntAct=EBI-1264675, EBI-15825247;
CC       Q15022; Q15156: PML-RAR; NbExp=6; IntAct=EBI-1264675, EBI-867256;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15231737}.
CC   -!- TISSUE SPECIFICITY: Overexpressed in breast and colon cancer.
CC       {ECO:0000269|PubMed:15231737, ECO:0000269|PubMed:15684044}.
CC   -!- DEVELOPMENTAL STAGE: Expressed at low levels in quiescent cells.
CC       Expression rises at the G1/S phase transition.
CC       {ECO:0000269|PubMed:15385962}.
CC   -!- INDUCTION: Expression is induced by E2F1, E2F2 and E2F3.
CC       {ECO:0000269|PubMed:11564866, ECO:0000269|PubMed:14532106}.
CC   -!- PTM: Sumoylated, probably by PIAS2. {ECO:0000269|PubMed:18628979}.
CC   -!- DISEASE: Note=A chromosomal aberration involving SUZ12 may be a cause
CC       of endometrial stromal tumors. Translocation t(7;17)(p15;q21) with
CC       JAZF1. The translocation generates the JAZF1-SUZ12 oncogene consisting
CC       of the N-terminus part of JAZF1 and the C-terminus part of SUZ12. It is
CC       frequently found in all cases of endometrial stromal tumors, except in
CC       endometrial stromal sarcomas, where it is rarer.
CC       {ECO:0000269|PubMed:11371647}.
CC   -!- DISEASE: Note=Defects in EED are associated with Weaver syndrome (WVS):
CC       A syndrome of accelerated growth and osseous maturation, unusual
CC       craniofacial appearance, hoarse and low-pitched cry, and hypertonia
CC       with camptodactyly. Distinguishing features of Weaver syndrome include
CC       broad forehead and face, ocular hypertelorism, prominent wide philtrum,
CC       micrognathia, deep horizontal chin groove, and deep-set nails. In
CC       addition, carpal bone development is advanced over the rest of the
CC       hand. {ECO:0000269|PubMed:28229514}.
CC   -!- MISCELLANEOUS: Under hypoxic conditions, the precursor SUZ12 RNA
CC       undergoes regulated trans-splicing with the JAZF1 RNA, resulting in a
CC       chimeric isoform which may be protective against apoptosis. The
CC       chimeric transcript is characterized by JAZF1 exons 1-3 joined to SUZ12
CC       exon 2-16. The chimeric transcript is expressed primarily in the
CC       endometrium from late secretory and early proliferative phases of the
CC       menstrual cycle, but not in normal myometrium at any phase of the
CC       cycle. Its expression is slightly induced by low levels of
CC       progesterone, but suppressed by both estrogen and high levels of
CC       progesterone (PubMed:18772439). {ECO:0000305|PubMed:18772439}.
CC   -!- SIMILARITY: Belongs to the VEFS (VRN2-EMF2-FIS2-SU(Z)12) family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Two variants of the PRC2 complex have been described, termed
CC       PRC3 and PRC4. Each of the three complexes may include a different
CC       complement of EED isoforms, although the precise sequences of the
CC       isoforms in each complex have not been determined. The PRC2 and PRC4
CC       complexes may also methylate 'Lys-26' of histone H1 in addition to
CC       'Lys-27' of histone H3 (PubMed:15099518 and PubMed:15684044), although
CC       other studies have demonstrated no methylation of 'Lys-26' of histone
CC       H1 by PRC2 (PubMed:16431907). {ECO:0000305|PubMed:16431907}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA09931.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/JJAZ1ID41039ch17q11.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D63881; BAA09931.2; ALT_INIT; mRNA.
DR   EMBL; BC015704; AAH15704.1; -; mRNA.
DR   CCDS; CCDS11270.1; -.
DR   RefSeq; NP_056170.2; NM_015355.3.
DR   PDB; 4W2R; X-ray; 2.81 A; S/T=545-725.
DR   PDB; 5HYN; X-ray; 2.95 A; C/H/M/S=558-685.
DR   PDB; 5IJ7; X-ray; 2.62 A; S/T=545-725.
DR   PDB; 5IJ8; X-ray; 2.99 A; S/T=545-725.
DR   PDB; 5LS6; X-ray; 3.47 A; C/F/I/L=558-685.
DR   PDB; 5WAI; X-ray; 2.90 A; B/F=76-545.
DR   PDB; 5WAK; X-ray; 3.20 A; B=76-545.
DR   PDB; 5WG6; X-ray; 3.90 A; A/C=543-695.
DR   PDB; 6B3W; X-ray; 3.05 A; S/T=545-725.
DR   PDB; 6C23; EM; 3.90 A; A/M/Q=1-739.
DR   PDB; 6C24; EM; 3.50 A; A/M/Q=1-739.
DR   PDBsum; 4W2R; -.
DR   PDBsum; 5HYN; -.
DR   PDBsum; 5IJ7; -.
DR   PDBsum; 5IJ8; -.
DR   PDBsum; 5LS6; -.
DR   PDBsum; 5WAI; -.
DR   PDBsum; 5WAK; -.
DR   PDBsum; 5WG6; -.
DR   PDBsum; 6B3W; -.
DR   PDBsum; 6C23; -.
DR   PDBsum; 6C24; -.
DR   SMR; Q15022; -.
DR   BioGrid; 117059; 546.
DR   CORUM; Q15022; -.
DR   DIP; DIP-38524N; -.
DR   IntAct; Q15022; 51.
DR   MINT; Q15022; -.
DR   STRING; 9606.ENSP00000316578; -.
DR   BindingDB; Q15022; -.
DR   ChEMBL; CHEMBL3137286; -.
DR   ChEMBL; CHEMBL3137287; -.
DR   ChEMBL; CHEMBL3301388; -.
DR   iPTMnet; Q15022; -.
DR   PhosphoSitePlus; Q15022; -.
DR   BioMuta; SUZ12; -.
DR   DMDM; 116242808; -.
DR   EPD; Q15022; -.
DR   jPOST; Q15022; -.
DR   MassIVE; Q15022; -.
DR   MaxQB; Q15022; -.
DR   PaxDb; Q15022; -.
DR   PeptideAtlas; Q15022; -.
DR   PRIDE; Q15022; -.
DR   ProteomicsDB; 60374; -.
DR   Antibodypedia; 27067; 339 antibodies.
DR   Ensembl; ENST00000322652; ENSP00000316578; ENSG00000178691.
DR   GeneID; 23512; -.
DR   KEGG; hsa:23512; -.
DR   UCSC; uc002hgs.3; human.
DR   CTD; 23512; -.
DR   DisGeNET; 23512; -.
DR   GeneCards; SUZ12; -.
DR   HGNC; HGNC:17101; SUZ12.
DR   HPA; ENSG00000178691; Low tissue specificity.
DR   MalaCards; SUZ12; -.
DR   MIM; 606245; gene.
DR   neXtProt; NX_Q15022; -.
DR   OpenTargets; ENSG00000178691; -.
DR   Orphanet; 213711; Endometrial stromal sarcoma.
DR   Orphanet; 3447; Weaver syndrome.
DR   PharmGKB; PA134936035; -.
DR   eggNOG; KOG2350; Eukaryota.
DR   eggNOG; ENOG410YJ29; LUCA.
DR   GeneTree; ENSGT00390000012364; -.
DR   InParanoid; Q15022; -.
DR   KO; K11463; -.
DR   OMA; RNEKMFG; -.
DR   OrthoDB; 516359at2759; -.
DR   PhylomeDB; Q15022; -.
DR   TreeFam; TF323249; -.
DR   Reactome; R-HSA-212300; PRC2 methylates histones and DNA.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-4551638; SUMOylation of chromatin organization proteins.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-8943724; Regulation of PTEN gene transcription.
DR   Reactome; R-HSA-8953750; Transcriptional Regulation by E2F6.
DR   Reactome; R-HSA-9609690; HCMV Early Events.
DR   SignaLink; Q15022; -.
DR   SIGNOR; Q15022; -.
DR   ChiTaRS; SUZ12; human.
DR   GeneWiki; SUZ12; -.
DR   GenomeRNAi; 23512; -.
DR   Pharos; Q15022; Tbio.
DR   PRO; PR:Q15022; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q15022; protein.
DR   Bgee; ENSG00000178691; Expressed in female gonad and 235 other tissues.
DR   ExpressionAtlas; Q15022; baseline and differential.
DR   Genevisible; Q15022; HS.
DR   GO; GO:0035098; C:ESC/E(Z) complex; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; IEA:Ensembl.
DR   GO; GO:0016586; C:RSC-type complex; IBA:GO_Central.
DR   GO; GO:0001739; C:sex chromatin; IEA:Ensembl.
DR   GO; GO:0031490; F:chromatin DNA binding; IBA:GO_Central.
DR   GO; GO:0042054; F:histone methyltransferase activity; IMP:MGI.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0035064; F:methylated histone binding; IDA:UniProtKB.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0070734; P:histone H3-K27 methylation; IEA:GOC.
DR   GO; GO:0016574; P:histone ubiquitination; IEA:Ensembl.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IMP:UniProtKB.
DR   GO; GO:0070317; P:negative regulation of G0 to G1 transition; TAS:Reactome.
DR   GO; GO:0045814; P:negative regulation of gene expression, epigenetic; TAS:Reactome.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IBA:GO_Central.
DR   InterPro; IPR019135; Polycomb_protein_VEFS-Box.
DR   Pfam; PF09733; VEFS-Box; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chromatin regulator; Chromosomal rearrangement;
KW   Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..739
FT                   /note="Polycomb protein SUZ12"
FT                   /id="PRO_0000047057"
FT   ZN_FING         448..471
FT                   /note="C2H2-type"
FT   REGION          563..639
FT                   /note="VEFS-box"
FT   COMPBIAS        7..50
FT                   /note="Gly-rich"
FT   COMPBIAS        51..59
FT                   /note="Poly-Ser"
FT   COMPBIAS        60..67
FT                   /note="Poly-Ala"
FT   SITE            93..94
FT                   /note="Breakpoint for translocation to form JAZF1-SUZ12
FT                   oncogene"
FT   MOD_RES         20
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         541
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         546
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983,
FT                   ECO:0000244|PubMed:18220336, ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:23186163"
FT   MOD_RES         583
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18220336"
FT   MOD_RES         726
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   CROSSLNK        72
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:18628979"
FT   CROSSLNK        73
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:18628979"
FT   CROSSLNK        75
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:18628979"
FT   CROSSLNK        75
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        223
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        390
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VARIANT         216
FT                   /note="N -> I (in dbSNP:rs17339444)"
FT                   /evidence="ECO:0000269|PubMed:8590280"
FT                   /id="VAR_028100"
FT   VARIANT         610
FT                   /note="E -> V (found in a patient with Weaver syndrome;
FT                   decreased trimethylation of 'Lys-27' of histone H3; no
FT                   effect on interaction with EZH2; dbSNP:rs1131692177)"
FT                   /evidence="ECO:0000269|PubMed:28229514"
FT                   /id="VAR_078318"
FT   HELIX           80..106
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   HELIX           112..114
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   HELIX           116..121
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   HELIX           128..131
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   HELIX           134..136
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   HELIX           137..146
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          156..165
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          185..192
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          203..207
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          229..233
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   HELIX           241..243
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          245..254
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          296..302
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          312..318
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          354..362
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          370..372
FT                   /evidence="ECO:0000244|PDB:5WAK"
FT   TURN            376..378
FT                   /evidence="ECO:0000244|PDB:5WAK"
FT   STRAND          427..434
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          437..443
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          446..449
FT                   /evidence="ECO:0000244|PDB:6C24"
FT   TURN            451..453
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   HELIX           460..470
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   TURN            471..473
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          474..481
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          484..491
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   TURN            503..506
FT                   /evidence="ECO:0000244|PDB:6C24"
FT   STRAND          507..509
FT                   /evidence="ECO:0000244|PDB:6C24"
FT   STRAND          516..518
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   STRAND          525..531
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   HELIX           541..543
FT                   /evidence="ECO:0000244|PDB:5WAI"
FT   HELIX           544..547
FT                   /evidence="ECO:0000244|PDB:6C24"
FT   TURN            568..570
FT                   /evidence="ECO:0000244|PDB:5IJ7"
FT   HELIX           576..578
FT                   /evidence="ECO:0000244|PDB:5IJ7"
FT   HELIX           590..601
FT                   /evidence="ECO:0000244|PDB:5IJ7"
FT   STRAND          604..606
FT                   /evidence="ECO:0000244|PDB:5IJ7"
FT   HELIX           608..624
FT                   /evidence="ECO:0000244|PDB:5IJ7"
FT   HELIX           629..631
FT                   /evidence="ECO:0000244|PDB:5IJ7"
FT   HELIX           632..649
FT                   /evidence="ECO:0000244|PDB:5IJ7"
FT   HELIX           653..665
FT                   /evidence="ECO:0000244|PDB:5IJ7"
FT   HELIX           671..686
FT                   /evidence="ECO:0000244|PDB:5IJ7"
SQ   SEQUENCE   739 AA;  83055 MW;  A8830EBC3FD38D56 CRC64;
     MAPQKHGGGG GGGSGPSAGS GGGGFGGSAA VAAATASGGK SGGGSCGGGG SYSASSSSSA
     AAAAGAAVLP VKKPKMEHVQ ADHELFLQAF EKPTQIYRFL RTRNLIAPIF LHRTLTYMSH
     RNSRTNIKRK TFKVDDMLSK VEKMKGEQES HSLSAHLQLT FTGFFHKNDK PSPNSENEQN
     SVTLEVLLVK VCHKKRKDVS CPIRQVPTGK KQVPLNPDLN QTKPGNFPSL AVSSNEFEPS
     NSHMVKSYSL LFRVTRPGRR EFNGMINGET NENIDVNEEL PARRKRNRED GEKTFVAQMT
     VFDKNRRLQL LDGEYEVAMQ EMEECPISKK RATWETILDG KRLPPFETFS QGPTLQFTLR
     WTGETNDKST APIAKPLATR NSESLHQENK PGSVKPTQTI AVKESLTTDL QTRKEKDTPN
     ENRQKLRIFY QFLYNNNTRQ QTEARDDLHC PWCTLNCRKL YSLLKHLKLC HSRFIFNYVY
     HPKGARIDVS INECYDGSYA GNPQDIHRQP GFAFSRNGPV KRTPITHILV CRPKRTKASM
     SEFLESEDGE VEQQRTYSSG HNRLYFHSDT CLPLRPQEME VDSEDEKDPE WLREKTITQI
     EEFSDVNEGE KEVMKLWNLH VMKHGFIADN QMNHACMLFV ENYGQKIIKK NLCRNFMLHL
     VSMHDFNLIS IMSIDKAVTK LREMQQKLEK GESASPANEE ITEEQNGTAN GFSEINSKEK
     ALETDSVSGV SKQSKKQKL
//
ID   TBL1R_HUMAN             Reviewed;         514 AA.
AC   Q9BZK7; D3DNQ9; Q14DC3; Q9H2I1; Q9H9A1;
DT   19-SEP-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   22-APR-2020, entry version 182.
DE   RecName: Full=F-box-like/WD repeat-containing protein TBL1XR1;
DE   AltName: Full=Nuclear receptor corepressor/HDAC3 complex subunit TBLR1;
DE   AltName: Full=TBL1-related protein 1;
DE   AltName: Full=Transducin beta-like 1X-related protein 1;
GN   Name=TBL1XR1; Synonyms=IRA1, TBLR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   COMPONENT OF THE N-COR COMPLEX WITH NCOR1; NCOR2; GPS2; TBL1X AND HDAC3.
RX   PubMed=11931768; DOI=10.1016/s1097-2765(02)00468-9;
RA   Zhang J., Kalkum M., Chait B.T., Roeder R.G.;
RT   "The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK
RT   pathway through the integral subunit GPS2.";
RL   Mol. Cell 9:611-623(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=11063877; DOI=10.1016/s0301-472x(00)00539-7;
RA   Zhang X., Dormady S.P., Basch R.S.;
RT   "Identification of four human cDNAs that are differentially expressed by
RT   early hematopoietic progenitors.";
RL   Exp. Hematol. 28:1286-1296(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Adrenal cortex, and Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   COMPONENT OF THE N-COR COMPLEX WITH TBL1X; CORO2A AND HDAC3, AND
RP   HISTONE-BINDING.
RX   PubMed=12628926; DOI=10.1093/emboj/cdg120;
RA   Yoon H.-G., Chan D.W., Huang Z.-Q., Li J., Fondell J.D., Qin J., Wong J.;
RT   "Purification and functional characterization of the human N-CoR complex:
RT   the roles of HDAC3, TBL1 and TBLR1.";
RL   EMBO J. 22:1336-1346(2003).
RN   [7]
RP   FUNCTION, AND RECRUITMENT OF 19S PROTEASOME COMPLEX.
RX   PubMed=14980219; DOI=10.1016/s0092-8674(04)00133-3;
RA   Perissi V., Aggarwal A., Glass C.K., Rose D.W., Rosenfeld M.G.;
RT   "A corepressor/coactivator exchange complex required for transcriptional
RT   activation by nuclear receptors and other regulated transcription
RT   factors.";
RL   Cell 116:511-526(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-119, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [12]
RP   INVOLVEMENT IN MRD41, AND VARIANT MRD41 PRO-282.
RX   PubMed=22495309; DOI=10.1038/nature10989;
RA   O'Roak B.J., Vives L., Girirajan S., Karakoc E., Krumm N., Coe B.P.,
RA   Levy R., Ko A., Lee C., Smith J.D., Turner E.H., Stanaway I.B., Vernot B.,
RA   Malig M., Baker C., Reilly B., Akey J.M., Borenstein E., Rieder M.J.,
RA   Nickerson D.A., Bernier R., Shendure J., Eichler E.E.;
RT   "Sporadic autism exomes reveal a highly interconnected protein network of
RT   de novo mutations.";
RL   Nature 485:246-250(2012).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [14]
RP   INVOLVEMENT IN MRD41.
RX   PubMed=23160955; DOI=10.1126/science.1227764;
RA   O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G.,
RA   Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B.,
RA   Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K.,
RA   Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M.,
RA   Bernier R., Eichler E.E., Shendure J.;
RT   "Multiplex targeted sequencing identifies recurrently mutated genes in
RT   autism spectrum disorders.";
RL   Science 338:1619-1622(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-119, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   INVOLVEMENT IN MRD41, VARIANT MRD41 ASP-70, AND VARIANTS SER-116; GLU-405
RP   AND SER-407.
RX   PubMed=25102098; DOI=10.1038/jhg.2014.71;
RA   Saitsu H., Tohyama J., Walsh T., Kato M., Kobayashi Y., Lee M.,
RA   Tsurusaki Y., Miyake N., Goto Y., Nishino I., Ohtake A., King M.C.,
RA   Matsumoto N.;
RT   "A girl with West syndrome and autistic features harboring a de novo
RT   TBL1XR1 mutation.";
RL   J. Hum. Genet. 59:581-583(2014).
RN   [17]
RP   INVOLVEMENT IN MRD41, AND VARIANT MRD41 CYS-245.
RX   PubMed=27133561; DOI=10.1002/ajmg.a.37684;
RG   FORGE Canada Consortium;
RA   Armour C.M., Smith A., Hartley T., Chardon J.W., Sawyer S.,
RA   Schwartzentruber J., Hennekam R., Majewski J., Bulman D.E., Suri M.,
RA   Boycott K.M.;
RT   "Syndrome disintegration: Exome sequencing reveals that Fitzsimmons
RT   syndrome is a co-occurrence of multiple events.";
RL   Am. J. Med. Genet. A 170:1820-1825(2016).
RN   [18]
RP   TISSUE SPECIFICITY, INVOLVEMENT IN PRPTS, VARIANT PRPTS CYS-446, AND
RP   CHARACTERIZATION OF VARIANT PRPTS CYS-446.
RX   PubMed=26769062; DOI=10.1136/jmedgenet-2015-103233;
RA   Heinen C.A., Jongejan A., Watson P.J., Redeker B., Boelen A.,
RA   Boudzovitch-Surovtseva O., Forzano F., Hordijk R., Kelley R., Olney A.H.,
RA   Pierpont M.E., Schaefer G.B., Stewart F., van Trotsenburg A.S., Fliers E.,
RA   Schwabe J.W., Hennekam R.C.;
RT   "A specific mutation in TBL1XR1 causes Pierpont syndrome.";
RL   J. Med. Genet. 53:330-337(2016).
RN   [19]
RP   ERRATUM OF PUBMED:26769062.
RX   PubMed=27221108; DOI=10.1136/jmedgenet-2015-103233corr1;
RA   Heinen C.A., Jongejan A., Watson P.J., Redeker B., Boelen A.,
RA   Boudzovitch-Surovtseva O., Forzano F., Hordijk R., Kelley R., Olney A.H.,
RA   Pierpont M.E., Schaefer G.B., Stewart F., van Trotsenburg A.S., Fliers E.,
RA   Schwabe J.W., Hennekam R.C.;
RL   J. Med. Genet. 53:430-430(2016).
RN   [20]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-277, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: F-box-like protein involved in the recruitment of the
CC       ubiquitin/19S proteasome complex to nuclear receptor-regulated
CC       transcription units. Plays an essential role in transcription
CC       activation mediated by nuclear receptors. Probably acts as integral
CC       component of the N-Cor corepressor complex that mediates the
CC       recruitment of the 19S proteasome complex, leading to the subsequent
CC       proteasomal degradation of N-Cor complex, thereby allowing cofactor
CC       exchange, and transcription activation. {ECO:0000269|PubMed:14980219}.
CC   -!- SUBUNIT: Component of the N-Cor repressor complex, at least composed of
CC       NCOR1, NCOR2, HDAC3, TBL1X, TBL1XR1, CORO2A and GPS2 (PubMed:11931768).
CC       Probable component of some E3 ubiquitin ligase complex. Interacts with
CC       histones H2B and H4 (PubMed:12628926). Interacts with MECP2; bridges
CC       interaction between MECP2 and NCOR1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q8BHJ5, ECO:0000269|PubMed:11931768,
CC       ECO:0000269|PubMed:12628926}.
CC   -!- INTERACTION:
CC       Q9BZK7; P36404: ARL2; NbExp=4; IntAct=EBI-765729, EBI-752365;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Widely expressed including the pituitary,
CC       hypothalamus, white and brown adipose tissue, muscle and liver.
CC       {ECO:0000269|PubMed:26769062}.
CC   -!- DOMAIN: The F-box-like domain is related to the F-box domain, and
CC       apparently displays the same function as component of ubiquitin E3
CC       ligase complexes. {ECO:0000250}.
CC   -!- DISEASE: Pierpont syndrome (PRPTS) [MIM:602342]: An autosomal dominant
CC       syndrome characterized by multiple congenital anomalies, global
CC       developmental delay, learning disability, palmar and plantar fat pads,
CC       and distinctive facial characteristics, especially when smiling.
CC       {ECO:0000269|PubMed:26769062}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Mental retardation, autosomal dominant 41 (MRD41)
CC       [MIM:616944]: A form of mental retardation, a disorder characterized by
CC       significantly below average general intellectual functioning associated
CC       with impairments in adaptive behavior and manifested during the
CC       developmental period. MRD41 patients manifest delayed psychomotor
CC       development, variable severity of intellectual disability, and delayed
CC       language. Non-specific dysmorphic features and autistic behavior is
CC       observed in some patients. {ECO:0000269|PubMed:22495309,
CC       ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:25102098,
CC       ECO:0000269|PubMed:27133561}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the WD repeat EBI family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH60320.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF314544; AAK00301.1; -; mRNA.
DR   EMBL; AF268193; AAG44736.1; -; mRNA.
DR   EMBL; AK022956; BAB14331.1; -; mRNA.
DR   EMBL; CH471052; EAW78438.1; -; Genomic_DNA.
DR   EMBL; BC060320; AAH60320.1; ALT_SEQ; mRNA.
DR   EMBL; BC113421; AAI13422.1; -; mRNA.
DR   CCDS; CCDS46961.1; -.
DR   RefSeq; NP_001308122.1; NM_001321193.1.
DR   RefSeq; NP_001308123.1; NM_001321194.1.
DR   RefSeq; NP_001308124.1; NM_001321195.1.
DR   RefSeq; NP_078941.2; NM_024665.5.
DR   RefSeq; XP_005247832.1; XM_005247775.2.
DR   RefSeq; XP_006713809.1; XM_006713746.1.
DR   RefSeq; XP_011511443.1; XM_011513141.1.
DR   RefSeq; XP_011511444.1; XM_011513142.2.
DR   RefSeq; XP_011511445.1; XM_011513143.2.
DR   RefSeq; XP_016862674.1; XM_017007185.1.
DR   PDB; 4LG9; X-ray; 2.28 A; A=134-514.
DR   PDBsum; 4LG9; -.
DR   SMR; Q9BZK7; -.
DR   BioGrid; 122834; 125.
DR   CORUM; Q9BZK7; -.
DR   DIP; DIP-34582N; -.
DR   IntAct; Q9BZK7; 44.
DR   MINT; Q9BZK7; -.
DR   STRING; 9606.ENSP00000405574; -.
DR   iPTMnet; Q9BZK7; -.
DR   PhosphoSitePlus; Q9BZK7; -.
DR   BioMuta; TBL1XR1; -.
DR   DMDM; 23396874; -.
DR   EPD; Q9BZK7; -.
DR   jPOST; Q9BZK7; -.
DR   MassIVE; Q9BZK7; -.
DR   MaxQB; Q9BZK7; -.
DR   PaxDb; Q9BZK7; -.
DR   PeptideAtlas; Q9BZK7; -.
DR   PRIDE; Q9BZK7; -.
DR   ProteomicsDB; 79864; -.
DR   Antibodypedia; 9317; 338 antibodies.
DR   Ensembl; ENST00000430069; ENSP00000405574; ENSG00000177565.
DR   Ensembl; ENST00000457928; ENSP00000413251; ENSG00000177565.
DR   GeneID; 79718; -.
DR   KEGG; hsa:79718; -.
DR   UCSC; uc003fiw.5; human.
DR   CTD; 79718; -.
DR   DisGeNET; 79718; -.
DR   GeneCards; TBL1XR1; -.
DR   HGNC; HGNC:29529; TBL1XR1.
DR   HPA; ENSG00000177565; Low tissue specificity.
DR   MalaCards; TBL1XR1; -.
DR   MIM; 602342; phenotype.
DR   MIM; 608628; gene.
DR   MIM; 616944; phenotype.
DR   neXtProt; NX_Q9BZK7; -.
DR   OpenTargets; ENSG00000177565; -.
DR   Orphanet; 520; Acute promyelocytic leukemia.
DR   Orphanet; 487825; Pierpont syndrome.
DR   PharmGKB; PA134928556; -.
DR   eggNOG; ENOG410IQU2; Eukaryota.
DR   eggNOG; COG2319; LUCA.
DR   GeneTree; ENSGT00940000153421; -.
DR   HOGENOM; CLU_007609_2_0_1; -.
DR   InParanoid; Q9BZK7; -.
DR   KO; K04508; -.
DR   OMA; LANNHSD; -.
DR   OrthoDB; 1463197at2759; -.
DR   PhylomeDB; Q9BZK7; -.
DR   TreeFam; TF323190; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-3214815; HDACs deacetylate histones.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by PPARalpha.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-9022537; Loss of MECP2 binding ability to the NCoR/SMRT complex.
DR   Reactome; R-HSA-9022692; Regulation of MECP2 expression and activity.
DR   Reactome; R-HSA-9029569; NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux.
DR   Reactome; R-HSA-9609690; HCMV Early Events.
DR   SignaLink; Q9BZK7; -.
DR   SIGNOR; Q9BZK7; -.
DR   ChiTaRS; TBL1XR1; human.
DR   GeneWiki; TBL1XR1; -.
DR   GenomeRNAi; 79718; -.
DR   Pharos; Q9BZK7; Tbio.
DR   PRO; PR:Q9BZK7; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9BZK7; protein.
DR   Bgee; ENSG00000177565; Expressed in forebrain and 209 other tissues.
DR   ExpressionAtlas; Q9BZK7; baseline and differential.
DR   Genevisible; Q9BZK7; HS.
DR   GO; GO:0000118; C:histone deacetylase complex; IDA:UniProtKB.
DR   GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0017053; C:transcriptional repressor complex; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0001835; P:blastocyst hatching; IEA:Ensembl.
DR   GO; GO:0060613; P:fat pad development; IEA:Ensembl.
DR   GO; GO:0016575; P:histone deacetylation; IBA:GO_Central.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:Ensembl.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; TAS:Reactome.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0090207; P:regulation of triglyceride metabolic process; IEA:Ensembl.
DR   GO; GO:0002021; P:response to dietary excess; IEA:Ensembl.
DR   GO; GO:0050872; P:white fat cell differentiation; IEA:Ensembl.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR020472; G-protein_beta_WD-40_rep.
DR   InterPro; IPR006594; LisH.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR019775; WD40_repeat_CS.
DR   InterPro; IPR017986; WD40_repeat_dom.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   Pfam; PF08513; LisH; 1.
DR   Pfam; PF00400; WD40; 6.
DR   PRINTS; PR00320; GPROTEINBRPT.
DR   SMART; SM00667; LisH; 1.
DR   SMART; SM00320; WD40; 8.
DR   SUPFAM; SSF50978; SSF50978; 2.
DR   PROSITE; PS50896; LISH; 1.
DR   PROSITE; PS00678; WD_REPEATS_1; 4.
DR   PROSITE; PS50082; WD_REPEATS_2; 6.
DR   PROSITE; PS50294; WD_REPEATS_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Chromatin regulator;
KW   Disease mutation; Isopeptide bond; Mental retardation; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; Repressor;
KW   Transcription; Transcription regulation; Ubl conjugation;
KW   Ubl conjugation pathway; WD repeat.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:22223895,
FT                   ECO:0000244|PubMed:22814378"
FT   CHAIN           2..514
FT                   /note="F-box-like/WD repeat-containing protein TBL1XR1"
FT                   /id="PRO_0000051266"
FT   DOMAIN          4..36
FT                   /note="LisH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00126"
FT   DOMAIN          41..86
FT                   /note="F-box-like"
FT   REPEAT          167..206
FT                   /note="WD 1"
FT   REPEAT          223..262
FT                   /note="WD 2"
FT   REPEAT          264..303
FT                   /note="WD 3"
FT   REPEAT          306..344
FT                   /note="WD 4"
FT   REPEAT          347..386
FT                   /note="WD 5"
FT   REPEAT          389..437
FT                   /note="WD 6"
FT   REPEAT          440..479
FT                   /note="WD 7"
FT   REPEAT          481..513
FT                   /note="WD 8"
FT   COMPBIAS        108..118
FT                   /note="Poly-Ala"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000244|PubMed:22223895,
FT                   ECO:0000244|PubMed:22814378"
FT   MOD_RES         102
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BHJ5"
FT   MOD_RES         119
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   CROSSLNK        277
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VARIANT         70
FT                   /note="G -> D (in MRD41; dbSNP:rs786205859)"
FT                   /evidence="ECO:0000269|PubMed:25102098"
FT                   /id="VAR_076753"
FT   VARIANT         116
FT                   /note="A -> S (in dbSNP:rs372813783)"
FT                   /evidence="ECO:0000269|PubMed:25102098"
FT                   /id="VAR_076754"
FT   VARIANT         245
FT                   /note="Y -> C (in MRD41; dbSNP:rs878854401)"
FT                   /evidence="ECO:0000269|PubMed:27133561"
FT                   /id="VAR_076755"
FT   VARIANT         282
FT                   /note="L -> P (in MRD41)"
FT                   /evidence="ECO:0000269|PubMed:22495309"
FT                   /id="VAR_076756"
FT   VARIANT         405
FT                   /note="G -> E (found in a patient with epilepsy; unknown
FT                   pathological significance; dbSNP:rs747932785)"
FT                   /evidence="ECO:0000269|PubMed:25102098"
FT                   /id="VAR_076757"
FT   VARIANT         407
FT                   /note="N -> S (found in a patient with epilepsy; unknown
FT                   pathological significance; dbSNP:rs781011308)"
FT                   /evidence="ECO:0000269|PubMed:25102098"
FT                   /id="VAR_076758"
FT   VARIANT         446
FT                   /note="Y -> C (in PRPTS; does not affect assembly into the
FT                   N-Cor repressor complex; dbSNP:rs878854402)"
FT                   /evidence="ECO:0000269|PubMed:26769062"
FT                   /id="VAR_076759"
FT   CONFLICT        31
FT                   /note="E -> K (in Ref. 2; AAG44736)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        59
FT                   /note="Y -> H (in Ref. 3; BAB14331)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        389
FT                   /note="A -> Q (in Ref. 2; AAG44736)"
FT                   /evidence="ECO:0000305"
FT   HELIX           159..161
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          162..165
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          172..177
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          179..188
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          191..197
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          208..212
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          228..233
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          237..244
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          247..253
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          258..264
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          269..274
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          276..285
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          290..294
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   TURN            295..298
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          299..304
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          311..326
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          331..335
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          342..345
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          352..357
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          361..368
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          371..377
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          384..388
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          394..399
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          406..408
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          415..419
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          424..428
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   TURN            429..432
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          433..438
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          445..450
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          454..461
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          464..470
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   TURN            471..473
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          476..481
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          486..491
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          495..502
FT                   /evidence="ECO:0000244|PDB:4LG9"
FT   STRAND          507..511
FT                   /evidence="ECO:0000244|PDB:4LG9"
SQ   SEQUENCE   514 AA;  55595 MW;  0B556D2EE4BA796D CRC64;
     MSISSDEVNF LVYRYLQESG FSHSAFTFGI ESHISQSNIN GALVPPAALI SIIQKGLQYV
     EAEVSINEDG TLFDGRPIES LSLIDAVMPD VVQTRQQAYR DKLAQQQAAA AAAAAAAASQ
     QGSAKNGENT ANGEENGAHT IANNHTDMME VDGDVEIPPN KAVVLRGHES EVFICAWNPV
     SDLLASGSGD STARIWNLSE NSTSGSTQLV LRHCIREGGQ DVPSNKDVTS LDWNSEGTLL
     ATGSYDGFAR IWTKDGNLAS TLGQHKGPIF ALKWNKKGNF ILSAGVDKTT IIWDAHTGEA
     KQQFPFHSAP ALDVDWQSNN TFASCSTDMC IHVCKLGQDR PIKTFQGHTN EVNAIKWDPT
     GNLLASCSDD MTLKIWSMKQ DNCVHDLQAH NKEIYTIKWS PTGPGTNNPN ANLMLASASF
     DSTVRLWDVD RGICIHTLTK HQEPVYSVAF SPDGRYLASG SFDKCVHIWN TQTGALVHSY
     RGTGGIFEVC WNAAGDKVGA SASDGSVCVL DLRK
//
ID   A0A0A0MRB7_HUMAN        Unreviewed;       600 AA.
AC   A0A0A0MRB7;
DT   07-JAN-2015, integrated into UniProtKB/TrEMBL.
DT   07-JAN-2015, sequence version 1.
DT   22-APR-2020, entry version 45.
DE   SubName: Full=Transcription factor E2-alpha {ECO:0000313|Ensembl:ENSP00000344375};
GN   Name=TCF3 {ECO:0000313|Ensembl:ENSP00000344375};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000344375, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000344375, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [2] {ECO:0000213|PubMed:16964243}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [3] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [4] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [5] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [6] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [7] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [8] {ECO:0000213|PubMed:25218447}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [9] {ECO:0000313|Ensembl:ENSP00000344375}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (NOV-2014) to UniProtKB.
RN   [10] {ECO:0000213|PubMed:25755297}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurethsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [11] {ECO:0000213|PubMed:28112733}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC005321; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006274; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KC877695; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; XP_011526529.1; XM_011528227.2.
DR   jPOST; A0A0A0MRB7; -.
DR   PeptideAtlas; A0A0A0MRB7; -.
DR   Antibodypedia; 4332; 545 antibodies.
DR   Ensembl; ENST00000344749; ENSP00000344375; ENSG00000071564.
DR   GeneID; 6929; -.
DR   UCSC; uc002ltn.4; human.
DR   CTD; 6929; -.
DR   EuPathDB; HostDB:ENSG00000071564.14; -.
DR   HGNC; HGNC:11633; TCF3.
DR   OpenTargets; ENSG00000071564; -.
DR   GeneTree; ENSGT00940000157036; -.
DR   OrthoDB; 571132at2759; -.
DR   ChiTaRS; TCF3; human.
DR   GenomeRNAi; 6929; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000071564; Expressed in testis and 231 other tissues.
DR   ExpressionAtlas; A0A0A0MRB7; baseline and differential.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   CDD; cd00083; HLH; 1.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   Pfam; PF00010; HLH; 1.
DR   SMART; SM00353; HLH; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   PROSITE; PS50888; BHLH; 1.
PE   1: Evidence at protein level;
KW   Proteomics identification {ECO:0000213|EPD:A0A0A0MRB7,
KW   ECO:0000213|MaxQB:A0A0A0MRB7, ECO:0000213|PeptideAtlas:A0A0A0MRB7,
KW   ECO:0000213|ProteomicsDB:A0A0A0MRB7};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   DOMAIN          495..548
FT                   /note="BHLH"
FT                   /evidence="ECO:0000259|PROSITE:PS50888"
FT   REGION          33..62
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          84..154
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          189..215
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          241..278
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          292..334
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          410..484
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          579..600
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        88..112
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        241..276
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        292..315
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        443..484
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   600 AA;  62045 MW;  FF458037E3BF2F30 CRC64;
     MNQPQRMAPV GTDKELSDLL DFSMMFPLPV TNGKGRPASL AGAQFGGSGK SGERGAYASF
     GRDAGVGGLT QAGFLSGELA LNSPGPLSPS GMKGTSQYYP SYSGSSRRRA ADGSLDTQPK
     KVRKVPPGLP SSVYPPSSGE DYGRDATAYP SAKTPSSTYP APFYVADGSL HPSAELWSPP
     GQAGFGPMLG GGSSPLPLPP GSGPVGSSGS SSTFGGLHQH ERMGYQLHGA EVNGGLPSAS
     SFSSAPGATY GGVSSHTPPV SGADSLLGSR GTTAGSSGDA LGKALASIYS PDHSSNNFSS
     SPSTPVGSPQ GLAGTSQWPR AGAPGALSPS YDGGLHGLQS KIEDHLDEAI HVLRSHAVGT
     AGDMHTLLPG HGALASGFTG PMSLGGRHAG LVGGSHPEDG LAGSTSLMHN HAALPSQPGT
     LPDLSRPPDS YSGLGRAGAT AAASEIKREE KEDEENTSAA DHSEEEKKEL KAPRARTSST
     DEVLSLEEKD LRDRERRMAN NARERVRVRD INEAFRELGR MCQMHLKSDK AQTKLLILQQ
     AVQVILGLEQ QVRERNLNPK AACLKRREEE KVSGVVGDPQ MVLSAPHPGL SEAHNPAGHM
//
ID   TFE2_HUMAN              Reviewed;         654 AA.
AC   P15923; P15883; Q14208; Q14635; Q14636; Q2TB39; Q2TB40; Q9UPI9;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   22-APR-2020, entry version 229.
DE   RecName: Full=Transcription factor E2-alpha;
DE   AltName: Full=Class B basic helix-loop-helix protein 21;
DE            Short=bHLHb21;
DE   AltName: Full=Immunoglobulin enhancer-binding factor E12/E47;
DE   AltName: Full=Immunoglobulin transcription factor 1;
DE   AltName: Full=Kappa-E2-binding factor;
DE   AltName: Full=Transcription factor 3;
DE            Short=TCF-3;
DE   AltName: Full=Transcription factor ITF-1;
GN   Name=TCF3; Synonyms=BHLHB21, E2A, ITF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM E12), AND CHROMOSOMAL TRANSLOCATION
RP   WITH PBX1.
RX   PubMed=1967983; DOI=10.1016/0092-8674(90)90658-2;
RA   Kamps M.P., Murre C., Sun X.-H., Baltimore D.;
RT   "A new homeobox gene contributes the DNA binding domain of the t(1;19)
RT   translocation protein in pre-B ALL.";
RL   Cell 60:547-555(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM E12).
RX   PubMed=1967982; DOI=10.1016/0092-8674(90)90657-z;
RA   Nourse J., Mellentin J.D., Galili N., Wilkinson J., Stanbridge E.,
RA   Smith S.D., Cleary M.L.;
RT   "Chromosomal translocation t(1;19) results in synthesis of a homeobox
RT   fusion mRNA that codes for a potential chimeric transcription factor.";
RL   Cell 60:535-545(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS E47 AND 3).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 214-654 (ISOFORMS E12 AND E47), AND DOMAIN
RP   BHLH.
RC   TISSUE=Lymphoma;
RX   PubMed=2493990; DOI=10.1016/0092-8674(89)90682-x;
RA   Murre C., McCaw P.S., Baltimore D.;
RT   "A new DNA binding and dimerization motif in immunoglobulin enhancer
RT   binding, daughterless, MyoD, and myc proteins.";
RL   Cell 56:777-783(1989).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 69-654 (ISOFORM E47).
RX   PubMed=2308859; DOI=10.1093/nar/18.3.677;
RA   Henthorn P., McCarrick-Walmsley R., Kadesch T.;
RT   "Sequence of the cDNA encoding ITF-1, a positive-acting transcription
RT   factor.";
RL   Nucleic Acids Res. 18:677-677(1990).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 511-654 (ISOFORM E47).
RX   PubMed=1818757; DOI=10.3109/10425179109039690;
RA   Zhang Y., Bina M.;
RT   "Sequence of a HeLa cDNA provides the DNA binding domain and carboxy
RT   terminus of HE47: a human helix-loop-helix protein related to the enhancer
RT   binding factor E47.";
RL   DNA Seq. 2:197-202(1991).
RN   [8]
RP   DISCUSSION OF SEQUENCE.
RX   PubMed=2105528; DOI=10.1126/science.2105528;
RA   Henthorn P., Kiledjian M., Kadesch T.;
RT   "Two distinct transcription factors that bind the immunoglobulin enhancer
RT   microE5/kappa 2 motif.";
RL   Science 247:467-470(1990).
RN   [9]
RP   MUTAGENESIS, DNA-BINDING, AND HOMODIMERIZATION.
RX   PubMed=2112746; DOI=10.1073/pnas.87.12.4722;
RA   Voronova A., Baltimore D.;
RT   "Mutations that disrupt DNA binding and dimer formation in the E47 helix-
RT   loop-helix protein map to distinct domains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4722-4726(1990).
RN   [10]
RP   CHROMOSOMAL TRANSLOCATION WITH PBX1.
RX   PubMed=1671560;
RA   Hunger S.P., Galili N., Carroll A.J., Crist W.M., Link M.P., Cleary M.L.;
RT   "The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding
RT   sequences in acute lymphoblastic leukemias.";
RL   Blood 77:687-693(1991).
RN   [11]
RP   CHROMOSOMAL TRANSLOCATION WITH HLF.
RX   PubMed=1386162; DOI=10.1126/science.1386162;
RA   Inaba T., Roberts W.M., Shapiro L.H., Jolly K.W., Raimondi S.C.,
RA   Smith S.D., Look A.T.;
RT   "Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-
RT   lineage leukemia.";
RL   Science 257:531-534(1992).
RN   [12]
RP   INTERACTION WITH UBE2I.
RX   PubMed=9409784; DOI=10.1016/s0378-1119(97)00444-7;
RA   Loveys D.A., Streiff M.B., Schaefer T.S., Kato G.J.;
RT   "The mUBC9 murine ubiquitin conjugating enzyme interacts with the E2A
RT   transcription factors.";
RL   Gene 201:169-177(1997).
RN   [13]
RP   CHROMOSOMAL TRANSLOCATION WITH TFPT.
RX   PubMed=10086727; DOI=10.1038/sj.leu.2401338;
RA   Brambillasca F., Mosna G., Colombo M., Rivolta A., Caslini C., Minuzzo M.,
RA   Giudici G., Mizzi L., Biondi A., Privitera E.;
RT   "Identification of a novel molecular partner of the E2A gene in childhood
RT   leukemia.";
RL   Leukemia 13:369-375(1999).
RN   [14]
RP   INTERACTION WITH NEUROD1 AND EP300, HOMODIMERIZATION, AND
RP   HETERODIMERIZATION.
RX   PubMed=14752053; DOI=10.1210/me.2003-0311;
RA   Kim J.Y., Chu K., Kim H.J., Seong H.A., Park K.C., Sanyal S., Takeda J.,
RA   Ha H., Shong M., Tsai M.J., Choi H.S.;
RT   "Orphan nuclear receptor small heterodimer partner, a novel corepressor for
RT   a basic helix-loop-helix transcription factor BETA2/neuroD.";
RL   Mol. Endocrinol. 18:776-790(2004).
RN   [15]
RP   INTERACTION WITH FIGLA.
RX   PubMed=15044608; DOI=10.1093/molehr/gah056;
RA   Bayne R.A.L., Martins da Silva S.J., Anderson R.A.;
RT   "Increased expression of the FIGLA transcription factor is associated with
RT   primordial follicle formation in the human fetal ovary.";
RL   Mol. Hum. Reprod. 10:373-381(2004).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-531 (ISOFORM E47), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-139 AND SER-359, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-134, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-379 AND SER-529, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   INTERACTION WITH BHLHA9.
RX   PubMed=25466284; DOI=10.1016/j.ajhg.2014.10.012;
RA   Malik S., Percin F.E., Bornholdt D., Albrecht B., Percesepe A., Koch M.C.,
RA   Landi A., Fritz B., Khan R., Mumtaz S., Akarsu N.A., Grzeschik K.H.;
RT   "Mutations affecting the BHLHA9 DNA-binding domain cause MSSD, mesoaxial
RT   synostotic syndactyly with phalangeal reduction, Malik-Percin type.";
RL   Am. J. Hum. Genet. 95:649-659(2014).
RN   [23]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-498, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-498, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [25]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-498 AND LYS-625, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [26]
RP   3D-STRUCTURE MODELING OF 549-610.
RX   PubMed=8433970; DOI=10.1093/protein/6.1.41;
RA   Gibson T.J., Thompson J.D., Abagyan R.A.;
RT   "Proposed structure for the DNA-binding domain of the helix-loop-helix
RT   family of eukaryotic gene regulatory proteins.";
RL   Protein Eng. 6:41-50(1993).
RN   [27]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-8.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [28]
RP   DOMAIN.
RX   PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003;
RA   Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M.;
RT   "Nine-amino-acid transactivation domain: establishment and prediction
RT   utilities.";
RL   Genomics 89:756-768(2007).
RN   [29]
RP   INVOLVEMENT IN AGM8, VARIANT AGM8 LYS-555 (ISOFORM E47), AND
RP   CHARACTERIZATION OF VARIANT AGM8 (ISOFORM E47) LYS-555.
RX   PubMed=24216514; DOI=10.1172/jci71927;
RA   Boisson B., Wang Y.D., Bosompem A., Ma C.S., Lim A., Kochetkov T.,
RA   Tangye S.G., Casanova J.L., Conley M.E.;
RT   "A recurrent dominant negative E47 mutation causes agammaglobulinemia and
RT   BCR(-) B cells.";
RL   J. Clin. Invest. 123:4781-4786(2013).
CC   -!- FUNCTION: Transcriptional regulator. Involved in the initiation of
CC       neuronal differentiation. Heterodimers between TCF3 and tissue-specific
CC       basic helix-loop-helix (bHLH) proteins play major roles in determining
CC       tissue-specific cell fate during embryogenesis, like muscle or early B-
CC       cell differentiation. Dimers bind DNA on E-box motifs: 5'-CANNTG-3'.
CC       Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer.
CC       Binds to IEB1 and IEB2, which are short DNA sequences in the insulin
CC       gene transcription control region. {ECO:0000250|UniProtKB:P15806}.
CC   -!- SUBUNIT: Forms a heterodimer with ASH1 and TWIST2. Isoform E12
CC       interacts with RALGAPA1 and FIGLA. Efficient DNA binding requires
CC       dimerization with another bHLH protein. Component of a nuclear TAL-1
CC       complex composed at least of CBFA2T3, LDB1, TAL1 and TCF3. Interacts
CC       with NEUROD2, PTF1A and TGFB1I1. Forms a heterodimer with MYOG;
CC       heterodimerization enhances MYOG DNA-binding and transcriptional
CC       activities (By similarity). Homodimer. Heterodimer. Forms a heterodimer
CC       with NEUROD1; the heterodimer is inhibited in presence of ID2, but not
CC       NR0B2, to E-box element. Interacts with EP300 and UBE2I. Interacts with
CC       BHLHA9 (PubMed:25466284). Forms a heterodimer with ATOH8; repress
CC       transcription of TCF3 and TCF3/NEUROG3 dimer-induced transactivation of
CC       E box-dependent promoters (By similarity).
CC       {ECO:0000250|UniProtKB:P15806, ECO:0000269|PubMed:14752053,
CC       ECO:0000269|PubMed:15044608, ECO:0000269|PubMed:25466284,
CC       ECO:0000269|PubMed:9409784}.
CC   -!- INTERACTION:
CC       P15923; P50553: ASCL1; NbExp=3; IntAct=EBI-769630, EBI-957042;
CC       P15923-3; Q9NQ33: ASCL3; NbExp=3; IntAct=EBI-12000326, EBI-12108222;
CC       P15923-1; O95273: CCNDBP1; NbExp=3; IntAct=EBI-769645, EBI-748961;
CC       P15923; O75593: FOXH1; NbExp=2; IntAct=EBI-769630, EBI-1759806;
CC       P15923-3; O96004: HAND1; NbExp=3; IntAct=EBI-12000326, EBI-11320290;
CC       P15923-3; P41134: ID1; NbExp=3; IntAct=EBI-12000326, EBI-1215527;
CC       P15923-1; Q02363: ID2; NbExp=3; IntAct=EBI-769645, EBI-713450;
CC       P15923; Q02535: ID3; NbExp=3; IntAct=EBI-769630, EBI-1387094;
CC       P15923-3; Q02535: ID3; NbExp=3; IntAct=EBI-12000326, EBI-1387094;
CC       P15923-1; P15172: MYOD1; NbExp=2; IntAct=EBI-769645, EBI-488878;
CC       P15923-1; O00233: PSMD9; NbExp=2; IntAct=EBI-769645, EBI-750973;
CC       P15923; P17542: TAL1; NbExp=7; IntAct=EBI-769630, EBI-1753878;
CC       P15923; Q9Y4C2: TCAF1; NbExp=3; IntAct=EBI-769630, EBI-750484;
CC       P15923-3; Q9Y4C2-2: TCAF1; NbExp=3; IntAct=EBI-12000326, EBI-11974855;
CC       P15923-3; Q8WVJ9: TWIST2; NbExp=3; IntAct=EBI-12000326, EBI-1797313;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=E12; Synonyms=PAN-2;
CC         IsoId=P15923-1; Sequence=Displayed;
CC       Name=E47; Synonyms=PAN-1;
CC         IsoId=P15923-2; Sequence=VSP_002155;
CC       Name=3;
CC         IsoId=P15923-3; Sequence=VSP_057277, VSP_057278;
CC   -!- DOMAIN: the 9aaTAD motif is a transactivation domain present in a large
CC       number of yeast and animal transcription factors.
CC       {ECO:0000269|PubMed:17467953, ECO:0000269|PubMed:2493990}.
CC   -!- PTM: Phosphorylated following NGF stimulation. {ECO:0000250}.
CC   -!- DISEASE: Note=Chromosomal aberrations involving TCF3 are cause of forms
CC       of pre-B-cell acute lymphoblastic leukemia (B-ALL). Translocation
CC       t(1;19)(q23;p13.3) with PBX1. TCF3-PBX1 transforms cells by
CC       constitutively activating transcription of genes regulated by PBX1 or
CC       by other members of the PBX protein family (PubMed:1967983,
CC       PubMed:1671560). Translocation t(17;19)(q22;p13.3) with HLF
CC       (PubMed:1386162). Inversion inv(19)(p13;q13) with TFPT
CC       (PubMed:10086727). {ECO:0000269|PubMed:10086727,
CC       ECO:0000269|PubMed:1386162, ECO:0000269|PubMed:1671560,
CC       ECO:0000269|PubMed:1967983}.
CC   -!- DISEASE: Agammaglobulinemia 8, autosomal dominant (AGM8) [MIM:616941]:
CC       A form of agammaglobulinemia, a primary immunodeficiency characterized
CC       by profoundly low or absent serum antibodies and low or absent
CC       circulating B-cells due to an early block of B-cell development.
CC       Affected individuals develop severe infections in the first years of
CC       life. {ECO:0000269|PubMed:24216514}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform E47]: The bHLH domain encompassing amino acids
CC       546 to 599 is sufficient to mediate DNA-binding and homodimerization.
CC       Combined mutagenesis of Phe-566 and Leu-569 to Asp-566 and Glu-569,
CC       mutagenesis of Lys-585 to Ala-585 or combined mutagenesis of Ile-588
CC       and Leu-589 to Asp-588 and Glu-589 prevents DNA-binding and
CC       homodimerization. Mutagenesis of Arg-548 to Lys-548, combined
CC       mutagenesis of Arg-547 and Arg-548 to Gly-547 and Gly-548, mutagenesis
CC       of Arg-556 to Lys-556, mutagenesis of Arg-558 to Lys-558, or combined
CC       mutagenesis of Arg-556 and Arg-558 to Gly-556 and Gly-558, alter DNA-
CC       binding but not dimerization. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA52331.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/E2AID50.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M31523; AAA61146.1; -; mRNA.
DR   EMBL; M31522; AAA36764.1; ALT_TERM; mRNA.
DR   EMBL; M31222; AAA52331.1; ALT_INIT; mRNA.
DR   EMBL; AC006274; AAC99797.1; -; Genomic_DNA.
DR   EMBL; AC005321; AAC27373.1; -; Genomic_DNA.
DR   EMBL; KC877695; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC110579; AAI10580.1; -; mRNA.
DR   EMBL; BC110580; AAI10581.1; -; mRNA.
DR   EMBL; M24404; AAA56829.1; -; mRNA.
DR   EMBL; M24405; AAA56830.1; -; mRNA.
DR   EMBL; X52078; CAA36297.1; -; mRNA.
DR   EMBL; M65214; AAC41693.1; -; mRNA.
DR   CCDS; CCDS12074.1; -. [P15923-1]
DR   CCDS; CCDS45899.1; -. [P15923-2]
DR   PIR; A34734; A34734.
DR   PIR; S10099; S10099.
DR   RefSeq; NP_001129611.1; NM_001136139.2. [P15923-2]
DR   RefSeq; NP_003191.1; NM_003200.3. [P15923-1]
DR   RefSeq; XP_016882669.1; XM_017027180.1. [P15923-3]
DR   RefSeq; XP_016882670.1; XM_017027181.1. [P15923-1]
DR   RefSeq; XP_016882671.1; XM_017027182.1.
DR   PDB; 1HLH; Model; -; A/B=549-610.
DR   PDB; 2MH0; NMR; -; A=1-37.
DR   PDB; 2YPA; X-ray; 2.80 A; B=546-616.
DR   PDB; 2YPB; X-ray; 2.87 A; B=546-616.
DR   PDB; 3U5V; X-ray; 1.70 A; A=563-613.
DR   PDB; 6MGN; X-ray; 1.90 A; A=561-612.
DR   PDBsum; 1HLH; -.
DR   PDBsum; 2MH0; -.
DR   PDBsum; 2YPA; -.
DR   PDBsum; 2YPB; -.
DR   PDBsum; 3U5V; -.
DR   PDBsum; 6MGN; -.
DR   SMR; P15923; -.
DR   BioGrid; 112791; 201.
DR   CORUM; P15923; -.
DR   DIP; DIP-74N; -.
DR   IntAct; P15923; 41.
DR   MINT; P15923; -.
DR   STRING; 9606.ENSP00000262965; -.
DR   iPTMnet; P15923; -.
DR   PhosphoSitePlus; P15923; -.
DR   BioMuta; TCF3; -.
DR   DMDM; 135655; -.
DR   EPD; P15923; -.
DR   jPOST; P15923; -.
DR   MassIVE; P15923; -.
DR   MaxQB; P15923; -.
DR   PaxDb; P15923; -.
DR   PeptideAtlas; P15923; -.
DR   PRIDE; P15923; -.
DR   ProteomicsDB; 53242; -. [P15923-1]
DR   ProteomicsDB; 53243; -. [P15923-2]
DR   ProteomicsDB; 61481; -.
DR   Antibodypedia; 4332; 545 antibodies.
DR   Ensembl; ENST00000262965; ENSP00000262965; ENSG00000071564. [P15923-1]
DR   Ensembl; ENST00000395423; ENSP00000378813; ENSG00000071564. [P15923-3]
DR   Ensembl; ENST00000588136; ENSP00000468487; ENSG00000071564. [P15923-2]
DR   Ensembl; ENST00000611869; ENSP00000480564; ENSG00000071564. [P15923-2]
DR   GeneID; 6929; -.
DR   KEGG; hsa:6929; -.
DR   UCSC; uc002ltr.3; human. [P15923-1]
DR   CTD; 6929; -.
DR   DisGeNET; 6929; -.
DR   GeneCards; TCF3; -.
DR   HGNC; HGNC:11633; TCF3.
DR   HPA; ENSG00000071564; Low tissue specificity.
DR   MalaCards; TCF3; -.
DR   MIM; 147141; gene.
DR   MIM; 616941; phenotype.
DR   neXtProt; NX_P15923; -.
DR   OpenTargets; ENSG00000071564; -.
DR   Orphanet; 33110; Autosomal agammaglobulinemia.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA164742580; -.
DR   eggNOG; KOG3910; Eukaryota.
DR   eggNOG; ENOG410XYUA; LUCA.
DR   GeneTree; ENSGT00940000157036; -.
DR   HOGENOM; CLU_021099_2_1_1; -.
DR   InParanoid; P15923; -.
DR   KO; K09063; -.
DR   OMA; AHVHRPH; -.
DR   OrthoDB; 571132at2759; -.
DR   PhylomeDB; P15923; -.
DR   TreeFam; TF321672; -.
DR   Reactome; R-HSA-525793; Myogenesis.
DR   Reactome; R-HSA-8939236; RUNX1 regulates transcription of genes involved in differentiation of HSCs.
DR   SignaLink; P15923; -.
DR   SIGNOR; P15923; -.
DR   ChiTaRS; TCF3; human.
DR   GeneWiki; TCF3; -.
DR   GenomeRNAi; 6929; -.
DR   Pharos; P15923; Tbio.
DR   PRO; PR:P15923; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P15923; protein.
DR   Bgee; ENSG00000071564; Expressed in testis and 231 other tissues.
DR   ExpressionAtlas; P15923; baseline and differential.
DR   Genevisible; P15923; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0090575; C:RNA polymerase II transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0005667; C:transcription factor complex; IDA:UniProtKB.
DR   GO; GO:0043425; F:bHLH transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0035326; F:cis-regulatory region binding; IC:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0070888; F:E-box binding; IDA:UniProtKB.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0070491; F:repressing transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0070644; F:vitamin D response element binding; IDA:BHF-UCL.
DR   GO; GO:0030183; P:B cell differentiation; NAS:UniProtKB.
DR   GO; GO:0002326; P:B cell lineage commitment; IDA:UniProtKB.
DR   GO; GO:0033152; P:immunoglobulin V(D)J recombination; IDA:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0051149; P:positive regulation of muscle cell differentiation; TAS:Reactome.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:2000045; P:regulation of G1/S transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IDA:UniProtKB.
DR   CDD; cd00083; HLH; 1.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   Pfam; PF00010; HLH; 1.
DR   SMART; SM00353; HLH; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   PROSITE; PS50888; BHLH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosomal rearrangement;
KW   Differentiation; Disease mutation; DNA-binding; Isopeptide bond;
KW   Methylation; Neurogenesis; Nucleus; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..654
FT                   /note="Transcription factor E2-alpha"
FT                   /id="PRO_0000127466"
FT   DOMAIN          549..602
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   REGION          389..425
FT                   /note="Leucine-zipper"
FT   MOTIF           19..27
FT                   /note="9aaTAD"
FT   MOTIF           170..176
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   SITE            483..484
FT                   /note="Breakpoint for translocation to form TCF3-PBX1
FT                   oncogene"
FT   MOD_RES         134
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231"
FT   MOD_RES         139
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         355
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P15806"
FT   MOD_RES         359
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         371
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P15806"
FT   MOD_RES         379
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         529
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   CROSSLNK        498
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:25755297, ECO:0000244|PubMed:28112733"
FT   CROSSLNK        625
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         49..99
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_057277"
FT   VAR_SEQ         528
FT                   /note="T -> TRCQPTPRHSPPSPHQDAHVHRPHAHRTHTGRPSAGPTLFPQPHCLP
FT                   LAPSRRPPH (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_057278"
FT   VAR_SEQ         530..601
FT                   /note="PDEDEDDLLPPEQKAEREKERRVANNARERLRVRDINEAFKELGRMCQLHLN
FT                   SEKPQTKLLILHQAVSVILN -> STDEVLSLEEKDLRDRERRMANNARERVRVRDINE
FT                   AFRELGRMCQMHLKSDKAQTKLLILQQAVQVILG (in isoform E47)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:1818757, ECO:0000303|PubMed:2308859,
FT                   ECO:0000303|PubMed:2493990"
FT                   /id="VSP_002155"
FT   VARIANT         8
FT                   /note="A -> V (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs376780559)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036396"
FT   VARIANT         120
FT                   /note="L -> P (in dbSNP:rs35354874)"
FT                   /id="VAR_049552"
FT   VARIANT         198
FT                   /note="T -> A (in dbSNP:rs11879402)"
FT                   /id="VAR_049553"
FT   VARIANT         431
FT                   /note="G -> S (in dbSNP:rs1052692)"
FT                   /id="VAR_049554"
FT   CONFLICT        69..99
FT                   /note="FDPSRTFSEGTHFTESHSSLSSSTFLGPGLG -> GGGECLAWCGPSAVHRC
FT                   ADVGLGMVSARTAP (in Ref. 6; CAA36297)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        214..216
FT                   /note="FYV -> EFR (in Ref. 5; AAA56830)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        302
FT                   /note="Missing (in Ref. 1; AAA36764)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        390
FT                   /note="Missing (in Ref. 5; AAA56830)"
FT                   /evidence="ECO:0000305"
FT   HELIX           12..25
FT                   /evidence="ECO:0000244|PDB:2MH0"
FT   HELIX           563..580
FT                   /evidence="ECO:0000244|PDB:3U5V"
FT   HELIX           588..608
FT                   /evidence="ECO:0000244|PDB:3U5V"
FT   MOD_RES         P15923-2:531
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   VARIANT         P15923-2:555
FT                   /note="E -> K (in AGM8, localizes normally to the nucleus,
FT                   does not perform proper DNA binding, acts in a dominant-
FT                   negative manner when coexpressed with wild-type) (Ref.29)"
FT                   /evidence="ECO:0000269|PubMed:24216514"
FT                   /id="VAR_082832"
SQ   SEQUENCE   654 AA;  67600 MW;  52F5E3DE1890AE13 CRC64;
     MNQPQRMAPV GTDKELSDLL DFSMMFPLPV TNGKGRPASL AGAQFGGSGL EDRPSSGSWG
     SGDQSSSSFD PSRTFSEGTH FTESHSSLSS STFLGPGLGG KSGERGAYAS FGRDAGVGGL
     TQAGFLSGEL ALNSPGPLSP SGMKGTSQYY PSYSGSSRRR AADGSLDTQP KKVRKVPPGL
     PSSVYPPSSG EDYGRDATAY PSAKTPSSTY PAPFYVADGS LHPSAELWSP PGQAGFGPML
     GGGSSPLPLP PGSGPVGSSG SSSTFGGLHQ HERMGYQLHG AEVNGGLPSA SSFSSAPGAT
     YGGVSSHTPP VSGADSLLGS RGTTAGSSGD ALGKALASIY SPDHSSNNFS SSPSTPVGSP
     QGLAGTSQWP RAGAPGALSP SYDGGLHGLQ SKIEDHLDEA IHVLRSHAVG TAGDMHTLLP
     GHGALASGFT GPMSLGGRHA GLVGGSHPED GLAGSTSLMH NHAALPSQPG TLPDLSRPPD
     SYSGLGRAGA TAAASEIKRE EKEDEENTSA ADHSEEEKKE LKAPRARTSP DEDEDDLLPP
     EQKAEREKER RVANNARERL RVRDINEAFK ELGRMCQLHL NSEKPQTKLL ILHQAVSVIL
     NLEQQVRERN LNPKAACLKR REEEKVSGVV GDPQMVLSAP HPGLSEAHNP AGHM
//
ID   X6REB3_HUMAN            Unreviewed;       679 AA.
AC   X6REB3;
DT   11-JUN-2014, integrated into UniProtKB/TrEMBL.
DT   29-OCT-2014, sequence version 2.
DT   22-APR-2020, entry version 49.
DE   SubName: Full=Transcription factor E2-alpha {ECO:0000313|Ensembl:ENSP00000396363};
GN   Name=TCF3 {ECO:0000313|Ensembl:ENSP00000396363};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000396363, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000396363, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [2] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [3] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [4] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [5] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [6] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [7] {ECO:0000213|PubMed:25218447}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [8] {ECO:0000313|Ensembl:ENSP00000396363}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (APR-2014) to UniProtKB.
RN   [9] {ECO:0000213|PubMed:25755297}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurethsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [10] {ECO:0000213|PubMed:28112733}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC005321; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006274; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KC877695; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; XP_006722920.1; XM_006722857.3.
DR   RefSeq; XP_006722921.1; XM_006722858.3.
DR   RefSeq; XP_011526523.1; XM_011528221.2.
DR   jPOST; X6REB3; -.
DR   PeptideAtlas; X6REB3; -.
DR   PRIDE; X6REB3; -.
DR   Antibodypedia; 4332; 545 antibodies.
DR   Ensembl; ENST00000453954; ENSP00000396363; ENSG00000071564.
DR   GeneID; 6929; -.
DR   UCSC; uc060ree.1; human.
DR   CTD; 6929; -.
DR   EuPathDB; HostDB:ENSG00000071564.14; -.
DR   HGNC; HGNC:11633; TCF3.
DR   OpenTargets; ENSG00000071564; -.
DR   GeneTree; ENSGT00940000157036; -.
DR   OrthoDB; 571132at2759; -.
DR   ChiTaRS; TCF3; human.
DR   GenomeRNAi; 6929; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000071564; Expressed in testis and 231 other tissues.
DR   ExpressionAtlas; X6REB3; baseline and differential.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   CDD; cd00083; HLH; 1.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   Pfam; PF00010; HLH; 1.
DR   SMART; SM00353; HLH; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   PROSITE; PS50888; BHLH; 1.
PE   1: Evidence at protein level;
KW   Proteomics identification {ECO:0000213|EPD:X6REB3,
KW   ECO:0000213|MaxQB:X6REB3, ECO:0000213|PeptideAtlas:X6REB3,
KW   ECO:0000213|ProteomicsDB:X6REB3};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   DOMAIN          574..627
FT                   /note="BHLH"
FT                   /evidence="ECO:0000259|PROSITE:PS50888"
FT   REGION          36..90
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          164..234
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          269..297
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          321..358
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          372..414
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          490..563
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          658..679
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        54..90
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        168..192
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        321..356
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        372..395
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        523..563
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   679 AA;  70075 MW;  A64B0EF1626FA35E CRC64;
     MNQPQRMAPV GTDKELSDLL DFSMMFPLPV TNGKGRPASL AGAQFGGSGL EDRPSSGSWG
     SGDQSSSSFD PSRTFSEGTH FTESHSSLSS STFLGPGLGG ECLAWCGPSA VHRCADVGLG
     MVSARTAPGK SGERGAYASF GRDAGVGGLT QAGFLSGELA LNSPGPLSPS GMKGTSQYYP
     SYSGSSRRRA ADGSLDTQPK KVRKVPPGLP SSVYPPSSGE DYGRDATAYP SAKTPSSTYP
     APFYVADGSL HPSAELWSPP GQAGFGPMLG GGSSPLPLPP GSGPVGSSGS SSTFGGLHQH
     ERMGYQLHGA EVNGGLPSAS SFSSAPGATY GGVSSHTPPV SGADSLLGSR GTTAGSSGDA
     LGKALASIYS PDHSSNNFSS SPSTPVGSPQ GLAGTSQWPR AGAPGALSPS YDGGLHGLQS
     KIEDHLDEAI HVLRSHAVGT AGDMHTLLPG HGALASGFTG PMSLGGRHAG LVGGSHPEDG
     LAGSTSLMHN HAALPSQPGT LPDLSRPPDS YSGLGRAGAT AAASEIKREE KEDEENTSAA
     DHSEEEKKEL KAPRARTSTD EVLSLEEKDL RDRERRMANN ARERVRVRDI NEAFRELGRM
     CQMHLKSDKA QTKLLILQQA VQVILGLEQQ VRERNLNPKA ACLKRREEEK VSGVVGDPQM
     VLSAPHPGLS EAHNPAGHM
//
ID   TET1_HUMAN              Reviewed;        2136 AA.
AC   Q8NFU7; Q5VUP7; Q7Z6B6; Q8TCR1; Q9C0I7;
DT   03-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 2.
DT   22-APR-2020, entry version 142.
DE   RecName: Full=Methylcytosine dioxygenase TET1;
DE            EC=1.14.11.n2 {ECO:0000269|PubMed:19372391, ECO:0000269|PubMed:21496894};
DE   AltName: Full=CXXC-type zinc finger protein 6;
DE   AltName: Full=Leukemia-associated protein with a CXXC domain;
DE   AltName: Full=Ten-eleven translocation 1 gene protein;
GN   Name=TET1 {ECO:0000303|PubMed:28397838, ECO:0000312|HGNC:HGNC:29484};
GN   Synonyms=CXXC6, KIAA1676, LCX;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANT MET-1123, FUNCTION, TISSUE SPECIFICITY,
RP   AND CHROMOSOMAL TRANSLOCATION WITH KMT2A/MLL1.
RC   TISSUE=Leukemia;
RX   PubMed=12124344;
RA   Ono R., Taki T., Taketani T., Taniwaki M., Kobayashi H., Hayashi Y.;
RT   "LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in
RT   acute myeloid leukemia with trilineage dysplasia having
RT   t(10;11)(q22;q23).";
RL   Cancer Res. 62:4075-4080(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1402-2136.
RC   TISSUE=Brain;
RX   PubMed=11214970; DOI=10.1093/dnares/7.6.347;
RA   Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIX. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:347-355(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1665-2074.
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1809-2136.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   CHROMOSOMAL TRANSLOCATION WITH KMT2A/MLL1, TISSUE SPECIFICITY, AND
RP   INVOLVEMENT IN ACUTE LEUKEMIAS.
RX   PubMed=12646957; DOI=10.1038/sj.leu.2402834;
RA   Lorsbach R.B., Moore J., Mathew S., Raimondi S.C., Mukatira S.T.,
RA   Downing J.R.;
RT   "TET1, a member of a novel protein family, is fused to MLL in acute myeloid
RT   leukemia containing the t(10;11)(q22;q23).";
RL   Leukemia 17:637-641(2003).
RN   [7]
RP   FUNCTION.
RX   PubMed=19372393; DOI=10.1126/science.1169786;
RA   Kriaucionis S., Heintz N.;
RT   "The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje
RT   neurons and the brain.";
RL   Science 324:929-930(2009).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, DNA-BINDING, COFACTOR, AND MUTAGENESIS OF
RP   HIS-1672 AND ASP-1674.
RX   PubMed=19372391; DOI=10.1126/science.1170116;
RA   Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y.,
RA   Agarwal S., Iyer L.M., Liu D.R., Aravind L., Rao A.;
RT   "Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA
RT   by the MLL fusion partner TET1.";
RL   Science 324:930-935(2009).
RN   [9]
RP   FUNCTION IN DNA DEMETHYLATION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF
RP   HIS-1672 AND ASP-1674.
RX   PubMed=21496894; DOI=10.1016/j.cell.2011.03.022;
RA   Guo J.U., Su Y., Zhong C., Ming G.L., Song H.;
RT   "Hydroxylation of 5-methylcytosine by TET1 promotes active DNA
RT   demethylation in the adult brain.";
RL   Cell 145:423-434(2011).
RN   [10]
RP   INTERACTION WITH SIN3A.
RX   PubMed=21490601; DOI=10.1038/nature10066;
RA   Williams K., Christensen J., Pedersen M.T., Johansen J.V., Cloos P.A.,
RA   Rappsilber J., Helin K.;
RT   "TET1 and hydroxymethylcytosine in transcription and DNA methylation
RT   fidelity.";
RL   Nature 473:343-348(2011).
RN   [11]
RP   FUNCTION.
RX   PubMed=21778364; DOI=10.1126/science.1210597;
RA   Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., He C.,
RA   Zhang Y.;
RT   "Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-
RT   carboxylcytosine.";
RL   Science 333:1300-1303(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-871, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=25284789; DOI=10.1016/j.celrep.2014.08.071;
RA   Takai H., Masuda K., Sato T., Sakaguchi Y., Suzuki T., Suzuki T.,
RA   Koyama-Nasu R., Nasu-Nishimura Y., Katou Y., Ogawa H., Morishita Y.,
RA   Kozuka-Hata H., Oyama M., Todo T., Ino Y., Mukasa A., Saito N.,
RA   Toyoshima C., Shirahige K., Akiyama T.;
RT   "5-Hydroxymethylcytosine plays a critical role in glioblastomagenesis by
RT   recruiting the CHTOP-methylosome complex.";
RL   Cell Rep. 9:48-60(2014).
RN   [14] {ECO:0000244|PDB:6ASD}
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 587-632 IN COMPLEX WITH CPG DNA,
RP   FUNCTION, DOMAIN CXXC-TYPE ZINC-FINGER, AND ZINC-BINDING.
RX   PubMed=29276034; DOI=10.1016/j.str.2017.11.022;
RA   Xu C., Liu K., Lei M., Yang A., Li Y., Hughes T.R., Min J.;
RT   "DNA Sequence Recognition of Human CXXC Domains and Their Structural
RT   Determinants.";
RL   Structure 26:85-95.e3(2018).
RN   [15]
RP   VARIANT ASN-2056.
RX   PubMed=28397838; DOI=10.1038/mp.2017.60;
RA   Harripaul R., Vasli N., Mikhailov A., Rafiq M.A., Mittal K.,
RA   Windpassinger C., Sheikh T.I., Noor A., Mahmood H., Downey S., Johnson M.,
RA   Vleuten K., Bell L., Ilyas M., Khan F.S., Khan V., Moradi M., Ayaz M.,
RA   Naeem F., Heidari A., Ahmed I., Ghadami S., Agha Z., Zeinali S., Qamar R.,
RA   Mozhdehipanah H., John P., Mir A., Ansar M., French L., Ayub M.,
RA   Vincent J.B.;
RT   "Mapping autosomal recessive intellectual disability: combined microarray
RT   and exome sequencing identifies 26 novel candidate genes in 192
RT   consanguineous families.";
RL   Mol. Psychiatry 23:973-984(2018).
CC   -!- FUNCTION: Dioxygenase that catalyzes the conversion of the modified
CC       genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC)
CC       and plays a key role in active DNA demethylation. Also mediates
CC       subsequent conversion of 5hmC into 5-formylcytosine (5fC), and
CC       conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into
CC       5hmC, 5fC and 5caC probably constitutes the first step in cytosine
CC       demethylation. Methylation at the C5 position of cytosine bases is an
CC       epigenetic modification of the mammalian genome which plays an
CC       important role in transcriptional regulation. In addition to its role
CC       in DNA demethylation, plays a more general role in chromatin
CC       regulation. Preferentially binds to CpG-rich sequences at promoters of
CC       both transcriptionally active and Polycomb-repressed genes. Involved in
CC       the recruitment of the O-GlcNAc transferase OGT to CpG-rich
CC       transcription start sites of active genes, thereby promoting histone
CC       H2B GlcNAcylation by OGT. Also involved in transcription repression of
CC       a subset of genes through recruitment of transcriptional repressors to
CC       promoters. Involved in the balance between pluripotency and lineage
CC       commitment of cells it plays a role in embryonic stem cells maintenance
CC       and inner cell mass cell specification. Plays an important role in the
CC       tumorigenicity of glioblastoma cells. TET1-mediated production of 5hmC
CC       acts as a recruitment signal for the CHTOP-methylosome complex to
CC       selective sites on the chromosome, where it methylates H4R3 and
CC       activates the transcription of genes involved in glioblastomagenesis
CC       (PubMed:25284789). Binds preferentially to DNA containing cytidine-
CC       phosphate-guanosine (CpG) dinucleotides over CpH (H=A, T, and C),
CC       hemimethylated-CpG and hemimethylated-hydroxymethyl-CpG
CC       (PubMed:29276034). {ECO:0000269|PubMed:12124344,
CC       ECO:0000269|PubMed:19372391, ECO:0000269|PubMed:19372393,
CC       ECO:0000269|PubMed:21496894, ECO:0000269|PubMed:21778364,
CC       ECO:0000269|PubMed:25284789, ECO:0000269|PubMed:29276034}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate + a 5-methyl-2'-deoxycytidine in DNA + O2 = a
CC         5-hydroxymethyl-2'-deoxycytidine in DNA + CO2 + succinate;
CC         Xref=Rhea:RHEA:52636, Rhea:RHEA-COMP:11370, Rhea:RHEA-COMP:13315,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:16526, ChEBI:CHEBI:16810,
CC         ChEBI:CHEBI:30031, ChEBI:CHEBI:85454, ChEBI:CHEBI:136731;
CC         EC=1.14.11.n2; Evidence={ECO:0000269|PubMed:19372391,
CC         ECO:0000269|PubMed:21496894};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate + a 5-hydroxymethyl-2'-deoxycytidine in DNA +
CC         O2 = a 5-formyl-2'-deoxycytidine in DNA + CO2 + H2O + succinate;
CC         Xref=Rhea:RHEA:53828, Rhea:RHEA-COMP:13315, Rhea:RHEA-COMP:13656,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:16810, ChEBI:CHEBI:30031, ChEBI:CHEBI:136731,
CC         ChEBI:CHEBI:137731; Evidence={ECO:0000305|PubMed:21778364};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate + a 5-formyl-2'-deoxycytidine in DNA + O2 = a
CC         5-carboxyl-2'-deoxycytidine in DNA + CO2 + H(+) + succinate;
CC         Xref=Rhea:RHEA:53832, Rhea:RHEA-COMP:13656, Rhea:RHEA-COMP:13657,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:16810, ChEBI:CHEBI:30031, ChEBI:CHEBI:137731,
CC         ChEBI:CHEBI:137732; Evidence={ECO:0000305|PubMed:21778364};
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC         Evidence={ECO:0000269|PubMed:19372391};
CC       Note=Binds 1 Fe(2+) ion per subunit. {ECO:0000269|PubMed:19372391};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:Q6N021};
CC       Note=Binds 3 zinc ions per subunit. The zinc ions have a structural
CC       role. {ECO:0000250|UniProtKB:Q6N021};
CC   -!- SUBUNIT: Interacts with HCFC1 and OGT (By similarity). Interacts with
CC       SIN3A; recruits the transcriptional corepressor SIN3A to gene promoters
CC       (PubMed:21490601). Found in a complex composed of at least SINHCAF,
CC       SIN3A, HDAC1, SAP30, RBBP4, OGT and TET1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q3URK3, ECO:0000269|PubMed:21490601}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Expressed in fetal heart, lung and brain, and in
CC       adult skeletal muscle, thymus and ovary. Not detected in adult heart,
CC       lung or brain. Up-regulated in glioblastoma cells (at protein level)
CC       (PubMed:25284789). {ECO:0000269|PubMed:12124344,
CC       ECO:0000269|PubMed:12646957, ECO:0000269|PubMed:25284789}.
CC   -!- DOMAIN: The CXXC zinc finger mediates binding to CpG-DNA.
CC       {ECO:0000269|PubMed:29276034}.
CC   -!- PTM: Glycosylated. Interaction with OGT leads to GlcNAcylation (By
CC       similarity). {ECO:0000250|UniProtKB:Q3URK3}.
CC   -!- DISEASE: Note=A chromosomal aberration involving TET1 may be a cause of
CC       acute leukemias (PubMed:12646957). Translocation t(10;11)(q22;q23) with
CC       KMT2A/MLL1. This is a rare chromosomal translocation 5' KMT2A/MLL1-TET1
CC       3' (PubMed:12124344, PubMed:12646957). {ECO:0000269|PubMed:12124344,
CC       ECO:0000269|PubMed:12646957}.
CC   -!- SIMILARITY: Belongs to the TET family. {ECO:0000305}.
CC   -!- CAUTION: Subsequent steps in cytosine demethylation are subject to
CC       discussion. According to a first model cytosine demethylation occurs
CC       through deamination of 5hmC into 5-hydroxymethyluracil (5hmU) and
CC       subsequent replacement by unmethylated cytosine by the base excision
CC       repair system (PubMed:21496894). According to another model, cytosine
CC       demethylation is rather mediated via conversion of 5hmC into 5fC and
CC       5caC, followed by excision by TDG and replacement by unmethylated
CC       cytosine. {ECO:0000305|PubMed:21496894}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD28467.3; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF430147; AAM88301.1; -; mRNA.
DR   EMBL; AL513534; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL713888; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB051463; BAB21767.1; -; mRNA.
DR   EMBL; AL713658; CAD28467.3; ALT_SEQ; mRNA.
DR   EMBL; BC053905; AAH53905.1; -; mRNA.
DR   CCDS; CCDS7281.1; -.
DR   RefSeq; NP_085128.2; NM_030625.2.
DR   PDB; 6ASD; X-ray; 1.85 A; C=587-632.
DR   PDBsum; 6ASD; -.
DR   SMR; Q8NFU7; -.
DR   BioGrid; 123225; 7.
DR   ComplexPortal; CPX-3323; SIN3A histone deacetylase complex, ES cell-specific variant.
DR   IntAct; Q8NFU7; 2.
DR   MINT; Q8NFU7; -.
DR   STRING; 9606.ENSP00000362748; -.
DR   iPTMnet; Q8NFU7; -.
DR   PhosphoSitePlus; Q8NFU7; -.
DR   BioMuta; TET1; -.
DR   DMDM; 115502139; -.
DR   EPD; Q8NFU7; -.
DR   MassIVE; Q8NFU7; -.
DR   PaxDb; Q8NFU7; -.
DR   PeptideAtlas; Q8NFU7; -.
DR   PRIDE; Q8NFU7; -.
DR   ProteomicsDB; 73363; -.
DR   Antibodypedia; 14634; 309 antibodies.
DR   DNASU; 80312; -.
DR   Ensembl; ENST00000373644; ENSP00000362748; ENSG00000138336.
DR   GeneID; 80312; -.
DR   KEGG; hsa:80312; -.
DR   UCSC; uc001jok.5; human.
DR   CTD; 80312; -.
DR   DisGeNET; 80312; -.
DR   GeneCards; TET1; -.
DR   HGNC; HGNC:29484; TET1.
DR   HPA; ENSG00000138336; Low tissue specificity.
DR   MIM; 607790; gene.
DR   neXtProt; NX_Q8NFU7; -.
DR   OpenTargets; ENSG00000138336; -.
DR   PharmGKB; PA162405605; -.
DR   eggNOG; ENOG410IE22; Eukaryota.
DR   eggNOG; ENOG410XPWW; LUCA.
DR   GeneTree; ENSGT00940000158935; -.
DR   HOGENOM; CLU_001618_2_0_1; -.
DR   InParanoid; Q8NFU7; -.
DR   KO; K13097; -.
DR   OMA; FHLKTES; -.
DR   OrthoDB; 29059at2759; -.
DR   PhylomeDB; Q8NFU7; -.
DR   TreeFam; TF324004; -.
DR   Reactome; R-HSA-5221030; TET1,2,3 and TDG demethylate DNA.
DR   SIGNOR; Q8NFU7; -.
DR   ChiTaRS; TET1; human.
DR   GeneWiki; Tet_methylcytosine_dioxygenase_1; -.
DR   GenomeRNAi; 80312; -.
DR   Pharos; Q8NFU7; Tbio.
DR   PRO; PR:Q8NFU7; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q8NFU7; protein.
DR   Bgee; ENSG00000138336; Expressed in heart and 102 other tissues.
DR   Genevisible; Q8NFU7; HS.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IDA:UniProtKB.
DR   GO; GO:0008327; F:methyl-CpG binding; IDA:UniProtKB.
DR   GO; GO:0070579; F:methylcytosine dioxygenase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006211; P:5-methylcytosine catabolic process; IBA:GO_Central.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0080111; P:DNA demethylation; IMP:UniProtKB.
DR   GO; GO:0001826; P:inner cell mass cell differentiation; ISS:UniProtKB.
DR   GO; GO:0090310; P:negative regulation of methylation-dependent chromatin silencing; IMP:UniProtKB.
DR   GO; GO:0070989; P:oxidative demethylation; IBA:GO_Central.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0031062; P:positive regulation of histone methylation; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0006493; P:protein O-linked glycosylation; ISS:UniProtKB.
DR   GO; GO:0019827; P:stem cell population maintenance; ISS:UniProtKB.
DR   InterPro; IPR024779; 2OGFeDO_noxygenase_dom.
DR   InterPro; IPR040175; TET1/2/3.
DR   InterPro; IPR002857; Znf_CXXC.
DR   PANTHER; PTHR23358; PTHR23358; 1.
DR   Pfam; PF12851; Tet_JBP; 1.
DR   Pfam; PF02008; zf-CXXC; 1.
DR   SMART; SM01333; Tet_JBP; 1.
DR   PROSITE; PS51058; ZF_CXXC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Chromatin regulator; Chromosomal rearrangement;
KW   Dioxygenase; DNA-binding; Glycoprotein; Iron; Metal-binding; Nucleus;
KW   Oxidoreductase; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repressor; Transcription; Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN           1..2136
FT                   /note="Methylcytosine dioxygenase TET1"
FT                   /id="PRO_0000251949"
FT   ZN_FING         584..625
FT                   /note="CXXC-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509,
FT                   ECO:0000269|PubMed:29276034"
FT   REGION          528..674
FT                   /note="Sufficient for binding to genomic CpG islands"
FT   REGION          1580..1593
FT                   /note="Interaction with DNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   REGION          2043..2045
FT                   /note="2-oxoglutarate binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   REGION          2049..2051
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           591
FT                   /note="Zinc"
FT                   /evidence="ECO:0000244|PDB:6ASD,
FT                   ECO:0000269|PubMed:29276034"
FT   METAL           594
FT                   /note="Zinc"
FT                   /evidence="ECO:0000244|PDB:6ASD,
FT                   ECO:0000269|PubMed:29276034"
FT   METAL           597
FT                   /note="Zinc"
FT                   /evidence="ECO:0000244|PDB:6ASD,
FT                   ECO:0000269|PubMed:29276034"
FT   METAL           603
FT                   /note="Zinc"
FT                   /evidence="ECO:0000244|PDB:6ASD,
FT                   ECO:0000269|PubMed:29276034"
FT   METAL           606
FT                   /note="Zinc"
FT                   /evidence="ECO:0000244|PDB:6ASD,
FT                   ECO:0000269|PubMed:29276034"
FT   METAL           609
FT                   /note="Zinc"
FT                   /evidence="ECO:0000244|PDB:6ASD,
FT                   ECO:0000269|PubMed:29276034"
FT   METAL           619
FT                   /note="Zinc"
FT                   /evidence="ECO:0000244|PDB:6ASD,
FT                   ECO:0000269|PubMed:29276034"
FT   METAL           624
FT                   /note="Zinc"
FT                   /evidence="ECO:0000244|PDB:6ASD,
FT                   ECO:0000269|PubMed:29276034"
FT   METAL           1422
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           1424
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           1482
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           1508
FT                   /note="Zinc 1; via pros nitrogen"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           1510
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           1561
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           1563
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           1579
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           1588
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           1648
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           1670
FT                   /note="Zinc 2; via tele nitrogen"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           1672
FT                   /note="Iron; catalytic"
FT                   /evidence="ECO:0000269|PubMed:21496894"
FT   METAL           1674
FT                   /note="Iron; catalytic"
FT                   /evidence="ECO:0000269|PubMed:21496894"
FT   METAL           2028
FT                   /note="Iron; catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   METAL           2059
FT                   /note="Zinc 3; via pros nitrogen"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   BINDING         1551
FT                   /note="2-oxoglutarate"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   BINDING         1664
FT                   /note="2-oxoglutarate"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   BINDING         1677
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   BINDING         1706
FT                   /note="2-oxoglutarate"
FT                   /evidence="ECO:0000250|UniProtKB:Q6N021"
FT   SITE            1608..1609
FT                   /note="Breakpoint for translocation to form KMT2A/MLL1-TET1
FT                   oncogene"
FT                   /evidence="ECO:0000269|PubMed:12124344"
FT   MOD_RES         871
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   VARIANT         162
FT                   /note="D -> G (in dbSNP:rs10823229)"
FT                   /id="VAR_027734"
FT   VARIANT         193
FT                   /note="S -> T (in dbSNP:rs12773594)"
FT                   /id="VAR_027735"
FT   VARIANT         256
FT                   /note="A -> V (in dbSNP:rs12221107)"
FT                   /id="VAR_027736"
FT   VARIANT         1018
FT                   /note="N -> S (in dbSNP:rs16925541)"
FT                   /id="VAR_027737"
FT   VARIANT         1123
FT                   /note="I -> M (in dbSNP:rs3998860)"
FT                   /evidence="ECO:0000269|PubMed:12124344"
FT                   /id="VAR_027738"
FT   VARIANT         2056
FT                   /note="K -> N (found in a consanguineous family with
FT                   intellectual disability; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:28397838"
FT                   /id="VAR_080763"
FT   MUTAGEN         1672
FT                   /note="H->Y: Loss of catalytic activity and loss of the
FT                   ability to induce DNA demethylation."
FT                   /evidence="ECO:0000269|PubMed:19372391,
FT                   ECO:0000269|PubMed:21496894"
FT   MUTAGEN         1674
FT                   /note="D->A: Loss of catalytic activity and loss of the
FT                   ability to induce DNA demethylation."
FT                   /evidence="ECO:0000269|PubMed:19372391,
FT                   ECO:0000269|PubMed:21496894"
FT   CONFLICT        2001
FT                   /note="F -> L (in Ref. 4; CAD28467)"
FT                   /evidence="ECO:0000305"
FT   HELIX           595..598
FT                   /evidence="ECO:0000244|PDB:6ASD"
FT   STRAND          604..606
FT                   /evidence="ECO:0000244|PDB:6ASD"
FT   HELIX           607..610
FT                   /evidence="ECO:0000244|PDB:6ASD"
FT   TURN            611..614
FT                   /evidence="ECO:0000244|PDB:6ASD"
FT   TURN            620..622
FT                   /evidence="ECO:0000244|PDB:6ASD"
FT   HELIX           625..628
FT                   /evidence="ECO:0000244|PDB:6ASD"
SQ   SEQUENCE   2136 AA;  235309 MW;  66E24EF0594A964C CRC64;
     MSRSRHARPS RLVRKEDVNK KKKNSQLRKT TKGANKNVAS VKTLSPGKLK QLIQERDVKK
     KTEPKPPVPV RSLLTRAGAA RMNLDRTEVL FQNPESLTCN GFTMALRSTS LSRRLSQPPL
     VVAKSKKVPL SKGLEKQHDC DYKILPALGV KHSENDSVPM QDTQVLPDIE TLIGVQNPSL
     LKGKSQETTQ FWSQRVEDSK INIPTHSGPA AEILPGPLEG TRCGEGLFSE ETLNDTSGSP
     KMFAQDTVCA PFPQRATPKV TSQGNPSIQL EELGSRVESL KLSDSYLDPI KSEHDCYPTS
     SLNKVIPDLN LRNCLALGGS TSPTSVIKFL LAGSKQATLG AKPDHQEAFE ATANQQEVSD
     TTSFLGQAFG AIPHQWELPG ADPVHGEALG ETPDLPEIPG AIPVQGEVFG TILDQQETLG
     MSGSVVPDLP VFLPVPPNPI ATFNAPSKWP EPQSTVSYGL AVQGAIQILP LGSGHTPQSS
     SNSEKNSLPP VMAISNVENE KQVHISFLPA NTQGFPLAPE RGLFHASLGI AQLSQAGPSK
     SDRGSSQVSV TSTVHVVNTT VVTMPVPMVS TSSSSYTTLL PTLEKKKRKR CGVCEPCQQK
     TNCGECTYCK NRKNSHQICK KRKCEELKKK PSVVVPLEVI KENKRPQREK KPKVLKADFD
     NKPVNGPKSE SMDYSRCGHG EEQKLELNPH TVENVTKNED SMTGIEVEKW TQNKKSQLTD
     HVKGDFSANV PEAEKSKNSE VDKKRTKSPK LFVQTVRNGI KHVHCLPAET NVSFKKFNIE
     EFGKTLENNS YKFLKDTANH KNAMSSVATD MSCDHLKGRS NVLVFQQPGF NCSSIPHSSH
     SIINHHASIH NEGDQPKTPE NIPSKEPKDG SPVQPSLLSL MKDRRLTLEQ VVAIEALTQL
     SEAPSENSSP SKSEKDEESE QRTASLLNSC KAILYTVRKD LQDPNLQGEP PKLNHCPSLE
     KQSSCNTVVF NGQTTTLSNS HINSATNQAS TKSHEYSKVT NSLSLFIPKS NSSKIDTNKS
     IAQGIITLDN CSNDLHQLPP RNNEVEYCNQ LLDSSKKLDS DDLSCQDATH TQIEEDVATQ
     LTQLASIIKI NYIKPEDKKV ESTPTSLVTC NVQQKYNQEK GTIQQKPPSS VHNNHGSSLT
     KQKNPTQKKT KSTPSRDRRK KKPTVVSYQE NDRQKWEKLS YMYGTICDIW IASKFQNFGQ
     FCPHDFPTVF GKISSSTKIW KPLAQTRSIM QPKTVFPPLT QIKLQRYPES AEEKVKVEPL
     DSLSLFHLKT ESNGKAFTDK AYNSQVQLTV NANQKAHPLT QPSSPPNQCA NVMAGDDQIR
     FQQVVKEQLM HQRLPTLPGI SHETPLPESA LTLRNVNVVC SGGITVVSTK SEEEVCSSSF
     GTSEFSTVDS AQKNFNDYAM NFFTNPTKNL VSITKDSELP TCSCLDRVIQ KDKGPYYTHL
     GAGPSVAAVR EIMENRYGQK GNAIRIEIVV YTGKEGKSSH GCPIAKWVLR RSSDEEKVLC
     LVRQRTGHHC PTAVMVVLIM VWDGIPLPMA DRLYTELTEN LKSYNGHPTD RRCTLNENRT
     CTCQGIDPET CGASFSFGCS WSMYFNGCKF GRSPSPRRFR IDPSSPLHEK NLEDNLQSLA
     TRLAPIYKQY APVAYQNQVE YENVARECRL GSKEGRPFSG VTACLDFCAH PHRDIHNMNN
     GSTVVCTLTR EDNRSLGVIP QDEQLHVLPL YKLSDTDEFG SKEGMEAKIK SGAIEVLAPR
     RKKRTCFTQP VPRSGKKRAA MMTEVLAHKI RAVEKKPIPR IKRKNNSTTT NNSKPSSLPT
     LGSNTETVQP EVKSETEPHF ILKSSDNTKT YSLMPSAPHP VKEASPGFSW SPKTASATPA
     PLKNDATASC GFSERSSTPH CTMPSGRLSG ANAAAADGPG ISQLGEVAPL PTLSAPVMEP
     LINSEPSTGV TEPLTPHQPN HQPSFLTSPQ DLASSPMEED EQHSEADEPP SDEPLSDDPL
     SPAEEKLPHI DEYWSDSEHI FLDANIGGVA IAPAHGSVLI ECARRELHAT TPVEHPNRNH
     PTRLSLVFYQ HKNLNKPQHG FELNKIKFEA KEAKNKKMKA SEQKDQAANE GPEQSSEVNE
     LNQIPSHKAL TLTHDNVVTV SPYALTHVAG PYNHWV
//
ID   A0A087WT22_HUMAN        Unreviewed;       187 AA.
AC   A0A087WT22;
DT   29-OCT-2014, integrated into UniProtKB/TrEMBL.
DT   29-OCT-2014, sequence version 1.
DT   22-APR-2020, entry version 43.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP53 {ECO:0000313|Ensembl:ENSP00000477531};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000477531, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000477531, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [2] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [3] {ECO:0000213|PubMed:21269460}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [4] {ECO:0000313|Ensembl:ENSP00000477531}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (SEP-2014) to UniProtKB.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological circumstances
CC       and cell type. Involved in cell cycle regulation as a trans-activator
CC       that acts to negatively regulate cell division by controlling a set of
CC       genes required for this process. One of the activated genes is an
CC       inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be
CC       mediated either by stimulation of BAX and FAS antigen expression, or by
CC       repression of Bcl-2 expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000256|RuleBase:RU003304}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001263628.1; NM_001276699.1.
DR   SMR; A0A087WT22; -.
DR   jPOST; A0A087WT22; -.
DR   PeptideAtlas; A0A087WT22; -.
DR   PRIDE; A0A087WT22; -.
DR   Antibodypedia; 3525; 8810 antibodies.
DR   Ensembl; ENST00000610623; ENSP00000477531; ENSG00000141510.
DR   GeneID; 7157; -.
DR   UCSC; uc010cnf.2; human.
DR   CTD; 7157; -.
DR   EuPathDB; HostDB:ENSG00000141510.16; -.
DR   HGNC; HGNC:11998; TP53.
DR   OpenTargets; ENSG00000141510; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00950000183153; -.
DR   ChiTaRS; TP53; human.
DR   GenomeRNAi; 7157; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141510; Expressed in epithelium of mammary gland and 169 other tissues.
DR   ExpressionAtlas; A0A087WT22; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Proteomics identification {ECO:0000213|EPD:A0A087WT22,
KW   ECO:0000213|MaxQB:A0A087WT22, ECO:0000213|PeptideAtlas:A0A087WT22,
KW   ECO:0000213|ProteomicsDB:A0A087WT22};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN          1..129
FT                   /note="P53"
FT                   /evidence="ECO:0000259|Pfam:PF00870"
FT   REGION          124..163
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        124..142
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        146..160
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   187 AA;  21416 MW;  C60E05EDDBC150C2 CRC64;
     MAIYKQSQHM TEVVRRCPHH ERCSDSDGLA PPQHLIRVEG NLRVEYLDDR NTFRHSVVVP
     YEPPEVGSDC TTIHYNYMCN SSCMGGMNRR PILTIITLED SSGNLLGRNS FEVRVCACPG
     RDRRTEEENL RKKGEPHHEL PPGSTKRALP NNTSSSPQPK KKPLDGEYFT LQMLLDLRWC
     YFLINSS
//
ID   A0A087WXZ1_HUMAN        Unreviewed;       182 AA.
AC   A0A087WXZ1;
DT   29-OCT-2014, integrated into UniProtKB/TrEMBL.
DT   29-OCT-2014, sequence version 1.
DT   22-APR-2020, entry version 43.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP53 {ECO:0000313|Ensembl:ENSP00000481401};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000481401, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000481401, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [2] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [3] {ECO:0000213|PubMed:21269460}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [4] {ECO:0000313|Ensembl:ENSP00000481401}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (SEP-2014) to UniProtKB.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological circumstances
CC       and cell type. Involved in cell cycle regulation as a trans-activator
CC       that acts to negatively regulate cell division by controlling a set of
CC       genes required for this process. One of the activated genes is an
CC       inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be
CC       mediated either by stimulation of BAX and FAS antigen expression, or by
CC       repression of Bcl-2 expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000256|RuleBase:RU003304}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001263627.1; NM_001276698.1.
DR   SMR; A0A087WXZ1; -.
DR   jPOST; A0A087WXZ1; -.
DR   PeptideAtlas; A0A087WXZ1; -.
DR   PRIDE; A0A087WXZ1; -.
DR   Antibodypedia; 3525; 8810 antibodies.
DR   Ensembl; ENST00000618944; ENSP00000481401; ENSG00000141510.
DR   GeneID; 7157; -.
DR   UCSC; uc010cng.2; human.
DR   CTD; 7157; -.
DR   EuPathDB; HostDB:ENSG00000141510.16; -.
DR   HGNC; HGNC:11998; TP53.
DR   OpenTargets; ENSG00000141510; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00950000183153; -.
DR   ChiTaRS; TP53; human.
DR   GenomeRNAi; 7157; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141510; Expressed in epithelium of mammary gland and 169 other tissues.
DR   ExpressionAtlas; A0A087WXZ1; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Proteomics identification {ECO:0000213|EPD:A0A087WXZ1,
KW   ECO:0000213|MaxQB:A0A087WXZ1, ECO:0000213|PeptideAtlas:A0A087WXZ1,
KW   ECO:0000213|ProteomicsDB:A0A087WXZ1};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN          1..129
FT                   /note="P53"
FT                   /evidence="ECO:0000259|Pfam:PF00870"
FT   REGION          124..182
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        124..142
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        146..160
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   182 AA;  20741 MW;  141DBA75C051D39D CRC64;
     MAIYKQSQHM TEVVRRCPHH ERCSDSDGLA PPQHLIRVEG NLRVEYLDDR NTFRHSVVVP
     YEPPEVGSDC TTIHYNYMCN SSCMGGMNRR PILTIITLED SSGNLLGRNS FEVRVCACPG
     RDRRTEEENL RKKGEPHHEL PPGSTKRALP NNTSSSPQPK KKPLDGEYFT LQDQTSFQKE
     NC
//
ID   A0A087X1Q1_HUMAN        Unreviewed;       234 AA.
AC   A0A087X1Q1;
DT   29-OCT-2014, integrated into UniProtKB/TrEMBL.
DT   29-OCT-2014, sequence version 1.
DT   22-APR-2020, entry version 45.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP53 {ECO:0000313|Ensembl:ENSP00000484375};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000484375, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000484375, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [2] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [3] {ECO:0000213|PubMed:19608861}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [4] {ECO:0000213|PubMed:21269460}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [5] {ECO:0000313|Ensembl:ENSP00000484375}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (SEP-2014) to UniProtKB.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological circumstances
CC       and cell type. Involved in cell cycle regulation as a trans-activator
CC       that acts to negatively regulate cell division by controlling a set of
CC       genes required for this process. One of the activated genes is an
CC       inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be
CC       mediated either by stimulation of BAX and FAS antigen expression, or by
CC       repression of Bcl-2 expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000256|RuleBase:RU003304}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001263626.1; NM_001276697.1.
DR   SMR; A0A087X1Q1; -.
DR   EPD; A0A087X1Q1; -.
DR   jPOST; A0A087X1Q1; -.
DR   PeptideAtlas; A0A087X1Q1; -.
DR   PRIDE; A0A087X1Q1; -.
DR   Antibodypedia; 3525; 8810 antibodies.
DR   Ensembl; ENST00000619186; ENSP00000484375; ENSG00000141510.
DR   GeneID; 7157; -.
DR   UCSC; uc002gii.2; human.
DR   CTD; 7157; -.
DR   EuPathDB; HostDB:ENSG00000141510.16; -.
DR   HGNC; HGNC:11998; TP53.
DR   OpenTargets; ENSG00000141510; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00950000183153; -.
DR   ChiTaRS; TP53; human.
DR   GenomeRNAi; 7157; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141510; Expressed in epithelium of mammary gland and 169 other tissues.
DR   ExpressionAtlas; A0A087X1Q1; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Proteomics identification {ECO:0000213|EPD:A0A087X1Q1,
KW   ECO:0000213|MaxQB:A0A087X1Q1, ECO:0000213|PeptideAtlas:A0A087X1Q1,
KW   ECO:0000213|ProteomicsDB:A0A087X1Q1};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN          1..129
FT                   /note="P53"
FT                   /evidence="ECO:0000259|Pfam:PF00870"
FT   DOMAIN          160..198
FT                   /note="P53_tetramer"
FT                   /evidence="ECO:0000259|Pfam:PF07710"
FT   REGION          123..166
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          192..234
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        123..142
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        146..160
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        207..221
FT                   /note="Basic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   234 AA;  26569 MW;  AABDD005298DDF31 CRC64;
     MAIYKQSQHM TEVVRRCPHH ERCSDSDGLA PPQHLIRVEG NLRVEYLDDR NTFRHSVVVP
     YEPPEVGSDC TTIHYNYMCN SSCMGGMNRR PILTIITLED SSGNLLGRNS FEVRVCACPG
     RDRRTEEENL RKKGEPHHEL PPGSTKRALP NNTSSSPQPK KKPLDGEYFT LQIRGRERFE
     MFRELNEALE LKDAQAGKEP GGSRAHSSHL KSKKGQSTSR HKKLMFKTEG PDSD
//
ID   H2EHT1_HUMAN            Unreviewed;       354 AA.
AC   H2EHT1;
DT   21-MAR-2012, integrated into UniProtKB/TrEMBL.
DT   21-MAR-2012, sequence version 1.
DT   22-APR-2020, entry version 61.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP53 {ECO:0000313|EMBL:AEX20383.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AEX20383.1};
RN   [1] {ECO:0000313|EMBL:AEX20383.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=21112961; DOI=10.1093/carcin/bgq253;
RA   Marcel V., Tran P.L., Sagne C., Martel-Planche G., Vaslin L.,
RA   Teulade-Fichou M.P., Hall J., Mergny J.L., Hainaut P., Van Dyck E.;
RT   "G-quadruplex structures in TP53 intron 3: role in alternative splicing and
RT   in production of p53 mRNA isoforms.";
RL   Carcinogenesis 32:271-278(2011).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological circumstances
CC       and cell type. Involved in cell cycle regulation as a trans-activator
CC       that acts to negatively regulate cell division by controlling a set of
CC       genes required for this process. One of the activated genes is an
CC       inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be
CC       mediated either by stimulation of BAX and FAS antigen expression, or by
CC       repression of Bcl-2 expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000256|RuleBase:RU003304}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; JN900492; AEX20383.1; -; mRNA.
DR   RefSeq; NP_001119590.1; NM_001126118.1.
DR   RefSeq; NP_001263689.1; NM_001276760.1.
DR   RefSeq; NP_001263690.1; NM_001276761.1.
DR   SMR; H2EHT1; -.
DR   PRIDE; H2EHT1; -.
DR   Antibodypedia; 3525; 8810 antibodies.
DR   GeneID; 7157; -.
DR   CTD; 7157; -.
DR   EuPathDB; HostDB:ENSG00000141510.16; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   ChiTaRS; TP53; human.
DR   GenomeRNAi; 7157; -.
DR   Bgee; ENSG00000141510; Expressed in epithelium of mammary gland and 169 other tissues.
DR   ExpressionAtlas; H2EHT1; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR040926; p53_TAD2.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF18521; TAD2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN          1..20
FT                   /note="TAD2"
FT                   /evidence="ECO:0000259|Pfam:PF18521"
FT   DOMAIN          61..249
FT                   /note="P53"
FT                   /evidence="ECO:0000259|Pfam:PF00870"
FT   DOMAIN          280..318
FT                   /note="P53_tetramer"
FT                   /evidence="ECO:0000259|Pfam:PF07710"
FT   REGION          1..56
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          243..286
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          312..354
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        25..53
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        243..262
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        266..280
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        327..341
FT                   /note="Basic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   354 AA;  39320 MW;  6F12310423325770 CRC64;
     MDDLMLSPDD IEQWFTEDPG PDEAPRMPEA APPVAPAPAA PTPAAPAPAP SWPLSSSVPS
     QKTYQGSYGF RLGFLHSGTA KSVTCTYSPA LNKMFCQLAK TCPVQLWVDS TPPPGTRVRA
     MAIYKQSQHM TEVVRRCPHH ERCSDSDGLA PPQHLIRVEG NLRVEYLDDR NTFRHSVVVP
     YEPPEVGSDC TTIHYNYMCN SSCMGGMNRR PILTIITLED SSGNLLGRNS FEVRVCACPG
     RDRRTEEENL RKKGEPHHEL PPGSTKRALP NNTSSSPQPK KKPLDGEYFT LQIRGRERFE
     MFRELNEALE LKDAQAGKEP GGSRAHSSHL KSKKGQSTSR HKKLMFKTEG PDSD
//
ID   K7PPA8_HUMAN            Unreviewed;       393 AA.
AC   K7PPA8;
DT   06-FEB-2013, integrated into UniProtKB/TrEMBL.
DT   06-FEB-2013, sequence version 1.
DT   22-APR-2020, entry version 70.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP53 {ECO:0000313|EMBL:AFN61604.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AFN61604.1};
RN   [1] {ECO:0000313|EMBL:AFN61604.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mahalingam D., Kong C.M., Lai J.K.H., Tay L.L., Yang H., Wang X.;
RT   "Reversal of aberrant cancer methylome and transcriptome upon direct
RT   reprogramming of lung cancer cells.";
RL   Submitted (FEB-2012) to the EMBL/GenBank/DDBJ databases.
RN   [2] {ECO:0000313|EMBL:AYE20619.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Kwong A., Shin V.Y., Law F.B.F., Au T., Ho C.Y.S., Chan C.T.L., Ma E.S.K.;
RT   "Full spectrum of TP53 mutations in Hong Kong.";
RL   Submitted (NOV-2017) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological circumstances
CC       and cell type. Involved in cell cycle regulation as a trans-activator
CC       that acts to negatively regulate cell division by controlling a set of
CC       genes required for this process. One of the activated genes is an
CC       inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be
CC       mediated either by stimulation of BAX and FAS antigen expression, or by
CC       repression of Bcl-2 expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000256|RuleBase:RU003304}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; JQ694049; AFN61604.1; -; mRNA.
DR   EMBL; JQ694050; AFN61605.1; -; mRNA.
DR   EMBL; MG595988; AYE20619.1; -; mRNA.
DR   RefSeq; NP_000537.3; NM_000546.5.
DR   RefSeq; NP_001119584.1; NM_001126112.2.
DR   Antibodypedia; 3525; 8810 antibodies.
DR   GeneID; 7157; -.
DR   KEGG; hsa:7157; -.
DR   CTD; 7157; -.
DR   EuPathDB; HostDB:ENSG00000141510.16; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   KO; K04451; -.
DR   OMA; FHKKGEP; -.
DR   OrthoDB; 257530at2759; -.
DR   ChiTaRS; TP53; human.
DR   GenomeRNAi; 7157; -.
DR   Bgee; ENSG00000141510; Expressed in epithelium of mammary gland and 169 other tissues.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:Ensembl.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005657; C:replication fork; IEA:Ensembl.
DR   GO; GO:0035861; C:site of double-strand break; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0035033; F:histone deacetylase regulator activity; IEA:Ensembl.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; IEA:Ensembl.
DR   GO; GO:0007569; P:cell aging; IEA:Ensembl.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl.
DR   GO; GO:0021549; P:cerebellum development; IEA:Ensembl.
DR   GO; GO:0051276; P:chromosome organization; IEA:Ensembl.
DR   GO; GO:0048512; P:circadian behavior; IEA:Ensembl.
DR   GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IEA:Ensembl.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IEA:Ensembl.
DR   GO; GO:0006302; P:double-strand break repair; IEA:Ensembl.
DR   GO; GO:0048568; P:embryonic organ development; IEA:Ensembl.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; IEA:Ensembl.
DR   GO; GO:0007369; P:gastrulation; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; IEA:Ensembl.
DR   GO; GO:0043504; P:mitochondrial DNA repair; IEA:Ensembl.
DR   GO; GO:0071850; P:mitotic cell cycle arrest; IEA:Ensembl.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0070266; P:necroptotic process; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008156; P:negative regulation of DNA replication; IEA:Ensembl.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:1904024; P:negative regulation of glucose catabolic process to lactate via pyruvate; IEA:Ensembl.
DR   GO; GO:1901525; P:negative regulation of mitophagy; IEA:Ensembl.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:1903799; P:negative regulation of production of miRNAs involved in gene silencing by miRNA; IEA:Ensembl.
DR   GO; GO:0045861; P:negative regulation of proteolysis; IEA:Ensembl.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0090343; P:positive regulation of cell aging; IEA:Ensembl.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IEA:Ensembl.
DR   GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IEA:Ensembl.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:1990440; P:positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; IEA:Ensembl.
DR   GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0050821; P:protein stabilization; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:2000772; P:regulation of cellular senescence; IEA:Ensembl.
DR   GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl.
DR   GO; GO:2000269; P:regulation of fibroblast apoptotic process; IEA:Ensembl.
DR   GO; GO:1902253; P:regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl.
DR   GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0034103; P:regulation of tissue remodeling; IEA:Ensembl.
DR   GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0009651; P:response to salt stress; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IEA:Ensembl.
DR   GO; GO:0009303; P:rRNA transcription; IEA:Ensembl.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0002309; P:T cell proliferation involved in immune response; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR040926; p53_TAD2.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF18521; TAD2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN          6..30
FT                   /note="P53_TAD"
FT                   /evidence="ECO:0000259|Pfam:PF08563"
FT   DOMAIN          35..59
FT                   /note="TAD2"
FT                   /evidence="ECO:0000259|Pfam:PF18521"
FT   DOMAIN          100..288
FT                   /note="P53"
FT                   /evidence="ECO:0000259|Pfam:PF00870"
FT   DOMAIN          319..357
FT                   /note="P53_tetramer"
FT                   /evidence="ECO:0000259|Pfam:PF07710"
FT   REGION          50..96
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          282..325
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          351..393
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        64..92
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        282..301
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        305..319
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        366..380
FT                   /note="Basic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   393 AA;  43653 MW;  AD5C149FD8106131 CRC64;
     MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
     DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
     SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG
     GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD
//
ID   P53_HUMAN               Reviewed;         393 AA.
AC   P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809; Q16810;
AC   Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4; Q3LRW5; Q86UG1;
AC   Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 4.
DT   22-APR-2020, entry version 285.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Antigen NY-CO-13;
DE   AltName: Full=Phosphoprotein p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=4006916; DOI=10.1002/j.1460-2075.1985.tb03768.x;
RA   Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.;
RT   "Human p53 cellular tumor antigen: cDNA sequence and expression in COS
RT   cells.";
RL   EMBO J. 4:1251-1255(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT GLY-76.
RX   PubMed=2946935; DOI=10.1128/mcb.6.5.1379;
RA   Lamb P., Crawford L.;
RT   "Characterization of the human p53 gene.";
RL   Mol. Cell. Biol. 6:1379-1385(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3894933; DOI=10.1128/mcb.5.7.1601;
RA   Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.;
RT   "Molecular cloning and in vitro expression of a cDNA clone for human
RT   cellular tumor antigen p53.";
RL   Mol. Cell. Biol. 5:1601-1610(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3025664; DOI=10.1128/mcb.6.12.4650;
RA   Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V.;
RT   "Molecular basis for heterogeneity of the human p53 protein.";
RL   Mol. Cell. Biol. 6:4650-4656(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5;
RA   Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P., Georgiev G.P.;
RT   "A variation in the structure of the protein-coding region of the human p53
RT   gene.";
RL   Gene 70:245-252(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS.
RX   PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x;
RA   Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
RX   PubMed=8316628; DOI=10.2307/3578196;
RA   Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D.,
RA   Mirzayans R.;
RT   "Isolation of two cell lines from a human malignant glioma specimen
RT   differing in sensitivity to radiation and chemotherapeutic drugs.";
RL   Radiat. Res. 134:349-354(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX.
RX   PubMed=11058590; DOI=10.1074/jbc.m007140200;
RA   Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B.,
RA   Zevotek N.;
RT   "Hyaluronidase induction of a WW domain-containing oxidoreductase that
RT   enhances tumor necrosis factor cytotoxicity.";
RL   J. Biol. Chem. 276:3361-3370(2001).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE
RP   SPLICING, INDUCTION, AND VARIANT ARG-72.
RC   TISSUE=Colon;
RX   PubMed=16131611; DOI=10.1101/gad.1339905;
RA   Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A.,
RA   Xirodimas D.P., Saville M.K., Lane D.P.;
RT   "p53 isoforms can regulate p53 transcriptional activity.";
RL   Genes Dev. 19:2122-2137(2005).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Chumakov P.M., Almazov V.P., Jenkins J.R.;
RL   Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Rozemuller E.H., Tilanus M.G.J.;
RT   "P53 genomic sequence. Corrections and polymorphism.";
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND
RP   ALA-366.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
RX   PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:htftmg]2.0.co;2;
RA   Anderson C.W., Allalunis-Turner M.J.;
RT   "Human TP53 from the malignant glioma-derived cell lines M059J and M059K
RT   has a cancer-associated mutation in exon 8.";
RL   Radiat. Res. 154:473-476(2000).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND SER-309.
RA   Azuma K., Shichijo S., Itoh K.;
RT   "Identification of a tumor-rejection antigen recognized by HLA-B46
RT   restricted CTL.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-72.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ALA-278.
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139 AND
RP   PRO-155.
RC   TISSUE=Lung carcinoma;
RX   PubMed=14660794; DOI=10.1073/pnas.2536558100;
RA   Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L.,
RA   Varga J.L.;
RT   "Inhibition of mutant p53 expression and growth of DMS-153 small cell lung
RT   carcinoma by antagonists of growth hormone-releasing hormone and
RT   bombesin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393.
RX   PubMed=6396087; DOI=10.1002/j.1460-2075.1984.tb02287.x;
RA   Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S.;
RT   "Isolation and characterization of a human p53 cDNA clone: expression of
RT   the human p53 gene.";
RL   EMBO J. 3:3257-3262(1984).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185.
RA   Pan X.L., Zhang A.H.;
RT   "Study on the effect of tumor suppressor gene p53 in arsenism patients.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282.
RC   TISSUE=Blood;
RA   Nimri L.F., Owais W., Momani E.;
RT   "Detection of P53 gene mutations and serum p53 antibodies associated with
RT   cigarette smoking.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262.
RC   TISSUE=Ovarian adenocarcinoma;
RA   Filippini G., Soldati G.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
RC   TISSUE=Glial cell, and Glial tumor;
RA   Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N., Joyce K.A.,
RA   Salisbury J., Sibson D.R., Vergote I., Walker C.;
RT   "Mutation detection utilizing a novel PCR approach for amplification of the
RT   p53 gene from microdissected tissue: application to archival tumor
RT   samples.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [25]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
RA   Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J.,
RA   Lipsky P.E.;
RT   "Bcl6 and P53 gene mutations in tonsillar B cells.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [26]
RP   PROTEIN SEQUENCE OF 320-337, SUBUNIT, INTERACTION WITH PRMT5, SUBCELLULAR
RP   LOCATION, METHYLATION AT ARG-333; ARG-335 AND ARG-337 BY PRMT5,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF 333-ARG--ARG-337.
RX   PubMed=19011621; DOI=10.1038/ncb1802;
RA   Jansson M., Durant S.T., Cho E.C., Sheahan S., Edelmann M., Kessler B.,
RA   La Thangue N.B.;
RT   "Arginine methylation regulates the p53 response.";
RL   Nat. Cell Biol. 10:1431-1439(2008).
RN   [27]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366.
RA   Pinto E.M., Mendonca B.B., Latronico A.C.;
RT   "Allelic variant in intron 9 of TP53 gene.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [28]
RP   INTERACTION WITH HUMAN PAPILLOMAVIRUS TYPE 6 AND 11 PROTEIN E6 (MICROBIAL
RP   INFECTION).
RX   PubMed=2175676; DOI=10.1016/0092-8674(90)90409-8;
RA   Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M.;
RT   "The E6 oncoprotein encoded by human papillomavirus types 16 and 18
RT   promotes the degradation of p53.";
RL   Cell 63:1129-1136(1990).
RN   [29]
RP   NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF LYS-319; LYS-320 AND
RP   LYS-321.
RX   PubMed=2156209;
RA   Addison C., Jenkins J.R., Sturzbecher H.-W.;
RT   "The p53 nuclear localisation signal is structurally linked to a p34cdc2
RT   kinase motif.";
RL   Oncogene 5:423-426(1990).
RN   [30]
RP   PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2.
RX   PubMed=2141171; DOI=10.1073/pnas.87.12.4766;
RA   Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.;
RT   "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
RN   [31]
RP   PHOSPHORYLATION.
RX   PubMed=1705009; DOI=10.1128/mcb.11.3.1598;
RA   Samad A., Carroll R.B.;
RT   "The tumor suppressor p53 is bound to RNA by a stable covalent linkage.";
RL   Mol. Cell. Biol. 11:1598-1606(1991).
RN   [32]
RP   DEPHOSPHORYLATION BY PP2A.
RX   PubMed=1848668; DOI=10.1128/mcb.11.4.1996;
RA   Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.;
RT   "Dephosphorylation of simian virus 40 large-T antigen and p53 protein by
RT   protein phosphatase 2A: inhibition by small-t antigen.";
RL   Mol. Cell. Biol. 11:1996-2003(1991).
RN   [33]
RP   ALTERNATIVE SPLICING.
RX   PubMed=8632903;
RA   Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M.,
RA   Gilbert D., Iggo R., Frebourg T.;
RT   "The human tumour suppressor gene p53 is alternatively spliced in normal
RT   cells.";
RL   Oncogene 12:813-818(1996).
RN   [34]
RP   GLYCOSYLATION.
RX   PubMed=8632915;
RA   Shaw P., Freeman J., Bovey R., Iggo R.;
RT   "Regulation of specific DNA binding by p53: evidence for a role for O-
RT   glycosylation and charged residues at the carboxy-terminus.";
RL   Oncogene 12:921-930(1996).
RN   [35]
RP   PHOSPHORYLATION AT SER-33.
RX   PubMed=9372954; DOI=10.1128/mcb.17.12.7220;
RA   Ko L.J., Shieh S.-Y., Chen X., Jayaraman L., Tamai K., Taya Y., Prives C.,
RA   Pan Z.-Q.;
RT   "p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner.";
RL   Mol. Cell. Biol. 17:7220-7229(1997).
RN   [36]
RP   FUNCTION, AND IDENTIFICATION IN COMPLEX WITH CAK.
RX   PubMed=9840937; DOI=10.1038/sj.onc.1202504;
RA   Schneider E., Montenarh M., Wagner P.;
RT   "Regulation of CAK kinase activity by p53.";
RL   Oncogene 17:2733-2741(1998).
RN   [37]
RP   SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386.
RA   Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E.,
RA   Scheffner M., Del Sal G.;
RT   "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1.";
RL   EMBO J. 18:6462-6471(1999).
RN   [38]
RP   PHOSPHORYLATION AT THR-18 BY CSNK1D/CK1.
RX   PubMed=10606744; DOI=10.1016/s0014-5793(99)01647-6;
RA   Dumaz N., Milne D.M., Meek D.W.;
RT   "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior
RT   phosphorylation of serine 15.";
RL   FEBS Lett. 463:312-316(1999).
RN   [39]
RP   BIPARTITE NUCLEAR LOCALIZATION SIGNAL, AND CHARACTERIZATION OF VARIANT
RP   ASN-305.
RX   PubMed=10551826; DOI=10.1074/jbc.274.46.32699;
RA   Liang S.H., Clarke M.F.;
RT   "A bipartite nuclear localization signal is required for p53 nuclear import
RT   regulated by a carboxyl-terminal domain.";
RL   J. Biol. Chem. 274:32699-32703(1999).
RN   [40]
RP   PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE,
RP   CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20 AND
RP   22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND MDM2.
RX   PubMed=10570149; DOI=10.1073/pnas.96.24.13777;
RA   Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.;
RT   "Phosphorylation of Ser-20 mediates stabilization of human p53 in response
RT   to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999).
RN   [41]
RP   UBIQUITINATION.
RX   PubMed=10722742; DOI=10.1074/jbc.275.12.8945;
RA   Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.;
RT   "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and
RT   p53.";
RL   J. Biol. Chem. 275:8945-8951(2000).
RN   [42]
RP   ACETYLATION AT LYS-373 AND LYS-382.
RX   PubMed=10656795; DOI=10.1006/jmbi.1999.3415;
RA   Abraham J., Kelly J., Thibault P., Benchimol S.;
RT   "Post-translational modification of p53 protein in response to ionizing
RT   radiation analyzed by mass spectrometry.";
RL   J. Mol. Biol. 295:853-864(2000).
RN   [43]
RP   PHOSPHORYLATION AT SER-315 AND SER-392 BY CDK2, AND MUTAGENESIS OF LYS-382;
RP   LEU-383 AND PHE-385.
RX   PubMed=10884347; DOI=10.1006/jmbi.2000.3830;
RA   Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.;
RT   "The C-terminal regulatory domain of p53 contains a functional docking site
RT   for cyclin A.";
RL   J. Mol. Biol. 300:503-518(2000).
RN   [44]
RP   FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION.
RX   PubMed=11025664; DOI=10.1038/35036365;
RA   Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.;
RT   "The function of PML in p53-dependent apoptosis.";
RL   Nat. Cell Biol. 2:730-736(2000).
RN   [45]
RP   INTERACTION WITH E4F1.
RX   PubMed=10644996; DOI=10.1038/sj.onc.1203250;
RA   Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J.,
RA   Schneider C., Del Sal G.;
RT   "p53 is involved in the p120E4F-mediated growth arrest.";
RL   Oncogene 19:188-199(2000).
RN   [46]
RP   PHOSPHORYLATION AT THR-18.
RX   PubMed=10951572; DOI=10.1038/sj.onc.1203709;
RA   Lopez-Borges S., Lazo P.A.;
RT   "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18
RT   within the mdm-2 binding site of the p53 tumour suppressor protein.";
RL   Oncogene 19:3656-3664(2000).
RN   [47]
RP   REVIEW ON ZINC-BINDING PROPERTIES.
RX   PubMed=11554448; DOI=10.1089/15230860152542961;
RA   Hainaut P., Mann K.;
RT   "Zinc binding and redox control of p53 structure and function.";
RL   Antioxid. Redox Signal. 3:611-623(2001).
RN   [48]
RP   PHOSPHORYLATION AT SER-15.
RX   PubMed=11554766; DOI=10.1006/bbrc.2001.5627;
RA   Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.;
RT   "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated
RT   protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-
RT   ribofuranoside, in a human hepatocellular carcinoma cell line.";
RL   Biochem. Biophys. Res. Commun. 287:562-567(2001).
RN   [49]
RP   DEACETYLATION AT LYS-382 BY SIRT1.
RX   PubMed=11672523; DOI=10.1016/s0092-8674(01)00527-x;
RA   Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A., Pandita T.K.,
RA   Guarente L., Weinberg R.A.;
RT   "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
RL   Cell 107:149-159(2001).
RN   [50]
RP   MINIMAL REPRESSION DOMAIN.
RX   PubMed=11007800; DOI=10.1074/jbc.m008231200;
RA   Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.;
RT   "p53 amino acids 339-346 represent the minimal p53 repression domain.";
RL   J. Biol. Chem. 276:1510-1515(2001).
RN   [51]
RP   PHOSPHORYLATION AT SER-20 BY PLK3.
RX   PubMed=11447225; DOI=10.1074/jbc.m104157200;
RA   Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.;
RT   "Reactive oxygen species-induced phosphorylation of p53 on serine 20 is
RT   mediated in part by polo-like kinase-3.";
RL   J. Biol. Chem. 276:36194-36199(2001).
RN   [52]
RP   PHOSPHORYLATION AT SER-20 BY PLK3.
RX   PubMed=11551930; DOI=10.1074/jbc.m106050200;
RA   Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C., Stambrook P.,
RA   Jhanwar-Uniyal M., Dai W.;
RT   "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at
RT   least in part via the p53 pathway.";
RL   J. Biol. Chem. 276:43305-43312(2001).
RN   [53]
RP   SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-385;
RP   LYS-386; THR-387 AND GLU-388.
RX   PubMed=11124955; DOI=10.1074/jbc.m009476200;
RA   Rodriguez M.S., Dargemont C., Hay R.T.;
RT   "SUMO-1 conjugation in vivo requires both a consensus modification motif
RT   and nuclear targeting.";
RL   J. Biol. Chem. 276:12654-12659(2001).
RN   [54]
RP   PHOSPHORYLATION BY PRPK.
RX   PubMed=11546806; DOI=10.1074/jbc.m105669200;
RA   Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N.,
RA   Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.;
RT   "Cloning and characterization of a p53-related protein kinase expressed in
RT   interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and
RT   the testes.";
RL   J. Biol. Chem. 276:44003-44011(2001).
RN   [55]
RP   PHOSPHORYLATION AT SER-392.
RX   PubMed=11239457; DOI=10.1016/s1097-2765(01)00176-9;
RA   Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R.,
RA   Lozano G., Zhao Y., Lu H.;
RT   "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16,
RT   and SSRP1.";
RL   Mol. Cell 7:283-292(2001).
RN   [56]
RP   INTERACTION WITH USP7.
RX   PubMed=12507430; DOI=10.1016/s0092-8674(02)01199-6;
RA   Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E., Shi Y.;
RT   "Crystal structure of a UBP-family deubiquitinating enzyme in isolation and
RT   in complex with ubiquitin aldehyde.";
RL   Cell 111:1041-1054(2002).
RN   [57]
RP   IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
RX   PubMed=11706030; DOI=10.1074/jbc.m108535200;
RA   Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
RT   "Differential effect of ik3-1/cables on p53- and p73-induced cell death.";
RL   J. Biol. Chem. 277:2951-2957(2002).
RN   [58]
RP   INTERACTION WITH HIPK2.
RX   PubMed=11925430; DOI=10.1074/jbc.m200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [59]
RP   INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF
RP   SER-46 AND LYS-382.
RX   PubMed=11740489; DOI=10.1038/ncb715;
RA   Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
RA   Will H., Schmitz M.L.;
RT   "Regulation of p53 activity by its interaction with homeodomain-interacting
RT   protein kinase-2.";
RL   Nat. Cell Biol. 4:1-10(2002).
RN   [60]
RP   INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46.
RX   PubMed=11780126; DOI=10.1038/ncb714;
RA   D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S.,
RA   Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M.,
RA   Appella E., Soddu S.;
RT   "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and
RT   mediates apoptosis.";
RL   Nat. Cell Biol. 4:11-19(2002).
RN   [61]
RP   INTERACTION WITH ING4.
RX   PubMed=12750254;
RA   Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K.,
RA   Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J., Harris C.C.;
RT   "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
RL   Cancer Res. 63:2373-2378(2003).
RN   [62]
RP   ACETYLATION AT LYS-305.
RX   PubMed=12724314; DOI=10.1074/jbc.m212574200;
RA   Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.;
RT   "Identification and characterization of a novel p300-mediated p53
RT   acetylation site, lysine 305.";
RL   J. Biol. Chem. 278:25568-25576(2003).
RN   [63]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML,
RP   UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20.
RX   PubMed=12810724; DOI=10.1074/jbc.m301264200;
RA   Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P.,
RA   Haupt Y.;
RT   "The promyelocytic leukemia protein protects p53 from Mdm2-mediated
RT   inhibition and degradation.";
RL   J. Biol. Chem. 278:33134-33141(2003).
RN   [64]
RP   INTERACTION WITH TP53INP1.
RX   PubMed=12851404; DOI=10.1074/jbc.m301979200;
RA   Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B., Soddu S.,
RA   Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
RT   "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
RT   partners in regulating p53 activity.";
RL   J. Biol. Chem. 278:37722-37729(2003).
RN   [65]
RP   NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL.
RX   PubMed=12944468; DOI=10.1128/mcb.23.18.6396-6405.2003;
RA   O'Keefe K., Li H., Zhang Y.;
RT   "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated
RT   cytoplasmic degradation but not ubiquitination.";
RL   Mol. Cell. Biol. 23:6396-6405(2003).
RN   [66]
RP   FUNCTION, AND INTERACTION WITH PPP1R13L; PPP1R13B AND TP53BP2.
RX   PubMed=12524540; DOI=10.1038/ng1070;
RA   Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T.,
RA   Hsieh J.-K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L.,
RA   Kuwabara P.E., Lu X.;
RT   "iASPP oncoprotein is a key inhibitor of p53 conserved from worm to
RT   human.";
RL   Nat. Genet. 33:162-167(2003).
RN   [67]
RP   INTERACTION WITH HIPK1.
RX   PubMed=12702766; DOI=10.1073/pnas.0530308100;
RA   Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
RA   Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W., Mak T.W.,
RA   Thukral S.K.;
RT   "Characterization of cells and gene-targeted mice deficient for the p53-
RT   binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
RN   [68]
RP   INTERACTION WITH CDKN2AIP.
RX   PubMed=15109303; DOI=10.1042/bj20040337;
RA   Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R.,
RA   Kaul S.C.;
RT   "Alternative reading frame protein (ARF)-independent function of CARF
RT   (collaborator of ARF) involves its interactions with p53: evidence for a
RT   novel p53-activation pathway and its negative feedback control.";
RL   Biochem. J. 380:605-610(2004).
RN   [69]
RP   INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION.
RX   PubMed=15186775; DOI=10.1016/j.cell.2004.05.009;
RA   An W., Kim J., Roeder R.G.;
RT   "Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional
RT   activation by p53.";
RL   Cell 117:735-748(2004).
RN   [70]
RP   INTERACTION WITH ANKRD2.
RX   PubMed=15136035; DOI=10.1016/j.jmb.2004.03.071;
RA   Kojic S., Medeot E., Guccione E., Krmac H., Zara I., Martinelli V.,
RA   Valle G., Faulkner G.;
RT   "The Ankrd2 protein, a link between the sarcomere and the nucleus in
RT   skeletal muscle.";
RL   J. Mol. Biol. 339:313-325(2004).
RN   [71]
RP   PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH
RP   TAF1.
RX   PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6;
RA   Li H.-H., Li A.G., Sheppard H.M., Liu X.;
RT   "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for
RT   TAF1 in cell G1 progression.";
RL   Mol. Cell 13:867-878(2004).
RN   [72]
RP   DEUBIQUITINATION BY USP7.
RX   PubMed=15053880; DOI=10.1016/s1097-2765(04)00157-1;
RA   Li M., Brooks C.L., Kon N., Gu W.;
RT   "A dynamic role of HAUSP in the p53-Mdm2 pathway.";
RL   Mol. Cell 13:879-886(2004).
RN   [73]
RP   ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND
RP   UBIQUITINATION.
RX   PubMed=15340061; DOI=10.1128/mcb.24.18.7987-7997.2004;
RA   Ghosh A., Stewart D., Matlashewski G.;
RT   "Regulation of human p53 activity and cell localization by alternative
RT   splicing.";
RL   Mol. Cell. Biol. 24:7987-7997(2004).
RN   [74]
RP   METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372.
RX   PubMed=15525938; DOI=10.1038/nature03117;
RA   Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S.,
RA   McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A., Reinberg D.;
RT   "Regulation of p53 activity through lysine methylation.";
RL   Nature 432:353-360(2004).
RN   [75]
RP   INTERACTION WITH AURKA, AND PHOSPHORYLATION AT SER-315.
RX   PubMed=14702041; DOI=10.1038/ng1279;
RA   Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F.,
RA   Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.;
RT   "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization
RT   and inhibition of p53.";
RL   Nat. Genet. 36:55-62(2004).
RN   [76]
RP   INTERACTION WITH NOC2L.
RX   PubMed=16322561; DOI=10.1101/gad.351205;
RA   Hublitz P., Kunowska N., Mayer U.P., Muller J.M., Heyne K., Yin N.,
RA   Fritzsche C., Poli C., Miguet L., Schupp I.W., van Grunsven L.A.,
RA   Potiers N., van Dorsselaer A., Metzger E., Roemer K., Schule R.;
RT   "NIR is a novel INHAT repressor that modulates the transcriptional activity
RT   of p53.";
RL   Genes Dev. 19:2912-2924(2005).
RN   [77]
RP   INTERACTION WITH BANP, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-15.
RX   PubMed=15701641; DOI=10.1074/jbc.m413200200;
RA   Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S.,
RA   Chattopadhyay S.;
RT   "Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-
RT   serine-rich motif.";
RL   J. Biol. Chem. 280:16019-16029(2005).
RN   [78]
RP   INTERACTION WITH PTK2/FAK1.
RX   PubMed=15855171; DOI=10.1074/jbc.m414172200;
RA   Golubovskaya V.M., Finch R., Cance W.G.;
RT   "Direct interaction of the N-terminal domain of focal adhesion kinase with
RT   the N-terminal transactivation domain of p53.";
RL   J. Biol. Chem. 280:25008-25021(2005).
RN   [79]
RP   INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46.
RX   PubMed=16219768; DOI=10.1074/jbc.m505590200;
RA   Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.;
RT   "WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-,
RT   and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds
RT   and stabilizes serine 46-phosphorylated p53.";
RL   J. Biol. Chem. 280:43100-43108(2005).
RN   [80]
RP   PHOSPHORYLATION AT SER-15.
RX   PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027;
RA   Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J.,
RA   Thompson C.B.;
RT   "AMP-activated protein kinase induces a p53-dependent metabolic
RT   checkpoint.";
RL   Mol. Cell 18:283-293(2005).
RN   [81]
RP   INTERACTION WITH STK11/LKB1, AND PHOSPHORYLATION AT SER-15 AND SER-392.
RX   PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999;
RA   Zeng P.Y., Berger S.L.;
RT   "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate
RT   transcriptional activation.";
RL   Cancer Res. 66:10701-10708(2006).
RN   [82]
RP   PHOSPHORYLATION AT THR-18.
RX   PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x;
RA   Blanco S., Klimcakova L., Vega F.M., Lazo P.A.;
RT   "The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms
RT   determines their different effect on p53 stability in tumour cell lines.";
RL   FEBS J. 273:2487-2504(2006).
RN   [83]
RP   INTERACTION WITH YWHAZ.
RX   PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024;
RA   Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.;
RT   "Protein kinase A phosphorylates and regulates dimerization of 14-3-3
RT   epsilon.";
RL   FEBS Lett. 580:305-310(2006).
RN   [84]
RP   PHOSPHORYLATION AT SER-46, AND INTERACTION WITH PRKCG.
RX   PubMed=16377624; DOI=10.1074/jbc.m512074200;
RA   Yoshida K., Liu H., Miki Y.;
RT   "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor
RT   suppressor in the apoptotic response to DNA damage.";
RL   J. Biol. Chem. 281:5734-5740(2006).
RN   [85]
RP   METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370.
RX   PubMed=17108971; DOI=10.1038/nature05287;
RA   Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M.,
RA   Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.;
RT   "Repression of p53 activity by Smyd2-mediated methylation.";
RL   Nature 444:629-632(2006).
RN   [86]
RP   INTERACTION WITH DAXX.
RX   PubMed=16845383; DOI=10.1038/ncb1442;
RA   Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y.,
RA   El-Deiry W.S., Yang X.;
RT   "Critical role for Daxx in regulating Mdm2.";
RL   Nat. Cell Biol. 8:855-862(2006).
RN   [87]
RP   MOTIF, AND METHYLATION AT LYS-372.
RX   PubMed=16415881; DOI=10.1038/nsmb1045;
RA   Couture J.-F., Collazo E., Hauk G., Trievel R.C.;
RT   "Structural basis for the methylation site specificity of SET7/9.";
RL   Nat. Struct. Mol. Biol. 13:140-146(2006).
RN   [88]
RP   INTERACTION WITH POU4F2.
RX   PubMed=17145718; DOI=10.1093/nar/gkl878;
RA   Budhram-Mahadeo V.S., Bowen S., Lee S., Perez-Sanchez C., Ensor E.,
RA   Morris P.J., Latchman D.S.;
RT   "Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of
RT   cell cycle arrest by cooperating in trans-activation of bax expression.";
RL   Nucleic Acids Res. 34:6640-6652(2006).
RN   [89]
RP   PHOSPHORYLATION AT SER-37, AND MUTAGENESIS OF SER-37.
RX   PubMed=17254968; DOI=10.1016/j.cell.2006.11.050;
RA   Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J.,
RA   Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III, Wright P.E.,
RA   Han J.;
RT   "PRAK is essential for ras-induced senescence and tumor suppression.";
RL   Cell 128:295-308(2007).
RN   [90]
RP   INTERACTION WITH ZNF385A, AND CHARACTERIZATION OF VARIANTS ALA-143; HIS-175
RP   AND PRO-175.
RX   PubMed=17719541; DOI=10.1016/j.cell.2007.06.013;
RA   Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A., Lee S.W.;
RT   "Hzf Determines cell survival upon genotoxic stress by modulating p53
RT   transactivation.";
RL   Cell 130:624-637(2007).
RN   [91]
RP   UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION.
RX   PubMed=17170702; DOI=10.1038/sj.emboj.7601490;
RA   Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T.,
RA   Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K., Yoo E.,
RA   Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S., Eguchi K.,
RA   Komiya S., Maruyama I., Higashi N., Sato M., Senoo H., Ochi T.,
RA   Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A., Nishioka K., Tanaka K.,
RA   Nakajima T.;
RT   "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident
RT   ubiquitin ligase 'Synoviolin'.";
RL   EMBO J. 26:113-122(2007).
RN   [92]
RP   INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C.
RX   PubMed=17245430; DOI=10.1038/sj.emboj.7601519;
RA   Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.;
RT   "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced
RT   dephosphorylation of p53 at Thr55.";
RL   EMBO J. 26:402-411(2007).
RN   [93]
RP   INTERACTION WITH ARMC10.
RX   PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025;
RA   Zhou X., Yang G., Huang R., Chen X., Hu G.;
RT   "SVH-B interacts directly with p53 and suppresses the transcriptional
RT   activity of p53.";
RL   FEBS Lett. 581:4943-4948(2007).
RN   [94]
RP   PHOSPHORYLATION AT SER-9.
RX   PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022;
RA   Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.;
RT   "Novel homeodomain-interacting protein kinase family member, HIPK4,
RT   phosphorylates human p53 at serine 9.";
RL   FEBS Lett. 581:5649-5657(2007).
RN   [95]
RP   DOMAIN.
RX   PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003;
RA   Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M.;
RT   "Nine-amino-acid transactivation domain: establishment and prediction
RT   utilities.";
RL   Genomics 89:756-768(2007).
RN   [96]
RP   INTERACTION WITH RFFL AND RNF34.
RX   PubMed=17121812; DOI=10.1074/jbc.m610793200;
RA   Yang W., Rozan L.M., McDonald E.R. III, Navaraj A., Liu J.J., Matthew E.M.,
RA   Wang W., Dicker D.T., El-Deiry W.S.;
RT   "CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-
RT   p53ser20 degradation.";
RL   J. Biol. Chem. 282:3273-3281(2007).
RN   [97]
RP   FUNCTION, AND INTERACTION WITH MAML1.
RX   PubMed=17317671; DOI=10.1074/jbc.m608974200;
RA   Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y., Gurumurthy C.B.,
RA   Germaniuk-Kurowska A., Reddi H.V., Solomon A., Zeng M.S., Kung A., Ma H.,
RA   Gao Q., Dimri G., Stanculescu A., Miele L., Wu L., Griffin J.D.,
RA   Wazer D.E., Band H., Band V.;
RT   "The notch regulator MAML1 interacts with p53 and functions as a
RT   coactivator.";
RL   J. Biol. Chem. 282:11969-11981(2007).
RN   [98]
RP   PHOSPHORYLATION AT SER-15; SER-33 AND SER-46, INTERACTION WITH CDK5, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=17591690; DOI=10.1242/jcs.03468;
RA   Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.;
RT   "Stabilization and activation of p53 induced by Cdk5 contributes to
RT   neuronal cell death.";
RL   J. Cell Sci. 120:2259-2271(2007).
RN   [99]
RP   INTERACTION WITH MORC3.
RX   PubMed=17332504; DOI=10.1091/mbc.e06-08-0747;
RA   Takahashi K., Yoshida N., Murakami N., Kawata K., Ishizaki H.,
RA   Tanaka-Okamoto M., Miyoshi J., Zinn A.R., Shime H., Inoue N.;
RT   "Dynamic regulation of p53 subnuclear localization and senescence by
RT   MORC3.";
RL   Mol. Biol. Cell 18:1701-1709(2007).
RN   [100]
RP   FUNCTION, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46.
RX   PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007;
RA   Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.;
RT   "DYRK2 is targeted to the nucleus and controls p53 via Ser46
RT   phosphorylation in the apoptotic response to DNA damage.";
RL   Mol. Cell 25:725-738(2007).
RN   [101]
RP   DEMETHYLATION BY KDM1A.
RX   PubMed=17805299; DOI=10.1038/nature06092;
RA   Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M.,
RA   Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.;
RT   "p53 is regulated by the lysine demethylase LSD1.";
RL   Nature 449:105-108(2007).
RN   [102]
RP   METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382.
RX   PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012;
RA   Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W.,
RA   Dutta S., Appella E., Gozani O.;
RT   "Modulation of p53 function by SET8-mediated methylation at lysine 382.";
RL   Mol. Cell 27:636-646(2007).
RN   [103]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [104]
RP   ACETYLATION, AND DEACETYLATION BY SIRT2.
RX   PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114;
RA   Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y., Lee K.Y.;
RT   "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of
RT   p53.";
RL   Biochem. Biophys. Res. Commun. 368:690-695(2008).
RN   [105]
RP   INTERACTION WITH SETD2.
RX   PubMed=18585004; DOI=10.1016/j.cellsig.2008.05.012;
RA   Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F.;
RT   "Histone methyltransferase protein SETD2 interacts with p53 and selectively
RT   regulates its downstream genes.";
RL   Cell. Signal. 20:1671-1678(2008).
RN   [106]
RP   INTERACTION WITH NUPR1.
RX   PubMed=18690848; DOI=10.2174/156800908785133196;
RA   Clark D.W., Mitra A., Fillmore R.A., Jiang W.G., Samant R.S., Fodstad O.,
RA   Shevde L.A.;
RT   "NUPR1 interacts with p53, transcriptionally regulates p21 and rescues
RT   breast epithelial cells from doxorubicin-induced genotoxic stress.";
RL   Curr. Cancer Drug Targets 8:421-430(2008).
RN   [107]
RP   UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031;
RA   Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K.,
RA   Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.;
RT   "Nuclear FAK promotes cell proliferation and survival through FERM-enhanced
RT   p53 degradation.";
RL   Mol. Cell 29:9-22(2008).
RN   [108]
RP   INTERACTION WITH KAT7.
RX   PubMed=17954561; DOI=10.1128/mcb.00662-07;
RA   Iizuka M., Sarmento O.F., Sekiya T., Scrable H., Allis C.D., Smith M.M.;
RT   "Hbo1 Links p53-dependent stress signaling to DNA replication licensing.";
RL   Mol. Cell. Biol. 28:140-153(2008).
RN   [109]
RP   INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT SER-15 BY
RP   ATM, AND MUTAGENESIS OF SER-15.
RX   PubMed=17967874; DOI=10.1128/mcb.00983-07;
RA   Shouse G.P., Cai X., Liu X.;
RT   "Serine 15 phosphorylation of p53 directs its interaction with B56gamma and
RT   the tumor suppressor activity of B56gamma-specific protein phosphatase
RT   2A.";
RL   Mol. Cell. Biol. 28:448-456(2008).
RN   [110]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [111]
RP   INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND UBIQUITINATION
RP   AT LYS-291 AND LYS-292 BY MKRN1.
RX   PubMed=19536131; DOI=10.1038/emboj.2009.164;
RA   Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C.,
RA   Lane D.P., Song J.;
RT   "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell
RT   cycle arrest and apoptosis.";
RL   EMBO J. 28:2100-2113(2009).
RN   [112]
RP   UBIQUITINATION BY TOPORS.
RX   PubMed=19473992; DOI=10.1074/jbc.c109.001560;
RA   Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.;
RT   "Plk1-mediated phosphorylation of Topors regulates p53 stability.";
RL   J. Biol. Chem. 284:18588-18592(2009).
RN   [113]
RP   INTERACTION WITH MTA1 AND COP1, AND UBIQUITINATION.
RX   PubMed=19837670; DOI=10.1074/jbc.m109.056499;
RA   Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y.,
RA   Rayala S.K., Kumar R.;
RT   "MTA1 coregulator regulates p53 stability and function.";
RL   J. Biol. Chem. 284:34545-34552(2009).
RN   [114]
RP   INTERACTION WITH HHV-5 PROTEIN UL123 (MICROBIAL INFECTION).
RX   PubMed=19776115; DOI=10.1128/jvi.00304-09;
RA   Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y., Huang E.S.;
RT   "Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-
RT   dependent transactivation by a mechanism different from that of IE2-86
RT   protein.";
RL   J. Virol. 83:12388-12398(2009).
RN   [115]
RP   INTERACTION WITH FBXO42.
RX   PubMed=19509332; DOI=10.1073/pnas.0901864106;
RA   Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y., Li R.,
RA   Yao X., Yi X., Shang Y.;
RT   "JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53
RT   regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009).
RN   [116]
RP   FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24.
RX   PubMed=19556538; DOI=10.1073/pnas.0813177106;
RA   Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J., Bergmann A.,
RA   Johnson R.L., Barton M.C.;
RT   "Trim24 targets endogenous p53 for degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009).
RN   [117]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-381 AND LYS-382, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [118]
RP   INTERACTION WITH TAF6 ISOFORMS 1 AND 4.
RX   PubMed=20096117; DOI=10.1186/1471-2199-11-10;
RA   Wilhelm E., Kornete M., Targat B., Vigneault-Edwards J., Frontini M.,
RA   Tora L., Benecke A., Bell B.;
RT   "TAF6delta orchestrates an apoptotic transcriptome profile and interacts
RT   functionally with p53.";
RL   BMC Mol. Biol. 11:10-10(2010).
RN   [119]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP10.
RX   PubMed=20096447; DOI=10.1016/j.cell.2009.12.032;
RA   Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.;
RT   "USP10 regulates p53 localization and stability by deubiquitinating p53.";
RL   Cell 140:384-396(2010).
RN   [120]
RP   FUNCTION.
RX   PubMed=20673990; DOI=10.1016/j.cell.2010.06.040;
RA   Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J.,
RA   Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M., Attardi L.D.,
RA   Regev A., Lander E.S., Jacks T., Rinn J.L.;
RT   "A large intergenic noncoding RNA induced by p53 mediates global gene
RT   repression in the p53 response.";
RL   Cell 142:409-419(2010).
RN   [121]
RP   PHOSPHORYLATION AT SER-20 BY CSNK1D/CK1.
RX   PubMed=20041275; DOI=10.1007/s00018-009-0236-7;
RA   Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.;
RT   "Isoform specific phosphorylation of p53 by protein kinase CK1.";
RL   Cell. Mol. Life Sci. 67:1105-1118(2010).
RN   [122]
RP   INTERACTION WITH SNAI1, CHARACTERIZATION OF VARIANTS LEU-110; PRO-155;
RP   HIS-175; SER-232; SER-249; HIS-273 AND TRP-282, AND MUTAGENESIS OF ARG-248.
RX   PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006;
RA   Lim S.O., Kim H., Jung G.;
RT   "p53 inhibits tumor cell invasion via the degradation of snail protein in
RT   hepatocellular carcinoma.";
RL   FEBS Lett. 584:2231-2236(2010).
RN   [123]
RP   INTERACTION WITH PTK2B/PYK2 AND MDM2, UBIQUITINATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19880522; DOI=10.1074/jbc.m109.064212;
RA   Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.;
RT   "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating
RT   cell proliferation and survival.";
RL   J. Biol. Chem. 285:1743-1753(2010).
RN   [124]
RP   METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373.
RX   PubMed=20118233; DOI=10.1074/jbc.m109.062588;
RA   Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T.,
RA   Reinberg D., Berger S.L.;
RT   "G9a and Glp methylate lysine 373 in the tumor suppressor p53.";
RL   J. Biol. Chem. 285:9636-9641(2010).
RN   [125]
RP   ERRATUM OF PUBMED:20118233.
RA   Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T.,
RA   Reinberg D., Berger S.L.;
RL   J. Biol. Chem. 285:18122-18122(2010).
RN   [126]
RP   PHOSPHORYLATION AT THR-55, AND INTERACTION WITH GRK5.
RX   PubMed=20124405; DOI=10.1074/jbc.m109.094243;
RA   Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.;
RT   "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA
RT   damage-induced apoptosis.";
RL   J. Biol. Chem. 285:12823-12830(2010).
RN   [127]
RP   INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382.
RX   PubMed=20228809; DOI=10.1038/ncb2038;
RA   Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H.,
RA   Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.;
RT   "BRD7 is a candidate tumour suppressor gene required for p53 function.";
RL   Nat. Cell Biol. 12:380-389(2010).
RN   [128]
RP   UBIQUITINATION BY RFWD3.
RX   PubMed=20173098; DOI=10.1073/pnas.0912094107;
RA   Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J., Jung S.Y.,
RA   O'Malley B.W., Gu W., Qin J., Wang Y.;
RT   "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in
RT   response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010).
RN   [129]
RP   INTERACTION WITH BRD7.
RX   PubMed=20660729; DOI=10.1073/pnas.1009559107;
RA   Burrows A.E., Smogorzewska A., Elledge S.J.;
RT   "Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are
RT   critical regulators of p53 required for induction of replicative
RT   senescence.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010).
RN   [130]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [131]
RP   INTERACTION WITH UHRF2.
RX   PubMed=21952639; DOI=10.4161/cc.10.19.17176;
RA   Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.;
RT   "NIRF constitutes a nodal point in the cell cycle network and is a
RT   candidate tumor suppressor.";
RL   Cell Cycle 10:3284-3299(2011).
RN   [132]
RP   FUNCTION, INTERACTION WITH AURKB AND NOC2L, PHOSPHORYLATION AT SER-183;
RP   SER-269 AND THR-284, CHARACTERIZATION OF VARIANT ALA-284, MUTAGENESIS OF
RP   SER-183 AND SER-269, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=20959462; DOI=10.1074/jbc.m110.174755;
RA   Wu L., Ma C.A., Zhao Y., Jain A.;
RT   "Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its
RT   DNA-binding domain and subsequent functional suppression.";
RL   J. Biol. Chem. 286:2236-2244(2011).
RN   [133]
RP   INVOLVEMENT IN BCC7.
RX   PubMed=21946351; DOI=10.1038/ng.926;
RA   Stacey S.N., Sulem P., Jonasdottir A., Masson G., Gudmundsson J.,
RA   Gudbjartsson D.F., Magnusson O.T., Gudjonsson S.A., Sigurgeirsson B.,
RA   Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Nexo B.A.,
RA   Tjonneland A., Overvad K., Rudnai P., Gurzau E., Koppova K., Hemminki K.,
RA   Corredera C., Fuentelsaz V., Grasa P., Navarrete S., Fuertes F.,
RA   Garcia-Prats M.D., Sanambrosio E., Panadero A., De Juan A., Garcia A.,
RA   Rivera F., Planelles D., Soriano V., Requena C., Aben K.K.,
RA   van Rossum M.M., Cremers R.G., van Oort I.M., van Spronsen D.J.,
RA   Schalken J.A., Peters W.H., Helfand B.T., Donovan J.L., Hamdy F.C.,
RA   Badescu D., Codreanu O., Jinga M., Csiki I.E., Constantinescu V., Badea P.,
RA   Mates I.N., Dinu D.E., Constantin A., Mates D., Kristjansdottir S.,
RA   Agnarsson B.A., Jonsson E., Barkardottir R.B., Einarsson G.V.,
RA   Sigurdsson F., Moller P.H., Stefansson T., Valdimarsson T.,
RA   Johannsson O.T., Sigurdsson H., Jonsson T., Jonasson J.G.,
RA   Tryggvadottir L., Rice T., Hansen H.M., Xiao Y., Lachance D.H.,
RA   O'Neill B.P., Kosel M.L., Decker P.A., Thorleifsson G., Johannsdottir H.,
RA   Helgadottir H.T., Sigurdsson A., Steinthorsdottir V., Lindblom A.,
RA   Sandler R.S., Keku T.O., Banasik K., Jorgensen T., Witte D.R., Hansen T.,
RA   Pedersen O., Jinga V., Neal D.E., Catalona W.J., Wrensch M., Wiencke J.,
RA   Jenkins R.B., Nagore E., Vogel U., Kiemeney L.A., Kumar R., Mayordomo J.I.,
RA   Olafsson J.H., Kong A., Thorsteinsdottir U., Rafnar T., Stefansson K.;
RT   "A germline variant in the TP53 polyadenylation signal confers cancer
RT   susceptibility.";
RL   Nat. Genet. 43:1098-1103(2011).
RN   [134]
RP   INTERACTION WITH NUAK1, AND PHOSPHORYLATION AT SER-15 AND SER-392.
RX   PubMed=21317932; DOI=10.1038/onc.2011.19;
RA   Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.;
RT   "A new role of NUAK1: directly phosphorylating p53 and regulating cell
RT   proliferation.";
RL   Oncogene 30:2933-2942(2011).
RN   [135]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPIF.
RX   PubMed=22726440; DOI=10.1016/j.cell.2012.05.014;
RA   Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S., Moll U.M.;
RT   "p53 opens the mitochondrial permeability transition pore to trigger
RT   necrosis.";
RL   Cell 149:1536-1548(2012).
RN   [136]
RP   INTERACTION WITH UBC9, PHOSPHORYLATION AT SER-392, AND SUMOYLATION AT
RP   LYS-386.
RX   PubMed=22214662; DOI=10.4161/cc.11.2.18999;
RA   Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.;
RT   "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and
RT   activation, leading to G(1) arrest.";
RL   Cell Cycle 11:407-417(2012).
RN   [137]
RP   INTERACTION WITH NOP53.
RX   PubMed=22522597; DOI=10.1038/cdd.2012.40;
RA   Lee S., Kim J.Y., Kim Y.J., Seok K.O., Kim J.H., Chang Y.J., Kang H.Y.,
RA   Park J.H.;
RT   "Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal
RT   stresses.";
RL   Cell Death Differ. 19:1613-1622(2012).
RN   [138]
RP   INTERACTION WITH ZNF385B.
RX   PubMed=22945289; DOI=10.1002/eji.201242530;
RA   Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S.,
RA   Kobayashi K., Okita H., Nakazawa A., Fujiwara S., Fujimoto J., Kiyokawa N.;
RT   "ZNF385B is characteristically expressed in germinal center B cells and
RT   involved in B-cell apoptosis.";
RL   Eur. J. Immunol. 42:3405-3415(2012).
RN   [139]
RP   METHYLATION AT LYS-370 AND LYS-382.
RX   PubMed=22864287; DOI=10.1038/nsmb.2353;
RA   Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F.,
RA   Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G.;
RT   "PHF20 is an effector protein of p53 double lysine methylation that
RT   stabilizes and activates p53.";
RL   Nat. Struct. Mol. Biol. 19:916-924(2012).
RN   [140]
RP   FUNCTION.
RX   PubMed=24051492; DOI=10.1038/ncomms3444;
RA   Miki T., Matsumoto T., Zhao Z., Lee C.C.;
RT   "p53 regulates Period2 expression and the circadian clock.";
RL   Nat. Commun. 4:2444-2444(2013).
RN   [141]
RP   INTERACTION WITH KAT6A, AND ACETYLATION AT LYS-120 AND LYS-382.
RX   PubMed=23431171; DOI=10.1073/pnas.1300490110;
RA   Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.;
RT   "MOZ increases p53 acetylation and premature senescence through its complex
RT   formation with PML.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013).
RN   [142]
RP   INTERACTION WITH UBD.
RX   PubMed=25422469; DOI=10.1073/pnas.1403383111;
RA   Theng S.S., Wang W., Mah W.C., Chan C., Zhuo J., Gao Y., Qin H., Lim L.,
RA   Chong S.S., Song J., Lee C.G.;
RT   "Disruption of FAT10-MAD2 binding inhibits tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:E5282-E5291(2014).
RN   [143]
RP   UBIQUITINATION.
RX   PubMed=25591766; DOI=10.1159/000369691;
RA   Yang L., Zhou B., Li X., Lu Z., Li W., Huo X., Miao Z.;
RT   "RNF125 is a ubiquitin-protein ligase that promotes p53 degradation.";
RL   Cell. Physiol. Biochem. 35:237-245(2015).
RN   [144]
RP   INTERACTION WITH HADV5 E1B-55K (MICROBIAL INFECTION).
RX   PubMed=25772236; DOI=10.1038/onc.2015.63;
RA   Wimmer P., Berscheminski J., Blanchette P., Groitl P., Branton P.E.,
RA   Hay R.T., Dobner T., Schreiner S.;
RT   "PML isoforms IV and V contribute to adenovirus-mediated oncogenic
RT   transformation by functionally inhibiting the tumor-suppressor p53.";
RL   Oncogene 35:69-82(2016).
RN   [145]
RP   INTERACTION WITH AFG1L, AND SUBCELLULAR LOCATION.
RX   PubMed=27323408; DOI=10.18632/oncotarget.9959;
RA   Cesnekova J., Spacilova J., Hansikova H., Houstek J., Zeman J.,
RA   Stiburek L.;
RT   "LACE1 interacts with p53 and mediates its mitochondrial translocation and
RT   apoptosis.";
RL   Oncotarget 7:47687-47698(2016).
RN   [146]
RP   INTERACTION WITH DDX3X AND GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION AT SER-15.
RX   PubMed=28842590; DOI=10.1038/s41598-017-09779-w;
RA   Chen W.J., Wang W.T., Tsai T.Y., Li H.K., Lee Y.W.;
RT   "DDX3 localizes to the centrosome and prevents multipolar mitosis by
RT   epigenetically and translationally modulating p53 expression.";
RL   Sci. Rep. 7:9411-9411(2017).
RN   [147]
RP   INVOLVEMENT IN BMFS5.
RX   PubMed=30146126; DOI=10.1016/j.ajhg.2018.07.020;
RA   Toki T., Yoshida K., Wang R., Nakamura S., Maekawa T., Goi K., Katoh M.C.,
RA   Mizuno S., Sugiyama F., Kanezaki R., Uechi T., Nakajima Y., Sato Y.,
RA   Okuno Y., Sato-Otsubo A., Shiozawa Y., Kataoka K., Shiraishi Y., Sanada M.,
RA   Chiba K., Tanaka H., Terui K., Sato T., Kamio T., Sakaguchi H., Ohga S.,
RA   Kuramitsu M., Hamaguchi I., Ohara A., Kanno H., Miyano S., Kojima S.,
RA   Ishiguro A., Sugita K., Kenmochi N., Takahashi S., Eto K., Ogawa S.,
RA   Ito E.;
RT   "De novo mutations activating germline TP53 in an inherited bone-marrow-
RT   failure syndrome.";
RL   Am. J. Hum. Genet. 103:440-447(2018).
RN   [148]
RP   STRUCTURE BY NMR OF 319-360.
RX   PubMed=8023159; DOI=10.1126/science.8023159;
RA   Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H.,
RA   Appella E., Gronenborn A.M.;
RT   "High-resolution structure of the oligomerization domain of p53 by
RT   multidimensional NMR.";
RL   Science 265:386-391(1994).
RN   [149]
RP   STRUCTURE BY NMR OF 325-355.
RX   PubMed=7773777; DOI=10.1038/nsb1294-877;
RA   Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.;
RT   "Solution structure of the tetrameric minimum transforming domain of p53.";
RL   Nat. Struct. Biol. 1:877-890(1994).
RN   [150]
RP   STRUCTURE BY NMR OF 326-354.
RX   PubMed=9321402; DOI=10.1093/emboj/16.20.6230;
RA   McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J.,
RA   Halazonetis T.D.;
RT   "Hydrophobic side-chain size is a determinant of the three-dimensional
RT   structure of the p53 oligomerization domain.";
RL   EMBO J. 16:6230-6236(1997).
RN   [151]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289.
RX   PubMed=8023157; DOI=10.1126/science.8023157;
RA   Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.;
RT   "Crystal structure of a p53 tumor suppressor-DNA complex: understanding
RT   tumorigenic mutations.";
RL   Science 265:346-355(1994).
RN   [152]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356.
RX   PubMed=7878469; DOI=10.1126/science.7878469;
RA   Jeffrey P.D., Gorina S., Pavletich N.P.;
RT   "Crystal structure of the tetramerization domain of the p53 tumor
RT   suppressor at 1.7 angstroms.";
RL   Science 267:1498-1502(1995).
RN   [153]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2.
RX   PubMed=8875929; DOI=10.1126/science.274.5289.948;
RA   Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J.,
RA   Pavletich N.P.;
RT   "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
RT   transactivation domain.";
RL   Science 274:948-953(1996).
RN   [154]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2.
RX   PubMed=8875926; DOI=10.1126/science.274.5289.1001;
RA   Gorina S., Pavletich N.P.;
RT   "Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains
RT   of 53BP2.";
RL   Science 274:1001-1005(1996).
RN   [155]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS,
RP   AND SUBUNIT.
RX   PubMed=14534297; DOI=10.1074/jbc.m309732200;
RA   Joerger A.C., Allen M.D., Fersht A.R.;
RT   "Crystal structure of a superstable mutant of human p53 core domain.
RT   Insights into the mechanism of rescuing oncogenic mutations.";
RL   J. Biol. Chem. 279:1291-1296(2004).
RN   [156]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND
RP   ZINC IONS, AND SUBUNIT.
RX   PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015;
RA   Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L.,
RA   Haran T.E., Shakked Z.;
RT   "Structural basis of DNA recognition by p53 tetramers.";
RL   Mol. Cell 22:741-753(2006).
RN   [157]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7, AND
RP   INTERACTION WITH USP7.
RX   PubMed=16474402; DOI=10.1038/nsmb1067;
RA   Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H.,
RA   Frappier L.;
RT   "Molecular recognition of p53 and MDM2 by USP7/HAUSP.";
RL   Nat. Struct. Mol. Biol. 13:285-291(2006).
RN   [158]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH USP7,
RP   MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION WITH USP7.
RX   PubMed=16402859; DOI=10.1371/journal.pbio.0040027;
RA   Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.;
RT   "Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7:
RT   implications for the regulation of the p53-MDM2 pathway.";
RL   PLoS Biol. 4:228-239(2006).
RN   [159]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 377-386, METHYLATION AT LYS-382,
RP   MUTAGENESIS OF LYS-382, AND INTERACTION WITH L3MBTL1.
RX   PubMed=20870725; DOI=10.1074/jbc.m110.139527;
RA   West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E.,
RA   Kutateladze T.G., Gozani O.;
RT   "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine
RT   382 to target gene repression.";
RL   J. Biol. Chem. 285:37725-37732(2010).
RN   [160]
RP   REVIEW.
RX   PubMed=8266092; DOI=10.1126/science.8266092;
RA   Harris C.C.;
RT   "p53: at the crossroads of molecular carcinogenesis and risk assessment.";
RL   Science 262:1980-1981(1993).
RN   [161]
RP   REVIEW ON VARIANTS.
RX   PubMed=1905840; DOI=10.1126/science.1905840;
RA   Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.;
RT   "p53 mutations in human cancers.";
RL   Science 253:49-53(1991).
RN   [162]
RP   REVIEW ON VARIANTS.
RX   PubMed=8829653;
RX   DOI=10.1002/(sici)1098-1004(1996)7:3<202::aid-humu4>3.0.co;2-c;
RA   de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H.,
RA   Liao D., Soussi T., Kovach J.S., Sommer S.S.;
RT   "Database of mutations in the p53 and APC tumor suppressor genes designed
RT   to facilitate molecular epidemiological analyses.";
RL   Hum. Mutat. 7:202-213(1996).
RN   [163]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS.
RX   PubMed=17015838; DOI=10.1073/pnas.0607286103;
RA   Joerger A.C., Ang H.C., Fersht A.R.;
RT   "Structural basis for understanding oncogenic p53 mutations and designing
RT   rescue drugs.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006).
RN   [164]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282.
RX   PubMed=18453682; DOI=10.1107/s0907444908003338;
RA   Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.;
RT   "Impact of low-frequency hotspot mutation R282Q on the structure of p53
RT   DNA-binding domain as revealed by crystallography at 1.54 angstroms
RT   resolution.";
RL   Acta Crystallogr. D 64:471-477(2008).
RN   [165]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN
RP   COMPLEX WITH ZINC IONS AND PHIKAN083.
RX   PubMed=18650397; DOI=10.1073/pnas.0805326105;
RA   Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B.,
RA   Fersht A.R.;
RT   "Targeted rescue of a destabilized mutant of p53 by an in silico screened
RT   drug.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008).
RN   [166]
RP   X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN
RP   COMPLEX WITH DNA.
RX   PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063;
RA   Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N., Shimon L.J.,
RA   Frolow F., Liran A., Rotter V., Shakked Z.;
RT   "Structural basis of restoring sequence-specific DNA binding and
RT   transactivation to mutant p53 by suppressor mutations.";
RL   J. Mol. Biol. 385:249-265(2009).
RN   [167]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC IONS.
RX   PubMed=19515728; DOI=10.1093/protein/gzp018;
RA   Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.;
RT   "Stabilising the DNA-binding domain of p53 by rational design of its
RT   hydrophobic core.";
RL   Protein Eng. Des. Sel. 22:421-430(2009).
RN   [168]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN
RP   COMPLEX WITH ZINC IONS.
RX   PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011;
RA   Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J.,
RA   Fersht A.R.;
RT   "Toward the rational design of p53-stabilizing drugs: probing the surface
RT   of the oncogenic Y220C mutant.";
RL   Chem. Biol. 17:46-56(2010).
RN   [169]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND
RP   ZINC IONS, AND SUBUNIT.
RX   PubMed=20364130; DOI=10.1038/nsmb.1800;
RA   Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B.,
RA   Shakked Z.;
RT   "Diversity in DNA recognition by p53 revealed by crystal structures with
RT   Hoogsteen base pairs.";
RL   Nat. Struct. Mol. Biol. 17:423-429(2010).
RN   [170]
RP   VARIANT ARG-72.
RX   PubMed=1999338; DOI=10.1007/bf00201836;
RA   Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.;
RT   "Characterization of a frequent polymorphism in the coding sequence of the
RT   Tp53 gene in colonic cancer patients and a control population.";
RL   Hum. Genet. 86:369-370(1991).
RN   [171]
RP   VARIANT LFS THR-133.
RX   PubMed=1933902;
RA   Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.;
RT   "A germ line mutation in exon 5 of the p53 gene in an extended cancer
RT   family.";
RL   Cancer Res. 51:6385-6387(1991).
RN   [172]
RP   VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258.
RX   PubMed=1978757; DOI=10.1126/science.1978757;
RA   Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H.,
RA   Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H.;
RT   "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas,
RT   and other neoplasms.";
RL   Science 250:1233-1238(1990).
RN   [173]
RP   VARIANT LFS ASP-245.
RX   PubMed=2259385; DOI=10.1038/348747a0;
RA   Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.;
RT   "Germ-line transmission of a mutated p53 gene in a cancer-prone family with
RT   Li-Fraumeni syndrome.";
RL   Nature 348:747-749(1990).
RN   [174]
RP   VARIANT LFS LEU-272.
RX   PubMed=1737852; DOI=10.1172/jci115630;
RA   Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I., Poplack D.G.,
RA   Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J., Knutsen T.,
RA   Minna J.D.;
RT   "Hereditary and acquired p53 gene mutations in childhood acute
RT   lymphoblastic leukemia.";
RL   J. Clin. Invest. 89:640-647(1992).
RN   [175]
RP   VARIANTS LFS HIS-273 AND VAL-325.
RX   PubMed=1565144; DOI=10.1056/nejm199205143262002;
RA   Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C.,
RA   Andersen T.I., Boerresen A.-L., Li F.P., Garber J., Strong L.C.;
RT   "Germline mutations of the p53 tumor-suppressor gene in children and young
RT   adults with second malignant neoplasms.";
RL   N. Engl. J. Med. 326:1309-1315(1992).
RN   [176]
RP   VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285.
RX   PubMed=1694291;
RA   Bartek J., Iggo R., Gannon J., Lane D.P.;
RT   "Genetic and immunochemical analysis of mutant p53 in human breast cancer
RT   cell lines.";
RL   Oncogene 5:893-899(1990).
RN   [177]
RP   VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273.
RX   PubMed=1699228; DOI=10.1073/pnas.87.19.7555;
RA   Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F.,
RA   Gannon J.V., Lane D.P.;
RT   "p53 mutations in colorectal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
RN   [178]
RP   VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND SER-278.
RX   PubMed=2263646; DOI=10.1073/pnas.87.24.9958;
RA   Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.;
RT   "Frequent mutation of the p53 gene in human esophageal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
RN   [179]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1647768; DOI=10.1016/0006-291x(91)90623-f;
RA   Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R.,
RA   Wakui A., Yamazaki T.;
RT   "Mutations of the P53 gene, including an intronic point mutation, in
RT   colorectal tumors.";
RL   Biochem. Biophys. Res. Commun. 177:901-906(1991).
RN   [180]
RP   VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND HIS-273.
RX   PubMed=1868473;
RA   Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B., Roth J.A.;
RT   "p53 gene mutations in Barrett's epithelium and esophageal cancer.";
RL   Cancer Res. 51:4495-4499(1991).
RN   [181]
RP   VARIANTS SPORADIC CANCERS IN CHINA.
RX   PubMed=1849234; DOI=10.1038/350427a0;
RA   Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.;
RT   "Mutational hotspot in the p53 gene in human hepatocellular carcinomas.";
RL   Nature 350:427-428(1991).
RN   [182]
RP   VARIANTS SPORADIC CANCERS IN SOUTH AFRICA.
RX   PubMed=1672732; DOI=10.1038/350429a0;
RA   Bressac B., Kew M., Wands J., Ozturk M.;
RT   "Selective G to T mutations of p53 gene in hepatocellular carcinoma from
RT   southern Africa.";
RL   Nature 350:429-431(1991).
RN   [183]
RP   VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273.
RX   PubMed=1394225;
RA   Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
RA   Casey G.;
RT   "Frequent p53 mutations in head and neck cancer.";
RL   Cancer Res. 52:5997-6000(1992).
RN   [184]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1327751; DOI=10.1002/j.1460-2075.1992.tb05487.x;
RA   Crook T., Vousden K.H.;
RT   "Properties of p53 mutations detected in primary and secondary cervical
RT   cancers suggest mechanisms of metastasis and involvement of environmental
RT   carcinogens.";
RL   EMBO J. 11:3935-3940(1992).
RN   [185]
RP   VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285.
RX   PubMed=1459726; DOI=10.1002/ijc.2910520606;
RA   Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S.,
RA   Yamamoto H., Tsuchida N.;
RT   "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-
RT   cell carcinoma.";
RL   Int. J. Cancer 52:867-872(1992).
RN   [186]
RP   VARIANT PRO-HIS-PRO-178 INS.
RX   PubMed=1303181; DOI=10.1093/hmg/1.3.207;
RA   Bhatia K., Guiterrez M.I., Magrath I.T.;
RT   "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.";
RL   Hum. Mol. Genet. 1:207-208(1992).
RN   [187]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1437144;
RA   Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E.,
RA   Appella E., May P.;
RT   "p53 mutations in Raji cells: characterization and localization relative to
RT   other Burkitt's lymphomas.";
RL   Oncogene 7:2161-2167(1992).
RN   [188]
RP   VARIANT SPORADIC CANCER THR-280.
RX   PubMed=1631151; DOI=10.1073/pnas.89.14.6516;
RA   Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Chen I.-H.,
RA   Cao Y., Yao K.-T., Colburn N.H.;
RT   "An infrequent point mutation of the p53 gene in human nasopharyngeal
RT   carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
RN   [189]
RP   VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220;
RP   GLN-248; LEU-248 AND HIS-273.
RX   PubMed=7682763;
RA   Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.;
RT   "p53 alterations in human squamous cell carcinomas and carcinoma cell
RT   lines.";
RL   Am. J. Pathol. 142:1131-1139(1993).
RN   [190]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=8402617;
RA   Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A.,
RA   Correo R., Eby Y.J., Ruppert J.M., Sidransky D.;
RT   "The incidence of p53 mutations increases with progression of head and neck
RT   cancer.";
RL   Cancer Res. 53:4477-4480(1993).
RN   [191]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=8336944;
RA   Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.;
RT   "Efficient screening of p53 mutations by denaturing gradient gel
RT   electrophoresis in colorectal tumors.";
RL   Oncogene 8:2213-2220(1993).
RN   [192]
RP   VARIANTS, AND INVOLVEMENT IN LFL.
RX   PubMed=8118819;
RA   Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A., Kelsey A.M.,
RA   Harris M., Jones P.H., Binchy A., Crowther D., Craft A.W., Eden O.B.,
RA   Evans D.G.R., Thompson E., Mann J.R., Martin J., Mitchell E.L.D.,
RA   Santibanez-Koref M.F.;
RT   "Prevalence and diversity of constitutional mutations in the p53 gene among
RT   21 Li-Fraumeni families.";
RL   Cancer Res. 54:1298-1304(1994).
RN   [193]
RP   CHARACTERIZATION OF VARIANT ALA-143.
RX   PubMed=8013454; DOI=10.1002/j.1460-2075.1994.tb06543.x;
RA   Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.;
RT   "A temperature-sensitive mutant of human p53.";
RL   EMBO J. 13:2535-2544(1994).
RN   [194]
RP   VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275.
RX   PubMed=7887414;
RA   Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M.,
RA   Fraumeni J.F. Jr., Li F.P., Friend S.H.;
RT   "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.";
RL   Am. J. Hum. Genet. 56:608-615(1995).
RN   [195]
RP   VARIANTS, AND INVOLVEMENT IN LFL.
RX   PubMed=8718514;
RA   Eeles R.A.;
RT   "Germline mutations in the TP53 gene.";
RL   Cancer Surv. 25:101-124(1995).
RN   [196]
RP   VARIANT LFS HIS-175.
RX   PubMed=8825920; DOI=10.1136/jmg.32.12.942;
RA   Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D.,
RA   Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M., Evans D.G.R.;
RT   "An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175
RT   mutation in TP53.";
RL   J. Med. Genet. 32:942-945(1995).
RN   [197]
RP   VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND GLN-286.
RX   PubMed=8829627;
RX   DOI=10.1002/(sici)1098-1004(1996)7:2<109::aid-humu4>3.0.co;2-7;
RA   Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B., Hardy E.,
RA   Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.;
RT   "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.";
RL   Hum. Mutat. 7:109-113(1996).
RN   [198]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=9101296;
RX   DOI=10.1002/(sici)1098-1004(1997)9:4<348::aid-humu8>3.0.co;2-1;
RA   Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V.,
RA   Zeuthen J.;
RT   "Single-step DGGE-based mutation scanning of the p53 gene: application to
RT   genetic diagnosis of colorectal cancer.";
RL   Hum. Mutat. 9:348-355(1997).
RN   [199]
RP   VARIANT SPORADIC CANCER ILE-157.
RX   PubMed=9419979; DOI=10.1038/sj.onc.1201668;
RA   Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K.,
RA   Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y.,
RA   Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.;
RT   "Drastic genetic instability of tumors and normal tissues in Turcot
RT   syndrome.";
RL   Oncogene 15:2877-2881(1997).
RN   [200]
RP   VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273 AND
RP   SER-278.
RX   PubMed=9450901;
RX   DOI=10.1002/(sici)1098-1004(1998)11:1<39::aid-humu6>3.0.co;2-g;
RA   van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J.,
RA   Raubenheimer E.J.;
RT   "Detection of p53 gene mutations in oral squamous cell carcinomas of a
RT   black African population sample.";
RL   Hum. Mutat. 11:39-44(1998).
RN   [201]
RP   VARIANT NON-CLASSICAL LFS CYS-337.
RX   PubMed=9452042; DOI=10.1002/humu.1380110121;
RA   Luca J.W., Strong L.C., Hansen M.F.;
RT   "A germline missense mutation R337C in exon 10 of the human p53 gene.";
RL   Hum. Mutat. Suppl. 1:S58-S61(1998).
RN   [202]
RP   VARIANT LFS ILE-292.
RX   PubMed=10484981; DOI=10.1016/s0165-4608(98)00276-3;
RA   Gueran S., Tunca Y., Imirzalioglu N.;
RT   "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-
RT   Fraumeni syndrome family.";
RL   Cancer Genet. Cytogenet. 113:145-151(1999).
RN   [203]
RP   VARIANTS.
RX   PubMed=10549356; DOI=10.1016/s0065-230x(08)60785-x;
RA   Hainaut P., Hollstein M.;
RT   "p53 and human cancer: the first ten thousand mutations.";
RL   Adv. Cancer Res. 77:81-137(2000).
RN   [204]
RP   VARIANT ADCC HIS-337.
RX   PubMed=11481490; DOI=10.1073/pnas.161479898;
RA   Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E.,
RA   Lafferty A.R., DeLacerda L., Rabin M., Cadwell C., Sampaio G., Cat I.,
RA   Stratakis C.A., Sandrini R.;
RT   "An inherited p53 mutation that contributes in a tissue-specific manner to
RT   pediatric adrenal cortical carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001).
RN   [205]
RP   INVOLVEMENT IN CPP.
RX   PubMed=12085209; DOI=10.1038/sj.bjc.6600269;
RA   Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P., Taylor G.R.,
RA   Lu X., Barnes D.M., Camplejohn R.S.;
RT   "Investigations on a clinically and functionally unusual and novel germline
RT   p53 mutation.";
RL   Br. J. Cancer 86:1592-1596(2002).
RN   [206]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175;
RP   ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248; SER-249;
RP   TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280 AND HIS-281.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [207]
RP   VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195; MET-216;
RP   ALA-241; MET-249; SER-251; TYR-259 AND CYS-273.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S.,
RA   Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M.,
RA   Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by expression
RT   profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
RN   [208]
RP   VARIANTS.
RX   PubMed=17311302; DOI=10.1002/humu.20495;
RA   Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P.,
RA   Olivier M.;
RT   "Impact of mutant p53 functional properties on TP53 mutation patterns and
RT   tumor phenotype: lessons from recent developments in the IARC TP53
RT   database.";
RL   Hum. Mutat. 28:622-629(2007).
RN   [209]
RP   CHARACTERIZATION OF VARIANT SPORADIC CANCER LYS-280, UBIQUITINATION,
RP   PROTEASOMAL DEGRADATION, AND INTERACTION WITH CCAR2.
RX   PubMed=25732823; DOI=10.1016/j.celrep.2015.01.066;
RA   Qin B., Minter-Dykhouse K., Yu J., Zhang J., Liu T., Zhang H., Lee S.,
RA   Kim J., Wang L., Lou Z.;
RT   "DBC1 functions as a tumor suppressor by regulating p53 stability.";
RL   Cell Rep. 10:1324-1334(2015).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological circumstances
CC       and cell type. Involved in cell cycle regulation as a trans-activator
CC       that acts to negatively regulate cell division by controlling a set of
CC       genes required for this process. One of the activated genes is an
CC       inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be
CC       mediated either by stimulation of BAX and FAS antigen expression, or by
CC       repression of Bcl-2 expression. Its pro-apoptotic activity is activated
CC       via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2
CC       (PubMed:12524540). However, this activity is inhibited when the
CC       interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by
CC       PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial
CC       PPIF is involved in activating oxidative stress-induced necrosis; the
CC       function is largely independent of transcription. Induces the
CC       transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and
CC       lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent
CC       transcriptional repression leading to apoptosis and seems to have an
CC       effect on cell-cycle regulation. Implicated in Notch signaling cross-
CC       over. Prevents CDK7 kinase activity when associated to CAK complex in
CC       response to DNA damage, thus stopping cell cycle progression. Isoform 2
CC       enhances the transactivation activity of isoform 1 from some but not
CC       all TP53-inducible promoters. Isoform 4 suppresses transactivation
CC       activity and impairs growth suppression mediated by isoform 1. Isoform
CC       7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock
CC       by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of
CC       PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664,
CC       ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061,
CC       ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17349958,
CC       ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:20673990,
CC       ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:22726440,
CC       ECO:0000269|PubMed:24051492, ECO:0000269|PubMed:9840937}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 1 zinc ion per subunit.;
CC   -!- SUBUNIT: Forms homodimers and homotetramers (PubMed:19011621). Binds
CC       DNA as a homotetramer. Interacts with AXIN1. Probably part of a complex
CC       consisting of TP53, HIPK2 and AXIN1 (By similarity). Interacts with
CC       histone acetyltransferases EP300 and methyltransferases HRMT1L2 and
CC       CARM1, and recruits them to promoters. Interacts (via C-terminus) with
CC       TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this
CC       interaction may be indirect. Found in a complex with CABLES1 and TP73.
CC       Interacts with HIPK1, HIPK2, and TP53INP1. Interacts with WWOX. May
CC       interact with HCV core protein. Interacts with USP7 and SYVN1.
CC       Interacts with HSP90AB1. Interacts with CHD8; leading to recruit
CC       histone H1 and prevent transactivation activity (By similarity).
CC       Interacts with ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and
CC       E4F1. Interacts with YWHAZ; the interaction enhances TP53
CC       transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits
CC       this interaction. Interacts (via DNA-binding domain) with MAML1 (via N-
CC       terminus). Interacts with MKRN1. Interacts with PML (via C-terminus).
CC       Interacts with MDM2; leading to ubiquitination and proteasomal
CC       degradation of TP53. Directly interacts with FBXO42; leading to
CC       ubiquitination and degradation of TP53. Interacts (phosphorylated at
CC       Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates
CC       stress-induced TP53-dependent inhibition of cell proliferation.
CC       Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24.
CC       Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1
CC       interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds
CC       to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage.
CC       Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and
CC       NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes
CC       ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes
CC       ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the
CC       association implicates preferentially tetrameric TP53, is induced by
CC       oxidative stress and is impaired by cyclosporin A (CsA). Interacts with
CC       SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated
CC       ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with
CC       KAT6A. Interacts with UBC9. Interacts with ZNF385B; the interaction is
CC       direct. Interacts (via DNA-binding domain) with ZNF385A; the
CC       interaction is direct and enhances p53/TP53 transactivation functions
CC       on cell-cycle arrest target genes, resulting in growth arrest.
CC       Interacts with ANKRD2. Interacts with RFFL and RNF34; involved in
CC       p53/TP53 ubiquitination. Interacts with MTA1 and COP1. Interacts with
CC       CCAR2 (via N-terminus). Interacts with MORC3 (PubMed:17332504).
CC       Interacts (via C-terminus) with POU4F2 isoform 1 (via C-terminus)
CC       (PubMed:17145718). Interacts (via oligomerization region) with NOP53;
CC       the interaction is direct and may prevent the MDM2-mediated proteasomal
CC       degradation of TP53 (PubMed:22522597). Interacts with AFG1L; mediates
CC       mitochondrial translocation of TP53 (PubMed:27323408). Interacts with
CC       UBD (PubMed:25422469). Interacts with TAF6 isoform 1 and isoform 4
CC       (PubMed:20096117). Interacts with C10orf90/FATS; the interaction
CC       inhibits binding of TP53 and MDM2 (By similarity). Interacts with
CC       NUPR1; interaction is stress-dependent (PubMed:18690848). Forms a
CC       complex with EP300 and NUPR1; this complex binds CDKN1A promoter
CC       leading to transcriptional induction of CDKN1A (PubMed:18690848).
CC       Interacts with PRMT5 in response to DNA damage; the interaction is
CC       STRAP dependent (PubMed:19011621). Interacts with PPP1R13L (via SH3
CC       domain and ANK repeats); the interaction inhibits pro-apoptotic
CC       activity of p53/TP53 (PubMed:12524540). Interacts with PPP1R13B/ASPP1
CC       and TP53BP2/ASPP2; the interactions promotes pro-apototic activity
CC       (PubMed:12524540). When phosphorylated at Ser-15, interacts with DDX3X
CC       and gamma-tubulin (PubMed:28842590). Interacts with KAT7/HBO1; leading
CC       to inhibit histone acetyltransferase activity of KAT7/HBO1
CC       (PubMed:17954561). {ECO:0000250|UniProtKB:P02340,
CC       ECO:0000250|UniProtKB:P10361, ECO:0000269|PubMed:12524540,
CC       ECO:0000269|PubMed:12750254, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:12851404, ECO:0000269|PubMed:14534297,
CC       ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879,
CC       ECO:0000269|PubMed:15109303, ECO:0000269|PubMed:15136035,
CC       ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15701641,
CC       ECO:0000269|PubMed:15855171, ECO:0000269|PubMed:16219768,
CC       ECO:0000269|PubMed:16322561, ECO:0000269|PubMed:16376338,
CC       ECO:0000269|PubMed:16377624, ECO:0000269|PubMed:16402859,
CC       ECO:0000269|PubMed:16474402, ECO:0000269|PubMed:16793544,
CC       ECO:0000269|PubMed:16845383, ECO:0000269|PubMed:17015838,
CC       ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17121812,
CC       ECO:0000269|PubMed:17145718, ECO:0000269|PubMed:17170702,
CC       ECO:0000269|PubMed:17245430, ECO:0000269|PubMed:17317671,
CC       ECO:0000269|PubMed:17332504, ECO:0000269|PubMed:17591690,
CC       ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:17904127,
CC       ECO:0000269|PubMed:17954561, ECO:0000269|PubMed:17967874,
CC       ECO:0000269|PubMed:18585004, ECO:0000269|PubMed:18650397,
CC       ECO:0000269|PubMed:18690848, ECO:0000269|PubMed:18996393,
CC       ECO:0000269|PubMed:19011621, ECO:0000269|PubMed:19509332,
CC       ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:19536131,
CC       ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19837670,
CC       ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20096117,
CC       ECO:0000269|PubMed:20124405, ECO:0000269|PubMed:20142040,
CC       ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:20364130,
CC       ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:20660729,
CC       ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:20959462,
CC       ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:21952639,
CC       ECO:0000269|PubMed:22214662, ECO:0000269|PubMed:22522597,
CC       ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:22945289,
CC       ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:25422469,
CC       ECO:0000269|PubMed:25732823, ECO:0000269|PubMed:27323408,
CC       ECO:0000269|PubMed:28842590, ECO:0000269|PubMed:8875926,
CC       ECO:0000269|PubMed:8875929, ECO:0000269|PubMed:9840937}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with cancer-associated/HPV E6
CC       viral proteins leading to ubiquitination and degradation of TP53 giving
CC       a possible model for cell growth regulation. This complex formation
CC       requires an additional factor, E6-AP, which stably associates with TP53
CC       in the presence of E6. {ECO:0000269|PubMed:2175676}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human
CC       cytomegalovirus/HHV-5 protein UL123. {ECO:0000269|PubMed:19776115}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with human
CC       adenovirus 5 E1B-55K protein; this interaction leads to the inhibition
CC       of TP53 function and/or its degradation. {ECO:0000269|PubMed:25772236}.
CC   -!- INTERACTION:
CC       P04637; P03070; Xeno; NbExp=20; IntAct=EBI-366083, EBI-617698;
CC       P04637; P04637; NbExp=25; IntAct=EBI-366083, EBI-366083;
CC       P04637; PRO_0000037536 [P26663]; Xeno; NbExp=9; IntAct=EBI-366083, EBI-6838571;
CC       P04637; Q7L7W2; NbExp=2; IntAct=EBI-366083, EBI-7210801;
CC       P04637; Q8QW27; Xeno; NbExp=2; IntAct=EBI-366083, EBI-6863726;
CC       P04637; Q13155: AIMP2; NbExp=6; IntAct=EBI-366083, EBI-745226;
CC       P04637; O95376: ARIH2; NbExp=5; IntAct=EBI-366083, EBI-711158;
CC       P04637; P49407: ARRB1; NbExp=5; IntAct=EBI-366083, EBI-743313;
CC       P04637; P29066: Arrb1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-4303019;
CC       P04637; Q9UBL3: ASH2L; NbExp=7; IntAct=EBI-366083, EBI-540797;
CC       P04637; O95352-2: ATG7; NbExp=4; IntAct=EBI-366083, EBI-15980880;
CC       P04637; O15169: AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484;
CC       P04637; Q8N9N5: BANP; NbExp=3; IntAct=EBI-366083, EBI-744695;
CC       P04637; P10415: BCL2; NbExp=5; IntAct=EBI-366083, EBI-77694;
CC       P04637; Q07817-1: BCL2L1; NbExp=26; IntAct=EBI-366083, EBI-287195;
CC       P04637; P11274: BCR; NbExp=2; IntAct=EBI-366083, EBI-712838;
CC       P04637; O14503: BHLHE40; NbExp=11; IntAct=EBI-366083, EBI-711810;
CC       P04637; P51587: BRCA2; NbExp=7; IntAct=EBI-366083, EBI-79792;
CC       P04637; Q9NPI1: BRD7; NbExp=9; IntAct=EBI-366083, EBI-711221;
CC       P04637; Q9BX70: BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091;
CC       P04637; Q9Y297: BTRC; NbExp=2; IntAct=EBI-366083, EBI-307461;
CC       P04637; Q9ESJ1: Cables1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-604411;
CC       P04637; Q9BWC9: CCDC106; NbExp=3; IntAct=EBI-366083, EBI-711501;
CC       P04637; P38936: CDKN1A; NbExp=3; IntAct=EBI-366083, EBI-375077;
CC       P04637; P17676: CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696;
CC       P04637; Q92793: CREBBP; NbExp=11; IntAct=EBI-366083, EBI-81215;
CC       P04637; P45481: Crebbp; Xeno; NbExp=9; IntAct=EBI-366083, EBI-296306;
CC       P04637; P55060: CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709;
CC       P04637; P68400: CSNK2A1; NbExp=2; IntAct=EBI-366083, EBI-347804;
CC       P04637; Q14999: CUL7; NbExp=5; IntAct=EBI-366083, EBI-308606;
CC       P04637; Q8IWT3: CUL9; NbExp=4; IntAct=EBI-366083, EBI-311123;
CC       P04637; Q9P0U4: CXXC1; NbExp=7; IntAct=EBI-366083, EBI-949911;
CC       P04637; Q9UER7: DAXX; NbExp=12; IntAct=EBI-366083, EBI-77321;
CC       P04637; Q92841: DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012;
CC       P04637; P17844: DDX5; NbExp=6; IntAct=EBI-366083, EBI-351962;
CC       P04637-1; P17844: DDX5; NbExp=2; IntAct=EBI-3895849, EBI-351962;
CC       P04637-7; P17844: DDX5; NbExp=2; IntAct=EBI-3895873, EBI-351962;
CC       P04637; Q9NRR4: DROSHA; NbExp=5; IntAct=EBI-366083, EBI-528367;
CC       P04637; Q9BV47: DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519;
CC       P04637; O14641: DVL2; NbExp=6; IntAct=EBI-366083, EBI-740850;
CC       P04637; P03126: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1177242;
CC       P04637; P06463: E6; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1186926;
CC       P04637; Q09472: EP300; NbExp=20; IntAct=EBI-366083, EBI-447295;
CC       P04637; P15036: ETS2; NbExp=4; IntAct=EBI-366083, EBI-1646991;
CC       P04637; Q86XK2: FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804;
CC       P04637; O43524: FOXO3; NbExp=2; IntAct=EBI-366083, EBI-1644164;
CC       P04637; P49841: GSK3B; NbExp=3; IntAct=EBI-366083, EBI-373586;
CC       P04637; P32780: GTF2H1; NbExp=12; IntAct=EBI-366083, EBI-715539;
CC       P04637; Q13547: HDAC1; NbExp=7; IntAct=EBI-366083, EBI-301834;
CC       P04637; Q86Z02: HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891;
CC       P04637; P09429: HMGB1; NbExp=9; IntAct=EBI-366083, EBI-389432;
CC       P04637; P61978: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-304185;
CC       P04637; P61978-2: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-7060731;
CC       P04637; P02829: HSP82; Xeno; NbExp=8; IntAct=EBI-366083, EBI-8659;
CC       P04637; P34931: HSPA1L; NbExp=2; IntAct=EBI-366083, EBI-354912;
CC       P04637; P38646: HSPA9; NbExp=6; IntAct=EBI-366083, EBI-354932;
CC       P04637; P04792: HSPB1; NbExp=3; IntAct=EBI-366083, EBI-352682;
CC       P04637; P42858: HTT; NbExp=4; IntAct=EBI-366083, EBI-466029;
CC       P04637; Q7Z6Z7: HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934;
CC       P04637; Q16666-2: IFI16; NbExp=6; IntAct=EBI-366083, EBI-6273540;
CC       P04637; Q08619: Ifi205b; Xeno; NbExp=2; IntAct=EBI-366083, EBI-8064290;
CC       P04637; O14920: IKBKB; NbExp=2; IntAct=EBI-366083, EBI-81266;
CC       P04637; Q9UHH9: IP6K2; NbExp=4; IntAct=EBI-366083, EBI-747509;
CC       P04637; Q6NYC1: JMJD6; NbExp=7; IntAct=EBI-366083, EBI-8464037;
CC       P04637; Q92993: KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080;
CC       P04637; Q9H7Z6: KAT8; NbExp=2; IntAct=EBI-366083, EBI-896414;
CC       P04637; O60341-1: KDM1A; NbExp=6; IntAct=EBI-366083, EBI-15599570;
CC       P04637; Q8IZD2: KMT2E; NbExp=4; IntAct=EBI-366083, EBI-2689959;
CC       P04637; Q16363: LAMA4; NbExp=2; IntAct=EBI-366083, EBI-711505;
CC       P04637; P43356: MAGEA2B; NbExp=7; IntAct=EBI-366083, EBI-5650739;
CC       P04637; Q96M61: MAGEB18; NbExp=3; IntAct=EBI-366083, EBI-741835;
CC       P04637; Q9UBF1: MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487;
CC       P04637; P46821: MAP1B; NbExp=6; IntAct=EBI-366083, EBI-764611;
CC       P04637; Q15759: MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304;
CC       P04637; Q8IW41: MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460;
CC       P04637; Q00987: MDM2; NbExp=93; IntAct=EBI-366083, EBI-389668;
CC       P04637; O15151: MDM4; NbExp=19; IntAct=EBI-366083, EBI-398437;
CC       P04637; Q9UHC7: MKRN1; NbExp=8; IntAct=EBI-366083, EBI-373524;
CC       P04637; O75970: MPDZ; NbExp=3; IntAct=EBI-366083, EBI-821405;
CC       P04637; P04731: MT1A; NbExp=3; IntAct=EBI-366083, EBI-8045030;
CC       P04637; P19338: NCL; NbExp=2; IntAct=EBI-366083, EBI-346967;
CC       P04637; Q9Y618: NCOR2; NbExp=7; IntAct=EBI-366083, EBI-80830;
CC       P04637; P23511: NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739;
CC       P04637; P25208: NFYB; NbExp=6; IntAct=EBI-366083, EBI-389728;
CC       P04637; Q9Y3T9: NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547;
CC       P04637; O60936: NOL3; NbExp=3; IntAct=EBI-366083, EBI-740992;
CC       P04637; P06748: NPM1; NbExp=6; IntAct=EBI-366083, EBI-78579;
CC       P04637; P06748-1: NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150;
CC       P04637; Q15466: NR0B2; NbExp=3; IntAct=EBI-366083, EBI-3910729;
CC       P04637; P22736: NR4A1; NbExp=6; IntAct=EBI-366083, EBI-721550;
CC       P04637; O43847: NRDC; NbExp=6; IntAct=EBI-366083, EBI-2371631;
CC       P04637; P89055: NSP1; Xeno; NbExp=6; IntAct=EBI-366083, EBI-9522973;
CC       P04637; O60285: NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789;
CC       P04637; P49757: NUMB; NbExp=5; IntAct=EBI-366083, EBI-915016;
CC       P04637; Q96FW1: OTUB1; NbExp=8; IntAct=EBI-366083, EBI-1058491;
CC       P04637; Q8TEW0: PARD3; NbExp=3; IntAct=EBI-366083, EBI-81968;
CC       P04637; P09874: PARP1; NbExp=3; IntAct=EBI-366083, EBI-355676;
CC       P04637; Q96KB5: PBK; NbExp=7; IntAct=EBI-366083, EBI-536853;
CC       P04637; P35232: PHB; NbExp=6; IntAct=EBI-366083, EBI-354213;
CC       P04637; O75925: PIAS1; NbExp=4; IntAct=EBI-366083, EBI-629434;
CC       P04637; O75928: PIAS2; NbExp=2; IntAct=EBI-366083, EBI-348555;
CC       P04637; Q8N2W9: PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160;
CC       P04637; Q13526: PIN1; NbExp=12; IntAct=EBI-366083, EBI-714158;
CC       P04637; P53350: PLK1; NbExp=6; IntAct=EBI-366083, EBI-476768;
CC       P04637; P29590: PML; NbExp=4; IntAct=EBI-366083, EBI-295890;
CC       P04637; P30405: PPIF; NbExp=4; IntAct=EBI-366083, EBI-5544229;
CC       P04637; P36873-1: PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289;
CC       P04637; Q8WUF5: PPP1R13L; NbExp=12; IntAct=EBI-366083, EBI-5550163;
CC       P04637; P30153: PPP2R1A; NbExp=3; IntAct=EBI-366083, EBI-302388;
CC       P04637; Q13362: PPP2R5C; NbExp=4; IntAct=EBI-366083, EBI-1266156;
CC       P04637; Q05655: PRKCD; NbExp=4; IntAct=EBI-366083, EBI-704279;
CC       P04637; P61289: PSME3; NbExp=7; IntAct=EBI-366083, EBI-355546;
CC       P04637; Q05397: PTK2; NbExp=13; IntAct=EBI-366083, EBI-702142;
CC       P04637; Q06609: RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202;
CC       P04637; Q06330: RBPJ; NbExp=5; IntAct=EBI-366083, EBI-632552;
CC       P04637; Q96PM5: RCHY1; NbExp=11; IntAct=EBI-366083, EBI-947779;
CC       P04637; Q6PCD5: RFWD3; NbExp=5; IntAct=EBI-366083, EBI-2129159;
CC       P04637; Q06587: RING1; NbExp=7; IntAct=EBI-366083, EBI-752313;
CC       P04637; P23396: RPS3; NbExp=4; IntAct=EBI-366083, EBI-351193;
CC       P04637; Q8N488: RYBP; NbExp=3; IntAct=EBI-366083, EBI-752324;
CC       P04637; P23297: S100A1; NbExp=2; IntAct=EBI-366083, EBI-743686;
CC       P04637; P29034: S100A2; NbExp=2; IntAct=EBI-366083, EBI-752230;
CC       P04637; P26447: S100A4; NbExp=7; IntAct=EBI-366083, EBI-717058;
CC       P04637; P04271: S100B; NbExp=2; IntAct=EBI-366083, EBI-458391;
CC       P04637; Q15424: SAFB; NbExp=5; IntAct=EBI-366083, EBI-348298;
CC       P04637; Q8WTS6: SETD7; NbExp=11; IntAct=EBI-366083, EBI-1268586;
CC       P04637; P31947: SFN; NbExp=4; IntAct=EBI-366083, EBI-476295;
CC       P04637; Q96ST3: SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218;
CC       P04637; Q96EB6: SIRT1; NbExp=18; IntAct=EBI-366083, EBI-1802965;
CC       P04637; Q923E4: Sirt1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-1802585;
CC       P04637; Q15796: SMAD2; NbExp=7; IntAct=EBI-366083, EBI-1040141;
CC       P04637; Q9NRG4: SMYD2; NbExp=6; IntAct=EBI-366083, EBI-1055671;
CC       P04637; Q8R5A0: Smyd2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-15612527;
CC       P04637; O95863: SNAI1; NbExp=2; IntAct=EBI-366083, EBI-1045459;
CC       P04637; Q06945: SOX4; NbExp=4; IntAct=EBI-366083, EBI-6672525;
CC       P04637; P08047: SP1; NbExp=3; IntAct=EBI-366083, EBI-298336;
CC       P04637; Q12772: SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059;
CC       P04637; Q96SB4: SRPK1; NbExp=3; IntAct=EBI-366083, EBI-539478;
CC       P04637; P63165: SUMO1; NbExp=3; IntAct=EBI-366083, EBI-80140;
CC       P04637; Q86TM6: SYVN1; NbExp=5; IntAct=EBI-366083, EBI-947849;
CC       P04637; P20226: TBP; NbExp=2; IntAct=EBI-366083, EBI-355371;
CC       P04637; P15884: TCF4; NbExp=2; IntAct=EBI-366083, EBI-533224;
CC       P04637; P32776: TFB1; Xeno; NbExp=7; IntAct=EBI-366083, EBI-19146;
CC       P04637; Q96GM8: TOE1; NbExp=3; IntAct=EBI-366083, EBI-717460;
CC       P04637; Q12888: TP53BP1; NbExp=6; IntAct=EBI-366083, EBI-396540;
CC       P04637; Q12888-1: TP53BP1; NbExp=17; IntAct=EBI-366083, EBI-8022649;
CC       P04637; Q13625: TP53BP2; NbExp=9; IntAct=EBI-366083, EBI-77642;
CC       P04637; Q9H3D4: TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775;
CC       P04637; O88898: Tp63; Xeno; NbExp=2; IntAct=EBI-366083, EBI-2338025;
CC       P04637; P13693: TPT1; NbExp=7; IntAct=EBI-366083, EBI-1783169;
CC       P04637; O15164: TRIM24; NbExp=3; IntAct=EBI-366083, EBI-2130378;
CC       P04637; Q15672: TWIST1; NbExp=10; IntAct=EBI-366083, EBI-1797287;
CC       P04637; P26687: Twist1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-6123119;
CC       P04637; P0CG48: UBC; NbExp=15; IntAct=EBI-366083, EBI-3390054;
CC       P04637; P63279: UBE2I; NbExp=3; IntAct=EBI-366083, EBI-80168;
CC       P04637; Q05086: UBE3A; NbExp=6; IntAct=EBI-366083, EBI-954357;
CC       P04637; Q96PU4: UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304;
CC       P04637; Q9H9J4: USP42; NbExp=2; IntAct=EBI-366083, EBI-2513638;
CC       P04637; Q9H9J4-2: USP42; NbExp=2; IntAct=EBI-366083, EBI-9118105;
CC       P04637; Q93009: USP7; NbExp=18; IntAct=EBI-366083, EBI-302474;
CC       P04637; P11473: VDR; NbExp=6; IntAct=EBI-366083, EBI-286357;
CC       P04637; Q99986: VRK1; NbExp=11; IntAct=EBI-366083, EBI-1769146;
CC       P04637; Q14191: WRN; NbExp=5; IntAct=EBI-366083, EBI-368417;
CC       P04637; Q9NZC7: WWOX; NbExp=2; IntAct=EBI-366083, EBI-4320739;
CC       P04637; O14980: XPO1; NbExp=3; IntAct=EBI-366083, EBI-355867;
CC       P04637; P12956: XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208;
CC       P04637; P61981: YWHAG; NbExp=5; IntAct=EBI-366083, EBI-359832;
CC       P04637; P63104: YWHAZ; NbExp=2; IntAct=EBI-366083, EBI-347088;
CC       P04637; Q8TAQ5: ZNF420; NbExp=4; IntAct=EBI-366083, EBI-3923307;
CC       P04637; Q9PST7: znf585b; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1782562;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15340061,
CC       ECO:0000269|PubMed:15701641, ECO:0000269|PubMed:17170702,
CC       ECO:0000269|PubMed:19011621, ECO:0000269|PubMed:22726440}. Nucleus
CC       {ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:15701641,
CC       ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17591690,
CC       ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621}. Nucleus, PML
CC       body {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724}.
CC       Endoplasmic reticulum {ECO:0000269|PubMed:17170702}. Mitochondrion
CC       matrix {ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:27323408}.
CC       Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:28842590}. Note=Interaction with BANP promotes
CC       nuclear localization (PubMed:15701641). Recruited into PML bodies
CC       together with CHEK2 (PubMed:12810724). Translocates to mitochondria
CC       upon oxidative stress (PubMed:22726440). Translocates to mitochondria
CC       in response to mitomycin C treatment (PubMed:27323408).
CC       {ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15701641,
CC       ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:27323408}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus. Cytoplasm.
CC       Note=Predominantly nuclear but localizes to the cytoplasm when
CC       expressed with isoform 4.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Note=Localized
CC       mainly in the nucleus with minor staining in the cytoplasm.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. Cytoplasm. Note=Localized
CC       in the nucleus in most cells but found in the cytoplasm in some cells.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. Cytoplasm.
CC       Note=Predominantly nuclear but translocates to the cytoplasm following
CC       cell stress.
CC   -!- SUBCELLULAR LOCATION: [Isoform 7]: Nucleus. Cytoplasm. Note=Localized
CC       mainly in the nucleus with minor staining in the cytoplasm.
CC   -!- SUBCELLULAR LOCATION: [Isoform 8]: Nucleus. Cytoplasm. Note=Localized
CC       in both nucleus and cytoplasm in most cells. In some cells, forms foci
CC       in the nucleus that are different from nucleoli.
CC   -!- SUBCELLULAR LOCATION: [Isoform 9]: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=9;
CC       Name=1; Synonyms=p53, p53alpha;
CC         IsoId=P04637-1; Sequence=Displayed;
CC       Name=2; Synonyms=I9RET, p53beta;
CC         IsoId=P04637-2; Sequence=VSP_006535, VSP_006536;
CC       Name=3; Synonyms=p53gamma;
CC         IsoId=P04637-3; Sequence=VSP_040560, VSP_040561;
CC       Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47;
CC         IsoId=P04637-4; Sequence=VSP_040832;
CC       Name=5; Synonyms=Del40-p53beta;
CC         IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536;
CC       Name=6; Synonyms=Del40-p53gamma;
CC         IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561;
CC       Name=7; Synonyms=Del133-p53, Del133-p53alpha;
CC         IsoId=P04637-7; Sequence=VSP_040833;
CC       Name=8; Synonyms=Del133-p53beta;
CC         IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536;
CC       Name=9; Synonyms=Del133-p53gamma;
CC         IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide range
CC       of normal tissues but in a tissue-dependent manner. Isoform 2 is
CC       expressed in most normal tissues but is not detected in brain, lung,
CC       prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3
CC       is expressed in most normal tissues but is not detected in lung,
CC       spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is
CC       expressed in most normal tissues but is not detected in prostate,
CC       uterus, skeletal muscle and breast. Isoform 8 is detected only in
CC       colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is
CC       expressed in most normal tissues but is not detected in brain, heart,
CC       lung, fetal liver, salivary gland, breast or intestine.
CC       {ECO:0000269|PubMed:16131611}.
CC   -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is not
CC       induced in tumor cells in response to stress.
CC       {ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:16131611}.
CC   -!- DOMAIN: The nuclear export signal acts as a transcriptional repression
CC       domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56)
CC       correspond both to 9aaTAD motifs which are transactivation domains
CC       present in a large number of yeast and animal transcription factors.
CC       {ECO:0000269|PubMed:17467953}.
CC   -!- PTM: Acetylated. Acetylation of Lys-382 by CREBBP enhances
CC       transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its
CC       ability to induce proapoptotic program and modulate cell senescence.
CC       Deacetylation by SIRT2 impairs its ability to induce transcription
CC       activation in a AKT-dependent manner. {ECO:0000269|PubMed:10656795,
CC       ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:23431171}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at
CC       Ser-9 by HIPK4 increases repression activity on BIRC5 promoter.
CC       Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in
CC       response to DNA damage, which prevents ubiquitination by MDM2.
CC       Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen species
CC       (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on Thr-55
CC       by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on
CC       Ser-33 by CDK7 in a CAK complex in response to DNA damage.
CC       Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation
CC       on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-
CC       392 following UV but not gamma irradiation. Phosphorylated on Ser-15
CC       upon ultraviolet irradiation; which is enhanced by interaction with
CC       BANP. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially
CC       thought to be mediated by STK11/LKB1 but it was later shown that it is
CC       indirect and that STK11/LKB1-dependent phosphorylation is probably
CC       mediated by downstream NUAK1 (PubMed:21317932). It is unclear whether
CC       AMP directly mediates phosphorylation at Ser-15. Phosphorylated on Thr-
CC       18 by isoform 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by
CC       isoform 2 of VRK2 results in a reduction in ubiquitination by MDM2 and
CC       an increase in acetylation by EP300. Stabilized by CDK5-mediated
CC       phosphorylation in response to genotoxic and oxidative stresses at Ser-
CC       15, Ser-33 and Ser-46, leading to accumulation of p53/TP53,
CC       particularly in the nucleus, thus inducing the transactivation of
CC       p53/TP53 target genes. Phosphorylated by DYRK2 at Ser-46 in response to
CC       genotoxic stress. Phosphorylated at Ser-315 and Ser-392 by CDK2 in
CC       response to DNA-damage. Phosphorylation at Ser-15 is required for
CC       interaction with DDX3X and gamma-tubulin (PubMed:28842590).
CC       {ECO:0000250, ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:10606744,
CC       ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10951572,
CC       ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11447225,
CC       ECO:0000269|PubMed:11546806, ECO:0000269|PubMed:11551930,
CC       ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:11740489,
CC       ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879,
CC       ECO:0000269|PubMed:15701641, ECO:0000269|PubMed:15866171,
CC       ECO:0000269|PubMed:16377624, ECO:0000269|PubMed:16704422,
CC       ECO:0000269|PubMed:1705009, ECO:0000269|PubMed:17108107,
CC       ECO:0000269|PubMed:17254968, ECO:0000269|PubMed:17349958,
CC       ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17967874,
CC       ECO:0000269|PubMed:18022393, ECO:0000269|PubMed:20041275,
CC       ECO:0000269|PubMed:20124405, ECO:0000269|PubMed:20959462,
CC       ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:2141171,
CC       ECO:0000269|PubMed:22214662, ECO:0000269|PubMed:28842590,
CC       ECO:0000269|PubMed:9372954}.
CC   -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small
CC       T antigen inhibits the dephosphorylation by the AC form of PP2A.
CC   -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied in
CC       EB-1 cell line. {ECO:0000269|PubMed:8632915}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061,
CC       PubMed:17170702, PubMed:19880522). Ubiquitinated by RFWD3, which works
CC       in cooperation with MDM2 and may catalyze the formation of short
CC       polyubiquitin chains on p53/TP53 that are not targeted to the
CC       proteasome (PubMed:10722742, PubMed:12810724, PubMed:20173098).
CC       Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to
CC       proteasomal degradation (PubMed:19536131). Deubiquitinated by USP10,
CC       leading to its stabilization (PubMed:20096447). Ubiquitinated by
CC       TRIM24, RFFL, RNF34 and RNF125, which leads to proteasomal degradation
CC       (PubMed:19556538). Ubiquitination by TOPORS induces degradation
CC       (PubMed:19473992). Deubiquitination by USP7, leading to stabilization
CC       (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2-
CC       independent manner (PubMed:15340061). Ubiquitinated by COP1, which
CC       leads to proteasomal degradation (PubMed:19837670). Ubiquitination and
CC       subsequent proteasomal degradation is negatively regulated by CCAR2
CC       (PubMed:25732823). Polyubiquitinated by C10orf90/FATS,
CC       polyubiquitination is 'Lys-48'-linkage independent and non-proteolytic,
CC       leading to TP53 stabilization (By similarity).
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000269|PubMed:10722742,
CC       ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15053880,
CC       ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17170702,
CC       ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19473992,
CC       ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:19556538,
CC       ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19880522,
CC       ECO:0000269|PubMed:20096447, ECO:0000269|PubMed:20173098,
CC       ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:25732823}.
CC   -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization and
CC       increased transcriptional activation (PubMed:15525938,
CC       PubMed:16415881). Monomethylated at Lys-370 by SMYD2, leading to
CC       decreased DNA-binding activity and subsequent transcriptional
CC       regulation activity (PubMed:17108971). Lys-372 monomethylation prevents
CC       interaction with SMYD2 and subsequent monomethylation at Lys-370
CC       (PubMed:17108971). Dimethylated at Lys-373 by EHMT1 and EHMT2
CC       (PubMed:20118233). Monomethylated at Lys-382 by KMT5A, promoting
CC       interaction with L3MBTL1 and leading to repress transcriptional
CC       activity (PubMed:17707234). Dimethylation at Lys-370 and Lys-382
CC       diminishes p53 ubiquitination, through stabilizing association with the
CC       methyl reader PHF20 (PubMed:22864287). Demethylation of dimethylated
CC       Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-
CC       mediated transcriptional activation (PubMed:17805299). Monomethylated
CC       at Arg-333 and dimethylated at Arg-335 and Arg-337 by PRMT5;
CC       methylation is increased after DNA damage and might possibly affect
CC       TP53 target gene specificity (PubMed:19011621).
CC       {ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16415881,
CC       ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:17707234,
CC       ECO:0000269|PubMed:17805299, ECO:0000269|PubMed:19011621,
CC       ECO:0000269|PubMed:20118233, ECO:0000269|PubMed:22864287}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9.
CC       {ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662,
CC       ECO:0000269|Ref.37}.
CC   -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety of
CC       transformed cells. TP53 is frequently mutated or inactivated in about
CC       60% of cancers. TP53 defects are found in Barrett metaplasia a
CC       condition in which the normally stratified squamous epithelium of the
CC       lower esophagus is replaced by a metaplastic columnar epithelium. The
CC       condition develops as a complication in approximately 10% of patients
CC       with chronic gastroesophageal reflux disease and predisposes to the
CC       development of esophageal adenocarcinoma.
CC   -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the
CC       esophagus. The most common types are esophageal squamous cell carcinoma
CC       and adenocarcinoma. Cancer of the esophagus remains a devastating
CC       disease because it is usually not detected until it has progressed to
CC       an advanced incurable stage. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: An autosomal dominant
CC       familial cancer syndrome that in its classic form is defined by the
CC       existence of a proband affected by a sarcoma before 45 years with a
CC       first degree relative affected by any tumor before 45 years and another
CC       first degree relative with any tumor before 45 years or a sarcoma at
CC       any age. Other clinical definitions for LFS have been proposed and
CC       called Li-Fraumeni like syndrome (LFL). In these families affected
CC       relatives develop a diverse set of malignancies at unusually early
CC       ages. Four types of cancers account for 80% of tumors occurring in TP53
CC       germline mutation carriers: breast cancers, soft tissue and bone
CC       sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas.
CC       Less frequent tumors include choroid plexus carcinoma or papilloma
CC       before the age of 15, rhabdomyosarcoma before the age of 5, leukemia,
CC       Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.
CC       {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144,
CC       ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902,
CC       ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385,
CC       ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920,
CC       ECO:0000269|PubMed:9452042}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC)
CC       [MIM:275355]: A non-melanoma skin cancer affecting the head and neck.
CC       The hallmark of cutaneous SCC is malignant transformation of normal
CC       epidermal keratinocytes. Note=The gene represented in this entry is
CC       involved in disease pathogenesis.
CC   -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting
CC       tissues of the lung. The most common form of lung cancer is non-small
CC       cell lung cancer (NSCLC) that can be divided into 3 major histologic
CC       subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung
CC       cancer. NSCLC is often diagnosed at an advanced stage and has a poor
CC       prognosis. Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor
CC       of neuroectodermal origin that generally occurs in childhood, but has
CC       also been reported in adults. Although generally found within the
CC       ventricular system, choroid plexus papillomas can arise ectopically in
CC       the brain parenchyma or disseminate throughout the neuraxis. Patients
CC       present with signs and symptoms of increased intracranial pressure
CC       including headache, hydrocephalus, papilledema, nausea, vomiting,
CC       cranial nerve deficits, gait impairment, and seizures.
CC       {ECO:0000269|PubMed:12085209}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant
CC       neoplasm of the adrenal cortex and a rare childhood tumor. It occurs
CC       with increased frequency in patients with Beckwith-Wiedemann syndrome
CC       and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant
CC       skin neoplasm that typically appears on hair-bearing skin, most
CC       commonly on sun-exposed areas. It is slow growing and rarely
CC       metastasizes, but has potentialities for local invasion and
CC       destruction. It usually develops as a flat, firm, pale area that is
CC       small, raised, pink or red, translucent, shiny, and waxy, and the area
CC       may bleed following minor injury. Tumor size can vary from a few
CC       millimeters to several centimeters in diameter.
CC       {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Bone marrow failure syndrome 5 (BMFS5) [MIM:618165]: A form of
CC       bone marrow failure syndrome, a heterogeneous group of life-threatening
CC       disorders characterized by hematopoietic defects in association with a
CC       range of variable extra hematopoietic features. BMFS5 is an autosomal
CC       dominant form characterized by infantile onset of severe red cell
CC       anemia requiring transfusion. Additional features include
CC       hypogammaglobulinemia, poor growth with microcephaly, developmental
CC       delay, and seizures. {ECO:0000269|PubMed:30146126}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Expressed in quiescent lymphocytes. Seems
CC       to be non-functional. May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Expressed in quiescent lymphocytes. Seems
CC       to be non-functional. May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative promoter usage and
CC       alternative splicing. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative promoter usage and
CC       alternative splicing. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=IARC TP53 mutation database; Note=Somatic and
CC       germline TP53 mutations in human cancers;
CC       URL="http://p53.iarc.fr/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/P53ID88.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tp53/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TP53";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry;
CC       URL="https://en.wikipedia.org/wiki/P53";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=On the right track - Issue
CC       206 of August 2018;
CC       URL="https://web.expasy.org/spotlight/back_issues/206/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X02469; CAA26306.1; -; mRNA.
DR   EMBL; M13121; AAA59987.1; -; Genomic_DNA.
DR   EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; K03199; AAA59989.1; -; mRNA.
DR   EMBL; M14694; AAA61211.1; -; mRNA.
DR   EMBL; M14695; AAA61212.1; -; mRNA.
DR   EMBL; M22898; AAA59988.1; -; Genomic_DNA.
DR   EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; X01405; CAA25652.1; -; mRNA.
DR   EMBL; X60011; CAA42626.1; -; mRNA.
DR   EMBL; X60012; CAA42627.1; ALT_TERM; mRNA.
DR   EMBL; X60013; CAA42628.1; -; mRNA.
DR   EMBL; X60014; CAA42629.1; -; mRNA.
DR   EMBL; X60015; CAA42630.1; -; mRNA.
DR   EMBL; X60016; CAA42631.1; -; mRNA.
DR   EMBL; X60017; CAA42632.1; -; mRNA.
DR   EMBL; X60018; CAA42633.1; -; mRNA.
DR   EMBL; X60019; CAA42634.1; -; mRNA.
DR   EMBL; X60020; CAA42635.1; -; mRNA.
DR   EMBL; AF307851; AAG28785.1; -; mRNA.
DR   EMBL; DQ186648; ABA29753.1; -; mRNA.
DR   EMBL; DQ186649; ABA29754.1; -; mRNA.
DR   EMBL; DQ186650; ABA29755.1; -; mRNA.
DR   EMBL; DQ186651; ABA29756.1; -; mRNA.
DR   EMBL; DQ186652; ABA29757.1; -; mRNA.
DR   EMBL; DQ191317; ABB80262.1; -; mRNA.
DR   EMBL; DQ286964; ABB80266.1; -; mRNA.
DR   EMBL; X54156; CAA38095.1; -; Genomic_DNA.
DR   EMBL; U94788; AAC12971.1; -; Genomic_DNA.
DR   EMBL; AY838896; AAV80424.1; -; Genomic_DNA.
DR   EMBL; AF135121; AAD28535.1; -; Genomic_DNA.
DR   EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA.
DR   EMBL; AF136271; AAD28628.1; -; Genomic_DNA.
DR   EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA.
DR   EMBL; AB082923; BAC16799.1; -; mRNA.
DR   EMBL; AK312568; BAG35463.1; -; mRNA.
DR   EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW90143.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90144.1; -; Genomic_DNA.
DR   EMBL; BC003596; AAH03596.1; -; mRNA.
DR   EMBL; AY429684; AAR10356.1; -; mRNA.
DR   EMBL; AY390341; AAQ90158.1; -; Genomic_DNA.
DR   EMBL; AY359814; AAR13239.1; -; Genomic_DNA.
DR   EMBL; U63714; AAB39322.1; -; Genomic_DNA.
DR   EMBL; AF209136; AAF36362.1; -; Genomic_DNA.
DR   EMBL; AF209128; AAF36354.1; -; Genomic_DNA.
DR   EMBL; AF209129; AAF36355.1; -; Genomic_DNA.
DR   EMBL; AF209130; AAF36356.1; -; Genomic_DNA.
DR   EMBL; AF209131; AAF36357.1; -; Genomic_DNA.
DR   EMBL; AF209132; AAF36358.1; -; Genomic_DNA.
DR   EMBL; AF209133; AAF36359.1; -; Genomic_DNA.
DR   EMBL; AF209134; AAF36360.1; -; Genomic_DNA.
DR   EMBL; AF209135; AAF36361.1; -; Genomic_DNA.
DR   EMBL; AF209148; AAF36374.1; -; Genomic_DNA.
DR   EMBL; AF209149; AAF36375.1; -; Genomic_DNA.
DR   EMBL; AF209150; AAF36376.1; -; Genomic_DNA.
DR   EMBL; AF209151; AAF36377.1; -; Genomic_DNA.
DR   EMBL; AF209152; AAF36378.1; -; Genomic_DNA.
DR   EMBL; AF209153; AAF36379.1; -; Genomic_DNA.
DR   EMBL; AF209154; AAF36380.1; -; Genomic_DNA.
DR   EMBL; AF209155; AAF36381.1; -; Genomic_DNA.
DR   EMBL; AF209156; AAF36382.1; -; Genomic_DNA.
DR   EMBL; AF210309; AAF63442.1; -; Genomic_DNA.
DR   EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA.
DR   EMBL; AF210310; AAF63443.1; -; Genomic_DNA.
DR   EMBL; AF240684; AAK76358.1; -; Genomic_DNA.
DR   EMBL; AF240685; AAK76359.1; -; Genomic_DNA.
DR   EMBL; AY270155; AAP30003.1; -; Genomic_DNA.
DR   CCDS; CCDS11118.1; -. [P04637-1]
DR   CCDS; CCDS45605.1; -. [P04637-3]
DR   CCDS; CCDS45606.1; -. [P04637-2]
DR   CCDS; CCDS73966.1; -. [P04637-7]
DR   CCDS; CCDS73967.1; -. [P04637-9]
DR   CCDS; CCDS73968.1; -. [P04637-8]
DR   CCDS; CCDS73969.1; -. [P04637-4]
DR   CCDS; CCDS73970.1; -. [P04637-6]
DR   CCDS; CCDS73971.1; -. [P04637-5]
DR   PIR; A25224; DNHU53.
DR   RefSeq; NP_000537.3; NM_000546.5. [P04637-1]
DR   RefSeq; NP_001119584.1; NM_001126112.2. [P04637-1]
DR   RefSeq; NP_001119585.1; NM_001126113.2. [P04637-3]
DR   RefSeq; NP_001119586.1; NM_001126114.2. [P04637-2]
DR   RefSeq; NP_001119587.1; NM_001126115.1. [P04637-7]
DR   RefSeq; NP_001119588.1; NM_001126116.1. [P04637-8]
DR   RefSeq; NP_001119589.1; NM_001126117.1. [P04637-9]
DR   RefSeq; NP_001119590.1; NM_001126118.1. [P04637-4]
DR   RefSeq; NP_001263624.1; NM_001276695.1. [P04637-6]
DR   RefSeq; NP_001263625.1; NM_001276696.1. [P04637-5]
DR   RefSeq; NP_001263626.1; NM_001276697.1.
DR   RefSeq; NP_001263627.1; NM_001276698.1.
DR   RefSeq; NP_001263628.1; NM_001276699.1.
DR   RefSeq; NP_001263689.1; NM_001276760.1. [P04637-4]
DR   RefSeq; NP_001263690.1; NM_001276761.1. [P04637-4]
DR   PDB; 1A1U; NMR; -; A/C=324-358.
DR   PDB; 1AIE; X-ray; 1.50 A; A=326-356.
DR   PDB; 1C26; X-ray; 1.70 A; A=325-356.
DR   PDB; 1DT7; NMR; -; X/Y=367-388.
DR   PDB; 1GZH; X-ray; 2.60 A; A/C=95-292.
DR   PDB; 1H26; X-ray; 2.24 A; E=376-386.
DR   PDB; 1HS5; NMR; -; A/B=324-357.
DR   PDB; 1JSP; NMR; -; A=367-386.
DR   PDB; 1KZY; X-ray; 2.50 A; A/B=95-289.
DR   PDB; 1MA3; X-ray; 2.00 A; B=372-389.
DR   PDB; 1OLG; NMR; -; A/B/C/D=319-360.
DR   PDB; 1OLH; NMR; -; A/B/C/D=319-360.
DR   PDB; 1PES; NMR; -; A/B/C/D=325-355.
DR   PDB; 1PET; NMR; -; A/B/C/D=325-355.
DR   PDB; 1SAE; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAF; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAK; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAL; NMR; -; A/B/C/D=319-360.
DR   PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312.
DR   PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312.
DR   PDB; 1UOL; X-ray; 1.90 A; A/B=94-312.
DR   PDB; 1XQH; X-ray; 1.75 A; B/F=369-377.
DR   PDB; 1YC5; X-ray; 1.40 A; B=372-389.
DR   PDB; 1YCQ; X-ray; 2.30 A; B=13-29.
DR   PDB; 1YCR; X-ray; 2.60 A; B=15-29.
DR   PDB; 1YCS; X-ray; 2.20 A; A=94-292.
DR   PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 2ADY; X-ray; 2.50 A; A/B=94-293.
DR   PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293.
DR   PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293.
DR   PDB; 2B3G; X-ray; 1.60 A; B=33-60.
DR   PDB; 2BIM; X-ray; 1.98 A; A/B=94-312.
DR   PDB; 2BIN; X-ray; 1.90 A; A=94-312.
DR   PDB; 2BIO; X-ray; 1.90 A; A=94-312.
DR   PDB; 2BIP; X-ray; 1.80 A; A=94-312.
DR   PDB; 2BIQ; X-ray; 1.80 A; A=94-312.
DR   PDB; 2F1X; X-ray; 2.30 A; A/B=359-368.
DR   PDB; 2FEJ; NMR; -; A=94-297.
DR   PDB; 2FOJ; X-ray; 1.60 A; B=361-367.
DR   PDB; 2FOO; X-ray; 2.20 A; B=358-363.
DR   PDB; 2GS0; NMR; -; B=20-73.
DR   PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292.
DR   PDB; 2H2D; X-ray; 1.70 A; B=372-389.
DR   PDB; 2H2F; X-ray; 2.20 A; B=372-389.
DR   PDB; 2H4F; X-ray; 2.00 A; D=372-389.
DR   PDB; 2H4H; X-ray; 1.99 A; B=372-389.
DR   PDB; 2H4J; X-ray; 2.10 A; D=372-389.
DR   PDB; 2H59; X-ray; 1.90 A; D/E=372-389.
DR   PDB; 2J0Z; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J10; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J11; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J1W; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J1X; X-ray; 1.65 A; A/B=94-312.
DR   PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293.
DR   PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J20; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J21; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 2K8F; NMR; -; B=1-39.
DR   PDB; 2L14; NMR; -; B=13-61.
DR   PDB; 2LY4; NMR; -; B=1-93.
DR   PDB; 2MEJ; NMR; -; B=96-312.
DR   PDB; 2MWO; NMR; -; B=363-377.
DR   PDB; 2MWP; NMR; -; B=376-387.
DR   PDB; 2MWY; NMR; -; B=15-29.
DR   PDB; 2MZD; NMR; -; B=35-59.
DR   PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312.
DR   PDB; 2PCX; X-ray; 1.54 A; A=94-292.
DR   PDB; 2RUK; NMR; -; A=41-62.
DR   PDB; 2VUK; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 2WGX; X-ray; 1.75 A; A/B=94-312.
DR   PDB; 2X0U; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 2X0V; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2X0W; X-ray; 2.10 A; A/B=94-312.
DR   PDB; 2XWR; X-ray; 1.68 A; A/B=89-293.
DR   PDB; 2YBG; X-ray; 1.90 A; A/B/C/D=94-293.
DR   PDB; 2YDR; X-ray; 2.75 A; P=144-154.
DR   PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29.
DR   PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29.
DR   PDB; 3D05; X-ray; 1.70 A; A=94-293.
DR   PDB; 3D06; X-ray; 1.20 A; A=94-293.
DR   PDB; 3D07; X-ray; 2.20 A; A/B=94-293.
DR   PDB; 3D08; X-ray; 1.40 A; A=94-293.
DR   PDB; 3D09; X-ray; 1.90 A; A=94-293.
DR   PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29.
DR   PDB; 3DAC; X-ray; 1.80 A; B/P=17-37.
DR   PDB; 3IGK; X-ray; 1.70 A; A=94-293.
DR   PDB; 3IGL; X-ray; 1.80 A; A=94-293.
DR   PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291.
DR   PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293.
DR   PDB; 3LW1; X-ray; 1.28 A; P=385-393.
DR   PDB; 3OQ5; X-ray; 2.50 A; D/E=377-386.
DR   PDB; 3PDH; X-ray; 1.80 A; D=372-389.
DR   PDB; 3Q01; X-ray; 2.10 A; A/B=94-356.
DR   PDB; 3Q05; X-ray; 2.40 A; A/B/C/D=94-356.
DR   PDB; 3Q06; X-ray; 3.20 A; A/B/C/D=96-354.
DR   PDB; 3SAK; NMR; -; A/B/C/D=319-360.
DR   PDB; 3TG5; X-ray; 2.30 A; B=365-375.
DR   PDB; 3TS8; X-ray; 2.80 A; A/B/C/D=94-356.
DR   PDB; 3ZME; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 4AGL; X-ray; 1.70 A; A/B=94-312.
DR   PDB; 4AGM; X-ray; 1.52 A; A/B=94-312.
DR   PDB; 4AGN; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 4AGO; X-ray; 1.45 A; A/B=94-312.
DR   PDB; 4AGP; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 4AGQ; X-ray; 1.42 A; A/B=94-312.
DR   PDB; 4BUZ; X-ray; 1.90 A; P=379-386.
DR   PDB; 4BV2; X-ray; 3.30 A; E/H=376-388.
DR   PDB; 4HFZ; X-ray; 2.69 A; B/D=15-29.
DR   PDB; 4HJE; X-ray; 1.91 A; A/B/C/D=92-291.
DR   PDB; 4IBQ; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 4IBS; X-ray; 1.78 A; A/B/C/D=94-293.
DR   PDB; 4IBT; X-ray; 1.70 A; A/B/C/D=94-293.
DR   PDB; 4IBU; X-ray; 1.70 A; A/B/C/D=94-293.
DR   PDB; 4IBV; X-ray; 2.10 A; A=94-293.
DR   PDB; 4IBW; X-ray; 1.79 A; A=94-293.
DR   PDB; 4IBY; X-ray; 1.45 A; A/B=94-293.
DR   PDB; 4IBZ; X-ray; 1.92 A; A/B/C/D=94-293.
DR   PDB; 4IJT; X-ray; 1.78 A; A=94-293.
DR   PDB; 4KVP; X-ray; 1.50 A; A/B/C/D=94-312.
DR   PDB; 4LO9; X-ray; 2.50 A; A/B/C/D=94-312.
DR   PDB; 4LOE; X-ray; 1.85 A; A/B/C/D=94-312.
DR   PDB; 4LOF; X-ray; 2.00 A; A=94-312.
DR   PDB; 4MZI; X-ray; 1.25 A; A=94-292.
DR   PDB; 4MZR; X-ray; 2.90 A; A/B/C/D=94-358.
DR   PDB; 4QO1; X-ray; 1.92 A; B=92-312.
DR   PDB; 4RP6; X-ray; 1.70 A; Z=252-258.
DR   PDB; 4RP7; X-ray; 1.58 A; Z=253-258.
DR   PDB; 4X34; X-ray; 1.80 A; C/D=377-386.
DR   PDB; 4XR8; X-ray; 2.25 A; C/D=94-292.
DR   PDB; 4ZZJ; X-ray; 2.74 A; B=379-383.
DR   PDB; 5A7B; X-ray; 1.40 A; A/B=94-312.
DR   PDB; 5AB9; X-ray; 1.36 A; A/B=94-312.
DR   PDB; 5ABA; X-ray; 1.62 A; A/B=94-312.
DR   PDB; 5AOI; X-ray; 1.78 A; A/B=94-312.
DR   PDB; 5AOJ; X-ray; 1.47 A; A/B=94-312.
DR   PDB; 5AOK; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 5AOL; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 5AOM; X-ray; 1.74 A; A/B=94-312.
DR   PDB; 5BUA; X-ray; 1.81 A; A=94-293.
DR   PDB; 5ECG; X-ray; 3.00 A; A/B=95-312.
DR   PDB; 5G4M; X-ray; 1.38 A; A/B=94-312.
DR   PDB; 5G4N; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 5G4O; X-ray; 1.48 A; A/B=94-312.
DR   PDB; 5HOU; NMR; -; A=1-61.
DR   PDB; 5HP0; NMR; -; A=37-61.
DR   PDB; 5HPD; NMR; -; A=2-61.
DR   PDB; 5LAP; X-ray; 1.42 A; A/B=94-312.
DR   PDB; 5LGY; X-ray; 2.92 A; A/B/C/D=94-291.
DR   PDB; 5MCT; X-ray; 1.45 A; A/B=94-293.
DR   PDB; 5MCU; X-ray; 1.70 A; A/B=94-293.
DR   PDB; 5MCV; X-ray; 1.60 A; A/B=94-293.
DR   PDB; 5MCW; X-ray; 1.90 A; A/B=94-293.
DR   PDB; 5MF7; X-ray; 1.59 A; A/B=94-293.
DR   PDB; 5MG7; X-ray; 1.45 A; A/B=94-293.
DR   PDB; 5MHC; X-ray; 1.20 A; P=382-393.
DR   PDB; 5MOC; X-ray; 1.80 A; P=382-393.
DR   PDB; 5O1A; X-ray; 1.44 A; A/B=94-312.
DR   PDB; 5O1B; X-ray; 1.43 A; A/B=94-312.
DR   PDB; 5O1C; X-ray; 1.32 A; A/B=94-312.
DR   PDB; 5O1D; X-ray; 1.36 A; A/B=94-312.
DR   PDB; 5O1E; X-ray; 1.30 A; A/B=94-312.
DR   PDB; 5O1F; X-ray; 1.38 A; A/B=94-312.
DR   PDB; 5O1G; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 5O1H; X-ray; 1.32 A; A/B=94-312.
DR   PDB; 5O1I; X-ray; 1.40 A; A/B=94-312.
DR   PDB; 5OL0; X-ray; 1.99 A; C/D=372-389.
DR   PDB; 5UN8; X-ray; 2.13 A; E/F/G/H=144-154.
DR   PDB; 5XZC; EM; 10.70 A; B/C/D/E=92-356.
DR   PDB; 6FF9; X-ray; 2.00 A; A/B/C/D=97-289.
DR   PDB; 6FJ5; X-ray; 2.05 A; A/B/C/D=94-293.
DR   PDB; 6GGA; X-ray; 1.55 A; A/B=94-312.
DR   PDB; 6GGB; X-ray; 1.32 A; A/B=94-312.
DR   PDB; 6GGC; X-ray; 1.24 A; A/B=94-312.
DR   PDB; 6GGD; X-ray; 1.40 A; A/B=94-312.
DR   PDB; 6GGE; X-ray; 1.25 A; A/B=94-312.
DR   PDB; 6GGF; X-ray; 1.32 A; A/B=94-312.
DR   PDB; 6RZ3; X-ray; 4.23 A; A=62-292.
DR   PDBsum; 1A1U; -.
DR   PDBsum; 1AIE; -.
DR   PDBsum; 1C26; -.
DR   PDBsum; 1DT7; -.
DR   PDBsum; 1GZH; -.
DR   PDBsum; 1H26; -.
DR   PDBsum; 1HS5; -.
DR   PDBsum; 1JSP; -.
DR   PDBsum; 1KZY; -.
DR   PDBsum; 1MA3; -.
DR   PDBsum; 1OLG; -.
DR   PDBsum; 1OLH; -.
DR   PDBsum; 1PES; -.
DR   PDBsum; 1PET; -.
DR   PDBsum; 1SAE; -.
DR   PDBsum; 1SAF; -.
DR   PDBsum; 1SAK; -.
DR   PDBsum; 1SAL; -.
DR   PDBsum; 1TSR; -.
DR   PDBsum; 1TUP; -.
DR   PDBsum; 1UOL; -.
DR   PDBsum; 1XQH; -.
DR   PDBsum; 1YC5; -.
DR   PDBsum; 1YCQ; -.
DR   PDBsum; 1YCR; -.
DR   PDBsum; 1YCS; -.
DR   PDBsum; 2AC0; -.
DR   PDBsum; 2ADY; -.
DR   PDBsum; 2AHI; -.
DR   PDBsum; 2ATA; -.
DR   PDBsum; 2B3G; -.
DR   PDBsum; 2BIM; -.
DR   PDBsum; 2BIN; -.
DR   PDBsum; 2BIO; -.
DR   PDBsum; 2BIP; -.
DR   PDBsum; 2BIQ; -.
DR   PDBsum; 2F1X; -.
DR   PDBsum; 2FEJ; -.
DR   PDBsum; 2FOJ; -.
DR   PDBsum; 2FOO; -.
DR   PDBsum; 2GS0; -.
DR   PDBsum; 2H1L; -.
DR   PDBsum; 2H2D; -.
DR   PDBsum; 2H2F; -.
DR   PDBsum; 2H4F; -.
DR   PDBsum; 2H4H; -.
DR   PDBsum; 2H4J; -.
DR   PDBsum; 2H59; -.
DR   PDBsum; 2J0Z; -.
DR   PDBsum; 2J10; -.
DR   PDBsum; 2J11; -.
DR   PDBsum; 2J1W; -.
DR   PDBsum; 2J1X; -.
DR   PDBsum; 2J1Y; -.
DR   PDBsum; 2J1Z; -.
DR   PDBsum; 2J20; -.
DR   PDBsum; 2J21; -.
DR   PDBsum; 2K8F; -.
DR   PDBsum; 2L14; -.
DR   PDBsum; 2LY4; -.
DR   PDBsum; 2MEJ; -.
DR   PDBsum; 2MWO; -.
DR   PDBsum; 2MWP; -.
DR   PDBsum; 2MWY; -.
DR   PDBsum; 2MZD; -.
DR   PDBsum; 2OCJ; -.
DR   PDBsum; 2PCX; -.
DR   PDBsum; 2RUK; -.
DR   PDBsum; 2VUK; -.
DR   PDBsum; 2WGX; -.
DR   PDBsum; 2X0U; -.
DR   PDBsum; 2X0V; -.
DR   PDBsum; 2X0W; -.
DR   PDBsum; 2XWR; -.
DR   PDBsum; 2YBG; -.
DR   PDBsum; 2YDR; -.
DR   PDBsum; 2Z5S; -.
DR   PDBsum; 2Z5T; -.
DR   PDBsum; 3D05; -.
DR   PDBsum; 3D06; -.
DR   PDBsum; 3D07; -.
DR   PDBsum; 3D08; -.
DR   PDBsum; 3D09; -.
DR   PDBsum; 3D0A; -.
DR   PDBsum; 3DAB; -.
DR   PDBsum; 3DAC; -.
DR   PDBsum; 3IGK; -.
DR   PDBsum; 3IGL; -.
DR   PDBsum; 3KMD; -.
DR   PDBsum; 3KZ8; -.
DR   PDBsum; 3LW1; -.
DR   PDBsum; 3OQ5; -.
DR   PDBsum; 3PDH; -.
DR   PDBsum; 3Q01; -.
DR   PDBsum; 3Q05; -.
DR   PDBsum; 3Q06; -.
DR   PDBsum; 3SAK; -.
DR   PDBsum; 3TG5; -.
DR   PDBsum; 3TS8; -.
DR   PDBsum; 3ZME; -.
DR   PDBsum; 4AGL; -.
DR   PDBsum; 4AGM; -.
DR   PDBsum; 4AGN; -.
DR   PDBsum; 4AGO; -.
DR   PDBsum; 4AGP; -.
DR   PDBsum; 4AGQ; -.
DR   PDBsum; 4BUZ; -.
DR   PDBsum; 4BV2; -.
DR   PDBsum; 4HFZ; -.
DR   PDBsum; 4HJE; -.
DR   PDBsum; 4IBQ; -.
DR   PDBsum; 4IBS; -.
DR   PDBsum; 4IBT; -.
DR   PDBsum; 4IBU; -.
DR   PDBsum; 4IBV; -.
DR   PDBsum; 4IBW; -.
DR   PDBsum; 4IBY; -.
DR   PDBsum; 4IBZ; -.
DR   PDBsum; 4IJT; -.
DR   PDBsum; 4KVP; -.
DR   PDBsum; 4LO9; -.
DR   PDBsum; 4LOE; -.
DR   PDBsum; 4LOF; -.
DR   PDBsum; 4MZI; -.
DR   PDBsum; 4MZR; -.
DR   PDBsum; 4QO1; -.
DR   PDBsum; 4RP6; -.
DR   PDBsum; 4RP7; -.
DR   PDBsum; 4X34; -.
DR   PDBsum; 4XR8; -.
DR   PDBsum; 4ZZJ; -.
DR   PDBsum; 5A7B; -.
DR   PDBsum; 5AB9; -.
DR   PDBsum; 5ABA; -.
DR   PDBsum; 5AOI; -.
DR   PDBsum; 5AOJ; -.
DR   PDBsum; 5AOK; -.
DR   PDBsum; 5AOL; -.
DR   PDBsum; 5AOM; -.
DR   PDBsum; 5BUA; -.
DR   PDBsum; 5ECG; -.
DR   PDBsum; 5G4M; -.
DR   PDBsum; 5G4N; -.
DR   PDBsum; 5G4O; -.
DR   PDBsum; 5HOU; -.
DR   PDBsum; 5HP0; -.
DR   PDBsum; 5HPD; -.
DR   PDBsum; 5LAP; -.
DR   PDBsum; 5LGY; -.
DR   PDBsum; 5MCT; -.
DR   PDBsum; 5MCU; -.
DR   PDBsum; 5MCV; -.
DR   PDBsum; 5MCW; -.
DR   PDBsum; 5MF7; -.
DR   PDBsum; 5MG7; -.
DR   PDBsum; 5MHC; -.
DR   PDBsum; 5MOC; -.
DR   PDBsum; 5O1A; -.
DR   PDBsum; 5O1B; -.
DR   PDBsum; 5O1C; -.
DR   PDBsum; 5O1D; -.
DR   PDBsum; 5O1E; -.
DR   PDBsum; 5O1F; -.
DR   PDBsum; 5O1G; -.
DR   PDBsum; 5O1H; -.
DR   PDBsum; 5O1I; -.
DR   PDBsum; 5OL0; -.
DR   PDBsum; 5UN8; -.
DR   PDBsum; 5XZC; -.
DR   PDBsum; 6FF9; -.
DR   PDBsum; 6FJ5; -.
DR   PDBsum; 6GGA; -.
DR   PDBsum; 6GGB; -.
DR   PDBsum; 6GGC; -.
DR   PDBsum; 6GGD; -.
DR   PDBsum; 6GGE; -.
DR   PDBsum; 6GGF; -.
DR   PDBsum; 6RZ3; -.
DR   SMR; P04637; -.
DR   BioGrid; 113010; 1174.
DR   CORUM; P04637; -.
DR   DIP; DIP-368N; -.
DR   ELM; P04637; -.
DR   IntAct; P04637; 487.
DR   MINT; P04637; -.
DR   STRING; 9606.ENSP00000269305; -.
DR   BindingDB; P04637; -.
DR   ChEMBL; CHEMBL4096; -.
DR   DrugBank; DB08363; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB05404; AZD 3355.
DR   DrugBank; DB03347; Triethyl Phosphate.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   MoonDB; P04637; Predicted.
DR   TCDB; 1.C.110.1.1; the pore-forming pnc-27 peptide of 32 aas from the p53 tumor suppressor protein (pnc-27) family.
DR   iPTMnet; P04637; -.
DR   MetOSite; P04637; -.
DR   PhosphoSitePlus; P04637; -.
DR   BioMuta; TP53; -.
DR   DMDM; 269849759; -.
DR   SWISS-2DPAGE; P04637; -.
DR   CPTAC; CPTAC-951; -.
DR   EPD; P04637; -.
DR   jPOST; P04637; -.
DR   MassIVE; P04637; -.
DR   MaxQB; P04637; -.
DR   PaxDb; P04637; -.
DR   PeptideAtlas; P04637; -.
DR   PRIDE; P04637; -.
DR   ProteomicsDB; 51728; -. [P04637-1]
DR   ProteomicsDB; 51729; -. [P04637-2]
DR   ProteomicsDB; 51730; -. [P04637-3]
DR   ProteomicsDB; 51731; -. [P04637-4]
DR   ProteomicsDB; 51732; -. [P04637-5]
DR   ProteomicsDB; 51733; -. [P04637-6]
DR   ProteomicsDB; 51734; -. [P04637-7]
DR   ProteomicsDB; 51735; -. [P04637-8]
DR   ProteomicsDB; 51736; -. [P04637-9]
DR   ABCD; P04637; -.
DR   Antibodypedia; 3525; 8810 antibodies.
DR   DNASU; 7157; -.
DR   Ensembl; ENST00000269305; ENSP00000269305; ENSG00000141510. [P04637-1]
DR   Ensembl; ENST00000420246; ENSP00000391127; ENSG00000141510. [P04637-2]
DR   Ensembl; ENST00000445888; ENSP00000391478; ENSG00000141510. [P04637-1]
DR   Ensembl; ENST00000455263; ENSP00000398846; ENSG00000141510. [P04637-3]
DR   Ensembl; ENST00000504290; ENSP00000484409; ENSG00000141510. [P04637-9]
DR   Ensembl; ENST00000504937; ENSP00000481179; ENSG00000141510. [P04637-7]
DR   Ensembl; ENST00000510385; ENSP00000478499; ENSG00000141510. [P04637-8]
DR   Ensembl; ENST00000610292; ENSP00000478219; ENSG00000141510. [P04637-4]
DR   Ensembl; ENST00000610538; ENSP00000480868; ENSG00000141510. [P04637-6]
DR   Ensembl; ENST00000617185; ENSP00000482258; ENSG00000141510. [P04637-2]
DR   Ensembl; ENST00000619485; ENSP00000482537; ENSG00000141510. [P04637-4]
DR   Ensembl; ENST00000620739; ENSP00000481638; ENSG00000141510. [P04637-4]
DR   Ensembl; ENST00000622645; ENSP00000482222; ENSG00000141510. [P04637-5]
DR   GeneID; 7157; -.
DR   KEGG; hsa:7157; -.
DR   UCSC; uc002gij.4; human. [P04637-1]
DR   CTD; 7157; -.
DR   DisGeNET; 7157; -.
DR   GeneCards; TP53; -.
DR   GeneReviews; TP53; -.
DR   HGNC; HGNC:11998; TP53.
DR   HPA; ENSG00000141510; Tissue enhanced (lymphoid).
DR   MalaCards; TP53; -.
DR   MIM; 133239; phenotype.
DR   MIM; 151623; phenotype.
DR   MIM; 191170; gene+phenotype.
DR   MIM; 202300; phenotype.
DR   MIM; 211980; phenotype.
DR   MIM; 260500; phenotype.
DR   MIM; 275355; phenotype.
DR   MIM; 614740; phenotype.
DR   MIM; 618165; phenotype.
DR   neXtProt; NX_P04637; -.
DR   OpenTargets; ENSG00000141510; -.
DR   Orphanet; 1501; Adrenocortical carcinoma.
DR   Orphanet; 210159; Adult hepatocellular carcinoma.
DR   Orphanet; 67038; B-cell chronic lymphocytic leukemia.
DR   Orphanet; 251899; Choroid plexus carcinoma.
DR   Orphanet; 3318; Essential thrombocythemia.
DR   Orphanet; 1333; Familial pancreatic carcinoma.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 145; Hereditary breast and ovarian cancer syndrome.
DR   Orphanet; 524; Li-Fraumeni syndrome.
DR   Orphanet; 668; Osteosarcoma.
DR   Orphanet; 2807; Papilloma of choroid plexus.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   Orphanet; 70573; Small cell lung cancer.
DR   PharmGKB; PA36679; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00950000183153; -.
DR   InParanoid; P04637; -.
DR   KO; K04451; -.
DR   OMA; FHKKGEP; -.
DR   OrthoDB; 233858at2759; -.
DR   PhylomeDB; P04637; -.
DR   TreeFam; TF106101; -.
DR   Reactome; R-HSA-111448; Activation of NOXA and translocation to mitochondria.
DR   Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF).
DR   Reactome; R-HSA-2559585; Oncogene Induced Senescence.
DR   Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1.
DR   Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain.
DR   Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases.
DR   Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands.
DR   Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest.
DR   Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain.
DR   Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest.
DR   Reactome; R-HSA-6804754; Regulation of TP53 Expression.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-HSA-69481; G2/M Checkpoints.
DR   Reactome; R-HSA-69541; Stabilization of p53.
DR   Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21.
DR   Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint.
DR   Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX.
DR   Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription.
DR   Reactome; R-HSA-8943724; Regulation of PTEN gene transcription.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SABIO-RK; P04637; -.
DR   SignaLink; P04637; -.
DR   SIGNOR; P04637; -.
DR   ChiTaRS; TP53; human.
DR   EvolutionaryTrace; P04637; -.
DR   GeneWiki; P53; -.
DR   GenomeRNAi; 7157; -.
DR   Pharos; P04637; Tchem.
DR   PRO; PR:P04637; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P04637; protein.
DR   Bgee; ENSG00000141510; Expressed in epithelium of mammary gland and 169 other tissues.
DR   ExpressionAtlas; P04637; baseline and differential.
DR   Genevisible; P04637; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:CAFA.
DR   GO; GO:0005657; C:replication fork; IEA:Ensembl.
DR   GO; GO:0035861; C:site of double-strand break; IEA:Ensembl.
DR   GO; GO:0005667; C:transcription factor complex; IGI:ARUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0051087; F:chaperone binding; IPI:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; IDA:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA.
DR   GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:ARUK-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:CAFA.
DR   GO; GO:0035033; F:histone deacetylase regulator activity; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl.
DR   GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:CAFA.
DR   GO; GO:0002039; F:p53 binding; IPI:CAFA.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IPI:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IPI:AgBase.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0001094; F:TFIID-class transcription factor complex binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IMP:CAFA.
DR   GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0048539; P:bone marrow development; IMP:UniProtKB.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; IEA:Ensembl.
DR   GO; GO:0007569; P:cell aging; IMP:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0034613; P:cellular protein localization; IDA:UniProtKB.
DR   GO; GO:0072717; P:cellular response to actinomycin D; IDA:CAFA.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; IEP:UniProtKB.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL.
DR   GO; GO:0034644; P:cellular response to UV; IDA:CAFA.
DR   GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl.
DR   GO; GO:0021549; P:cerebellum development; IEA:Ensembl.
DR   GO; GO:0031497; P:chromatin assembly; IDA:UniProtKB.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IMP:CAFA.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IDA:CAFA.
DR   GO; GO:0000733; P:DNA strand renaturation; IDA:UniProtKB.
DR   GO; GO:0006302; P:double-strand break repair; IEA:Ensembl.
DR   GO; GO:0048568; P:embryonic organ development; IEA:Ensembl.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; IDA:MGI.
DR   GO; GO:0007369; P:gastrulation; IEA:Ensembl.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:UniProtKB.
DR   GO; GO:0060218; P:hematopoietic stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:HGNC-UCL.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; IEA:Ensembl.
DR   GO; GO:0043504; P:mitochondrial DNA repair; IEA:Ensembl.
DR   GO; GO:0071850; P:mitotic cell cycle arrest; IEA:Ensembl.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IMP:BHF-UCL.
DR   GO; GO:0009299; P:mRNA transcription; IMP:UniProtKB.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0070266; P:necroptotic process; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:CACAO.
DR   GO; GO:0008156; P:negative regulation of DNA replication; IEA:Ensembl.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:UniProtKB.
DR   GO; GO:1904024; P:negative regulation of glucose catabolic process to lactate via pyruvate; IEA:Ensembl.
DR   GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB.
DR   GO; GO:1901525; P:negative regulation of mitophagy; IEA:Ensembl.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:1905856; P:negative regulation of pentose-phosphate shunt; IMP:CACAO.
DR   GO; GO:1903799; P:negative regulation of production of miRNAs involved in gene silencing by miRNA; IEA:Ensembl.
DR   GO; GO:0045861; P:negative regulation of proteolysis; IEA:Ensembl.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0051974; P:negative regulation of telomerase activity; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; IDA:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0090343; P:positive regulation of cell aging; IEA:Ensembl.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IDA:CAFA.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:AgBase.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:CAFA.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IEA:Ensembl.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:1903800; P:positive regulation of production of miRNAs involved in gene silencing by miRNA; IDA:BHF-UCL.
DR   GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IEA:Ensembl.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; TAS:Reactome.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB.
DR   GO; GO:0045899; P:positive regulation of RNA polymerase II transcriptional preinitiation complex assembly; IDA:BHF-UCL.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:1990440; P:positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; IEA:Ensembl.
DR   GO; GO:0036003; P:positive regulation of transcription from RNA polymerase II promoter in response to stress; IDA:ARUK-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0008104; P:protein localization; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; IDA:MGI.
DR   GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; TAS:Reactome.
DR   GO; GO:2000772; P:regulation of cellular senescence; IEA:Ensembl.
DR   GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl.
DR   GO; GO:2000269; P:regulation of fibroblast apoptotic process; IEA:Ensembl.
DR   GO; GO:1902253; P:regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl.
DR   GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0034103; P:regulation of tissue remodeling; IEA:Ensembl.
DR   GO; GO:1990248; P:regulation of transcription from RNA polymerase II promoter in response to DNA damage; IDA:ARUK-UCL.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Ensembl.
DR   GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL.
DR   GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB.
DR   GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0009651; P:response to salt stress; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IEA:Ensembl.
DR   GO; GO:0051123; P:RNA polymerase II preinitiation complex assembly; IDA:BHF-UCL.
DR   GO; GO:0009303; P:rRNA transcription; IEA:Ensembl.
DR   GO; GO:0072331; P:signal transduction by p53 class mediator; IDA:CAFA.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0002309; P:T cell proliferation involved in immune response; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; IMP:CACAO.
DR   CDD; cd08367; P53; 1.
DR   DisProt; DP00086; -.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR040926; p53_TAD2.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF18521; TAD2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative promoter usage;
KW   Alternative splicing; Apoptosis; Biological rhythms; Cell cycle; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Disease mutation; DNA-binding;
KW   Endoplasmic reticulum; Glycoprotein; Host-virus interaction;
KW   Isopeptide bond; Li-Fraumeni syndrome; Metal-binding; Methylation;
KW   Mitochondrion; Necrosis; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repressor; Transcription; Transcription regulation;
KW   Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN           1..393
FT                   /note="Cellular tumor antigen p53"
FT                   /id="PRO_0000185703"
FT   DNA_BIND        102..292
FT   REGION          1..320
FT                   /note="Interaction with CCAR2"
FT                   /evidence="ECO:0000269|PubMed:25732823"
FT   REGION          1..83
FT                   /note="Interaction with HRMT1L2"
FT                   /evidence="ECO:0000269|PubMed:15186775"
FT   REGION          1..44
FT                   /note="Transcription activation (acidic)"
FT   REGION          66..110
FT                   /note="Interaction with WWOX"
FT   REGION          100..370
FT                   /note="Interaction with HIPK1"
FT                   /evidence="ECO:0000250"
FT   REGION          100..300
FT                   /note="Required for interaction with ZNF385A"
FT                   /evidence="ECO:0000269|PubMed:17719541"
FT   REGION          113..236
FT                   /note="Required for interaction with FBXO42"
FT                   /evidence="ECO:0000269|PubMed:19509332"
FT   REGION          116..292
FT                   /note="Interaction with AXIN1"
FT                   /evidence="ECO:0000250"
FT   REGION          241..248
FT                   /note="Interaction with the 53BP2 SH3 domain"
FT   REGION          256..294
FT                   /note="Interaction with E4F1"
FT                   /evidence="ECO:0000269|PubMed:10644996"
FT   REGION          273..280
FT                   /note="Interaction with DNA"
FT   REGION          300..393
FT                   /note="Interaction with CARM1"
FT                   /evidence="ECO:0000269|PubMed:15186775"
FT   REGION          319..360
FT                   /note="Interaction with HIPK2"
FT   REGION          325..356
FT                   /note="Oligomerization"
FT   REGION          359..363
FT                   /note="Interaction with USP7"
FT   REGION          368..387
FT                   /note="Basic (repression of DNA-binding)"
FT   MOTIF           17..25
FT                   /note="TADI"
FT   MOTIF           48..56
FT                   /note="TADII"
FT   MOTIF           305..321
FT                   /note="Bipartite nuclear localization signal"
FT   MOTIF           339..350
FT                   /note="Nuclear export signal"
FT   MOTIF           370..372
FT                   /note="[KR]-[STA]-K motif"
FT   METAL           176
FT                   /note="Zinc"
FT   METAL           179
FT                   /note="Zinc"
FT   METAL           238
FT                   /note="Zinc"
FT   METAL           242
FT                   /note="Zinc"
FT   SITE            120
FT                   /note="Interaction with DNA"
FT   MOD_RES         9
FT                   /note="Phosphoserine; by HIPK4"
FT                   /evidence="ECO:0000269|PubMed:18022393"
FT   MOD_RES         15
FT                   /note="Phosphoserine; by CDK5, PRPK, AMPK, NUAK1 and ATM"
FT                   /evidence="ECO:0000269|PubMed:10570149,
FT                   ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:15701641,
FT                   ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:17108107,
FT                   ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17967874,
FT                   ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:28842590"
FT   MOD_RES         18
FT                   /note="Phosphothreonine; by CK1, VRK1 and VRK2"
FT                   /evidence="ECO:0000269|PubMed:10606744,
FT                   ECO:0000269|PubMed:10951572, ECO:0000269|PubMed:16704422"
FT   MOD_RES         20
FT                   /note="Phosphoserine; by CHEK2, CK1 and PLK3"
FT                   /evidence="ECO:0000269|PubMed:10570149,
FT                   ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930,
FT                   ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:20041275"
FT   MOD_RES         33
FT                   /note="Phosphoserine; by CDK5 and CDK7"
FT                   /evidence="ECO:0000269|PubMed:17591690,
FT                   ECO:0000269|PubMed:9372954"
FT   MOD_RES         37
FT                   /note="Phosphoserine; by MAPKAPK5"
FT                   /evidence="ECO:0000269|PubMed:17254968"
FT   MOD_RES         46
FT                   /note="Phosphoserine; by CDK5, DYRK2, HIPK2 and PKC/PRKCG"
FT                   /evidence="ECO:0000269|PubMed:11740489,
FT                   ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:16377624,
FT                   ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690"
FT   MOD_RES         55
FT                   /note="Phosphothreonine; by TAF1 and GRK5"
FT                   /evidence="ECO:0000269|PubMed:15053879,
FT                   ECO:0000269|PubMed:20124405"
FT   MOD_RES         120
FT                   /note="N6-acetyllysine; by KAT6A"
FT                   /evidence="ECO:0000269|PubMed:23431171"
FT   MOD_RES         183
FT                   /note="Phosphoserine; by AURKB"
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MOD_RES         269
FT                   /note="Phosphoserine; by AURKB"
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MOD_RES         284
FT                   /note="Phosphothreonine; by AURKB"
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MOD_RES         305
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:12724314"
FT   MOD_RES         315
FT                   /note="Phosphoserine; by AURKA, CDK1 and CDK2"
FT                   /evidence="ECO:0000269|PubMed:10884347,
FT                   ECO:0000269|PubMed:14702041"
FT   MOD_RES         321
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P02340"
FT   MOD_RES         333
FT                   /note="Omega-N-methylarginine; by PRMT5"
FT                   /evidence="ECO:0000269|PubMed:19011621"
FT   MOD_RES         335
FT                   /note="Symmetric dimethylarginine; by PRMT5"
FT                   /evidence="ECO:0000269|PubMed:19011621"
FT   MOD_RES         337
FT                   /note="Symmetric dimethylarginine; by PRMT5"
FT                   /evidence="ECO:0000269|PubMed:19011621"
FT   MOD_RES         370
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:17108971,
FT                   ECO:0000269|PubMed:22864287"
FT   MOD_RES         370
FT                   /note="N6-methyllysine; by SMYD2; alternate"
FT                   /evidence="ECO:0000269|PubMed:17108971,
FT                   ECO:0000269|PubMed:22864287"
FT   MOD_RES         372
FT                   /note="N6-methyllysine; by SETD7"
FT                   /evidence="ECO:0000269|PubMed:15525938,
FT                   ECO:0000269|PubMed:16415881"
FT   MOD_RES         373
FT                   /note="N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate"
FT                   /evidence="ECO:0000269|PubMed:20118233"
FT   MOD_RES         373
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:10656795"
FT   MOD_RES         381
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         382
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:17707234,
FT                   ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287"
FT   MOD_RES         382
FT                   /note="N6-acetyllysine; by KAT6A; alternate"
FT                   /evidence="ECO:0000244|PubMed:19608861,
FT                   ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:20228809,
FT                   ECO:0000269|PubMed:23431171"
FT   MOD_RES         382
FT                   /note="N6-methyllysine; by KMT5A; alternate"
FT                   /evidence="ECO:0000269|PubMed:17707234,
FT                   ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287"
FT   MOD_RES         392
FT                   /note="Phosphoserine; by CK2, CDK2 and NUAK1"
FT                   /evidence="ECO:0000269|PubMed:10884347,
FT                   ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:17108107,
FT                   ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:22214662"
FT   CROSSLNK        291
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:19536131"
FT   CROSSLNK        292
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:19536131"
FT   CROSSLNK        386
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:11124955,
FT                   ECO:0000269|PubMed:22214662, ECO:0000269|Ref.37"
FT   VAR_SEQ         1..132
FT                   /note="Missing (in isoform 7, isoform 8 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:16131611"
FT                   /id="VSP_040833"
FT   VAR_SEQ         1..39
FT                   /note="Missing (in isoform 4, isoform 5 and isoform 6)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_040832"
FT   VAR_SEQ         332..346
FT                   /note="IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in isoform 3,
FT                   isoform 6 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:16131611"
FT                   /id="VSP_040560"
FT   VAR_SEQ         332..341
FT                   /note="IRGRERFEMF -> DQTSFQKENC (in isoform 2, isoform 5
FT                   and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:16131611"
FT                   /id="VSP_006535"
FT   VAR_SEQ         342..393
FT                   /note="Missing (in isoform 2, isoform 5 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:16131611"
FT                   /id="VSP_006536"
FT   VAR_SEQ         347..393
FT                   /note="Missing (in isoform 3, isoform 6 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:16131611"
FT                   /id="VSP_040561"
FT   VARIANT         5
FT                   /note="Q -> H (in a sporadic cancer; somatic mutation;
FT                   abolishes strongly phosphorylation)"
FT                   /id="VAR_044543"
FT   VARIANT         6
FT                   /note="S -> L (in a sporadic cancer; somatic mutation;
FT                   reduces interaction with ZNF385A)"
FT                   /id="VAR_044544"
FT   VARIANT         7
FT                   /note="D -> H (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587782646)"
FT                   /id="VAR_005851"
FT   VARIANT         8
FT                   /note="P -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044545"
FT   VARIANT         10
FT                   /note="V -> I (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs535274413)"
FT                   /id="VAR_044546"
FT   VARIANT         11
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs201382018)"
FT                   /id="VAR_044547"
FT   VARIANT         11
FT                   /note="E -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs201382018)"
FT                   /id="VAR_044548"
FT   VARIANT         15
FT                   /note="S -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044549"
FT   VARIANT         16
FT                   /note="Q -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044550"
FT   VARIANT         17
FT                   /note="E -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044551"
FT   VARIANT         24
FT                   /note="K -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044552"
FT   VARIANT         28
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044553"
FT   VARIANT         29..30
FT                   /note="NN -> KD (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047158"
FT   VARIANT         31
FT                   /note="V -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs201753350)"
FT                   /id="VAR_044554"
FT   VARIANT         33
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044555"
FT   VARIANT         34
FT                   /note="P -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044556"
FT   VARIANT         35
FT                   /note="L -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912661)"
FT                   /id="VAR_005852"
FT   VARIANT         36
FT                   /note="P -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587781866)"
FT                   /id="VAR_044557"
FT   VARIANT         37
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044558"
FT   VARIANT         37
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044559"
FT   VARIANT         39
FT                   /note="A -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044560"
FT   VARIANT         39
FT                   /note="A -> V (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1353016807)"
FT                   /id="VAR_044561"
FT   VARIANT         42
FT                   /note="D -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044562"
FT   VARIANT         43
FT                   /note="L -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_005853"
FT   VARIANT         44
FT                   /note="M -> I (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1060501190)"
FT                   /id="VAR_044563"
FT   VARIANT         44
FT                   /note="M -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044564"
FT   VARIANT         44
FT                   /note="M -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044565"
FT   VARIANT         45
FT                   /note="L -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044566"
FT   VARIANT         46
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044567"
FT   VARIANT         46
FT                   /note="S -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659630)"
FT                   /id="VAR_044568"
FT   VARIANT         47
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044569"
FT   VARIANT         47
FT                   /note="P -> S (in dbSNP:rs1800371)"
FT                   /evidence="ECO:0000269|Ref.12"
FT                   /id="VAR_014632"
FT   VARIANT         48
FT                   /note="D -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044570"
FT   VARIANT         49
FT                   /note="D -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780728)"
FT                   /id="VAR_044571"
FT   VARIANT         49
FT                   /note="D -> N (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587780728)"
FT                   /id="VAR_044572"
FT   VARIANT         49
FT                   /note="D -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044573"
FT   VARIANT         52
FT                   /note="Q -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044574"
FT   VARIANT         53
FT                   /note="W -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005854"
FT   VARIANT         53
FT                   /note="W -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044575"
FT   VARIANT         54
FT                   /note="F -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555526742)"
FT                   /id="VAR_044576"
FT   VARIANT         54
FT                   /note="F -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044577"
FT   VARIANT         56
FT                   /note="E -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044578"
FT   VARIANT         56
FT                   /note="E -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044579"
FT   VARIANT         58
FT                   /note="P -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044580"
FT   VARIANT         58
FT                   /note="P -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044581"
FT   VARIANT         59
FT                   /note="G -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1237722021)"
FT                   /id="VAR_044582"
FT   VARIANT         59
FT                   /note="G -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044583"
FT   VARIANT         59
FT                   /note="G -> N (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045783"
FT   VARIANT         60
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044584"
FT   VARIANT         60
FT                   /note="P -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044585"
FT   VARIANT         60
FT                   /note="P -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_005855"
FT   VARIANT         61
FT                   /note="D -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1460793472)"
FT                   /id="VAR_044586"
FT   VARIANT         61
FT                   /note="D -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044587"
FT   VARIANT         62
FT                   /note="E -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044588"
FT   VARIANT         63
FT                   /note="A -> T (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs876658902)"
FT                   /id="VAR_044589"
FT   VARIANT         63
FT                   /note="A -> V (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs372201428)"
FT                   /id="VAR_044590"
FT   VARIANT         65
FT                   /note="R -> T (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1060501210)"
FT                   /id="VAR_044591"
FT   VARIANT         66
FT                   /note="M -> I (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555526711)"
FT                   /id="VAR_044592"
FT   VARIANT         66
FT                   /note="M -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044593"
FT   VARIANT         67
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044594"
FT   VARIANT         67
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044595"
FT   VARIANT         67
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044596"
FT   VARIANT         68
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044597"
FT   VARIANT         68
FT                   /note="E -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044598"
FT   VARIANT         69
FT                   /note="A -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044599"
FT   VARIANT         69
FT                   /note="A -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs756233241)"
FT                   /id="VAR_044600"
FT   VARIANT         69
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044601"
FT   VARIANT         69
FT                   /note="A -> V (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs756233241)"
FT                   /id="VAR_044602"
FT   VARIANT         70
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044603"
FT   VARIANT         71
FT                   /note="P -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044604"
FT   VARIANT         72
FT                   /note="P -> C (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions; dbSNP:rs730882014)"
FT                   /id="VAR_045784"
FT   VARIANT         72
FT                   /note="P -> G (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045785"
FT   VARIANT         72
FT                   /note="P -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1042522)"
FT                   /id="VAR_045786"
FT   VARIANT         72
FT                   /note="P -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045787"
FT   VARIANT         72
FT                   /note="P -> R (in dbSNP:rs1042522)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:16131611, ECO:0000269|PubMed:1999338,
FT                   ECO:0000269|Ref.17"
FT                   /id="VAR_005856"
FT   VARIANT         73
FT                   /note="V -> E (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044605"
FT   VARIANT         73
FT                   /note="V -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044606"
FT   VARIANT         73
FT                   /note="V -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782423)"
FT                   /id="VAR_044607"
FT   VARIANT         74
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044608"
FT   VARIANT         75
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044609"
FT   VARIANT         75
FT                   /note="P -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044610"
FT   VARIANT         75
FT                   /note="P -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044611"
FT   VARIANT         76
FT                   /note="A -> G (in a sporadic cancer; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:2946935"
FT                   /id="VAR_044612"
FT   VARIANT         76
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044613"
FT   VARIANT         77
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044614"
FT   VARIANT         78
FT                   /note="A -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044615"
FT   VARIANT         79
FT                   /note="A -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044616"
FT   VARIANT         79
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_005857"
FT   VARIANT         79
FT                   /note="A -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044617"
FT   VARIANT         80
FT                   /note="P -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044618"
FT   VARIANT         80
FT                   /note="P -> S (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1060501204)"
FT                   /id="VAR_044619"
FT   VARIANT         81
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044620"
FT   VARIANT         82
FT                   /note="P -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs534447939)"
FT                   /id="VAR_044621"
FT   VARIANT         82
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044622"
FT   VARIANT         83
FT                   /note="A -> E (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs201717599)"
FT                   /id="VAR_044623"
FT   VARIANT         83
FT                   /note="A -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs201717599)"
FT                   /id="VAR_044624"
FT   VARIANT         84
FT                   /note="A -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044625"
FT   VARIANT         84
FT                   /note="A -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044626"
FT   VARIANT         85
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044627"
FT   VARIANT         85
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044628"
FT   VARIANT         86
FT                   /note="A -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044629"
FT   VARIANT         87
FT                   /note="P -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005858"
FT   VARIANT         88
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044630"
FT   VARIANT         88
FT                   /note="A -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526631)"
FT                   /id="VAR_044631"
FT   VARIANT         89
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730881994)"
FT                   /id="VAR_044632"
FT   VARIANT         89
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044633"
FT   VARIANT         90
FT                   /note="S -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526625)"
FT                   /id="VAR_044634"
FT   VARIANT         90
FT                   /note="S -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044635"
FT   VARIANT         91
FT                   /note="W -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044636"
FT   VARIANT         92
FT                   /note="P -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044637"
FT   VARIANT         92
FT                   /note="P -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1210700121)"
FT                   /id="VAR_044638"
FT   VARIANT         92
FT                   /note="P -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044639"
FT   VARIANT         93
FT                   /note="L -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044640"
FT   VARIANT         93
FT                   /note="L -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044641"
FT   VARIANT         94
FT                   /note="S -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044642"
FT   VARIANT         94
FT                   /note="S -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005859"
FT   VARIANT         95
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044643"
FT   VARIANT         95
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044644"
FT   VARIANT         96
FT                   /note="S -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044645"
FT   VARIANT         96
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044646"
FT   VARIANT         96
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044647"
FT   VARIANT         97
FT                   /note="V -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044648"
FT   VARIANT         97
FT                   /note="V -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044649"
FT   VARIANT         97
FT                   /note="V -> I (in familial cancer not matching LFS;
FT                   germline mutation and in a sporadic cancer; somatic
FT                   mutation; dbSNP:rs730882023)"
FT                   /id="VAR_044650"
FT   VARIANT         98
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1245723119)"
FT                   /id="VAR_044651"
FT   VARIANT         98
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044652"
FT   VARIANT         99
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044653"
FT   VARIANT         99
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044654"
FT   VARIANT         100
FT                   /note="Q -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044655"
FT   VARIANT         101
FT                   /note="K -> N (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs878854069)"
FT                   /id="VAR_044656"
FT   VARIANT         101
FT                   /note="K -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044657"
FT   VARIANT         102
FT                   /note="T -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786202717)"
FT                   /id="VAR_044658"
FT   VARIANT         104
FT                   /note="Q -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044659"
FT   VARIANT         104
FT                   /note="Q -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044660"
FT   VARIANT         105
FT                   /note="G -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_044661"
FT   VARIANT         105
FT                   /note="G -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781504)"
FT                   /id="VAR_044662"
FT   VARIANT         105
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501195)"
FT                   /id="VAR_044663"
FT   VARIANT         105
FT                   /note="G -> S (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1060501195)"
FT                   /id="VAR_044664"
FT   VARIANT         105
FT                   /note="G -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044665"
FT   VARIANT         106
FT                   /note="S -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044666"
FT   VARIANT         106
FT                   /note="S -> R (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs1555526581)"
FT                   /id="VAR_044667"
FT   VARIANT         107
FT                   /note="Y -> C (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587782447)"
FT                   /id="VAR_044668"
FT   VARIANT         107
FT                   /note="Y -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044669"
FT   VARIANT         107
FT                   /note="Y -> H (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs368771578)"
FT                   /id="VAR_044670"
FT   VARIANT         108
FT                   /note="G -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044671"
FT   VARIANT         108
FT                   /note="G -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782461)"
FT                   /id="VAR_044672"
FT   VARIANT         109
FT                   /note="F -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044673"
FT   VARIANT         109
FT                   /note="F -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044674"
FT   VARIANT         109
FT                   /note="F -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064796722)"
FT                   /id="VAR_044675"
FT   VARIANT         110
FT                   /note="R -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781371)"
FT                   /id="VAR_005860"
FT   VARIANT         110
FT                   /note="R -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044676"
FT   VARIANT         110
FT                   /note="R -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs11540654)"
FT                   /id="VAR_044677"
FT   VARIANT         110
FT                   /note="R -> L (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; does not induce SNAI1 degradation;
FT                   dbSNP:rs11540654)"
FT                   /evidence="ECO:0000269|PubMed:20385133"
FT                   /id="VAR_005861"
FT   VARIANT         110
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs11540654)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_005862"
FT   VARIANT         110
FT                   /note="R -> S (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587781371)"
FT                   /id="VAR_044678"
FT   VARIANT         111
FT                   /note="L -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044679"
FT   VARIANT         111
FT                   /note="L -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519997)"
FT                   /id="VAR_044680"
FT   VARIANT         111
FT                   /note="L -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519997)"
FT                   /id="VAR_044681"
FT   VARIANT         111
FT                   /note="L -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519997)"
FT                   /id="VAR_044682"
FT   VARIANT         112
FT                   /note="G -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044683"
FT   VARIANT         112
FT                   /note="G -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1423803759)"
FT                   /id="VAR_044684"
FT   VARIANT         113
FT                   /note="F -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005863"
FT   VARIANT         113
FT                   /note="F -> G (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045788"
FT   VARIANT         113
FT                   /note="F -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044685"
FT   VARIANT         113
FT                   /note="F -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044686"
FT   VARIANT         113
FT                   /note="F -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044687"
FT   VARIANT         113
FT                   /note="F -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781642)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033033"
FT   VARIANT         115
FT                   /note="H -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044688"
FT   VARIANT         116
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044689"
FT   VARIANT         116
FT                   /note="S -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044690"
FT   VARIANT         116
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044691"
FT   VARIANT         117
FT                   /note="G -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs755238756)"
FT                   /id="VAR_044692"
FT   VARIANT         117
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526518)"
FT                   /id="VAR_044693"
FT   VARIANT         118
FT                   /note="T -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044694"
FT   VARIANT         118
FT                   /note="T -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064794141)"
FT                   /id="VAR_044695"
FT   VARIANT         118
FT                   /note="T -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044696"
FT   VARIANT         119
FT                   /note="A -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044697"
FT   VARIANT         119
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044698"
FT   VARIANT         120
FT                   /note="K -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912658)"
FT                   /id="VAR_044699"
FT   VARIANT         120
FT                   /note="K -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044700"
FT   VARIANT         120
FT                   /note="K -> Q (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs121912658)"
FT                   /id="VAR_044701"
FT   VARIANT         120
FT                   /note="K -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044702"
FT   VARIANT         121
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044703"
FT   VARIANT         122
FT                   /note="V -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044704"
FT   VARIANT         123
FT                   /note="T -> I (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555526486)"
FT                   /id="VAR_044705"
FT   VARIANT         123
FT                   /note="T -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044706"
FT   VARIANT         124
FT                   /note="C -> G (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs730881997)"
FT                   /id="VAR_044707"
FT   VARIANT         124
FT                   /note="C -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044708"
FT   VARIANT         124
FT                   /note="C -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730881997)"
FT                   /id="VAR_044709"
FT   VARIANT         124
FT                   /note="C -> W (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044710"
FT   VARIANT         124
FT                   /note="C -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044711"
FT   VARIANT         125
FT                   /note="T -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044712"
FT   VARIANT         125
FT                   /note="T -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201057)"
FT                   /id="VAR_044713"
FT   VARIANT         125
FT                   /note="T -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201057)"
FT                   /id="VAR_005864"
FT   VARIANT         125
FT                   /note="T -> P (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1057520003)"
FT                   /id="VAR_044714"
FT   VARIANT         125
FT                   /note="T -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201057)"
FT                   /id="VAR_044715"
FT   VARIANT         126
FT                   /note="Y -> C (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs1555526335)"
FT                   /id="VAR_044716"
FT   VARIANT         126
FT                   /note="Y -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs886039483)"
FT                   /id="VAR_005865"
FT   VARIANT         126
FT                   /note="Y -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044717"
FT   VARIANT         126
FT                   /note="Y -> G (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045789"
FT   VARIANT         126
FT                   /note="Y -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044718"
FT   VARIANT         126
FT                   /note="Y -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs886039483)"
FT                   /id="VAR_005866"
FT   VARIANT         126
FT                   /note="Y -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044719"
FT   VARIANT         127
FT                   /note="S -> C (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs730881999)"
FT                   /id="VAR_044720"
FT   VARIANT         127
FT                   /note="S -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730881999)"
FT                   /id="VAR_005867"
FT   VARIANT         127
FT                   /note="S -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044721"
FT   VARIANT         127
FT                   /note="S -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044722"
FT   VARIANT         127
FT                   /note="S -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044723"
FT   VARIANT         128
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044724"
FT   VARIANT         128
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044725"
FT   VARIANT         128
FT                   /note="P -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044726"
FT   VARIANT         128
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005868"
FT   VARIANT         129
FT                   /note="A -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005869"
FT   VARIANT         129
FT                   /note="A -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044727"
FT   VARIANT         129
FT                   /note="A -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1438095083)"
FT                   /id="VAR_044728"
FT   VARIANT         129
FT                   /note="A -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs137852792)"
FT                   /id="VAR_044729"
FT   VARIANT         130
FT                   /note="L -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs863224683)"
FT                   /id="VAR_044730"
FT   VARIANT         130
FT                   /note="L -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044731"
FT   VARIANT         130
FT                   /note="L -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044732"
FT   VARIANT         130
FT                   /note="L -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691013)"
FT                   /id="VAR_044733"
FT   VARIANT         130
FT                   /note="L -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005870"
FT   VARIANT         130
FT                   /note="L -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs863224683)"
FT                   /id="VAR_044734"
FT   VARIANT         131
FT                   /note="N -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044735"
FT   VARIANT         131
FT                   /note="N -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044736"
FT   VARIANT         131
FT                   /note="N -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691037)"
FT                   /id="VAR_044737"
FT   VARIANT         131
FT                   /note="N -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs769270327)"
FT                   /id="VAR_005872"
FT   VARIANT         131
FT                   /note="N -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005871"
FT   VARIANT         131
FT                   /note="N -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044738"
FT   VARIANT         131
FT                   /note="N -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782160)"
FT                   /id="VAR_044739"
FT   VARIANT         132..133
FT                   /note="KM -> NL (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047159"
FT   VARIANT         132
FT                   /note="K -> E (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs747342068)"
FT                   /id="VAR_044740"
FT   VARIANT         132
FT                   /note="K -> L (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045790"
FT   VARIANT         132
FT                   /note="K -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519996)"
FT                   /id="VAR_005873"
FT   VARIANT         132
FT                   /note="K -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs866775781)"
FT                   /id="VAR_044741"
FT   VARIANT         132
FT                   /note="K -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs747342068)"
FT                   /evidence="ECO:0000269|PubMed:1694291"
FT                   /id="VAR_005874"
FT   VARIANT         132
FT                   /note="K -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519996)"
FT                   /id="VAR_044742"
FT   VARIANT         132
FT                   /note="K -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519996)"
FT                   /id="VAR_044743"
FT   VARIANT         132
FT                   /note="K -> W (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045791"
FT   VARIANT         133
FT                   /note="M -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795139)"
FT                   /id="VAR_044744"
FT   VARIANT         133
FT                   /note="M -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044745"
FT   VARIANT         133
FT                   /note="M -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044746"
FT   VARIANT         133
FT                   /note="M -> R (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_044747"
FT   VARIANT         133
FT                   /note="M -> T (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934873)"
FT                   /evidence="ECO:0000269|PubMed:1933902"
FT                   /id="VAR_005875"
FT   VARIANT         133
FT                   /note="M -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057280220)"
FT                   /id="VAR_044748"
FT   VARIANT         134
FT                   /note="F -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs780442292)"
FT                   /id="VAR_044749"
FT   VARIANT         134
FT                   /note="F -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044750"
FT   VARIANT         134
FT                   /note="F -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs267605077)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036504"
FT   VARIANT         134
FT                   /note="F -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044751"
FT   VARIANT         134
FT                   /note="F -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044752"
FT   VARIANT         135
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781991)"
FT                   /id="VAR_005877"
FT   VARIANT         135
FT                   /note="C -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519975)"
FT                   /id="VAR_044753"
FT   VARIANT         135
FT                   /note="C -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519975)"
FT                   /id="VAR_044754"
FT   VARIANT         135
FT                   /note="C -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519975)"
FT                   /id="VAR_005876"
FT   VARIANT         135
FT                   /note="C -> T (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045792"
FT   VARIANT         135
FT                   /note="C -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519976)"
FT                   /id="VAR_044755"
FT   VARIANT         135
FT                   /note="C -> Y (in sporadic cancers; somatic mutation;
FT                   decreased E6-mediated binding to E6-AP; dbSNP:rs587781991)"
FT                   /id="VAR_044756"
FT   VARIANT         136
FT                   /note="Q -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526268)"
FT                   /id="VAR_005878"
FT   VARIANT         136
FT                   /note="Q -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs758781593)"
FT                   /id="VAR_044757"
FT   VARIANT         136
FT                   /note="Q -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_005879"
FT   VARIANT         136
FT                   /note="Q -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044758"
FT   VARIANT         136
FT                   /note="Q -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044759"
FT   VARIANT         137
FT                   /note="L -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044760"
FT   VARIANT         137
FT                   /note="L -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044761"
FT   VARIANT         137
FT                   /note="L -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005880"
FT   VARIANT         137
FT                   /note="L -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044762"
FT   VARIANT         138
FT                   /note="A -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044763"
FT   VARIANT         138
FT                   /note="A -> P (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934875)"
FT                   /id="VAR_005881"
FT   VARIANT         138
FT                   /note="A -> S (in LFS; germline mutation)"
FT                   /id="VAR_044764"
FT   VARIANT         138
FT                   /note="A -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044765"
FT   VARIANT         138
FT                   /note="A -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs750600586)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033034"
FT   VARIANT         139
FT                   /note="K -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1212996409)"
FT                   /id="VAR_044766"
FT   VARIANT         139
FT                   /note="K -> N (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:14660794"
FT                   /id="VAR_005882"
FT   VARIANT         139
FT                   /note="K -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044767"
FT   VARIANT         139
FT                   /note="K -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044768"
FT   VARIANT         139
FT                   /note="K -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044769"
FT   VARIANT         140
FT                   /note="T -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044770"
FT   VARIANT         140
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044771"
FT   VARIANT         140
FT                   /note="T -> N (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs786202561)"
FT                   /id="VAR_044772"
FT   VARIANT         140
FT                   /note="T -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044773"
FT   VARIANT         140
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044774"
FT   VARIANT         141
FT                   /note="C -> A (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045793"
FT   VARIANT         141
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781288)"
FT                   /id="VAR_005885"
FT   VARIANT         141
FT                   /note="C -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519978)"
FT                   /id="VAR_005884"
FT   VARIANT         141
FT                   /note="C -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519978)"
FT                   /id="VAR_044775"
FT   VARIANT         141
FT                   /note="C -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519978)"
FT                   /id="VAR_044776"
FT   VARIANT         141
FT                   /note="C -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519977)"
FT                   /id="VAR_044777"
FT   VARIANT         141
FT                   /note="C -> Y (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587781288)"
FT                   /id="VAR_005886"
FT   VARIANT         142
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044778"
FT   VARIANT         142
FT                   /note="P -> F (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045794"
FT   VARIANT         142
FT                   /note="P -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044779"
FT   VARIANT         142
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs779196500)"
FT                   /id="VAR_044780"
FT   VARIANT         142
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044781"
FT   VARIANT         142
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044782"
FT   VARIANT         142
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044783"
FT   VARIANT         143
FT                   /note="V -> A (in sporadic cancers; somatic mutation;
FT                   strong DNA binding ability at 32.5 degrees Celsius; strong
FT                   reduction of transcriptional activity at 37.5 degrees
FT                   Celsius; severely represses interaction with ZNF385A)"
FT                   /evidence="ECO:0000269|PubMed:17719541,
FT                   ECO:0000269|PubMed:8013454"
FT                   /id="VAR_005887"
FT   VARIANT         143
FT                   /note="V -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044784"
FT   VARIANT         143
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526241)"
FT                   /id="VAR_044785"
FT   VARIANT         143
FT                   /note="V -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782620)"
FT                   /id="VAR_044786"
FT   VARIANT         143
FT                   /note="V -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782620)"
FT                   /id="VAR_044787"
FT   VARIANT         144
FT                   /note="Q -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201419)"
FT                   /id="VAR_044788"
FT   VARIANT         144
FT                   /note="Q -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044789"
FT   VARIANT         144
FT                   /note="Q -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs786203071)"
FT                   /id="VAR_044790"
FT   VARIANT         144
FT                   /note="Q -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203071)"
FT                   /id="VAR_005888"
FT   VARIANT         144
FT                   /note="Q -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044791"
FT   VARIANT         145
FT                   /note="L -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044792"
FT   VARIANT         145
FT                   /note="L -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782197)"
FT                   /id="VAR_005889"
FT   VARIANT         145
FT                   /note="L -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005890"
FT   VARIANT         145
FT                   /note="L -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044793"
FT   VARIANT         145
FT                   /note="L -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044794"
FT   VARIANT         146
FT                   /note="W -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044795"
FT   VARIANT         146
FT                   /note="W -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203064)"
FT                   /id="VAR_044796"
FT   VARIANT         146
FT                   /note="W -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044797"
FT   VARIANT         146
FT                   /note="W -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044798"
FT   VARIANT         146
FT                   /note="W -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044799"
FT   VARIANT         147
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044800"
FT   VARIANT         147
FT                   /note="V -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005891"
FT   VARIANT         147
FT                   /note="V -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044801"
FT   VARIANT         147
FT                   /note="V -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044802"
FT   VARIANT         147
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1453167097)"
FT                   /id="VAR_005892"
FT   VARIANT         147
FT                   /note="V -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526226)"
FT                   /id="VAR_044803"
FT   VARIANT         148
FT                   /note="D -> A (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1046611742)"
FT                   /id="VAR_044804"
FT   VARIANT         148
FT                   /note="D -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044805"
FT   VARIANT         148
FT                   /note="D -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044806"
FT   VARIANT         148
FT                   /note="D -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044807"
FT   VARIANT         148
FT                   /note="D -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044808"
FT   VARIANT         148
FT                   /note="D -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691007)"
FT                   /id="VAR_044809"
FT   VARIANT         149
FT                   /note="S -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526214)"
FT                   /id="VAR_044810"
FT   VARIANT         149
FT                   /note="S -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005893"
FT   VARIANT         149
FT                   /note="S -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044811"
FT   VARIANT         150
FT                   /note="T -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044812"
FT   VARIANT         150
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044813"
FT   VARIANT         150
FT                   /note="T -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044814"
FT   VARIANT         150
FT                   /note="T -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044815"
FT   VARIANT         150
FT                   /note="T -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044816"
FT   VARIANT         150
FT                   /note="T -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044817"
FT   VARIANT         151
FT                   /note="P -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs28934874)"
FT                   /id="VAR_005894"
FT   VARIANT         151
FT                   /note="P -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520000)"
FT                   /id="VAR_044818"
FT   VARIANT         151
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044819"
FT   VARIANT         151
FT                   /note="P -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520000)"
FT                   /id="VAR_044820"
FT   VARIANT         151
FT                   /note="P -> S (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934874)"
FT                   /evidence="ECO:0000269|PubMed:7682763"
FT                   /id="VAR_005895"
FT   VARIANT         151
FT                   /note="P -> T (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934874)"
FT                   /id="VAR_005896"
FT   VARIANT         152
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044821"
FT   VARIANT         152
FT                   /note="P -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587782705)"
FT                   /evidence="ECO:0000269|PubMed:1868473"
FT                   /id="VAR_005897"
FT   VARIANT         152
FT                   /note="P -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044822"
FT   VARIANT         152
FT                   /note="P -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044823"
FT   VARIANT         152
FT                   /note="P -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs767328513)"
FT                   /evidence="ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005898"
FT   VARIANT         152
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044824"
FT   VARIANT         153
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044825"
FT   VARIANT         153
FT                   /note="P -> F (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045795"
FT   VARIANT         153
FT                   /note="P -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044826"
FT   VARIANT         153
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044827"
FT   VARIANT         153
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044828"
FT   VARIANT         153
FT                   /note="P -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795860)"
FT                   /id="VAR_044829"
FT   VARIANT         153
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005899"
FT   VARIANT         154
FT                   /note="G -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044830"
FT   VARIANT         154
FT                   /note="G -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044831"
FT   VARIANT         154
FT                   /note="G -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs762846821)"
FT                   /id="VAR_044832"
FT   VARIANT         154
FT                   /note="G -> I (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045796"
FT   VARIANT         154
FT                   /note="G -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs137852789)"
FT                   /id="VAR_044833"
FT   VARIANT         154
FT                   /note="G -> V (in a brain tumor with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs762846821)"
FT                   /evidence="ECO:0000269|PubMed:2263646"
FT                   /id="VAR_005900"
FT   VARIANT         155
FT                   /note="T -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs772683278)"
FT                   /evidence="ECO:0000269|PubMed:1868473"
FT                   /id="VAR_005901"
FT   VARIANT         155
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044834"
FT   VARIANT         155
FT                   /note="T -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044835"
FT   VARIANT         155
FT                   /note="T -> N (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs786202752)"
FT                   /id="VAR_044836"
FT   VARIANT         155
FT                   /note="T -> P (in sporadic cancers; somatic mutation; does
FT                   not induce SNAI1 degradation)"
FT                   /evidence="ECO:0000269|PubMed:14660794,
FT                   ECO:0000269|PubMed:20385133"
FT                   /id="VAR_044837"
FT   VARIANT         155
FT                   /note="T -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786202752)"
FT                   /id="VAR_044838"
FT   VARIANT         156
FT                   /note="R -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs563378859)"
FT                   /id="VAR_044839"
FT   VARIANT         156
FT                   /note="R -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044840"
FT   VARIANT         156
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs371524413)"
FT                   /id="VAR_044841"
FT   VARIANT         156
FT                   /note="R -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044842"
FT   VARIANT         156
FT                   /note="R -> P (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:7682763"
FT                   /id="VAR_005902"
FT   VARIANT         156
FT                   /note="R -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044843"
FT   VARIANT         157
FT                   /note="V -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691023)"
FT                   /id="VAR_044844"
FT   VARIANT         157
FT                   /note="V -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005903"
FT   VARIANT         157
FT                   /note="V -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912654)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_005904"
FT   VARIANT         157
FT                   /note="V -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044845"
FT   VARIANT         157
FT                   /note="V -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912654)"
FT                   /evidence="ECO:0000269|PubMed:9419979"
FT                   /id="VAR_012977"
FT   VARIANT         157
FT                   /note="V -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044846"
FT   VARIANT         158
FT                   /note="R -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780068)"
FT                   /id="VAR_005905"
FT   VARIANT         158
FT                   /note="R -> F (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045797"
FT   VARIANT         158
FT                   /note="R -> G (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_005906"
FT   VARIANT         158
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587782144)"
FT                   /id="VAR_005907"
FT   VARIANT         158
FT                   /note="R -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044847"
FT   VARIANT         158
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782144)"
FT                   /id="VAR_044848"
FT   VARIANT         158
FT                   /note="R -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044849"
FT   VARIANT         158
FT                   /note="R -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044850"
FT   VARIANT         158
FT                   /note="R -> Y (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045798"
FT   VARIANT         159
FT                   /note="A -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044851"
FT   VARIANT         159
FT                   /note="A -> F (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions; dbSNP:rs730882022)"
FT                   /id="VAR_045799"
FT   VARIANT         159
FT                   /note="A -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044852"
FT   VARIANT         159
FT                   /note="A -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882000)"
FT                   /id="VAR_044853"
FT   VARIANT         159
FT                   /note="A -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044854"
FT   VARIANT         159
FT                   /note="A -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882000)"
FT                   /id="VAR_044855"
FT   VARIANT         159
FT                   /note="A -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526131)"
FT                   /id="VAR_044856"
FT   VARIANT         160..161
FT                   /note="MA -> IP (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047160"
FT   VARIANT         160..161
FT                   /note="MA -> IS (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047161"
FT   VARIANT         160..161
FT                   /note="MA -> IT (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047162"
FT   VARIANT         160
FT                   /note="M -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs772354334)"
FT                   /id="VAR_005908"
FT   VARIANT         160
FT                   /note="M -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044857"
FT   VARIANT         160
FT                   /note="M -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044858"
FT   VARIANT         160
FT                   /note="M -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs377274728)"
FT                   /id="VAR_044859"
FT   VARIANT         161
FT                   /note="A -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795691)"
FT                   /id="VAR_044860"
FT   VARIANT         161
FT                   /note="A -> F (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045800"
FT   VARIANT         161
FT                   /note="A -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044861"
FT   VARIANT         161
FT                   /note="A -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044862"
FT   VARIANT         161
FT                   /note="A -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005909"
FT   VARIANT         161
FT                   /note="A -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs193920817)"
FT                   /id="VAR_044863"
FT   VARIANT         161
FT                   /note="A -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044864"
FT   VARIANT         162
FT                   /note="I -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044865"
FT   VARIANT         162
FT                   /note="I -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044866"
FT   VARIANT         162
FT                   /note="I -> N (in a breast cancer with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_044867"
FT   VARIANT         162
FT                   /note="I -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780069)"
FT                   /id="VAR_005910"
FT   VARIANT         162
FT                   /note="I -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044868"
FT   VARIANT         162
FT                   /note="I -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005911"
FT   VARIANT         163
FT                   /note="Y -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs148924904)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033035"
FT   VARIANT         163
FT                   /note="Y -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203436)"
FT                   /id="VAR_044869"
FT   VARIANT         163
FT                   /note="Y -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044870"
FT   VARIANT         163
FT                   /note="Y -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203436)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_005912"
FT   VARIANT         163
FT                   /note="Y -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203436)"
FT                   /id="VAR_044871"
FT   VARIANT         163
FT                   /note="Y -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044872"
FT   VARIANT         164
FT                   /note="K -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs879254249)"
FT                   /id="VAR_044873"
FT   VARIANT         164
FT                   /note="K -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044874"
FT   VARIANT         164
FT                   /note="K -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691034)"
FT                   /id="VAR_005913"
FT   VARIANT         164
FT                   /note="K -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005914"
FT   VARIANT         164
FT                   /note="K -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044875"
FT   VARIANT         164
FT                   /note="K -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044876"
FT   VARIANT         165
FT                   /note="Q -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044877"
FT   VARIANT         165
FT                   /note="Q -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044878"
FT   VARIANT         165
FT                   /note="Q -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005915"
FT   VARIANT         165
FT                   /note="Q -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044879"
FT   VARIANT         165
FT                   /note="Q -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005916"
FT   VARIANT         166
FT                   /note="S -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044880"
FT   VARIANT         166
FT                   /note="S -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044881"
FT   VARIANT         166
FT                   /note="S -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526101)"
FT                   /id="VAR_005917"
FT   VARIANT         166
FT                   /note="S -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044882"
FT   VARIANT         166
FT                   /note="S -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044883"
FT   VARIANT         167..168
FT                   /note="QH -> HD (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047163"
FT   VARIANT         167..168
FT                   /note="QH -> YL (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047164"
FT   VARIANT         167
FT                   /note="Q -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044884"
FT   VARIANT         167
FT                   /note="Q -> K (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation)"
FT                   /id="VAR_044885"
FT   VARIANT         167
FT                   /note="Q -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044886"
FT   VARIANT         167
FT                   /note="Q -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044887"
FT   VARIANT         168..169
FT                   /note="HM -> LI (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047165"
FT   VARIANT         168
FT                   /note="H -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044888"
FT   VARIANT         168
FT                   /note="H -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044889"
FT   VARIANT         168
FT                   /note="H -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044890"
FT   VARIANT         168
FT                   /note="H -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044891"
FT   VARIANT         168
FT                   /note="H -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044892"
FT   VARIANT         168
FT                   /note="H -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs867114783)"
FT                   /id="VAR_005918"
FT   VARIANT         168
FT                   /note="H -> V (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045801"
FT   VARIANT         168
FT                   /note="H -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044893"
FT   VARIANT         169..170
FT                   /note="MT -> IS (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047166"
FT   VARIANT         169
FT                   /note="M -> I (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005919"
FT   VARIANT         169
FT                   /note="M -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044894"
FT   VARIANT         169
FT                   /note="M -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005920"
FT   VARIANT         169
FT                   /note="M -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044895"
FT   VARIANT         170
FT                   /note="T -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780729)"
FT                   /id="VAR_044896"
FT   VARIANT         170
FT                   /note="T -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044897"
FT   VARIANT         170
FT                   /note="T -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs779000871)"
FT                   /id="VAR_005921"
FT   VARIANT         170
FT                   /note="T -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044898"
FT   VARIANT         170
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005922"
FT   VARIANT         171
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044899"
FT   VARIANT         171
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044900"
FT   VARIANT         171
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044901"
FT   VARIANT         171
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781845)"
FT                   /id="VAR_044902"
FT   VARIANT         171
FT                   /note="E -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044903"
FT   VARIANT         171
FT                   /note="E -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044904"
FT   VARIANT         172
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005923"
FT   VARIANT         172
FT                   /note="V -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044905"
FT   VARIANT         172
FT                   /note="V -> F (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs1131691043)"
FT                   /id="VAR_044906"
FT   VARIANT         172
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691021)"
FT                   /id="VAR_044907"
FT   VARIANT         172
FT                   /note="V -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044908"
FT   VARIANT         173
FT                   /note="V -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519747)"
FT                   /id="VAR_044909"
FT   VARIANT         173
FT                   /note="V -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519747)"
FT                   /id="VAR_005924"
FT   VARIANT         173
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519747)"
FT                   /id="VAR_044910"
FT   VARIANT         173
FT                   /note="V -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660754)"
FT                   /id="VAR_005925"
FT   VARIANT         173
FT                   /note="V -> M (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs876660754)"
FT                   /id="VAR_005926"
FT   VARIANT         173
FT                   /note="V -> W (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045802"
FT   VARIANT         174
FT                   /note="R -> G (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation; dbSNP:rs864622115)"
FT                   /id="VAR_044911"
FT   VARIANT         174
FT                   /note="R -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064796681)"
FT                   /evidence="ECO:0000269|PubMed:7682763"
FT                   /id="VAR_005927"
FT   VARIANT         174
FT                   /note="R -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044912"
FT   VARIANT         174
FT                   /note="R -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044913"
FT   VARIANT         174
FT                   /note="R -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044914"
FT   VARIANT         174
FT                   /note="R -> W (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044915"
FT   VARIANT         175
FT                   /note="R -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs138729528)"
FT                   /id="VAR_005928"
FT   VARIANT         175
FT                   /note="R -> G (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs138729528)"
FT                   /id="VAR_005929"
FT   VARIANT         175
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; does not induce SNAI1
FT                   degradation; reduces interaction with ZNF385A;
FT                   dbSNP:rs28934578)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:1868473,
FT                   ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:7887414,
FT                   ECO:0000269|PubMed:8825920"
FT                   /id="VAR_005932"
FT   VARIANT         175
FT                   /note="R -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934578)"
FT                   /id="VAR_005930"
FT   VARIANT         175
FT                   /note="R -> P (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17719541"
FT                   /id="VAR_005931"
FT   VARIANT         175
FT                   /note="R -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044916"
FT   VARIANT         175
FT                   /note="R -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044917"
FT   VARIANT         176..177
FT                   /note="CP -> FS (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047167"
FT   VARIANT         176
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786202962)"
FT                   /evidence="ECO:0000269|PubMed:1394225,
FT                   ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:8829627,
FT                   ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005933"
FT   VARIANT         176
FT                   /note="C -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044918"
FT   VARIANT         176
FT                   /note="C -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044919"
FT   VARIANT         176
FT                   /note="C -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs967461896)"
FT                   /id="VAR_044920"
FT   VARIANT         176
FT                   /note="C -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519980)"
FT                   /id="VAR_005934"
FT   VARIANT         176
FT                   /note="C -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786202962)"
FT                   /id="VAR_044921"
FT   VARIANT         177
FT                   /note="P -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044922"
FT   VARIANT         177
FT                   /note="P -> F (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045803"
FT   VARIANT         177
FT                   /note="P -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044923"
FT   VARIANT         177
FT                   /note="P -> I (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045804"
FT   VARIANT         177
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs751477326)"
FT                   /id="VAR_005935"
FT   VARIANT         177
FT                   /note="P -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs751477326)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036505"
FT   VARIANT         177
FT                   /note="P -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs147002414)"
FT                   /id="VAR_044924"
FT   VARIANT         177
FT                   /note="P -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044925"
FT   VARIANT         178..179
FT                   /note="HH -> QS (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047168"
FT   VARIANT         178
FT                   /note="H -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044926"
FT   VARIANT         178
FT                   /note="H -> HPHP (in a Burkitt lymphoma)"
FT                   /evidence="ECO:0000269|PubMed:1303181"
FT                   /id="VAR_005936"
FT   VARIANT         178
FT                   /note="H -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044927"
FT   VARIANT         178
FT                   /note="H -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795203)"
FT                   /id="VAR_044928"
FT   VARIANT         178
FT                   /note="H -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526004)"
FT                   /id="VAR_044929"
FT   VARIANT         178
FT                   /note="H -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044930"
FT   VARIANT         178
FT                   /note="H -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044931"
FT   VARIANT         178
FT                   /note="H -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044932"
FT   VARIANT         179
FT                   /note="H -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780070)"
FT                   /id="VAR_044933"
FT   VARIANT         179
FT                   /note="H -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519991)"
FT                   /id="VAR_044934"
FT   VARIANT         179
FT                   /note="H -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780070)"
FT                   /id="VAR_044935"
FT   VARIANT         179
FT                   /note="H -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519991)"
FT                   /id="VAR_044936"
FT   VARIANT         179
FT                   /note="H -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660821)"
FT                   /id="VAR_044937"
FT   VARIANT         179
FT                   /note="H -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519991)"
FT                   /id="VAR_044938"
FT   VARIANT         179
FT                   /note="H -> Y (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587780070)"
FT                   /id="VAR_044939"
FT   VARIANT         180
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044940"
FT   VARIANT         180
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044941"
FT   VARIANT         180
FT                   /note="E -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044942"
FT   VARIANT         180
FT                   /note="E -> K (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs879253911)"
FT                   /id="VAR_044943"
FT   VARIANT         180
FT                   /note="E -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044944"
FT   VARIANT         180
FT                   /note="E -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044945"
FT   VARIANT         181
FT                   /note="R -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587782596)"
FT                   /id="VAR_044946"
FT   VARIANT         181
FT                   /note="R -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044947"
FT   VARIANT         181
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs397514495)"
FT                   /id="VAR_044948"
FT   VARIANT         181
FT                   /note="R -> L (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs397514495)"
FT                   /id="VAR_005937"
FT   VARIANT         181
FT                   /note="R -> P (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_044949"
FT   VARIANT         181
FT                   /note="R -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782596)"
FT                   /id="VAR_044950"
FT   VARIANT         182
FT                   /note="C -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044951"
FT   VARIANT         182
FT                   /note="C -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005938"
FT   VARIANT         182
FT                   /note="C -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044952"
FT   VARIANT         183
FT                   /note="S -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525970)"
FT                   /id="VAR_044953"
FT   VARIANT         183
FT                   /note="S -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044954"
FT   VARIANT         184
FT                   /note="D -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501209)"
FT                   /id="VAR_044955"
FT   VARIANT         184
FT                   /note="D -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044956"
FT   VARIANT         184
FT                   /note="D -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs72661117)"
FT                   /id="VAR_047169"
FT   VARIANT         184
FT                   /note="D -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044957"
FT   VARIANT         184
FT                   /note="D -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005939"
FT   VARIANT         185
FT                   /note="S -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044958"
FT   VARIANT         185
FT                   /note="S -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044959"
FT   VARIANT         185
FT                   /note="S -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044960"
FT   VARIANT         185
FT                   /note="S -> N (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs150607408)"
FT                   /id="VAR_044961"
FT   VARIANT         185
FT                   /note="S -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044962"
FT   VARIANT         185
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044963"
FT   VARIANT         186
FT                   /note="D -> E (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs375275361)"
FT                   /id="VAR_044964"
FT   VARIANT         186
FT                   /note="D -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044965"
FT   VARIANT         186
FT                   /note="D -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044966"
FT   VARIANT         186
FT                   /note="D -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501206)"
FT                   /id="VAR_044967"
FT   VARIANT         186
FT                   /note="D -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044968"
FT   VARIANT         186
FT                   /note="D -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_005940"
FT   VARIANT         187
FT                   /note="G -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005941"
FT   VARIANT         187
FT                   /note="G -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044969"
FT   VARIANT         187
FT                   /note="G -> N (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045805"
FT   VARIANT         187
FT                   /note="G -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044970"
FT   VARIANT         187
FT                   /note="G -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs776167460)"
FT                   /id="VAR_005942"
FT   VARIANT         187
FT                   /note="G -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044971"
FT   VARIANT         188
FT                   /note="L -> P (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1199893366)"
FT                   /id="VAR_044972"
FT   VARIANT         188
FT                   /note="L -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044973"
FT   VARIANT         189
FT                   /note="A -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044974"
FT   VARIANT         189
FT                   /note="A -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044975"
FT   VARIANT         189
FT                   /note="A -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005943"
FT   VARIANT         189
FT                   /note="A -> S (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555525921)"
FT                   /id="VAR_044976"
FT   VARIANT         189
FT                   /note="A -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044977"
FT   VARIANT         189
FT                   /note="A -> V (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs121912665)"
FT                   /id="VAR_044978"
FT   VARIANT         190
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044979"
FT   VARIANT         190
FT                   /note="P -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044980"
FT   VARIANT         190
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660825)"
FT                   /id="VAR_005944"
FT   VARIANT         190
FT                   /note="P -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660825)"
FT                   /id="VAR_044981"
FT   VARIANT         190
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044982"
FT   VARIANT         190
FT                   /note="P -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660254)"
FT                   /id="VAR_044983"
FT   VARIANT         191
FT                   /note="P -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587778718)"
FT                   /id="VAR_044984"
FT   VARIANT         191
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587778718)"
FT                   /id="VAR_044985"
FT   VARIANT         191
FT                   /note="P -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587778718)"
FT                   /id="VAR_044986"
FT   VARIANT         191
FT                   /note="P -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs868590738)"
FT                   /id="VAR_044987"
FT   VARIANT         191
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005945"
FT   VARIANT         192..193
FT                   /note="QH -> HN (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047170"
FT   VARIANT         192..193
FT                   /note="QH -> HY (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047171"
FT   VARIANT         192
FT                   /note="Q -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044988"
FT   VARIANT         192
FT                   /note="Q -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044989"
FT   VARIANT         192
FT                   /note="Q -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044990"
FT   VARIANT         192
FT                   /note="Q -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044991"
FT   VARIANT         192
FT                   /note="Q -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882002)"
FT                   /id="VAR_005946"
FT   VARIANT         193
FT                   /note="H -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876658468)"
FT                   /id="VAR_005947"
FT   VARIANT         193
FT                   /note="H -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201838)"
FT                   /id="VAR_044992"
FT   VARIANT         193
FT                   /note="H -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876658468)"
FT                   /id="VAR_044993"
FT   VARIANT         193
FT                   /note="H -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201838)"
FT                   /id="VAR_044994"
FT   VARIANT         193
FT                   /note="H -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044995"
FT   VARIANT         193
FT                   /note="H -> R (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs786201838)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:7887414"
FT                   /id="VAR_005948"
FT   VARIANT         193
FT                   /note="H -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876658468)"
FT                   /id="VAR_044996"
FT   VARIANT         194
FT                   /note="L -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780071)"
FT                   /id="VAR_044997"
FT   VARIANT         194
FT                   /note="L -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519998)"
FT                   /id="VAR_044998"
FT   VARIANT         194
FT                   /note="L -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044999"
FT   VARIANT         194
FT                   /note="L -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519998)"
FT                   /id="VAR_005949"
FT   VARIANT         194
FT                   /note="L -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519998)"
FT                   /evidence="ECO:0000269|PubMed:7682763"
FT                   /id="VAR_005950"
FT   VARIANT         194
FT                   /note="L -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045000"
FT   VARIANT         195
FT                   /note="I -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs942158624)"
FT                   /id="VAR_045001"
FT   VARIANT         195
FT                   /note="I -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047172"
FT   VARIANT         195
FT                   /note="I -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs760043106)"
FT                   /id="VAR_045002"
FT   VARIANT         195
FT                   /note="I -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs760043106)"
FT                   /id="VAR_045003"
FT   VARIANT         195
FT                   /note="I -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs760043106)"
FT                   /evidence="ECO:0000269|PubMed:17224074,
FT                   ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005951"
FT   VARIANT         195
FT                   /note="I -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045004"
FT   VARIANT         195
FT                   /note="I -> Y (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045806"
FT   VARIANT         196
FT                   /note="R -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs397516435)"
FT                   /id="VAR_045005"
FT   VARIANT         196
FT                   /note="R -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs483352697)"
FT                   /id="VAR_045006"
FT   VARIANT         196
FT                   /note="R -> P (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs483352697)"
FT                   /id="VAR_045007"
FT   VARIANT         196
FT                   /note="R -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs483352697)"
FT                   /id="VAR_045008"
FT   VARIANT         196
FT                   /note="R -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045009"
FT   VARIANT         197
FT                   /note="V -> E (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_045010"
FT   VARIANT         197
FT                   /note="V -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045011"
FT   VARIANT         197
FT                   /note="V -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786204041)"
FT                   /id="VAR_045012"
FT   VARIANT         197
FT                   /note="V -> M (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs786204041)"
FT                   /id="VAR_045013"
FT   VARIANT         198
FT                   /note="E -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045014"
FT   VARIANT         198
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045015"
FT   VARIANT         198
FT                   /note="E -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005952"
FT   VARIANT         198
FT                   /note="E -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045016"
FT   VARIANT         198
FT                   /note="E -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045017"
FT   VARIANT         199
FT                   /note="G -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045018"
FT   VARIANT         199
FT                   /note="G -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045019"
FT   VARIANT         199
FT                   /note="G -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045020"
FT   VARIANT         199
FT                   /note="G -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525857)"
FT                   /id="VAR_045021"
FT   VARIANT         200
FT                   /note="N -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045022"
FT   VARIANT         200
FT                   /note="N -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045023"
FT   VARIANT         200
FT                   /note="N -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045024"
FT   VARIANT         200
FT                   /note="N -> P (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045807"
FT   VARIANT         200
FT                   /note="N -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045025"
FT   VARIANT         200
FT                   /note="N -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045026"
FT   VARIANT         201..202
FT                   /note="LR -> FC (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047173"
FT   VARIANT         201
FT                   /note="L -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882024)"
FT                   /id="VAR_045027"
FT   VARIANT         201
FT                   /note="L -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045028"
FT   VARIANT         201
FT                   /note="L -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045029"
FT   VARIANT         202
FT                   /note="R -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780072)"
FT                   /id="VAR_045030"
FT   VARIANT         202
FT                   /note="R -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780072)"
FT                   /id="VAR_045031"
FT   VARIANT         202
FT                   /note="R -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587778719)"
FT                   /id="VAR_045032"
FT   VARIANT         202
FT                   /note="R -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587778719)"
FT                   /id="VAR_045033"
FT   VARIANT         202
FT                   /note="R -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045034"
FT   VARIANT         202
FT                   /note="R -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045035"
FT   VARIANT         203..204
FT                   /note="VE -> LV (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047174"
FT   VARIANT         203
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045036"
FT   VARIANT         203
FT                   /note="V -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045037"
FT   VARIANT         203
FT                   /note="V -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045038"
FT   VARIANT         203
FT                   /note="V -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882003)"
FT                   /id="VAR_045039"
FT   VARIANT         203
FT                   /note="V -> W (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045808"
FT   VARIANT         204
FT                   /note="E -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045040"
FT   VARIANT         204
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045041"
FT   VARIANT         204
FT                   /note="E -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1260903787)"
FT                   /id="VAR_045042"
FT   VARIANT         204
FT                   /note="E -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045043"
FT   VARIANT         204
FT                   /note="E -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045044"
FT   VARIANT         204
FT                   /note="E -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045045"
FT   VARIANT         205
FT                   /note="Y -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520007)"
FT                   /evidence="ECO:0000269|PubMed:1459726"
FT                   /id="VAR_005953"
FT   VARIANT         205
FT                   /note="Y -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520008)"
FT                   /id="VAR_005954"
FT   VARIANT         205
FT                   /note="Y -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520007)"
FT                   /id="VAR_047175"
FT   VARIANT         205
FT                   /note="Y -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520008)"
FT                   /id="VAR_045046"
FT   VARIANT         205
FT                   /note="Y -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520008)"
FT                   /id="VAR_045047"
FT   VARIANT         205
FT                   /note="Y -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520007)"
FT                   /id="VAR_045048"
FT   VARIANT         206
FT                   /note="L -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045049"
FT   VARIANT         206
FT                   /note="L -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045050"
FT   VARIANT         207..208
FT                   /note="DD -> EY (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047176"
FT   VARIANT         207
FT                   /note="D -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045051"
FT   VARIANT         207
FT                   /note="D -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045052"
FT   VARIANT         207
FT                   /note="D -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045053"
FT   VARIANT         207
FT                   /note="D -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs923100890)"
FT                   /id="VAR_045054"
FT   VARIANT         207
FT                   /note="D -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045055"
FT   VARIANT         207
FT                   /note="D -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045056"
FT   VARIANT         208
FT                   /note="D -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045057"
FT   VARIANT         208
FT                   /note="D -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045058"
FT   VARIANT         208
FT                   /note="D -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045059"
FT   VARIANT         208
FT                   /note="D -> I (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045809"
FT   VARIANT         208
FT                   /note="D -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045060"
FT   VARIANT         208
FT                   /note="D -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1464727668)"
FT                   /id="VAR_045061"
FT   VARIANT         208
FT                   /note="D -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045062"
FT   VARIANT         209
FT                   /note="R -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045063"
FT   VARIANT         209
FT                   /note="R -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045064"
FT   VARIANT         209
FT                   /note="R -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045065"
FT   VARIANT         209
FT                   /note="R -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045066"
FT   VARIANT         210
FT                   /note="N -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045067"
FT   VARIANT         210
FT                   /note="N -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045068"
FT   VARIANT         210
FT                   /note="N -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045069"
FT   VARIANT         210
FT                   /note="N -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045070"
FT   VARIANT         210
FT                   /note="N -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045071"
FT   VARIANT         210
FT                   /note="N -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045072"
FT   VARIANT         210
FT                   /note="N -> Y (in a familial cancer not matching LFS;
FT                   germline mutation; dbSNP:rs1060501200)"
FT                   /id="VAR_045073"
FT   VARIANT         211
FT                   /note="T -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501198)"
FT                   /id="VAR_045074"
FT   VARIANT         211
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045075"
FT   VARIANT         211
FT                   /note="T -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045076"
FT   VARIANT         211
FT                   /note="T -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045077"
FT   VARIANT         211
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045078"
FT   VARIANT         212
FT                   /note="F -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795766)"
FT                   /id="VAR_045079"
FT   VARIANT         212
FT                   /note="F -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045080"
FT   VARIANT         212
FT                   /note="F -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045081"
FT   VARIANT         212
FT                   /note="F -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045082"
FT   VARIANT         212
FT                   /note="F -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045083"
FT   VARIANT         213
FT                   /note="R -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs397516436)"
FT                   /id="VAR_045084"
FT   VARIANT         213
FT                   /note="R -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587778720)"
FT                   /id="VAR_045085"
FT   VARIANT         213
FT                   /note="R -> P (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587778720)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036506"
FT   VARIANT         213
FT                   /note="R -> Q (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587778720)"
FT                   /id="VAR_005955"
FT   VARIANT         213
FT                   /note="R -> W (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045086"
FT   VARIANT         214
FT                   /note="H -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045087"
FT   VARIANT         214
FT                   /note="H -> P (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1057519992)"
FT                   /id="VAR_045088"
FT   VARIANT         214
FT                   /note="H -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781386)"
FT                   /id="VAR_047177"
FT   VARIANT         214
FT                   /note="H -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519992)"
FT                   /id="VAR_045089"
FT   VARIANT         214
FT                   /note="H -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045090"
FT   VARIANT         215
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045091"
FT   VARIANT         215
FT                   /note="S -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs886039484)"
FT                   /id="VAR_045092"
FT   VARIANT         215
FT                   /note="S -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782177)"
FT                   /id="VAR_045093"
FT   VARIANT         215
FT                   /note="S -> K (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045810"
FT   VARIANT         215
FT                   /note="S -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782177)"
FT                   /id="VAR_045094"
FT   VARIANT         215
FT                   /note="S -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520001)"
FT                   /id="VAR_045095"
FT   VARIANT         215
FT                   /note="S -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782177)"
FT                   /id="VAR_045096"
FT   VARIANT         216
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045097"
FT   VARIANT         216
FT                   /note="V -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520004)"
FT                   /id="VAR_045098"
FT   VARIANT         216
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520004)"
FT                   /id="VAR_045099"
FT   VARIANT         216
FT                   /note="V -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882025)"
FT                   /id="VAR_045100"
FT   VARIANT         216
FT                   /note="V -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882025)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_005956"
FT   VARIANT         216
FT                   /note="V -> W (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045811"
FT   VARIANT         217
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045101"
FT   VARIANT         217
FT                   /note="V -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045102"
FT   VARIANT         217
FT                   /note="V -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045103"
FT   VARIANT         217
FT                   /note="V -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045104"
FT   VARIANT         217
FT                   /note="V -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045105"
FT   VARIANT         217
FT                   /note="V -> M (in dbSNP:rs35163653)"
FT                   /id="VAR_047178"
FT   VARIANT         218
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045106"
FT   VARIANT         218
FT                   /note="V -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045107"
FT   VARIANT         218
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525743)"
FT                   /id="VAR_045108"
FT   VARIANT         218
FT                   /note="V -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045109"
FT   VARIANT         218
FT                   /note="V -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs878854072)"
FT                   /id="VAR_045110"
FT   VARIANT         219
FT                   /note="P -> C (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045812"
FT   VARIANT         219
FT                   /note="P -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045111"
FT   VARIANT         219
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1420675064)"
FT                   /id="VAR_045112"
FT   VARIANT         219
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045113"
FT   VARIANT         219
FT                   /note="P -> S (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs879253894)"
FT                   /id="VAR_045114"
FT   VARIANT         219
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045115"
FT   VARIANT         220
FT                   /note="Y -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912666)"
FT                   /evidence="ECO:0000269|PubMed:7682763,
FT                   ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005957"
FT   VARIANT         220
FT                   /note="Y -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs530941076)"
FT                   /id="VAR_045116"
FT   VARIANT         220
FT                   /note="Y -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045117"
FT   VARIANT         220
FT                   /note="Y -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs530941076)"
FT                   /id="VAR_005958"
FT   VARIANT         220
FT                   /note="Y -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs530941076)"
FT                   /id="VAR_045118"
FT   VARIANT         220
FT                   /note="Y -> S (in a brain tumor with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs121912666)"
FT                   /id="VAR_005959"
FT   VARIANT         221
FT                   /note="E -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045119"
FT   VARIANT         221
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045120"
FT   VARIANT         221
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045121"
FT   VARIANT         221
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201592)"
FT                   /id="VAR_045122"
FT   VARIANT         221
FT                   /note="E -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045123"
FT   VARIANT         222
FT                   /note="P -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045124"
FT   VARIANT         222
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs146340390)"
FT                   /id="VAR_045125"
FT   VARIANT         222
FT                   /note="P -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045126"
FT   VARIANT         222
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045127"
FT   VARIANT         222
FT                   /note="P -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501203)"
FT                   /id="VAR_045128"
FT   VARIANT         222
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045129"
FT   VARIANT         223
FT                   /note="P -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047179"
FT   VARIANT         223
FT                   /note="P -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs138983188)"
FT                   /id="VAR_045130"
FT   VARIANT         223
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs138983188)"
FT                   /id="VAR_045131"
FT   VARIANT         223
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045132"
FT   VARIANT         223
FT                   /note="P -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045133"
FT   VARIANT         223
FT                   /note="P -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045134"
FT   VARIANT         224
FT                   /note="E -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs267605076)"
FT                   /id="VAR_045135"
FT   VARIANT         224
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045136"
FT   VARIANT         224
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525707)"
FT                   /id="VAR_045137"
FT   VARIANT         224
FT                   /note="E -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045138"
FT   VARIANT         225
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045139"
FT   VARIANT         225
FT                   /note="V -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045140"
FT   VARIANT         225
FT                   /note="V -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045141"
FT   VARIANT         225
FT                   /note="V -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045142"
FT   VARIANT         225
FT                   /note="V -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045143"
FT   VARIANT         225
FT                   /note="V -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs746504075)"
FT                   /id="VAR_045144"
FT   VARIANT         226
FT                   /note="G -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045145"
FT   VARIANT         226
FT                   /note="G -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047180"
FT   VARIANT         226
FT                   /note="G -> N (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045844"
FT   VARIANT         226
FT                   /note="G -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045146"
FT   VARIANT         226
FT                   /note="G -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs970212462)"
FT                   /id="VAR_045147"
FT   VARIANT         227
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045148"
FT   VARIANT         227
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045149"
FT   VARIANT         227
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045150"
FT   VARIANT         227
FT                   /note="S -> T (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation)"
FT                   /id="VAR_045151"
FT   VARIANT         228
FT                   /note="D -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045152"
FT   VARIANT         228
FT                   /note="D -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005960"
FT   VARIANT         228
FT                   /note="D -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045153"
FT   VARIANT         228
FT                   /note="D -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045154"
FT   VARIANT         228
FT                   /note="D -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045155"
FT   VARIANT         228
FT                   /note="D -> P (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045845"
FT   VARIANT         228
FT                   /note="D -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045156"
FT   VARIANT         228
FT                   /note="D -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045157"
FT   VARIANT         229
FT                   /note="C -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045158"
FT   VARIANT         229
FT                   /note="C -> N (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045846"
FT   VARIANT         229
FT                   /note="C -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064794312)"
FT                   /id="VAR_045159"
FT   VARIANT         229
FT                   /note="C -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045160"
FT   VARIANT         229
FT                   /note="C -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064793603)"
FT                   /id="VAR_045161"
FT   VARIANT         230
FT                   /note="T -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045162"
FT   VARIANT         230
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005961"
FT   VARIANT         230
FT                   /note="T -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045163"
FT   VARIANT         230
FT                   /note="T -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045164"
FT   VARIANT         230
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045165"
FT   VARIANT         231
FT                   /note="T -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045166"
FT   VARIANT         231
FT                   /note="T -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525564)"
FT                   /id="VAR_045167"
FT   VARIANT         231
FT                   /note="T -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045168"
FT   VARIANT         231
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045169"
FT   VARIANT         232
FT                   /note="I -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045170"
FT   VARIANT         232
FT                   /note="I -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525562)"
FT                   /id="VAR_045171"
FT   VARIANT         232
FT                   /note="I -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045172"
FT   VARIANT         232
FT                   /note="I -> S (in sporadic cancers; somatic mutation; does
FT                   not induce SNAI1 degradation)"
FT                   /evidence="ECO:0000269|PubMed:20385133"
FT                   /id="VAR_045173"
FT   VARIANT         232
FT                   /note="I -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781589)"
FT                   /id="VAR_005962"
FT   VARIANT         232
FT                   /note="I -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045174"
FT   VARIANT         233
FT                   /note="H -> D (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation)"
FT                   /id="VAR_045175"
FT   VARIANT         233
FT                   /note="H -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045176"
FT   VARIANT         233
FT                   /note="H -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045177"
FT   VARIANT         233
FT                   /note="H -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045178"
FT   VARIANT         233
FT                   /note="H -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs879254233)"
FT                   /id="VAR_047181"
FT   VARIANT         233
FT                   /note="H -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045179"
FT   VARIANT         234
FT                   /note="Y -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587780073)"
FT                   /id="VAR_005963"
FT   VARIANT         234
FT                   /note="Y -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs864622237)"
FT                   /id="VAR_045180"
FT   VARIANT         234
FT                   /note="Y -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045181"
FT   VARIANT         234
FT                   /note="Y -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs864622237)"
FT                   /id="VAR_005964"
FT   VARIANT         234
FT                   /note="Y -> K (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045847"
FT   VARIANT         234
FT                   /note="Y -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs864622237)"
FT                   /id="VAR_045182"
FT   VARIANT         234
FT                   /note="Y -> Q (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045848"
FT   VARIANT         234
FT                   /note="Y -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780073)"
FT                   /id="VAR_045183"
FT   VARIANT         235
FT                   /note="N -> D (in an adrenocortical carcinoma with no
FT                   family history; germline mutation and in sporadic cancers;
FT                   somatic mutation)"
FT                   /id="VAR_047182"
FT   VARIANT         235
FT                   /note="N -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045184"
FT   VARIANT         235
FT                   /note="N -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs144340710)"
FT                   /id="VAR_045185"
FT   VARIANT         235
FT                   /note="N -> M (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045849"
FT   VARIANT         235
FT                   /note="N -> S (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs144340710)"
FT                   /id="VAR_045186"
FT   VARIANT         235
FT                   /note="N -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045187"
FT   VARIANT         235
FT                   /note="N -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786204145)"
FT                   /id="VAR_045188"
FT   VARIANT         236
FT                   /note="Y -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs730882026)"
FT                   /id="VAR_045189"
FT   VARIANT         236
FT                   /note="Y -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782289)"
FT                   /id="VAR_045190"
FT   VARIANT         236
FT                   /note="Y -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045191"
FT   VARIANT         236
FT                   /note="Y -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782289)"
FT                   /id="VAR_045192"
FT   VARIANT         236
FT                   /note="Y -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782289)"
FT                   /id="VAR_045193"
FT   VARIANT         236
FT                   /note="Y -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882026)"
FT                   /id="VAR_045194"
FT   VARIANT         237
FT                   /note="M -> I (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587782664)"
FT                   /id="VAR_005965"
FT   VARIANT         237
FT                   /note="M -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs765848205)"
FT                   /id="VAR_045195"
FT   VARIANT         237
FT                   /note="M -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045196"
FT   VARIANT         237
FT                   /note="M -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs765848205)"
FT                   /id="VAR_045197"
FT   VARIANT         237
FT                   /note="M -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045198"
FT   VARIANT         237
FT                   /note="M -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882004)"
FT                   /id="VAR_045199"
FT   VARIANT         238
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882005)"
FT                   /id="VAR_005966"
FT   VARIANT         238
FT                   /note="C -> G (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs1057519981)"
FT                   /id="VAR_045200"
FT   VARIANT         238
FT                   /note="C -> H (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045850"
FT   VARIANT         238
FT                   /note="C -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519981)"
FT                   /id="VAR_045201"
FT   VARIANT         238
FT                   /note="C -> S (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs730882005)"
FT                   /id="VAR_045202"
FT   VARIANT         238
FT                   /note="C -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs193920789)"
FT                   /id="VAR_045203"
FT   VARIANT         238
FT                   /note="C -> Y (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs730882005)"
FT                   /id="VAR_005967"
FT   VARIANT         239
FT                   /note="N -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660807)"
FT                   /id="VAR_045204"
FT   VARIANT         239
FT                   /note="N -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045205"
FT   VARIANT         239
FT                   /note="N -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045206"
FT   VARIANT         239
FT                   /note="N -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057522275)"
FT                   /id="VAR_045207"
FT   VARIANT         239
FT                   /note="N -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519999)"
FT                   /id="VAR_045208"
FT   VARIANT         239
FT                   /note="N -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519999)"
FT                   /id="VAR_045209"
FT   VARIANT         239
FT                   /note="N -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045210"
FT   VARIANT         240
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045211"
FT   VARIANT         240
FT                   /note="S -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045212"
FT   VARIANT         240
FT                   /note="S -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005968"
FT   VARIANT         240
FT                   /note="S -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045213"
FT   VARIANT         240
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045214"
FT   VARIANT         240
FT                   /note="S -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045215"
FT   VARIANT         240
FT                   /note="S -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045216"
FT   VARIANT         241
FT                   /note="S -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520002)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033036"
FT   VARIANT         241
FT                   /note="S -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs28934573)"
FT                   /id="VAR_045217"
FT   VARIANT         241
FT                   /note="S -> F (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934573)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:1699228"
FT                   /id="VAR_005969"
FT   VARIANT         241
FT                   /note="S -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520002)"
FT                   /id="VAR_045218"
FT   VARIANT         241
FT                   /note="S -> T (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_047183"
FT   VARIANT         241
FT                   /note="S -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs28934573)"
FT                   /id="VAR_045219"
FT   VARIANT         242
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912655)"
FT                   /evidence="ECO:0000269|PubMed:1394225,
FT                   ECO:0000269|PubMed:16959974"
FT                   /id="VAR_005970"
FT   VARIANT         242
FT                   /note="C -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519982)"
FT                   /id="VAR_045220"
FT   VARIANT         242
FT                   /note="C -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045221"
FT   VARIANT         242
FT                   /note="C -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912655)"
FT                   /id="VAR_045222"
FT   VARIANT         242
FT                   /note="C -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs375874539)"
FT                   /id="VAR_045223"
FT   VARIANT         242
FT                   /note="C -> Y (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs121912655)"
FT                   /id="VAR_045224"
FT   VARIANT         243..244
FT                   /note="MG -> IC (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047184"
FT   VARIANT         243..244
FT                   /note="MG -> IS (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047185"
FT   VARIANT         243
FT                   /note="M -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045225"
FT   VARIANT         243
FT                   /note="M -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045226"
FT   VARIANT         243
FT                   /note="M -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203117)"
FT                   /id="VAR_045227"
FT   VARIANT         243
FT                   /note="M -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045228"
FT   VARIANT         243
FT                   /note="M -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882006)"
FT                   /id="VAR_045229"
FT   VARIANT         243
FT                   /note="M -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203117)"
FT                   /id="VAR_045230"
FT   VARIANT         244
FT                   /note="G -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs985033810)"
FT                   /id="VAR_047186"
FT   VARIANT         244
FT                   /note="G -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519989)"
FT                   /id="VAR_045231"
FT   VARIANT         244
FT                   /note="G -> D (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs1057517983)"
FT                   /id="VAR_045232"
FT   VARIANT         244
FT                   /note="G -> E (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045233"
FT   VARIANT         244
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519989)"
FT                   /id="VAR_045234"
FT   VARIANT         244
FT                   /note="G -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519989)"
FT                   /id="VAR_045235"
FT   VARIANT         244
FT                   /note="G -> V (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs985033810)"
FT                   /id="VAR_045236"
FT   VARIANT         245
FT                   /note="G -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912656)"
FT                   /id="VAR_005971"
FT   VARIANT         245
FT                   /note="G -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934575)"
FT                   /evidence="ECO:0000269|PubMed:1394225,
FT                   ECO:0000269|PubMed:1978757"
FT                   /id="VAR_005972"
FT   VARIANT         245
FT                   /note="G -> D (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912656)"
FT                   /evidence="ECO:0000269|PubMed:2259385"
FT                   /id="VAR_005973"
FT   VARIANT         245
FT                   /note="G -> E (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045237"
FT   VARIANT         245
FT                   /note="G -> F (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045851"
FT   VARIANT         245
FT                   /note="G -> H (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045852"
FT   VARIANT         245
FT                   /note="G -> L (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045853"
FT   VARIANT         245
FT                   /note="G -> N (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045854"
FT   VARIANT         245
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs28934575)"
FT                   /id="VAR_045238"
FT   VARIANT         245
FT                   /note="G -> S (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934575)"
FT                   /evidence="ECO:0000269|PubMed:8829627"
FT                   /id="VAR_005974"
FT   VARIANT         245
FT                   /note="G -> V (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912656)"
FT                   /evidence="ECO:0000269|PubMed:2263646"
FT                   /id="VAR_005975"
FT   VARIANT         246
FT                   /note="M -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1019340046)"
FT                   /id="VAR_045239"
FT   VARIANT         246
FT                   /note="M -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045240"
FT   VARIANT         246
FT                   /note="M -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs483352695)"
FT                   /id="VAR_044020"
FT   VARIANT         246
FT                   /note="M -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780074)"
FT                   /id="VAR_005976"
FT   VARIANT         246
FT                   /note="M -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780074)"
FT                   /id="VAR_005977"
FT   VARIANT         246
FT                   /note="M -> V (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs483352695)"
FT                   /id="VAR_005978"
FT   VARIANT         247..248
FT                   /note="NR -> IP (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047187"
FT   VARIANT         247..248
FT                   /note="NR -> KW (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047188"
FT   VARIANT         247
FT                   /note="N -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1452189221)"
FT                   /id="VAR_045241"
FT   VARIANT         247
FT                   /note="N -> F (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045855"
FT   VARIANT         247
FT                   /note="N -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201762)"
FT                   /id="VAR_005980"
FT   VARIANT         247
FT                   /note="N -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045242"
FT   VARIANT         247
FT                   /note="N -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201762)"
FT                   /id="VAR_045243"
FT   VARIANT         247
FT                   /note="N -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047189"
FT   VARIANT         247
FT                   /note="N -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045244"
FT   VARIANT         248
FT                   /note="R -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045245"
FT   VARIANT         248
FT                   /note="R -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912651)"
FT                   /id="VAR_005981"
FT   VARIANT         248
FT                   /note="R -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs11540652)"
FT                   /evidence="ECO:0000269|PubMed:1394225,
FT                   ECO:0000269|PubMed:7682763"
FT                   /id="VAR_005982"
FT   VARIANT         248
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs11540652)"
FT                   /id="VAR_045246"
FT   VARIANT         248
FT                   /note="R -> Q (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs11540652)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:7682763,
FT                   ECO:0000269|PubMed:7887414"
FT                   /id="VAR_005983"
FT   VARIANT         248
FT                   /note="R -> W (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912651)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:8829627"
FT                   /id="VAR_005984"
FT   VARIANT         249..250
FT                   /note="RP -> SA (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047190"
FT   VARIANT         249..250
FT                   /note="RP -> SS (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047191"
FT   VARIANT         249
FT                   /note="R -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782082)"
FT                   /id="VAR_005985"
FT   VARIANT         249
FT                   /note="R -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045247"
FT   VARIANT         249
FT                   /note="R -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782329)"
FT                   /id="VAR_045248"
FT   VARIANT         249
FT                   /note="R -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782329)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033037"
FT   VARIANT         249
FT                   /note="R -> N (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045856"
FT   VARIANT         249
FT                   /note="R -> S (in sporadic cancers; somatic mutation; does
FT                   not induce SNAI1 degradation; dbSNP:rs28934571)"
FT                   /evidence="ECO:0000269|PubMed:1694291,
FT                   ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:20385133"
FT                   /id="VAR_005986"
FT   VARIANT         249
FT                   /note="R -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782329)"
FT                   /id="VAR_045249"
FT   VARIANT         249
FT                   /note="R -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782082)"
FT                   /id="VAR_045250"
FT   VARIANT         250
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045251"
FT   VARIANT         250
FT                   /note="P -> F (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045857"
FT   VARIANT         250
FT                   /note="P -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045252"
FT   VARIANT         250
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064794311)"
FT                   /id="VAR_047192"
FT   VARIANT         250
FT                   /note="P -> N (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045858"
FT   VARIANT         250
FT                   /note="P -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045253"
FT   VARIANT         250
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045254"
FT   VARIANT         250
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045255"
FT   VARIANT         251
FT                   /note="I -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045256"
FT   VARIANT         251
FT                   /note="I -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882007)"
FT                   /id="VAR_045257"
FT   VARIANT         251
FT                   /note="I -> M (in LFS; germline mutation;
FT                   dbSNP:rs878854074)"
FT                   /id="VAR_045258"
FT   VARIANT         251
FT                   /note="I -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005987"
FT   VARIANT         251
FT                   /note="I -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882027)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033038"
FT   VARIANT         251
FT                   /note="I -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045259"
FT   VARIANT         251
FT                   /note="I -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045260"
FT   VARIANT         252
FT                   /note="L -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045261"
FT   VARIANT         252
FT                   /note="L -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045262"
FT   VARIANT         252
FT                   /note="L -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045263"
FT   VARIANT         252
FT                   /note="L -> P (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912653)"
FT                   /evidence="ECO:0000269|PubMed:1978757"
FT                   /id="VAR_005988"
FT   VARIANT         252
FT                   /note="L -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045264"
FT   VARIANT         253
FT                   /note="T -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045265"
FT   VARIANT         253
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045266"
FT   VARIANT         253
FT                   /note="T -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525465)"
FT                   /id="VAR_045267"
FT   VARIANT         253
FT                   /note="T -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047193"
FT   VARIANT         253
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045268"
FT   VARIANT         254
FT                   /note="I -> D (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045859"
FT   VARIANT         254
FT                   /note="I -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045269"
FT   VARIANT         254
FT                   /note="I -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045270"
FT   VARIANT         254
FT                   /note="I -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045271"
FT   VARIANT         254
FT                   /note="I -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_017908"
FT   VARIANT         254
FT                   /note="I -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1330865474)"
FT                   /id="VAR_045272"
FT   VARIANT         254
FT                   /note="I -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_017909"
FT   VARIANT         254
FT                   /note="I -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs746601313)"
FT                   /id="VAR_045273"
FT   VARIANT         255
FT                   /note="I -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519995)"
FT                   /id="VAR_045274"
FT   VARIANT         255
FT                   /note="I -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045275"
FT   VARIANT         255
FT                   /note="I -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659675)"
FT                   /id="VAR_045276"
FT   VARIANT         255
FT                   /note="I -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659675)"
FT                   /id="VAR_045277"
FT   VARIANT         255
FT                   /note="I -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659675)"
FT                   /id="VAR_045278"
FT   VARIANT         255
FT                   /note="I -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045279"
FT   VARIANT         256
FT                   /note="T -> I (in a brain tumor with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_045280"
FT   VARIANT         256
FT                   /note="T -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045281"
FT   VARIANT         256
FT                   /note="T -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045282"
FT   VARIANT         256
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045283"
FT   VARIANT         257
FT                   /note="L -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005989"
FT   VARIANT         257
FT                   /note="L -> Q (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934577)"
FT                   /id="VAR_045284"
FT   VARIANT         257
FT                   /note="L -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs28934577)"
FT                   /id="VAR_045285"
FT   VARIANT         257
FT                   /note="L -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045286"
FT   VARIANT         258
FT                   /note="E -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045287"
FT   VARIANT         258
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005990"
FT   VARIANT         258
FT                   /note="E -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501201)"
FT                   /id="VAR_045288"
FT   VARIANT         258
FT                   /note="E -> K (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912652)"
FT                   /evidence="ECO:0000269|PubMed:1978757"
FT                   /id="VAR_005991"
FT   VARIANT         258
FT                   /note="E -> L (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045860"
FT   VARIANT         258
FT                   /note="E -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045289"
FT   VARIANT         258
FT                   /note="E -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045290"
FT   VARIANT         259
FT                   /note="D -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047194"
FT   VARIANT         259
FT                   /note="D -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045291"
FT   VARIANT         259
FT                   /note="D -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs745425759)"
FT                   /id="VAR_045292"
FT   VARIANT         259
FT                   /note="D -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045293"
FT   VARIANT         259
FT                   /note="D -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045294"
FT   VARIANT         259
FT                   /note="D -> P (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045861"
FT   VARIANT         259
FT                   /note="D -> S (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045862"
FT   VARIANT         259
FT                   /note="D -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045295"
FT   VARIANT         259
FT                   /note="D -> Y (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033039"
FT   VARIANT         260
FT                   /note="S -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045296"
FT   VARIANT         260
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045297"
FT   VARIANT         260
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045298"
FT   VARIANT         260
FT                   /note="S -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045299"
FT   VARIANT         260
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045300"
FT   VARIANT         260
FT                   /note="S -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876658916)"
FT                   /id="VAR_045301"
FT   VARIANT         261
FT                   /note="S -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045302"
FT   VARIANT         261
FT                   /note="S -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045303"
FT   VARIANT         261
FT                   /note="S -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045304"
FT   VARIANT         261
FT                   /note="S -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045305"
FT   VARIANT         261
FT                   /note="S -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045306"
FT   VARIANT         262..263
FT                   /note="GN -> PD (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047195"
FT   VARIANT         262
FT                   /note="G -> C (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs200579969)"
FT                   /id="VAR_045307"
FT   VARIANT         262
FT                   /note="G -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047196"
FT   VARIANT         262
FT                   /note="G -> H (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045863"
FT   VARIANT         262
FT                   /note="G -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs200579969)"
FT                   /id="VAR_045308"
FT   VARIANT         262
FT                   /note="G -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691025)"
FT                   /evidence="ECO:0000269|Ref.23"
FT                   /id="VAR_045309"
FT   VARIANT         263
FT                   /note="N -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs72661119)"
FT                   /id="VAR_045310"
FT   VARIANT         263
FT                   /note="N -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045311"
FT   VARIANT         263
FT                   /note="N -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045312"
FT   VARIANT         263
FT                   /note="N -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045313"
FT   VARIANT         263
FT                   /note="N -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045314"
FT   VARIANT         264
FT                   /note="L -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045315"
FT   VARIANT         264
FT                   /note="L -> P (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555525353)"
FT                   /id="VAR_045316"
FT   VARIANT         264
FT                   /note="L -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045317"
FT   VARIANT         264
FT                   /note="L -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045318"
FT   VARIANT         264
FT                   /note="L -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045319"
FT   VARIANT         265
FT                   /note="L -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045320"
FT   VARIANT         265
FT                   /note="L -> P (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs879253942)"
FT                   /id="VAR_045321"
FT   VARIANT         265
FT                   /note="L -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045322"
FT   VARIANT         265
FT                   /note="L -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047197"
FT   VARIANT         266
FT                   /note="G -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045323"
FT   VARIANT         266
FT                   /note="G -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs193920774)"
FT                   /id="VAR_045324"
FT   VARIANT         266
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519990)"
FT                   /id="VAR_045325"
FT   VARIANT         266
FT                   /note="G -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs193920774)"
FT                   /id="VAR_045326"
FT   VARIANT         267
FT                   /note="R -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045327"
FT   VARIANT         267
FT                   /note="R -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045328"
FT   VARIANT         267
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780075)"
FT                   /id="VAR_045329"
FT   VARIANT         267
FT                   /note="R -> Q (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587780075)"
FT                   /id="VAR_045330"
FT   VARIANT         267
FT                   /note="R -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs55832599)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036507"
FT   VARIANT         268
FT                   /note="N -> F (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045864"
FT   VARIANT         268
FT                   /note="N -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045331"
FT   VARIANT         268
FT                   /note="N -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045332"
FT   VARIANT         268
FT                   /note="N -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045333"
FT   VARIANT         268
FT                   /note="N -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045334"
FT   VARIANT         268
FT                   /note="N -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045335"
FT   VARIANT         269
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045336"
FT   VARIANT         269
FT                   /note="S -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045337"
FT   VARIANT         269
FT                   /note="S -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047198"
FT   VARIANT         269
FT                   /note="S -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045338"
FT   VARIANT         269
FT                   /note="S -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045339"
FT   VARIANT         269
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045340"
FT   VARIANT         270
FT                   /note="F -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519986)"
FT                   /id="VAR_045341"
FT   VARIANT         270
FT                   /note="F -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519988)"
FT                   /id="VAR_045342"
FT   VARIANT         270
FT                   /note="F -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519987)"
FT                   /id="VAR_045343"
FT   VARIANT         270
FT                   /note="F -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519986)"
FT                   /id="VAR_045344"
FT   VARIANT         270
FT                   /note="F -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519988)"
FT                   /id="VAR_045345"
FT   VARIANT         270
FT                   /note="F -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045346"
FT   VARIANT         271
FT                   /note="E -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045347"
FT   VARIANT         271
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045348"
FT   VARIANT         271
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045349"
FT   VARIANT         271
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501191)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036508"
FT   VARIANT         271
FT                   /note="E -> P (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045865"
FT   VARIANT         271
FT                   /note="E -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045350"
FT   VARIANT         271
FT                   /note="E -> R (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045866"
FT   VARIANT         271
FT                   /note="E -> V (in an osteosarcoma with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_047199"
FT   VARIANT         272
FT                   /note="V -> A (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_045351"
FT   VARIANT         272
FT                   /note="V -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660333)"
FT                   /id="VAR_045352"
FT   VARIANT         272
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660333)"
FT                   /id="VAR_045353"
FT   VARIANT         272
FT                   /note="V -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912657)"
FT                   /evidence="ECO:0000269|PubMed:1737852"
FT                   /id="VAR_005992"
FT   VARIANT         272
FT                   /note="V -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912657)"
FT                   /id="VAR_045354"
FT   VARIANT         273
FT                   /note="R -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121913343)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:17224074, ECO:0000269|PubMed:7887414,
FT                   ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005993"
FT   VARIANT         273
FT                   /note="R -> G (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_005994"
FT   VARIANT         273
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; abolishes sequence-specific DNA
FT                   binding; does not induce SNAI1 degradation;
FT                   dbSNP:rs28934576)"
FT                   /evidence="ECO:0000269|PubMed:10570149,
FT                   ECO:0000269|PubMed:1394225, ECO:0000269|PubMed:1565144,
FT                   ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:1699228,
FT                   ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:20385133,
FT                   ECO:0000269|PubMed:7682763, ECO:0000269|Ref.14"
FT                   /id="VAR_005995"
FT   VARIANT         273
FT                   /note="R -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934576)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036509"
FT   VARIANT         273
FT                   /note="R -> N (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045867"
FT   VARIANT         273
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs28934576)"
FT                   /id="VAR_045355"
FT   VARIANT         273
FT                   /note="R -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045356"
FT   VARIANT         273
FT                   /note="R -> S (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs121913343)"
FT                   /id="VAR_045357"
FT   VARIANT         273
FT                   /note="R -> Y (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045868"
FT   VARIANT         274
FT                   /note="V -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520006)"
FT                   /id="VAR_045358"
FT   VARIANT         274
FT                   /note="V -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520006)"
FT                   /id="VAR_045359"
FT   VARIANT         274
FT                   /note="V -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520005)"
FT                   /id="VAR_005997"
FT   VARIANT         274
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520006)"
FT                   /id="VAR_047200"
FT   VARIANT         274
FT                   /note="V -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045360"
FT   VARIANT         274
FT                   /note="V -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520005)"
FT                   /id="VAR_045361"
FT   VARIANT         275
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs863224451)"
FT                   /id="VAR_045362"
FT   VARIANT         275
FT                   /note="C -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045363"
FT   VARIANT         275
FT                   /note="C -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519983)"
FT                   /id="VAR_045364"
FT   VARIANT         275
FT                   /note="C -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs863224451)"
FT                   /id="VAR_045365"
FT   VARIANT         275
FT                   /note="C -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525279)"
FT                   /id="VAR_005999"
FT   VARIANT         275
FT                   /note="C -> Y (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs863224451)"
FT                   /evidence="ECO:0000269|PubMed:7887414"
FT                   /id="VAR_005998"
FT   VARIANT         276
FT                   /note="A -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786202082)"
FT                   /id="VAR_045366"
FT   VARIANT         276
FT                   /note="A -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786202082)"
FT                   /id="VAR_045367"
FT   VARIANT         276
FT                   /note="A -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691029)"
FT                   /id="VAR_045368"
FT   VARIANT         276
FT                   /note="A -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045369"
FT   VARIANT         276
FT                   /note="A -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045370"
FT   VARIANT         276
FT                   /note="A -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045371"
FT   VARIANT         277
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs763098116)"
FT                   /id="VAR_045372"
FT   VARIANT         277
FT                   /note="C -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795369)"
FT                   /id="VAR_006000"
FT   VARIANT         277
FT                   /note="C -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795369)"
FT                   /id="VAR_045373"
FT   VARIANT         277
FT                   /note="C -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045374"
FT   VARIANT         277
FT                   /note="C -> W (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047201"
FT   VARIANT         277
FT                   /note="C -> Y (in an osteosarcoma with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs763098116)"
FT                   /id="VAR_045375"
FT   VARIANT         278
FT                   /note="P -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs17849781)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_006001"
FT   VARIANT         278
FT                   /note="P -> F (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045869"
FT   VARIANT         278
FT                   /note="P -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659802)"
FT                   /id="VAR_006002"
FT   VARIANT         278
FT                   /note="P -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs876659802)"
FT                   /evidence="ECO:0000269|PubMed:2263646"
FT                   /id="VAR_006003"
FT   VARIANT         278
FT                   /note="P -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659802)"
FT                   /id="VAR_045376"
FT   VARIANT         278
FT                   /note="P -> S (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs17849781)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:9450901"
FT                   /id="VAR_006004"
FT   VARIANT         278
FT                   /note="P -> T (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs17849781)"
FT                   /id="VAR_006005"
FT   VARIANT         279
FT                   /note="G -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064793881)"
FT                   /id="VAR_006006"
FT   VARIANT         279
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525248)"
FT                   /id="VAR_045377"
FT   VARIANT         279
FT                   /note="G -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045378"
FT   VARIANT         279
FT                   /note="G -> W (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045379"
FT   VARIANT         280
FT                   /note="R -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs753660142)"
FT                   /id="VAR_045380"
FT   VARIANT         280
FT                   /note="R -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912660)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_006008"
FT   VARIANT         280
FT                   /note="R -> K (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; no effect on interaction with CCAR2;
FT                   dbSNP:rs121912660)"
FT                   /evidence="ECO:0000269|PubMed:1694291,
FT                   ECO:0000269|PubMed:25732823"
FT                   /id="VAR_006007"
FT   VARIANT         280
FT                   /note="R -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045381"
FT   VARIANT         280
FT                   /note="R -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045382"
FT   VARIANT         280
FT                   /note="R -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912660)"
FT                   /evidence="ECO:0000269|PubMed:1631151"
FT                   /id="VAR_006009"
FT   VARIANT         281..282
FT                   /note="DR -> EW (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047203"
FT   VARIANT         281
FT                   /note="D -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781525)"
FT                   /id="VAR_006010"
FT   VARIANT         281
FT                   /note="D -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519984)"
FT                   /evidence="ECO:0000269|PubMed:1459726"
FT                   /id="VAR_006011"
FT   VARIANT         281
FT                   /note="D -> G (in a brain tumor with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs587781525)"
FT                   /id="VAR_006012"
FT   VARIANT         281
FT                   /note="D -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs764146326)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_006013"
FT   VARIANT         281
FT                   /note="D -> N (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs764146326)"
FT                   /id="VAR_047202"
FT   VARIANT         281
FT                   /note="D -> R (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045870"
FT   VARIANT         281
FT                   /note="D -> V (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs587781525)"
FT                   /id="VAR_006014"
FT   VARIANT         281
FT                   /note="D -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs764146326)"
FT                   /id="VAR_045383"
FT   VARIANT         282
FT                   /note="R -> G (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934574)"
FT                   /id="VAR_045384"
FT   VARIANT         282
FT                   /note="R -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045385"
FT   VARIANT         282
FT                   /note="R -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882008)"
FT                   /id="VAR_006015"
FT   VARIANT         282
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882008)"
FT                   /id="VAR_045386"
FT   VARIANT         282
FT                   /note="R -> Q (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs730882008)"
FT                   /evidence="ECO:0000269|PubMed:18453682, ECO:0000269|Ref.22"
FT                   /id="VAR_045387"
FT   VARIANT         282
FT                   /note="R -> W (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; does not induce SNAI1
FT                   degradation; dbSNP:rs28934574)"
FT                   /evidence="ECO:0000269|PubMed:20385133,
FT                   ECO:0000269|PubMed:8829627"
FT                   /id="VAR_006016"
FT   VARIANT         283
FT                   /note="R -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs149633775)"
FT                   /id="VAR_006017"
FT   VARIANT         283
FT                   /note="R -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_006018"
FT   VARIANT         283
FT                   /note="R -> H (in a brain tumor with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs371409680)"
FT                   /id="VAR_006019"
FT   VARIANT         283
FT                   /note="R -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045388"
FT   VARIANT         283
FT                   /note="R -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_006020"
FT   VARIANT         283
FT                   /note="R -> S (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs149633775)"
FT                   /id="VAR_045389"
FT   VARIANT         284
FT                   /note="T -> A (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT                   /id="VAR_006021"
FT   VARIANT         284
FT                   /note="T -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs863224685)"
FT                   /id="VAR_045390"
FT   VARIANT         284
FT                   /note="T -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045391"
FT   VARIANT         284
FT                   /note="T -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1204379654)"
FT                   /id="VAR_006022"
FT   VARIANT         285
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045392"
FT   VARIANT         285
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045393"
FT   VARIANT         285
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045394"
FT   VARIANT         285
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs112431538)"
FT                   /evidence="ECO:0000269|PubMed:1459726,
FT                   ECO:0000269|PubMed:1694291"
FT                   /id="VAR_006023"
FT   VARIANT         285
FT                   /note="E -> Q (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_006024"
FT   VARIANT         285
FT                   /note="E -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912667)"
FT                   /id="VAR_006025"
FT   VARIANT         286
FT                   /note="E -> A (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs1057519985)"
FT                   /id="VAR_006026"
FT   VARIANT         286
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_006027"
FT   VARIANT         286
FT                   /note="E -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519985)"
FT                   /id="VAR_006028"
FT   VARIANT         286
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201059)"
FT                   /evidence="ECO:0000269|PubMed:11023613,
FT                   ECO:0000269|PubMed:8316628"
FT                   /id="VAR_006029"
FT   VARIANT         286
FT                   /note="E -> L (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045871"
FT   VARIANT         286
FT                   /note="E -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201059)"
FT                   /evidence="ECO:0000269|PubMed:8829627"
FT                   /id="VAR_006030"
FT   VARIANT         286
FT                   /note="E -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519985)"
FT                   /id="VAR_045395"
FT   VARIANT         287
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047204"
FT   VARIANT         287
FT                   /note="E -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs748891343)"
FT                   /id="VAR_045396"
FT   VARIANT         287
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045397"
FT   VARIANT         287
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782006)"
FT                   /id="VAR_045398"
FT   VARIANT         287
FT                   /note="E -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045399"
FT   VARIANT         288
FT                   /note="N -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045400"
FT   VARIANT         288
FT                   /note="N -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045401"
FT   VARIANT         288
FT                   /note="N -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045402"
FT   VARIANT         288
FT                   /note="N -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045403"
FT   VARIANT         288
FT                   /note="N -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045404"
FT   VARIANT         289
FT                   /note="L -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045405"
FT   VARIANT         289
FT                   /note="L -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045406"
FT   VARIANT         289
FT                   /note="L -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045407"
FT   VARIANT         289
FT                   /note="L -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045408"
FT   VARIANT         289
FT                   /note="L -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525154)"
FT                   /id="VAR_045409"
FT   VARIANT         290
FT                   /note="R -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs770374782)"
FT                   /id="VAR_045410"
FT   VARIANT         290
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs55819519)"
FT                   /id="VAR_045411"
FT   VARIANT         290
FT                   /note="R -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_045412"
FT   VARIANT         291
FT                   /note="K -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525126)"
FT                   /id="VAR_045413"
FT   VARIANT         291
FT                   /note="K -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045414"
FT   VARIANT         291
FT                   /note="K -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs372613518)"
FT                   /id="VAR_045415"
FT   VARIANT         291
FT                   /note="K -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047205"
FT   VARIANT         291
FT                   /note="K -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs781490101)"
FT                   /id="VAR_045416"
FT   VARIANT         291
FT                   /note="K -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045417"
FT   VARIANT         292
FT                   /note="K -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045418"
FT   VARIANT         292
FT                   /note="K -> G (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045872"
FT   VARIANT         292
FT                   /note="K -> I (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation; dbSNP:rs121912663)"
FT                   /evidence="ECO:0000269|PubMed:10484981"
FT                   /id="VAR_015819"
FT   VARIANT         292
FT                   /note="K -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045419"
FT   VARIANT         292
FT                   /note="K -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045420"
FT   VARIANT         292
FT                   /note="K -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912663)"
FT                   /id="VAR_045421"
FT   VARIANT         292
FT                   /note="K -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045422"
FT   VARIANT         293
FT                   /note="G -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045423"
FT   VARIANT         293
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780076)"
FT                   /id="VAR_045424"
FT   VARIANT         293
FT                   /note="G -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045425"
FT   VARIANT         293
FT                   /note="G -> W (in a brain tumor with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs587780076)"
FT                   /id="VAR_045426"
FT   VARIANT         294
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045427"
FT   VARIANT         294
FT                   /note="E -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1305324490)"
FT                   /id="VAR_045428"
FT   VARIANT         294
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045429"
FT   VARIANT         294
FT                   /note="E -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047206"
FT   VARIANT         294
FT                   /note="E -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045430"
FT   VARIANT         294
FT                   /note="E -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045431"
FT   VARIANT         295
FT                   /note="P -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045432"
FT   VARIANT         295
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs751713111)"
FT                   /id="VAR_045433"
FT   VARIANT         295
FT                   /note="P -> R (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs751713111)"
FT                   /id="VAR_045434"
FT   VARIANT         295
FT                   /note="P -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691006)"
FT                   /id="VAR_045435"
FT   VARIANT         296
FT                   /note="H -> C (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045873"
FT   VARIANT         296
FT                   /note="H -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045436"
FT   VARIANT         296
FT                   /note="H -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047207"
FT   VARIANT         296
FT                   /note="H -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045437"
FT   VARIANT         296
FT                   /note="H -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_006031"
FT   VARIANT         296
FT                   /note="H -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045438"
FT   VARIANT         296
FT                   /note="H -> R (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs483352696)"
FT                   /id="VAR_045439"
FT   VARIANT         296
FT                   /note="H -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs672601296)"
FT                   /id="VAR_045440"
FT   VARIANT         297
FT                   /note="H -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045441"
FT   VARIANT         297
FT                   /note="H -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045442"
FT   VARIANT         297
FT                   /note="H -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045443"
FT   VARIANT         297
FT                   /note="H -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659477)"
FT                   /id="VAR_045444"
FT   VARIANT         297
FT                   /note="H -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045445"
FT   VARIANT         298
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045446"
FT   VARIANT         298
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045447"
FT   VARIANT         298
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs201744589)"
FT                   /id="VAR_045448"
FT   VARIANT         298
FT                   /note="E -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs201744589)"
FT                   /id="VAR_045449"
FT   VARIANT         298
FT                   /note="E -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045450"
FT   VARIANT         299
FT                   /note="L -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045451"
FT   VARIANT         299
FT                   /note="L -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045452"
FT   VARIANT         299
FT                   /note="L -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045453"
FT   VARIANT         299
FT                   /note="L -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045454"
FT   VARIANT         300
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045455"
FT   VARIANT         300
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs909643864)"
FT                   /id="VAR_045456"
FT   VARIANT         300
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_006032"
FT   VARIANT         300
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045457"
FT   VARIANT         301
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045458"
FT   VARIANT         301
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525067)"
FT                   /id="VAR_006033"
FT   VARIANT         301
FT                   /note="P -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045459"
FT   VARIANT         301
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045460"
FT   VARIANT         301
FT                   /note="P -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047208"
FT   VARIANT         302
FT                   /note="G -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045461"
FT   VARIANT         302
FT                   /note="G -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501202)"
FT                   /id="VAR_006034"
FT   VARIANT         302
FT                   /note="G -> R (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs863224686)"
FT                   /id="VAR_045462"
FT   VARIANT         302
FT                   /note="G -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_006035"
FT   VARIANT         303
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045463"
FT   VARIANT         303
FT                   /note="S -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045464"
FT   VARIANT         303
FT                   /note="S -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876658714)"
FT                   /id="VAR_045465"
FT   VARIANT         303
FT                   /note="S -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045466"
FT   VARIANT         304
FT                   /note="T -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782654)"
FT                   /id="VAR_045467"
FT   VARIANT         304
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045468"
FT   VARIANT         304
FT                   /note="T -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045469"
FT   VARIANT         304
FT                   /note="T -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047209"
FT   VARIANT         305
FT                   /note="K -> E (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045470"
FT   VARIANT         305
FT                   /note="K -> M (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_045471"
FT   VARIANT         305
FT                   /note="K -> N (in sporadic cancers; somatic mutation; loss
FT                   of nuclear localization)"
FT                   /evidence="ECO:0000269|PubMed:10551826"
FT                   /id="VAR_045472"
FT   VARIANT         305
FT                   /note="K -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045473"
FT   VARIANT         305
FT                   /note="K -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045474"
FT   VARIANT         306
FT                   /note="R -> P (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation)"
FT                   /id="VAR_045475"
FT   VARIANT         306
FT                   /note="R -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1048095040)"
FT                   /id="VAR_006036"
FT   VARIANT         307
FT                   /note="A -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045476"
FT   VARIANT         307
FT                   /note="A -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045477"
FT   VARIANT         307
FT                   /note="A -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_006037"
FT   VARIANT         308
FT                   /note="L -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045478"
FT   VARIANT         308
FT                   /note="L -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045479"
FT   VARIANT         309
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045480"
FT   VARIANT         309
FT                   /note="P -> S (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs1555525012)"
FT                   /evidence="ECO:0000269|Ref.14"
FT                   /id="VAR_006038"
FT   VARIANT         310
FT                   /note="N -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045481"
FT   VARIANT         310
FT                   /note="N -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045482"
FT   VARIANT         311
FT                   /note="N -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525007)"
FT                   /id="VAR_045483"
FT   VARIANT         311
FT                   /note="N -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045484"
FT   VARIANT         311
FT                   /note="N -> S (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs56184981)"
FT                   /id="VAR_045485"
FT   VARIANT         311
FT                   /note="N -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs56184981)"
FT                   /id="VAR_045486"
FT   VARIANT         312
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045487"
FT   VARIANT         312
FT                   /note="T -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs145151284)"
FT                   /id="VAR_045488"
FT   VARIANT         313
FT                   /note="S -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045489"
FT   VARIANT         313
FT                   /note="S -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045490"
FT   VARIANT         313
FT                   /note="S -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045491"
FT   VARIANT         313
FT                   /note="S -> R (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1367492395)"
FT                   /id="VAR_045492"
FT   VARIANT         314
FT                   /note="S -> F (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs751440465)"
FT                   /id="VAR_045493"
FT   VARIANT         315
FT                   /note="S -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045494"
FT   VARIANT         315
FT                   /note="S -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045495"
FT   VARIANT         315
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045496"
FT   VARIANT         316
FT                   /note="P -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555524979)"
FT                   /id="VAR_045497"
FT   VARIANT         316
FT                   /note="P -> T (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs772773208)"
FT                   /id="VAR_045498"
FT   VARIANT         317
FT                   /note="Q -> H (in a kidney cancer with no family history;
FT                   germline mutation and in a sporadic cancer; somatic
FT                   mutation; dbSNP:rs1060501199)"
FT                   /id="VAR_045499"
FT   VARIANT         317
FT                   /note="Q -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs764735889)"
FT                   /id="VAR_045500"
FT   VARIANT         317
FT                   /note="Q -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047210"
FT   VARIANT         317
FT                   /note="Q -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045501"
FT   VARIANT         317
FT                   /note="Q -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1159579789)"
FT                   /id="VAR_045502"
FT   VARIANT         318
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555524975)"
FT                   /id="VAR_045503"
FT   VARIANT         319
FT                   /note="K -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045504"
FT   VARIANT         319
FT                   /note="K -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045505"
FT   VARIANT         319
FT                   /note="K -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045506"
FT   VARIANT         320
FT                   /note="K -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045507"
FT   VARIANT         321
FT                   /note="K -> E (in kidney cancer; germline mutation)"
FT                   /id="VAR_045508"
FT   VARIANT         321
FT                   /note="K -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045509"
FT   VARIANT         322
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045510"
FT   VARIANT         322
FT                   /note="P -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045511"
FT   VARIANT         323
FT                   /note="L -> G (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045874"
FT   VARIANT         323
FT                   /note="L -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045512"
FT   VARIANT         323
FT                   /note="L -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045513"
FT   VARIANT         323
FT                   /note="L -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045514"
FT   VARIANT         323
FT                   /note="L -> V (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1432281680)"
FT                   /id="VAR_047211"
FT   VARIANT         324
FT                   /note="D -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045515"
FT   VARIANT         324
FT                   /note="D -> S (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045875"
FT   VARIANT         324
FT                   /note="D -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045516"
FT   VARIANT         325
FT                   /note="G -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045517"
FT   VARIANT         325
FT                   /note="G -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045518"
FT   VARIANT         325
FT                   /note="G -> V (in LFS; germline mutation;
FT                   dbSNP:rs121912659)"
FT                   /evidence="ECO:0000269|PubMed:1565144"
FT                   /id="VAR_006039"
FT   VARIANT         326
FT                   /note="E -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045519"
FT   VARIANT         327
FT                   /note="Y -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045520"
FT   VARIANT         327
FT                   /note="Y -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045521"
FT   VARIANT         328
FT                   /note="F -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045522"
FT   VARIANT         328
FT                   /note="F -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045523"
FT   VARIANT         328
FT                   /note="F -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045524"
FT   VARIANT         329
FT                   /note="T -> I (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs969930693)"
FT                   /id="VAR_045525"
FT   VARIANT         329
FT                   /note="T -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045526"
FT   VARIANT         330
FT                   /note="L -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045527"
FT   VARIANT         330
FT                   /note="L -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047212"
FT   VARIANT         330
FT                   /note="L -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045528"
FT   VARIANT         331
FT                   /note="Q -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs11575996)"
FT                   /id="VAR_045529"
FT   VARIANT         331
FT                   /note="Q -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045530"
FT   VARIANT         331
FT                   /note="Q -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795056)"
FT                   /id="VAR_045531"
FT   VARIANT         332
FT                   /note="I -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045532"
FT   VARIANT         334
FT                   /note="G -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_006040"
FT   VARIANT         334
FT                   /note="G -> W (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs730882028)"
FT                   /id="VAR_045533"
FT   VARIANT         335
FT                   /note="R -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045534"
FT   VARIANT         335
FT                   /note="R -> H (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs771939956)"
FT                   /id="VAR_045535"
FT   VARIANT         335
FT                   /note="R -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045536"
FT   VARIANT         337
FT                   /note="R -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587782529)"
FT                   /evidence="ECO:0000269|PubMed:9452042"
FT                   /id="VAR_006041"
FT   VARIANT         337
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912664)"
FT                   /evidence="ECO:0000269|PubMed:11481490"
FT                   /id="VAR_035016"
FT   VARIANT         337
FT                   /note="R -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912664)"
FT                   /id="VAR_045537"
FT   VARIANT         337
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912664)"
FT                   /id="VAR_045538"
FT   VARIANT         338
FT                   /note="F -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045539"
FT   VARIANT         338
FT                   /note="F -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs150293825)"
FT                   /id="VAR_045540"
FT   VARIANT         339
FT                   /note="E -> K (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs17882252)"
FT                   /evidence="ECO:0000269|Ref.12"
FT                   /id="VAR_022316"
FT   VARIANT         339
FT                   /note="E -> Q (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs17882252)"
FT                   /id="VAR_045541"
FT   VARIANT         341
FT                   /note="F -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045542"
FT   VARIANT         342
FT                   /note="R -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045543"
FT   VARIANT         342
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs375338359)"
FT                   /id="VAR_045544"
FT   VARIANT         342
FT                   /note="R -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs375338359)"
FT                   /id="VAR_047213"
FT   VARIANT         343
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045545"
FT   VARIANT         344
FT                   /note="L -> P (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation; dbSNP:rs121912662)"
FT                   /id="VAR_045546"
FT   VARIANT         344
FT                   /note="L -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045547"
FT   VARIANT         346
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045548"
FT   VARIANT         347
FT                   /note="A -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045549"
FT   VARIANT         347
FT                   /note="A -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045550"
FT   VARIANT         348
FT                   /note="L -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045551"
FT   VARIANT         348
FT                   /note="L -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045552"
FT   VARIANT         349
FT                   /note="E -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045553"
FT   VARIANT         352
FT                   /note="D -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045554"
FT   VARIANT         353
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045555"
FT   VARIANT         354
FT                   /note="Q -> E (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045556"
FT   VARIANT         354
FT                   /note="Q -> K (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs755394212)"
FT                   /id="VAR_045557"
FT   VARIANT         354
FT                   /note="Q -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs752142489)"
FT                   /id="VAR_047214"
FT   VARIANT         356
FT                   /note="G -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045558"
FT   VARIANT         356
FT                   /note="G -> W (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045559"
FT   VARIANT         358
FT                   /note="E -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045560"
FT   VARIANT         358
FT                   /note="E -> K (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587782237)"
FT                   /id="VAR_045561"
FT   VARIANT         360
FT                   /note="G -> A (in dbSNP:rs35993958)"
FT                   /id="VAR_045562"
FT   VARIANT         360
FT                   /note="G -> V (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs35993958)"
FT                   /id="VAR_045563"
FT   VARIANT         363
FT                   /note="R -> K (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs876660285)"
FT                   /id="VAR_045564"
FT   VARIANT         364
FT                   /note="A -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045565"
FT   VARIANT         364
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045566"
FT   VARIANT         364
FT                   /note="A -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045567"
FT   VARIANT         365
FT                   /note="H -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047215"
FT   VARIANT         365
FT                   /note="H -> Y (in a familial cancer not matching LFS;
FT                   germline mutation and in a sporadic cancer; somatic
FT                   mutation; dbSNP:rs267605075)"
FT                   /id="VAR_045568"
FT   VARIANT         366
FT                   /note="S -> A (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs17881470)"
FT                   /evidence="ECO:0000269|Ref.12"
FT                   /id="VAR_022317"
FT   VARIANT         370
FT                   /note="K -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045569"
FT   VARIANT         376
FT                   /note="S -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045570"
FT   VARIANT         376
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045571"
FT   VARIANT         379
FT                   /note="R -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs863224682)"
FT                   /id="VAR_045572"
FT   VARIANT         385
FT                   /note="F -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555524094)"
FT                   /id="VAR_045573"
FT   VARIANT         389
FT                   /note="G -> W (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587783064)"
FT                   /id="VAR_045574"
FT   VARIANT         392
FT                   /note="S -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045575"
FT   MUTAGEN         15
FT                   /note="S->A: Loss of interaction with PPP2R5C, PPP2CA AND
FT                   PPP2R1A."
FT                   /evidence="ECO:0000269|PubMed:17967874"
FT   MUTAGEN         18
FT                   /note="T->A: No effect on interaction with MDM2 and
FT                   increase in protein levels after DNA damage."
FT                   /evidence="ECO:0000269|PubMed:10570149"
FT   MUTAGEN         20
FT                   /note="S->A: Abolishes phosphorylation site. Abolishes
FT                   increase in protein levels after DNA damage."
FT                   /evidence="ECO:0000269|PubMed:10570149"
FT   MUTAGEN         20
FT                   /note="S->D: Constitutively increased TP53 protein levels."
FT                   /evidence="ECO:0000269|PubMed:10570149"
FT   MUTAGEN         22..23
FT                   /note="LW->QS: Loss of interaction with MDM2, leading to
FT                   constitutively increased TP53 protein levels."
FT                   /evidence="ECO:0000269|PubMed:10570149"
FT   MUTAGEN         37
FT                   /note="S->D: Abolihes phosphorylation by MAPKAPK5."
FT                   /evidence="ECO:0000269|PubMed:17254968"
FT   MUTAGEN         46
FT                   /note="S->A: Abolishes phosphorylation by DYRK2 and HIPK2
FT                   and acetylation of K-382 by CREBBP."
FT                   /evidence="ECO:0000269|PubMed:11740489,
FT                   ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958"
FT   MUTAGEN         46
FT                   /note="Missing: Alters interaction with WWOX."
FT                   /evidence="ECO:0000269|PubMed:11740489,
FT                   ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958"
FT   MUTAGEN         55
FT                   /note="T->A: Blocks phosphorylation by TAF1."
FT                   /evidence="ECO:0000269|PubMed:15053879"
FT   MUTAGEN         183
FT                   /note="S->A: Abolishes strongly phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MUTAGEN         183
FT                   /note="S->E: Inhibits slightly its transcriptional
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MUTAGEN         248
FT                   /note="R->S: Does not induce SNAI1 degradation."
FT                   /evidence="ECO:0000269|PubMed:20385133"
FT   MUTAGEN         269
FT                   /note="S->A: Abolishes phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MUTAGEN         269
FT                   /note="S->E: Inhibits strongly its transcriptional
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MUTAGEN         284
FT                   /note="T->E: Inhibits strongly its transcriptional
FT                   activity."
FT   MUTAGEN         291..292
FT                   /note="KK->RR: Abolishes polyubiquitination by MKRN1."
FT                   /evidence="ECO:0000269|PubMed:19536131"
FT   MUTAGEN         319
FT                   /note="K->A: Loss of nuclear localization; when associated
FT                   with A-320 and A-321."
FT                   /evidence="ECO:0000269|PubMed:2156209"
FT   MUTAGEN         320
FT                   /note="K->A: Loss of nuclear localization; when associated
FT                   with A-319 and A-321."
FT                   /evidence="ECO:0000269|PubMed:2156209"
FT   MUTAGEN         321
FT                   /note="K->A: Loss of nuclear localization; when associated
FT                   with A-319 and A-320."
FT                   /evidence="ECO:0000269|PubMed:2156209"
FT   MUTAGEN         333..337
FT                   /note="RGRER->KGKEK: Reduced methylation by PRMT5. Reduced
FT                   nuclear localization. Decreased binding to promoters of
FT                   target genes. Reduced transcriptional activity. Decrease in
FT                   cell cycle arrest."
FT                   /evidence="ECO:0000269|PubMed:19011621"
FT   MUTAGEN         359
FT                   /note="P->D: Abolishes binding to USP7."
FT                   /evidence="ECO:0000269|PubMed:16402859"
FT   MUTAGEN         361
FT                   /note="G->E: Abolishes binding to USP7."
FT                   /evidence="ECO:0000269|PubMed:16402859"
FT   MUTAGEN         362
FT                   /note="S->A: Abolishes binding to USP7."
FT                   /evidence="ECO:0000269|PubMed:16402859"
FT   MUTAGEN         370
FT                   /note="K->R: Induces a decrease in methylation by SMYD2."
FT                   /evidence="ECO:0000269|PubMed:17108971"
FT   MUTAGEN         372
FT                   /note="K->R: Induces a decrease in protein stabilization."
FT                   /evidence="ECO:0000269|PubMed:15525938"
FT   MUTAGEN         373
FT                   /note="K->R: Abolishes dimethylation by EHMT1 and EHMT2."
FT                   /evidence="ECO:0000269|PubMed:20118233"
FT   MUTAGEN         382
FT                   /note="K->A: Abolishes acetylation by CREBBP."
FT                   /evidence="ECO:0000269|PubMed:10884347,
FT                   ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234,
FT                   ECO:0000269|PubMed:20870725"
FT   MUTAGEN         382
FT                   /note="K->R: Abolishes monomethylation by KMT5A."
FT                   /evidence="ECO:0000269|PubMed:10884347,
FT                   ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234,
FT                   ECO:0000269|PubMed:20870725"
FT   MUTAGEN         383
FT                   /note="L->A: Abolishes S-315 phosphorylation by CDK2/cyclin
FT                   A."
FT                   /evidence="ECO:0000269|PubMed:10884347"
FT   MUTAGEN         385
FT                   /note="F->A: Reduced SUMO1 conjugation."
FT                   /evidence="ECO:0000269|PubMed:10884347,
FT                   ECO:0000269|PubMed:11124955"
FT   MUTAGEN         386
FT                   /note="K->A: Abolishes SUMO1 conjugation, in vitro and in
FT                   vivo."
FT                   /evidence="ECO:0000269|PubMed:11124955, ECO:0000269|Ref.37"
FT   MUTAGEN         387
FT                   /note="T->A: No effect SUMO1 conjugation."
FT                   /evidence="ECO:0000269|PubMed:11124955"
FT   MUTAGEN         388
FT                   /note="E->A: Abolishes SUMO1 conjugation."
FT                   /evidence="ECO:0000269|PubMed:11124955"
FT   HELIX           3..6
FT                   /evidence="ECO:0000244|PDB:5HOU"
FT   TURN            8..10
FT                   /evidence="ECO:0000244|PDB:5HOU"
FT   HELIX           19..23
FT                   /evidence="ECO:0000244|PDB:3DAC"
FT   STRAND          27..29
FT                   /evidence="ECO:0000244|PDB:2K8F"
FT   HELIX           30..32
FT                   /evidence="ECO:0000244|PDB:5HPD"
FT   STRAND          33..35
FT                   /evidence="ECO:0000244|PDB:2L14"
FT   HELIX           36..38
FT                   /evidence="ECO:0000244|PDB:2B3G"
FT   HELIX           41..44
FT                   /evidence="ECO:0000244|PDB:2B3G"
FT   HELIX           47..55
FT                   /evidence="ECO:0000244|PDB:2B3G"
FT   TURN            105..108
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          110..112
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          118..120
FT                   /evidence="ECO:0000244|PDB:3Q05"
FT   TURN            121..123
FT                   /evidence="ECO:0000244|PDB:3Q05"
FT   STRAND          124..127
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   TURN            128..131
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          132..135
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          141..146
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          148..150
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          156..165
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   HELIX           166..168
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   HELIX           177..180
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          181..183
FT                   /evidence="ECO:0000244|PDB:4KVP"
FT   STRAND          187..189
FT                   /evidence="ECO:0000244|PDB:6GGC"
FT   STRAND          194..199
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          204..207
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   TURN            209..211
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          214..219
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   TURN            225..227
FT                   /evidence="ECO:0000244|PDB:2FEJ"
FT   STRAND          228..236
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   HELIX           240..242
FT                   /evidence="ECO:0000244|PDB:3D07"
FT   TURN            243..248
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          251..258
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          260..262
FT                   /evidence="ECO:0000244|PDB:2ADY"
FT   STRAND          264..274
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   HELIX           278..287
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   HELIX           288..290
FT                   /evidence="ECO:0000244|PDB:4HJE"
FT   HELIX           322..324
FT                   /evidence="ECO:0000244|PDB:3Q01"
FT   STRAND          327..334
FT                   /evidence="ECO:0000244|PDB:3Q01"
FT   HELIX           335..354
FT                   /evidence="ECO:0000244|PDB:1AIE"
FT   HELIX           375..380
FT                   /evidence="ECO:0000244|PDB:1YC5"
SQ   SEQUENCE   393 AA;  43653 MW;  AD5C149FD8106131 CRC64;
     MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
     DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
     SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG
     GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD
//
ID   Q53GA5_HUMAN            Unreviewed;       158 AA.
AC   Q53GA5;
DT   24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT   24-MAY-2005, sequence version 1.
DT   11-DEC-2019, entry version 103.
DE   SubName: Full=Tumor protein p53 variant {ECO:0000313|EMBL:BAD96746.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD96746.1};
RN   [1] {ECO:0000313|EMBL:BAD96746.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thyroid {ECO:0000313|EMBL:BAD96746.1};
RX   PubMed=8125298; DOI=10.1016/0378-1119(94)90802-8;
RA   Maruyama K., Sugano S.;
RT   "Oligo-capping: a simple method to replace the cap structure of eukaryotic
RT   mRNAs with oligoribonucleotides.";
RL   Gene 138:171-174(1994).
RN   [2] {ECO:0000313|EMBL:BAD96746.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thyroid {ECO:0000313|EMBL:BAD96746.1};
RX   PubMed=9373149; DOI=10.1016/S0378-1119(97)00411-3;
RA   Suzuki Y., Yoshitomo K., Maruyama K., Suyama A., Sugano S.;
RT   "Construction and characterization of a full length-enriched and a 5'-end-
RT   enriched cDNA library.";
RL   Gene 200:149-156(1997).
RN   [3] {ECO:0000313|EMBL:BAD96746.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thyroid {ECO:0000313|EMBL:BAD96746.1};
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK223026; BAD96746.1; -; mRNA.
DR   RefSeq; NP_000537.3; NM_000546.5.
DR   RefSeq; NP_001119584.1; NM_001126112.2.
DR   RefSeq; NP_001119585.1; NM_001126113.2.
DR   RefSeq; NP_001119586.1; NM_001126114.2.
DR   RefSeq; NP_001119587.1; NM_001126115.1.
DR   RefSeq; NP_001119588.1; NM_001126116.1.
DR   RefSeq; NP_001119589.1; NM_001126117.1.
DR   RefSeq; NP_001119590.1; NM_001126118.1.
DR   RefSeq; NP_001263624.1; NM_001276695.1.
DR   RefSeq; NP_001263625.1; NM_001276696.1.
DR   RefSeq; NP_001263626.1; NM_001276697.1.
DR   RefSeq; NP_001263627.1; NM_001276698.1.
DR   RefSeq; NP_001263628.1; NM_001276699.1.
DR   RefSeq; NP_001263689.1; NM_001276760.1.
DR   RefSeq; NP_001263690.1; NM_001276761.1.
DR   PeptideAtlas; Q53GA5; -.
DR   PRIDE; Q53GA5; -.
DR   DNASU; 7157; -.
DR   GeneID; 7157; -.
DR   KEGG; hsa:7157; -.
DR   CTD; 7157; -.
DR   PharmGKB; PA36679; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   KO; K04451; -.
DR   OrthoDB; 257530at2759; -.
DR   GenomeRNAi; 7157; -.
DR   Genevisible; Q53GA5; HS.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:InterPro.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
PE   2: Evidence at transcript level;
FT   DOMAIN          1..53
FT                   /note="P53"
FT                   /evidence="ECO:0000259|Pfam:PF00870"
FT   DOMAIN          84..122
FT                   /note="P53_tetramer"
FT                   /evidence="ECO:0000259|Pfam:PF07710"
FT   REGION          47..93
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          116..158
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        47..66
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        70..84
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        131..145
FT                   /note="Basic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:BAD96746.1"
SQ   SEQUENCE   158 AA;  17656 MW;  5C1AD3B95EB611D7 CRC64;
     YMCNSSCMGG MNGRPILTII TLEDSSGNLL GRNSFEVRVC ACPGRDRRTE EENLRKKGEP
     HHELPPGSTK RALPNNTSSS PQPKKKPLDG EYFTLQIRGR ERFEMFRELN EALELKDAQA
     GKEPGGSRAH SSHLKSKKGQ STSRHKKLMF KTEGPDSD
//
ID   A0A024R784_HUMAN        Unreviewed;      1016 AA.
AC   A0A024R784;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   22-APR-2020, entry version 52.
DE   SubName: Full=Tripartite motif-containing 24, isoform CRA_a {ECO:0000313|EMBL:EAW83886.1};
GN   Name=TRIM24 {ECO:0000313|EMBL:EAW83886.1};
GN   ORFNames=hCG_16386 {ECO:0000313|EMBL:EAW83886.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAW83886.1};
RN   [1] {ECO:0000313|EMBL:EAW83886.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW83886.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CH471070; EAW83886.1; -; Genomic_DNA.
DR   RefSeq; NP_003843.3; NM_003852.3.
DR   SMR; A0A024R784; -.
DR   PRIDE; A0A024R784; -.
DR   Antibodypedia; 32326; 495 antibodies.
DR   GeneID; 8805; -.
DR   CTD; 8805; -.
DR   EuPathDB; HostDB:ENSG00000122779.16; -.
DR   eggNOG; ENOG410KDQG; Eukaryota.
DR   eggNOG; COG5076; LUCA.
DR   HOGENOM; CLU_005817_0_1_1; -.
DR   ChiTaRS; TRIM24; human.
DR   GenomeRNAi; 8805; -.
DR   Bgee; ENSG00000122779; Expressed in sperm and 227 other tissues.
DR   ExpressionAtlas; A0A024R784; baseline and differential.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   CDD; cd00021; BBOX; 1.
DR   Gene3D; 1.20.920.10; -; 1.
DR   InterPro; IPR003649; Bbox_C.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR000315; Znf_B-box.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF00643; zf-B_box; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00502; BBC; 1.
DR   SMART; SM00336; BBOX; 2.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00249; PHD; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS50119; ZF_BBOX; 2.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   4: Predicted;
KW   Bromodomain {ECO:0000256|PROSITE-ProRule:PRU00035,
KW   ECO:0000256|SAAS:SAAS00735317}; Coiled coil {ECO:0000256|SAM:Coils};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00024,
KW   ECO:0000256|SAAS:SAAS01007077};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00024, ECO:0000256|SAAS:SAAS01007077};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00024,
KW   ECO:0000256|SAAS:SAAS01007077}.
FT   DOMAIN          56..131
FT                   /note="RING-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50089"
FT   DOMAIN          158..211
FT                   /note="B box-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50119"
FT   DOMAIN          218..259
FT                   /note="B box-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50119"
FT   DOMAIN          792..839
FT                   /note="PHD-type"
FT                   /evidence="ECO:0000259|PROSITE:PS50016"
FT   DOMAIN          898..953
FT                   /note="Bromo"
FT                   /evidence="ECO:0000259|PROSITE:PS50014"
FT   REGION          15..44
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          429..456
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          473..510
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          537..560
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          609..678
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          732..790
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          977..1002
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          328..355
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        431..456
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        473..491
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        492..506
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        614..637
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        646..672
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        732..772
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   1016 AA;  113018 MW;  4621C94EB3A74AE2 CRC64;
     MEVAVEKAVA AAAAASAAAS GGPSAAPSGE NEAESRQGPD SERGGEAARL NLLDTCAVCH
     QNIQSRAPKL LPCLHSFCQR CLPAPQRYLM LPAPMLGSAE TPPPVPAPGS PVSGSSPFAT
     QVGVIRCPVC SQECAERHII DNFFVKDTTE VPSSTVEKSN QVCTSCEDNA EANGFCVECV
     EWLCKTCIRA HQRVKFTKDH TVRQKEEVSP EAVGVTSQRP VFCPFHKKEQ LKLYCETCDK
     LTCRDCQLLE HKEHRYQFIE EAFQNQKVII DTLITKLMEK TKYIKFTGNQ IQNRIIEVNQ
     NQKQVEQDIK VAIFTLMVEI NKKGKALLHQ LESLAKDHRM KLMQQQQEVA GLSKQLEHVM
     HFSKWAVSSG SSTALLYSKR LITYRLRHLL RARCDASPVT NNTIQFHCDP SFWAQNIINL
     GSLVIEDKES QPQMPKQNPV VEQNSQPPSG LSSNQLSKFP TQISLAQLRL QHMQQQQPPP
     RLINFQNHSP KPNGPVLPPH PQQLRYPPNQ NIPRQAIKPN PLQMAFLAQQ AIKQWQISSG
     QGTPSTTNST SSTPSSPTIT SAAGYDGKAF GSPMIDLSSP VGGSYNLPSL PDIDCSSTIM
     LDNIVRKDTN IDHGQPRPPS NRTVQSPNSS VPSPGLAGPV TMTSVHPPIR SPSASSVGSR
     GSSGSSSKPA GADSTHKVPV VMLEPIRIKQ ENSGPPENYD FPVVIVKQES DEESRPQNAN
     YPRSILTSLL LNSSQSSTSE ETVLRSDAPD STGDQPGLHQ DNSSNGKSEW LDPSQKSPLH
     VGETRKEDDP NEDWCAVCQN GGELLCCEKC PKVFHLSCHV PTLTNFPSGE WICTFCRDLS
     KPEVEYDCDA PSHNSEKKKT EGLVKLTPID KRKCERLLLF LYCHEMSLAF QDPVPLTVPD
     YYKIIKNPMD LSTIKKRLQE DYSMYSKPED FVADFRLIFQ NCAEFNEPDS EVANAGIKLE
     NYFEELLKNL YPEKRFPKPE FRNESEDNKF SDDSDDDFVQ PRKKRLKSIE ERQLLK
//
ID   TIF1A_HUMAN             Reviewed;        1050 AA.
AC   O15164; A4D1R7; A4D1R8; O95854;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2001, sequence version 3.
DT   22-APR-2020, entry version 207.
DE   RecName: Full=Transcription intermediary factor 1-alpha;
DE            Short=TIF1-alpha;
DE            EC=2.3.2.27;
DE   AltName: Full=E3 ubiquitin-protein ligase TRIM24;
DE   AltName: Full=RING finger protein 82;
DE   AltName: Full=RING-type E3 ubiquitin transferase TIF1-alpha {ECO:0000305};
DE   AltName: Full=Tripartite motif-containing protein 24;
GN   Name=TRIM24; Synonyms=RNF82, TIF1, TIF1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND SUBUNIT.
RC   TISSUE=Mammary cancer;
RX   PubMed=9115274; DOI=10.1074/jbc.272.18.12062;
RA   Thenot S., Henriquet C., Rochefort H., Cavailles V.;
RT   "Differential interaction of nuclear receptors with the putative human
RT   transcriptional coactivator hTIF1.";
RL   J. Biol. Chem. 272:12062-12068(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RX   PubMed=10022127; DOI=10.1038/sj.onc.1202655;
RA   Venturini L., You J., Stadler M., Galien R., Lallemand V., Koken M.H.M.,
RA   Mattei M.-G., Ganser A., Chambon P., Losson R., De The H.;
RT   "TIF1gamma, a novel member of the transcriptional intermediary factor 1
RT   family.";
RL   Oncogene 18:1209-1217(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Retinoblastoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 477-510 (ISOFORM LONG).
RC   TISSUE=Mammary cancer;
RA   Cavailles V.;
RL   Submitted (JAN-1999) to UniProtKB.
RN   [8]
RP   INTERACTION WITH NR3C2.
RX   PubMed=10935545; DOI=10.1210/mend.14.8.0502;
RA   Hellal-Levy C., Fagart J., Souque A., Wurtz J.-M., Moras D.,
RA   Rafestin-Oblin M.-E.;
RT   "Crucial role of the H11-H12 loop in stabilizing the active conformation of
RT   the human mineralocorticoid receptor.";
RL   Mol. Endocrinol. 14:1210-1221(2000).
RN   [9]
RP   CHROMOSOMAL TRANSLOCATION WITH RET.
RC   TISSUE=Thyroid;
RX   PubMed=10439047; DOI=10.1038/sj.onc.1202824;
RA   Klugbauer S., Rabes H.M.;
RT   "The transcription coactivator HTIF1 and a related protein are fused to the
RT   RET receptor tyrosine kinase in childhood papillary thyroid carcinomas.";
RL   Oncogene 18:4388-4393(1999).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-811; SER-1025 AND SER-1028,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   FUNCTION.
RX   PubMed=16322096; DOI=10.1210/me.2005-0393;
RA   Teyssier C., Ou C.Y., Khetchoumian K., Losson R., Stallcup M.R.;
RT   "Transcriptional intermediary factor 1alpha mediates physical interaction
RT   and functional synergy between the coactivator-associated arginine
RT   methyltransferase 1 and glucocorticoid receptor-interacting protein 1
RT   nuclear receptor coactivators.";
RL   Mol. Endocrinol. 20:1276-1286(2006).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667; SER-768; SER-808 AND
RP   SER-811, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   INTERACTION WITH AR.
RX   PubMed=19909775; DOI=10.1016/j.bbamcr.2009.11.001;
RA   Kikuchi M., Okumura F., Tsukiyama T., Watanabe M., Miyajima N., Tanaka J.,
RA   Imamura M., Hatakeyama S.;
RT   "TRIM24 mediates ligand-dependent activation of androgen receptor and is
RT   repressed by a bromodomain-containing protein, BRD7, in prostate cancer
RT   cells.";
RL   Biochim. Biophys. Acta 1793:1828-1836(2009).
RN   [15]
RP   FUNCTION AS E3 UBIQUITIN LIGASE, AND INTERACTION WITH TP53.
RX   PubMed=19556538; DOI=10.1073/pnas.0813177106;
RA   Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J., Bergmann A.,
RA   Johnson R.L., Barton M.C.;
RT   "Trim24 targets endogenous p53 for degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1025 AND SER-1028, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-101; SER-110; SER-768 AND
RP   SER-811, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744; SER-811; THR-818;
RP   SER-1019; SER-1028 AND SER-1042, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   INTERACTION WITH TRIM16.
RX   PubMed=22629402; DOI=10.1371/journal.pone.0037470;
RA   Bell J.L., Malyukova A., Holien J.K., Koach J., Parker M.W., Kavallaris M.,
RA   Marshall G.M., Cheung B.B.;
RT   "TRIM16 acts as an E3 ubiquitin ligase and can heterodimerize with other
RT   TRIM family members.";
RL   PLoS ONE 7:E37470-E37470(2012).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-654; SER-744; SER-811;
RP   SER-1025 AND SER-1028, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-711; LYS-723 AND LYS-949, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [25]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-723 AND LYS-741, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [26]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-702; LYS-723 AND LYS-1041, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-723, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [28]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-7; LYS-205; LYS-276; LYS-436;
RP   LYS-458; LYS-552; LYS-641; LYS-702; LYS-711; LYS-723; LYS-741; LYS-801;
RP   LYS-810; LYS-875 AND LYS-992, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 891-1012.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Crystal structure of human bromodomain protein.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 824-1006 IN COMPLEXES WITH
RP   METHYLATED HISTONE PEPTIDES AND ZINC IONS, FUNCTION, MUTAGENESIS OF
RP   ASP-827; CYS-840 AND 979-PHE-ASN-980, SUBCELLULAR LOCATION, SUBUNIT, AND
RP   INDUCTION.
RX   PubMed=21164480; DOI=10.1038/nature09542;
RA   Tsai W.W., Wang Z., Yiu T.T., Akdemir K.C., Xia W., Winter S., Tsai C.Y.,
RA   Shi X., Schwarzer D., Plunkett W., Aronow B., Gozani O., Fischle W.,
RA   Hung M.C., Patel D.J., Barton M.C.;
RT   "TRIM24 links a non-canonical histone signature to breast cancer.";
RL   Nature 468:927-932(2010).
RN   [31]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-320; ASN-403; ASN-762 AND SER-1009.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Transcriptional coactivator that interacts with numerous
CC       nuclear receptors and coactivators and modulates the transcription of
CC       target genes. Interacts with chromatin depending on histone H3
CC       modifications, having the highest affinity for histone H3 that is both
CC       unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac).
CC       Has E3 protein-ubiquitin ligase activity. Promotes ubiquitination and
CC       proteasomal degradation of p53/TP53. Plays a role in the regulation of
CC       cell proliferation and apoptosis, at least in part via its effects on
CC       p53/TP53 levels. Up-regulates ligand-dependent transcription activation
CC       by AR, GCR/NR3C1, thyroid hormone receptor (TR) and ESR1. Modulates
CC       transcription activation by retinoic acid (RA) receptors, including
CC       RARA. Plays a role in regulating retinoic acid-dependent proliferation
CC       of hepatocytes (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:16322096, ECO:0000269|PubMed:19556538,
CC       ECO:0000269|PubMed:21164480}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27;
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with CARM1, NCOA2/GRIP1, PML, KAT5/TIP60, BRD7,
CC       CBX1, CBX3 and CBX5. Part of a coactivator complex containing TRIM24,
CC       NCOA2 and CARM1 (By similarity). Interacts with NR3C2/MCR. Interacts
CC       with the ligand-binding domain of estrogen receptors (in vitro).
CC       Interaction with DNA-bound estrogen receptors requires the presence of
CC       estradiol. Interacts with AR and p53/TP53. Interacts (via bromo domain)
CC       with histone H3 (via N-terminus), provided that it is not methylated at
CC       'Lys-4' (H3K4me0). Does not interact with histone H3 that is methylated
CC       at 'Lys-4' (H3K4me1, H3K4me2 or H3K4me3). Interacts (via bromo domain)
CC       with histone H3 (via N-terminus) that is acetylated at 'Lys-23'
CC       (H3K23ac). Has the highest affinity for histone H3 that is both
CC       unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac).
CC       Has very low affinity for histone H3 that is methylated at 'Lys-9'
CC       (H3K9me), or acetylated at both 'Lys-9' (H3K9ac) and 'Lys-14'
CC       (H3K14ac), or acetylated at 'Lys-27' (H3K27ac) (in vitro). Interacts
CC       with TRIM16. {ECO:0000250, ECO:0000269|PubMed:10935545,
CC       ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19909775,
CC       ECO:0000269|PubMed:21164480, ECO:0000269|PubMed:22629402,
CC       ECO:0000269|PubMed:9115274}.
CC   -!- INTERACTION:
CC       O15164; P03372: ESR1; NbExp=3; IntAct=EBI-2130378, EBI-78473;
CC       O15164; P04637: TP53; NbExp=3; IntAct=EBI-2130378, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:21164480}. Cytoplasm
CC       {ECO:0000269|PubMed:21164480}. Note=Colocalizes with sites of active
CC       transcription. Detected both in nucleus and cytoplasm in some breast
CC       cancer samples. Predominantly nuclear.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=O15164-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=O15164-2; Sequence=VSP_005772;
CC   -!- INDUCTION: Up-regulated in some cases of breast cancer.
CC       {ECO:0000269|PubMed:21164480}.
CC   -!- PTM: Sumoylated. {ECO:0000250}.
CC   -!- DISEASE: Note=A chromosomal aberration involving TRIM24/TIF1 is found
CC       in papillary thyroid carcinomas (PTCs). Translocation t(7;10)(q32;q11)
CC       with RET. The translocation generates the TRIM24/RET (PTC6) oncogene.
CC       {ECO:0000269|PubMed:10439047}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TRIM24ID504ch7q34.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF009353; AAB63585.1; -; mRNA.
DR   EMBL; AF119042; AAD17258.1; -; mRNA.
DR   EMBL; AK075306; BAG52105.1; -; mRNA.
DR   EMBL; AC008265; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC013429; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236950; EAL24046.1; -; Genomic_DNA.
DR   EMBL; CH236950; EAL24047.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83884.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83885.1; -; Genomic_DNA.
DR   EMBL; BC028689; AAH28689.2; -; mRNA.
DR   CCDS; CCDS47720.1; -. [O15164-2]
DR   CCDS; CCDS5847.1; -. [O15164-1]
DR   RefSeq; NP_003843.3; NM_003852.3. [O15164-2]
DR   RefSeq; NP_056989.2; NM_015905.2. [O15164-1]
DR   PDB; 2YYN; X-ray; 2.50 A; A/B/C/D=891-1012.
DR   PDB; 3O33; X-ray; 2.00 A; A/B/C/D=824-1006.
DR   PDB; 3O34; X-ray; 1.90 A; A=824-1006.
DR   PDB; 3O35; X-ray; 1.76 A; A/B=824-1006.
DR   PDB; 3O36; X-ray; 1.70 A; A/B=824-1006.
DR   PDB; 3O37; X-ray; 2.00 A; A/B/C/D=824-1006.
DR   PDB; 4YAB; X-ray; 1.90 A; A/B=824-1006.
DR   PDB; 4YAD; X-ray; 1.73 A; A/B=824-1006.
DR   PDB; 4YAT; X-ray; 2.18 A; A/B=824-1006.
DR   PDB; 4YAX; X-ray; 2.25 A; A/B=824-1006.
DR   PDB; 4YBM; X-ray; 1.46 A; A/B=824-1006.
DR   PDB; 4YBS; X-ray; 1.83 A; A=824-1006.
DR   PDB; 4YBT; X-ray; 1.82 A; A=824-1006.
DR   PDB; 4YC9; X-ray; 1.82 A; A=824-1006.
DR   PDB; 4ZQL; X-ray; 1.79 A; A/B=825-1006.
DR   PDB; 5H1T; X-ray; 1.95 A; A/B/C/D=824-1006.
DR   PDB; 5H1U; X-ray; 1.90 A; A/B/C/D=824-1006.
DR   PDB; 5H1V; X-ray; 2.00 A; A/B=824-1006.
DR   PDBsum; 2YYN; -.
DR   PDBsum; 3O33; -.
DR   PDBsum; 3O34; -.
DR   PDBsum; 3O35; -.
DR   PDBsum; 3O36; -.
DR   PDBsum; 3O37; -.
DR   PDBsum; 4YAB; -.
DR   PDBsum; 4YAD; -.
DR   PDBsum; 4YAT; -.
DR   PDBsum; 4YAX; -.
DR   PDBsum; 4YBM; -.
DR   PDBsum; 4YBS; -.
DR   PDBsum; 4YBT; -.
DR   PDBsum; 4YC9; -.
DR   PDBsum; 4ZQL; -.
DR   PDBsum; 5H1T; -.
DR   PDBsum; 5H1U; -.
DR   PDBsum; 5H1V; -.
DR   SMR; O15164; -.
DR   BioGrid; 114333; 111.
DR   DIP; DIP-52713N; -.
DR   ELM; O15164; -.
DR   IntAct; O15164; 39.
DR   MINT; O15164; -.
DR   STRING; 9606.ENSP00000340507; -.
DR   BindingDB; O15164; -.
DR   ChEMBL; CHEMBL3108638; -.
DR   GuidetoPHARMACOLOGY; 2252; -.
DR   iPTMnet; O15164; -.
DR   MetOSite; O15164; -.
DR   PhosphoSitePlus; O15164; -.
DR   BioMuta; TRIM24; -.
DR   EPD; O15164; -.
DR   jPOST; O15164; -.
DR   MassIVE; O15164; -.
DR   MaxQB; O15164; -.
DR   PaxDb; O15164; -.
DR   PeptideAtlas; O15164; -.
DR   PRIDE; O15164; -.
DR   ProteomicsDB; 48484; -. [O15164-1]
DR   ProteomicsDB; 48485; -. [O15164-2]
DR   Antibodypedia; 32326; 495 antibodies.
DR   DNASU; 8805; -.
DR   Ensembl; ENST00000343526; ENSP00000340507; ENSG00000122779. [O15164-1]
DR   Ensembl; ENST00000415680; ENSP00000390829; ENSG00000122779. [O15164-2]
DR   GeneID; 8805; -.
DR   KEGG; hsa:8805; -.
DR   UCSC; uc003vub.4; human. [O15164-1]
DR   CTD; 8805; -.
DR   DisGeNET; 8805; -.
DR   GeneCards; TRIM24; -.
DR   HGNC; HGNC:11812; TRIM24.
DR   HPA; ENSG00000122779; Low tissue specificity.
DR   MalaCards; TRIM24; -.
DR   MIM; 603406; gene.
DR   neXtProt; NX_O15164; -.
DR   OpenTargets; ENSG00000122779; -.
DR   Orphanet; 146; Differentiated thyroid carcinoma.
DR   PharmGKB; PA36519; -.
DR   eggNOG; ENOG410KDQG; Eukaryota.
DR   eggNOG; COG5076; LUCA.
DR   GeneTree; ENSGT00940000159863; -.
DR   HOGENOM; CLU_005817_0_1_1; -.
DR   InParanoid; O15164; -.
DR   KO; K08881; -.
DR   OMA; VCMSCDD; -.
DR   OrthoDB; 756911at2759; -.
DR   PhylomeDB; O15164; -.
DR   TreeFam; TF106455; -.
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   SIGNOR; O15164; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; TRIM24; human.
DR   EvolutionaryTrace; O15164; -.
DR   GeneWiki; TRIM24; -.
DR   GenomeRNAi; 8805; -.
DR   Pharos; O15164; Tchem.
DR   PRO; PR:O15164; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; O15164; protein.
DR   Bgee; ENSG00000122779; Expressed in sperm and 227 other tissues.
DR   ExpressionAtlas; O15164; baseline and differential.
DR   Genevisible; O15164; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005719; C:nuclear euchromatin; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005726; C:perichromatin fibrils; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0034056; F:estrogen response element binding; IDA:UniProtKB.
DR   GO; GO:0070577; F:lysine-acetylated histone binding; IDA:UniProtKB.
DR   GO; GO:0016922; F:nuclear receptor binding; IEA:Ensembl.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IEA:Ensembl.
DR   GO; GO:0005102; F:signaling receptor binding; TAS:ProtInc.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0055074; P:calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0030163; P:protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0070562; P:regulation of vitamin D receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:ProtInc.
DR   CDD; cd00021; BBOX; 1.
DR   Gene3D; 1.20.920.10; -; 1.
DR   InterPro; IPR003649; Bbox_C.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR000315; Znf_B-box.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF00643; zf-B_box; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00502; BBC; 1.
DR   SMART; SM00336; BBOX; 2.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00249; PHD; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS50119; ZF_BBOX; 2.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Bromodomain; Chromosomal rearrangement;
KW   Coiled coil; Cytoplasm; Direct protein sequencing; DNA-binding;
KW   Isopeptide bond; Metal-binding; Methylation; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Transferase; Tumor suppressor; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..1050
FT                   /note="Transcription intermediary factor 1-alpha"
FT                   /id="PRO_0000056390"
FT   DOMAIN          932..987
FT                   /note="Bromo"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   ZN_FING         56..82
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   ZN_FING         158..211
FT                   /note="B box-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   ZN_FING         218..259
FT                   /note="B box-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   ZN_FING         826..873
FT                   /note="PHD-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   REGION          754..779
FT                   /note="Nuclear receptor binding site (NRBS)"
FT   REGION          834..840
FT                   /note="Interaction with histone H3 that is not methylated
FT                   at 'Lys-4' (H3K4me0)"
FT   REGION          979..980
FT                   /note="Interaction with histone H3 that is acetylated at
FT                   'Lys-23' (H3K23ac)"
FT   COILED          289..359
FT                   /evidence="ECO:0000255"
FT   MOTIF           891..907
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        9..15
FT                   /note="Poly-Ala"
FT   COMPBIAS        344..347
FT                   /note="Poly-Gln"
FT   SITE            476..477
FT                   /note="Breakpoint for translocation to form TRIM24-RET
FT                   oncogene"
FT   SITE            827
FT                   /note="Interaction with histone H3 that is not methylated
FT                   at 'Lys-4' (H3K4me0)"
FT   MOD_RES         101
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:20068231"
FT   MOD_RES         110
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231"
FT   MOD_RES         469
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64127"
FT   MOD_RES         654
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         660
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64127"
FT   MOD_RES         667
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         744
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         768
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231"
FT   MOD_RES         808
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         811
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983,
FT                   ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:23186163"
FT   MOD_RES         818
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:21406692"
FT   MOD_RES         1019
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21406692"
FT   MOD_RES         1025
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:23186163"
FT   MOD_RES         1028
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         1042
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21406692"
FT   CROSSLNK        7
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        205
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        276
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        436
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        458
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        552
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        641
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        702
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25772364,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        711
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        723
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000244|PubMed:25114211"
FT   CROSSLNK        723
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000244|PubMed:25114211,
FT                   ECO:0000244|PubMed:25218447, ECO:0000244|PubMed:25755297,
FT                   ECO:0000244|PubMed:25772364, ECO:0000244|PubMed:28112733"
FT   CROSSLNK        741
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25114211,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        801
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        810
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        875
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        949
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447"
FT   CROSSLNK        992
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1041
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25772364"
FT   VAR_SEQ         477..510
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:10022127,
FT                   ECO:0000303|PubMed:9115274"
FT                   /id="VSP_005772"
FT   VARIANT         320
FT                   /note="I -> T (in an ovarian serous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042382"
FT   VARIANT         403
FT                   /note="T -> N (in a lung squamous cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042383"
FT   VARIANT         762
FT                   /note="S -> N"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042384"
FT   VARIANT         796
FT                   /note="N -> S (in dbSNP:rs35356723)"
FT                   /id="VAR_052148"
FT   VARIANT         1009
FT                   /note="R -> S (in dbSNP:rs34585297)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042385"
FT   MUTAGEN         827
FT                   /note="D->A: Strongly reduced affinity for histone H3 that
FT                   is not methylated at 'Lys-4' (H3K4me0)."
FT                   /evidence="ECO:0000269|PubMed:21164480"
FT   MUTAGEN         840
FT                   /note="C->W: Abolishes interaction with histone H3."
FT                   /evidence="ECO:0000269|PubMed:21164480"
FT   MUTAGEN         979..980
FT                   /note="FN->AA: Strongly reduced affinity for histone H3
FT                   that is acetylated at 'Lys-23' (H3K23ac)."
FT                   /evidence="ECO:0000269|PubMed:21164480"
FT   CONFLICT        14..20
FT                   /note="AASAAAS -> RLGCAP (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        24..28
FT                   /note="SAAPS -> RGG (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        109..114
FT                   /note="GSPVSG -> ARRSA (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        350
FT                   /note="A -> T (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        600
FT                   /note="D -> N (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        608
FT                   /note="M -> I (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        967
FT                   /note="A -> R (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   STRAND          827..829
FT                   /evidence="ECO:0000244|PDB:3O33"
FT   TURN            830..832
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   STRAND          836..840
FT                   /evidence="ECO:0000244|PDB:3O37"
FT   STRAND          842..845
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   TURN            850..852
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   STRAND          853..855
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   TURN            868..870
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   STRAND          873..875
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   HELIX           881..883
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   TURN            889..891
FT                   /evidence="ECO:0000244|PDB:3O36"
FT   HELIX           902..917
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   HELIX           919..921
FT                   /evidence="ECO:0000244|PDB:3O37"
FT   HELIX           922..924
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   HELIX           935..938
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   HELIX           945..953
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   TURN            954..956
FT                   /evidence="ECO:0000244|PDB:4YC9"
FT   HELIX           962..979
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   HELIX           985..1004
FT                   /evidence="ECO:0000244|PDB:4YBM"
FT   STRAND          1005..1007
FT                   /evidence="ECO:0000244|PDB:2YYN"
SQ   SEQUENCE   1050 AA;  116831 MW;  D341E8022AACC67E CRC64;
     MEVAVEKAVA AAAAASAAAS GGPSAAPSGE NEAESRQGPD SERGGEAARL NLLDTCAVCH
     QNIQSRAPKL LPCLHSFCQR CLPAPQRYLM LPAPMLGSAE TPPPVPAPGS PVSGSSPFAT
     QVGVIRCPVC SQECAERHII DNFFVKDTTE VPSSTVEKSN QVCTSCEDNA EANGFCVECV
     EWLCKTCIRA HQRVKFTKDH TVRQKEEVSP EAVGVTSQRP VFCPFHKKEQ LKLYCETCDK
     LTCRDCQLLE HKEHRYQFIE EAFQNQKVII DTLITKLMEK TKYIKFTGNQ IQNRIIEVNQ
     NQKQVEQDIK VAIFTLMVEI NKKGKALLHQ LESLAKDHRM KLMQQQQEVA GLSKQLEHVM
     HFSKWAVSSG SSTALLYSKR LITYRLRHLL RARCDASPVT NNTIQFHCDP SFWAQNIINL
     GSLVIEDKES QPQMPKQNPV VEQNSQPPSG LSSNQLSKFP TQISLAQLRL QHMQQQVMAQ
     RQQVQRRPAP VGLPNPRMQG PIQQPSISHQ QPPPRLINFQ NHSPKPNGPV LPPHPQQLRY
     PPNQNIPRQA IKPNPLQMAF LAQQAIKQWQ ISSGQGTPST TNSTSSTPSS PTITSAAGYD
     GKAFGSPMID LSSPVGGSYN LPSLPDIDCS STIMLDNIVR KDTNIDHGQP RPPSNRTVQS
     PNSSVPSPGL AGPVTMTSVH PPIRSPSASS VGSRGSSGSS SKPAGADSTH KVPVVMLEPI
     RIKQENSGPP ENYDFPVVIV KQESDEESRP QNANYPRSIL TSLLLNSSQS STSEETVLRS
     DAPDSTGDQP GLHQDNSSNG KSEWLDPSQK SPLHVGETRK EDDPNEDWCA VCQNGGELLC
     CEKCPKVFHL SCHVPTLTNF PSGEWICTFC RDLSKPEVEY DCDAPSHNSE KKKTEGLVKL
     TPIDKRKCER LLLFLYCHEM SLAFQDPVPL TVPDYYKIIK NPMDLSTIKK RLQEDYSMYS
     KPEDFVADFR LIFQNCAEFN EPDSEVANAG IKLENYFEEL LKNLYPEKRF PKPEFRNESE
     DNKFSDDSDD DFVQPRKKRL KSIEERQLLK
//
ID   WT1_HUMAN               Reviewed;         449 AA.
AC   P19544; A8K6S1; B3KSA5; Q15881; Q16256; Q16575; Q4VXV4; Q4VXV5; Q4VXV6;
AC   Q8IYZ5;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 2.
DT   22-APR-2020, entry version 239.
DE   RecName: Full=Wilms tumor protein;
DE   AltName: Full=WT33;
GN   Name=WT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7).
RC   TISSUE=Fetal kidney;
RX   PubMed=2154702; DOI=10.1038/343774a0;
RA   Gessler M., Poustka A., Cavenee W., Neve R.L., Orkin S.H., Bruns G.A.P.;
RT   "Homozygous deletion in Wilms tumours of a zinc-finger gene identified by
RT   chromosome jumping.";
RL   Nature 343:774-778(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS 1; 2;
RP   3 AND 4).
RC   TISSUE=Placenta;
RX   PubMed=1658787; DOI=10.1073/pnas.88.21.9618;
RA   Haber D.A., Sohn R.L., Buckler A.J., Pelletier J., Call K.M., Housman D.E.;
RT   "Alternative splicing and genomic structure of the Wilms tumor gene WT1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9618-9622(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM 4).
RX   PubMed=1572653; DOI=10.1016/0888-7543(92)90313-h;
RA   Gessler M., Konig A., Bruns G.A.P.;
RT   "The genomic organization and expression of the WT1 gene.";
RL   Genomics 12:807-813(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4 AND 9).
RC   TISSUE=Placenta, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM 1).
RG   NIEHS SNPs program;
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 85-449 (ISOFORM 2).
RX   PubMed=2154335; DOI=10.1016/0092-8674(90)90601-a;
RA   Call K.M., Glaser T., Ito C.Y., Buckler A.J., Pelletier J., Haber D.A.,
RA   Rose E.A., Kral A., Yeger H., Lewis W.H., Jones C., Housman D.E.;
RT   "Isolation and characterization of a zinc finger polypeptide gene at the
RT   human chromosome 11 Wilms' tumor locus.";
RL   Cell 60:509-520(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 301-449 (ISOFORMS 2/4/6), AND FUNCTION.
RC   TISSUE=Fetal kidney;
RX   PubMed=7862533; DOI=10.1093/nar/23.2.277;
RA   Hamilton T.B., Barilla K.C., Romaniuk P.J.;
RT   "High affinity binding sites for the Wilms' tumour suppressor protein
RT   WT1.";
RL   Nucleic Acids Res. 23:277-284(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 385-405, AND VARIANTS DDS.
RX   PubMed=1655284; DOI=10.1016/0092-8674(91)90194-4;
RA   Pelletier J., Bruening W., Kashtan C.E., Mauer S.M., Manivel J.C.,
RA   Striegel J.E., Houghton D.C., Junien C., Habib R., Fouser L., Fine R.N.,
RA   Silverman B.L., Haber D.A., Housman D.E.;
RT   "Germline mutations in the Wilms' tumor suppressor gene are associated with
RT   abnormal urogenital development in Denys-Drash syndrome.";
RL   Cell 67:437-447(1991).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 385-405, AND VARIANTS DDS TYR-330;
RP   PRO-394 AND TRP-394.
RX   PubMed=1302008; DOI=10.1038/ng0592-144;
RA   Bruening W., Bardeesy N., Silverman B.L., Cohn R.A., Machin G.A.,
RA   Aronson A.J., Housman D., Pelletier J.;
RT   "Germline intronic and exonic mutations in the Wilms' tumour gene (WT1)
RT   affecting urogenital development.";
RL   Nat. Genet. 1:144-148(1992).
RN   [13]
RP   IDENTIFICATION OF START CODON, AND ALTERNATIVE SPLICING.
RX   PubMed=1671709; DOI=10.1128/mcb.11.3.1707;
RA   Buckler A.J., Pelletier J., Haber D.A., Glaser T., Housman D.E.;
RT   "Isolation, characterization, and expression of the murine Wilms' tumor
RT   gene (WT1) during kidney development.";
RL   Mol. Cell. Biol. 11:1707-1712(1991).
RN   [14]
RP   RNA EDITING OF POSITION 281.
RX   PubMed=7926762; DOI=10.1101/gad.8.6.720;
RA   Sharma P.M., Bowman M., Madden S.L., Rauscher F.J. III, Sukumar S.;
RT   "RNA editing in the Wilms' tumor susceptibility gene, WT1.";
RL   Genes Dev. 8:720-731(1994).
RN   [15]
RP   ALTERNATIVE INITIATION, AND ALTERNATIVE SPLICING (ISOFORMS 7 AND 8).
RX   PubMed=8621495; DOI=10.1074/jbc.271.15.8646;
RA   Bruening W., Pelletier J.;
RT   "A non-AUG translational initiation event generates novel WT1 isoforms.";
RL   J. Biol. Chem. 271:8646-8654(1996).
RN   [16]
RP   INTERACTION WITH WTAP.
RX   PubMed=11001926; DOI=10.1093/oxfordjournals.hmg.a018914;
RA   Little N.A., Hastie N.D., Davies R.C.;
RT   "Identification of WTAP, a novel Wilms' tumour 1-associating protein.";
RL   Hum. Mol. Genet. 9:2231-2239(2000).
RN   [17]
RP   INTERACTION WITH ZNF224.
RX   PubMed=12239212; DOI=10.1074/jbc.m205667200;
RA   Lee T.H., Lwu S., Kim J., Pelletier J.;
RT   "Inhibition of Wilms tumor 1 transactivation by bone marrow zinc finger 2,
RT   a novel transcriptional repressor.";
RL   J. Biol. Chem. 277:44826-44837(2002).
RN   [18]
RP   INTERACTION WITH SRY.
RX   PubMed=12970737; DOI=10.1038/sj.onc.1206717;
RA   Matsuzawa-Watanabe Y., Inoue J., Semba K.;
RT   "Transcriptional activity of testis-determining factor SRY is modulated by
RT   the Wilms' tumor 1 gene product, WT1.";
RL   Oncogene 22:7900-7904(2003).
RN   [19]
RP   REVIEW.
RX   PubMed=1313285;
RA   Haber D.A., Buckler A.J.;
RT   "WT1: a novel tumor suppressor gene inactivated in Wilms' tumor.";
RL   New Biol. 4:97-106(1992).
RN   [20]
RP   REVIEW.
RX   PubMed=8393820; DOI=10.1096/fasebj.7.10.8393820;
RA   Rauscher F.J. III;
RT   "The WT1 Wilms tumor gene product: a developmentally regulated
RT   transcription factor in the kidney that functions as a tumor suppressor.";
RL   FASEB J. 7:896-903(1993).
RN   [21]
RP   INVOLVEMENT IN WILMS TUMOR.
RX   PubMed=1654525; DOI=10.1038/353431a0;
RA   Pelletier J., Bruening W., Li F.P., Haber D.A., Glaser T., Housman D.E.;
RT   "WT1 mutations contribute to abnormal genital system development and
RT   hereditary Wilms' tumour.";
RL   Nature 353:431-434(1991).
RN   [22]
RP   REVIEW.
RX   PubMed=17361230; DOI=10.1038/sj.leu.2404624;
RA   Yang L., Han Y., Suarez Saiz F., Minden M.D.;
RT   "A tumor suppressor and oncogene: the WT1 story.";
RL   Leukemia 21:868-876(2007).
RN   [23]
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-73 AND LYS-177, AND SUMOYLATION AT
RP   LYS-73 AND LYS-177.
RX   PubMed=15520190; DOI=10.1158/0008-5472.can-04-1502;
RA   Smolen G.A., Vassileva M.T., Wells J., Matunis M.J., Haber D.A.;
RT   "SUMO-1 modification of the Wilms' tumor suppressor WT1.";
RL   Cancer Res. 64:7846-7851(2004).
RN   [24]
RP   INTERACTION WITH RBM4, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=16934801; DOI=10.1016/j.yexcr.2006.07.008;
RA   Markus M.A., Heinrich B., Raitskin O., Adams D.J., Mangs H., Goy C.,
RA   Ladomery M., Sperling R., Stamm S., Morris B.J.;
RT   "WT1 interacts with the splicing protein RBM4 and regulates its ability to
RT   modulate alternative splicing in vivo.";
RL   Exp. Cell Res. 312:3379-3388(2006).
RN   [25]
RP   FUNCTION, AND MUTAGENESIS OF HIS-343; ARG-366; ARG-372; ARG-394 AND
RP   HIS-434.
RX   PubMed=19123921; DOI=10.1021/bi801586a;
RA   Weiss T.C., Romaniuk P.J.;
RT   "Contribution of individual amino acids to the RNA binding activity of the
RT   Wilms' tumor suppressor protein WT1.";
RL   Biochemistry 48:148-155(2009).
RN   [26]
RP   INTERACTION WITH AMER1, AND FUNCTION.
RX   PubMed=19416806; DOI=10.1073/pnas.0811349106;
RA   Rivera M.N., Kim W.J., Wells J., Stone A., Burger A., Coffman E.J.,
RA   Zhang J., Haber D.A.;
RT   "The tumor suppressor WTX shuttles to the nucleus and modulates WT1
RT   activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:8338-8343(2009).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-444, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [28]
RP   9AATAD MOTIF.
RX   PubMed=31375868; DOI=10.1007/s00018-019-03251-w;
RA   Piskacek M., Havelka M., Jendruchova K., Knight A., Keegan L.P.;
RT   "The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with
RT   valines and intron reservoirs.";
RL   Cell. Mol. Life Sci. 0:0-0(2019).
RN   [29]
RP   STRUCTURE BY NMR OF 381-407 IN COMPLEX WITH ZINC IONS.
RX   PubMed=15518539; DOI=10.1021/bi0491999;
RA   Lachenmann M.J., Ladbury J.E., Dong J., Huang K., Carey P., Weiss M.A.;
RT   "Why zinc fingers prefer zinc: ligand-field symmetry and the hidden
RT   thermodynamics of metal ion selectivity.";
RL   Biochemistry 43:13910-13925(2004).
RN   [30]
RP   STRUCTURE BY NMR OF 318-438 IN COMPLEX WITH DNA AND ZINC IONS (ISOFORM 4),
RP   X-RAY CRYSTALLOGRAPHY (3.15 ANGSTROMS) OF 318-438 IN COMPLEX WITH DNA AND
RP   ZINC IONS, AND FUNCTION.
RX   PubMed=17716689; DOI=10.1016/j.jmb.2007.07.017;
RA   Stoll R., Lee B.M., Debler E.W., Laity J.H., Wilson I.A., Dyson H.J.,
RA   Wright P.E.;
RT   "Structure of the Wilms tumor suppressor protein zinc finger domain bound
RT   to DNA.";
RL   J. Mol. Biol. 372:1227-1245(2007).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 350-440 IN COMPLEX WITH ZINC AND
RP   TARGET DNA, FUNCTION, AND DOMAIN.
RX   PubMed=25258363; DOI=10.1101/gad.250746.114;
RA   Hashimoto H., Olanrewaju Y.O., Zheng Y., Wilson G.G., Zhang X., Cheng X.;
RT   "Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA
RT   sequence.";
RL   Genes Dev. 28:2304-2313(2014).
RN   [32]
RP   VARIANT WT1 CYS-366.
RX   PubMed=1317572; DOI=10.1073/pnas.89.11.4791;
RA   Little M.H., Prosser J., Condie A., Smith P.J., van Heyningen V.,
RA   Hastie N.D.;
RT   "Zinc finger point mutations within the WT1 gene in Wilms tumor patients.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:4791-4795(1992).
RN   [33]
RP   VARIANTS DDS.
RX   PubMed=1338906; DOI=10.1093/hmg/1.5.301;
RA   Baird P.N., Santos A., Groves N., Jadresic L., Cowell J.K.;
RT   "Constitutional mutations in the WT1 gene in patients with Denys-Drash
RT   syndrome.";
RL   Hum. Mol. Genet. 1:301-305(1992).
RN   [34]
RP   VARIANTS DDS.
RX   PubMed=8388765; DOI=10.1093/hmg/2.3.259;
RA   Little M.H., Williamson K.A., Mannens M., Kelsey A., Gosden C.,
RA   Hastie N.D., van Heyningen V.;
RT   "Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a
RT   dominant-negative fashion.";
RL   Hum. Mol. Genet. 2:259-264(1993).
RN   [35]
RP   VARIANT DDS TYR-401.
RX   PubMed=8111391; DOI=10.1093/hmg/2.12.2193;
RA   Baird P.N., Cowell J.K.;
RT   "A novel zinc finger mutation in a patient with Denys-Drash syndrome.";
RL   Hum. Mol. Genet. 2:2193-2194(1993).
RN   [36]
RP   VARIANTS DDS TRP-394 AND PRO-398.
RX   PubMed=8295405; DOI=10.1007/bf00714282;
RA   Tsuda M., Sakiyama T., Kitagawa T., Watanabe S., Watanabe T., Takahashi S.,
RA   Kawaguchi H., Ito K.;
RT   "Molecular analysis of two Japanese cases of Denys-Drash syndrome.";
RL   J. Inherit. Metab. Dis. 16:876-880(1993).
RN   [37]
RP   VARIANTS DDS TYR-360 AND TRP-394.
RX   PubMed=8411073; DOI=10.1136/jmg.30.9.767;
RA   Clarkson P.A., Davies H.R., Williams D.M., Chaudhary R., Hughes I.A.,
RA   Patterson M.N.;
RT   "Mutational screening of the Wilms's tumour gene, WT1, in males with
RT   genital abnormalities.";
RL   J. Med. Genet. 30:767-772(1993).
RN   [38]
RP   VARIANT GLY-273, AND INVOLVEMENT IN MESOM.
RX   PubMed=8401592; DOI=10.1038/ng0893-415;
RA   Park S., Schalling M., Bernard A., Maheswaran S., Shipley G.C., Roberts D.,
RA   Fletcher J., Shipman R., Rheinwald J., Demetri G., Griffin J., Minden M.,
RA   Housman D.E., Haber D.A.;
RT   "The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues
RT   and mutated in a human mesothelioma.";
RL   Nat. Genet. 4:415-420(1993).
RN   [39]
RP   VARIANT DDS ARG-377.
RX   PubMed=8112732; DOI=10.1007/bf00210593;
RA   Nordenskjold A., Friedman E., Anvret M.;
RT   "WT1 mutations in patients with Denys-Drash syndrome: a novel mutation in
RT   exon 8 and paternal allele origin.";
RL   Hum. Genet. 93:115-120(1994).
RN   [40]
RP   VARIANT DDS LEU-366.
RX   PubMed=8741319; DOI=10.1111/j.1442-200x.1996.tb03483.x;
RA   Tsuda M., Sakiyama T., Owada M., Chiba Y.;
RT   "A newly identified exonic mutation of the WT1 gene in a patient with
RT   Denys-Drash syndrome.";
RL   Acta Paediatr. Jpn. Overseas Ed. 38:265-266(1996).
RN   [41]
RP   VARIANT DDS TYR-373.
RX   PubMed=8956030; DOI=10.1159/000154374;
RA   Ghahremani M., Chan C.B., Bistritzer T., Aladjem M.M., Tieder M.,
RA   Pelletier J.;
RT   "A novel mutation H373Y in the Wilms' tumor suppressor gene, WT1,
RT   associated with Denys-Drash syndrome.";
RL   Hum. Hered. 46:336-338(1996).
RN   [42]
RP   VARIANTS WT1 SER-181 AND ALA-253.
RX   PubMed=9108089; DOI=10.1073/pnas.94.8.3972;
RA   Schumacher V., Schneider S., Figge A., Wildhardt G., Harms D., Schmidt D.,
RA   Weirich A., Ludwig R., Royer-Pokora B.;
RT   "Correlation of germ-line mutations and two-hit inactivation of the WT1
RT   gene with Wilms tumors of stromal-predominant histology.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:3972-3977(1997).
RN   [43]
RP   VARIANTS NPHS4 TYR-377; LEU-383 AND ASN-396, VARIANTS DDS CYS-366; GLN-394;
RP   TRP-394 AND PRO-398, AND VARIANT WT1 ASN-223.
RX   PubMed=9529364; DOI=10.1086/301806;
RA   Jeanpierre C., Denamur E., Henry I., Cabanis M.-O., Luce S., Cecille A.,
RA   Elion J., Peuchmaur M., Loirat C., Niaudet P., Gubler M.-C., Junien C.;
RT   "Identification of constitutional WT1 mutations, in patients with isolated
RT   diffuse mesangial sclerosis, and analysis of genotype/phenotype
RT   correlations by use of a computerized mutation database.";
RL   Am. J. Hum. Genet. 62:824-833(1998).
RN   [44]
RP   VARIANTS DDS TYR-355; HIS-366 AND ARG-385.
RX   PubMed=9475094; DOI=10.1136/jmg.35.1.45;
RA   Kikuchi H., Takata A., Akasaka Y., Fukuzawa R., Yoneyama H., Kurosawa Y.,
RA   Honda M., Kamiyama Y., Hata J.;
RT   "Do intronic mutations affecting splicing of WT1 exon 9 cause Frasier
RT   syndrome?";
RL   J. Med. Genet. 35:45-48(1998).
RN   [45]
RP   VARIANTS NPHS4 LEU-364; HIS-366; CYS-379; ARG-385; GLN-394; TRP-394 AND
RP   ASN-396.
RX   PubMed=9607189; DOI=10.1046/j.1523-1755.1998.00948.x;
RA   Schumacher V., Schaerer K., Wuehl E., Altrogge H., Bonzel K.-E.,
RA   Guschmann M., Neuhaus T.J., Pollastro R.M., Kuwertz-Broeking E., Bulla M.,
RA   Tondera A.-M., Mundel P., Helmchen U., Waldherr R., Weirich A.,
RA   Royer-Pokora B.;
RT   "Spectrum of early onset nephrotic syndrome associated with WT1 missense
RT   mutations.";
RL   Kidney Int. 53:1594-1600(1998).
RN   [46]
RP   VARIANT FS LEU-392.
RX   PubMed=10571943;
RX   DOI=10.1002/(sici)1098-1004(199912)14:6<466::aid-humu4>3.0.co;2-6;
RA   Kohsaka T., Tagawa M., Takekoshi Y., Yanagisawa H., Tadokoro K., Yamada M.;
RT   "Exon 9 mutations in the WT1 gene, without influencing KTS splice isoforms,
RT   are also responsible for Frasier syndrome.";
RL   Hum. Mutat. 14:466-470(1999).
RN   [47]
RP   VARIANT DDS TYR-396.
RX   PubMed=10738002;
RX   DOI=10.1002/(sici)1098-1004(200004)15:4<389::aid-humu29>3.0.co;2-e;
RA   Little M., Carman G., Donaldson E.;
RT   "Novel WT1 exon 9 mutation (D396Y) in a patient with early onset Denys
RT   Drash syndrome.";
RL   Hum. Mutat. 15:389-389(2000).
RN   [48]
RP   VARIANTS DDS ARG-342; TYR-355; HIS-366; ARG-385; PHE-388; TRP-394 AND
RP   ASN-396, AND VARIANT NPHS4 GLN-312.
RX   PubMed=11182928; DOI=10.1136/jmg.37.9.698;
RA   Takata A., Kikuchi H., Fukuzawa R., Ito S., Honda M., Hata J.;
RT   "Constitutional WT1 correlate with clinical features in children with
RT   progressive nephropathy.";
RL   J. Med. Genet. 37:698-701(2000).
RN   [49]
RP   VARIANT DDS PRO-369.
RX   PubMed=10799199; DOI=10.1016/s0022-5347(05)67560-x;
RA   Ohta S., Ozawa T., Izumino K., Sakuragawa N., Fuse H.;
RT   "A novel missense mutation of the WT1 gene causing Denys-Drash syndrome
RT   with exceptionally mild renal manifestations.";
RL   J. Urol. 163:1857-1858(2000).
RN   [50]
RP   VARIANT DDS TYR-388.
RX   PubMed=11519891; DOI=10.1007/s004670100626;
RA   Swiatecka-Urban A., Mokrzycki M.H., Kaskel F., Da Silva F., Denamur E.;
RT   "Novel WT1 mutation (C388Y) in a female child with Denys-Drash syndrome.";
RL   Pediatr. Nephrol. 16:627-630(2001).
RN   [51]
RP   VARIANTS WT1 SER-181; GLY-355; CYS-366; HIS-366; GLN-373; TRP-394 AND
RP   LEU-394.
RX   PubMed=15150775; DOI=10.1002/ajmg.a.30015;
RA   Royer-Pokora B., Beier M., Henzler M., Alam R., Schumacher V., Weirich A.,
RA   Huff V.;
RT   "Twenty-four new cases of WT1 germline mutations and review of the
RT   literature: genotype/phenotype correlations for Wilms tumor development.";
RL   Am. J. Med. Genet. A 127:249-257(2004).
RN   [52]
RP   VARIANT THR-131.
RX   PubMed=15266301; DOI=10.1038/sj.ejhg.5201232;
RA   Wang Y., Li Q., Xu J., Liu Q., Wang W., Lin Y., Ma F., Chen T., Li S.,
RA   Shen Y.;
RT   "Mutation analysis of five candidate genes in Chinese patients with
RT   hypospadias.";
RL   Eur. J. Hum. Genet. 12:706-712(2004).
RN   [53]
RP   VARIANTS NPHS4 ARG-388 AND PRO-397.
RX   PubMed=15253707; DOI=10.1111/j.1523-1755.2004.00775.x;
RG   Members of the APN study group;
RA   Ruf R.G., Schultheiss M., Lichtenberger A., Karle S.M., Zalewski I.,
RA   Mucha B., Everding A.S., Neuhaus T., Patzer L., Plank C., Haas J.P.,
RA   Ozaltin F., Imm A., Fuchshuber A., Bakkaloglu A., Hildebrandt F.;
RT   "Prevalence of WT1 mutations in a large cohort of patients with steroid-
RT   resistant and steroid-sensitive nephrotic syndrome.";
RL   Kidney Int. 66:564-570(2004).
RN   [54]
RP   VARIANT DDS ARG-405.
RX   PubMed=15349765; DOI=10.1007/s00467-004-1564-3;
RA   Hu M., Craig J., Howard N., Kan A., Chaitow J., Little D., Alexander S.I.;
RT   "A novel mutation of WT1 exon 9 in a patient with Denys-Drash syndrome and
RT   pyloric stenosis.";
RL   Pediatr. Nephrol. 19:1160-1163(2004).
RN   [55]
RP   VARIANTS MEACHS CYS-366 AND TRP-394.
RX   PubMed=17853480; DOI=10.1002/ajmg.a.31924;
RA   Suri M., Kelehan P., O'neill D., Vadeyar S., Grant J., Ahmed S.F.,
RA   Tolmie J., McCann E., Lam W., Smith S., FitzPatrick D., Hastie N.D.,
RA   Reardon W.;
RT   "WT1 mutations in Meacham syndrome suggest a coelomic mesothelial origin of
RT   the cardiac and diaphragmatic malformations.";
RL   Am. J. Med. Genet. A 143:2312-2320(2007).
RN   [56]
RP   VARIANTS NPHS4 ARG-388; GLN-394; TRP-394 AND PRO-397.
RX   PubMed=20798252; DOI=10.2215/cjn.01190210;
RA   Buescher A.K., Kranz B., Buescher R., Hildebrandt F., Dworniczak B.,
RA   Pennekamp P., Kuwertz-Broeking E., Wingen A.M., John U., Kemper M.,
RA   Monnens L., Hoyer P.F., Weber S., Konrad M.;
RT   "Immunosuppression and renal outcome in congenital and pediatric steroid-
RT   resistant nephrotic syndrome.";
RL   Clin. J. Am. Soc. Nephrol. 5:2075-2084(2010).
CC   -!- FUNCTION: Transcription factor that plays an important role in cellular
CC       development and cell survival (PubMed:7862533). Recognizes and binds to
CC       the DNA sequence 5'-GCG(T/G)GGGCG-3' (PubMed:7862533, PubMed:17716689,
CC       PubMed:25258363). Regulates the expression of numerous target genes,
CC       including EPO. Plays an essential role for development of the
CC       urogenital system. It has a tumor suppressor as well as an oncogenic
CC       role in tumor formation. Function may be isoform-specific: isoforms
CC       lacking the KTS motif may act as transcription factors
CC       (PubMed:15520190). Isoforms containing the KTS motif may bind mRNA and
CC       play a role in mRNA metabolism or splicing (PubMed:16934801). Isoform 1
CC       has lower affinity for DNA, and can bind RNA (PubMed:19123921).
CC       {ECO:0000269|PubMed:15520190, ECO:0000269|PubMed:16934801,
CC       ECO:0000269|PubMed:17716689, ECO:0000269|PubMed:19123921,
CC       ECO:0000269|PubMed:19416806, ECO:0000269|PubMed:25258363,
CC       ECO:0000269|PubMed:7862533}.
CC   -!- SUBUNIT: Homodimer. Interacts with WTIP. Interacts with actively
CC       translating polysomes. Detected in nuclear ribonucleoprotein (mRNP)
CC       particles. Interacts with HNRNPU via the zinc-finger region. Interacts
CC       with U2AF2. Interacts with CITED2 (By similarity). Interacts with
CC       ZNF224 via the zinc-finger region. Interacts with WTAP and SRY.
CC       Interacts with AMER1. Interacts with RBM4. {ECO:0000250,
CC       ECO:0000269|PubMed:11001926, ECO:0000269|PubMed:12239212,
CC       ECO:0000269|PubMed:12970737, ECO:0000269|PubMed:15518539,
CC       ECO:0000269|PubMed:16934801, ECO:0000269|PubMed:17716689,
CC       ECO:0000269|PubMed:19416806}.
CC   -!- INTERACTION:
CC       P19544-6; O14503: BHLHE40; NbExp=3; IntAct=EBI-11745701, EBI-711810;
CC       P19544-6; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-11745701, EBI-3867333;
CC       P19544-6; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-11745701, EBI-2549423;
CC       P19544-6; O15397: IPO8; NbExp=3; IntAct=EBI-11745701, EBI-358808;
CC       P19544; Q6A162: KRT40; NbExp=4; IntAct=EBI-2320534, EBI-10171697;
CC       P19544-6; P60371: KRTAP10-6; NbExp=3; IntAct=EBI-11745701, EBI-12012928;
CC       P19544-6; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-11745701, EBI-10172290;
CC       P19544; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-2320534, EBI-10171774;
CC       P19544-6; Q9H4L5: OSBPL3; NbExp=3; IntAct=EBI-11745701, EBI-1051317;
CC       P19544-6; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-11745701, EBI-79165;
CC       P19544; Q6N021: TET2; NbExp=9; IntAct=EBI-2320534, EBI-310727;
CC       P19544-6; Q15007: WTAP; NbExp=3; IntAct=EBI-11745701, EBI-751647;
CC       P19544-6; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-11745701, EBI-527853;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15520190}. Nucleus,
CC       nucleolus. Cytoplasm {ECO:0000250}. Note=Isoforms lacking the KTS motif
CC       have a diffuse nuclear location (PubMed:15520190). Shuttles between
CC       nucleus and cytoplasm. {ECO:0000250, ECO:0000269|PubMed:15520190}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus speckle
CC       {ECO:0000269|PubMed:15520190}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:15520190}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=8;
CC       Name=1;
CC         IsoId=P19544-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P19544-2; Sequence=VSP_006866, VSP_006867;
CC       Name=3;
CC         IsoId=P19544-3; Sequence=VSP_006866;
CC       Name=4;
CC         IsoId=P19544-4; Sequence=VSP_006867;
CC       Name=6;
CC         IsoId=P19544-6; Sequence=VSP_037582, VSP_037584, VSP_006867;
CC       Name=7;
CC         IsoId=P19544-7; Sequence=VSP_037583;
CC       Name=8;
CC         IsoId=P19544-8; Sequence=VSP_037583, VSP_006866;
CC       Name=9;
CC         IsoId=P19544-9; Sequence=VSP_037582, VSP_037584, VSP_006866;
CC   -!- TISSUE SPECIFICITY: Expressed in the kidney and a subset of
CC       hematopoietic cells.
CC   -!- DOMAIN: Binds to DNA motifs with the sequence 5'-GCG(T/G)GGGCG-3' via
CC       its C2H2-type zinc fingers. Starting from the N-terminus, the second
CC       zinc finger binds to the 3'-GCG motif, the middle zinc finger interacts
CC       with the central TGG motif, and the C-terminal zinc finger binds to the
CC       5'-GCG motif. Binds double-stranded target DNA, irrespective of the
CC       cytosine methylation status. Has reduced affinity for target DNA where
CC       the cytosines have been oxidized to 5-hydroxymethylcytosine, 5-
CC       formylcytosine or 5-carboxylcytosine. {ECO:0000269|PubMed:25258363}.
CC   -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large
CC       number of yeast and animal transcription factors.
CC       {ECO:0000269|PubMed:31375868}.
CC   -!- RNA EDITING: Modified_positions=281 {ECO:0000269|PubMed:7926762};
CC       Note=Partially edited.;
CC   -!- DISEASE: Frasier syndrome (FS) [MIM:136680]: Characterized by a slowly
CC       progressing nephropathy leading to renal failure in adolescence or
CC       early adulthood, male pseudohermaphroditism, and no Wilms tumor. As for
CC       histological findings of the kidneys, focal glomerular sclerosis is
CC       often observed. There is phenotypic overlap with Denys-Drash syndrome.
CC       Inheritance is autosomal dominant. {ECO:0000269|PubMed:10571943}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Wilms tumor 1 (WT1) [MIM:194070]: Embryonal malignancy of the
CC       kidney that affects approximately 1 in 10'000 infants and young
CC       children. It occurs both in sporadic and hereditary forms.
CC       {ECO:0000269|PubMed:1317572, ECO:0000269|PubMed:15150775,
CC       ECO:0000269|PubMed:9108089, ECO:0000269|PubMed:9529364}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Denys-Drash syndrome (DDS) [MIM:194080]: Typical nephropathy
CC       characterized by diffuse mesangial sclerosis, genital abnormalities,
CC       and/or Wilms tumor. There is phenotypic overlap with WAGR syndrome and
CC       Frasier syndrome. Inheritance is autosomal dominant, but most cases are
CC       sporadic. {ECO:0000269|PubMed:10738002, ECO:0000269|PubMed:10799199,
CC       ECO:0000269|PubMed:11182928, ECO:0000269|PubMed:11519891,
CC       ECO:0000269|PubMed:1302008, ECO:0000269|PubMed:1338906,
CC       ECO:0000269|PubMed:15349765, ECO:0000269|PubMed:1655284,
CC       ECO:0000269|PubMed:8111391, ECO:0000269|PubMed:8112732,
CC       ECO:0000269|PubMed:8295405, ECO:0000269|PubMed:8388765,
CC       ECO:0000269|PubMed:8411073, ECO:0000269|PubMed:8741319,
CC       ECO:0000269|PubMed:8956030, ECO:0000269|PubMed:9475094,
CC       ECO:0000269|PubMed:9529364}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Nephrotic syndrome 4 (NPHS4) [MIM:256370]: A form of nephrotic
CC       syndrome, a renal disease clinically characterized by severe
CC       proteinuria, resulting in complications such as hypoalbuminemia,
CC       hyperlipidemia and edema. Kidney biopsies show non-specific histologic
CC       changes such as focal segmental glomerulosclerosis and diffuse
CC       mesangial proliferation. Some affected individuals have an inherited
CC       steroid-resistant form and progress to end-stage renal failure. Most
CC       patients with NPHS4 show diffuse mesangial sclerosis on renal biopsy,
CC       which is a pathologic entity characterized by mesangial matrix
CC       expansion with no mesangial hypercellularity, hypertrophy of the
CC       podocytes, vacuolized podocytes, thickened basement membranes, and
CC       diminished patency of the capillary lumen.
CC       {ECO:0000269|PubMed:11182928, ECO:0000269|PubMed:15253707,
CC       ECO:0000269|PubMed:20798252, ECO:0000269|PubMed:9529364,
CC       ECO:0000269|PubMed:9607189}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Meacham syndrome (MEACHS) [MIM:608978]: Rare sporadically
CC       occurring multiple malformation syndrome characterized by male
CC       pseudohermaphroditism with abnormal internal female genitalia
CC       comprising a uterus and double or septate vagina, complex congenital
CC       heart defect and diaphragmatic abnormalities.
CC       {ECO:0000269|PubMed:17853480}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving WT1 may be a cause of
CC       desmoplastic small round cell tumor (DSRCT). Translocation
CC       t(11;22)(p13;q12) with EWSR1.
CC   -!- DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive
CC       neoplasm of the serosal lining of the chest. It appears as broad sheets
CC       of cells, with some regions containing spindle-shaped, sarcoma-like
CC       cells and other regions showing adenomatous patterns. Pleural
CC       mesotheliomas have been linked to exposure to asbestos.
CC       {ECO:0000269|PubMed:8401592}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Presence of the KTS motif hinders interactions between
CC       DNA and zinc-finger 4.
CC   -!- MISCELLANEOUS: [Isoform 1]: Detected in nucleus speckle, may bind mRNA.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative initiation of
CC       isoform 1. Extended N-terminus. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative initiation of
CC       isoform 1. Extended N-terminus. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the EGR C2H2-type zinc-finger protein family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB33443.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA35956.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA35956.1; Type=Miscellaneous discrepancy; Note=Unusual initiator. The initiator methionine is coded by a non-canonical CTG leucine codon.; Evidence={ECO:0000305};
CC       Sequence=CAC39220.3; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAI95758.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAI95759.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/WT1ID78.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/wt1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X51630; CAA35956.1; ALT_SEQ; mRNA.
DR   EMBL; M80232; AAA61299.1; -; Genomic_DNA.
DR   EMBL; M80217; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80218; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80219; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80220; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80221; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80228; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80229; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80231; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; X61631; CAA43819.1; -; Genomic_DNA.
DR   EMBL; X61632; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61633; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61634; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61635; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61636; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61637; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61638; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; AK093168; BAG52667.1; -; mRNA.
DR   EMBL; AK291736; BAF84425.1; -; mRNA.
DR   EMBL; AY245105; AAO61088.1; -; Genomic_DNA.
DR   EMBL; AL049692; CAC39220.3; ALT_INIT; Genomic_DNA.
DR   EMBL; AL049692; CAI95758.2; ALT_INIT; Genomic_DNA.
DR   EMBL; AL049692; CAI95759.2; ALT_INIT; Genomic_DNA.
DR   EMBL; AL049692; CAI95760.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68220.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68223.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68224.1; -; Genomic_DNA.
DR   EMBL; BC032861; AAH32861.1; -; mRNA.
DR   EMBL; M30393; AAA36810.1; -; mRNA.
DR   EMBL; S75264; AAB33443.1; ALT_SEQ; mRNA.
DR   EMBL; S61515; AAB20110.1; -; Genomic_DNA.
DR   EMBL; S61522; AAB20111.1; -; Genomic_DNA.
DR   EMBL; S61524; AAB20112.1; -; Genomic_DNA.
DR   EMBL; S60755; AAC60605.1; -; Genomic_DNA.
DR   CCDS; CCDS55750.1; -. [P19544-9]
DR   CCDS; CCDS55751.1; -. [P19544-6]
DR   CCDS; CCDS7878.2; -. [P19544-7]
DR   PIR; A38080; A38080.
DR   RefSeq; NP_000369.3; NM_000378.4.
DR   RefSeq; NP_001185480.1; NM_001198551.1. [P19544-6]
DR   RefSeq; NP_001185481.1; NM_001198552.1. [P19544-9]
DR   RefSeq; NP_077742.2; NM_024424.3.
DR   RefSeq; NP_077744.3; NM_024426.4. [P19544-7]
DR   PDB; 1LU6; Model; -; A=310-449.
DR   PDB; 1XF7; NMR; -; A=381-407.
DR   PDB; 2G7T; Model; -; A=310-449.
DR   PDB; 2G7V; Model; -; A=310-449.
DR   PDB; 2G7W; Model; -; A=310-449.
DR   PDB; 2G7X; Model; -; A=310-449.
DR   PDB; 2JP9; NMR; -; A=318-438.
DR   PDB; 2JPA; NMR; -; A=318-438.
DR   PDB; 2PRT; X-ray; 3.15 A; A=318-438.
DR   PDB; 3HPJ; X-ray; 2.00 A; C/F=126-134.
DR   PDB; 3MYJ; X-ray; 1.89 A; C/F=126-134.
DR   PDB; 4R2E; X-ray; 1.84 A; A=350-440.
DR   PDB; 4R2P; X-ray; 1.79 A; A=350-440.
DR   PDB; 4R2Q; X-ray; 1.54 A; A=350-440.
DR   PDB; 4R2R; X-ray; 2.09 A; A=350-440.
DR   PDB; 4R2S; X-ray; 2.49 A; A=350-440.
DR   PDB; 4WUU; X-ray; 3.05 A; C=126-134.
DR   PDB; 5KL2; X-ray; 1.69 A; A=350-440.
DR   PDB; 5KL3; X-ray; 1.45 A; A=350-440.
DR   PDB; 5KL4; X-ray; 1.78 A; A/D=350-440.
DR   PDB; 5KL5; X-ray; 2.29 A; A=350-440.
DR   PDB; 5KL6; X-ray; 1.64 A; A=350-440.
DR   PDB; 5KL7; X-ray; 1.58 A; A=350-440.
DR   PDB; 6B0O; X-ray; 1.55 A; A/D=321-440.
DR   PDB; 6B0P; X-ray; 2.08 A; A/D=321-440.
DR   PDB; 6B0Q; X-ray; 2.79 A; A/D=321-440.
DR   PDB; 6B0R; X-ray; 1.82 A; A/D=321-440.
DR   PDB; 6BLW; X-ray; 1.83 A; A=319-440.
DR   PDBsum; 1LU6; -.
DR   PDBsum; 1XF7; -.
DR   PDBsum; 2G7T; -.
DR   PDBsum; 2G7V; -.
DR   PDBsum; 2G7W; -.
DR   PDBsum; 2G7X; -.
DR   PDBsum; 2JP9; -.
DR   PDBsum; 2JPA; -.
DR   PDBsum; 2PRT; -.
DR   PDBsum; 3HPJ; -.
DR   PDBsum; 3MYJ; -.
DR   PDBsum; 4R2E; -.
DR   PDBsum; 4R2P; -.
DR   PDBsum; 4R2Q; -.
DR   PDBsum; 4R2R; -.
DR   PDBsum; 4R2S; -.
DR   PDBsum; 4WUU; -.
DR   PDBsum; 5KL2; -.
DR   PDBsum; 5KL3; -.
DR   PDBsum; 5KL4; -.
DR   PDBsum; 5KL5; -.
DR   PDBsum; 5KL6; -.
DR   PDBsum; 5KL7; -.
DR   PDBsum; 6B0O; -.
DR   PDBsum; 6B0P; -.
DR   PDBsum; 6B0Q; -.
DR   PDBsum; 6B0R; -.
DR   PDBsum; 6BLW; -.
DR   SMR; P19544; -.
DR   BioGrid; 113327; 56.
DR   IntAct; P19544; 27.
DR   MINT; P19544; -.
DR   STRING; 9606.ENSP00000331327; -.
DR   iPTMnet; P19544; -.
DR   PhosphoSitePlus; P19544; -.
DR   BioMuta; WT1; -.
DR   DMDM; 139778; -.
DR   MassIVE; P19544; -.
DR   MaxQB; P19544; -.
DR   PaxDb; P19544; -.
DR   PeptideAtlas; P19544; -.
DR   PRIDE; P19544; -.
DR   ProteomicsDB; 53673; -. [P19544-1]
DR   ProteomicsDB; 53674; -. [P19544-2]
DR   ProteomicsDB; 53675; -. [P19544-3]
DR   ProteomicsDB; 53676; -. [P19544-4]
DR   ProteomicsDB; 53677; -. [P19544-6]
DR   ProteomicsDB; 53678; -. [P19544-7]
DR   ProteomicsDB; 53679; -. [P19544-8]
DR   ProteomicsDB; 53680; -. [P19544-9]
DR   ABCD; P19544; -.
DR   Antibodypedia; 3523; 1065 antibodies.
DR   DNASU; 7490; -.
DR   Ensembl; ENST00000379079; ENSP00000368370; ENSG00000184937. [P19544-6]
DR   Ensembl; ENST00000530998; ENSP00000435307; ENSG00000184937. [P19544-9]
DR   GeneID; 7490; -.
DR   KEGG; hsa:7490; -.
DR   UCSC; uc001mtl.3; human. [P19544-1]
DR   CTD; 7490; -.
DR   DisGeNET; 7490; -.
DR   GeneCards; WT1; -.
DR   GeneReviews; WT1; -.
DR   HGNC; HGNC:12796; WT1.
DR   HPA; ENSG00000184937; Tissue enhanced (endometrium, fallopian tube, ovary).
DR   MalaCards; WT1; -.
DR   MIM; 136680; phenotype.
DR   MIM; 156240; phenotype.
DR   MIM; 194070; phenotype.
DR   MIM; 194080; phenotype.
DR   MIM; 256370; phenotype.
DR   MIM; 607102; gene.
DR   MIM; 608978; phenotype.
DR   neXtProt; NX_P19544; -.
DR   OpenTargets; ENSG00000184937; -.
DR   Orphanet; 242; 46,XY complete gonadal dysgenesis.
DR   Orphanet; 251510; 46,XY partial gonadal dysgenesis.
DR   Orphanet; 220; Denys-Drash syndrome.
DR   Orphanet; 83469; Desmoplastic small round cell tumor.
DR   Orphanet; 347; Frasier syndrome.
DR   Orphanet; 656; Genetic steroid-resistant nephrotic syndrome.
DR   Orphanet; 3097; Meacham syndrome.
DR   Orphanet; 654; Nephroblastoma.
DR   Orphanet; 893; WAGR syndrome.
DR   PharmGKB; PA37395; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   GeneTree; ENSGT00940000156734; -.
DR   InParanoid; P19544; -.
DR   KO; K09234; -.
DR   OrthoDB; 1318335at2759; -.
DR   PhylomeDB; P19544; -.
DR   SignaLink; P19544; -.
DR   SIGNOR; P19544; -.
DR   ChiTaRS; WT1; human.
DR   EvolutionaryTrace; P19544; -.
DR   GeneWiki; WT1; -.
DR   GenomeRNAi; 7490; -.
DR   Pharos; P19544; Tbio.
DR   PRO; PR:P19544; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P19544; protein.
DR   Bgee; ENSG00000184937; Expressed in germinal epithelium of ovary and 115 other tissues.
DR   ExpressionAtlas; P19544; baseline and differential.
DR   Genevisible; P19544; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0070742; F:C2H2 zinc finger domain binding; IPI:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:ARUK-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISM:NTNU_SB.
DR   GO; GO:0010385; F:double-stranded methylated DNA binding; IDA:UniProtKB.
DR   GO; GO:0044729; F:hemi-methylated DNA-binding; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0035802; P:adrenal cortex formation; ISS:UniProtKB.
DR   GO; GO:0030325; P:adrenal gland development; IGI:UniProtKB.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IGI:UniProtKB.
DR   GO; GO:0043010; P:camera-type eye development; ISS:UniProtKB.
DR   GO; GO:0060923; P:cardiac muscle cell fate commitment; ISS:BHF-UCL.
DR   GO; GO:0071320; P:cellular response to cAMP; IEP:UniProtKB.
DR   GO; GO:0071371; P:cellular response to gonadotropin stimulus; IDA:UniProtKB.
DR   GO; GO:0060539; P:diaphragm development; ISS:UniProtKB.
DR   GO; GO:0030855; P:epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0007281; P:germ cell development; ISS:UniProtKB.
DR   GO; GO:0032836; P:glomerular basement membrane development; IMP:UniProtKB.
DR   GO; GO:0072112; P:glomerular visceral epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0032835; P:glomerulus development; IGI:UniProtKB.
DR   GO; GO:0008406; P:gonad development; ISS:UniProtKB.
DR   GO; GO:0007507; P:heart development; IGI:UniProtKB.
DR   GO; GO:0001822; P:kidney development; IGI:UniProtKB.
DR   GO; GO:0030539; P:male genitalia development; ISS:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; IEP:UniProtKB.
DR   GO; GO:0060231; P:mesenchymal to epithelial transition; ISS:UniProtKB.
DR   GO; GO:0072207; P:metanephric epithelium development; IEP:UniProtKB.
DR   GO; GO:0072075; P:metanephric mesenchyme development; ISS:UniProtKB.
DR   GO; GO:0072284; P:metanephric S-shaped body morphogenesis; IGI:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IGI:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:2000195; P:negative regulation of female gonad development; ISS:UniProtKB.
DR   GO; GO:0072302; P:negative regulation of metanephric glomerular mesangial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:1905643; P:positive regulation of DNA methylation; IMP:ARUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:0060421; P:positive regulation of heart growth; ISS:UniProtKB.
DR   GO; GO:2000020; P:positive regulation of male gonad development; ISS:UniProtKB.
DR   GO; GO:2001076; P:positive regulation of metanephric ureteric bud development; ISS:UniProtKB.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription by RNA polymerase II; IMP:ARUK-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ARUK-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0072166; P:posterior mesonephric tubule development; ISS:UniProtKB.
DR   GO; GO:0003156; P:regulation of animal organ formation; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0008380; P:RNA splicing; ISS:UniProtKB.
DR   GO; GO:0007530; P:sex determination; IDA:UniProtKB.
DR   GO; GO:0007356; P:thorax and anterior abdomen determination; ISS:UniProtKB.
DR   GO; GO:0009888; P:tissue development; ISS:UniProtKB.
DR   GO; GO:0001657; P:ureteric bud development; ISS:UniProtKB.
DR   GO; GO:0001570; P:vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0061032; P:visceral serous pericardium development; IGI:UniProtKB.
DR   InterPro; IPR017987; Wilms_tumour.
DR   InterPro; IPR000976; Wilms_tumour_N.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR23235:SF49; PTHR23235:SF49; 1.
DR   Pfam; PF02165; WT1; 1.
DR   Pfam; PF00096; zf-C2H2; 2.
DR   SMART; SM00355; ZnF_C2H2; 4.
DR   SUPFAM; SSF57667; SSF57667; 2.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 4.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative splicing;
KW   Chromosomal rearrangement; Cytoplasm; Disease mutation; DNA-binding;
KW   Isopeptide bond; Metal-binding; Nucleus; Reference proteome; Repeat;
KW   RNA editing; RNA-binding; Transcription; Transcription regulation;
KW   Tumor suppressor; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..449
FT                   /note="Wilms tumor protein"
FT                   /id="PRO_0000047131"
FT   ZN_FING         323..347
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         353..377
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         383..405
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         414..438
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          367..381
FT                   /note="Important for interaction with target DNA"
FT   REGION          393..401
FT                   /note="Important for interaction with target DNA"
FT   MOTIF           236..244
FT                   /note="9aaTAD"
FT                   /evidence="ECO:0000269|PubMed:31375868"
FT   MOTIF           408..410
FT                   /note="KTS motif"
FT   COMPBIAS        27..83
FT                   /note="Pro-rich"
FT   SITE            424
FT                   /note="Important for interaction with target DNA"
FT   SITE            430
FT                   /note="Important for interaction with target DNA"
FT   CROSSLNK        73
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:15520190"
FT   CROSSLNK        177
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:15520190"
FT   CROSSLNK        444
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         1..144
FT                   /note="Missing (in isoform 6 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_037582"
FT   VAR_SEQ         1
FT                   /note="M -> MDFLLLQDPASTCVPEPASQHTLRSGPGCLQQPEQQGVRDPGGIWAK
FT                   LGAAEASAERLQGRRSRGASGSEPQQM (in isoform 7 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:2154702"
FT                   /id="VSP_037583"
FT   VAR_SEQ         145..147
FT                   /note="RNQ -> MEK (in isoform 6 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_037584"
FT   VAR_SEQ         250..266
FT                   /note="Missing (in isoform 2, isoform 3, isoform 8 and
FT                   isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:2154335"
FT                   /id="VSP_006866"
FT   VAR_SEQ         408..410
FT                   /note="Missing (in isoform 2, isoform 4 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:2154335"
FT                   /id="VSP_006867"
FT   VARIANT         131
FT                   /note="A -> T (in a patient with hypospadias)"
FT                   /evidence="ECO:0000269|PubMed:15266301"
FT                   /id="VAR_043798"
FT   VARIANT         181
FT                   /note="P -> S (in WT1; dbSNP:rs2234584)"
FT                   /evidence="ECO:0000269|PubMed:15150775,
FT                   ECO:0000269|PubMed:9108089"
FT                   /id="VAR_007739"
FT   VARIANT         223
FT                   /note="S -> N (in WT1)"
FT                   /evidence="ECO:0000269|PubMed:9529364"
FT                   /id="VAR_007740"
FT   VARIANT         253
FT                   /note="G -> A (in WT1)"
FT                   /evidence="ECO:0000269|PubMed:9108089"
FT                   /id="VAR_007741"
FT   VARIANT         273
FT                   /note="S -> G (found in a mesothelioma sample; somatic
FT                   mutation; dbSNP:rs121907908)"
FT                   /evidence="ECO:0000269|PubMed:8401592"
FT                   /id="VAR_007742"
FT   VARIANT         281
FT                   /note="L -> P (in RNA edited version)"
FT                   /id="VAR_058021"
FT   VARIANT         312
FT                   /note="R -> Q (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:11182928"
FT                   /id="VAR_015053"
FT   VARIANT         330
FT                   /note="C -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:1302008"
FT                   /id="VAR_007743"
FT   VARIANT         342
FT                   /note="M -> R (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:11182928"
FT                   /id="VAR_015054"
FT   VARIANT         355
FT                   /note="C -> G (in WT1)"
FT                   /evidence="ECO:0000269|PubMed:15150775"
FT                   /id="VAR_043799"
FT   VARIANT         355
FT                   /note="C -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:11182928,
FT                   ECO:0000269|PubMed:9475094"
FT                   /id="VAR_015055"
FT   VARIANT         360
FT                   /note="C -> G (in DDS)"
FT                   /id="VAR_007744"
FT   VARIANT         360
FT                   /note="C -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:8411073"
FT                   /id="VAR_043800"
FT   VARIANT         364
FT                   /note="F -> L (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:9607189"
FT                   /id="VAR_043801"
FT   VARIANT         366
FT                   /note="R -> C (in WT1, DDS and MEACHS)"
FT                   /evidence="ECO:0000269|PubMed:1317572,
FT                   ECO:0000269|PubMed:15150775, ECO:0000269|PubMed:17853480,
FT                   ECO:0000269|PubMed:9529364"
FT                   /id="VAR_007745"
FT   VARIANT         366
FT                   /note="R -> H (in DDS and WT1)"
FT                   /evidence="ECO:0000269|PubMed:11182928,
FT                   ECO:0000269|PubMed:15150775, ECO:0000269|PubMed:9475094,
FT                   ECO:0000269|PubMed:9607189"
FT                   /id="VAR_007746"
FT   VARIANT         366
FT                   /note="R -> L (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:8741319"
FT                   /id="VAR_043802"
FT   VARIANT         369
FT                   /note="Q -> P (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:10799199"
FT                   /id="VAR_043803"
FT   VARIANT         373
FT                   /note="H -> Q (in DDS and WT1)"
FT                   /evidence="ECO:0000269|PubMed:15150775"
FT                   /id="VAR_007747"
FT   VARIANT         373
FT                   /note="H -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:8956030"
FT                   /id="VAR_015056"
FT   VARIANT         377
FT                   /note="H -> R (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:8112732"
FT                   /id="VAR_015057"
FT   VARIANT         377
FT                   /note="H -> Y (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:9529364"
FT                   /id="VAR_007748"
FT   VARIANT         379
FT                   /note="G -> C (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:9607189"
FT                   /id="VAR_043804"
FT   VARIANT         383
FT                   /note="F -> L (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:9529364"
FT                   /id="VAR_007749"
FT   VARIANT         385
FT                   /note="C -> R (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:11182928,
FT                   ECO:0000269|PubMed:9475094, ECO:0000269|PubMed:9607189"
FT                   /id="VAR_015058"
FT   VARIANT         388
FT                   /note="C -> F (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:11182928"
FT                   /id="VAR_015059"
FT   VARIANT         388
FT                   /note="C -> R (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:15253707,
FT                   ECO:0000269|PubMed:20798252"
FT                   /id="VAR_043805"
FT   VARIANT         388
FT                   /note="C -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:11519891"
FT                   /id="VAR_043806"
FT   VARIANT         392
FT                   /note="F -> L (in FS)"
FT                   /evidence="ECO:0000269|PubMed:10571943"
FT                   /id="VAR_015060"
FT   VARIANT         394
FT                   /note="R -> L (in WT1)"
FT                   /evidence="ECO:0000269|PubMed:15150775"
FT                   /id="VAR_043807"
FT   VARIANT         394
FT                   /note="R -> P (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:1302008"
FT                   /id="VAR_043808"
FT   VARIANT         394
FT                   /note="R -> Q (in DDS and NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:20798252,
FT                   ECO:0000269|PubMed:9529364, ECO:0000269|PubMed:9607189"
FT                   /id="VAR_015061"
FT   VARIANT         394
FT                   /note="R -> W (in DDS, WT1, MEACHS and NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:11182928,
FT                   ECO:0000269|PubMed:1302008, ECO:0000269|PubMed:15150775,
FT                   ECO:0000269|PubMed:17853480, ECO:0000269|PubMed:20798252,
FT                   ECO:0000269|PubMed:8295405, ECO:0000269|PubMed:8411073,
FT                   ECO:0000269|PubMed:9529364, ECO:0000269|PubMed:9607189"
FT                   /id="VAR_007750"
FT   VARIANT         396
FT                   /note="D -> G (in DDS)"
FT                   /id="VAR_007752"
FT   VARIANT         396
FT                   /note="D -> N (in DDS and NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:11182928,
FT                   ECO:0000269|PubMed:9529364, ECO:0000269|PubMed:9607189"
FT                   /id="VAR_007751"
FT   VARIANT         396
FT                   /note="D -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:10738002"
FT                   /id="VAR_043809"
FT   VARIANT         397
FT                   /note="H -> P (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:15253707,
FT                   ECO:0000269|PubMed:20798252"
FT                   /id="VAR_043810"
FT   VARIANT         398
FT                   /note="L -> P (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:8295405,
FT                   ECO:0000269|PubMed:9529364"
FT                   /id="VAR_015062"
FT   VARIANT         401
FT                   /note="H -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:8111391"
FT                   /id="VAR_043811"
FT   VARIANT         405
FT                   /note="H -> R (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:15349765"
FT                   /id="VAR_043812"
FT   MUTAGEN         73
FT                   /note="K->R: Abolishes sumoylation; when associated with R-
FT                   177."
FT                   /evidence="ECO:0000269|PubMed:15520190"
FT   MUTAGEN         177
FT                   /note="K->R: Abolishes sumoylation; when associated with R-
FT                   77."
FT                   /evidence="ECO:0000269|PubMed:15520190"
FT   MUTAGEN         343
FT                   /note="H->A: Reduced RNA binding."
FT                   /evidence="ECO:0000269|PubMed:19123921"
FT   MUTAGEN         366
FT                   /note="R->A: Strongly reduced binding of DNA and RNA."
FT                   /evidence="ECO:0000269|PubMed:19123921"
FT   MUTAGEN         372
FT                   /note="R->A: Strongly reduced binding of DNA and RNA."
FT                   /evidence="ECO:0000269|PubMed:19123921"
FT   MUTAGEN         394
FT                   /note="R->A,S: Strongly reduced binding of DNA and RNA."
FT                   /evidence="ECO:0000269|PubMed:19123921"
FT   MUTAGEN         434
FT                   /note="H->A: Reduced RNA binding."
FT                   /evidence="ECO:0000269|PubMed:19123921"
FT   CONFLICT        288
FT                   /note="I -> M (in Ref. 8; AAH32861)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        365
FT                   /note="S -> F (in Ref. 9; AAA36810 and 10; AAB33443)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        387
FT                   /note="T -> A (in Ref. 3; CAA43819)"
FT                   /evidence="ECO:0000305"
FT   STRAND          322..324
FT                   /evidence="ECO:0000244|PDB:6B0Q"
FT   TURN            328..330
FT                   /evidence="ECO:0000244|PDB:6B0R"
FT   STRAND          333..336
FT                   /evidence="ECO:0000244|PDB:6B0O"
FT   HELIX           337..348
FT                   /evidence="ECO:0000244|PDB:6B0O"
FT   STRAND          357..359
FT                   /evidence="ECO:0000244|PDB:6B0R"
FT   STRAND          363..366
FT                   /evidence="ECO:0000244|PDB:5KL3"
FT   HELIX           367..378
FT                   /evidence="ECO:0000244|PDB:5KL3"
FT   TURN            386..388
FT                   /evidence="ECO:0000244|PDB:5KL3"
FT   STRAND          391..393
FT                   /evidence="ECO:0000244|PDB:5KL3"
FT   HELIX           395..401
FT                   /evidence="ECO:0000244|PDB:5KL3"
FT   HELIX           403..406
FT                   /evidence="ECO:0000244|PDB:5KL3"
FT   STRAND          418..420
FT                   /evidence="ECO:0000244|PDB:6BLW"
FT   STRAND          424..427
FT                   /evidence="ECO:0000244|PDB:5KL3"
FT   HELIX           428..438
FT                   /evidence="ECO:0000244|PDB:5KL3"
SQ   SEQUENCE   449 AA;  49188 MW;  11C7FA3D485096B2 CRC64;
     MGSDVRDLNA LLPAVPSLGG GGGCALPVSG AAQWAPVLDF APPGASAYGS LGGPAPPPAP
     PPPPPPPPHS FIKQEPSWGG AEPHEEQCLS AFTVHFSGQF TGTAGACRYG PFGPPPPSQA
     SSGQARMFPN APYLPSCLES QPAIRNQGYS TVTFDGTPSY GHTPSHHAAQ FPNHSFKHED
     PMGQQGSLGE QQYSVPPPVY GCHTPTDSCT GSQALLLRTP YSSDNLYQMT SQLECMTWNQ
     MNLGATLKGV AAGSSSSVKW TEGQSNHSTG YESDNHTTPI LCGAQYRIHT HGVFRGIQDV
     RRVPGVAPTL VRSASETSEK RPFMCAYPGC NKRYFKLSHL QMHSRKHTGE KPYQCDFKDC
     ERRFSRSDQL KRHQRRHTGV KPFQCKTCQR KFSRSDHLKT HTRTHTGKTS EKPFSCRWPS
     CQKKFARSDE LVRHHNMHQR NMTKLQLAL
//
ID   Q6PI38_HUMAN            Unreviewed;       331 AA.
AC   Q6PI38;
DT   05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT   05-SEP-2006, sequence version 2.
DT   22-APR-2020, entry version 81.
DE   SubName: Full=WT1 protein {ECO:0000313|EMBL:AAH46461.2};
DE   Flags: Fragment;
GN   Name=WT1 {ECO:0000313|EMBL:AAH46461.2};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAH46461.2};
RN   [1] {ECO:0000313|EMBL:AAH46461.2}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain {ECO:0000313|EMBL:AAH46461.2};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC046461; AAH46461.2; -; mRNA.
DR   RefSeq; NP_000369.3; NM_000378.4.
DR   RefSeq; NP_001185480.1; NM_001198551.1.
DR   RefSeq; NP_001185481.1; NM_001198552.1.
DR   RefSeq; NP_077742.2; NM_024424.3.
DR   RefSeq; NP_077744.3; NM_024426.4.
DR   IntAct; Q6PI38; 3.
DR   PeptideAtlas; Q6PI38; -.
DR   DNASU; 7490; -.
DR   GeneID; 7490; -.
DR   KEGG; hsa:7490; -.
DR   CTD; 7490; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   KO; K09234; -.
DR   OrthoDB; 1318335at2759; -.
DR   ChiTaRS; WT1; human.
DR   GenomeRNAi; 7490; -.
DR   Genevisible; Q6PI38; HS.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:InterPro.
DR   InterPro; IPR017987; Wilms_tumour.
DR   InterPro; IPR000976; Wilms_tumour_N.
DR   PANTHER; PTHR23235:SF49; PTHR23235:SF49; 1.
DR   Pfam; PF02165; WT1; 1.
PE   2: Evidence at transcript level;
KW   Signal {ECO:0000256|SAM:SignalP}.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000256|SAM:SignalP"
FT   CHAIN           22..331
FT                   /evidence="ECO:0000256|SAM:SignalP"
FT                   /id="PRO_5004279522"
FT   DOMAIN          83..331
FT                   /note="WT1"
FT                   /evidence="ECO:0000259|Pfam:PF02165"
FT   REGION          23..84
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          130..166
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        23..41
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        135..154
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:AAH46461.2"
SQ   SEQUENCE   331 AA;  34592 MW;  BA8AA8FA79475F68 CRC64;
     GPRRLLAAIL DFLLLQDPAS TCVPEPASQH TLRSGPGCLQ QPEQQGVRDP GGIWAKLGAA
     EASAERLQGR RSRGASGSEP QQMGSDVRDL NALLPAVPSL GGGGGCALPV SGAAQWAPVL
     DFAPPGASAY GSLGGPAPPP APPPPPPPPP HSFIKQEPSW GGAEPHEEQC LSAFTVHFSG
     QFTGTAGACR YGPFGPPPPS QASSGQARMF PNAPYLPSCL ESQPAIRNQG YSTVTFDGTP
     SYGHTPSHHA AQFPNHSFKH EDPMGQQGSL GEQQYSVPPP VYGCHTPTDS CTGSQALLLR
     TPYSSDNLYQ MTSQLECMTW NQMNLGATLK G
//
